id,"name","description_var_evidence",disease_id,"disease_name","disease_display_name",disease_doid,"disease_url","evidence_level","evidence_type","evidence_direction","clinical_significance","variant_origin",variant_id,rating,"drug_interaction_type","status",open_change_count,"type",source_id,"source_name","source_citation",source_pubmed_id,"source_source_url","source_open_access","source_pmc_id","source_publication_date_year","source_publication_date_month","source_publication_date_day","source_journal","source_full_journal_title","source_status","drugs0_id","drugs0_name","drugs0_pubchem_id","drugs1_id","drugs1_name","drugs1_pubchem_id","drugs2_id","drugs2_name","drugs2_pubchem_id","drugs3_id","drugs3_name","drugs3_pubchem_id","drugs4_id","drugs4_name","drugs4_pubchem_id"
1,"EID1","JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL).",1,"Lymphoid Leukemia","Lymphoid Leukemia",10747,"http://www.disease-ontology.org/?id=DOID:10747","B","Diagnostic","Supports","Negative","Somatic Mutation",64,4,NULL,"accepted",0,"evidence",51,"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.","Levine et al., 2005, Blood",16081687,"http://www.ncbi.nlm.nih.gov/pubmed/16081687","true","PMC1895066","2005","11","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
2,"EID2","GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Diagnostic","Supports","Negative","Somatic Mutation",99,3,NULL,"accepted",0,"evidence",52,"A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.","Lasota et al., 2004, Lab. Invest.",15146165,"http://www.ncbi.nlm.nih.gov/pubmed/15146165",NULL,NULL,"2004","7",NULL,"Lab. Invest.","Laboratory investigation; a journal of technical methods and pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
3,"EID3","DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",32,2,NULL,"accepted",0,"evidence",53,"Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.","LaRochelle et al., 2011, Oncotarget",22081665,"http://www.ncbi.nlm.nih.gov/pubmed/22081665","true","PMC3260002","2011","11",NULL,"Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
4,"EID4","Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",54,"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.","Ribeiro et al., 2012, Blood",22490330,"http://www.ncbi.nlm.nih.gov/pubmed/22490330",NULL,NULL,"2012","6","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
5,"EID5","JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML).",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Diagnostic","Supports","Positive","Somatic Mutation",64,4,NULL,"accepted",0,"evidence",51,"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.","Levine et al., 2005, Blood",16081687,"http://www.ncbi.nlm.nih.gov/pubmed/16081687","true","PMC1895066","2005","11","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
6,"EID6","JAK2 V617F is associated with myeloid neoplasms (AML, MDS, CMML/aCML).",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Diagnostic","Supports","Positive","Somatic Mutation",64,4,NULL,"accepted",0,"evidence",51,"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.","Levine et al., 2005, Blood",16081687,"http://www.ncbi.nlm.nih.gov/pubmed/16081687","true","PMC1895066","2005","11","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
7,"EID7","The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer.",5,"Bone Marrow Cancer","Bone Marrow Cancer",4960,"http://www.disease-ontology.org/?id=DOID:4960","B","Diagnostic","Supports","Positive","Somatic Mutation",64,4,NULL,"accepted",0,"evidence",55,"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.","Kilpivaara et al., 2009, Nat. Genet.",19287384,"http://www.ncbi.nlm.nih.gov/pubmed/19287384","true","PMC3676425","2009","4",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
8,"EID8","Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.",6,"Acute Leukemia","Acute Leukemia",12603,"http://www.disease-ontology.org/?id=DOID:12603","B","Diagnostic","Supports","Positive","Somatic Mutation",76,3,NULL,"accepted",0,"evidence",56,"RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures.","Andrade et al., 2014, BMC Cancer",24571676,"http://www.ncbi.nlm.nih.gov/pubmed/24571676","true","PMC3946262","2014",NULL,NULL,"BMC Cancer","BMC cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
10,"EID10","Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Diagnostic","Supports","Positive","Somatic Mutation",94,3,NULL,"accepted",0,"evidence",57,"NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.","Tschandl et al., 2013, PLoS ONE",23861977,"http://www.ncbi.nlm.nih.gov/pubmed/23861977","true","PMC3704624","2013",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
11,"EID11","Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",53,"Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.","LaRochelle et al., 2011, Oncotarget",22081665,"http://www.ncbi.nlm.nih.gov/pubmed/22081665","true","PMC3260002","2011","11",NULL,"Oncotarget","Oncotarget","fully curated","2","Daunorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
12,"EID12","A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",82,3,NULL,"accepted",0,"evidence",58,"MEK1 mutations confer resistance to MEK and B-RAF inhibition.","Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",19915144,"http://www.ncbi.nlm.nih.gov/pubmed/19915144","true","PMC2777185","2009","12","1","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
13,"EID13","A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",83,3,NULL,"accepted",0,"evidence",58,"MEK1 mutations confer resistance to MEK and B-RAF inhibition.","Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",19915144,"http://www.ncbi.nlm.nih.gov/pubmed/19915144","true","PMC2777185","2009","12","1","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
14,"EID14","Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",94,4,NULL,"accepted",0,"evidence",60,"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.","Trunzer et al., 2013, J. Clin. Oncol.",23569304,"http://www.ncbi.nlm.nih.gov/pubmed/23569304",NULL,NULL,"2013","5","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
15,"EID15","GIST cancer with D842V mutation is resistant to imatinib.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",99,4,NULL,"accepted",0,"evidence",61,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.","Corless et al., 2005, J. Clin. Oncol.",15928335,"http://www.ncbi.nlm.nih.gov/pubmed/15928335",NULL,NULL,"2005","8","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
16,"EID16","While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",99,4,NULL,"accepted",0,"evidence",62,"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.","Heinrich et al., 2006, J. Clin. Oncol.",16954519,"http://www.ncbi.nlm.nih.gov/pubmed/16954519",NULL,NULL,"2006","10","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
17,"EID17","In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",10,2,NULL,"accepted",0,"evidence",63,"Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.","Imielinski et al., 2014, J. Clin. Invest.",24569458,"http://www.ncbi.nlm.nih.gov/pubmed/24569458","true","PMC3973082","2014","4",NULL,"J. Clin. Invest.","The Journal of clinical investigation","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
18,"EID18","Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",53,"Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.","LaRochelle et al., 2011, Oncotarget",22081665,"http://www.ncbi.nlm.nih.gov/pubmed/22081665","true","PMC3260002","2011","11",NULL,"Oncotarget","Oncotarget","fully curated","7","Idarubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
19,"EID19","In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F.",9,"Polycythemia Vera","Polycythemia Vera",8997,"http://www.disease-ontology.org/?id=DOID:8997","B","Predictive","Supports","Sensitivity","Somatic Mutation",64,4,NULL,"accepted",0,"evidence",64,"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.","Kiladjian et al., 2006, Blood",16709929,"http://www.ncbi.nlm.nih.gov/pubmed/16709929",NULL,NULL,"2006","9","15","Blood","Blood","fully curated","8","Pegylated IFN-alphaâ€“2a",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
20,"EID20","TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.",9,"Polycythemia Vera","Polycythemia Vera",8997,"http://www.disease-ontology.org/?id=DOID:8997","D","Predictive","Supports","Sensitivity","Somatic Mutation",64,3,NULL,"accepted",0,"evidence",65,"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.","Wernig et al., 2008, Cancer Cell",18394554,"http://www.ncbi.nlm.nih.gov/pubmed/18394554",NULL,NULL,"2008","4",NULL,"Cancer Cell","Cancer cell","fully curated","9","TG101348",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
21,"EID21","Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",93,2,NULL,"accepted",0,"evidence",66,"BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.","Banerji et al., 2008, Mol. Cancer Ther.",18375819,"http://www.ncbi.nlm.nih.gov/pubmed/18375819",NULL,NULL,"2008","4",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","10","17-AAG",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
22,"EID22","In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",95,2,NULL,"accepted",0,"evidence",67,"NRAS-mutant melanoma: response to chemotherapy.","Soon et al., 2011, Arch Dermatol",21576590,"http://www.ncbi.nlm.nih.gov/pubmed/21576590",NULL,NULL,"2011","5",NULL,"Arch Dermatol","Archives of dermatology","fully curated","11","Temozolomide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
23,"EID23","In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",96,2,NULL,"accepted",0,"evidence",67,"NRAS-mutant melanoma: response to chemotherapy.","Soon et al., 2011, Arch Dermatol",21576590,"http://www.ncbi.nlm.nih.gov/pubmed/21576590",NULL,NULL,"2011","5",NULL,"Arch Dermatol","Archives of dermatology","fully curated","11","Temozolomide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
24,"EID24","There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",53,"Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.","LaRochelle et al., 2011, Oncotarget",22081665,"http://www.ncbi.nlm.nih.gov/pubmed/22081665","true","PMC3260002","2011","11",NULL,"Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
25,"EID25","De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",68,"DNMT3A mutations in acute myeloid leukemia.","Ley et al., 2010, N. Engl. J. Med.",21067377,"http://www.ncbi.nlm.nih.gov/pubmed/21067377","true","PMC3201818","2010","12","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
26,"EID26","In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",65,4,NULL,"accepted",0,"evidence",69,"Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.","Cairoli et al., 2006, Blood",16384925,"http://www.ncbi.nlm.nih.gov/pubmed/16384925",NULL,NULL,"2006","5","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
27,"EID27","Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",208,3,NULL,"accepted",0,"evidence",70,"The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.","Therkildsen et al., 2014, Acta Oncol",24666267,"http://www.ncbi.nlm.nih.gov/pubmed/24666267",NULL,NULL,"2014","7",NULL,"Acta Oncol","Acta oncologica (Stockholm, Sweden)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
30,"EID30","BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Diagnostic","Supports","Positive","Somatic Mutation",17,4,NULL,"accepted",0,"evidence",71,"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.","Lee et al., 2011, Br. J. Dermatol.",21166657,"http://www.ncbi.nlm.nih.gov/pubmed/21166657",NULL,NULL,"2011","4",NULL,"Br. J. Dermatol.","The British journal of dermatology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
31,"EID31","DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",72,"DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.","El Ghannam et al., Blood Cells Mol. Dis.",24512939,"http://www.ncbi.nlm.nih.gov/pubmed/24512939",NULL,NULL,NULL,NULL,NULL,"Blood Cells Mol. Dis.","Blood cells, molecules & diseases","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
32,"EID32","Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.",12,"Inflammatory Myofibroblastic Tumor","Inflammatory Myofibroblastic Tumor",50905,"http://www.disease-ontology.org/?id=DOID:0050905","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",8,3,NULL,"accepted",0,"evidence",73,"The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.","Sasaki et al., 2010, Cancer Res.",21030459,"http://www.ncbi.nlm.nih.gov/pubmed/21030459","true","PMC3045808","2010","12","15","Cancer Res.","Cancer research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
33,"EID33","Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",8,3,NULL,"accepted",0,"evidence",73,"The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.","Sasaki et al., 2010, Cancer Res.",21030459,"http://www.ncbi.nlm.nih.gov/pubmed/21030459","true","PMC3045808","2010","12","15","Cancer Res.","Cancer research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
34,"EID34","The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",72,3,NULL,"accepted",0,"evidence",74,"Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.","Woodman et al., 2009, Mol. Cancer Ther.",19671763,"http://www.ncbi.nlm.nih.gov/pubmed/19671763","true","PMC3346953","2009","8",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","6","Sorafenib",NULL,"13","Nilotinib",NULL,"5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
35,"EID35","In NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib and erlotinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",75,3,NULL,"accepted",0,"evidence",75,"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.","Pao et al., 2005, PLoS Med.",15696205,"http://www.ncbi.nlm.nih.gov/pubmed/15696205","true","PMC545207","2005","1",NULL,"PLoS Med.","PLoS medicine","fully curated","15","Erlotinib",NULL,"14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
36,"EID36","Chemotherapy-refractory patients with colorectal cancer harboring NRAS mutation (primarily Q61) have a significantly lower response rate to cetuximab than patients wildtype for NRAS.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",94,3,NULL,"accepted",0,"evidence",76,"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","De Roock et al., 2010, Lancet Oncol.",20619739,"http://www.ncbi.nlm.nih.gov/pubmed/20619739",NULL,NULL,"2010","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
37,"EID37","CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",8,3,NULL,"accepted",0,"evidence",77,"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.","Sakamoto et al., 2011, Cancer Cell",21575866,"http://www.ncbi.nlm.nih.gov/pubmed/21575866",NULL,NULL,"2011","5","17","Cancer Cell","Cancer cell","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
38,"EID38","High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",8,3,NULL,"accepted",0,"evidence",78,"ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.","Heuckmann et al., 2011, Clin. Cancer Res.",21948233,"http://www.ncbi.nlm.nih.gov/pubmed/21948233","true","PMC3382103","2011","12","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
39,"EID39","TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",9,3,NULL,"accepted",0,"evidence",79,"Activating mutations in ALK provide a therapeutic target in neuroblastoma.","George et al., 2008, Nature",18923525,"http://www.ncbi.nlm.nih.gov/pubmed/18923525","true","PMC2587486","2008","10","16","Nature","Nature","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
40,"EID40","Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",10,3,NULL,"accepted",0,"evidence",63,"Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.","Imielinski et al., 2014, J. Clin. Invest.",24569458,"http://www.ncbi.nlm.nih.gov/pubmed/24569458","true","PMC3973082","2014","4",NULL,"J. Clin. Invest.","The Journal of clinical investigation","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
41,"EID41","Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",10,3,NULL,"accepted",0,"evidence",63,"Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.","Imielinski et al., 2014, J. Clin. Invest.",24569458,"http://www.ncbi.nlm.nih.gov/pubmed/24569458","true","PMC3973082","2014","4",NULL,"J. Clin. Invest.","The Journal of clinical investigation","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
42,"EID42","The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",72,3,NULL,"accepted",0,"evidence",74,"Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.","Woodman et al., 2009, Mol. Cancer Ther.",19671763,"http://www.ncbi.nlm.nih.gov/pubmed/19671763","true","PMC3346953","2009","8",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
43,"EID43","In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Sensitivity","Somatic Mutation",98,4,NULL,"accepted",0,"evidence",80,"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.","Heinrich et al., 2012, Clin. Cancer Res.",22745105,"http://www.ncbi.nlm.nih.gov/pubmed/22745105",NULL,NULL,"2012","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","21","Crenolanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
44,"EID44","In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Sensitivity","Somatic Mutation",99,4,NULL,"accepted",0,"evidence",80,"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.","Heinrich et al., 2012, Clin. Cancer Res.",22745105,"http://www.ncbi.nlm.nih.gov/pubmed/22745105",NULL,NULL,"2012","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","21","Crenolanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
45,"EID45","In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Sensitivity","Somatic Mutation",100,4,NULL,"accepted",0,"evidence",80,"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.","Heinrich et al., 2012, Clin. Cancer Res.",22745105,"http://www.ncbi.nlm.nih.gov/pubmed/22745105",NULL,NULL,"2012","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","21","Crenolanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
46,"EID46","In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Sensitivity","Somatic Mutation",101,3,NULL,"accepted",0,"evidence",80,"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.","Heinrich et al., 2012, Clin. Cancer Res.",22745105,"http://www.ncbi.nlm.nih.gov/pubmed/22745105",NULL,NULL,"2012","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","21","Crenolanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
47,"EID47","In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Sensitivity","Somatic Mutation",102,4,NULL,"accepted",0,"evidence",80,"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.","Heinrich et al., 2012, Clin. Cancer Res.",22745105,"http://www.ncbi.nlm.nih.gov/pubmed/22745105",NULL,NULL,"2012","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","21","Crenolanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
48,"EID48","The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",9,3,NULL,"accepted",0,"evidence",79,"Activating mutations in ALK provide a therapeutic target in neuroblastoma.","George et al., 2008, Nature",18923525,"http://www.ncbi.nlm.nih.gov/pubmed/18923525","true","PMC2587486","2008","10","16","Nature","Nature","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
49,"EID49","In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",81,"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","Gaidzik et al., 2013, Blood",23632886,"http://www.ncbi.nlm.nih.gov/pubmed/23632886",NULL,NULL,"2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
50,"EID50","In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival. This was true for cytogenetically normal AML and the entire cohort.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",81,"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","Gaidzik et al., 2013, Blood",23632886,"http://www.ncbi.nlm.nih.gov/pubmed/23632886",NULL,NULL,"2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
51,"EID51","In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",54,"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.","Ribeiro et al., 2012, Blood",22490330,"http://www.ncbi.nlm.nih.gov/pubmed/22490330",NULL,NULL,"2012","6","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
52,"EID52","In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",54,"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.","Ribeiro et al., 2012, Blood",22490330,"http://www.ncbi.nlm.nih.gov/pubmed/22490330",NULL,NULL,"2012","6","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
53,"EID53","There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Prognostic","Does Not Support","N/A","Somatic Mutation",66,3,NULL,"accepted",0,"evidence",82,"Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.","Wardelmann et al., 2006, Clin. Cancer Res.",16551858,"http://www.ncbi.nlm.nih.gov/pubmed/16551858",NULL,NULL,"2006","3","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
56,"EID56","The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",208,3,NULL,"accepted",0,"evidence",83,"RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.","Bowen et al., 2005, Blood",15951308,"http://www.ncbi.nlm.nih.gov/pubmed/15951308",NULL,NULL,"2005","9","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
57,"EID57","NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",92,3,NULL,"accepted",0,"evidence",84,"Implications of NRAS mutations in AML: a study of 2502 patients.","Bacher et al., 2006, Blood",16434492,"http://www.ncbi.nlm.nih.gov/pubmed/16434492",NULL,NULL,"2006","5","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
58,"EID58","Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",66,3,NULL,"accepted",0,"evidence",85,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.","Hodi et al., 2013, J. Clin. Oncol.",23775962,"http://www.ncbi.nlm.nih.gov/pubmed/23775962","true","PMC4878082","2013","9","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
61,"EID61","In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","A","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",81,"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","Gaidzik et al., 2013, Blood",23632886,"http://www.ncbi.nlm.nih.gov/pubmed/23632886",NULL,NULL,"2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
62,"EID62","AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,5,NULL,"accepted",0,"evidence",68,"DNMT3A mutations in acute myeloid leukemia.","Ley et al., 2010, N. Engl. J. Med.",21067377,"http://www.ncbi.nlm.nih.gov/pubmed/21067377","true","PMC3201818","2010","12","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
63,"EID63","DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",81,"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","Gaidzik et al., 2013, Blood",23632886,"http://www.ncbi.nlm.nih.gov/pubmed/23632886",NULL,NULL,"2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
64,"EID64","In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,5,NULL,"accepted",0,"evidence",68,"DNMT3A mutations in acute myeloid leukemia.","Ley et al., 2010, N. Engl. J. Med.",21067377,"http://www.ncbi.nlm.nih.gov/pubmed/21067377","true","PMC3201818","2010","12","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
65,"EID65","In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,5,NULL,"accepted",0,"evidence",72,"DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.","El Ghannam et al., Blood Cells Mol. Dis.",24512939,"http://www.ncbi.nlm.nih.gov/pubmed/24512939",NULL,NULL,NULL,NULL,NULL,"Blood Cells Mol. Dis.","Blood cells, molecules & diseases","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
66,"EID66","In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",86,"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.","Marcucci et al., 2012, J. Clin. Oncol.",22291079,"http://www.ncbi.nlm.nih.gov/pubmed/22291079","true","PMC3295550","2012","3","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
67,"EID67","In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",54,"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.","Ribeiro et al., 2012, Blood",22490330,"http://www.ncbi.nlm.nih.gov/pubmed/22490330",NULL,NULL,"2012","6","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
68,"EID68","In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",86,"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.","Marcucci et al., 2012, J. Clin. Oncol.",22291079,"http://www.ncbi.nlm.nih.gov/pubmed/22291079","true","PMC3295550","2012","3","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
69,"EID69","In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,5,NULL,"accepted",0,"evidence",68,"DNMT3A mutations in acute myeloid leukemia.","Ley et al., 2010, N. Engl. J. Med.",21067377,"http://www.ncbi.nlm.nih.gov/pubmed/21067377","true","PMC3201818","2010","12","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
70,"EID70","GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",69,3,NULL,"accepted",0,"evidence",82,"Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.","Wardelmann et al., 2006, Clin. Cancer Res.",16551858,"http://www.ncbi.nlm.nih.gov/pubmed/16551858",NULL,NULL,"2006","3","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
71,"EID71","In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",208,3,NULL,"accepted",0,"evidence",87,"NRAS mutation status is an independent prognostic factor in metastatic melanoma.","Jakob et al., 2012, Cancer",22180178,"http://www.ncbi.nlm.nih.gov/pubmed/22180178","true","PMC3310961","2012","8","15","Cancer","Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
73,"EID73","A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",13,3,NULL,"accepted",0,"evidence",88,"Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.","Ponti et al., 2012, J Hematol Oncol",23031422,"http://www.ncbi.nlm.nih.gov/pubmed/23031422","true","PMC3473234","2012",NULL,NULL,"J Hematol Oncol","Journal of hematology & oncology","fully curated","22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
74,"EID74","In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.",15,"Thyroid Medullary Carcinoma","Thyroid Medullary Carcinoma",3973,"http://www.disease-ontology.org/?id=DOID:3973","B","Diagnostic","Supports","Positive","Somatic Mutation",113,5,NULL,"accepted",0,"evidence",89,"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.","Elisei et al., 2008, J. Clin. Endocrinol. Metab.",18073307,"http://www.ncbi.nlm.nih.gov/pubmed/18073307",NULL,NULL,"2008","3",NULL,"J. Clin. Endocrinol. Metab.","The Journal of clinical endocrinology and metabolism","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
75,"EID75","Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET.",15,"Thyroid Medullary Carcinoma","Thyroid Medullary Carcinoma",3973,"http://www.disease-ontology.org/?id=DOID:3973","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",112,3,NULL,"accepted",0,"evidence",90,"Anti-tumor activity of motesanib in a medullary thyroid cancer model.","Coxon et al., 2012, J. Endocrinol. Invest.",21422803,"http://www.ncbi.nlm.nih.gov/pubmed/21422803",NULL,NULL,"2012","2",NULL,"J. Endocrinol. Invest.","Journal of endocrinological investigation","fully curated","23","Motesanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
76,"EID76","Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.",15,"Thyroid Medullary Carcinoma","Thyroid Medullary Carcinoma",3973,"http://www.disease-ontology.org/?id=DOID:3973","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",113,3,NULL,"accepted",0,"evidence",90,"Anti-tumor activity of motesanib in a medullary thyroid cancer model.","Coxon et al., 2012, J. Endocrinol. Invest.",21422803,"http://www.ncbi.nlm.nih.gov/pubmed/21422803",NULL,NULL,"2012","2",NULL,"J. Endocrinol. Invest.","Journal of endocrinological investigation","fully curated","23","Motesanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
77,"EID77","The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.",15,"Thyroid Medullary Carcinoma","Thyroid Medullary Carcinoma",3973,"http://www.disease-ontology.org/?id=DOID:3973","D","Predictive","Supports","Sensitivity","Somatic Mutation",113,3,NULL,"accepted",0,"evidence",91,"AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.","Couto et al., 2012, PLoS ONE",23056499,"http://www.ncbi.nlm.nih.gov/pubmed/23056499","true","PMC3462763","2012",NULL,NULL,"PLoS ONE","PloS one","fully curated","24","AZD1480",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
78,"EID78","Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer.",15,"Thyroid Medullary Carcinoma","Thyroid Medullary Carcinoma",3973,"http://www.disease-ontology.org/?id=DOID:3973","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",113,4,NULL,"accepted",0,"evidence",92,"Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.","Egawa et al., 1998, Jpn. J. Clin. Oncol.",9839497,"http://www.ncbi.nlm.nih.gov/pubmed/9839497",NULL,NULL,"1998","10",NULL,"Jpn. J. Clin. Oncol.","Japanese journal of clinical oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
79,"EID79","BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Diagnostic","Supports","Positive","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",93,"Both BRAF V600E mutation and older age (â‰¥ 65 years) are associated with recurrent papillary thyroid cancer.","Howell et al., 2011, Ann. Surg. Oncol.",21594703,"http://www.ncbi.nlm.nih.gov/pubmed/21594703",NULL,NULL,"2011","12",NULL,"Ann. Surg. Oncol.","Annals of surgical oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
80,"EID80","Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Diagnostic","Supports","Positive","Somatic Mutation",12,5,NULL,"accepted",0,"evidence",94,"Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.","Crescenzi et al., 2014, Horm. Metab. Res.",24570209,"http://www.ncbi.nlm.nih.gov/pubmed/24570209",NULL,NULL,"2014","5",NULL,"Horm. Metab. Res.","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et meÌtabolisme","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
82,"EID82","BRAF status does not predict prognosis in patients treated with dacarbazine or temozolomide.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Does Not Support","N/A","Somatic Mutation",12,2,NULL,"accepted",0,"evidence",96,"BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.","Meckbach et al., 2014, PLoS ONE",24586605,"http://www.ncbi.nlm.nih.gov/pubmed/24586605","true","PMC3930670","2014",NULL,NULL,"PLoS ONE","PloS one","fully curated","11","Temozolomide",NULL,"25","Dacarbazine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
83,"EID83","PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","N/A","Somatic Mutation",103,4,NULL,"accepted",0,"evidence",97,"Regorafenib in metastatic colorectal cancer.","Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther",24559322,"http://www.ncbi.nlm.nih.gov/pubmed/24559322",NULL,NULL,"2014","3",NULL,"Expert Rev Anticancer Ther","Expert review of anticancer therapy","fully curated","27","Regorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
86,"EID86","In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",12,3,"Substitutes","accepted",0,"evidence",98,"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.","Nissan et al., 2014, Cancer Res.",24576830,"http://www.ncbi.nlm.nih.gov/pubmed/24576830","true","PMC4005042","2014","4","15","Cancer Res.","Cancer research","fully curated","29","PD0325901",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
87,"EID87","KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",75,4,NULL,"accepted",0,"evidence",97,"Regorafenib in metastatic colorectal cancer.","Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther",24559322,"http://www.ncbi.nlm.nih.gov/pubmed/24559322",NULL,NULL,"2014","3",NULL,"Expert Rev Anticancer Ther","Expert review of anticancer therapy","fully curated","27","Regorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
88,"EID88","In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",17,3,NULL,"accepted",0,"evidence",99,"Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.","Peeters et al., 2013, Clin. Cancer Res.",23325582,"http://www.ncbi.nlm.nih.gov/pubmed/23325582",NULL,NULL,"2013","4","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
89,"EID89","Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",100,"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.","Di Nicolantonio et al., 2008, J. Clin. Oncol.",19001320,"http://www.ncbi.nlm.nih.gov/pubmed/19001320",NULL,NULL,"2008","12","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
90,"EID90","In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",98,"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.","Nissan et al., 2014, Cancer Res.",24576830,"http://www.ncbi.nlm.nih.gov/pubmed/24576830","true","PMC4005042","2014","4","15","Cancer Res.","Cancer research","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
91,"EID91","In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",12,2,NULL,"accepted",0,"evidence",101,"Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.","Rudin et al., 2013, J Thorac Oncol",23524406,"http://www.ncbi.nlm.nih.gov/pubmed/23524406","true","PMC3634121","2013","5",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
92,"EID92","COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF V600E gene.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","E","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",14,4,NULL,"accepted",0,"evidence",102,"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.","Corcoran et al., 2010, Sci Signal",21098728,"http://www.ncbi.nlm.nih.gov/pubmed/21098728","true","PMC3372405","2010",NULL,NULL,"Sci Signal","Science signaling","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
93,"EID93","Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",17,3,NULL,"accepted",0,"evidence",103,"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","Flaherty et al., 2012, N. Engl. J. Med.",23020132,"http://www.ncbi.nlm.nih.gov/pubmed/23020132","true","PMC3549295","2012","11",NULL,"N. Engl. J. Med.","The New England journal of medicine","fully curated","19","Trametinib",NULL,"22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
94,"EID94","Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",11,5,NULL,"accepted",0,"evidence",104,"The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.","Ponti et al., 2013, J. Clin. Pathol.",23463675,"http://www.ncbi.nlm.nih.gov/pubmed/23463675",NULL,NULL,"2013","5",NULL,"J. Clin. Pathol.","Journal of clinical pathology","fully curated","22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
95,"EID95","Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",12,5,"Combination","accepted",0,"evidence",105,"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.","Menzies et al., 2014, Clin. Cancer Res.",24583796,"http://www.ncbi.nlm.nih.gov/pubmed/24583796",NULL,NULL,"2014","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","19","Trametinib",NULL,"22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
96,"EID96","Combined MEK inhibitor PD0325901 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",106,"A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.","Rad et al., 2013, Cancer Cell",23845441,"http://www.ncbi.nlm.nih.gov/pubmed/23845441","true","PMC3706745","2013","7","8","Cancer Cell","Cancer cell","fully curated","30","PLX4720",NULL,"29","PD0325901",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
97,"EID97","Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",12,2,NULL,"accepted",0,"evidence",107,"Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.","Ji et al., 2013, Clin. Cancer Res.",23812671,"http://www.ncbi.nlm.nih.gov/pubmed/23812671","true","PMC3777641","2013","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","31","Nutlin-3",NULL,"30","PLX4720",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
98,"EID98","Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",12,2,NULL,"accepted",0,"evidence",108,"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.","Yang et al., 2012, Cancer Res.",22180495,"http://www.ncbi.nlm.nih.gov/pubmed/22180495",NULL,NULL,"2012","2","1","Cancer Res.","Cancer research","fully curated","33","Bevacizumab",NULL,"4","Vemurafenib",NULL,"32","Capecitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL
99,"EID99","Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",12,2,NULL,"accepted",0,"evidence",108,"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.","Yang et al., 2012, Cancer Res.",22180495,"http://www.ncbi.nlm.nih.gov/pubmed/22180495",NULL,NULL,"2012","2","1","Cancer Res.","Cancer research","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
102,"EID102","Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",12,5,NULL,"accepted",0,"evidence",109,"The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?","Walczyk et al., 2014, Clin. Endocrinol. (Oxf)",24354346,"http://www.ncbi.nlm.nih.gov/pubmed/24354346",NULL,NULL,"2014","6",NULL,"Clin. Endocrinol. (Oxf)","Clinical endocrinology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
103,"EID103","V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","A","Prognostic","Supports","Poor Outcome","Somatic Mutation",12,5,NULL,"accepted",0,"evidence",110,"BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.","Chen et al., 2014, PLoS ONE",24594804,"http://www.ncbi.nlm.nih.gov/pubmed/24594804","true","PMC3940924","2014",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
104,"EID104","BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",111,"Prognostic value of BRAF mutations in localized cutaneous melanoma.","Nagore et al., 2014, J. Am. Acad. Dermatol.",24388723,"http://www.ncbi.nlm.nih.gov/pubmed/24388723",NULL,NULL,"2014","5",NULL,"J. Am. Acad. Dermatol.","Journal of the American Academy of Dermatology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
105,"EID105","BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",93,"Both BRAF V600E mutation and older age (â‰¥ 65 years) are associated with recurrent papillary thyroid cancer.","Howell et al., 2011, Ann. Surg. Oncol.",21594703,"http://www.ncbi.nlm.nih.gov/pubmed/21594703",NULL,NULL,"2011","12",NULL,"Ann. Surg. Oncol.","Annals of surgical oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
106,"EID106","BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",112,"Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.","He et al., 2014, Oncol Lett",24396464,"http://www.ncbi.nlm.nih.gov/pubmed/24396464","true","PMC3881916","2014","2",NULL,"Oncol Lett","Oncology letters","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
107,"EID107","V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",93,"Both BRAF V600E mutation and older age (â‰¥ 65 years) are associated with recurrent papillary thyroid cancer.","Howell et al., 2011, Ann. Surg. Oncol.",21594703,"http://www.ncbi.nlm.nih.gov/pubmed/21594703",NULL,NULL,"2011","12",NULL,"Ann. Surg. Oncol.","Annals of surgical oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
108,"EID108","NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Does Not Support","Positive","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",113,"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).","Thiede et al., 2006, Blood",16455956,"http://www.ncbi.nlm.nih.gov/pubmed/16455956",NULL,NULL,"2006","5","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
109,"EID109","No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Does Not Support","Positive","Somatic Mutation",87,4,NULL,"accepted",0,"evidence",68,"DNMT3A mutations in acute myeloid leukemia.","Ley et al., 2010, N. Engl. J. Med.",21067377,"http://www.ncbi.nlm.nih.gov/pubmed/21067377","true","PMC3201818","2010","12","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
110,"EID110","Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Negative","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",81,"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","Gaidzik et al., 2013, Blood",23632886,"http://www.ncbi.nlm.nih.gov/pubmed/23632886",NULL,NULL,"2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
111,"EID111","NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Negative","Somatic Mutation",86,4,NULL,"accepted",0,"evidence",114,"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.","Schnittger et al., 2005, Blood",16076867,"http://www.ncbi.nlm.nih.gov/pubmed/16076867",NULL,NULL,"2005","12","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
112,"EID112","DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",32,5,NULL,"accepted",0,"evidence",68,"DNMT3A mutations in acute myeloid leukemia.","Ley et al., 2010, N. Engl. J. Med.",21067377,"http://www.ncbi.nlm.nih.gov/pubmed/21067377","true","PMC3201818","2010","12","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
113,"EID113","DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",68,"DNMT3A mutations in acute myeloid leukemia.","Ley et al., 2010, N. Engl. J. Med.",21067377,"http://www.ncbi.nlm.nih.gov/pubmed/21067377","true","PMC3201818","2010","12","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
114,"EID114","DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",81,"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","Gaidzik et al., 2013, Blood",23632886,"http://www.ncbi.nlm.nih.gov/pubmed/23632886",NULL,NULL,"2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
115,"EID115","DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",81,"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","Gaidzik et al., 2013, Blood",23632886,"http://www.ncbi.nlm.nih.gov/pubmed/23632886",NULL,NULL,"2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
116,"EID116","AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","A","Diagnostic","Supports","Positive","Somatic Mutation",86,5,NULL,"accepted",0,"evidence",19,"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","Vardiman et al., 2009, Blood",19357394,"http://www.ncbi.nlm.nih.gov/pubmed/19357394",NULL,NULL,"2009","7","30","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
117,"EID117","NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",86,2,NULL,"accepted",0,"evidence",116,"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.","Gale et al., 2008, Blood",17957027,"http://www.ncbi.nlm.nih.gov/pubmed/17957027",NULL,NULL,"2008","3","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
118,"EID118","NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",86,4,NULL,"accepted",0,"evidence",114,"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.","Schnittger et al., 2005, Blood",16076867,"http://www.ncbi.nlm.nih.gov/pubmed/16076867",NULL,NULL,"2005","12","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
119,"EID119","NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",113,"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).","Thiede et al., 2006, Blood",16455956,"http://www.ncbi.nlm.nih.gov/pubmed/16455956",NULL,NULL,"2006","5","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
120,"EID120","NPM1 mutations were associated with normal karyotype in older (>60) patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",117,"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.","Schlenk et al., 2009, Haematologica",19059939,"http://www.ncbi.nlm.nih.gov/pubmed/19059939","true","PMC2625424","2009","1",NULL,"Haematologica","Haematologica","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
121,"EID121","NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",87,4,NULL,"accepted",0,"evidence",68,"DNMT3A mutations in acute myeloid leukemia.","Ley et al., 2010, N. Engl. J. Med.",21067377,"http://www.ncbi.nlm.nih.gov/pubmed/21067377","true","PMC3201818","2010","12","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
122,"EID122","In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",29,3,NULL,"accepted",0,"evidence",118,"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.","Burnett et al., 2010, Blood",19965647,"http://www.ncbi.nlm.nih.gov/pubmed/19965647",NULL,NULL,"2010","2","4","Blood","Blood","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
123,"EID123","In chemotherapy-refractory patients with colorectal cancer, Exon 9 PIK3CA mutations (Exon 9) had no significant impact on response rate, disease control rate, progression free surivival or overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","N/A","Somatic Mutation",106,3,NULL,"accepted",0,"evidence",76,"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","De Roock et al., 2010, Lancet Oncol.",20619739,"http://www.ncbi.nlm.nih.gov/pubmed/20619739",NULL,NULL,"2010","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
124,"EID124","In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",94,3,NULL,"accepted",0,"evidence",76,"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","De Roock et al., 2010, Lancet Oncol.",20619739,"http://www.ncbi.nlm.nih.gov/pubmed/20619739",NULL,NULL,"2010","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
125,"EID125","Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",8,3,NULL,"accepted",0,"evidence",119,"Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.","Bresler et al., 2011, Sci Transl Med",22072639,"http://www.ncbi.nlm.nih.gov/pubmed/22072639","true","PMC3319004","2011","11","9","Sci Transl Med","Science translational medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
126,"EID126","Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",76,"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","De Roock et al., 2010, Lancet Oncol.",20619739,"http://www.ncbi.nlm.nih.gov/pubmed/20619739",NULL,NULL,"2010","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
127,"EID127","ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",120,"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.","Burnett et al., 2010, Blood",19965647,"http://www.ncbi.nlm.nih.gov/pubmed/19965647",NULL,NULL,"2010","2","4","Blood","Blood","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
128,"EID128","FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",116,"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.","Gale et al., 2008, Blood",17957027,"http://www.ncbi.nlm.nih.gov/pubmed/17957027",NULL,NULL,"2008","3","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
129,"EID129","Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",116,"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.","Gale et al., 2008, Blood",17957027,"http://www.ncbi.nlm.nih.gov/pubmed/17957027",NULL,NULL,"2008","3","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
130,"EID130","Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",121,"FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).","Bagrintseva et al., 2005, Blood",15626738,"http://www.ncbi.nlm.nih.gov/pubmed/15626738",NULL,NULL,"2005","5","1","Blood","Blood","fully curated","2","Daunorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
131,"EID131","Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",121,"FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).","Bagrintseva et al., 2005, Blood",15626738,"http://www.ncbi.nlm.nih.gov/pubmed/15626738",NULL,NULL,"2005","5","1","Blood","Blood","fully curated","35","SU5614",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
134,"EID134","Chemotherapy-refractory patients with colorectal cancer harboring KRAS mutations (primarily G12/G13) had lower response and disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",77,3,NULL,"accepted",0,"evidence",76,"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","De Roock et al., 2010, Lancet Oncol.",20619739,"http://www.ncbi.nlm.nih.gov/pubmed/20619739",NULL,NULL,"2010","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
135,"EID135","KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",77,3,NULL,"accepted",0,"evidence",122,"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.","LiÃ¨vre et al., 2008, J. Clin. Oncol.",18202412,"http://www.ncbi.nlm.nih.gov/pubmed/18202412",NULL,NULL,"2008","1","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
136,"EID136","Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",425,4,NULL,"accepted",0,"evidence",123,"Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.","De Roock et al., 2010, JAMA",20978259,"http://www.ncbi.nlm.nih.gov/pubmed/20978259",NULL,NULL,"2010","10","27","JAMA","JAMA","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
137,"EID137","ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",120,"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.","Burnett et al., 2010, Blood",19965647,"http://www.ncbi.nlm.nih.gov/pubmed/19965647",NULL,NULL,"2010","2","4","Blood","Blood","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
138,"EID138","Chemotherapy-refractory patients with colorectal cancer harboring Exon 20 PIK3CA mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",105,3,NULL,"accepted",0,"evidence",76,"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","De Roock et al., 2010, Lancet Oncol.",20619739,"http://www.ncbi.nlm.nih.gov/pubmed/20619739",NULL,NULL,"2010","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
139,"EID139","WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",129,3,"Combination","accepted",0,"evidence",124,"Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.","Virappane et al., 2008, J. Clin. Oncol.",18591546,"http://www.ncbi.nlm.nih.gov/pubmed/18591546",NULL,NULL,"2008","11","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","173","Cytarabine",NULL,"2","Daunorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
141,"EID141","CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or EML4-ALK with the L1196M mutation.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",7,3,NULL,"accepted",0,"evidence",77,"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.","Sakamoto et al., 2011, Cancer Cell",21575866,"http://www.ncbi.nlm.nih.gov/pubmed/21575866",NULL,NULL,"2011","5","17","Cancer Cell","Cancer cell","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
142,"EID142","SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",8,4,NULL,"accepted",0,"evidence",79,"Activating mutations in ALK provide a therapeutic target in neuroblastoma.","George et al., 2008, Nature",18923525,"http://www.ncbi.nlm.nih.gov/pubmed/18923525","true","PMC2587486","2008","10","16","Nature","Nature","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
143,"EID143","Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",9,3,NULL,"accepted",0,"evidence",119,"Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.","Bresler et al., 2011, Sci Transl Med",22072639,"http://www.ncbi.nlm.nih.gov/pubmed/22072639","true","PMC3319004","2011","11","9","Sci Transl Med","Science translational medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
144,"EID144","Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and increased cellular proliferation consistent with FGFR activation. Mouse xenografts using the bladder cell line SW780 which harbors an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR inhibitor PD173074.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","D","Predictive","Supports","Sensitivity","Somatic Mutation",53,3,NULL,"accepted",0,"evidence",125,"Identification of targetable FGFR gene fusions in diverse cancers.","Wu et al., 2013, Cancer Discov",23558953,"http://www.ncbi.nlm.nih.gov/pubmed/23558953","true","PMC3694764","2013","6",NULL,"Cancer Discov","Cancer discovery","fully curated","36","PD173074",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
145,"EID145","Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",81,4,NULL,"accepted",0,"evidence",123,"Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.","De Roock et al., 2010, JAMA",20978259,"http://www.ncbi.nlm.nih.gov/pubmed/20978259",NULL,NULL,"2010","10","27","JAMA","JAMA","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
146,"EID146","ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",86,2,NULL,"accepted",0,"evidence",117,"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.","Schlenk et al., 2009, Haematologica",19059939,"http://www.ncbi.nlm.nih.gov/pubmed/19059939","true","PMC2625424","2009","1",NULL,"Haematologica","Haematologica","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
147,"EID147","Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",86,2,NULL,"accepted",0,"evidence",126,"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.","Patel et al., 2012, N. Engl. J. Med.",22417203,"http://www.ncbi.nlm.nih.gov/pubmed/22417203","true","PMC3545649","2012","3","22","N. Engl. J. Med.","The New England journal of medicine","fully curated","2","Daunorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
148,"EID148","For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",86,2,NULL,"accepted",0,"evidence",127,"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.","Tassara et al., 2014, Blood",24797300,"http://www.ncbi.nlm.nih.gov/pubmed/24797300",NULL,NULL,"2014","6","26","Blood","Blood","fully curated","37","Valproic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
149,"EID149","NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Sensitivity","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",128,"Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.","Balusu et al., 2011, Blood",21719597,"http://www.ncbi.nlm.nih.gov/pubmed/21719597",NULL,NULL,"2011","9","15","Blood","Blood","fully curated","265","All-trans Retinoic Acid",NULL,"38","NSC348884",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
150,"EID150","CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","E","Predictive","Supports","Sensitivity","Somatic Mutation",86,2,"Combination","accepted",0,"evidence",129,"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.","Ehninger et al., 2014, Blood Cancer J",24927407,"http://www.ncbi.nlm.nih.gov/pubmed/24927407","true","PMC4080210","2014",NULL,NULL,"Blood Cancer J","Blood cancer journal","fully curated","269","Anti-CD123",NULL,"268","Anti-CD33",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
151,"EID151","CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","E","Predictive","Supports","Sensitivity","Somatic Mutation",86,2,NULL,"accepted",0,"evidence",129,"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.","Ehninger et al., 2014, Blood Cancer J",24927407,"http://www.ncbi.nlm.nih.gov/pubmed/24927407","true","PMC4080210","2014",NULL,NULL,"Blood Cancer J","Blood cancer journal","fully curated","268","Anti-CD33",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
152,"EID152","NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Sensitivity","Somatic Mutation",87,3,NULL,"accepted",0,"evidence",128,"Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.","Balusu et al., 2011, Blood",21719597,"http://www.ncbi.nlm.nih.gov/pubmed/21719597",NULL,NULL,"2011","9","15","Blood","Blood","fully curated","38","NSC348884",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
153,"EID153","NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","E","Predictive","Supports","Sensitivity","Somatic Mutation",87,3,NULL,"accepted",0,"evidence",130,"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.","Falini et al., 2005, N. Engl. J. Med.",15659725,"http://www.ncbi.nlm.nih.gov/pubmed/15659725",NULL,NULL,"2005","1","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","39","Induction Therapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
154,"EID154","Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",124,3,NULL,"accepted",0,"evidence",131,"TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.","Liang et al., 2010, Oncogene",19966866,"http://www.ncbi.nlm.nih.gov/pubmed/19966866","true","PMC2841700","2010","3","18","Oncogene","Oncogene","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
155,"EID155","Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","B","Predictive","Supports","Sensitivity","Somatic Mutation",125,3,NULL,"accepted",0,"evidence",132,"Genome sequencing identifies a basis for everolimus sensitivity.","Iyer et al., 2012, Science",22923433,"http://www.ncbi.nlm.nih.gov/pubmed/22923433","true","PMC3633467","2012","10","12","Science","Science (New York, N.Y.)","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
156,"EID156","FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 mutations (8 FLT3-ITD, 2 FLT3-D835).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",519,2,NULL,"accepted",0,"evidence",133,"CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.","FrÃ¶hling et al., 2004, J. Clin. Oncol.",14726504,"http://www.ncbi.nlm.nih.gov/pubmed/14726504",NULL,NULL,"2004","2","15","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
157,"EID157","Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",86,"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.","Marcucci et al., 2012, J. Clin. Oncol.",22291079,"http://www.ncbi.nlm.nih.gov/pubmed/22291079","true","PMC3295550","2012","3","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
158,"EID158","FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",134,"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.","Schnittger et al., 2011, Leukemia",21537333,"http://www.ncbi.nlm.nih.gov/pubmed/21537333",NULL,NULL,"2011","8",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
159,"EID159","Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",55,2,NULL,"accepted",0,"evidence",116,"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.","Gale et al., 2008, Blood",17957027,"http://www.ncbi.nlm.nih.gov/pubmed/17957027",NULL,NULL,"2008","3","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
160,"EID160","Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",58,3,NULL,"accepted",0,"evidence",135,"IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.","Schnittger et al., 2010, Blood",20805365,"http://www.ncbi.nlm.nih.gov/pubmed/20805365",NULL,NULL,"2010","12","16","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
162,"EID162","No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",129,3,NULL,"accepted",0,"evidence",136,"Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.","Gaidzik et al., 2009, Blood",19221039,"http://www.ncbi.nlm.nih.gov/pubmed/19221039",NULL,NULL,"2009","5","7","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
163,"EID163","Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",129,4,NULL,"accepted",0,"evidence",136,"Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.","Gaidzik et al., 2009, Blood",19221039,"http://www.ncbi.nlm.nih.gov/pubmed/19221039",NULL,NULL,"2009","5","7","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
165,"EID165","Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",130,4,NULL,"accepted",0,"evidence",136,"Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.","Gaidzik et al., 2009, Blood",19221039,"http://www.ncbi.nlm.nih.gov/pubmed/19221039",NULL,NULL,"2009","5","7","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
166,"EID166","In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall survival (36% vs 31%; P = .04) than those with wildtype CEBPA.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",29,3,NULL,"accepted",0,"evidence",118,"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.","Burnett et al., 2010, Blood",19965647,"http://www.ncbi.nlm.nih.gov/pubmed/19965647",NULL,NULL,"2010","2","4","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
167,"EID167","In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (odds ratio, 1.33; 95% confidence interval [CI], 1.01 to 1.74). Multivariate analysis was performed on all patients  that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. Only 509 patients in the study were evaluated for CEBPA, 67 of which had a mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",29,4,NULL,"accepted",0,"evidence",137,"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.","Schlenk et al., 2008, N. Engl. J. Med.",18450602,"http://www.ncbi.nlm.nih.gov/pubmed/18450602",NULL,NULL,"2008","5","1","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
168,"EID168","Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",29,3,NULL,"accepted",0,"evidence",133,"CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.","FrÃ¶hling et al., 2004, J. Clin. Oncol.",14726504,"http://www.ncbi.nlm.nih.gov/pubmed/14726504",NULL,NULL,"2004","2","15","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
170,"EID170","DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",81,"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","Gaidzik et al., 2013, Blood",23632886,"http://www.ncbi.nlm.nih.gov/pubmed/23632886",NULL,NULL,"2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
171,"EID171","Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",56,3,NULL,"accepted",0,"evidence",138,"Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.","Bacher et al., 2008, Blood",17965322,"http://www.ncbi.nlm.nih.gov/pubmed/17965322",NULL,NULL,"2008","3","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
172,"EID172","MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Prognostic","Supports","Better Outcome","Somatic Mutation",85,4,NULL,"accepted",0,"evidence",139,"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.","Esteller et al., 2000, N. Engl. J. Med.",11070098,"http://www.ncbi.nlm.nih.gov/pubmed/11070098",NULL,NULL,"2000","11","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
173,"EID173","NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,4,NULL,"accepted",0,"evidence",116,"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.","Gale et al., 2008, Blood",17957027,"http://www.ncbi.nlm.nih.gov/pubmed/17957027",NULL,NULL,"2008","3","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
174,"EID174","Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",117,"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.","Schlenk et al., 2009, Haematologica",19059939,"http://www.ncbi.nlm.nih.gov/pubmed/19059939","true","PMC2625424","2009","1",NULL,"Haematologica","Haematologica","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
175,"EID175","Complete remission rates were higher (P<0.001) and both disease-free survival (N=205 vs 352, P=0.041) and overall survival (N=372 vs 956, P=0.022) were longer for AML patients with Exon 12 NPM1 mutations (irrespective of FLT3 status) than those with wildtype NPM1. Improved CR rates were also higher for those with NPM1 exon 12 mutations and normal karyotype. In multivariate analysis, NPM1 mutation alone (FLT3 wildtype) was associated with improved overall survival (but not DFS) in the entire cohort and in normal karyotype patients <60 years old.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",113,"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).","Thiede et al., 2006, Blood",16455956,"http://www.ncbi.nlm.nih.gov/pubmed/16455956",NULL,NULL,"2006","5","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
176,"EID176","Complete remission rates were higher (70.5% vs 54.7%, P = 0.003) and event-free survival was longer (median, 428 vs 336 days; P = 0.012) for normal karyotype AML patients (median age 60.3 years) with Exon 12 NPM1 mutations (N=212) compared to those with wildtype NPM1 (N=189).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,5,NULL,"accepted",0,"evidence",114,"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.","Schnittger et al., 2005, Blood",16076867,"http://www.ncbi.nlm.nih.gov/pubmed/16076867",NULL,NULL,"2005","12","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
177,"EID177","Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",130,"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.","Falini et al., 2005, N. Engl. J. Med.",15659725,"http://www.ncbi.nlm.nih.gov/pubmed/15659725",NULL,NULL,"2005","1","20","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
179,"EID179","Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,2,NULL,"accepted",0,"evidence",126,"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.","Patel et al., 2012, N. Engl. J. Med.",22417203,"http://www.ncbi.nlm.nih.gov/pubmed/22417203","true","PMC3545649","2012","3","22","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
180,"EID180","Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",140,"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.","BÃ¼chner et al., 2009, J. Clin. Oncol.",19047294,"http://www.ncbi.nlm.nih.gov/pubmed/19047294",NULL,NULL,"2009","1","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
181,"EID181","NPM1 mutation (N=724) was associated with higher complete remission rates (92% vs 82%; P < 0.0001), lower cumulative incidence of relapse (42% vs 58%; P < 0.0001) and higher overall survival (48% vs 27%; P < .0001) than NPM1 wildtype status (N=885) in intermediate risk, young adult AML patients (median age 46 years).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,4,NULL,"accepted",0,"evidence",141,"Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.","Linch et al., 2014, Blood",24855211,"http://www.ncbi.nlm.nih.gov/pubmed/24855211",NULL,NULL,"2014","7","10","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
182,"EID182","NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",142,"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.","Gaidzik et al., 2012, J. Clin. Oncol.",22430270,"http://www.ncbi.nlm.nih.gov/pubmed/22430270",NULL,NULL,"2012","4","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
183,"EID183","In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, NPM1 mutation without FLT3-ITD was significantly associated with complete remission in multivariate analysis (odds ratio, 1.48; 95% CI, 1.21 to 1.80). Multivariate analysis was performed on all patients that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. 130 patients had NPM1 mutations without FLT3-ITD. NPM1 mutations were evaluated in 570 patients (310 mutated).  FLT3-ITD was evaluated in 531 patients (164 mutated).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",137,"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.","Schlenk et al., 2008, N. Engl. J. Med.",18450602,"http://www.ncbi.nlm.nih.gov/pubmed/18450602",NULL,NULL,"2008","5","1","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
184,"EID184","NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,4,NULL,"accepted",0,"evidence",143,"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.","Becker et al., 2010, J. Clin. Oncol.",20026798,"http://www.ncbi.nlm.nih.gov/pubmed/20026798","true","PMC2815994","2010","2","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
185,"EID185","Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival (N=74, P = .001), relapse-free survival (N=86, P < .001) and response to induction chemotherapy. Multivariate analysis identified NPM1 mutation in the absence of FLT3-ITD as a prognostic marker for the achievement of CR (P=0.004).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",144,"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.","DÃ¶hner et al., 2005, Blood",16051734,"http://www.ncbi.nlm.nih.gov/pubmed/16051734",NULL,NULL,"2005","12","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
186,"EID186","Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",54,"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.","Ribeiro et al., 2012, Blood",22490330,"http://www.ncbi.nlm.nih.gov/pubmed/22490330",NULL,NULL,"2012","6","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
187,"EID187","DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,4,NULL,"accepted",0,"evidence",86,"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.","Marcucci et al., 2012, J. Clin. Oncol.",22291079,"http://www.ncbi.nlm.nih.gov/pubmed/22291079","true","PMC3295550","2012","3","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
188,"EID188","Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",189,3,NULL,"accepted",0,"evidence",54,"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.","Ribeiro et al., 2012, Blood",22490330,"http://www.ncbi.nlm.nih.gov/pubmed/22490330",NULL,NULL,"2012","6","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
189,"EID189","Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",32,3,NULL,"accepted",0,"evidence",54,"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.","Ribeiro et al., 2012, Blood",22490330,"http://www.ncbi.nlm.nih.gov/pubmed/22490330",NULL,NULL,"2012","6","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
190,"EID190","Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","A","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",145,"Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.","Port et al., 2014, Ann. Hematol.",24801015,"http://www.ncbi.nlm.nih.gov/pubmed/24801015",NULL,NULL,"2014","8",NULL,"Ann. Hematol.","Annals of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
191,"EID191","A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",134,"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.","Schnittger et al., 2011, Leukemia",21537333,"http://www.ncbi.nlm.nih.gov/pubmed/21537333",NULL,NULL,"2011","8",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
192,"EID192","Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",134,"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.","Schnittger et al., 2011, Leukemia",21537333,"http://www.ncbi.nlm.nih.gov/pubmed/21537333",NULL,NULL,"2011","8",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
193,"EID193","Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",134,"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.","Schnittger et al., 2011, Leukemia",21537333,"http://www.ncbi.nlm.nih.gov/pubmed/21537333",NULL,NULL,"2011","8",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
194,"EID194","KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Prognostic","Supports","Poor Outcome","Somatic Mutation",77,3,NULL,"accepted",0,"evidence",122,"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.","LiÃ¨vre et al., 2008, J. Clin. Oncol.",18202412,"http://www.ncbi.nlm.nih.gov/pubmed/18202412",NULL,NULL,"2008","1","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
195,"EID195","Coocurrence of FLT3-ITD mutations significantly reduced overall (N=74 vs 95, P=0.003) and disease-free survival (N=43 vs 67, P=0.02) of normal karyotype AML patients (<60 years old) compared to patients with NPM1 mutations alone.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",113,"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).","Thiede et al., 2006, Blood",16455956,"http://www.ncbi.nlm.nih.gov/pubmed/16455956",NULL,NULL,"2006","5","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
196,"EID196","Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",86,2,NULL,"accepted",0,"evidence",146,"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.","Schnittger et al., 2009, Blood",19587375,"http://www.ncbi.nlm.nih.gov/pubmed/19587375",NULL,NULL,"2009","9","10","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
198,"EID198","Patients with NPM1 mutations and low (<25%, N=63), intermediate (25-50%, N=156) or high (>50%, N=66) levels of FLT3-ITD have worse overall survival (P<0.0001 for trend) and cumulative incidence of relapse (P<0.001) than those with NPM1 mutations alone (N=387) in young adult, intermediate risk AML patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",141,"Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.","Linch et al., 2014, Blood",24855211,"http://www.ncbi.nlm.nih.gov/pubmed/24855211",NULL,NULL,"2014","7","10","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
199,"EID199","TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",147,"TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.","Tian et al., 2014, Int. J. Hematol.",24859829,"http://www.ncbi.nlm.nih.gov/pubmed/24859829",NULL,NULL,"2014","7",NULL,"Int. J. Hematol.","International journal of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
201,"EID201","Mutations  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",129,2,NULL,"accepted",0,"evidence",148,"Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.","Renneville et al., 2009, Cancer",19536888,"http://www.ncbi.nlm.nih.gov/pubmed/19536888",NULL,NULL,"2009","8","15","Cancer","Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
202,"EID202","Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",129,2,NULL,"accepted",0,"evidence",148,"Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.","Renneville et al., 2009, Cancer",19536888,"http://www.ncbi.nlm.nih.gov/pubmed/19536888",NULL,NULL,"2009","8","15","Cancer","Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
203,"EID203","Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",129,3,NULL,"accepted",0,"evidence",136,"Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.","Gaidzik et al., 2009, Blood",19221039,"http://www.ncbi.nlm.nih.gov/pubmed/19221039",NULL,NULL,"2009","5","7","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
204,"EID204","WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",129,3,NULL,"accepted",0,"evidence",149,"Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.","Paschka et al., 2008, J. Clin. Oncol.",18559874,"http://www.ncbi.nlm.nih.gov/pubmed/18559874","true","PMC2653131","2008","10","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
205,"EID205","WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",129,3,NULL,"accepted",0,"evidence",124,"Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.","Virappane et al., 2008, J. Clin. Oncol.",18591546,"http://www.ncbi.nlm.nih.gov/pubmed/18591546",NULL,NULL,"2008","11","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
206,"EID206","WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",129,3,NULL,"accepted",0,"evidence",124,"Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.","Virappane et al., 2008, J. Clin. Oncol.",18591546,"http://www.ncbi.nlm.nih.gov/pubmed/18591546",NULL,NULL,"2008","11","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
210,"EID210","WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",130,3,NULL,"accepted",0,"evidence",149,"Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.","Paschka et al., 2008, J. Clin. Oncol.",18559874,"http://www.ncbi.nlm.nih.gov/pubmed/18559874","true","PMC2653131","2008","10","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
211,"EID211","The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Germline Mutation",131,4,NULL,"accepted",0,"evidence",150,"Advanced ovarian cancer: what should be the standard of care?","Goff, 2013, J Gynecol Oncol",23346317,"http://www.ncbi.nlm.nih.gov/pubmed/23346317","true","PMC3549512","2013","1",NULL,"J Gynecol Oncol","Journal of gynecologic oncology","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
212,"EID212","The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Germline Mutation",132,4,NULL,"accepted",0,"evidence",150,"Advanced ovarian cancer: what should be the standard of care?","Goff, 2013, J Gynecol Oncol",23346317,"http://www.ncbi.nlm.nih.gov/pubmed/23346317","true","PMC3549512","2013","1",NULL,"J Gynecol Oncol","Journal of gynecologic oncology","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
213,"EID213","Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","C","Diagnostic","Does Not Support","Positive","Somatic Mutation",1,2,NULL,"accepted",0,"evidence",151,"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.","Schmidt et al., 2014, Leukemia",25212276,"http://www.ncbi.nlm.nih.gov/pubmed/25212276",NULL,NULL,"2014","12",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
214,"EID214","WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Does Not Support","Positive","Somatic Mutation",56,3,NULL,"accepted",0,"evidence",152,"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.","Yamamoto et al., 2001, Blood",11290608,"http://www.ncbi.nlm.nih.gov/pubmed/11290608",NULL,NULL,"2001","4","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
215,"EID215","KRAS mutations in lung cancer patients are not associated with smoking history, age or gender.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Diagnostic","Does Not Support","Positive","Somatic Mutation",76,3,NULL,"accepted",0,"evidence",153,"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.","Riely et al., 2008, Clin. Cancer Res.",18794081,"http://www.ncbi.nlm.nih.gov/pubmed/18794081","true","PMC2754127","2008","9","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
217,"EID217","Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Does Not Support","Positive","Somatic Mutation",127,3,NULL,"accepted",0,"evidence",154,"U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.","Qian et al., 2012, PLoS ONE",23029227,"http://www.ncbi.nlm.nih.gov/pubmed/23029227","true","PMC3446943","2012",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
218,"EID218","Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Does Not Support","Positive","Somatic Mutation",128,3,NULL,"accepted",0,"evidence",154,"U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.","Qian et al., 2012, PLoS ONE",23029227,"http://www.ncbi.nlm.nih.gov/pubmed/23029227","true","PMC3446943","2012",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
219,"EID219","CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","D","Diagnostic","Supports","Negative","Somatic Mutation",22,3,NULL,"accepted",0,"evidence",155,"Promoter methylation of cyclin D2 gene in gastric carcinoma.","Oshimo et al., 2003, Int. J. Oncol.",14612939,"http://www.ncbi.nlm.nih.gov/pubmed/14612939",NULL,NULL,"2003","12",NULL,"Int. J. Oncol.","International journal of oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
220,"EID220","The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","A","Diagnostic","Supports","Positive","Somatic Mutation",1,4,NULL,"accepted",0,"evidence",156,"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.","An et al., 2010, Leuk. Res.",20537386,"http://www.ncbi.nlm.nih.gov/pubmed/20537386",NULL,NULL,"2010","10",NULL,"Leuk. Res.","Leukemia research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
221,"EID221","Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Diagnostic","Supports","Positive","Somatic Mutation",20,4,NULL,"accepted",0,"evidence",157,"Cyclin D1 in breast cancer pathogenesis.","Arnold et al., 2005, J. Clin. Oncol.",15961768,"http://www.ncbi.nlm.nih.gov/pubmed/15961768",NULL,NULL,"2005","6","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
222,"EID222","WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",152,"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.","Yamamoto et al., 2001, Blood",11290608,"http://www.ncbi.nlm.nih.gov/pubmed/11290608",NULL,NULL,"2001","4","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
223,"EID223","In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",58,2,NULL,"accepted",0,"evidence",158,"Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.","Ho et al., 2010, Leukemia",20376086,"http://www.ncbi.nlm.nih.gov/pubmed/20376086","true","PMC2945692","2010","5",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
224,"EID224","IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",59,3,NULL,"accepted",0,"evidence",159,"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.","Abbas et al., 2010, Blood",20538800,"http://www.ncbi.nlm.nih.gov/pubmed/20538800",NULL,NULL,"2010","9","23","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
225,"EID225","KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Diagnostic","Supports","Positive","Somatic Mutation",66,2,NULL,"accepted",0,"evidence",160,"Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.","Taniguchi et al., 1999, Cancer Res.",10485475,"http://www.ncbi.nlm.nih.gov/pubmed/10485475",NULL,NULL,"1999","9","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
227,"EID227","KRAS G12C occur more frequently in women than men.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","B","Diagnostic","Supports","Positive","Somatic Mutation",78,2,NULL,"accepted",0,"evidence",161,"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.","Dogan et al., 2012, Clin. Cancer Res.",23014527,"http://www.ncbi.nlm.nih.gov/pubmed/23014527","true","PMC3500422","2012","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
228,"EID228","KRAS G12D mutation occurs in never smokers significantly more often than in smokers.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","B","Diagnostic","Supports","Positive","Somatic Mutation",79,3,NULL,"accepted",0,"evidence",161,"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.","Dogan et al., 2012, Clin. Cancer Res.",23014527,"http://www.ncbi.nlm.nih.gov/pubmed/23014527","true","PMC3500422","2012","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
229,"EID229","There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib in the EGFR L858R setting.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Does Not Support","N/A","Somatic Mutation",33,3,NULL,"accepted",0,"evidence",162,"Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.","Lim et al., 2014, J Thorac Oncol",24736073,"http://www.ncbi.nlm.nih.gov/pubmed/24736073",NULL,NULL,"2014","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","15","Erlotinib",NULL,"14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
231,"EID231","Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",4,3,NULL,"accepted",0,"evidence",163,"PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.","Beaver et al., 2013, Clin. Cancer Res.",23888070,"http://www.ncbi.nlm.nih.gov/pubmed/23888070","true","PMC3805128","2013","10","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","43","MK-2206",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
232,"EID232","BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",1,3,NULL,"accepted",0,"evidence",164,"Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.","Nimmanapalli et al., 2002, Oncogene",12476305,"http://www.ncbi.nlm.nih.gov/pubmed/12476305",NULL,NULL,"2002","12","9","Oncogene","Oncogene","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
233,"EID233","COS7 cell lines transfected with BCR-ABL constructs harboring E255K mutations were shown to be resistant to imatinib and exhibited increased kinase activity.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",3,4,NULL,"accepted",0,"evidence",165,"The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.","Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.",15194504,"http://www.ncbi.nlm.nih.gov/pubmed/15194504",NULL,NULL,"2004","7","9","Biochem. Biophys. Res. Commun.","Biochemical and biophysical research communications","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
234,"EID234","In chronic myeloid leukemia patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",2,4,NULL,"accepted",0,"evidence",156,"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.","An et al., 2010, Leuk. Res.",20537386,"http://www.ncbi.nlm.nih.gov/pubmed/20537386",NULL,NULL,"2010","10",NULL,"Leuk. Res.","Leukemia research","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
235,"EID235","COS7 cell lines transfected with BCR-ABL constructs harboring T315I mutations were shown to be resistant to imatinib and exhibited increased kinase activity.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",2,4,NULL,"accepted",0,"evidence",165,"The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.","Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.",15194504,"http://www.ncbi.nlm.nih.gov/pubmed/15194504",NULL,NULL,"2004","7","9","Biochem. Biophys. Res. Commun.","Biochemical and biophysical research communications","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
236,"EID236","A 28 year old patient with T4N3M1 stage lung adenocarcinoma harboring an EML4-ALK variant 1 fusion was treated with crizotinib after failing conventional therapy. The patient achieved a partial response but progressed after 5 months of treatment. Molecular analysis at this time identified two missense mutations in ALK C1156Y and L1196M. Ba/F3 cells expressing EML4-ALK L1196M or EML4-ALK C1156Y were more resistant to crizontinib treatment than those expressing EML4-ALK wildtype.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",608,4,NULL,"accepted",0,"evidence",166,"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.","Choi et al., 2010, N. Engl. J. Med.",20979473,"http://www.ncbi.nlm.nih.gov/pubmed/20979473",NULL,NULL,"2010","10","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
237,"EID237","In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",7,4,NULL,"accepted",0,"evidence",166,"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.","Choi et al., 2010, N. Engl. J. Med.",20979473,"http://www.ncbi.nlm.nih.gov/pubmed/20979473",NULL,NULL,"2010","10","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
238,"EID238","The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","A","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",34,5,NULL,"accepted",0,"evidence",167,"EGFR T790M resistance mutation in non small-cell lung carcinoma.","Denis et al., 2015, Clin. Chim. Acta",25668228,"http://www.ncbi.nlm.nih.gov/pubmed/25668228",NULL,NULL,"2015","4","15","Clin. Chim. Acta","Clinica chimica acta; international journal of clinical chemistry","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
239,"EID239","In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",34,3,NULL,"accepted",0,"evidence",168,"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.","Kobayashi et al., 2005, N. Engl. J. Med.",15728811,"http://www.ncbi.nlm.nih.gov/pubmed/15728811",NULL,NULL,"2005","2","24","N. Engl. J. Med.","The New England journal of medicine","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
240,"EID240","In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",34,4,NULL,"accepted",0,"evidence",169,"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.","Sequist et al., 2011, Sci Transl Med",21430269,"http://www.ncbi.nlm.nih.gov/pubmed/21430269","true","PMC3132801","2011","3","23","Sci Transl Med","Science translational medicine","fully curated","44","Dacomitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
241,"EID241","The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",39,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
242,"EID242","MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",46,3,NULL,"accepted",0,"evidence",171,"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.","Toy et al., 2013, Nat. Genet.",24185512,"http://www.ncbi.nlm.nih.gov/pubmed/24185512","true","PMC3903423","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","46","Hormone Therapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
243,"EID243","MCF7 cell lines harboring the N538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",47,3,NULL,"accepted",0,"evidence",171,"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.","Toy et al., 2013, Nat. Genet.",24185512,"http://www.ncbi.nlm.nih.gov/pubmed/24185512","true","PMC3903423","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","46","Hormone Therapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
244,"EID244","MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",48,3,NULL,"accepted",0,"evidence",171,"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.","Toy et al., 2013, Nat. Genet.",24185512,"http://www.ncbi.nlm.nih.gov/pubmed/24185512","true","PMC3903423","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","46","Hormone Therapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
245,"EID245","MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",49,3,NULL,"accepted",0,"evidence",171,"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.","Toy et al., 2013, Nat. Genet.",24185512,"http://www.ncbi.nlm.nih.gov/pubmed/24185512","true","PMC3903423","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","46","Hormone Therapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
246,"EID246","MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",50,3,NULL,"accepted",0,"evidence",171,"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.","Toy et al., 2013, Nat. Genet.",24185512,"http://www.ncbi.nlm.nih.gov/pubmed/24185512","true","PMC3903423","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","46","Hormone Therapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
247,"EID247","Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",56,4,NULL,"accepted",0,"evidence",172,"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.","Man et al., 2012, Blood",22368270,"http://www.ncbi.nlm.nih.gov/pubmed/22368270",NULL,NULL,"2012","5","31","Blood","Blood","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
248,"EID248","Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",56,4,NULL,"accepted",0,"evidence",173,"Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.","Zhang et al., 2008, J. Natl. Cancer Inst.",18230792,"http://www.ncbi.nlm.nih.gov/pubmed/18230792",NULL,NULL,"2008","2","6","J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
249,"EID249","KIT V654A results in imatinib resistance in GIST patient-derived cell lines.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",73,3,NULL,"accepted",0,"evidence",62,"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.","Heinrich et al., 2006, J. Clin. Oncol.",16954519,"http://www.ncbi.nlm.nih.gov/pubmed/16954519",NULL,NULL,"2006","10","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
250,"EID250","Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",75,3,NULL,"accepted",0,"evidence",174,"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.","LiÃ¨vre et al., 2006, Cancer Res.",16618717,"http://www.ncbi.nlm.nih.gov/pubmed/16618717",NULL,NULL,"2006","4","15","Cancer Res.","Cancer research","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
251,"EID251","KRAS G12 mutations were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",148,3,NULL,"accepted",0,"evidence",175,"Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.","Marchetti et al., 2009, Neoplasia",19794967,"http://www.ncbi.nlm.nih.gov/pubmed/19794967","true","PMC2745674","2009","10",NULL,"Neoplasia","Neoplasia (New York, N.Y.)","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
256,"EID256","The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20 were associated with lack of panitumumab or cetuximab response.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",103,3,NULL,"accepted",0,"evidence",176,"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.","Sartore-Bianchi et al., 2009, Cancer Res.",19223544,"http://www.ncbi.nlm.nih.gov/pubmed/19223544",NULL,NULL,"2009","3","1","Cancer Res.","Cancer research","fully curated","28","Panitumumab",NULL,"16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
258,"EID258","The presence of a PIK3CA mutation in exon 9 or exon 20 (such as H1047R) were associated with lack of panitumumab or cetuximab response.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",107,3,NULL,"accepted",0,"evidence",176,"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.","Sartore-Bianchi et al., 2009, Cancer Res.",19223544,"http://www.ncbi.nlm.nih.gov/pubmed/19223544",NULL,NULL,"2009","3","1","Cancer Res.","Cancer research","fully curated","16","Cetuximab",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
259,"EID259","Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","A","Predictive","Supports","Sensitivity","Somatic Mutation",1,5,NULL,"accepted",0,"evidence",164,"Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.","Nimmanapalli et al., 2002, Oncogene",12476305,"http://www.ncbi.nlm.nih.gov/pubmed/12476305",NULL,NULL,"2002","12","9","Oncogene","Oncogene","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
260,"EID260","The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","A","Predictive","Supports","Sensitivity","Somatic Mutation",1,5,NULL,"accepted",0,"evidence",156,"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.","An et al., 2010, Leuk. Res.",20537386,"http://www.ncbi.nlm.nih.gov/pubmed/20537386",NULL,NULL,"2010","10",NULL,"Leuk. Res.","Leukemia research","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
261,"EID261","The use of second-generation BCR-ABL targeted therapies has been effective in patients resistant to imatinib.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Predictive","Supports","Sensitivity","Somatic Mutation",1,4,NULL,"accepted",0,"evidence",156,"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.","An et al., 2010, Leuk. Res.",20537386,"http://www.ncbi.nlm.nih.gov/pubmed/20537386",NULL,NULL,"2010","10",NULL,"Leuk. Res.","Leukemia research","fully curated","20","Dasatinib",NULL,"13","Nilotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
262,"EID262","In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective in acheiving stable disease.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",5,4,NULL,"accepted",0,"evidence",166,"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.","Choi et al., 2010, N. Engl. J. Med.",20979473,"http://www.ncbi.nlm.nih.gov/pubmed/20979473",NULL,NULL,"2010","10","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
263,"EID263","Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.",27,"T-cell Leukemia","T-cell Leukemia",715,"http://www.disease-ontology.org/?id=DOID:715","D","Predictive","Supports","Sensitivity","Somatic Mutation",23,3,NULL,"accepted",0,"evidence",177,"Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.","Sawai et al., 2012, Cancer Cell",23079656,"http://www.ncbi.nlm.nih.gov/pubmed/23079656","true","PMC3493168","2012","10","16","Cancer Cell","Cancer cell","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
264,"EID264","In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions.",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","D","Predictive","Supports","Sensitivity","Somatic Mutation",25,4,NULL,"accepted",0,"evidence",178,"CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.","Vora et al., 2014, Cancer Cell",25002028,"http://www.ncbi.nlm.nih.gov/pubmed/25002028","true","PMC4155598","2014","7","14","Cancer Cell","Cancer cell","fully curated","339","BYL719 (Alpelisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
266,"EID266","In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",141,4,NULL,"accepted",0,"evidence",179,"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.","Hammerman et al., 2011, Cancer Discov",22328973,"http://www.ncbi.nlm.nih.gov/pubmed/22328973","true","PMC3274752","2011","6",NULL,"Cancer Discov","Cancer discovery","fully curated","20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
267,"EID267","In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",142,4,NULL,"accepted",0,"evidence",179,"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.","Hammerman et al., 2011, Cancer Discov",22328973,"http://www.ncbi.nlm.nih.gov/pubmed/22328973","true","PMC3274752","2011","6",NULL,"Cancer Discov","Cancer discovery","fully curated","20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
268,"EID268","In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",144,4,NULL,"accepted",0,"evidence",179,"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.","Hammerman et al., 2011, Cancer Discov",22328973,"http://www.ncbi.nlm.nih.gov/pubmed/22328973","true","PMC3274752","2011","6",NULL,"Cancer Discov","Cancer discovery","fully curated","20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
269,"EID269","In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",143,4,NULL,"accepted",0,"evidence",179,"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.","Hammerman et al., 2011, Cancer Discov",22328973,"http://www.ncbi.nlm.nih.gov/pubmed/22328973","true","PMC3274752","2011","6",NULL,"Cancer Discov","Cancer discovery","fully curated","20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
270,"EID270","In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",140,4,NULL,"accepted",0,"evidence",179,"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.","Hammerman et al., 2011, Cancer Discov",22328973,"http://www.ncbi.nlm.nih.gov/pubmed/22328973","true","PMC3274752","2011","6",NULL,"Cancer Discov","Cancer discovery","fully curated","20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
271,"EID271","In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",139,4,NULL,"accepted",0,"evidence",179,"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.","Hammerman et al., 2011, Cancer Discov",22328973,"http://www.ncbi.nlm.nih.gov/pubmed/22328973","true","PMC3274752","2011","6",NULL,"Cancer Discov","Cancer discovery","fully curated","20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
272,"EID272","In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",145,3,NULL,"accepted",0,"evidence",179,"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.","Hammerman et al., 2011, Cancer Discov",22328973,"http://www.ncbi.nlm.nih.gov/pubmed/22328973","true","PMC3274752","2011","6",NULL,"Cancer Discov","Cancer discovery","fully curated","20","Dasatinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
273,"EID273","Exon 19 deletion has been shown to be correlated with gefitinib response.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",133,4,NULL,"accepted",0,"evidence",180,"The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.","Ji et al., 2006, Cancer Cell",16730237,"http://www.ncbi.nlm.nih.gov/pubmed/16730237",NULL,NULL,"2006","6",NULL,"Cancer Cell","Cancer cell","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
274,"EID274","Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",134,4,NULL,"accepted",0,"evidence",181,"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.","Paez et al., 2004, Science",15118125,"http://www.ncbi.nlm.nih.gov/pubmed/15118125",NULL,NULL,"2004","6","4","Science","Science (New York, N.Y.)","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
275,"EID275","In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",33,4,"Substitutes","accepted",0,"evidence",182,"Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.","Fukihara et al., 2014, Oncology",24457318,"http://www.ncbi.nlm.nih.gov/pubmed/24457318",NULL,NULL,"2014",NULL,NULL,"Oncology","Oncology","fully curated","15","Erlotinib",NULL,"14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
276,"EID276","Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",33,4,NULL,"accepted",0,"evidence",181,"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.","Paez et al., 2004, Science",15118125,"http://www.ncbi.nlm.nih.gov/pubmed/15118125",NULL,NULL,"2004","6","4","Science","Science (New York, N.Y.)","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
277,"EID277","In a NSCLC patient with T790M and L858R mutation, combination treatment with erlotinib and premetrexed has shown to be effective, reducing tumor size and resulting in stable disease.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",34,3,NULL,"accepted",0,"evidence",183,"Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.","Li et al., 2014, Lung Cancer",24636847,"http://www.ncbi.nlm.nih.gov/pubmed/24636847",NULL,NULL,"2014","5",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","15","Erlotinib",NULL,"156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
278,"EID278","In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","E","Predictive","Supports","Sensitivity","Somatic Mutation",34,1,NULL,"accepted",0,"evidence",184,"A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.","Ai et al., 2014, Amino Acids",24658966,"http://www.ncbi.nlm.nih.gov/pubmed/24658966",NULL,NULL,"2014","7",NULL,"Amino Acids","Amino acids","fully curated","51","Staurosporine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
279,"EID279","In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",35,4,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
280,"EID280","In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",36,4,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
281,"EID281","In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",37,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
282,"EID282","In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",38,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
283,"EID283","The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",39,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
284,"EID284","MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",40,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
285,"EID285","In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",41,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
286,"EID286","MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",42,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,"45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
287,"EID287","In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",43,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
288,"EID288","In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",44,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
289,"EID289","In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",45,5,NULL,"accepted",0,"evidence",170,"Activating HER2 mutations in HER2 gene amplification negative breast cancer.","Bose et al., 2013, Cancer Discov",23220880,"http://www.ncbi.nlm.nih.gov/pubmed/23220880","true","PMC3570596","2013","2",NULL,"Cancer Discov","Cancer discovery","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
290,"EID290","The L536Q ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in MCF7 cell lines.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",46,5,NULL,"accepted",0,"evidence",185,"Activating ESR1 mutations in hormone-resistant metastatic breast cancer.","Robinson et al., 2013, Nat. Genet.",24185510,"http://www.ncbi.nlm.nih.gov/pubmed/24185510","true","PMC4009946","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","54","Fulvestrant",NULL,"53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
291,"EID291","The N538G ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",47,5,NULL,"accepted",0,"evidence",185,"Activating ESR1 mutations in hormone-resistant metastatic breast cancer.","Robinson et al., 2013, Nat. Genet.",24185510,"http://www.ncbi.nlm.nih.gov/pubmed/24185510","true","PMC4009946","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","54","Fulvestrant",NULL,"53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
292,"EID292","The Y537C ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",48,5,NULL,"accepted",0,"evidence",185,"Activating ESR1 mutations in hormone-resistant metastatic breast cancer.","Robinson et al., 2013, Nat. Genet.",24185510,"http://www.ncbi.nlm.nih.gov/pubmed/24185510","true","PMC4009946","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","53","Tamoxifen",NULL,"54","Fulvestrant",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
293,"EID293","The Y537N ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",49,5,NULL,"accepted",0,"evidence",185,"Activating ESR1 mutations in hormone-resistant metastatic breast cancer.","Robinson et al., 2013, Nat. Genet.",24185510,"http://www.ncbi.nlm.nih.gov/pubmed/24185510","true","PMC4009946","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","54","Fulvestrant",NULL,"53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
294,"EID294","The Y537S ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",50,5,NULL,"accepted",0,"evidence",185,"Activating ESR1 mutations in hormone-resistant metastatic breast cancer.","Robinson et al., 2013, Nat. Genet.",24185510,"http://www.ncbi.nlm.nih.gov/pubmed/24185510","true","PMC4009946","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","54","Fulvestrant",NULL,"53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
295,"EID295","In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response.",29,"Cholangiocarcinoma","Cholangiocarcinoma",4947,"http://www.disease-ontology.org/?id=DOID:4947","C","Predictive","Supports","Sensitivity","Somatic Mutation",52,2,NULL,"accepted",0,"evidence",186,"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.","Borad et al., 2014, PLoS Genet.",24550739,"http://www.ncbi.nlm.nih.gov/pubmed/24550739","true","PMC3923676","2014","2",NULL,"PLoS Genet.","PLoS genetics","partially curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
296,"EID296","In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.",29,"Cholangiocarcinoma","Cholangiocarcinoma",4947,"http://www.disease-ontology.org/?id=DOID:4947","C","Predictive","Supports","Sensitivity","Somatic Mutation",54,3,NULL,"accepted",0,"evidence",186,"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.","Borad et al., 2014, PLoS Genet.",24550739,"http://www.ncbi.nlm.nih.gov/pubmed/24550739","true","PMC3923676","2014","2",NULL,"PLoS Genet.","PLoS genetics","partially curated","55","Ponatinib",NULL,"56","Pazopanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
297,"EID297","CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",187,"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.","Smith et al., 2004, Blood",14726387,"http://www.ncbi.nlm.nih.gov/pubmed/14726387",NULL,NULL,"2004","5","15","Blood","Blood","fully curated","260","Lestaurtinib (CEP-701)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
298,"EID298","Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",173,"Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.","Zhang et al., 2008, J. Natl. Cancer Inst.",18230792,"http://www.ncbi.nlm.nih.gov/pubmed/18230792",NULL,NULL,"2008","2","6","J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
299,"EID299","AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Sensitivity","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",188,"Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.","Tse et al., 2002, Leukemia",12357354,"http://www.ncbi.nlm.nih.gov/pubmed/12357354",NULL,NULL,"2002","10",NULL,"Leukemia","Leukemia","fully curated","58","AG1296",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
301,"EID301","Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.",30,"Bronchogenic Lung Adenocarcinoma","Bronchogenic Lung Adenocarcinoma",3909,"http://www.disease-ontology.org/?id=DOID:3909","D","Predictive","Supports","Sensitivity","Somatic Mutation",57,4,"Combination","accepted",0,"evidence",35,"The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.","Kumar et al., 2012, Cell",22541434,"http://www.ncbi.nlm.nih.gov/pubmed/22541434",NULL,NULL,"2012","4","27","Cell","Cell","fully curated","60","Fasudil",NULL,"59","Bortezomib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
302,"EID302","In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment.",31,"Malignant Anus Melanoma","Malignant Anus Melanoma",14145,"http://www.disease-ontology.org/?id=DOID:14145","C","Predictive","Supports","Sensitivity","Somatic Mutation",67,3,NULL,"accepted",0,"evidence",190,"Major response to imatinib mesylate in KIT-mutated melanoma.","Hodi et al., 2008, J. Clin. Oncol.",18421059,"http://www.ncbi.nlm.nih.gov/pubmed/18421059",NULL,NULL,"2008","4","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
303,"EID303","Ba/F3 cells harboring the KIT L576P mutation are sensitive to dasantinib, nilotinib and imatinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",72,3,NULL,"accepted",0,"evidence",191,"L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.","Antonescu et al., 2007, Int. J. Cancer",17372901,"http://www.ncbi.nlm.nih.gov/pubmed/17372901",NULL,NULL,"2007","7","15","Int. J. Cancer","International journal of cancer","fully curated","13","Nilotinib",NULL,"5","Imatinib",NULL,"20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
304,"EID304","In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Predictive","Supports","Sensitivity","Somatic Mutation",73,3,NULL,"accepted",0,"evidence",192,"Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.","Prenen et al., 2006, Clin. Cancer Res.",16638875,"http://www.ncbi.nlm.nih.gov/pubmed/16638875",NULL,NULL,"2006","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
305,"EID305","The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",79,4,NULL,"accepted",0,"evidence",193,"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.","Engelman et al., 2008, Nat. Med.",19029981,"http://www.ncbi.nlm.nih.gov/pubmed/19029981","true","PMC2683415","2008","12",NULL,"Nat. Med.","Nature medicine","fully curated","63","ARRY-142886",NULL,"343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
306,"EID306","KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",81,4,NULL,"accepted",0,"evidence",123,"Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.","De Roock et al., 2010, JAMA",20978259,"http://www.ncbi.nlm.nih.gov/pubmed/20978259",NULL,NULL,"2010","10","27","JAMA","JAMA","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
307,"EID307","In a randomized clinical trial, patients with MGMT promoter methyaltion benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","A","Predictive","Supports","Sensitivity","Somatic Mutation",85,5,NULL,"accepted",0,"evidence",194,"MGMT gene silencing and benefit from temozolomide in glioblastoma.","Hegi et al., 2005, N. Engl. J. Med.",15758010,"http://www.ncbi.nlm.nih.gov/pubmed/15758010",NULL,NULL,"2005","3","10","N. Engl. J. Med.","The New England journal of medicine","fully curated","11","Temozolomide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
308,"EID308","MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Predictive","Supports","Sensitivity","Somatic Mutation",85,4,NULL,"accepted",0,"evidence",139,"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.","Esteller et al., 2000, N. Engl. J. Med.",11070098,"http://www.ncbi.nlm.nih.gov/pubmed/11070098",NULL,NULL,"2000","11","9","N. Engl. J. Med.","The New England journal of medicine","fully curated","64","Carmustine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
309,"EID309","In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","E","Predictive","Supports","Sensitivity","Somatic Mutation",85,4,NULL,"accepted",0,"evidence",139,"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.","Esteller et al., 2000, N. Engl. J. Med.",11070098,"http://www.ncbi.nlm.nih.gov/pubmed/11070098",NULL,NULL,"2000","11","9","N. Engl. J. Med.","The New England journal of medicine","fully curated","65","O(6)-benzylguanine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
310,"EID310","Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",103,4,NULL,"accepted",0,"evidence",195,"The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.","Tanaka et al., 2011, Clin. Cancer Res.",21558396,"http://www.ncbi.nlm.nih.gov/pubmed/21558396",NULL,NULL,"2011","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","66","CH5132799",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
311,"EID311","Rapamycin inhibits transformation induced by mutation in PIK3CA.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",103,3,NULL,"accepted",0,"evidence",196,"Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.","Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A.",15647370,"http://www.ncbi.nlm.nih.gov/pubmed/15647370","true","PMC545580","2005","1","18","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
314,"EID314","Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,4,NULL,"accepted",0,"evidence",195,"The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.","Tanaka et al., 2011, Clin. Cancer Res.",21558396,"http://www.ncbi.nlm.nih.gov/pubmed/21558396",NULL,NULL,"2011","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","66","CH5132799",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
316,"EID316","Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","B","Predictive","Supports","Sensitivity","Somatic Mutation",108,5,NULL,"accepted",0,"evidence",197,"Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.","Yoshida et al., 1996, Cancer Res.",8674046,"http://www.ncbi.nlm.nih.gov/pubmed/8674046",NULL,NULL,"1996","7","1","Cancer Res.","Cancer research","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
317,"EID317","Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",110,4,NULL,"accepted",0,"evidence",198,"The PI3K pathway as drug target in human cancer.","Courtney et al., 2010, J. Clin. Oncol.",20085938,"http://www.ncbi.nlm.nih.gov/pubmed/20085938","true","PMC2834432","2010","2","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","67","MTOR Inhibitors",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
319,"EID319","Breast tumors in a mouse model with R175H mutation are more responsive to doxorubicin than breast tumors with wild type TP53.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",116,3,NULL,"accepted",0,"evidence",199,"p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.","Jackson et al., 2012, Cancer Cell",22698404,"http://www.ncbi.nlm.nih.gov/pubmed/22698404","true","PMC3376352","2012","6","12","Cancer Cell","Cancer cell","fully curated","68","Doxorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
320,"EID320","A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation. 2/3 additional patients with TSC1 mutations also had mild responses to everolimus.",33,"Invasive Bladder Transitional Cell Carcinoma","Invasive Bladder Transitional Cell Carcinoma",6477,"http://www.disease-ontology.org/?id=DOID:6477","B","Predictive","Supports","Sensitivity","Somatic Mutation",124,3,NULL,"accepted",0,"evidence",132,"Genome sequencing identifies a basis for everolimus sensitivity.","Iyer et al., 2012, Science",22923433,"http://www.ncbi.nlm.nih.gov/pubmed/22923433","true","PMC3633467","2012","10","12","Science","Science (New York, N.Y.)","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
322,"EID322","AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",56,3,NULL,"accepted",0,"evidence",152,"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.","Yamamoto et al., 2001, Blood",11290608,"http://www.ncbi.nlm.nih.gov/pubmed/11290608",NULL,NULL,"2001","4","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
323,"EID323","The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",58,2,NULL,"accepted",0,"evidence",201,"Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.","Wagner et al., 2010, J. Clin. Oncol.",20368538,"http://www.ncbi.nlm.nih.gov/pubmed/20368538",NULL,NULL,"2010","5","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
324,"EID324","IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",59,2,NULL,"accepted",0,"evidence",159,"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.","Abbas et al., 2010, Blood",20538800,"http://www.ncbi.nlm.nih.gov/pubmed/20538800",NULL,NULL,"2010","9","23","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
327,"EID327","In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild-type IDH2.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",62,2,NULL,"accepted",0,"evidence",202,"Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.","Zhou et al., 2012, Leuk. Lymphoma",22616558,"http://www.ncbi.nlm.nih.gov/pubmed/22616558",NULL,NULL,"2012","12",NULL,"Leuk. Lymphoma","Leukemia & lymphoma","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
328,"EID328","In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",570,3,NULL,"accepted",0,"evidence",203,"Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.","Thol et al., 2010, Blood",20421455,"http://www.ncbi.nlm.nih.gov/pubmed/20421455",NULL,NULL,"2010","7","29","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
329,"EID329","In patients with myelodysplastic syndrome, the presence of IDH2 R140Q (N=3) or IDH1 R132 (N=2) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients (N=61; P=0.794).",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Does Not Support","N/A","Somatic Mutation",62,2,NULL,"accepted",0,"evidence",204,"IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.","Lin et al., 2012, Ann. Hematol.",21997850,"http://www.ncbi.nlm.nih.gov/pubmed/21997850",NULL,NULL,"2012","4",NULL,"Ann. Hematol.","Annals of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
330,"EID330","R140Q mutation in IDH2 does not have prognostic value in patients with MDS.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Does Not Support","N/A","Somatic Mutation",62,3,NULL,"accepted",0,"evidence",205,"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.","Patnaik et al., 2012, Leukemia",22033490,"http://www.ncbi.nlm.nih.gov/pubmed/22033490",NULL,NULL,"2012","1",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
331,"EID331","AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild-type IDH2.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",63,2,NULL,"accepted",0,"evidence",202,"Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.","Zhou et al., 2012, Leuk. Lymphoma",22616558,"http://www.ncbi.nlm.nih.gov/pubmed/22616558",NULL,NULL,"2012","12",NULL,"Leuk. Lymphoma","Leukemia & lymphoma","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
332,"EID332","In patients suffering from MDS, the presence of IDH2 mutations such as R172K do not confer prognostic value (overall survival).",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Does Not Support","N/A","Somatic Mutation",63,2,NULL,"accepted",0,"evidence",204,"IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.","Lin et al., 2012, Ann. Hematol.",21997850,"http://www.ncbi.nlm.nih.gov/pubmed/21997850",NULL,NULL,"2012","4",NULL,"Ann. Hematol.","Annals of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
333,"EID333","KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Prognostic","Does Not Support","N/A","Somatic Mutation",66,3,NULL,"accepted",0,"evidence",206,"KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.","Corless et al., 2002, Am. J. Pathol.",12000708,"http://www.ncbi.nlm.nih.gov/pubmed/12000708","true","PMC1850861","2002","5",NULL,"Am. J. Pathol.","The American journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
334,"EID334","KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","B","Prognostic","Does Not Support","N/A","Somatic Mutation",66,2,NULL,"accepted",0,"evidence",207,"Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.","Boldrini et al., 2004, Clin. Cancer Res.",15217946,"http://www.ncbi.nlm.nih.gov/pubmed/15217946",NULL,NULL,"2004","6","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
336,"EID336","In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Does Not Support","N/A","Somatic Mutation",76,4,NULL,"accepted",0,"evidence",208,"KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.","Ogino et al., 2009, Clin. Cancer Res.",19934290,"http://www.ncbi.nlm.nih.gov/pubmed/19934290","true","PMC2787689","2009","12","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
337,"EID337","There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Does Not Support","N/A","Somatic Mutation",76,3,NULL,"accepted",0,"evidence",209,"Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.","Schiller et al., 2001, J. Clin. Oncol.",11208838,"http://www.ncbi.nlm.nih.gov/pubmed/11208838",NULL,NULL,"2001","1","15","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
338,"EID338","In patients with AML, those who harbor Q157P/R mutation of U2AF1 do not show a statistically significant difference in complete remission rate compared to those who harbor wild type U2AF1.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",127,2,NULL,"accepted",0,"evidence",154,"U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.","Qian et al., 2012, PLoS ONE",23029227,"http://www.ncbi.nlm.nih.gov/pubmed/23029227","true","PMC3446943","2012",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
339,"EID339","In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Does Not Support","N/A","Somatic Mutation",127,2,NULL,"accepted",0,"evidence",154,"U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.","Qian et al., 2012, PLoS ONE",23029227,"http://www.ncbi.nlm.nih.gov/pubmed/23029227","true","PMC3446943","2012",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
340,"EID340","In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",128,2,NULL,"accepted",0,"evidence",154,"U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.","Qian et al., 2012, PLoS ONE",23029227,"http://www.ncbi.nlm.nih.gov/pubmed/23029227","true","PMC3446943","2012",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
342,"EID342","Three studies have found no significant survival impact for CCND1 in lung cancer.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",19,3,NULL,"accepted",0,"evidence",210,"Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.","Gautschi et al., 2007, Lung Cancer",17070615,"http://www.ncbi.nlm.nih.gov/pubmed/17070615",NULL,NULL,"2007","1",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
343,"EID343","PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",110,3,NULL,"accepted",0,"evidence",211,"Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.","Carico et al., 2012, PLoS ONE",22479427,"http://www.ncbi.nlm.nih.gov/pubmed/22479427","true","PMC3315579","2012",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
344,"EID344","BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","A","Predictive","Supports","Sensitivity","Somatic Mutation",1,5,NULL,"accepted",0,"evidence",156,"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.","An et al., 2010, Leuk. Res.",20537386,"http://www.ncbi.nlm.nih.gov/pubmed/20537386",NULL,NULL,"2010","10",NULL,"Leuk. Res.","Leukemia research","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
345,"EID345","Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer.",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","B","Predictive","Supports","Sensitivity","Somatic Mutation",25,3,NULL,"submitted",1,"evidence",212,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.","Logan et al., 2013, Anticancer Res.",23898052,"http://www.ncbi.nlm.nih.gov/pubmed/23898052",NULL,NULL,"2013","8",NULL,"Anticancer Res.","Anticancer research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
347,"EID347","Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Better Outcome","Somatic Mutation",33,3,NULL,"accepted",0,"evidence",213,"Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.","Douillard et al., 2014, J Thorac Oncol",24662454,"http://www.ncbi.nlm.nih.gov/pubmed/24662454",NULL,NULL,"2014","5",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
348,"EID348","In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation.",35,"Astrocytoma","Astrocytoma",3069,"http://www.disease-ontology.org/?id=DOID:3069","B","Prognostic","Supports","Better Outcome","Somatic Mutation",58,3,NULL,"accepted",0,"evidence",214,"IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.","Dubbink et al., 2009, Neurology",19933982,"http://www.ncbi.nlm.nih.gov/pubmed/19933982",NULL,NULL,"2009","11","24","Neurology","Neurology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
349,"EID349","In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Prognostic","Supports","Better Outcome","Somatic Mutation",58,3,NULL,"accepted",0,"evidence",215,"The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.","Bleeker et al., 2010, Acta Neuropathol.",20127344,"http://www.ncbi.nlm.nih.gov/pubmed/20127344","true","PMC2841753","2010","4",NULL,"Acta Neuropathol.","Acta neuropathologica","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
350,"EID350","In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild-type IDH2.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",62,3,NULL,"accepted",0,"evidence",216,"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.","Green et al., 2011, Blood",21596855,"http://www.ncbi.nlm.nih.gov/pubmed/21596855",NULL,NULL,"2011","7","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
352,"EID352","Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Supports","Better Outcome","Somatic Mutation",215,3,NULL,"accepted",0,"evidence",46,"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.","Papaemmanuil et al., 2011, N. Engl. J. Med.",21995386,"http://www.ncbi.nlm.nih.gov/pubmed/21995386","true","PMC3322589","2011","10","13","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
354,"EID354","Inceased copy number of CCND1 is associated with poorer overall survival.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",18,3,NULL,"accepted",0,"evidence",210,"Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.","Gautschi et al., 2007, Lung Cancer",17070615,"http://www.ncbi.nlm.nih.gov/pubmed/17070615",NULL,NULL,"2007","1",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
355,"EID355","Three studies have associated CCND1 expression with poorer survival.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",19,3,NULL,"accepted",0,"evidence",210,"Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.","Gautschi et al., 2007, Lung Cancer",17070615,"http://www.ncbi.nlm.nih.gov/pubmed/17070615",NULL,NULL,"2007","1",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
356,"EID356","In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",20,4,NULL,"accepted",0,"evidence",157,"Cyclin D1 in breast cancer pathogenesis.","Arnold et al., 2005, J. Clin. Oncol.",15961768,"http://www.ncbi.nlm.nih.gov/pubmed/15961768",NULL,NULL,"2005","6","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
357,"EID357","Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",20,4,NULL,"accepted",0,"evidence",218,"Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.","Thomas et al., 2005, Int J Exp Pathol",16309541,"http://www.ncbi.nlm.nih.gov/pubmed/16309541","true","PMC2517451","2005","12",NULL,"Int J Exp Pathol","International journal of experimental pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
358,"EID358","Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.",38,"Mantle Cell Lymphoma","Mantle Cell Lymphoma",50746,"http://www.disease-ontology.org/?id=DOID:0050746","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",20,4,NULL,"accepted",0,"evidence",219,"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.","Jares et al., 2007, Nat. Rev. Cancer",17891190,"http://www.ncbi.nlm.nih.gov/pubmed/17891190",NULL,NULL,"2007","10",NULL,"Nat. Rev. Cancer","Nature reviews. Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
359,"EID359","Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","D","Prognostic","Supports","Poor Outcome","Somatic Mutation",21,4,NULL,"accepted",0,"evidence",220,"Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis.","Takano et al., 1999, J. Pathol.",10547574,"http://www.ncbi.nlm.nih.gov/pubmed/10547574",NULL,NULL,"1999","10",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
360,"EID360","Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","D","Prognostic","Supports","Poor Outcome","Somatic Mutation",21,4,NULL,"accepted",0,"evidence",220,"Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis.","Takano et al., 1999, J. Pathol.",10547574,"http://www.ncbi.nlm.nih.gov/pubmed/10547574",NULL,NULL,"1999","10",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
361,"EID361","Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","D","Prognostic","Supports","Poor Outcome","Somatic Mutation",21,4,NULL,"accepted",0,"evidence",220,"Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis.","Takano et al., 1999, J. Pathol.",10547574,"http://www.ncbi.nlm.nih.gov/pubmed/10547574",NULL,NULL,"1999","10",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
362,"EID362","Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers.",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","D","Prognostic","Supports","Poor Outcome","Somatic Mutation",21,4,NULL,"accepted",0,"evidence",220,"Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis.","Takano et al., 1999, J. Pathol.",10547574,"http://www.ncbi.nlm.nih.gov/pubmed/10547574",NULL,NULL,"1999","10",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
363,"EID363","Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",24,4,NULL,"accepted",0,"evidence",221,"Cyclin E and survival in patients with breast cancer.","Keyomarsi et al., 2002, N. Engl. J. Med.",12432043,"http://www.ncbi.nlm.nih.gov/pubmed/12432043",NULL,NULL,"2002","11","14","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
364,"EID364","Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.",39,"Gastric Adenosquamous Carcinoma","Gastric Adenosquamous Carcinoma",5635,"http://www.disease-ontology.org/?id=DOID:5635","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",24,4,NULL,"accepted",0,"evidence",222,"Cyclin E in human cancers.","Donnellan et al., 1999, FASEB J.",10224221,"http://www.ncbi.nlm.nih.gov/pubmed/10224221",NULL,NULL,"1999","5",NULL,"FASEB J.","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
365,"EID365","Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.",39,"Gastric Adenosquamous Carcinoma","Gastric Adenosquamous Carcinoma",5635,"http://www.disease-ontology.org/?id=DOID:5635","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",24,4,NULL,"accepted",0,"evidence",222,"Cyclin E in human cancers.","Donnellan et al., 1999, FASEB J.",10224221,"http://www.ncbi.nlm.nih.gov/pubmed/10224221",NULL,NULL,"1999","5",NULL,"FASEB J.","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
367,"EID367","In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",27,3,NULL,"accepted",0,"evidence",18,"CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.","Bradly et al., 2012, Diagn. Mol. Pathol.",23111194,"http://www.ncbi.nlm.nih.gov/pubmed/23111194",NULL,NULL,"2012","12",NULL,"Diagn. Mol. Pathol.","Diagnostic molecular pathology : the American journal of surgical pathology, part B","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
369,"EID369","In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",34,4,NULL,"accepted",0,"evidence",224,"The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis.","Ding et al., 2014, Onco Targets Ther",24623981,"http://www.ncbi.nlm.nih.gov/pubmed/24623981","true","PMC3949752","2014",NULL,NULL,"Onco Targets Ther","OncoTargets and therapy","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
370,"EID370","Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",34,4,NULL,"accepted",0,"evidence",225,"Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.","Li et al., 2014, Onco Targets Ther",24729716,"http://www.ncbi.nlm.nih.gov/pubmed/24729716","true","PMC3979794","2014",NULL,NULL,"Onco Targets Ther","OncoTargets and therapy","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
371,"EID371","AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",152,"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.","Yamamoto et al., 2001, Blood",11290608,"http://www.ncbi.nlm.nih.gov/pubmed/11290608",NULL,NULL,"2001","4","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
372,"EID372","Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,4,NULL,"accepted",0,"evidence",226,"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.","Whitman et al., 2001, Cancer Res.",11585760,"http://www.ncbi.nlm.nih.gov/pubmed/11585760",NULL,NULL,"2001","10","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
373,"EID373","In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",56,4,NULL,"accepted",0,"evidence",227,"FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.","Whitman et al., 2008, Blood",17940205,"http://www.ncbi.nlm.nih.gov/pubmed/17940205","true","PMC2214747","2008","2","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
374,"EID374","IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",58,4,NULL,"accepted",0,"evidence",228,"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.","Thol et al., 2010, Haematologica",20494930,"http://www.ncbi.nlm.nih.gov/pubmed/20494930","true","PMC2948091","2010","10",NULL,"Haematologica","Haematologica","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
375,"EID375","In AML, patients with an IDH2 R172K mutation have worse overall survival compared to those with wild-type IDH2.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",63,3,NULL,"accepted",0,"evidence",216,"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.","Green et al., 2011, Blood",21596855,"http://www.ncbi.nlm.nih.gov/pubmed/21596855",NULL,NULL,"2011","7","14","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
376,"EID376","KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",66,3,NULL,"accepted",0,"evidence",160,"Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.","Taniguchi et al., 1999, Cancer Res.",10485475,"http://www.ncbi.nlm.nih.gov/pubmed/10485475",NULL,NULL,"1999","9","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
377,"EID377","The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival.",41,"Multiple Myeloma","Multiple Myeloma",9538,"http://www.disease-ontology.org/?id=DOID:9538","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",76,3,NULL,"accepted",0,"evidence",229,"Clinical and biological significance of RAS mutations in multiple myeloma.","Chng et al., 2008, Leukemia",18528420,"http://www.ncbi.nlm.nih.gov/pubmed/18528420","true","PMC3864109","2008","12",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
378,"EID378","A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",76,3,NULL,"accepted",0,"evidence",230,"The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.","Mascaux et al., 2005, Br. J. Cancer",15597105,"http://www.ncbi.nlm.nih.gov/pubmed/15597105","true","PMC2361730","2005","1","17","Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
380,"EID380","NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",135,4,NULL,"accepted",0,"evidence",231,"Alterations of the Notch pathway in lung cancer.","Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",20007775,"http://www.ncbi.nlm.nih.gov/pubmed/20007775","true","PMC2799768","2009","12","29","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
381,"EID381","NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",136,4,NULL,"accepted",0,"evidence",231,"Alterations of the Notch pathway in lung cancer.","Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",20007775,"http://www.ncbi.nlm.nih.gov/pubmed/20007775","true","PMC2799768","2009","12","29","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
382,"EID382","NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",138,4,NULL,"accepted",0,"evidence",231,"Alterations of the Notch pathway in lung cancer.","Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",20007775,"http://www.ncbi.nlm.nih.gov/pubmed/20007775","true","PMC2799768","2009","12","29","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
383,"EID383","NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",137,4,NULL,"accepted",0,"evidence",231,"Alterations of the Notch pathway in lung cancer.","Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",20007775,"http://www.ncbi.nlm.nih.gov/pubmed/20007775","true","PMC2799768","2009","12","29","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
384,"EID384","Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not either alone, is prognostic for worse overall survival and cancer specific survival.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","E","Prognostic","Supports","Poor Outcome","Somatic Mutation",103,2,NULL,"accepted",0,"evidence",232,"Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.","Liao et al., 2012, Clin. Cancer Res.",22357840,"http://www.ncbi.nlm.nih.gov/pubmed/22357840","true","PMC3628835","2012","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
385,"EID385","The presence of exon 9 (such as E542K) or exon 20 mutations were associated with poorer survival compared to those with wild-type PIK3CA mutation (P = 0.035).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",103,3,NULL,"accepted",0,"evidence",176,"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.","Sartore-Bianchi et al., 2009, Cancer Res.",19223544,"http://www.ncbi.nlm.nih.gov/pubmed/19223544",NULL,NULL,"2009","3","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
387,"EID387","Mutational analysis of PIK3CA and KRAS and evaluation of the PTEN protein status in a cohort of 110 patients with mCRC treated with anti-EGFR moAbs. 15 (13.6%) PIK3CA mutations were observed. The presence of exon 9 (such as E545K) or exon 20 mutation may result in poorer survival compared to those with wild-type PIK3CA Mutation (progression-free survival P = 0.035).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",104,3,NULL,"accepted",0,"evidence",176,"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.","Sartore-Bianchi et al., 2009, Cancer Res.",19223544,"http://www.ncbi.nlm.nih.gov/pubmed/19223544",NULL,NULL,"2009","3","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
388,"EID388","The presence of exon 20 (such as H1047R) or exon 9 mutation may result in poorer survival compared to those with wild-type PIK3CA mutation.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",107,3,NULL,"accepted",0,"evidence",176,"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.","Sartore-Bianchi et al., 2009, Cancer Res.",19223544,"http://www.ncbi.nlm.nih.gov/pubmed/19223544",NULL,NULL,"2009","3","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
389,"EID389","Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",116,3,NULL,"accepted",0,"evidence",233,"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.","Olivier et al., 2006, Clin. Cancer Res.",16489069,"http://www.ncbi.nlm.nih.gov/pubmed/16489069",NULL,NULL,"2006","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
390,"EID390","Breast cancer patients who harbor a R248Q mutation (N=18) have worse overall survival than those with wild type TP53 (N=1460), but have better prognosis than those with a R248W mutation (N=8).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",117,3,NULL,"accepted",0,"evidence",233,"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.","Olivier et al., 2006, Clin. Cancer Res.",16489069,"http://www.ncbi.nlm.nih.gov/pubmed/16489069",NULL,NULL,"2006","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
391,"EID391","In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",117,3,NULL,"accepted",0,"evidence",234,"Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.","Berns et al., 1998, Br. J. Cancer",9569050,"http://www.ncbi.nlm.nih.gov/pubmed/9569050","true","PMC2150115","1998","4",NULL,"Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
392,"EID392","In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",118,3,NULL,"accepted",0,"evidence",233,"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.","Olivier et al., 2006, Clin. Cancer Res.",16489069,"http://www.ncbi.nlm.nih.gov/pubmed/16489069",NULL,NULL,"2006","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
393,"EID393","In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",119,3,NULL,"accepted",0,"evidence",234,"Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.","Berns et al., 1998, Br. J. Cancer",9569050,"http://www.ncbi.nlm.nih.gov/pubmed/9569050","true","PMC2150115","1998","4",NULL,"Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
395,"EID395","Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",121,3,NULL,"accepted",0,"evidence",233,"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.","Olivier et al., 2006, Clin. Cancer Res.",16489069,"http://www.ncbi.nlm.nih.gov/pubmed/16489069",NULL,NULL,"2006","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
396,"EID396","In breast cancer patients  harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",121,3,NULL,"accepted",0,"evidence",234,"Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.","Berns et al., 1998, Br. J. Cancer",9569050,"http://www.ncbi.nlm.nih.gov/pubmed/9569050","true","PMC2150115","1998","4",NULL,"Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
397,"EID397","Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",122,3,NULL,"accepted",0,"evidence",233,"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.","Olivier et al., 2006, Clin. Cancer Res.",16489069,"http://www.ncbi.nlm.nih.gov/pubmed/16489069",NULL,NULL,"2006","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
398,"EID398","In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",122,3,NULL,"accepted",0,"evidence",234,"Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.","Berns et al., 1998, Br. J. Cancer",9569050,"http://www.ncbi.nlm.nih.gov/pubmed/9569050","true","PMC2150115","1998","4",NULL,"Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
399,"EID399","Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",119,3,NULL,"accepted",0,"evidence",234,"Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.","Berns et al., 1998, Br. J. Cancer",9569050,"http://www.ncbi.nlm.nih.gov/pubmed/9569050","true","PMC2150115","1998","4",NULL,"Br. J. Cancer","British journal of cancer","fully curated","68","Doxorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
400,"EID400","After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",127,3,NULL,"accepted",0,"evidence",235,"Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.","Wu et al., 2013, Am. J. Hematol.",23861105,"http://www.ncbi.nlm.nih.gov/pubmed/23861105",NULL,NULL,"2013","11",NULL,"Am. J. Hematol.","American journal of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
401,"EID401","After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",128,3,NULL,"accepted",0,"evidence",235,"Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.","Wu et al., 2013, Am. J. Hematol.",23861105,"http://www.ncbi.nlm.nih.gov/pubmed/23861105",NULL,NULL,"2013","11",NULL,"Am. J. Hematol.","American journal of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
403,"EID403","Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","D","Predictive","Supports","Sensitivity","Somatic Mutation",30,3,NULL,"accepted",0,"evidence",237,"RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.","LilljebjÃ¶rn et al., 2014, Leukemia",24186003,"http://www.ncbi.nlm.nih.gov/pubmed/24186003",NULL,NULL,"2014","4",NULL,"Leukemia","Leukemia","fully curated","70","GW-2580",NULL,"5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
405,"EID405","A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.",44,"Hepatocellular Fibrolamellar Carcinoma","Hepatocellular Fibrolamellar Carcinoma",5015,"http://www.disease-ontology.org/?id=DOID:5015","B","Diagnostic","Supports","Positive","Somatic Mutation",31,4,NULL,"accepted",0,"evidence",22,"Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.","Honeyman et al., 2014, Science",24578576,"http://www.ncbi.nlm.nih.gov/pubmed/24578576","true","PMC4286414","2014","2","28","Science","Science (New York, N.Y.)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
407,"EID407","The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-cellâ€“like diffuse large-B-cell lymphomas.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","B","Diagnostic","Supports","Positive","Somatic Mutation",151,4,NULL,"accepted",0,"evidence",239,"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.","Rosenwald et al., 2002, N. Engl. J. Med.",12075054,"http://www.ncbi.nlm.nih.gov/pubmed/12075054",NULL,NULL,"2002","6","20","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
408,"EID408","Amplification of FOXP1 is shown to be associated with ABC DLBCL.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","B","Diagnostic","Supports","Positive","Somatic Mutation",153,3,NULL,"accepted",0,"evidence",240,"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.","Lenz et al., 2008, Proc. Natl. Acad. Sci. U.S.A.",18765795,"http://www.ncbi.nlm.nih.gov/pubmed/18765795","true","PMC2533222","2008","9","9","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
409,"EID409","Amplification of REL is shown to be associated with germinal-center B-cellâ€“like diffuse large-B-cell lymphomas.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","B","Diagnostic","Supports","Positive","Somatic Mutation",154,4,NULL,"accepted",0,"evidence",239,"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.","Rosenwald et al., 2002, N. Engl. J. Med.",12075054,"http://www.ncbi.nlm.nih.gov/pubmed/12075054",NULL,NULL,"2002","6","20","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
411,"EID411","In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",155,4,NULL,"accepted",0,"evidence",241,"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.","Gaidzik et al., 2011, J. Clin. Oncol.",21343560,"http://www.ncbi.nlm.nih.gov/pubmed/21343560",NULL,NULL,"2011","4","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","173","Cytarabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
412,"EID412","OSI-906, an IGF1R/INSR inhibitor, does not have a significant effect on chemotherapy resistant castration-resistant prostate cancer cell lines.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Predictive","Supports","N/A","Somatic Mutation",156,3,NULL,"accepted",0,"evidence",242,"A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.","Vidal et al., 2015, Cancer Cell",25670080,"http://www.ncbi.nlm.nih.gov/pubmed/25670080","true","PMC4356948","2015","2","9","Cancer Cell","Cancer cell","fully curated","72","OSI-906 (Linsitinib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
413,"EID413","NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib and erlotinib (38 versus 17 months; P = 0.04).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",133,4,NULL,"accepted",0,"evidence",243,"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.","Jackman et al., 2006, Clin. Cancer Res.",16818686,"http://www.ncbi.nlm.nih.gov/pubmed/16818686",NULL,NULL,"2006","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","15","Erlotinib",NULL,"14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
414,"EID414","OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in chemotherapy resistant CRPC cell lines.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Predictive","Supports","Sensitivity","Somatic Mutation",156,3,NULL,"accepted",0,"evidence",244,"A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.","Vidal et al., 2015, Cancer Cell",25670080,"http://www.ncbi.nlm.nih.gov/pubmed/25670080","true","PMC4356948","2015","2","9","Cancer Cell","Cancer cell","fully curated","73","Docetaxel",NULL,"74","Cabazitaxel",NULL,"72","OSI-906 (Linsitinib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL
415,"EID415","In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",157,4,NULL,"accepted",0,"evidence",245,"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.","Gaidzik et al., 2012, J. Clin. Oncol.",22430270,"http://www.ncbi.nlm.nih.gov/pubmed/22430270",NULL,NULL,"2012","4","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
416,"EID416","In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expression.",47,"Ovarian Carcinoma","Ovarian Carcinoma",4001,"http://www.disease-ontology.org/?id=DOID:4001","B","Prognostic","Supports","Better Outcome","Somatic Mutation",158,3,NULL,"accepted",0,"evidence",246,"Aurora kinases as prognostic biomarkers in ovarian carcinoma.","Mendiola et al., 2009, Hum. Pathol.",19157502,"http://www.ncbi.nlm.nih.gov/pubmed/19157502",NULL,NULL,"2009","5",NULL,"Hum. Pathol.","Human pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
417,"EID417","In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Supports","Better Outcome","Somatic Mutation",157,4,NULL,"accepted",0,"evidence",247,"TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).","Kosmider et al., 2009, Blood",19666869,"http://www.ncbi.nlm.nih.gov/pubmed/19666869",NULL,NULL,"2009","10","8","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
418,"EID418","In patients with renal clear cell carcinoma, patients with VHL mutations had longer cancer-specific survival.",48,"Renal Clear Cell Carcinoma","Renal Clear Cell Carcinoma",4467,"http://www.disease-ontology.org/?id=DOID:4467","B","Prognostic","Supports","Better Outcome","Somatic Mutation",160,4,NULL,"accepted",0,"evidence",248,"Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.","Patard et al., 2008, Int. J. Cancer",18464292,"http://www.ncbi.nlm.nih.gov/pubmed/18464292","true","PMC2721857","2008","7","15","Int. J. Cancer","International journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
419,"EID419","In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",157,4,NULL,"accepted",0,"evidence",245,"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.","Gaidzik et al., 2012, J. Clin. Oncol.",22430270,"http://www.ncbi.nlm.nih.gov/pubmed/22430270",NULL,NULL,"2012","4","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
420,"EID420","In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival.",48,"Renal Clear Cell Carcinoma","Renal Clear Cell Carcinoma",4467,"http://www.disease-ontology.org/?id=DOID:4467","B","Prognostic","Supports","N/A","Somatic Mutation",161,3,NULL,"accepted",0,"evidence",249,"Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.","Hakimi et al., 2013, Clin. Cancer Res.",23620406,"http://www.ncbi.nlm.nih.gov/pubmed/23620406","true","PMC3708609","2013","6","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
421,"EID421","In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","N/A","Somatic Mutation",157,4,NULL,"accepted",0,"evidence",250,"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.","Metzeler et al., 2011, J. Clin. Oncol.",21343549,"http://www.ncbi.nlm.nih.gov/pubmed/21343549","true","PMC3084003","2011","4","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
422,"EID422","In renal clear cell carcinoma, patients with VHL mutations did not have a significant impact on cancer specific survival.",48,"Renal Clear Cell Carcinoma","Renal Clear Cell Carcinoma",4467,"http://www.disease-ontology.org/?id=DOID:4467","B","Prognostic","Supports","N/A","Somatic Mutation",160,3,NULL,"accepted",0,"evidence",249,"Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.","Hakimi et al., 2013, Clin. Cancer Res.",23620406,"http://www.ncbi.nlm.nih.gov/pubmed/23620406","true","PMC3708609","2013","6","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
423,"EID423","In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",152,4,NULL,"accepted",0,"evidence",251,"Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.","Gascoyne et al., 1997, Blood",9207459,"http://www.ncbi.nlm.nih.gov/pubmed/9207459",NULL,NULL,"1997","7","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
424,"EID424","In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased OS, DFS, and RFS.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",152,4,NULL,"accepted",0,"evidence",251,"Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.","Gascoyne et al., 1997, Blood",9207459,"http://www.ncbi.nlm.nih.gov/pubmed/9207459",NULL,NULL,"1997","7","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
425,"EID425","In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild-type counterparts.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",163,3,NULL,"accepted",0,"evidence",252,"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.","Nikoloski et al., 2010, Nat. Genet.",20601954,"http://www.ncbi.nlm.nih.gov/pubmed/20601954",NULL,NULL,"2010","8",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
426,"EID426","In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",157,4,NULL,"accepted",0,"evidence",253,"TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.","Chou et al., 2011, Blood",21828143,"http://www.ncbi.nlm.nih.gov/pubmed/21828143",NULL,NULL,"2011","10","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
427,"EID427","In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",157,4,NULL,"accepted",0,"evidence",250,"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.","Metzeler et al., 2011, J. Clin. Oncol.",21343549,"http://www.ncbi.nlm.nih.gov/pubmed/21343549","true","PMC3084003","2011","4","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
428,"EID428","In patients with renal clear cell carcinoma, patients with loss of function VHL mutations had shorter tumor-specific survival.",48,"Renal Clear Cell Carcinoma","Renal Clear Cell Carcinoma",4467,"http://www.disease-ontology.org/?id=DOID:4467","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",159,3,NULL,"accepted",0,"evidence",254,"VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.","Schraml et al., 2002, J. Pathol.",11793370,"http://www.ncbi.nlm.nih.gov/pubmed/11793370",NULL,NULL,"2002","2",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
429,"EID429","In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",155,4,NULL,"accepted",0,"evidence",241,"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.","Gaidzik et al., 2011, J. Clin. Oncol.",21343560,"http://www.ncbi.nlm.nih.gov/pubmed/21343560",NULL,NULL,"2011","4","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
430,"EID430","In 878 non-APL patients with AML (18-60 years), those who had mutations in RUNX1 (N=53) had shorter event-free survival (8% vs 30%, P<0.0001) and relapse-free survival (26% vs 44%, P=0.022) relative to wild-type. EFS was also shorter for the cytogenetically normal (CN) subgroup with RUNX1 mutations (N=34; 10% vs 34%; P<0.0001) compared to wild-type (N=499), but only trending for relapse-free survival (29% vs 43%; P=0.21). For multivariate analysis, RUNX1 was a significant marker of inferior EFS in the entire cohort (P=0.011) and the intermediate-risk (P=0.005) subgroup but not the CN subgroup.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",155,4,NULL,"accepted",0,"evidence",241,"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.","Gaidzik et al., 2011, J. Clin. Oncol.",21343560,"http://www.ncbi.nlm.nih.gov/pubmed/21343560",NULL,NULL,"2011","4","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
431,"EID431","In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions.",50,"Peripheral Primitive Neuroectodermal Tumor","Peripheral Primitive Neuroectodermal Tumor",3369,"http://www.disease-ontology.org/?id=DOID:3369","B","Prognostic","Supports","Positive","Somatic Mutation",164,4,NULL,"accepted",0,"evidence",255,"EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.","de Alava et al., 1998, J. Clin. Oncol.",9552022,"http://www.ncbi.nlm.nih.gov/pubmed/9552022",NULL,NULL,"1998","4",NULL,"J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
432,"EID432","Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of GCB-DLBCL in 35 / 320 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","B","Diagnostic","Supports","Positive","Somatic Mutation",165,4,NULL,"accepted",0,"evidence",256,"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","Morin et al., 2010, Nat. Genet.",20081860,"http://www.ncbi.nlm.nih.gov/pubmed/20081860","true","PMC2850970","2010","2",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
433,"EID433","Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of Follicular non-Hodgkin Lymphoma in 18 / 251 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls.",51,"Follicular Lymphoma","Follicular Lymphoma",50873,"http://www.disease-ontology.org/?id=DOID:0050873","B","Diagnostic","Supports","Positive","Somatic Mutation",165,4,NULL,"accepted",0,"evidence",256,"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","Morin et al., 2010, Nat. Genet.",20081860,"http://www.ncbi.nlm.nih.gov/pubmed/20081860","true","PMC2850970","2010","2",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
435,"EID435","MLL2 was found to be the most frequently mutated gene in a sample of 31/35 follicular lymphoma patients and was not mutated in normal centroblast samples. Furthermore, MLL2 mutations were as frequently observed as t(14;18) Igh-BCL2 translocations, which are the most common clinically significant genetic event observed in follicular lymphoma. Mutations were predicted to be loss-of-function.",51,"Follicular Lymphoma","Follicular Lymphoma",50873,"http://www.disease-ontology.org/?id=DOID:0050873","B","Diagnostic","Supports","Positive","Somatic Mutation",167,3,NULL,"accepted",0,"evidence",258,"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.","Morin et al., 2011, Nature",21796119,"http://www.ncbi.nlm.nih.gov/pubmed/21796119","true","PMC3210554","2011","8","18","Nature","Nature","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
436,"EID436","Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",168,4,NULL,"accepted",0,"evidence",259,"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.","Woyach et al., 2014, N. Engl. J. Med.",24869598,"http://www.ncbi.nlm.nih.gov/pubmed/24869598","true","PMC4144824","2014","6","12","N. Engl. J. Med.","The New England journal of medicine","fully curated","227","Ibrutinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
439,"EID439","The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",169,4,NULL,"accepted",0,"evidence",261,"A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.","Shi et al., 2014, Cancer Discov",24265152,"http://www.ncbi.nlm.nih.gov/pubmed/24265152","true","PMC3893054","2014","1",NULL,"Cancer Discov","Cancer discovery","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
440,"EID440","Amplification of wild-type EML4-ALK in the non-small cell lung carcinoma cell line, H3122, caused resistance to crizotinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",170,3,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
441,"EID441","The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",171,4,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
442,"EID442","The L1196M mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",7,4,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
443,"EID443","The S1206Y mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",172,4,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
444,"EID444","A lung adenocarcinoma patient responded to crizotinib treatment for 12 months, after which the cancer relapsed and sequencing of the ALK tyrosine kinase domain revealed a 1151insT mutation. This mutation was not found in the pre-crizotinib biopsy. EML4-ALK T1151insT was expressed In Ba/F3 cells and an IC50 of 431.8 nM was obtained, which was 16 times higher than for EML4-ALK wild-type, indicating strong crizotinib resistance. EML4-ALK containing H3122 NSCLC cells were incubated in increasing levels of crizotinib inducing resistance. The resulting cell line H3122 CR2 had IC50 10x greater to crizotinib than parental H3122, and was found to contain 1151 insT mutation. In western blots, pALK levels in H3122 CR2 cells remained apparent under 1000 nM crizotinib, whereas pALK signal was ablated under these conditions in parental H3122 cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",173,4,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
445,"EID445","Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment.",210,"Colon Carcinoma","Colon Carcinoma",1520,"http://www.disease-ontology.org/?id=DOID:1520","D","Predictive","Supports","Sensitivity","Somatic Mutation",174,3,NULL,"accepted",0,"evidence",263,"A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.","Waaler et al., 2012, Cancer Res.",22440753,"http://www.ncbi.nlm.nih.gov/pubmed/22440753",NULL,NULL,"2012","6","1","Cancer Res.","Cancer research","fully curated","75","JW55",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
446,"EID446","G007-LK inhibits in vivo tumor growth in a subset of APC-mutant colorectal cancers xenograft models but may be limited by intestinal toxicity.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",174,4,NULL,"accepted",0,"evidence",264,"A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.","Lau et al., 2013, Cancer Res.",23539443,"http://www.ncbi.nlm.nih.gov/pubmed/23539443",NULL,NULL,"2013","5","15","Cancer Res.","Cancer research","fully curated","76","G007-LK",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
447,"EID447","Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer cell lines.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",175,4,"Substitutes","accepted",0,"evidence",265,"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.","Joseph et al., 2013, Cancer Discov",23779130,"http://www.ncbi.nlm.nih.gov/pubmed/23779130",NULL,NULL,"2013","9",NULL,"Cancer Discov","Cancer discovery","fully curated","163","Enzalutamide",NULL,"364","ARN-509",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
448,"EID448","LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.",101,"Prostate Carcinoma","Prostate Carcinoma",10286,"http://www.disease-ontology.org/?id=DOID:10286","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",176,4,NULL,"accepted",0,"evidence",266,"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.","Hara et al., 2003, Cancer Res.",12517791,"http://www.ncbi.nlm.nih.gov/pubmed/12517791",NULL,NULL,"2003","1","1","Cancer Res.","Cancer research","fully curated","78","Bicalutamide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
449,"EID449","In patients with acute myeloid leukemia, in a univariate analysis those with mutations in ASXL1 had worse overall survival than wild-type.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",177,2,NULL,"accepted",0,"evidence",267,"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.","Ohgami et al., 2015, Mod. Pathol.",25412851,"http://www.ncbi.nlm.nih.gov/pubmed/25412851",NULL,NULL,"2015","5",NULL,"Mod. Pathol.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
450,"EID450","Among patients with AML, those with mutations in ASXL1 were more likely to have the AML with myelodysplasia-related changes (AML-MRC) subtype.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Diagnostic","Supports","Positive","Somatic Mutation",177,3,NULL,"accepted",0,"evidence",267,"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.","Ohgami et al., 2015, Mod. Pathol.",25412851,"http://www.ncbi.nlm.nih.gov/pubmed/25412851",NULL,NULL,"2015","5",NULL,"Mod. Pathol.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
451,"EID451","In a meta-analysis of six studies totalling 3311 patients with non-M3 acute myeloid leukemia, those with mutations in ASXL1 had worse overall survival than wild-type patients (Hazard ratio 1.86, 95% CI 1.49-2.33).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",177,4,NULL,"accepted",0,"evidence",268,"ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.","Shivarov et al., 2015, Leuk. Lymphoma",25308295,"http://www.ncbi.nlm.nih.gov/pubmed/25308295",NULL,NULL,"2015","6",NULL,"Leuk. Lymphoma","Leukemia & lymphoma","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
452,"EID452","Glioblastoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","D","Predictive","Supports","Sensitivity","Somatic Mutation",178,3,NULL,"accepted",0,"evidence",269,"Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.","Eich et al., 2013, Mol. Cancer Ther.",23960094,"http://www.ncbi.nlm.nih.gov/pubmed/23960094",NULL,NULL,"2013","11",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","11","Temozolomide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
453,"EID453","Melanoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",178,3,NULL,"accepted",0,"evidence",269,"Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.","Eich et al., 2013, Mol. Cancer Ther.",23960094,"http://www.ncbi.nlm.nih.gov/pubmed/23960094",NULL,NULL,"2013","11",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","11","Temozolomide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
454,"EID454","ATM-deficient H1395 and HT144 cancer cell lines showed growth inhibition when treated with DNA PKcs inhibitors KU-0060648 and NU7441. These agents also increased the lifespan of mice transfused with ATM-deficient lymphoma cells when compared with etoposide or control.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",179,5,"Substitutes","accepted",0,"evidence",270,"Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.","Riabinska et al., 2013, Sci Transl Med",23761041,"http://www.ncbi.nlm.nih.gov/pubmed/23761041",NULL,NULL,"2013","6","12","Sci Transl Med","Science translational medicine","fully curated","405","KU-0060648",NULL,"406","NU7441",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
455,"EID455","Olaparib was found to inhibit cancer cell growth in ATM mutant cell lines of several blood cancers including Lymphoblastoid Leukemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and in a murine xenograft model of Mantle Cell Lymphoma.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","D","Predictive","Supports","Sensitivity","Somatic Mutation",178,5,NULL,"accepted",0,"evidence",271,"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.","Weston et al., 2010, Blood",20739657,"http://www.ncbi.nlm.nih.gov/pubmed/20739657",NULL,NULL,"2010","11","25","Blood","Blood","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
456,"EID456","Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin.",170,"Esophagus Adenocarcinoma","Esophagus Adenocarcinoma",4914,"http://www.disease-ontology.org/?id=DOID:4914","E","Predictive","Supports","Sensitivity","Somatic Mutation",180,3,"Combination","accepted",0,"evidence",272,"The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.","Sehdev et al., 2012, Mol. Cancer Ther.",22302096,"http://www.ncbi.nlm.nih.gov/pubmed/22302096","true","PMC3297687","2012","3",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","363","Alisertib",NULL,"326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
457,"EID457","In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol.",219,"Cervical Adenocarcinoma","Cervical Adenocarcinoma",3702,"http://www.disease-ontology.org/?id=DOID:3702","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",181,3,NULL,"accepted",0,"evidence",273,"AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.","Anand et al., 2003, Cancer Cell",12559175,"http://www.ncbi.nlm.nih.gov/pubmed/12559175",NULL,NULL,"2003","1",NULL,"Cancer Cell","Cancer cell","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
458,"EID458","In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","B","Prognostic","Supports","Better Outcome","Somatic Mutation",182,3,NULL,"accepted",0,"evidence",274,"Prognostic parameters in uveal melanoma and their association with BAP1 expression.","van Essen et al., 2014, Br J Ophthalmol",25147369,"http://www.ncbi.nlm.nih.gov/pubmed/25147369","true","PMC4966163","2014","12",NULL,"Br J Ophthalmol","The British journal of ophthalmology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
459,"EID459","In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type.",48,"Renal Clear Cell Carcinoma","Renal Clear Cell Carcinoma",4467,"http://www.disease-ontology.org/?id=DOID:4467","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",183,5,NULL,"accepted",0,"evidence",275,"Integrated molecular analysis of clear-cell renal cell carcinoma.","Sato et al., 2013, Nat. Genet.",23797736,"http://www.ncbi.nlm.nih.gov/pubmed/23797736",NULL,NULL,"2013","8",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
460,"EID460","In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",183,5,NULL,"accepted",0,"evidence",275,"Integrated molecular analysis of clear-cell renal cell carcinoma.","Sato et al., 2013, Nat. Genet.",23797736,"http://www.ncbi.nlm.nih.gov/pubmed/23797736",NULL,NULL,"2013","8",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
461,"EID461","In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type.",48,"Renal Clear Cell Carcinoma","Renal Clear Cell Carcinoma",4467,"http://www.disease-ontology.org/?id=DOID:4467","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",183,5,NULL,"accepted",0,"evidence",276,"Comprehensive molecular characterization of clear cell renal cell carcinoma.","2013, Nature",23792563,"http://www.ncbi.nlm.nih.gov/pubmed/23792563","true","PMC3771322","2013","7","4","Nature","Nature","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
462,"EID462","The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant.",156,"Papillary Thyroid Carcinoma","Papillary Thyroid Carcinoma",3969,"http://www.disease-ontology.org/?id=DOID:3969","B","Diagnostic","Supports","Positive","Somatic Mutation",184,4,NULL,"accepted",0,"evidence",277,"Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.","Ciampi et al., 2005, J. Clin. Invest.",15630448,"http://www.ncbi.nlm.nih.gov/pubmed/15630448","true","PMC539203","2005","1",NULL,"J. Clin. Invest.","The Journal of clinical investigation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
463,"EID463","In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type.",224,"Myeloma","Myeloma",70004,"http://www.disease-ontology.org/?id=DOID:70004","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",278,"Targeting the BRAF V600E mutation in multiple myeloma.","Andrulis et al., 2013, Cancer Discov",23612012,"http://www.ncbi.nlm.nih.gov/pubmed/23612012",NULL,NULL,"2013","8",NULL,"Cancer Discov","Cancer discovery","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
464,"EID464","In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.",225,"Epithelial Ovarian Cancer","Epithelial Ovarian Cancer",2152,"http://www.disease-ontology.org/?id=DOID:2152","B","Prognostic","Supports","Better Outcome","Germline Mutation",185,3,NULL,"accepted",0,"evidence",279,"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.","Bolton et al., 2012, JAMA",22274685,"http://www.ncbi.nlm.nih.gov/pubmed/22274685","true","PMC3727895","2012","1","25","JAMA","JAMA","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
465,"EID465","In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.",225,"Epithelial Ovarian Cancer","Epithelial Ovarian Cancer",2152,"http://www.disease-ontology.org/?id=DOID:2152","B","Prognostic","Supports","Better Outcome","Germline Mutation",186,3,NULL,"accepted",0,"evidence",279,"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.","Bolton et al., 2012, JAMA",22274685,"http://www.ncbi.nlm.nih.gov/pubmed/22274685","true","PMC3727895","2012","1","25","JAMA","JAMA","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
466,"EID466","In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.",47,"Ovarian Carcinoma","Ovarian Carcinoma",4001,"http://www.disease-ontology.org/?id=DOID:4001","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",187,4,NULL,"accepted",0,"evidence",280,"Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.","Nakayama et al., 2010, Cancer",20336784,"http://www.ncbi.nlm.nih.gov/pubmed/20336784",NULL,NULL,"2010","6","1","Cancer","Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
467,"EID467","In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",29,4,NULL,"accepted",0,"evidence",281,"Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.","Ho et al., 2009, Blood",19304957,"http://www.ncbi.nlm.nih.gov/pubmed/19304957","true","PMC2943755","2009","6","25","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
468,"EID468","In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA. Those with mutations had better overall survival than wild-type patients.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",29,4,NULL,"accepted",0,"evidence",282,"Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.","Matsuo et al., 2014, Blood Cancer J",25014773,"http://www.ncbi.nlm.nih.gov/pubmed/25014773","true","PMC4219441","2014",NULL,NULL,"Blood Cancer J","Blood cancer journal","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
469,"EID469","In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than wild-type patients (n=59; p=0.011). This was also true for the subset of patients with early T-ALL DNMT3A-mutated (n = 8) compared to wild-type patients (n = 22; p=0.005).",227,"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Leukemia",5603,"http://www.disease-ontology.org/?id=DOID:5603","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",189,4,NULL,"accepted",0,"evidence",283,"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.","Grossmann et al., 2013, Genes Chromosomes Cancer",23341344,"http://www.ncbi.nlm.nih.gov/pubmed/23341344",NULL,NULL,"2013","4",NULL,"Genes Chromosomes Cancer","Genes, chromosomes & cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
470,"EID470","In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.",228,"Barrett's Adenocarcinoma","Barrett's Adenocarcinoma",7941,"http://www.disease-ontology.org/?id=DOID:7941","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",190,3,NULL,"accepted",0,"evidence",284,"Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.","Marx et al., 2010, Histopathology",20840671,"http://www.ncbi.nlm.nih.gov/pubmed/20840671",NULL,NULL,"2010","9",NULL,"Histopathology","Histopathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
471,"EID471","In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.",148,"Cervical Squamous Cell Carcinoma","Cervical Squamous Cell Carcinoma",3744,"http://www.disease-ontology.org/?id=DOID:3744","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",190,3,NULL,"accepted",0,"evidence",285,"EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.","Iida et al., 2011, Br. J. Cancer",21730982,"http://www.ncbi.nlm.nih.gov/pubmed/21730982","true","PMC3172895","2011","7","26","Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
472,"EID472","In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and disease-free survival.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",191,4,NULL,"accepted",0,"evidence",286,"Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.","Temam et al., 2007, J. Clin. Oncol.",17538160,"http://www.ncbi.nlm.nih.gov/pubmed/17538160",NULL,NULL,"2007","6","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
473,"EID473","The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",190,4,NULL,"accepted",0,"evidence",287,"Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.","Chung et al., 2006, J. Clin. Oncol.",16943533,"http://www.ncbi.nlm.nih.gov/pubmed/16943533",NULL,NULL,"2006","9","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
474,"EID474","In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival.",231,"Supratentorial Glioblastoma Multiforme","Supratentorial Glioblastoma Multiforme",3073,"http://www.disease-ontology.org/?id=DOID:3073","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",193,3,NULL,"accepted",0,"evidence",288,"Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.","Shinojima et al., 2003, Cancer Res.",14583498,"http://www.ncbi.nlm.nih.gov/pubmed/14583498",NULL,NULL,"2003","10","15","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
475,"EID475","t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease.",50,"Peripheral Primitive Neuroectodermal Tumor","Peripheral Primitive Neuroectodermal Tumor",3369,"http://www.disease-ontology.org/?id=DOID:3369","B","Diagnostic","Supports","Positive","Somatic Mutation",194,5,NULL,"accepted",0,"evidence",289,"Integrated multimodal genetic testing of Ewing sarcoma--a single-institution experience.","Warren et al., 2013, Hum. Pathol.",23706910,"http://www.ncbi.nlm.nih.gov/pubmed/23706910",NULL,NULL,"2013","10",NULL,"Hum. Pathol.","Human pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
476,"EID476","TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples.",101,"Prostate Carcinoma","Prostate Carcinoma",10286,"http://www.disease-ontology.org/?id=DOID:10286","B","Diagnostic","Supports","Positive","Somatic Mutation",195,3,NULL,"accepted",0,"evidence",290,"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.","Tomlins et al., 2005, Science",16254181,"http://www.ncbi.nlm.nih.gov/pubmed/16254181",NULL,NULL,"2005","10","28","Science","Science (New York, N.Y.)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
477,"EID477","Y375C mutation results in activation of FGFR3 and is associated with bladder carcinoma. Patients with low-grade tumors were more likely to have FGFR3 mutations than those with high-grade tumors.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","B","Diagnostic","Supports","Positive","Somatic Mutation",196,3,NULL,"accepted",0,"evidence",291,"FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.","Bodoor et al., 2010, Cancer Epidemiol",20542753,"http://www.ncbi.nlm.nih.gov/pubmed/20542753",NULL,NULL,"2010","12",NULL,"Cancer Epidemiol","Cancer epidemiology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
478,"EID478","t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples.",50,"Peripheral Primitive Neuroectodermal Tumor","Peripheral Primitive Neuroectodermal Tumor",3369,"http://www.disease-ontology.org/?id=DOID:3369","B","Diagnostic","Supports","Positive","Somatic Mutation",197,5,NULL,"accepted",0,"evidence",289,"Integrated multimodal genetic testing of Ewing sarcoma--a single-institution experience.","Warren et al., 2013, Hum. Pathol.",23706910,"http://www.ncbi.nlm.nih.gov/pubmed/23706910",NULL,NULL,"2013","10",NULL,"Hum. Pathol.","Human pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
479,"EID479","FOXL2 C134W mutation was found in 52 / 56 adult granulosa cell tumors, and is absent in other types of sex-cord stromal tumors, and juvenile granulosa tumors.",235,"Ovarian Granulosa Cell Tumor","Ovarian Granulosa Cell Tumor",2999,"http://www.disease-ontology.org/?id=DOID:2999","B","Diagnostic","Supports","Positive","Somatic Mutation",198,4,NULL,"accepted",0,"evidence",292,"The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary.","Jamieson et al., 2010, Mod. Pathol.",20693978,"http://www.ncbi.nlm.nih.gov/pubmed/20693978",NULL,NULL,"2010","11",NULL,"Mod. Pathol.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
480,"EID480","In patients with a glioblastoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Prognostic","Supports","Better Outcome","Somatic Mutation",58,5,NULL,"accepted",0,"evidence",293,"IDH1 and IDH2 mutations in gliomas.","Yan et al., 2009, N. Engl. J. Med.",19228619,"http://www.ncbi.nlm.nih.gov/pubmed/19228619","true","PMC2820383","2009","2","19","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
481,"EID481","In patients with anaplastic astrocytoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients.",35,"Astrocytoma","Astrocytoma",3069,"http://www.disease-ontology.org/?id=DOID:3069","B","Prognostic","Supports","Better Outcome","Somatic Mutation",58,5,NULL,"accepted",0,"evidence",293,"IDH1 and IDH2 mutations in gliomas.","Yan et al., 2009, N. Engl. J. Med.",19228619,"http://www.ncbi.nlm.nih.gov/pubmed/19228619","true","PMC2820383","2009","2","19","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
482,"EID482","In patients with a glioblastoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Prognostic","Supports","Better Outcome","Somatic Mutation",199,5,NULL,"accepted",0,"evidence",293,"IDH1 and IDH2 mutations in gliomas.","Yan et al., 2009, N. Engl. J. Med.",19228619,"http://www.ncbi.nlm.nih.gov/pubmed/19228619","true","PMC2820383","2009","2","19","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
483,"EID483","In patients with anaplastic astrocytoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients.",35,"Astrocytoma","Astrocytoma",3069,"http://www.disease-ontology.org/?id=DOID:3069","B","Prognostic","Supports","Better Outcome","Somatic Mutation",199,5,NULL,"accepted",0,"evidence",293,"IDH1 and IDH2 mutations in gliomas.","Yan et al., 2009, N. Engl. J. Med.",19228619,"http://www.ncbi.nlm.nih.gov/pubmed/19228619","true","PMC2820383","2009","2","19","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
484,"EID484","In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, those with deletions of IKZF1 had worse event-free and overall survival than patients without deletions.",237,"Precursor B Lymphoblastic Lymphoma/leukemia","Precursor B Lymphoblastic Lymphoma/leukemia",7061,"http://www.disease-ontology.org/?id=DOID:7061","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",200,4,NULL,"accepted",0,"evidence",294,"Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.","Krentz et al., 2013, Leukemia",22699455,"http://www.ncbi.nlm.nih.gov/pubmed/22699455",NULL,NULL,"2013","2",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
485,"EID485","M541L mutation was not associated with CML in caucasian patients, and was common among healthy controls (8.1%), in contrast to a previous study in a Japanese CML patient population in which M541L was strongly associated with CML disease.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Diagnostic","Does Not Support","Negative","Somatic Mutation",201,4,NULL,"accepted",0,"evidence",295,"The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians.","KrÃ¼ger et al., 2006, Leukemia",16307017,"http://www.ncbi.nlm.nih.gov/pubmed/16307017",NULL,NULL,"2006","2",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
486,"EID486","In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib.",239,"Thymic Carcinoma","Thymic Carcinoma",3284,"http://www.disease-ontology.org/?id=DOID:3284","C","Predictive","Supports","Sensitivity","Somatic Mutation",202,5,NULL,"accepted",0,"evidence",296,"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.","StrÃ¶bel et al., 2004, N. Engl. J. Med.",15201427,"http://www.ncbi.nlm.nih.gov/pubmed/15201427",NULL,NULL,"2004","6","17","N. Engl. J. Med.","The New England journal of medicine","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
487,"EID487","In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations.",41,"Multiple Myeloma","Multiple Myeloma",9538,"http://www.disease-ontology.org/?id=DOID:9538","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",76,4,NULL,"accepted",0,"evidence",229,"Clinical and biological significance of RAS mutations in multiple myeloma.","Chng et al., 2008, Leukemia",18528420,"http://www.ncbi.nlm.nih.gov/pubmed/18528420","true","PMC3864109","2008","12",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
488,"EID488","In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations.",41,"Multiple Myeloma","Multiple Myeloma",9538,"http://www.disease-ontology.org/?id=DOID:9538","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",80,4,NULL,"accepted",0,"evidence",229,"Clinical and biological significance of RAS mutations in multiple myeloma.","Chng et al., 2008, Leukemia",18528420,"http://www.ncbi.nlm.nih.gov/pubmed/18528420","true","PMC3864109","2008","12",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
489,"EID489","In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those without mutations.",240,"Multiple Myeloma","Multiple Myeloma",9583,"http://www.disease-ontology.org/?id=DOID:9583","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",203,4,NULL,"accepted",0,"evidence",297,"Clinical and biological significance of RAS mutations in multiple myeloma.","Chng et al., 2008, Leukemia",18528420,"http://www.ncbi.nlm.nih.gov/pubmed/18528420","true","PMC3864109","2008","12",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
490,"EID490","In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival.",241,"Anaplastic Oligodendroglioma","Anaplastic Oligodendroglioma",3181,"http://www.disease-ontology.org/?id=DOID:3181","B","Prognostic","Supports","Better Outcome","Somatic Mutation",85,4,NULL,"accepted",0,"evidence",298,"MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.","van den Bent et al., 2009, J. Clin. Oncol.",19901104,"http://www.ncbi.nlm.nih.gov/pubmed/19901104","true","PMC2793037","2009","12","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
491,"EID491","In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Prognostic","Supports","Better Outcome","Somatic Mutation",85,5,NULL,"accepted",0,"evidence",299,"MGMT gene silencing and benefit from temozolomide in glioblastoma.","Hegi et al., 2005, N. Engl. J. Med.",15758010,"http://www.ncbi.nlm.nih.gov/pubmed/15758010",NULL,NULL,"2005","3","10","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
492,"EID492","In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",204,3,NULL,"accepted",0,"evidence",300,"Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.","Burandt et al., 2013, Breast Cancer Res. Treat.",23322234,"http://www.ncbi.nlm.nih.gov/pubmed/23322234",NULL,NULL,"2013","2",NULL,"Breast Cancer Res. Treat.","Breast cancer research and treatment","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
493,"EID493","High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",205,3,NULL,"accepted",0,"evidence",300,"Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.","Burandt et al., 2013, Breast Cancer Res. Treat.",23322234,"http://www.ncbi.nlm.nih.gov/pubmed/23322234",NULL,NULL,"2013","2",NULL,"Breast Cancer Res. Treat.","Breast cancer research and treatment","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
494,"EID494","14 out of 121 patient samples contained mutations in NOTCH1. Those with mutations had worse overall survival than wild-type (median OS, 1.43 years vs. 3.86 years).",243,"Mantle Cell Lymphoma","Mantle Cell Lymphoma",50476,"http://www.disease-ontology.org/?id=DOID:50476","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",206,3,NULL,"accepted",0,"evidence",301,"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.","Kridel et al., 2012, Blood",22210878,"http://www.ncbi.nlm.nih.gov/pubmed/22210878",NULL,NULL,"2012","3","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
495,"EID495","In a cohort of 120 patients with chronic lymphoytic leukemia, those with P2515 frameshift deletions in NOTCH1 at diagnosis had worse overall and treatment free survival. NOTCH1 mutations were also found to be an independent poor predictor of survival regardless of TP53 and IGHV status.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",207,3,NULL,"accepted",0,"evidence",302,"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.","Fabbri et al., 2011, J. Exp. Med.",21670202,"http://www.ncbi.nlm.nih.gov/pubmed/21670202","true","PMC3135373","2011","7","4","J. Exp. Med.","The Journal of experimental medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
496,"EID496","In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival.",41,"Multiple Myeloma","Multiple Myeloma",9538,"http://www.disease-ontology.org/?id=DOID:9538","B","Prognostic","Supports","N/A","Somatic Mutation",208,4,NULL,"accepted",0,"evidence",297,"Clinical and biological significance of RAS mutations in multiple myeloma.","Chng et al., 2008, Leukemia",18528420,"http://www.ncbi.nlm.nih.gov/pubmed/18528420","true","PMC3864109","2008","12",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
497,"EID497","In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36).",246,"Follicular Thyroid Carcinoma","Follicular Thyroid Carcinoma",3962,"http://www.disease-ontology.org/?id=DOID:3962","B","Prognostic","Supports","N/A","Somatic Mutation",94,3,NULL,"accepted",0,"evidence",303,"The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.","Fukahori et al., 2012, Thyroid",22650231,"http://www.ncbi.nlm.nih.gov/pubmed/22650231",NULL,NULL,"2012","7",NULL,"Thyroid","Thyroid : official journal of the American Thyroid Association","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
498,"EID498","PAX8â€“PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid HÃ¼rthle cell tumors.",246,"Follicular Thyroid Carcinoma","Follicular Thyroid Carcinoma",3962,"http://www.disease-ontology.org/?id=DOID:3962","B","Diagnostic","Supports","Positive","Somatic Mutation",209,3,NULL,"accepted",0,"evidence",304,"RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.","Nikiforova et al., 2003, J. Clin. Endocrinol. Metab.",12727991,"http://www.ncbi.nlm.nih.gov/pubmed/12727991",NULL,NULL,"2003","5",NULL,"J. Clin. Endocrinol. Metab.","The Journal of clinical endocrinology and metabolism","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
499,"EID499","In patients with sporatic clear cell renal cell carcinoma, those with mutations in PBRM1 had better overall survival than patients with BAP1 mutations.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Prognostic","Supports","Better Outcome","Somatic Mutation",161,3,NULL,"accepted",0,"evidence",305,"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.","Kapur et al., 2013, Lancet Oncol.",23333114,"http://www.ncbi.nlm.nih.gov/pubmed/23333114","true","PMC4674067","2013","2",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
500,"EID500","In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Better Outcome","Somatic Mutation",210,3,NULL,"accepted",0,"evidence",306,"Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.","Dowsett et al., 2006, Ann. Oncol.",16497822,"http://www.ncbi.nlm.nih.gov/pubmed/16497822",NULL,NULL,"2006","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
501,"EID501","In patients with ER-Positive breast cancer, expression of PgR does not effect the outcome of treatment with tamoxifen.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Does Not Support","N/A","Somatic Mutation",210,3,NULL,"accepted",0,"evidence",307,"Biomarkers for the clinical management of breast cancer: international perspective.","Patani et al., 2013, Int. J. Cancer",23280579,"http://www.ncbi.nlm.nih.gov/pubmed/23280579",NULL,NULL,"2013","7",NULL,"Int. J. Cancer","International journal of cancer","fully curated","53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
502,"EID502","In patients with breast cancer, those with low expression of PgR treated with tamoxifen had the same disease-free survial as those with high expression of PgR.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Does Not Support","N/A","Somatic Mutation",210,4,"Substitutes","accepted",0,"evidence",308,"Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.","Bartlett et al., 2011, J. Clin. Oncol.",21422407,"http://www.ncbi.nlm.nih.gov/pubmed/21422407","true","PMC3082973","2011","4","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","82","Exemestane",NULL,"53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
503,"EID503","In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",210,4,NULL,"accepted",0,"evidence",308,"Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.","Bartlett et al., 2011, J. Clin. Oncol.",21422407,"http://www.ncbi.nlm.nih.gov/pubmed/21422407","true","PMC3082973","2011","4","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
504,"EID504","In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",212,3,NULL,"accepted",0,"evidence",309,"Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.","Shi et al., 2012, BMC Cancer",22292935,"http://www.ncbi.nlm.nih.gov/pubmed/22292935","true","PMC3299648","2012",NULL,NULL,"BMC Cancer","BMC cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
505,"EID505","In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those without deletions.",122,"Prostate Adenocarcinoma","Prostate Adenocarcinoma",2526,"http://www.disease-ontology.org/?id=DOID:2526","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",213,4,NULL,"accepted",0,"evidence",310,"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.","Yoshimoto et al., 2007, Br. J. Cancer",17700571,"http://www.ncbi.nlm.nih.gov/pubmed/17700571","true","PMC2360375","2007","9","3","Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
506,"EID506","In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",214,3,NULL,"accepted",0,"evidence",311,"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.","De Roock et al., 2011, Lancet Oncol.",21163703,"http://www.ncbi.nlm.nih.gov/pubmed/21163703",NULL,NULL,"2011","6",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
507,"EID507","In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Predictive","Supports","Sensitivity","Somatic Mutation",214,4,NULL,"accepted",0,"evidence",312,"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.","Neshat et al., 2001, Proc. Natl. Acad. Sci. U.S.A.",11504908,"http://www.ncbi.nlm.nih.gov/pubmed/11504908","true","PMC56958","2001","8","28","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","83","Temsirolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
508,"EID508","In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mutated, 62 wild type patients; P=0.014) and the early subtype (N=7 mutated, 23 wild type patients; P=0.027). RUNX1 mutations were associated with other poor-risk parameters, early subtype and older age.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",155,3,NULL,"accepted",0,"evidence",283,"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.","Grossmann et al., 2013, Genes Chromosomes Cancer",23341344,"http://www.ncbi.nlm.nih.gov/pubmed/23341344",NULL,NULL,"2013","4",NULL,"Genes Chromosomes Cancer","Genes, chromosomes & cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
509,"EID509","In a study of patients with cytogenically normal acute myeloid leukemia, RUNX1 mutations were more frequent in patients 60 years old or older. Patients with RUNX1 mutations had shorter disease-free (younger, P = 0.058; older, P < 0.001), event-free (both, P < 0.001), and overall survival (younger, P = 0.003; older, P < 0.001) as well as lower complete remission rates (younger, P = 0.005; older, P = 0.006).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",155,4,NULL,"accepted",0,"evidence",313,"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.","Mendler et al., 2012, J. Clin. Oncol.",22753902,"http://www.ncbi.nlm.nih.gov/pubmed/22753902","true","PMC3732007","2012","9","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
510,"EID510","In patients with chronic lymphocytic leukemia, those with mutations in SF3B1 had shorter time to treatment, progression-free survival, and overall survival. A majority of the mutations are in the C-terminal domain with the most frequent location being K700E (50% of reported cases).",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",215,4,NULL,"accepted",0,"evidence",314,"SF3B1 mutations in chronic lymphocytic leukemia.","Wan et al., 2013, Blood",23568491,"http://www.ncbi.nlm.nih.gov/pubmed/23568491","true","PMC3674664","2013","6","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
511,"EID511","In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients.",158,"Pancreas Adenocarcinoma","Pancreas Adenocarcinoma",4074,"http://www.disease-ontology.org/?id=DOID:4074","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",216,3,NULL,"accepted",0,"evidence",315,"SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.","Blackford et al., 2009, Clin. Cancer Res.",19584151,"http://www.ncbi.nlm.nih.gov/pubmed/19584151","true","PMC2819274","2009","7","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
512,"EID512","Nonsense mutations in SMARCA4 were associated with small cell carcinoma of the ovary, hypercalcemic type in 10/10 tumor samples, and were rarely found in other solid tumor types catalogued by TCGA.",253,"Small Cell Carcinoma Of The Ovary Hypercalcemic Type","Small Cell Carcinoma Of The Ovary Hypercalcemic Type",7651,"http://www.disease-ontology.org/?id=DOID:7651","B","Diagnostic","Supports","Positive","Somatic Mutation",217,5,NULL,"accepted",0,"evidence",316,"Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.","Jelinic et al., 2014, Nat. Genet.",24658004,"http://www.ncbi.nlm.nih.gov/pubmed/24658004",NULL,NULL,"2014","5",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
513,"EID513","In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",218,4,NULL,"accepted",0,"evidence",316,"Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.","Jelinic et al., 2014, Nat. Genet.",24658004,"http://www.ncbi.nlm.nih.gov/pubmed/24658004",NULL,NULL,"2014","5",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
514,"EID514","In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival.",192,"Acral Lentiginous Melanoma","Acral Lentiginous Melanoma",6367,"http://www.disease-ontology.org/?id=DOID:6367","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",219,3,NULL,"accepted",0,"evidence",317,"TERT gene amplification is associated with poor outcome in acral lentiginous melanoma.","Diaz et al., 2014, J. Am. Acad. Dermatol.",25219713,"http://www.ncbi.nlm.nih.gov/pubmed/25219713",NULL,NULL,"2014","10",NULL,"J. Am. Acad. Dermatol.","Journal of the American Academy of Dermatology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
515,"EID515","In patients with nonacral cutaneous melanoma, those with mutations in the TERT promoter had shorter overall survival than wild-type patients.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",220,3,NULL,"accepted",0,"evidence",318,"TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.","Griewank et al., 2014, J. Natl. Cancer Inst.",25217772,"http://www.ncbi.nlm.nih.gov/pubmed/25217772","true","PMC4200061","2014","9",NULL,"J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
516,"EID516","In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27% of mutants). However, most of the Prognostic value of TERT mutations is thought to be derived from their inverse coorelation with IDH1 mutations.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",220,4,NULL,"accepted",0,"evidence",319,"TERT promoter mutations in primary and secondary glioblastomas.","Nonoguchi et al., 2013, Acta Neuropathol.",23955565,"http://www.ncbi.nlm.nih.gov/pubmed/23955565",NULL,NULL,"2013","12",NULL,"Acta Neuropathol.","Acta neuropathologica","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
517,"EID517","In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those without mutations or with nondisruptive mutations.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",221,3,NULL,"accepted",0,"evidence",320,"TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.","Skinner et al., 2012, Clin. Cancer Res.",22090360,"http://www.ncbi.nlm.nih.gov/pubmed/22090360","true","PMC3251726","2012","1","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
518,"EID518","Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutations.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",222,3,NULL,"accepted",0,"evidence",321,"p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.","Koch et al., 1996, J. Natl. Cancer Inst.",8901856,"http://www.ncbi.nlm.nih.gov/pubmed/8901856",NULL,NULL,"1996","11","6","J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
519,"EID519","In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",322,"p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.","Yamasaki et al., 2010, Ann. Surg. Oncol.",19941080,"http://www.ncbi.nlm.nih.gov/pubmed/19941080",NULL,NULL,"2010","2",NULL,"Ann. Surg. Oncol.","Annals of surgical oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
520,"EID520","In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations.",237,"Precursor B Lymphoblastic Lymphoma/leukemia","Precursor B Lymphoblastic Lymphoma/leukemia",7061,"http://www.disease-ontology.org/?id=DOID:7061","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",294,"Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.","Krentz et al., 2013, Leukemia",22699455,"http://www.ncbi.nlm.nih.gov/pubmed/22699455",NULL,NULL,"2013","2",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
521,"EID521","In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",323,"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.","Bally et al., 2014, Leuk. Res.",24836762,"http://www.ncbi.nlm.nih.gov/pubmed/24836762",NULL,NULL,"2014","7",NULL,"Leuk. Res.","Leukemia research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
522,"EID522","In patients with myeloma, those with mutations in TP53 had worse overall survival than those without.",224,"Myeloma","Myeloma",70004,"http://www.disease-ontology.org/?id=DOID:70004","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",324,"Clinical significance of TP53 mutation in myeloma.","Chng et al., 2007, Leukemia",17215851,"http://www.ncbi.nlm.nih.gov/pubmed/17215851",NULL,NULL,"2007","3",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
523,"EID523","Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with surgery did not show a significant difference in rates of loco-regional control between those with and without mutations in TP53.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",325,"TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.","Alsner et al., 2001, Radiother Oncol",11325447,"http://www.ncbi.nlm.nih.gov/pubmed/11325447",NULL,NULL,"2001","5",NULL,"Radiother Oncol","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
524,"EID524","Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of loco-regional control and shorter disease-free, disease-specific, and overall survival.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",325,"TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.","Alsner et al., 2001, Radiother Oncol",11325447,"http://www.ncbi.nlm.nih.gov/pubmed/11325447",NULL,NULL,"2001","5",NULL,"Radiother Oncol","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
525,"EID525","In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",223,4,NULL,"accepted",0,"evidence",326,"Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.","Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res.",21467160,"http://www.ncbi.nlm.nih.gov/pubmed/21467160",NULL,NULL,"2011","6","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
526,"EID526","In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate analysis.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",223,4,NULL,"accepted",0,"evidence",326,"Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.","Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res.",21467160,"http://www.ncbi.nlm.nih.gov/pubmed/21467160",NULL,NULL,"2011","6","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
527,"EID527","6 of 89 patients with lung adenocarcinoma had amplification of TTF1. There was no statistical difference in overall survival between patients with and without gene amplification.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Prognostic","Does Not Support","N/A","Somatic Mutation",224,3,NULL,"accepted",0,"evidence",327,"Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.","Barletta et al., 2009, J. Cell. Mol. Med.",19040416,"http://www.ncbi.nlm.nih.gov/pubmed/19040416","true","PMC2830395","2009","8",NULL,"J. Cell. Mol. Med.","Journal of cellular and molecular medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
528,"EID528","A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,5,NULL,"accepted",0,"evidence",328,"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","Slamon et al., 2001, N. Engl. J. Med.",11248153,"http://www.ncbi.nlm.nih.gov/pubmed/11248153",NULL,NULL,"2001","3","15","N. Engl. J. Med.","The New England journal of medicine","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
529,"EID529","A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,5,NULL,"accepted",0,"evidence",329,"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.","Marty et al., 2005, J. Clin. Oncol.",15911866,"http://www.ncbi.nlm.nih.gov/pubmed/15911866",NULL,NULL,"2005","7","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
531,"EID531","Heterozygous germline truncating (frameshift) and missense mutations confer highly penetrant predisposition to multiple cancer types including sarcoma, breast cancer, and brain tumors. Screening of individuals with Li-Fraumeni syndrome but lacking TP53 mutations identified 1/4 classical and 2/18 LFS variant presentation. This included 1 large family pedigree with strong co-segregation of the mutation with cancer development.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predisposing","Supports","Positive","Germline Mutation",230,5,NULL,"accepted",0,"evidence",331,"Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.","Bell et al., 1999, Science",10617473,"http://www.ncbi.nlm.nih.gov/pubmed/10617473",NULL,NULL,"1999","12","24","Science","Science (New York, N.Y.)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
532,"EID532","RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas). FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas. Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma.",44,"Hepatocellular Fibrolamellar Carcinoma","Hepatocellular Fibrolamellar Carcinoma",5015,"http://www.disease-ontology.org/?id=DOID:5015","B","Diagnostic","Supports","Positive","Somatic Mutation",31,5,NULL,"accepted",0,"evidence",260,"DNAJB1-PRKACA is specific for fibrolamellar carcinoma.","Graham et al., 2015, Mod. Pathol.",25698061,"http://www.ncbi.nlm.nih.gov/pubmed/25698061",NULL,NULL,"2015","6",NULL,"Mod. Pathol.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
622,"EID622","Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastatic adenocarcinoma of the pancreas.",158,"Pancreas Adenocarcinoma","Pancreas Adenocarcinoma",4074,"http://www.disease-ontology.org/?id=DOID:4074","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",77,4,"Combination","accepted",0,"evidence",385,"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.","Infante et al., 2014, Eur. J. Cancer",24915778,"http://www.ncbi.nlm.nih.gov/pubmed/24915778",NULL,NULL,"2014","8",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","19","Trametinib",NULL,"85","Gemcitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
623,"EID623","In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1.",87,"Ovarian Serous Carcinoma","Ovarian Serous Carcinoma",50933,"http://www.disease-ontology.org/?id=DOID:0050933","D","Predictive","Supports","Sensitivity","Somatic Mutation",236,4,NULL,"accepted",0,"evidence",386,"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.","Bajrami et al., 2014, Cancer Res.",24240700,"http://www.ncbi.nlm.nih.gov/pubmed/24240700","true","PMC4886090","2014","1","1","Cancer Res.","Cancer research","partially curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
624,"EID624","IKZF1 deletions are associated with poor outcome in patients with childhood BCR-ABLâ€“positive B-cell precursor acute lymphoblastic leukemia even when treated with imatinib. This phenomenon was observed in patients treated in the pre-TKI era as well as those treated with imatinib when compared to wild-type patients undergoing similar treatment.",237,"Precursor B Lymphoblastic Lymphoma/leukemia","Precursor B Lymphoblastic Lymphoma/leukemia",7061,"http://www.disease-ontology.org/?id=DOID:7061","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",200,3,NULL,"accepted",0,"evidence",387,"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.","van der Veer et al., 2014, Blood",24366361,"http://www.ncbi.nlm.nih.gov/pubmed/24366361",NULL,NULL,"2014","3","13","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
625,"EID625","IKZF1 deletions in patients with BCR-ABLâ€“positive adult acute lymphoblastic leukemia were associated with reduced disease-free survival compared to wild type patients.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",200,3,NULL,"accepted",0,"evidence",388,"IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.","Martinelli et al., 2009, J. Clin. Oncol.",19770381,"http://www.ncbi.nlm.nih.gov/pubmed/19770381",NULL,NULL,"2009","11","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
626,"EID626","A targeted copy number screen of 131 precursor B-ALL cases revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates. Furthermore non-high-risk patients with IKZF1 deletions exhibited a ~12-fold higher relative relapse rate than those without IKZF1 deletions.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",200,3,NULL,"accepted",0,"evidence",389,"IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.","Kuiper et al., 2010, Leukemia",20445578,"http://www.ncbi.nlm.nih.gov/pubmed/20445578",NULL,NULL,"2010","7",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
627,"EID627","In patients with angioimmunoblastic T-cell lymphoma (a subtype of peripheral T-cell lymphoma), IDH2 R172 mutations (N=16) had no impact on overall survival when compared to patients with wildtype IDH2 (N=24).",56,"Peripheral T-cell Lymphoma","Peripheral T-cell Lymphoma",50749,"http://www.disease-ontology.org/?id=DOID:0050749","B","Prognostic","Does Not Support","Better Outcome","Somatic Mutation",199,3,NULL,"accepted",0,"evidence",390,"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.","Wang et al., 2015, Blood",26268241,"http://www.ncbi.nlm.nih.gov/pubmed/26268241","true","PMC4600014","2015","10","8","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
628,"EID628","IDH2 R172 mutations were frequently observed in patients with the angioimmunoblastic T-cell lymphoma subtype of peripheral T-cell lymphomas but not observed in other subtypes.",56,"Peripheral T-cell Lymphoma","Peripheral T-cell Lymphoma",50749,"http://www.disease-ontology.org/?id=DOID:0050749","B","Diagnostic","Supports","Positive","Somatic Mutation",199,4,NULL,"accepted",0,"evidence",391,"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.","Cairns et al., 2012, Blood",22215888,"http://www.ncbi.nlm.nih.gov/pubmed/22215888","true","PMC3293643","2012","2","23","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
629,"EID629","In patients with Philadelphia Chromosome negative B-cell precursor acute lymphoblastic leukemia, focal deletion involving 3-5 exons of IKZF1 was associated with higher cumulative incidence of relapse (CIR) than wildtype IKZF1.",237,"Precursor B Lymphoblastic Lymphoma/leukemia","Precursor B Lymphoblastic Lymphoma/leukemia",7061,"http://www.disease-ontology.org/?id=DOID:7061","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",200,4,NULL,"accepted",0,"evidence",392,"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.","Beldjord et al., 2014, Blood",24740809,"http://www.ncbi.nlm.nih.gov/pubmed/24740809",NULL,NULL,"2014","6","12","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
630,"EID630","CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins.",227,"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Leukemia",5603,"http://www.disease-ontology.org/?id=DOID:5603","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",238,4,"Substitutes","accepted",0,"evidence",399,"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.","Tzoneva et al., 2013, Nat. Med.",23377281,"http://www.ncbi.nlm.nih.gov/pubmed/23377281","true","PMC3594483","2013","3",NULL,"Nat. Med.","Nature medicine","fully curated","86","6-mercaptopurine",NULL,"87","6-thioguanine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
631,"EID631","CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins.",227,"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Leukemia",5603,"http://www.disease-ontology.org/?id=DOID:5603","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",239,4,"Substitutes","accepted",0,"evidence",399,"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.","Tzoneva et al., 2013, Nat. Med.",23377281,"http://www.ncbi.nlm.nih.gov/pubmed/23377281","true","PMC3594483","2013","3",NULL,"Nat. Med.","Nature medicine","fully curated","87","6-thioguanine",NULL,"86","6-mercaptopurine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
632,"EID632","CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype protein.",227,"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Leukemia",5603,"http://www.disease-ontology.org/?id=DOID:5603","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",240,4,"Substitutes","accepted",0,"evidence",399,"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.","Tzoneva et al., 2013, Nat. Med.",23377281,"http://www.ncbi.nlm.nih.gov/pubmed/23377281","true","PMC3594483","2013","3",NULL,"Nat. Med.","Nature medicine","fully curated","87","6-thioguanine",NULL,"86","6-mercaptopurine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
633,"EID633","CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone.",227,"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Leukemia",5603,"http://www.disease-ontology.org/?id=DOID:5603","D","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",238,4,"Substitutes","accepted",0,"evidence",399,"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.","Tzoneva et al., 2013, Nat. Med.",23377281,"http://www.ncbi.nlm.nih.gov/pubmed/23377281","true","PMC3594483","2013","3",NULL,"Nat. Med.","Nature medicine","fully curated","88","Nelarabine",NULL,"89","Arabinosylguanine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
635,"EID635","CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone.",227,"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Leukemia",5603,"http://www.disease-ontology.org/?id=DOID:5603","D","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",240,4,"Substitutes","accepted",0,"evidence",399,"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.","Tzoneva et al., 2013, Nat. Med.",23377281,"http://www.ncbi.nlm.nih.gov/pubmed/23377281","true","PMC3594483","2013","3",NULL,"Nat. Med.","Nature medicine","fully curated","89","Arabinosylguanine",NULL,"88","Nelarabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
636,"EID636","CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone.",227,"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Leukemia",5603,"http://www.disease-ontology.org/?id=DOID:5603","D","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",239,4,"Substitutes","accepted",0,"evidence",399,"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.","Tzoneva et al., 2013, Nat. Med.",23377281,"http://www.ncbi.nlm.nih.gov/pubmed/23377281","true","PMC3594483","2013","3",NULL,"Nat. Med.","Nature medicine","fully curated","89","Arabinosylguanine",NULL,"88","Nelarabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
637,"EID637","BCR-ABL F317L has been shown to confer resistance to dasatinib in patients with CML.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",241,5,NULL,"accepted",0,"evidence",400,"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.","Jabbour et al., 2008, Blood",18818391,"http://www.ncbi.nlm.nih.gov/pubmed/18818391","true","PMC4186640","2008","12","15","Blood","Blood","fully curated","20","Dasatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
638,"EID638","Molecular dynamics simulations and calculated solvated interaction energies indicate BCR-ABL F317L mutations are Ponatinib sensitive.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","D","Predictive","Supports","Sensitivity","Somatic Mutation",241,3,NULL,"accepted",0,"evidence",401,"Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.","Tanneeru et al., 2013, PLoS ONE",24236021,"http://www.ncbi.nlm.nih.gov/pubmed/24236021","true","PMC3827254","2013",NULL,NULL,"PLoS ONE","PloS one","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
639,"EID639","Ponatinib has shown to be effective in patients with BCR-ABL kinase domain mutations like F317L.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Predictive","Supports","Sensitivity","Somatic Mutation",241,5,NULL,"accepted",0,"evidence",402,"Resistant mutations in CML and Ph(+)ALL - role of ponatinib.","Miller et al., 2014, Biologics",25349473,"http://www.ncbi.nlm.nih.gov/pubmed/25349473","true","PMC4208348","2014",NULL,NULL,"Biologics","Biologics : targets & therapy","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
640,"EID640","In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall survival when compared to TP53 wildtype patients.",237,"Precursor B Lymphoblastic Lymphoma/leukemia","Precursor B Lymphoblastic Lymphoma/leukemia",7061,"http://www.disease-ontology.org/?id=DOID:7061","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",403,"Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.","Hof et al., 2011, J. Clin. Oncol.",21747090,"http://www.ncbi.nlm.nih.gov/pubmed/21747090",NULL,NULL,"2011","8","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
641,"EID641","Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutations outside of this DNA binding domain. These mutations were also significantly associated with locoregional failure, cervical lymph node metastasis and distant metastasis, likely contributing to this finding.",58,"Oral Squamous Cell Carcinoma","Oral Squamous Cell Carcinoma",50866,"http://www.disease-ontology.org/?id=DOID:0050866","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",242,4,NULL,"accepted",0,"evidence",404,"Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma.","Yamazaki et al., 2003, Oral Oncol.",12509970,"http://www.ncbi.nlm.nih.gov/pubmed/12509970",NULL,NULL,"2003","2",NULL,"Oral Oncol.","Oral oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
642,"EID642","Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",34,5,"Sequential","accepted",0,"evidence",405,"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.","Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A.",18227510,"http://www.ncbi.nlm.nih.gov/pubmed/18227510","true","PMC2538882","2008","2","12","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","14","Gefitinib",NULL,"90","AEE788",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
643,"EID643","PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",214,4,NULL,"accepted",0,"evidence",310,"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.","Yoshimoto et al., 2007, Br. J. Cancer",17700571,"http://www.ncbi.nlm.nih.gov/pubmed/17700571","true","PMC2360375","2007","9","3","Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
644,"EID644","PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",214,4,NULL,"accepted",0,"evidence",407,"PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.","Seront et al., 2013, Br. J. Cancer",23989949,"http://www.ncbi.nlm.nih.gov/pubmed/23989949","true","PMC3777009","2013","9","17","Br. J. Cancer","British journal of cancer","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
645,"EID645","PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",214,1,NULL,"accepted",0,"evidence",406,"Therapeutic targeting of cancers with loss of PTEN function.","Dillon et al., 2014, Curr Drug Targets",24387334,"http://www.ncbi.nlm.nih.gov/pubmed/24387334","true","PMC4310752","2014","1",NULL,"Curr Drug Targets","Current drug targets","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
646,"EID646","In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",34,4,NULL,"accepted",0,"evidence",408,"Rociletinib in EGFR-mutated non-small-cell lung cancer.","Sequist et al., 2015, N. Engl. J. Med.",25923550,"http://www.ncbi.nlm.nih.gov/pubmed/25923550",NULL,NULL,"2015","4","30","N. Engl. J. Med.","The New England journal of medicine","fully curated","91","Rociletinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
647,"EID647","Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage. No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","C","Predictive","Supports","Sensitivity","Somatic Mutation",243,3,NULL,"accepted",0,"evidence",409,"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.","Mateo et al., 2015, N. Engl. J. Med.",26510020,"http://www.ncbi.nlm.nih.gov/pubmed/26510020",NULL,NULL,"2015","10","29","N. Engl. J. Med.","The New England journal of medicine","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
648,"EID648","Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","C","Predictive","Supports","Sensitivity","Somatic Mutation",244,3,NULL,"accepted",0,"evidence",409,"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.","Mateo et al., 2015, N. Engl. J. Med.",26510020,"http://www.ncbi.nlm.nih.gov/pubmed/26510020",NULL,NULL,"2015","10","29","N. Engl. J. Med.","The New England journal of medicine","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
649,"EID649","A frameshift mutation in NF2 at position Y177 was found in a patient who did not respond to the standard platinum doublet chemotherapy regimen.",111,"Peritoneal Mesothelioma","Peritoneal Mesothelioma",1788,"http://www.disease-ontology.org/?id=DOID:1788","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",245,3,"Substitutes","accepted",0,"evidence",410,"Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.","Sheffield et al., 2015, PLoS ONE",25798586,"http://www.ncbi.nlm.nih.gov/pubmed/25798586","true","PMC4370594","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated","93","Carboplatin",NULL,"92","Cisplatin-4-methylpyridine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
650,"EID650","In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predictive","Supports","Sensitivity","Somatic Mutation",132,4,NULL,"accepted",0,"evidence",409,"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.","Mateo et al., 2015, N. Engl. J. Med.",26510020,"http://www.ncbi.nlm.nih.gov/pubmed/26510020",NULL,NULL,"2015","10","29","N. Engl. J. Med.","The New England journal of medicine","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
651,"EID651","When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",99,3,NULL,"accepted",0,"evidence",411,"Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.","Hirota et al., 2003, Gastroenterology",12949711,"http://www.ncbi.nlm.nih.gov/pubmed/12949711",NULL,NULL,"2003","9",NULL,"Gastroenterology","Gastroenterology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
652,"EID652","293T cells stably transduced with PDGFRA V561A showed constitutive tyrosine phosphorylation in the absense of ligand; however, when treated with imatinib, this phosphorylation was inhibited similarly to that of wildtype PDGFRA, consistent with sensitivity to this inhibitor.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Sensitivity","Somatic Mutation",247,3,NULL,"accepted",0,"evidence",411,"Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.","Hirota et al., 2003, Gastroenterology",12949711,"http://www.ncbi.nlm.nih.gov/pubmed/12949711",NULL,NULL,"2003","9",NULL,"Gastroenterology","Gastroenterology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
653,"EID653","Patients with Exon 11 Kit mutations (N=85) had significantly better event-free and overall survival than patients with Exon 9 Kit mutations (N=23) or no Kit mutations (N=9).",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Prognostic","Supports","Better Outcome","Somatic Mutation",66,4,NULL,"rejected",0,"evidence",412,"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.","Heinrich et al., 2003, J. Clin. Oncol.",14645423,"http://www.ncbi.nlm.nih.gov/pubmed/14645423",NULL,NULL,"2003","12","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
654,"EID654","In a Phase II trial for the treatment of GIST patients with imatinib, patients with Exon 11 Kit mutations (N=85) had significantly better event-free and overall survival than patients with Exon 9 Kit mutations (N=23) or no Kit mutations (N=9).",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Predictive","Supports","Sensitivity","Somatic Mutation",66,4,NULL,"accepted",0,"evidence",412,"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.","Heinrich et al., 2003, J. Clin. Oncol.",14645423,"http://www.ncbi.nlm.nih.gov/pubmed/14645423",NULL,NULL,"2003","12","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
655,"EID655","In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene.",156,"Papillary Thyroid Carcinoma","Papillary Thyroid Carcinoma",3969,"http://www.disease-ontology.org/?id=DOID:3969","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",248,5,NULL,"accepted",0,"evidence",413,"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.","Xing et al., 2014, J. Clin. Oncol.",25024077,"http://www.ncbi.nlm.nih.gov/pubmed/25024077","true","PMC4145183","2014","9","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
656,"EID656","In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene.",156,"Papillary Thyroid Carcinoma","Papillary Thyroid Carcinoma",3969,"http://www.disease-ontology.org/?id=DOID:3969","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",12,5,NULL,"accepted",0,"evidence",413,"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.","Xing et al., 2014, J. Clin. Oncol.",25024077,"http://www.ncbi.nlm.nih.gov/pubmed/25024077","true","PMC4145183","2014","9","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
657,"EID657","TERT promoter mutations are prevalent in aggressive sub-types of thyroid cancers. This work showed that TERT promoter mutations were significantly more prevalent in the tall cell papillary thyroid carcinoma (PTC) samples than in the conventional PTC and follicular variant PTC samples.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Diagnostic","Supports","Positive","Somatic Mutation",220,3,NULL,"accepted",0,"evidence",414,"Highly prevalent TERT promoter mutations in aggressive thyroid cancers.","Liu et al., 2013, Endocr. Relat. Cancer",23766237,"http://www.ncbi.nlm.nih.gov/pubmed/23766237","true","PMC3782569","2013","8",NULL,"Endocr. Relat. Cancer","Endocrine-related cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
658,"EID658","TERT promoter mutation C228T is significantly associated with BRAF V600E mutation in papillary thyroid cancer(PTC). Conversely, the BRAF V600E mutation is significantly more common in PTC cases with the TERT C228T mutation than in cases with the wild-type allele of TERT.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",220,3,NULL,"accepted",0,"evidence",414,"Highly prevalent TERT promoter mutations in aggressive thyroid cancers.","Liu et al., 2013, Endocr. Relat. Cancer",23766237,"http://www.ncbi.nlm.nih.gov/pubmed/23766237","true","PMC3782569","2013","8",NULL,"Endocr. Relat. Cancer","Endocrine-related cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
659,"EID659","The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC). 82 patients with Stage IV NSCLC who had not previously been treated with chemotherapy were used in this study.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Germline Mutation",249,4,"Substitutes","accepted",0,"evidence",416,"Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.","Sun et al., 2009, Lung Cancer",19157633,"http://www.ncbi.nlm.nih.gov/pubmed/19157633",NULL,NULL,"2009","8",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","73","Docetaxel",NULL,"96","Vinorelbine",NULL,"85","Gemcitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL
660,"EID660","Stable GSTP1 knockdown in ovarian carcinoma A2780 cell lines showed increased sensitivity to platinum-based chemotherapy drugs carboplatin, cisplatinum, carboplatin, and paclitaxel. For each drug, 3 biological replicates were performed for this study, and effectiveness was evaluated using an MTT assay. There was not a significant difference in sensitivity to other chemotherapy drugs such as gemcitabine, topotecan, and doxorubicin.",47,"Ovarian Carcinoma","Ovarian Carcinoma",4001,"http://www.disease-ontology.org/?id=DOID:4001","D","Predictive","Supports","Sensitivity","Somatic Mutation",250,4,"Substitutes","accepted",0,"evidence",417,"Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.","Sawers et al., 2014, Br. J. Cancer",25010864,"http://www.ncbi.nlm.nih.gov/pubmed/25010864","true","PMC4453841","2014","9","9","Br. J. Cancer","British journal of cancer","fully curated","326","Cisplatin",NULL,"81","Paclitaxel",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL
661,"EID661","Livin (BIRC7) overexpression in two colon cancer cell lines (RKO and SW620) increased resistance of these cells to cisplatin. siRNA knockdown of Livin rendered the cells more sensitive to cisplatin. The study also further showed that cytoplasmic Livin levels increased in four colon cancer cell lines (RKO, SW620, HCT116, and KM12C) after cisplatin treatment in a dose-dependent manner. This study highlighted Livin as a potential player in colon cancer therapy.",119,"Colon Cancer","Colon Cancer",219,"http://www.disease-ontology.org/?id=DOID:219","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",251,4,NULL,"accepted",0,"evidence",418,"Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells.","Ding et al., 2013, Tumour Biol.",23188704,"http://www.ncbi.nlm.nih.gov/pubmed/23188704",NULL,NULL,"2013","4",NULL,"Tumour Biol.","Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
662,"EID662","A variant of EGFR with exon 4 deletion (de4 EGFR) enhanced the invasiveness and cisplatin resistance of epithelial ovarian cancer cell lines (SKOV3, CAOV3, ES2) in vitro when compared with wild-type EGFR. The three cell lines were infected with lentivirus for either EGFR or de4 EGFR, and lentivirus-infected cells were used to perform transwell migration assays, invasion assays, and cisplatin sensitivity assays.",225,"Epithelial Ovarian Cancer","Epithelial Ovarian Cancer",2152,"http://www.disease-ontology.org/?id=DOID:2152","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",252,4,NULL,"accepted",0,"evidence",419,"Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.","Zhang et al., 2013, Carcinogenesis",23764753,"http://www.ncbi.nlm.nih.gov/pubmed/23764753",NULL,NULL,"2013","11",NULL,"Carcinogenesis","Carcinogenesis","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
663,"EID663","The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EOC patients without BRCA mutations were used in this study. Furthermore, the researchers tested a KRAS-variant EOC cell line (BG1) and found it has much greater platinum-based chemotherapy resistance than a non-KRAS-variant cell line (CAOV3).",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",253,4,"Substitutes","rejected",0,"evidence",420,"A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.","Ratner et al., 2012, Oncogene",22139083,"http://www.ncbi.nlm.nih.gov/pubmed/22139083","true","PMC3342446","2012","10","18","Oncogene","Oncogene","fully curated","81","Paclitaxel",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
664,"EID664","The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EOC patients without BRCA mutations were used in this study. Furthermore, the researchers tested a KRAS-variant EOC cell line (BG1) and found it has much greater platinum-based chemotherapy resistance than a non-KRAS-variant cell line (CAOV3).",225,"Epithelial Ovarian Cancer","Epithelial Ovarian Cancer",2152,"http://www.disease-ontology.org/?id=DOID:2152","B","Predictive","Supports","Resistance or Non-Response","Germline Polymorphism",254,3,"Substitutes","accepted",0,"evidence",420,"A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.","Ratner et al., 2012, Oncogene",22139083,"http://www.ncbi.nlm.nih.gov/pubmed/22139083","true","PMC3342446","2012","10","18","Oncogene","Oncogene","fully curated","81","Paclitaxel",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
665,"EID665","The rs751402 polymorphism in the 5' UTR of ERCC5 was correlated with reduced progression free-survival in children with ependymoma that had been treated with platinum-based therapies. 55 post-operative frozen samples were used in this study. The results were also confirmed in vitro by treating neuroblastoma and B-cell lines expressing the wild-type or rs751402 polymorphism and finding that the rs751402 polymorphism was correlated with higher survival.",65,"Parietal Lobe Ependymoma","Parietal Lobe Ependymoma",50903,"http://www.disease-ontology.org/?id=DOID:0050903","B","Prognostic","Supports","Poor Outcome","Germline Polymorphism",255,3,NULL,"accepted",0,"evidence",421,"A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy.","Somers et al., 2015, Genes Dev.",26338418,"http://www.ncbi.nlm.nih.gov/pubmed/26338418","true","PMC4579346","2015","9","15","Genes Dev.","Genes & development","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
666,"EID666","The rs17084733 variant in the 3' UTR of KIT was correlated with susceptibility to melanoma when comparing 70 melanoma patients to 94 healthy individuals from the same community. This variant was most strongly correlated with acral lentigious melanoma.",192,"Acral Lentiginous Melanoma","Acral Lentiginous Melanoma",6367,"http://www.disease-ontology.org/?id=DOID:6367","B","Diagnostic","Supports","Positive","Germline Polymorphism",256,3,NULL,"accepted",0,"evidence",422,"A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.","Godshalk et al., 2011, Oncogene",21119596,"http://www.ncbi.nlm.nih.gov/pubmed/21119596","true","PMC3069149","2011","3","31","Oncogene","Oncogene","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
667,"EID667","The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt MÃ¼nster Clinical Trials.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",239,4,NULL,"accepted",0,"evidence",399,"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.","Tzoneva et al., 2013, Nat. Med.",23377281,"http://www.ncbi.nlm.nih.gov/pubmed/23377281","true","PMC3594483","2013","3",NULL,"Nat. Med.","Nature medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
668,"EID668","The rs3757441 variant in Intron 6 of EZH2 (C/C versus C/T or T/T) was significantly correlated with lower progression free survival and overall survival in patients with metastatic Colorectal Cancer (mCRC). Blood samples from 106 patients with mCRC before and after treatment were used for this study.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Germline Polymorphism",257,4,NULL,"accepted",0,"evidence",423,"An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.","Crea et al., 2012, Ann. Oncol.",21926398,"http://www.ncbi.nlm.nih.gov/pubmed/21926398",NULL,NULL,"2012","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
669,"EID669","The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment.",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","B","Predictive","Supports","Sensitivity","Germline Mutation",258,3,NULL,"accepted",0,"evidence",424,"The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.","Huang et al., 2009, Cancer Chemother. Pharmacol.",18704422,"http://www.ncbi.nlm.nih.gov/pubmed/18704422",NULL,NULL,"2009","4",NULL,"Cancer Chemother. Pharmacol.","Cancer chemotherapy and pharmacology","fully curated","395","5-fluorouracil",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
670,"EID670","Patients with the GSTP1 I105V variant had greater response to FOLFOX-4 treatment, longer progression-free survival, and longer overall survival. 166 Chinese patients with metastatic colorectal carcinoma who had been treated with FOLFOX-4 were used in this study.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Germline Mutation",259,4,NULL,"accepted",0,"evidence",425,"Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.","Chen et al., 2010, Cancer Sci.",19922504,"http://www.ncbi.nlm.nih.gov/pubmed/19922504",NULL,NULL,"2010","2",NULL,"Cancer Sci.","Cancer science","fully curated","99","FolfoxProtocol",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
671,"EID671","The ABCG2 Q141K variant was correlated with  higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Prognostic","Supports","Better Outcome","Germline Polymorphism",260,3,NULL,"accepted",0,"evidence",426,"Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.","Tian et al., 2012, Gynecol. Oncol.",22112610,"http://www.ncbi.nlm.nih.gov/pubmed/22112610","true","PMC3278512","2012","3",NULL,"Gynecol. Oncol.","Gynecologic oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
672,"EID672","The XRCC1 R399Q variant was significantly correlated with higher overall survival in non-small cell lung carcinoma (NSCLC) patients treated with gemcitabine and platinum. 62 patients with either Stage IIIB or Stage IV NSCLC were used for this study.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Better Outcome","Germline Mutation",261,4,NULL,"accepted",0,"evidence",427,"Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.","Liao et al., 2012, J Thorac Oncol",22551904,"http://www.ncbi.nlm.nih.gov/pubmed/22551904",NULL,NULL,"2012","6",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
673,"EID673","The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (greater than 4 cm in size) cervical carcinomas were used in this study.",159,"Cervical Cancer","Cervical Cancer",4362,"http://www.disease-ontology.org/?id=DOID:4362","B","Predictive","Supports","Sensitivity","Germline Mutation",261,4,NULL,"accepted",0,"evidence",907,"XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.","Chung et al., 2006, Gynecol. Oncol.",16875718,"http://www.ncbi.nlm.nih.gov/pubmed/16875718",NULL,NULL,"2006","12",NULL,"Gynecol. Oncol.","Gynecologic oncology","fully curated","326","Cisplatin",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
674,"EID674","The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Germline Mutation",262,3,NULL,"accepted",0,"evidence",428,"mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.","GrÃ©en et al., 2006, Clin. Cancer Res.",16467099,"http://www.ncbi.nlm.nih.gov/pubmed/16467099",NULL,NULL,"2006","2","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
675,"EID675","The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).  103 Chinese patients with NSCLC were evaluated in this study. However, there was not a significant correlation between the mutation and overall survival.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Germline Mutation",263,2,"Substitutes","accepted",0,"evidence",429,"Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer.","Yan et al., 2011, Asian Pac. J. Cancer Prev.",22296372,"http://www.ncbi.nlm.nih.gov/pubmed/22296372",NULL,NULL,"2011",NULL,NULL,"Asian Pac. J. Cancer Prev.","Asian Pacific journal of cancer prevention : APJCP","fully curated","326","Cisplatin",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
676,"EID676","The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.",134,"Osteosarcoma","Osteosarcoma",3347,"http://www.disease-ontology.org/?id=DOID:3347","B","Predictive","Supports","Resistance or Non-Response","Germline Mutation",264,4,NULL,"accepted",0,"evidence",430,"Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.","Caronia et al., 2009, Pharmacogenomics J.",19434073,"http://www.ncbi.nlm.nih.gov/pubmed/19434073",NULL,NULL,"2009","10",NULL,"Pharmacogenomics J.","The pharmacogenomics journal","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
677,"EID677","The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Germline Mutation",264,3,"Combination","accepted",0,"evidence",431,"Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.","Gandara et al., 2009, J. Clin. Oncol.",19470925,"http://www.ncbi.nlm.nih.gov/pubmed/19470925","true","PMC2717760","2009","7","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","93","Carboplatin",NULL,"81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
678,"EID678","The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients. 149 metastatic CRC patients treated with irinotecan/5FU as first-line chemotherapy were followed in this study.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Germline Mutation",265,3,"Combination","accepted",0,"evidence",432,"UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.","Martinez-Balibrea et al., 2010, Br. J. Cancer",20628391,"http://www.ncbi.nlm.nih.gov/pubmed/20628391","true","PMC2939780","2010","8","10","Br. J. Cancer","British journal of cancer","fully curated","395","5-fluorouracil",NULL,"101","Irinotecan",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
679,"EID679","A minimum common region of deletion of 0.19Mb, encompassing exons 12â€“22 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance. Transfection of mLRP1B4, a fully functional minigene of LRP1B, in IGROV1 and OVCAR4 ovarian cell lines with low expression of LRP1B4 increased sensitivity to liposomal doxorubicin but not doxorubicin. siRNA knockdown of LRP1B4 in JHOS3 and Kuramochi ovarian cancer cell lines decreased sensitivity to liposomal doxorubicin but not doxorubicin.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",266,3,NULL,"accepted",0,"evidence",433,"LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.","Cowin et al., 2012, Cancer Res.",22896685,"http://www.ncbi.nlm.nih.gov/pubmed/22896685",NULL,NULL,"2012","8","15","Cancer Res.","Cancer research","fully curated","68","Doxorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
680,"EID680","Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were highly sensitive to PD173074. This sensitivity was confirmed in a mouse xenograft. Clinical trials are currently ongoing.",153,"Lung Squamous Cell Carcinoma","Lung Squamous Cell Carcinoma",3907,"http://www.disease-ontology.org/?id=DOID:3907","D","Predictive","Supports","Sensitivity","Somatic Mutation",267,5,NULL,"accepted",0,"evidence",434,"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.","Weiss et al., 2010, Sci Transl Med",21160078,"http://www.ncbi.nlm.nih.gov/pubmed/21160078","true","PMC3990281","2010","12","15","Sci Transl Med","Science translational medicine","fully curated","36","PD173074",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
681,"EID681","Preclinical evidence (in-vitro) for predictive value of FGFR1 mRNA and protein expression as well as mRNA expression of FGF2 and FGF9 for sensitivity to FGFR1 inhibition. The authors suggested that FGFR1 expression is a better predictive marker than FGFR1 amplification and proposes a connection between KRAS and PIK3CA mutations. This study used 58 cell lines, of which 14 exhibited ponatinib sensitivity. This sensitivity was correlated with FGFR1 mRNA and protein expression.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","D","Predictive","Supports","Sensitivity","N/A",268,4,NULL,"accepted",0,"evidence",435,"FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.","Wynes et al., 2014, Clin. Cancer Res.",24771645,"http://www.ncbi.nlm.nih.gov/pubmed/24771645","true","PMC4062100","2014","6","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
682,"EID682","In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates with cigarette smoking.",153,"Lung Squamous Cell Carcinoma","Lung Squamous Cell Carcinoma",3907,"http://www.disease-ontology.org/?id=DOID:3907","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",267,4,NULL,"accepted",0,"evidence",436,"Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.","Kim et al., 2013, J. Clin. Oncol.",23182986,"http://www.ncbi.nlm.nih.gov/pubmed/23182986",NULL,NULL,"2013","2","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
683,"EID683","This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis.",153,"Lung Squamous Cell Carcinoma","Lung Squamous Cell Carcinoma",3907,"http://www.disease-ontology.org/?id=DOID:3907","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",267,3,NULL,"accepted",0,"evidence",437,"FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.","Seo et al., 2014, Virchows Arch.",25086725,"http://www.ncbi.nlm.nih.gov/pubmed/25086725",NULL,NULL,"2014","11",NULL,"Virchows Arch.","Virchows Archiv : an international journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
684,"EID684","This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Better Outcome","Somatic Mutation",267,2,NULL,"accepted",0,"evidence",438,"Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.","Tran et al., 2013, Lung Cancer",23806793,"http://www.ncbi.nlm.nih.gov/pubmed/23806793",NULL,NULL,"2013","9",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
685,"EID685","Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification.
However, larger studies are warranted for confirmation.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",267,4,NULL,"accepted",0,"evidence",439,"Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.","Chang et al., 2014, PLoS ONE",25171497,"http://www.ncbi.nlm.nih.gov/pubmed/25171497","true","PMC4149366","2014",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
686,"EID686","Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",267,4,NULL,"accepted",0,"evidence",440,"Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.","Dutt et al., 2011, PLoS ONE",21666749,"http://www.ncbi.nlm.nih.gov/pubmed/21666749","true","PMC3110189","2011",NULL,NULL,"PLoS ONE","PloS one","fully curated","36","PD173074",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
687,"EID687","Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metastasis.",153,"Lung Squamous Cell Carcinoma","Lung Squamous Cell Carcinoma",3907,"http://www.disease-ontology.org/?id=DOID:3907","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",267,4,NULL,"accepted",0,"evidence",441,"FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis.","Jiang et al., 2015, Lung Cancer",25433983,"http://www.ncbi.nlm.nih.gov/pubmed/25433983",NULL,NULL,"2015","1",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
688,"EID688","An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement. The study did not compare to patients without rearrangement that were treated with Crizotinib.  Several different ROS1 fusion partners were identified, but no clinical differences in outcome were associated with the identity of the 5' partner.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",269,4,NULL,"accepted",0,"evidence",447,"Crizotinib in ROS1-rearranged non-small-cell lung cancer.","Shaw et al., 2014, N. Engl. J. Med.",25264305,"http://www.ncbi.nlm.nih.gov/pubmed/25264305","true","PMC4264527","2014","11","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
689,"EID689","A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response on MET-Inhibitor MetMAb (Onartuzumab) for 2 years and mixed response after recurrence with resistance in some of the newly developing metastases.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","C","Predictive","Supports","Sensitivity","Somatic Mutation",270,3,NULL,"accepted",0,"evidence",448,"Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.","Catenacci et al., 2011, Cancer Discov",22389872,"http://www.ncbi.nlm.nih.gov/pubmed/22389872","true","PMC3289149","2011","12",NULL,"Cancer Discov","Cancer discovery","fully curated","121","Onartuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
690,"EID690","Extension and reduction of the ATR exon 10 A10 repeat (alters codon I774) was associated with poorer overall and disease-free survival in patients with endometrioid endometrial cancer when compared to patients with wildtype ATR and with or without microsatellite instability. These ATR mutations were observed in 12 of 248 patients (4.8%, 3 insertions, 9 deletions).",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",271,4,NULL,"accepted",0,"evidence",449,"ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.","Zighelboim et al., 2009, J. Clin. Oncol.",19470935,"http://www.ncbi.nlm.nih.gov/pubmed/19470935","true","PMC2716934","2009","7","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
691,"EID691","EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",190,4,NULL,"accepted",0,"evidence",450,"Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.","Licitra et al., 2011, Ann. Oncol.",21048039,"http://www.ncbi.nlm.nih.gov/pubmed/21048039","true","PMC3082162","2011","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","395","5-fluorouracil",NULL,"103","PLATINUM",NULL,"16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL
692,"EID692","EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Does Not Support","Sensitivity","N/A",193,4,NULL,"accepted",0,"evidence",451,"Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.","Licitra et al., 2013, Eur. J. Cancer",23265711,"http://www.ncbi.nlm.nih.gov/pubmed/23265711",NULL,NULL,"2013","4",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
693,"EID693","EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",193,4,NULL,"accepted",0,"evidence",452,"EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.","Pirker et al., 2012, Lancet Oncol.",22056021,"http://www.ncbi.nlm.nih.gov/pubmed/22056021",NULL,NULL,"2012","1",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
694,"EID694","In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors).",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",272,3,NULL,"accepted",0,"evidence",453,"Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.","Vermorken et al., 2014, Ann. Oncol.",24577117,"http://www.ncbi.nlm.nih.gov/pubmed/24577117","true","PMC3969553","2014","4",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
695,"EID695","p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Better Outcome","Somatic Mutation",272,4,NULL,"accepted",0,"evidence",454,"Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.","Argiris et al., 2014, Ann. Oncol.",24799460,"http://www.ncbi.nlm.nih.gov/pubmed/24799460","true","PMC4071756","2014","7",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
696,"EID696","In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",272,3,NULL,"accepted",0,"evidence",455,"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.","Vermorken et al., 2013, Lancet Oncol.",23746666,"http://www.ncbi.nlm.nih.gov/pubmed/23746666",NULL,NULL,"2013","7",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
697,"EID697","In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assayed in 69 HNSCC patients by IHC.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",272,4,NULL,"accepted",0,"evidence",456,"Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.","Pogorzelski et al., 2014, Cell Death Dis",24577089,"http://www.ncbi.nlm.nih.gov/pubmed/24577089","true","PMC3944273","2014",NULL,NULL,"Cell Death Dis","Cell death & disease","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
698,"EID698","A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",273,2,NULL,"accepted",0,"evidence",378,"A patient with lung adenocarcinoma and RET fusion treated with vandetanib.","Gautschi et al., 2013, J Thorac Oncol",23584301,"http://www.ncbi.nlm.nih.gov/pubmed/23584301",NULL,NULL,"2013","5",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","117","Hydroxy Vandetanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
699,"EID699","Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",274,3,NULL,"accepted",0,"evidence",457,"HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.","Boidot et al., 2016, Int J Colorectal Dis",26561417,"http://www.ncbi.nlm.nih.gov/pubmed/26561417",NULL,NULL,"2016","6",NULL,"Int J Colorectal Dis","International journal of colorectal disease","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
700,"EID700","A pre-clinical study in 10 solid cancer cell lines. HRAS mutations (Q61L, Q61R and G12V) sensitized cell lines toward MEK inhibitors (AZD6244/selumetinib, MEK162 and PD0325901) and mTOR inhibitors (Everolimus and AZD8055).",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",275,3,"Substitutes","accepted",0,"evidence",458,"Mutant HRAS as novel target for MEK and mTOR inhibitors.","Kiessling et al., 2015, Oncotarget",26544513,"http://www.ncbi.nlm.nih.gov/pubmed/26544513","true","PMC4747218","2015","12","8","Oncotarget","Oncotarget","fully curated","355","Binimetinib (MEK162)",NULL,"124","AZD8055",NULL,"122","Selumetinib (AZD6244)",NULL,"41","Everolimus",NULL,"29","PD0325901",NULL
701,"EID701","This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",276,4,NULL,"accepted",0,"evidence",459,"Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.","Zhong et al., 2015, Onco Targets Ther",26664143,"http://www.ncbi.nlm.nih.gov/pubmed/26664143","true","PMC4671817","2015",NULL,NULL,"Onco Targets Ther","OncoTargets and therapy","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
702,"EID702","In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).",153,"Lung Squamous Cell Carcinoma","Lung Squamous Cell Carcinoma",3907,"http://www.disease-ontology.org/?id=DOID:3907","B","Prognostic","Supports","Better Outcome","N/A",276,3,NULL,"accepted",0,"evidence",460,"PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.","Schmidt et al., 2015, PLoS ONE",26313362,"http://www.ncbi.nlm.nih.gov/pubmed/26313362","true","PMC4552388","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
703,"EID703","High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).",87,"Ovarian Serous Carcinoma","Ovarian Serous Carcinoma",50933,"http://www.disease-ontology.org/?id=DOID:0050933","B","Prognostic","Supports","Better Outcome","N/A",276,3,NULL,"accepted",0,"evidence",461,"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.","Darb-Esfahani et al., 2016, Oncotarget",26625204,"http://www.ncbi.nlm.nih.gov/pubmed/26625204","true","PMC4811475","2016","1","12","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
704,"EID704","Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","N/A",276,4,"Substitutes","accepted",0,"evidence",462,"Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.","Carbognin et al., 2015, PLoS ONE",26086854,"http://www.ncbi.nlm.nih.gov/pubmed/26086854","true","PMC4472786","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated","138","Pembrolizumab",NULL,"137","Nivolumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
705,"EID705","A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib. Mutations E2014K and E2419K were shown to be activating in-vitro.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","C","Predictive","Supports","Sensitivity","Somatic Mutation",277,3,"Combination","accepted",0,"evidence",463,"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.","Wagle et al., 2014, Cancer Discov",24625776,"http://www.ncbi.nlm.nih.gov/pubmed/24625776","true","PMC4122326","2014","5",NULL,"Cancer Discov","Cancer discovery","fully curated","56","Pazopanib",NULL,"41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
706,"EID706","In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",278,3,NULL,"accepted",0,"evidence",464,"Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.","Grell et al., 2012, Int. J. Oncol.",22842582,"http://www.ncbi.nlm.nih.gov/pubmed/22842582","true","PMC3583615","2012","10",NULL,"Int. J. Oncol.","International journal of oncology","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
707,"EID707","A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",4,2,NULL,"accepted",0,"evidence",465,"Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.","Lassen et al., 2014, Mol. Cancer",24735930,"http://www.ncbi.nlm.nih.gov/pubmed/24735930","true","PMC4021505","2014",NULL,NULL,"Mol. Cancer","Molecular cancer","fully curated","111","GSK2141795",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
708,"EID708","Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor
GSK2141795B.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",214,2,NULL,"accepted",0,"evidence",465,"Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.","Lassen et al., 2014, Mol. Cancer",24735930,"http://www.ncbi.nlm.nih.gov/pubmed/24735930","true","PMC4021505","2014",NULL,NULL,"Mol. Cancer","Molecular cancer","fully curated","111","GSK2141795",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
709,"EID709","In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Predictive","Supports","Sensitivity","Somatic Mutation",4,3,NULL,"accepted",0,"evidence",466,"Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.","Davies et al., 2015, Mol. Cancer Ther.",26351323,"http://www.ncbi.nlm.nih.gov/pubmed/26351323",NULL,NULL,"2015","11",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
710,"EID710","PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",104,3,"Substitutes","accepted",0,"evidence",163,"PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.","Beaver et al., 2013, Clin. Cancer Res.",23888070,"http://www.ncbi.nlm.nih.gov/pubmed/23888070","true","PMC3805128","2013","10","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","43","MK-2206",NULL,"141","Pictilisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
711,"EID711","Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",214,2,NULL,"accepted",0,"evidence",467,"Inhibition of PI3KÎ² signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.","Hancox et al., 2015, Mol. Cancer Ther.",25398829,"http://www.ncbi.nlm.nih.gov/pubmed/25398829",NULL,NULL,"2015","1",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","114","AZD8186",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
712,"EID712","Median overall survival of patients with nonsynonymous mutations in mTOR was shorter.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",277,3,NULL,"accepted",0,"evidence",468,"Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.","Kong et al., 2016, Clin. Cancer Res.",26490311,"http://www.ncbi.nlm.nih.gov/pubmed/26490311",NULL,NULL,"2016","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
713,"EID713","In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",283,3,"Substitutes","accepted",0,"evidence",468,"Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.","Kong et al., 2016, Clin. Cancer Res.",26490311,"http://www.ncbi.nlm.nih.gov/pubmed/26490311",NULL,NULL,"2016","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","112","AZD5363",NULL,"115","LY294002",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
714,"EID714","All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Supports","Sensitivity","Somatic Mutation",214,3,"Combination","accepted",0,"evidence",469,"Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.","Hyman et al., 2015, Cancer Chemother. Pharmacol.",25672916,"http://www.ncbi.nlm.nih.gov/pubmed/25672916",NULL,NULL,"2015","4",NULL,"Cancer Chemother. Pharmacol.","Cancer chemotherapy and pharmacology","fully curated","81","Paclitaxel",NULL,"116","Buparlisib",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL
715,"EID715","23 patients were treated with temsirolimus containing regimens. 1 patient with a complete response >3 years had a K159fs*16 mutation in NF2. 2 patients were tested for NF2 mutations.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Predictive","Supports","Sensitivity","Somatic Mutation",279,3,NULL,"accepted",0,"evidence",470,"Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.","Moulder et al., 2015, Ann. Oncol.",25878190,"http://www.ncbi.nlm.nih.gov/pubmed/25878190",NULL,NULL,"2015","7",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","83","Temsirolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
716,"EID716","A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",214,4,NULL,"accepted",0,"evidence",471,"Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor.","Juric et al., 2015, Nature",25409150,"http://www.ncbi.nlm.nih.gov/pubmed/25409150","true","PMC4326538","2015","2","12","Nature","Nature","fully curated","339","BYL719 (Alpelisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
717,"EID717","In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",453,4,NULL,"accepted",0,"evidence",472,"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.","Montagut et al., 2012, Nat. Med.",22270724,"http://www.ncbi.nlm.nih.gov/pubmed/22270724",NULL,NULL,"2012","2",NULL,"Nat. Med.","Nature medicine","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
718,"EID718","65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",281,2,"Substitutes","accepted",0,"evidence",473,"Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.","Lupini et al., 2015, BMC Cancer",26508446,"http://www.ncbi.nlm.nih.gov/pubmed/26508446","true","PMC4624582","2015",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","28","Panitumumab",NULL,"16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
719,"EID719","In a retrospective analysis of 65 patients with metastatic colorectal cancer, SMAD4 mutations were more common among patients with no benefit from EGFR-inhibition (cetuximab or panitumumab) (4 patients) than with patients with response to EGFR directed treatment (1 patient).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",216,2,"Substitutes","accepted",0,"evidence",473,"Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.","Lupini et al., 2015, BMC Cancer",26508446,"http://www.ncbi.nlm.nih.gov/pubmed/26508446","true","PMC4624582","2015",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","16","Cetuximab",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
720,"EID720","In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",282,3,NULL,"accepted",0,"evidence",474,"Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.","Cheng et al., 2015, Cancer Biol. Ther.",26046389,"http://www.ncbi.nlm.nih.gov/pubmed/26046389","true","PMC4623002","2015",NULL,NULL,"Cancer Biol. Ther.","Cancer biology & therapy","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
721,"EID721","In a cell line with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",283,3,NULL,"rejected",0,"evidence",468,"Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.","Kong et al., 2016, Clin. Cancer Res.",26490311,"http://www.ncbi.nlm.nih.gov/pubmed/26490311",NULL,NULL,"2016","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
722,"EID722","In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",284,3,"Combination","accepted",0,"evidence",468,"Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.","Kong et al., 2016, Clin. Cancer Res.",26490311,"http://www.ncbi.nlm.nih.gov/pubmed/26490311",NULL,NULL,"2016","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","115","LY294002",NULL,"112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
723,"EID723","BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",285,2,NULL,"accepted",0,"evidence",475,"Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.","Botton et al., 2013, Pigment Cell Melanoma Res",23890088,"http://www.ncbi.nlm.nih.gov/pubmed/23890088","true","PMC3808507","2013","11",NULL,"Pigment Cell Melanoma Res","Pigment cell & melanoma research","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
724,"EID724","A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",285,2,NULL,"accepted",0,"evidence",475,"Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.","Botton et al., 2013, Pigment Cell Melanoma Res",23890088,"http://www.ncbi.nlm.nih.gov/pubmed/23890088","true","PMC3808507","2013","11",NULL,"Pigment Cell Melanoma Res","Pigment cell & melanoma research","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
725,"EID725","BRAF-fusion in \"pan-negative\" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",286,3,NULL,"accepted",0,"evidence",476,"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.","Hutchinson et al., 2013, Clin. Cancer Res.",24345920,"http://www.ncbi.nlm.nih.gov/pubmed/24345920","true","PMC3880773","2013","12","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
726,"EID726","BRAF-fusion in \"pan-negative\" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",286,3,NULL,"accepted",0,"evidence",476,"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.","Hutchinson et al., 2013, Clin. Cancer Res.",24345920,"http://www.ncbi.nlm.nih.gov/pubmed/24345920","true","PMC3880773","2013","12","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
727,"EID727","A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was \"pan-negative\" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",287,3,NULL,"accepted",0,"evidence",476,"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.","Hutchinson et al., 2013, Clin. Cancer Res.",24345920,"http://www.ncbi.nlm.nih.gov/pubmed/24345920","true","PMC3880773","2013","12","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
728,"EID728","A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",288,4,NULL,"accepted",0,"evidence",477,"Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.","Bahadoran et al., 2013, J. Clin. Oncol.",23715574,"http://www.ncbi.nlm.nih.gov/pubmed/23715574",NULL,NULL,"2013","7","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
729,"EID729","High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were available for 103 patients.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",289,4,NULL,"accepted",0,"evidence",478,"Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).","Cushman et al., 2015, Clin. Cancer Res.",25520391,"http://www.ncbi.nlm.nih.gov/pubmed/25520391","true","PMC4772749","2015","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
730,"EID730","CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",290,3,NULL,"accepted",0,"evidence",478,"Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).","Cushman et al., 2015, Clin. Cancer Res.",25520391,"http://www.ncbi.nlm.nih.gov/pubmed/25520391","true","PMC4772749","2015","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
731,"EID731","High expression of EZH2 was associated with poorer outcome in a meta-analysis encompassing 51 studies and 9444 patients.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",291,4,NULL,"accepted",0,"evidence",479,"Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.","Jiang et al., 2016, Oncotarget",26683709,"http://www.ncbi.nlm.nih.gov/pubmed/26683709","true","PMC4826228","2016","1","26","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
732,"EID732","Newly developed allosteric inhibitors (GSK321) of IDH1 led to granulocytic differentiation in-vitro and in-vivo.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Sensitivity","Somatic Mutation",59,3,NULL,"accepted",0,"evidence",480,"New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.","Okoye-Okafor et al., 2015, Nat. Chem. Biol.",26436839,"http://www.ncbi.nlm.nih.gov/pubmed/26436839",NULL,NULL,"2015","11",NULL,"Nat. Chem. Biol.","Nature chemical biology","fully curated","195","GSK321",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
733,"EID733","In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET.  Resistance was conferred by the MET amplification driving ERBB3 (HER3)-dependent activation of PI3K.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",270,4,NULL,"accepted",0,"evidence",481,"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.","Engelman et al., 2007, Science",17463250,"http://www.ncbi.nlm.nih.gov/pubmed/17463250",NULL,NULL,"2007","5","18","Science","Science (New York, N.Y.)","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
734,"EID734","In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated  with poor survival. In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-lines with high MYD88 expression.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",292,2,NULL,"accepted",0,"evidence",482,"Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.","Xiang et al., 2016, Tumour Biol.",26596839,"http://www.ncbi.nlm.nih.gov/pubmed/26596839",NULL,NULL,"2016","5",NULL,"Tumour Biol.","Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
735,"EID735","A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",270,3,NULL,"accepted",0,"evidence",483,"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.","Ou et al., 2011, J Thorac Oncol",21623265,"http://www.ncbi.nlm.nih.gov/pubmed/21623265",NULL,NULL,"2011","5",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
736,"EID736","The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib. MET exon 14 deletion results in an in-frame deletion in the MET protein. Recurrent splice site mutations that result in exon 14 skipping have been observed in ~3% of all lung cancers.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",324,3,NULL,"accepted",0,"evidence",484,"MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.","Togashi et al., 2015, Lung Cancer",26547802,"http://www.ncbi.nlm.nih.gov/pubmed/26547802",NULL,NULL,"2015","12",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
737,"EID737","In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",193,3,NULL,"accepted",0,"evidence",485,"Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.","Park et al., 2015, Oncotarget",26439803,"http://www.ncbi.nlm.nih.gov/pubmed/26439803","true","PMC4741578","2015","10","13","Oncotarget","Oncotarget","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
738,"EID738","823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months).",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",99,4,NULL,"accepted",0,"evidence",486,"Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.","Yoo et al., 2016, Cancer Res Treat",26130666,"http://www.ncbi.nlm.nih.gov/pubmed/26130666","true","PMC4843750","2016","4",NULL,"Cancer Res Treat","Cancer research and treatment : official journal of Korean Cancer Association","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
739,"EID739","A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.",311,"Merkel Cell Carcinoma","Merkel Cell Carcinoma",3965,"http://www.disease-ontology.org/?id=DOID:3965","C","Predictive","Supports","Sensitivity","Somatic Mutation",294,3,NULL,"accepted",0,"evidence",487,"Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.","Shiver et al., 2015, N. Engl. J. Med.",26466009,"http://www.ncbi.nlm.nih.gov/pubmed/26466009","true","PMC4652581","2015","10","15","N. Engl. J. Med.","The New England journal of medicine","fully curated","120","Idelalisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
740,"EID740","Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandetanib slowed tumor growth.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",295,2,NULL,"accepted",0,"evidence",488,"Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.","Hatem et al., 2016, Int. J. Cancer",26686064,"http://www.ncbi.nlm.nih.gov/pubmed/26686064",NULL,NULL,"2016","5","15","Int. J. Cancer","International journal of cancer","fully curated","117","Hydroxy Vandetanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
741,"EID741","After preliminary studies in cell lines, GEO datasets and fresh frozen tissues, RIT1 expression was determined in 257 tumors and 31 normal tissues. Elevated expression of RIT1 was correlated with poorer overall survival, pathological type, clinical stage, grade and vascular invasion.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",296,3,NULL,"accepted",0,"evidence",489,"Elevated expression of RIT1 correlates with poor prognosis in endometrial cancer.","Xu et al., 2015, Int J Clin Exp Pathol",26617739,"http://www.ncbi.nlm.nih.gov/pubmed/26617739","true","PMC4637554","2015",NULL,NULL,"Int J Clin Exp Pathol","International journal of clinical and experimental pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
742,"EID742","RIT1 mutations were identified in approx. 2% of lung adenocarcinomas (5/87 in the \"oncogene negative\" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation). GDC-0941 impaired tumor growth of NCI-H2110 (RIT1 M90I mutated) xenografts in nude mice. GDC-0941 and AZD-6244 (selumetinib) impaired colony formation in-vitro. Combined PI3K/MEK inhibition was more effective than single agent treatment in-vitro.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","D","Predictive","Supports","Sensitivity","Somatic Mutation",297,3,"Substitutes","accepted",0,"evidence",490,"Oncogenic RIT1 mutations in lung adenocarcinoma.","Berger et al., 2014, Oncogene",24469055,"http://www.ncbi.nlm.nih.gov/pubmed/24469055","true","PMC4150988","2014","8","28","Oncogene","Oncogene","fully curated","141","Pictilisib",NULL,"122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
743,"EID743","Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",276,4,"Substitutes","accepted",0,"evidence",462,"Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.","Carbognin et al., 2015, PLoS ONE",26086854,"http://www.ncbi.nlm.nih.gov/pubmed/26086854","true","PMC4472786","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated","138","Pembrolizumab",NULL,"137","Nivolumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
744,"EID744","The drug CBL0137 (a drug that interacts with SSRP1 aka FACT) exhibited a synergistic effect with standard chemotherapy (cyclophosphamide, etoposide, cisplatin, vincristine, etc.) by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells. High MYCN expression was found to sensitize neuroblastoma cells to CBL0137.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",298,3,NULL,"accepted",0,"evidence",491,"Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.","Carter et al., 2015, Sci Transl Med",26537256,"http://www.ncbi.nlm.nih.gov/pubmed/26537256",NULL,NULL,"2015","11","4","Sci Transl Med","Science translational medicine","fully curated","193","CBL0137",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
745,"EID745","In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib).",97,"Brain Medulloblastoma","Brain Medulloblastoma",60105,"http://www.disease-ontology.org/?id=DOID:0060105","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",299,3,NULL,"accepted",0,"evidence",492,"Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.","Yauch et al., 2009, Science",19726788,"http://www.ncbi.nlm.nih.gov/pubmed/19726788",NULL,NULL,"2009","10","23","Science","Science (New York, N.Y.)","fully curated","190","Vismodegib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
746,"EID746","In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib. SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patients.",314,"Basal Cell Carcinoma","Basal Cell Carcinoma",2513,"http://www.disease-ontology.org/?id=DOID:2513","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",300,4,NULL,"accepted",0,"evidence",493,"Smoothened variants explain the majority of drug resistance in basal cell carcinoma.","Atwood et al., 2015, Cancer Cell",25759020,"http://www.ncbi.nlm.nih.gov/pubmed/25759020","true","PMC4357167","2015","3","9","Cancer Cell","Cancer cell","fully curated","190","Vismodegib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
747,"EID747","Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-Î¹/Î»/GLI inhibitor) or arsenic trioxide.",314,"Basal Cell Carcinoma","Basal Cell Carcinoma",2513,"http://www.disease-ontology.org/?id=DOID:2513","D","Predictive","Supports","Sensitivity","Somatic Mutation",300,4,"Substitutes","accepted",0,"evidence",493,"Smoothened variants explain the majority of drug resistance in basal cell carcinoma.","Atwood et al., 2015, Cancer Cell",25759020,"http://www.ncbi.nlm.nih.gov/pubmed/25759020","true","PMC4357167","2015","3","9","Cancer Cell","Cancer cell","fully curated","271","PSI",NULL,"47","Arsenic Trioxide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
748,"EID748","133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of types including: stop gain, splice site, frameshift, etc.). Functional models also showed PTCH1 mutant xenografts to be sensitive to SHH inhibition with vismodegib.",97,"Brain Medulloblastoma","Brain Medulloblastoma",60105,"http://www.disease-ontology.org/?id=DOID:0060105","B","Predictive","Supports","Sensitivity","Somatic Mutation",301,4,NULL,"accepted",0,"evidence",494,"Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.","Kool et al., 2014, Cancer Cell",24651015,"http://www.ncbi.nlm.nih.gov/pubmed/24651015","true","PMC4493053","2014","3","17","Cancer Cell","Cancer cell","fully curated","190","Vismodegib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
749,"EID749","Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449). 43 patients total were enrolled for this study.",97,"Brain Medulloblastoma","Brain Medulloblastoma",60105,"http://www.disease-ontology.org/?id=DOID:0060105","B","Predictive","Supports","Sensitivity","Somatic Mutation",302,2,NULL,"accepted",0,"evidence",495,"Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.","Robinson et al., 2015, J. Clin. Oncol.",26169613,"http://www.ncbi.nlm.nih.gov/pubmed/26169613","true","PMC4534527","2015","8","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","190","Vismodegib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
750,"EID750","In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivariate analysis. Results were validated in public datasets.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",303,4,NULL,"accepted",0,"evidence",496,"Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.","PÃ©cuchet et al., 2015, Oncotarget",26625312,"http://www.ncbi.nlm.nih.gov/pubmed/26625312",NULL,NULL,"2015","11","25","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
751,"EID751","STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Predictive","Supports","Sensitivity","Somatic Mutation",304,2,NULL,"accepted",0,"evidence",497,"Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.","Grossi et al., 2015, Autophagy",26391455,"http://www.ncbi.nlm.nih.gov/pubmed/26391455","true","PMC4824604","2015","11","2","Autophagy","Autophagy","fully curated","133","SB202190",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
752,"EID752","Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel. Inhibition of SYK with R406 resensitized cell lines to paclitaxel.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",305,3,NULL,"accepted",0,"evidence",498,"Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.","Yu et al., 2015, Cancer Cell",26096845,"http://www.ncbi.nlm.nih.gov/pubmed/26096845",NULL,NULL,"2015","7","13","Cancer Cell","Cancer cell","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
753,"EID753","p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Supports","Sensitivity","Somatic Mutation",272,3,NULL,"accepted",0,"evidence",455,"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.","Vermorken et al., 2013, Lancet Oncol.",23746666,"http://www.ncbi.nlm.nih.gov/pubmed/23746666",NULL,NULL,"2013","7",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
754,"EID754","The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.",44,"Hepatocellular Fibrolamellar Carcinoma","Hepatocellular Fibrolamellar Carcinoma",5015,"http://www.disease-ontology.org/?id=DOID:5015","B","Diagnostic","Supports","Positive","Somatic Mutation",31,4,NULL,"accepted",0,"evidence",499,"Unique genomic profile of fibrolamellar hepatocellular carcinoma.","Cornella et al., 2015, Gastroenterology",25557953,"http://www.ncbi.nlm.nih.gov/pubmed/25557953","true","PMC4521774","2015","4",NULL,"Gastroenterology","Gastroenterology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
755,"EID755","D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib. SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO.",314,"Basal Cell Carcinoma","Basal Cell Carcinoma",2513,"http://www.disease-ontology.org/?id=DOID:2513","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",299,3,NULL,"accepted",0,"evidence",493,"Smoothened variants explain the majority of drug resistance in basal cell carcinoma.","Atwood et al., 2015, Cancer Cell",25759020,"http://www.ncbi.nlm.nih.gov/pubmed/25759020","true","PMC4357167","2015","3","9","Cancer Cell","Cancer cell","fully curated","190","Vismodegib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
756,"EID756","One platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response on treatment with PI3K inhibitor pictilisib (GDC-0941) in this phase 1 study. A total of 60 patients with advanced solid tumors were enrolled in this study.",225,"Epithelial Ovarian Cancer","Epithelial Ovarian Cancer",2152,"http://www.disease-ontology.org/?id=DOID:2152","C","Predictive","Supports","Sensitivity","Somatic Mutation",212,2,NULL,"accepted",0,"evidence",500,"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.","Sarker et al., 2015, Clin. Cancer Res.",25370471,"http://www.ncbi.nlm.nih.gov/pubmed/25370471","true","PMC4287394","2015","1","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","141","Pictilisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
757,"EID757","One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",12,2,NULL,"accepted",0,"evidence",500,"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.","Sarker et al., 2015, Clin. Cancer Res.",25370471,"http://www.ncbi.nlm.nih.gov/pubmed/25370471","true","PMC4287394","2015","1","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","141","Pictilisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
758,"EID758","720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to patients with HPV-negative/p16 negative tumors. HPV/p16 status was shown to be a strong and independent risk factor in oropharyngeal carcinoma.",204,"Oropharynx Cancer","Oropharynx Cancer",8557,"http://www.disease-ontology.org/?id=DOID:8557","A","Prognostic","Supports","Better Outcome","Somatic Mutation",272,4,NULL,"accepted",0,"evidence",501,"Human papillomavirus and survival of patients with oropharyngeal cancer.","Ang et al., 2010, N. Engl. J. Med.",20530316,"http://www.ncbi.nlm.nih.gov/pubmed/20530316","true","PMC2943767","2010","7","1","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
759,"EID759","This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated.",204,"Oropharynx Cancer","Oropharynx Cancer",8557,"http://www.disease-ontology.org/?id=DOID:8557","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",272,4,NULL,"accepted",0,"evidence",502,"Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.","Rosenthal et al., 2016, J. Clin. Oncol.",26712222,"http://www.ncbi.nlm.nih.gov/pubmed/26712222",NULL,NULL,"2016","4","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
760,"EID760","Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",503,"Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.","She et al., 2008, PLoS ONE",18725974,"http://www.ncbi.nlm.nih.gov/pubmed/18725974","true","PMC2516933","2008",NULL,NULL,"PLoS ONE","PloS one","fully curated","169","AKTi-1/2",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
761,"EID761","Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",504,"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.","Burstein et al., 2010, J. Clin. Oncol.",20142587,"http://www.ncbi.nlm.nih.gov/pubmed/20142587",NULL,NULL,"2010","3","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
762,"EID762","CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",34,3,NULL,"accepted",0,"evidence",505,"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.","Walter et al., 2013, Cancer Discov",24065731,"http://www.ncbi.nlm.nih.gov/pubmed/24065731","true","PMC4048995","2013","12",NULL,"Cancer Discov","Cancer discovery","fully curated","91","Rociletinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
763,"EID763","Case-report of a patient with an acquired ALK L1152R mutation and resistance to crizotinib treatment. A cell line model also showed resistance against ALK inhibition.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",307,4,NULL,"accepted",0,"evidence",506,"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.","Sasaki et al., 2011, Cancer Res.",21791641,"http://www.ncbi.nlm.nih.gov/pubmed/21791641","true","PMC3278914","2011","9","15","Cancer Res.","Cancer research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
764,"EID764","11 patients with crizotinib-resistant NSCLC were analyzed for this study. Two harbored the G1269A mutation that also led to crizotinib-resistance in-vitro.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",308,4,NULL,"accepted",0,"evidence",507,"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.","Doebele et al., 2012, Clin. Cancer Res.",22235099,"http://www.ncbi.nlm.nih.gov/pubmed/22235099","true","PMC3311875","2012","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
765,"EID765","2 out of 7 patients with an acquired resistance to crizotinib had a G1269A mutation. One of these patients also harbored a L1196M mutation. In vitro follow-up showed reduced crizotinib-induced ALK dephosphorylation (293T) and apoptosis (Ba/F3) when EML4-ALK G1269A overexpression was compared to EML4-ALK overexpression in these cell lines.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",308,3,NULL,"accepted",0,"evidence",508,"Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.","Kim et al., 2013, J Thorac Oncol",23344087,"http://www.ncbi.nlm.nih.gov/pubmed/23344087",NULL,NULL,"2013","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
766,"EID766","Two out of 11 patients with an acquired crizotinib resistance showed new ALK copy-number gain (defined as more than 2-fold increase in the mean of the rearranged gene per cell in the posttreatment specimen compared with the pretreatment specimen), both with >4 fold increase. One of them also harbored a resistance mutation (G1269A).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",170,3,NULL,"accepted",0,"evidence",507,"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.","Doebele et al., 2012, Clin. Cancer Res.",22235099,"http://www.ncbi.nlm.nih.gov/pubmed/22235099","true","PMC3311875","2012","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
767,"EID767","One patient with ALK-rearranged non-small cell lung cancer and an acquired resistance to crizotinib showed new ALK amplification (4.1 fold increase compared to pre-crizotinib specimen as measured by FISH) and harbored an EGFR L858R mutation.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",170,2,NULL,"accepted",0,"evidence",508,"Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.","Kim et al., 2013, J Thorac Oncol",23344087,"http://www.ncbi.nlm.nih.gov/pubmed/23344087",NULL,NULL,"2013","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
768,"EID768","A cell line (DFCI076 ) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibition of both pathways led to decreases cell-growth. Amphiregulin production was identified as a potential mediator of EGFR-activation (no other alterations detectable). 
The same mechanism could be reproduced in a cell line (H3122) without EML1-ALK mutation and resistance to crizotinib that was acquired in-vitro.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",309,3,NULL,"rejected",0,"evidence",506,"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.","Sasaki et al., 2011, Cancer Res.",21791641,"http://www.ncbi.nlm.nih.gov/pubmed/21791641","true","PMC3278914","2011","9","15","Cancer Res.","Cancer research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
769,"EID769","Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",309,2,NULL,"rejected",0,"evidence",508,"Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.","Kim et al., 2013, J Thorac Oncol",23344087,"http://www.ncbi.nlm.nih.gov/pubmed/23344087",NULL,NULL,"2013","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
770,"EID770","ERBB4 was the most commonly mutated protein tyrosine kinase in this study in melanoma (19% in 79 patients). Seven of the identified mutations in ERBB4 (E317K, E452K, E542K, R544W, E563K, E836K and E872K) were transforming and activating in-vitro. ERBB4 inhibition with shRNA or lapatinib led to reduced cell growth.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",310,4,NULL,"accepted",0,"evidence",509,"Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.","Prickett et al., 2009, Nat. Genet.",19718025,"http://www.ncbi.nlm.nih.gov/pubmed/19718025","true","PMC2897709","2009","10",NULL,"Nat. Genet.","Nature genetics","fully curated","45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
771,"EID771","20 patient-derived colorectal cancer xenografts were treated with cabozantinib, a c-MET and VEGFR2 inhibitor. 16 xenografts showed sensitivity (as defined by TGII: tumor growth of treated compared to controlâ€‰â‰¤â€‰20%). Among the genes tested for mutations (KRAS, TP53, PIK3CA, MET, VEGFR2, RET and AXL), PIK3CA mutations (4 PDTX) showed a significant enrichment in sensitive xenografts. PIK3CA mutations were observed in 4/5 of the most responsive tumors. Treating xenografts derived from isogenic PIK3CA wildtype or mutant cell lines corroborated this finding with PIK3CA mutant xenografts showing greater sensitivity to cabozantinib.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,3,NULL,"accepted",0,"evidence",510,"Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.","Song et al., 2015, Int. J. Cancer",25242168,"http://www.ncbi.nlm.nih.gov/pubmed/25242168","true","PMC4323738","2015","4","15","Int. J. Cancer","International journal of cancer","fully curated","144","Cabozantinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
772,"EID772","49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Predictive","Supports","Sensitivity","Somatic Mutation",312,4,NULL,"accepted",0,"evidence",514,"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.","Mellinghoff et al., 2005, N. Engl. J. Med.",16282176,"http://www.ncbi.nlm.nih.gov/pubmed/16282176",NULL,NULL,"2005","11","10","N. Engl. J. Med.","The New England journal of medicine","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
773,"EID773","Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles. Afatinib and temozolomide led to disease regression. At last assessment 63 treatment cycles had been completed and the patient had survived for about 5 years since recurrence. Identified EGFR aberrations included EGFRvIII positivity, EGFR gene amplification and three somatic EGFR mutations.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","C","Predictive","Supports","Sensitivity","Somatic Mutation",312,2,NULL,"accepted",0,"evidence",515,"Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.","Alshami et al., 2015, Oncotarget",26423602,"http://www.ncbi.nlm.nih.gov/pubmed/26423602","true","PMC4741824","2015","10","20","Oncotarget","Oncotarget","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
774,"EID774","49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Predictive","Supports","Sensitivity","Somatic Mutation",313,4,NULL,"accepted",0,"evidence",514,"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.","Mellinghoff et al., 2005, N. Engl. J. Med.",16282176,"http://www.ncbi.nlm.nih.gov/pubmed/16282176",NULL,NULL,"2005","11","10","N. Engl. J. Med.","The New England journal of medicine","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
775,"EID775","In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII mutation). It was less effective in one cell-line with PTEN deletion.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","D","Predictive","Supports","Sensitivity","Somatic Mutation",313,2,NULL,"accepted",0,"evidence",516,"Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.","Zahonero et al., 2015, Mol. Cancer Ther.",25939761,"http://www.ncbi.nlm.nih.gov/pubmed/25939761",NULL,NULL,"2015","7",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","44","Dacomitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
776,"EID776","In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified in head and neck cancer cell lines.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Sensitivity","N/A",314,4,NULL,"accepted",0,"evidence",517,"Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.","Wilson et al., 2011, Cancer Cell",21840482,"http://www.ncbi.nlm.nih.gov/pubmed/21840482",NULL,NULL,"2011","8","16","Cancer Cell","Cancer cell","fully curated","45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
777,"EID777","NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","N/A",314,4,NULL,"accepted",0,"evidence",518,"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.","Yonesaka et al., 2011, Sci Transl Med",21900593,"http://www.ncbi.nlm.nih.gov/pubmed/21900593","true","PMC3268675","2011","9","7","Sci Transl Med","Science translational medicine","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
778,"EID778","An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vivo. An ERBB3 directed antibody (MM-121) inhibited tumor-growth in-vivo.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Sensitivity","N/A",314,3,NULL,"accepted",0,"evidence",519,"An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.","Sheng et al., 2010, Cancer Cell",20227043,"http://www.ncbi.nlm.nih.gov/pubmed/20227043","true","PMC2897158","2010","3","16","Cancer Cell","Cancer cell","fully curated","221","Anti-ERBB3 Agents",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
779,"EID779","In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decreased tumor growth and enhanced magnitude and response to chemotherapy.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","N/A",314,3,"Substitutes","accepted",0,"evidence",520,"Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.","Hegde et al., 2013, Sci Transl Med",23390248,"http://www.ncbi.nlm.nih.gov/pubmed/23390248",NULL,NULL,"2013","2","6","Sci Transl Med","Science translational medicine","fully curated","81","Paclitaxel",NULL,"326","Cisplatin",NULL,"85","Gemcitabine",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL
780,"EID780","A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibition of both pathways led to decreased cell-growth. Amphiregulin (AREG) production was identified as a potential mediator of EGFR-activation (no other alterations detectable). The same mechanism could be reproduced in a cell line (H3122) without EML1-ALK mutation and resistance to crizotinib that was acquired in-vitro.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","N/A",315,3,NULL,"accepted",0,"evidence",506,"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.","Sasaki et al., 2011, Cancer Res.",21791641,"http://www.ncbi.nlm.nih.gov/pubmed/21791641","true","PMC3278914","2011","9","15","Cancer Res.","Cancer research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
781,"EID781","Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","N/A",315,2,NULL,"accepted",0,"evidence",508,"Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.","Kim et al., 2013, J Thorac Oncol",23344087,"http://www.ncbi.nlm.nih.gov/pubmed/23344087",NULL,NULL,"2013","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
782,"EID782","Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","N/A",193,3,NULL,"accepted",0,"evidence",521,"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.","Rubin Grandis et al., 1998, J. Natl. Cancer Inst.",9625170,"http://www.ncbi.nlm.nih.gov/pubmed/9625170",NULL,NULL,"1998","6","3","J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
783,"EID783","55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts).",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",193,3,NULL,"accepted",0,"evidence",522,"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.","Jia et al., 2016, Clin Transl Oncol",26459251,"http://www.ncbi.nlm.nih.gov/pubmed/26459251",NULL,NULL,"2016","6",NULL,"Clin Transl Oncol","Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","fully curated","188","Nimotuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
784,"EID784","55 tumor samples were analyzed for EGFR expression using IHC.
PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 Â± 0.5 vs. 11.0 Â± 2.8 months, P = 0.007; OS: 9.7 Â± 0.5 vs. 21.5 Â± 1.5 months, P = 0.03.",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Prognostic","Supports","Poor Outcome","N/A",193,3,NULL,"accepted",0,"evidence",522,"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.","Jia et al., 2016, Clin Transl Oncol",26459251,"http://www.ncbi.nlm.nih.gov/pubmed/26459251",NULL,NULL,"2016","6",NULL,"Clin Transl Oncol","Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
785,"EID785","Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",316,3,NULL,"accepted",0,"evidence",521,"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.","Rubin Grandis et al., 1998, J. Natl. Cancer Inst.",9625170,"http://www.ncbi.nlm.nih.gov/pubmed/9625170",NULL,NULL,"1998","6","3","J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
786,"EID786","Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",317,4,NULL,"accepted",0,"evidence",523,"Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.","Cho et al., 2014, Mol. Cancer",24894453,"http://www.ncbi.nlm.nih.gov/pubmed/24894453","true","PMC4072491","2014",NULL,NULL,"Mol. Cancer","Molecular cancer","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
787,"EID787","Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules. The same in-vitro results could be reproduced for the G719S mutation.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",134,4,NULL,"accepted",0,"evidence",523,"Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.","Cho et al., 2014, Mol. Cancer",24894453,"http://www.ncbi.nlm.nih.gov/pubmed/24894453","true","PMC4072491","2014",NULL,NULL,"Mol. Cancer","Molecular cancer","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
788,"EID788","226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15â€‰months, p=0.0005).  
Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutated CRC.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",315,3,NULL,"accepted",0,"evidence",524,"Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.","Pentheroudakis et al., 2013, BMC Cancer",23374602,"http://www.ncbi.nlm.nih.gov/pubmed/23374602","true","PMC3599697","2013",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
789,"EID789","226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",318,3,NULL,"accepted",0,"evidence",524,"Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.","Pentheroudakis et al., 2013, BMC Cancer",23374602,"http://www.ncbi.nlm.nih.gov/pubmed/23374602","true","PMC3599697","2013",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
790,"EID790","226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",319,3,NULL,"rejected",0,"evidence",524,"Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.","Pentheroudakis et al., 2013, BMC Cancer",23374602,"http://www.ncbi.nlm.nih.gov/pubmed/23374602","true","PMC3599697","2013",NULL,NULL,"BMC Cancer","BMC cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
791,"EID791","Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild-type line.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","C","Predictive","Supports","Sensitivity","Somatic Mutation",320,4,NULL,"accepted",0,"evidence",525,"Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.","Van Allen et al., 2015, JAMA Oncol",26181029,"http://www.ncbi.nlm.nih.gov/pubmed/26181029","true","PMC4557203","2015","5",NULL,"JAMA Oncol","JAMA oncology","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
792,"EID792","Resistance to WZ4002 was induced in cell lines. Amplification of MAPK1 or downregulation of ERK-pathway inhibitors led to resistance to EGFR inhibition with WZ4002. Chemical inhibition (MEK inhibition with either CI-1040 or GSK1120212) or shRNA knockdown of MAPK1 resensitized cells to EGFR inhibition with WZ4002 in-vitro. Additionally, MAPK1 amplification was identified in 1/21 erlotinib-resistant NSCLC patients. MAPK1 amplification was not observed in the pretreatment tumor, only the post-treatment resistant tumor which lacked other more common drug-resistance mechanisms EGFR T790M or MET amplification.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",321,4,NULL,"accepted",0,"evidence",526,"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.","Ercan et al., 2012, Cancer Discov",22961667,"http://www.ncbi.nlm.nih.gov/pubmed/22961667","true","PMC3477553","2012","10",NULL,"Cancer Discov","Cancer discovery","fully curated","147","WZ4002",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
793,"EID793","FGFR1 expression, was assessed by IHC in 1,086 invasive breast cancers. FGFR1 expression was mainly associated with luminal cancer subtypes. Multivariate Cox regression analysis showed FGFR1 to be an independent poor prognostic marker in luminal A cancers for disease free survival (hazard ratio = 3.341, p = 0.008). In luminal A cancers, FGFR1 expression was also significantly associated with higher pN (lymph node metastases; p = 0.023) and pT (unfavorable tumor characteristics; p = 0.003) stages and lymphovascular invasion (p = 0.010).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",268,2,NULL,"accepted",0,"evidence",527,"FGFR1 is an adverse outcome indicator for luminal A breast cancers.","Shi et al., 2016, Oncotarget",26673008,"http://www.ncbi.nlm.nih.gov/pubmed/26673008","true","PMC4826266","2016","1","26","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
794,"EID794","Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led to administration of CDK4 inhibitor LY2835219. Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4. The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",322,2,NULL,"accepted",0,"evidence",528,"Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.","Van Allen et al., 2014, Nat. Med.",24836576,"http://www.ncbi.nlm.nih.gov/pubmed/24836576","true","PMC4048335","2014","6",NULL,"Nat. Med.","Nature medicine","fully curated","148","LY2835219",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
795,"EID795","In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treated with vehicle developed lesions at the end of the treatment.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",425,1,NULL,"accepted",0,"evidence",529,"A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.","Puyol et al., 2010, Cancer Cell",20609353,"http://www.ncbi.nlm.nih.gov/pubmed/20609353",NULL,NULL,"2010","7","13","Cancer Cell","Cancer cell","fully curated","149","PD0332991",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
796,"EID796","In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate.  A response was observed in 5 of 10 (50%) vs. 5 of 57 (8.8%) patients with and without germline MET mutations, respectively.",162,"Papillary Renal Cell Carcinoma","Papillary Renal Cell Carcinoma",4465,"http://www.disease-ontology.org/?id=DOID:4465","B","Predictive","Supports","Sensitivity","Germline Mutation",323,3,NULL,"accepted",0,"evidence",530,"Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.","Choueiri et al., 2013, J. Clin. Oncol.",23213094,"http://www.ncbi.nlm.nih.gov/pubmed/23213094","true","PMC3532390","2013","1","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","150","Foretinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
797,"EID797","We now report responses to the MET inhibitors crizotinib
and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading
to MET exon 14 skipping.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",324,3,NULL,"accepted",0,"evidence",531,"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.","Paik et al., 2015, Cancer Discov",25971939,"http://www.ncbi.nlm.nih.gov/pubmed/25971939","true","PMC4658654","2015","8",NULL,"Cancer Discov","Cancer discovery","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
798,"EID798","This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. Evidence was found for the expression of FGFR1 in cancer-associated fibroblasts, other results were conflicting. Significant risk of bias was reported for the included studies.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",268,2,NULL,"accepted",0,"evidence",532,"Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.","Ipenburg et al., 2016, Target Oncol",26115874,"http://www.ncbi.nlm.nih.gov/pubmed/26115874","true","PMC4759209","2016","2",NULL,"Target Oncol","Targeted oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
799,"EID799","FGFR1 mRNA expression, rather than copy number alterations, were predictive of response to FGFR inhibitor BGJ398 in cell lines and patient derived xenografts.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Sensitivity","N/A",268,3,NULL,"accepted",0,"evidence",533,"FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.","GÃ¶ke et al., 2015, Clin. Cancer Res.",26015511,"http://www.ncbi.nlm.nih.gov/pubmed/26015511","true","PMC4592392","2015","10","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","151","BGJ398",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
800,"EID800","FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","D","Predictive","Supports","Sensitivity","N/A",268,2,NULL,"accepted",0,"evidence",534,"Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.","Schmidt et al., 2015, Anticancer Res.",26637881,"http://www.ncbi.nlm.nih.gov/pubmed/26637881",NULL,NULL,"2015","12",NULL,"Anticancer Res.","Anticancer research","fully curated","151","BGJ398",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
801,"EID801","One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors  (SU5402, TKI258 or PD173074).",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","D","Predictive","Supports","Sensitivity","N/A",268,2,"Substitutes","accepted",0,"evidence",535,"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.","Lamont et al., 2011, Br. J. Cancer",21119661,"http://www.ncbi.nlm.nih.gov/pubmed/21119661","true","PMC3039817","2011","1","4","Br. J. Cancer","British journal of cancer","fully curated","152","Dovitinib Dilactic Acid (TKI258 Dilactic Acid)",NULL,"36","PD173074",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
802,"EID802","FGFR1 expression was increased in urothelial carcinoma cell lines and patient tumours, independent of stage and grade. FGFR1 knockdown resulted in decreases proliferation and survival in some of the cell lines.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","D","Predictive","Supports","Sensitivity","Somatic Mutation",268,2,NULL,"rejected",0,"evidence",536,"Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.","Tomlinson et al., 2009, Cancer Res.",19458078,"http://www.ncbi.nlm.nih.gov/pubmed/19458078","true","PMC2737316","2009","6","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
803,"EID803","The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","D","Predictive","Supports","Sensitivity","N/A",325,3,"Substitutes","accepted",0,"evidence",535,"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.","Lamont et al., 2011, Br. J. Cancer",21119661,"http://www.ncbi.nlm.nih.gov/pubmed/21119661","true","PMC3039817","2011","1","4","Br. J. Cancer","British journal of cancer","fully curated","36","PD173074",NULL,"153","SU-5402",NULL,"228","Dovitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
804,"EID804","Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expression in non-oropharyngeal HNSSC was also prognostic and associated with a better outcome. However, p16-positive oropharyngeal HNSSC still had better PFS and OS than p16-positive non-oropharyngeal HNSSC.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Better Outcome","Somatic Mutation",272,3,NULL,"accepted",0,"evidence",538,"p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.","Chung et al., 2014, J. Clin. Oncol.",25267748,"http://www.ncbi.nlm.nih.gov/pubmed/25267748","true","PMC4251957","2014","12","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
805,"EID805","The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro. In other words, expression of CBLC is predicted to confer resistance to olaparib.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Resistance or Non-Response","N/A",326,2,NULL,"accepted",0,"evidence",539,"Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.","Frankum et al., 2015, Oncotarget",25883215,"http://www.ncbi.nlm.nih.gov/pubmed/25883215","true","PMC4484416","2015","5","10","Oncotarget","Oncotarget","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
806,"EID806","This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations. Univariate analysis did not show any differences between these groups. Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",81,2,NULL,"accepted",0,"evidence",540,"Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.","Osumi et al., 2015, Mol Clin Oncol",26623049,"http://www.ncbi.nlm.nih.gov/pubmed/26623049","true","PMC4534836","2015","9",NULL,"Mol Clin Oncol","Molecular and clinical oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
807,"EID807","In this preclinical study, loss-of-function of PTPRD was mainly caused by mutation in head and neck cancer, as identified in TCGA data. PTPRD mutated cell-lines were more sensitive to STAT3 inhibition (JSI-124) than wild-type cells. The authors generated several representative HNSCC-derived PTPRD mutants by site-directed mutagenesis (S384R, K1502M, T1100M and L1147F).",109,"Head And Neck Carcinoma","Head And Neck Carcinoma",1542,"http://www.disease-ontology.org/?id=DOID:1542","D","Predictive","Supports","Sensitivity","Somatic Mutation",327,3,NULL,"accepted",0,"evidence",541,"Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.","Peyser et al., 2015, PLoS ONE",26267899,"http://www.ncbi.nlm.nih.gov/pubmed/26267899","true","PMC4534317","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated","154","JSI-124",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
808,"EID808","Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were validated in 10 patients.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predictive","Supports","Sensitivity","N/A",328,2,NULL,"accepted",0,"evidence",542,"Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.","Kohli et al., 2015, Onco Targets Ther",26261420,"http://www.ncbi.nlm.nih.gov/pubmed/26261420","true","PMC4527520","2015",NULL,NULL,"Onco Targets Ther","OncoTargets and therapy","fully curated","73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
809,"EID809","Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","B","Predictive","Does Not Support","Sensitivity","N/A",329,4,NULL,"accepted",0,"evidence",543,"ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.","Klatte et al., 2015, J. Urol.",26162296,"http://www.ncbi.nlm.nih.gov/pubmed/26162296",NULL,NULL,"2015","11",NULL,"J. Urol.","The Journal of urology","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
810,"EID810","ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","B","Prognostic","Supports","Better Outcome","N/A",329,2,NULL,"accepted",0,"evidence",543,"ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.","Klatte et al., 2015, J. Urol.",26162296,"http://www.ncbi.nlm.nih.gov/pubmed/26162296",NULL,NULL,"2015","11",NULL,"J. Urol.","The Journal of urology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
811,"EID811","NOTCH1 copy-number gain in a patient-derived tumor xenograft model of colorectal cancer, was associated with increased NOTCH1 and JAG1 activity and response to a NOTCH1-targeting antibody (PF-06293622).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",330,2,NULL,"accepted",0,"evidence",544,"A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.","Arcaroli et al., 2016, Int. J. Cancer",26152787,"http://www.ncbi.nlm.nih.gov/pubmed/26152787","true","PMC4618491","2016","1","1","Int. J. Cancer","International journal of cancer","fully curated","230","NOTCH1 Antibody",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
812,"EID812","NOTCH1 amplifications (as determined by FISH) were significantly (log-rank pâ€‰=â€‰0.025) associated with worse survival in a cohort of 116 patients with colorectal cancer.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",330,2,NULL,"accepted",0,"evidence",544,"A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.","Arcaroli et al., 2016, Int. J. Cancer",26152787,"http://www.ncbi.nlm.nih.gov/pubmed/26152787","true","PMC4618491","2016","1","1","Int. J. Cancer","International journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
813,"EID813","In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding. NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",314,4,NULL,"accepted",0,"evidence",545,"Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.","Mendell et al., 2015, EBioMedicine",26137564,"http://www.ncbi.nlm.nih.gov/pubmed/26137564","true","PMC4484825","2015","3",NULL,"EBioMedicine","EBioMedicine","fully curated","262","Patritumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
814,"EID814","The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associated with efficacy. 663 patients were tested. The authors showed that rs3910384 is closely linked with the putative functional WEE1 promoter at SNPs rs6486433, rs3763869 and rs3763868.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Germline Polymorphism",331,3,"Combination","accepted",0,"evidence",546,"WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.","Liu et al., 2015, Sci Rep",26057002,"http://www.ncbi.nlm.nih.gov/pubmed/26057002","true","PMC4460872","2015",NULL,NULL,"Sci Rep","Scientific reports","fully curated","85","Gemcitabine",NULL,"103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
815,"EID815","57 from 105 patients in the AGo-OVAR-15 trial were retrospectively genotyped for FNTB polymorphisms. Resistance to lonafarnib-containing treatment was limited to patients with a FNTB rs11623866 (c.-609Gâ€‰>â€‰C) GG genotype (HRPFS 6.2, 95%CIâ€‰=â€‰2.01, 19.41, Pâ€‰=â€‰0.002; HROS 9.6, 95%CIâ€‰=â€‰1.89, 48.54, Pâ€‰=â€‰0.006).",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Resistance or Non-Response","Germline Polymorphism",332,2,NULL,"accepted",0,"evidence",547,"The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.","Bachmann et al., 2015, Br J Clin Pharmacol",26033044,"http://www.ncbi.nlm.nih.gov/pubmed/26033044","true","PMC4631186","2015","11",NULL,"Br J Clin Pharmacol","British journal of clinical pharmacology","fully curated","270","Lonafarnib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
816,"EID816","This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF. In other words, the authors believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF. In these studies, mutant BRAF specifically meant the V600E mutation.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",12,4,"Substitutes","accepted",0,"evidence",548,"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.","Rowland et al., 2015, Br. J. Cancer",25989278,"http://www.ncbi.nlm.nih.gov/pubmed/25989278","true","PMC4580381","2015","6","9","Br. J. Cancer","British journal of cancer","fully curated","16","Cetuximab",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
817,"EID817","PTPRT promoter hypermethylation was associated with increased sensitivity to STAT3 inhibition in this preclinical study in HNSCC. The authors found that PTPRT promoter methylation and sensitivity to Stattic (a STAT3 SH2 domain inhibitor) or JSI-124 (a JAK/STAT3 pathway inhibitor) are significantly correlated (P<0.05).",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Sensitivity","Somatic Mutation",333,2,"Substitutes","accepted",0,"evidence",549,"Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.","Peyser et al., 2016, Oncogene",25982282,"http://www.ncbi.nlm.nih.gov/pubmed/25982282","true","PMC4651851","2016","3","3","Oncogene","Oncogene","fully curated","154","JSI-124",NULL,"231","Stattic",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
818,"EID818","Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",334,2,"Combination","accepted",0,"evidence",550,"Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.","Tsai et al., 2015, Int J Clin Exp Pathol",25973082,"http://www.ncbi.nlm.nih.gov/pubmed/25973082","true","PMC4396259","2015",NULL,NULL,"Int J Clin Exp Pathol","International journal of clinical and experimental pathology","fully curated","395","5-fluorouracil",NULL,"33","Bevacizumab",NULL,"215","L-Folinic Acid",NULL,"101","Irinotecan",NULL,NULL,NULL,NULL
819,"EID819","DNMT1 expression (mRNA expression from an independent study) correlated with sensitivity to decitabine (Ï, âˆ’0.443, Pearson regression analysis) in this preclinical study of 45 solid tumor cell lines. DNMT1 protein expression was also evaluated in two KRAS-mutant ovarian cancer cell lines pre and post-decitabine treatment showing downregulation following treatment.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Sensitivity","N/A",335,3,NULL,"accepted",0,"evidence",551,"KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.","Stewart et al., 2015, Cancer Res.",25968887,"http://www.ncbi.nlm.nih.gov/pubmed/25968887","true","PMC4506246","2015","7","15","Cancer Res.","Cancer research","fully curated","155","Decitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
820,"EID820","KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines. The authors profiled the response of 45 ovarian, melanoma, and breast cancer cell lines over 9 days of treatment with decitabine. 4 ovarian lines with KRAS mutation were among the most sensitive to decitabine.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,3,NULL,"accepted",0,"evidence",551,"KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.","Stewart et al., 2015, Cancer Res.",25968887,"http://www.ncbi.nlm.nih.gov/pubmed/25968887","true","PMC4506246","2015","7","15","Cancer Res.","Cancer research","fully curated","155","Decitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
821,"EID821","PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","B","Predictive","Supports","Sensitivity","Somatic Mutation",337,4,NULL,"accepted",0,"evidence",552,"Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4.","Xu et al., 2015, J. Proteome Res.",25928036,"http://www.ncbi.nlm.nih.gov/pubmed/25928036",NULL,NULL,"2015","6","5","J. Proteome Res.","Journal of proteome research","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
822,"EID822","The T allele of the rs16906252 SNP was associated with MGMT methylation and low protein expression. Germline presence of the T allele increased the risk of glioblastoma development (adjusted odds ratio, 1.96; P = .013). Temozolomide treatment led to better survival in patients with the rs16906252 T genotype irrespective of methylation status.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Predictive","Supports","Sensitivity","Germline Polymorphism",338,3,NULL,"accepted",0,"evidence",553,"The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.","Rapkins et al., 2015, Neuro-oncology",25910840,"http://www.ncbi.nlm.nih.gov/pubmed/25910840","true","PMC4633927","2015","12",NULL,"Neuro-oncology","Neuro-oncology","fully curated","11","Temozolomide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
823,"EID823","TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethimide or oophorectomy) and outperformed ER, PR and TFF1 as biomarkers.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","N/A",339,3,"Substitutes","accepted",0,"evidence",554,"TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.","May et al., 2015, Endocr. Relat. Cancer",25900183,"http://www.ncbi.nlm.nih.gov/pubmed/25900183","true","PMC4455223","2015","6",NULL,"Endocr. Relat. Cancer","Endocrine-related cancer","fully curated","235","Aminoglutethimide",NULL,"53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
824,"EID824","Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemotherapy (FOLFOX, FOLFIRI, or 5-FU) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)].",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","N/A",340,3,"Combination","accepted",0,"evidence",555,"Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.","Aguilera et al., 2015, Oncotarget",25788273,"http://www.ncbi.nlm.nih.gov/pubmed/25788273","true","PMC4467410","2015","3","20","Oncotarget","Oncotarget","fully curated","215","L-Folinic Acid",NULL,"395","5-fluorouracil",NULL,"237","Oxaliplatin",NULL,"101","Irinotecan",NULL,NULL,NULL,NULL
825,"EID825","CD44 isoform expression (especially CD44s) was identified to predict response to CD44 antibody RG7356 preclinically. Retrospective evaluation of 13 patients from a phase 1 study, treated with RG7356, identified 3 patients with CD44s isoform. 2/3 patients with CD44s had SD as best response. Overall, 5 patients had an OR.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","N/A",341,3,NULL,"accepted",0,"evidence",556,"CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.","Birzele et al., 2015, Clin. Cancer Res.",25762343,"http://www.ncbi.nlm.nih.gov/pubmed/25762343",NULL,NULL,"2015","6","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","240","RG7356",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
826,"EID826","3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amphiregulin and epiregulin were inconclusive.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Resistance or Non-Response","N/A",342,3,NULL,"accepted",0,"evidence",557,"Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.","Ansell et al., 2016, J. Oral Pathol. Med.",25677871,"http://www.ncbi.nlm.nih.gov/pubmed/25677871",NULL,NULL,"2016","1",NULL,"J. Oral Pathol. Med.","Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
827,"EID827","72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with cisplatin and pemetrexed (standard of care therapy).",199,"Malignant Pleural Mesothelioma","Malignant Pleural Mesothelioma",7474,"http://www.disease-ontology.org/?id=DOID:7474","B","Predictive","Supports","Resistance or Non-Response","N/A",343,1,"Combination","accepted",0,"evidence",558,"MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.","Walter et al., 2015, Br. J. Cancer",25668009,"http://www.ncbi.nlm.nih.gov/pubmed/25668009","true","PMC4453955","2015","3","3","Br. J. Cancer","British journal of cancer","fully curated","326","Cisplatin",NULL,"156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
828,"EID828","72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with standard of care therapy (cisplatin and pemetrexed).",199,"Malignant Pleural Mesothelioma","Malignant Pleural Mesothelioma",7474,"http://www.disease-ontology.org/?id=DOID:7474","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",343,3,NULL,"accepted",0,"evidence",558,"MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.","Walter et al., 2015, Br. J. Cancer",25668009,"http://www.ncbi.nlm.nih.gov/pubmed/25668009","true","PMC4453955","2015","3","3","Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
829,"EID829","In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% versus 92.9%, P<0.01), shorter progression-free survival (4.4 versus 42 months, P=0.022) and poor overall survival (Ï‡ (2)=4.775, P=0.029) in patients receiving sorafenib or sunitinib.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Predictive","Supports","Resistance or Non-Response","N/A",344,3,"Substitutes","accepted",0,"evidence",559,"Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.","Zheng et al., 2015, Onco Targets Ther",26309414,"http://www.ncbi.nlm.nih.gov/pubmed/26309414","true","PMC4539079","2015",NULL,NULL,"Onco Targets Ther","OncoTargets and therapy","fully curated","157","Sunitinib",NULL,"6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
830,"EID830","SPHK1 protein expression was assessed in 287 cervical cancer and 5 normal cervical tissue samples using IHC. Univariate analysis for OS showed SPHK1 expression (p = 0.033; Figure 1C), tumor size (p = 0.033), and lymph node metastasis (p = 0.008) as associated with OS. SPHK1 expression did not directly predict OS.
High SPHK1 expression was also associated with larger tumor size (p < 0.001), deeper invasion depth (p < 0.001), presence of lymph node metastasis (p = 0.029), higher FIGO stage (p = 0.029), presence of lymphovascular invasion (p = 0.045), and higher preoperative squamous cell carcinoma (SCC) antigen level (p = 0.009).",159,"Cervical Cancer","Cervical Cancer",4362,"http://www.disease-ontology.org/?id=DOID:4362","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",345,2,NULL,"accepted",0,"evidence",560,"Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.","Kim et al., 2015, Oncotarget",26311741,"http://www.ncbi.nlm.nih.gov/pubmed/26311741","true","PMC4694949","2015","9","29","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
831,"EID831","In-vitro and in-vivo sensitivity to DR5 antibody conatumumab was correlated with expression of caspase-8.",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","D","Predictive","Supports","Sensitivity","N/A",346,3,NULL,"accepted",0,"evidence",561,"Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma.","Kang et al., 2015, Br. J. Cancer",26291055,"http://www.ncbi.nlm.nih.gov/pubmed/26291055","true","PMC4578089","2015","9","15","Br. J. Cancer","British journal of cancer","fully curated","158","Conatumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
832,"EID832","mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy. Response rate with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). Patients with low expression exhibited a benefit in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","N/A",347,3,NULL,"accepted",0,"evidence",562,"Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.","Chamizo et al., 2015, BMC Pulm Med",26502926,"http://www.ncbi.nlm.nih.gov/pubmed/26502926","true","PMC4623912","2015",NULL,NULL,"BMC Pulm Med","BMC pulmonary medicine","fully curated","156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
833,"EID833","Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS.",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",193,3,NULL,"rejected",0,"evidence",522,"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.","Jia et al., 2016, Clin Transl Oncol",26459251,"http://www.ncbi.nlm.nih.gov/pubmed/26459251",NULL,NULL,"2016","6",NULL,"Clin Transl Oncol","Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
834,"EID834","Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS  (PFS: 5.8 Â± 0.5 vs. 11.0 Â± 2.8 months, P = 0.007; OS: 9.7 Â± 0.5 vs. 21.5 Â± 1.5 months, P = 0.03).",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",193,3,NULL,"rejected",0,"evidence",522,"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.","Jia et al., 2016, Clin Transl Oncol",26459251,"http://www.ncbi.nlm.nih.gov/pubmed/26459251",NULL,NULL,"2016","6",NULL,"Clin Transl Oncol","Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
835,"EID835","TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",348,3,NULL,"accepted",0,"evidence",563,"TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.","Li et al., 2016, Oncotarget",26745678,"http://www.ncbi.nlm.nih.gov/pubmed/26745678","true","PMC4872746","2016","2","9","Oncotarget","Oncotarget","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
836,"EID836","Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",270,2,NULL,"accepted",0,"evidence",564,"Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.","Zhang et al., 2016, J Thorac Oncol",26724472,"http://www.ncbi.nlm.nih.gov/pubmed/26724472",NULL,NULL,"2016","5",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
837,"EID837","SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",349,3,"Combination","accepted",0,"evidence",565,"SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.","Bell et al., 2016, Clin. Cancer Res.",26671993,"http://www.ncbi.nlm.nih.gov/pubmed/26671993","true","PMC4867280","2016","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","326","Cisplatin",NULL,"96","Vinorelbine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
838,"EID838","SMARCA4 expression was determined with gene expression microarray in 133 patients. Reduced overall survival was observed in patients with low SMARCA4 expression compared to intermediate (P<0
.001) or high expression (P=0.009). In multivariate analysis, compared to low, high SMARCA4 expression predicted a decrease in risk of death (HR=0.6, 95% CI: 0.4-0.8, P=0.002).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",349,3,NULL,"accepted",0,"evidence",565,"SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.","Bell et al., 2016, Clin. Cancer Res.",26671993,"http://www.ncbi.nlm.nih.gov/pubmed/26671993","true","PMC4867280","2016","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
839,"EID839","Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. Targeted sequencing of 70 aCML patients identified SETBP1 mutations between codons 858 and 871 in 24.3% of the patients. Patients with this mutation had a 22 month median survival compared to 77 months in aCML patients without the mutation (P=.01).",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",350,3,NULL,"accepted",0,"evidence",566,"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.","Piazza et al., 2013, Nat. Genet.",23222956,"http://www.ncbi.nlm.nih.gov/pubmed/23222956","true","PMC3588142","2013","1",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
840,"EID840","Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. The researchers transfected 293T cells with SETBP1 G870S, a variant found to be associated with poor prognosis in aCML, and found those cells had higher proliferation and higher expression of SET and SETBP1 proteins. This may be linked to the mutation abrogating a ubiquitination site.",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","D","Prognostic","Supports","Poor Outcome","Somatic Mutation",351,3,NULL,"accepted",0,"evidence",566,"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.","Piazza et al., 2013, Nat. Genet.",23222956,"http://www.ncbi.nlm.nih.gov/pubmed/23222956","true","PMC3588142","2013","1",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
841,"EID841","In this case report, a patient with metastatic, ALK-rearranged NSCLC with C1156Y mutation had tumor progression under sequential treatment with first crizotinib, then ceritinib and finally AUY922. Subsequent chemotherapy (carboplatinâ€“pemetrexed) was administered and the patient had a response for 6 months before progression. Exome sequencing revealed the C1156Y mutation was present in <7% of the pretreatment tumor and in ~50% of the crizotinib tumor prior to ceritinib therapy.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",6,3,"Sequential","accepted",0,"evidence",567,"Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.","Shaw et al., 2016, N. Engl. J. Med.",26698910,"http://www.ncbi.nlm.nih.gov/pubmed/26698910","true","PMC4773904","2016","1","7","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,"159","Ceritinib",NULL,"160","AUY922",NULL,NULL,NULL,NULL,NULL,NULL,NULL
842,"EID842","Case report of a patient with metastatic ALK-rearranged NSCLC after progression under sequential crizotinib, ceritinib, HSP90 inhibitor AUY922 and chemotherapy followed by crizotinib again. Third generation ALK inhibitor lorlatinib led to a partial response that lasted for 8 months. The C1156Y mutation was confirmed in a sample prior to initial crizotinib (<7% of cells), following crizotinib treatment (~50% of cells) and following lorlatinib resistance (100% of cells). However, a second ALK mutation (C1156Y & L1198F) was detected in the lorlatinib resistant tumor.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",6,3,NULL,"accepted",0,"evidence",567,"Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.","Shaw et al., 2016, N. Engl. J. Med.",26698910,"http://www.ncbi.nlm.nih.gov/pubmed/26698910","true","PMC4773904","2016","1","7","N. Engl. J. Med.","The New England journal of medicine","fully curated","241","Lorlatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
843,"EID843","Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response with the third generation ALK-inhibitor lorlatinib. The patient progressed on lorlatinib after 8 months, at which point whole exome sequencing revealed an EML4-ALK C1156Yâ€“L1198F double mutation. In vitro, the double mutation was resistant to lorlatinib but sensitive to crizotinib. The patient was started on crizotinib again and had a clinical response that lasted for 6 months.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",352,4,NULL,"accepted",0,"evidence",567,"Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.","Shaw et al., 2016, N. Engl. J. Med.",26698910,"http://www.ncbi.nlm.nih.gov/pubmed/26698910","true","PMC4773904","2016","1","7","N. Engl. J. Med.","The New England journal of medicine","fully curated","241","Lorlatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
844,"EID844","Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response with the third generation ALK-inhibitor lorlatinib. The patient progressed on lorlatinib after 8 months, at which point whole exome sequencing revealed an EML4-ALK C1156Yâ€“L1198F double mutation. In vitro, the double mutation was resistant to lorlatinib but sensitive to crizotinib. The patient was started on crizotinib again and had a clinical response that lasted for 6 months.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",352,4,NULL,"accepted",0,"evidence",567,"Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.","Shaw et al., 2016, N. Engl. J. Med.",26698910,"http://www.ncbi.nlm.nih.gov/pubmed/26698910","true","PMC4773904","2016","1","7","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
845,"EID845","1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","C","Predictive","Supports","Sensitivity","Somatic Mutation",131,2,NULL,"accepted",0,"evidence",409,"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.","Mateo et al., 2015, N. Engl. J. Med.",26510020,"http://www.ncbi.nlm.nih.gov/pubmed/26510020",NULL,NULL,"2015","10","29","N. Engl. J. Med.","The New England journal of medicine","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
846,"EID846","47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tumor cells was associated with reduced overall survival  (hazard ratio: 2.2, P = 0.002) and progression free survival (hazard ratio: 2.2, P = 0.016) compared to patients with low AREG expression score. AREG was an independent prognosticator of OS in multivariate Cox analysis. High EGFRvIII and AREG expression levels identified SCCHN (squamous cell carcinoma, head and neck) patients that were less likely to benefit from combination treatment with cetuximab and docetaxel.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Supports","Resistance or Non-Response","N/A",315,2,"Combination","accepted",0,"evidence",568,"Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.","Tinhofer et al., 2011, Clin. Cancer Res.",21653686,"http://www.ncbi.nlm.nih.gov/pubmed/21653686",NULL,NULL,"2011","8","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","16","Cetuximab",NULL,"73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
847,"EID847","47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tumor cells was associated with reduced OS (HR: 2.2, P = 0.002) and PFS (HR 2.2, P = 0.019) compared with patients with low expression score. AREG was an independent prognosticator of OS in multivariate Cox analysis.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",315,3,NULL,"rejected",0,"evidence",568,"Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.","Tinhofer et al., 2011, Clin. Cancer Res.",21653686,"http://www.ncbi.nlm.nih.gov/pubmed/21653686",NULL,NULL,"2011","8","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
848,"EID848","47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression was associated with reduced disease control rate (DCR) and shortened progression free survival (PFS) (HR: 3.3, P = 0.005) but not with OS.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",312,2,"Combination","accepted",0,"evidence",568,"Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.","Tinhofer et al., 2011, Clin. Cancer Res.",21653686,"http://www.ncbi.nlm.nih.gov/pubmed/21653686",NULL,NULL,"2011","8","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","16","Cetuximab",NULL,"73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
849,"EID849","47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFRvIII. EGFR expression had no impact on PFS or OS.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",354,3,"Combination","accepted",0,"evidence",568,"Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.","Tinhofer et al., 2011, Clin. Cancer Res.",21653686,"http://www.ncbi.nlm.nih.gov/pubmed/21653686",NULL,NULL,"2011","8","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","73","Docetaxel",NULL,"16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
850,"EID850","In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006).",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Predictive","Supports","Sensitivity","Somatic Mutation",222,3,NULL,"accepted",0,"evidence",569,"Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.","Xu et al., 2014, PLoS ONE",24740294,"http://www.ncbi.nlm.nih.gov/pubmed/24740294","true","PMC3989310","2014",NULL,NULL,"PLoS ONE","PloS one","fully curated","199","Chemotherapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
851,"EID851","In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-induced cell-arrest under chemotherapy even in the context of heterozygous TP53 point mutations or absence of p21. Thus the status of both TP53 alleles should be assessed because even one copy of wild-type TP53 may contribute to poor response to chemotherapy.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",199,"p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.","Jackson et al., 2012, Cancer Cell",22698404,"http://www.ncbi.nlm.nih.gov/pubmed/22698404","true","PMC3376352","2012","6","12","Cancer Cell","Cancer cell","fully curated","68","Doxorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
852,"EID852","112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1Î± and ALDH1. High pretreatment p21 (CDKN1A) expression was significantly associated with non-pCR (pâ€‰=â€‰0.022) and poor disease free survival (median DFS - low vs high p21: 75.8 vs 58.1 months, pâ€‰=â€‰0.002). Multivariate analysis was also significant (pâ€‰=â€‰0.001, HR 6.14; 95% CI 2.03, 18.55).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","N/A",355,3,NULL,"accepted",0,"evidence",570,"P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.","Sim et al., 2014, BMC Cancer",24708484,"http://www.ncbi.nlm.nih.gov/pubmed/24708484","true","PMC4101833","2014",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","395","5-fluorouracil",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
853,"EID853","112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1Î± and ALDH1. Pretreatment CD166 (ALCAM) expression level was associated with poor disease free survival (pâ€‰=â€‰0.003; HR 5.61; 95% CI 1.81, 17.35).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","N/A",356,3,NULL,"accepted",0,"evidence",570,"P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.","Sim et al., 2014, BMC Cancer",24708484,"http://www.ncbi.nlm.nih.gov/pubmed/24708484","true","PMC4101833","2014",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","395","5-fluorouracil",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
854,"EID854","In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",190,3,"Substitutes","accepted",0,"evidence",571,"EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.","Shen et al., 2014, Chin. J. Cancer Res.",24653627,"http://www.ncbi.nlm.nih.gov/pubmed/24653627","true","PMC3937753","2014","2",NULL,"Chin. J. Cancer Res.","Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","fully curated","16","Cetuximab",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
855,"EID855","33 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this conclusion with pre-clinical studies that showed that knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel.",123,"Endometrial Carcinoma","Endometrial Carcinoma",2871,"http://www.disease-ontology.org/?id=DOID:2871","B","Predictive","Supports","Resistance or Non-Response","N/A",357,3,NULL,"accepted",0,"evidence",572,"Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.","Werner et al., 2014, PLoS ONE",24587245,"http://www.ncbi.nlm.nih.gov/pubmed/24587245","true","PMC3934991","2014",NULL,NULL,"PLoS ONE","PloS one","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
856,"EID856","The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","B","Predictive","Supports","Resistance or Non-Response","N/A",20,3,NULL,"accepted",0,"evidence",573,"Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.","Stendahl et al., 2004, Br. J. Cancer",15138475,"http://www.ncbi.nlm.nih.gov/pubmed/15138475","true","PMC2409465","2004","5","17","Br. J. Cancer","British journal of cancer","fully curated","53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
857,"EID857","In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 placebo). 381 patients without amplification did show a benefit compared to placebo (187 treated vs 194 placebo).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",358,2,NULL,"accepted",0,"evidence",574,"RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.","Keilty et al., 2013, PLoS ONE",24367492,"http://www.ncbi.nlm.nih.gov/pubmed/24367492","true","PMC3868649","2013",NULL,NULL,"PLoS ONE","PloS one","fully curated","53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
858,"EID858","In this retrospective analysis, CCND1 amplification was analyzed in 442 patients. No interaction with treatment was observed.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",18,3,NULL,"accepted",0,"evidence",574,"RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.","Keilty et al., 2013, PLoS ONE",24367492,"http://www.ncbi.nlm.nih.gov/pubmed/24367492","true","PMC3868649","2013",NULL,NULL,"PLoS ONE","PloS one","fully curated","53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
859,"EID859","In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroduction of AR expression resensitized nonresponsive AR-negative cells to NVP-BEZ235. A dihydrotestosterone (DHT) and NVP-BEZ235 combination achieved tumor regression and complete response in AR/ER expressing tumors (xenografts).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",359,3,NULL,"accepted",0,"evidence",575,"Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.","Wang et al., 2014, Mol. Cancer Ther.",24356815,"http://www.ncbi.nlm.nih.gov/pubmed/24356815",NULL,NULL,"2014","2",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
860,"EID860","Cytoplasmic localization of p27 (CDKN1B) leads to lapatinib resistance in HER2+ breast cancer cell lines. p27 knockout resensitiuzed cells to lapatinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",360,3,NULL,"accepted",0,"evidence",576,"Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.","Zhao et al., 2014, Oncotarget",25587029,"http://www.ncbi.nlm.nih.gov/pubmed/25587029","true","PMC4350358","2014","12","30","Oncotarget","Oncotarget","fully curated","45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
861,"EID861","This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203.
ERBB3 expression was not predictive of response.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","N/A",314,3,NULL,"accepted",0,"evidence",577,"Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.","Meetze et al., 2015, Clin. Cancer Res.",25542901,"http://www.ncbi.nlm.nih.gov/pubmed/25542901",NULL,NULL,"2015","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","225","AV-203",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
862,"EID862","The authors conducted an in vivo efficacy study of AV-203 (ERBB3 inhibitory antibody) using a panel of 32 xenograft models representing 12 human cancer types. To identify biomarkers that can predict response to AV-203, the relationship between tumor growth inhibition (TGI) by AV-203 and the expression levels of ERBB3 and NRG1 were evaluated in these tumor models. ERBB3 expression was not predictive of response.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Does Not Support","Sensitivity","N/A",361,3,NULL,"accepted",0,"evidence",577,"Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.","Meetze et al., 2015, Clin. Cancer Res.",25542901,"http://www.ncbi.nlm.nih.gov/pubmed/25542901",NULL,NULL,"2015","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","225","AV-203",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
863,"EID863","Detection of AR-V7 in circulating tumor cells of 62 patients treated with either enzalitamide (n=31) or arbiraterone (n=31), was correlated with lower PSA response rates and PSA PFS in men receiving enzalutamide or abiraterone.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predictive","Supports","Resistance or Non-Response","N/A",362,3,"Substitutes","accepted",0,"evidence",578,"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.","Antonarakis et al., 2014, N. Engl. J. Med.",25184630,"http://www.ncbi.nlm.nih.gov/pubmed/25184630","true","PMC4201502","2014","9","11","N. Engl. J. Med.","The New England journal of medicine","fully curated","164","Abiraterone",NULL,"163","Enzalutamide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
864,"EID864","In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9). Response rates did not differ between groups.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Predictive","Supports","Resistance or Non-Response","N/A",214,2,"Substitutes","accepted",0,"evidence",579,"PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.","Zhang et al., 2015, Oncology",25300346,"http://www.ncbi.nlm.nih.gov/pubmed/25300346",NULL,NULL,"2015",NULL,NULL,"Oncology","Oncology","fully curated","84","Trastuzumab",NULL,"45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
865,"EID865","In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agent pertuzumab might also be increased through ERBB3 expression.",141,"Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma",3498,"http://www.disease-ontology.org/?id=DOID:3498","D","Predictive","Supports","Sensitivity","N/A",361,3,"Combination","accepted",0,"evidence",580,"HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.","Thomas et al., 2014, Oncotarget",25216528,"http://www.ncbi.nlm.nih.gov/pubmed/25216528","true","PMC4196190","2014","8","30","Oncotarget","Oncotarget","fully curated","247","Pertuzumab",NULL,"248","9F7-F11",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
866,"EID866","Colorectal cancer cell lines were evaluated for response to the HSP90 inhibitor ganetespib.  Correlating cell line-specific IC50s with the corresponding gene expression patterns revealed a possible relationship to UGT1A expression. High UGT1A expression was correlated with ganetespib resistance. Knockdown of UGT1A sensitized HT29 cells to HSP90 inhibition. HCT116 and SW480 cell lines became resistant through UGT1A overexpression.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","N/A",363,3,NULL,"accepted",0,"evidence",581,"UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.","Landmann et al., 2014, Cell Death Dis",25210794,"http://www.ncbi.nlm.nih.gov/pubmed/25210794","true","PMC4540199","2014",NULL,NULL,"Cell Death Dis","Cell death & disease","fully curated","165","Ganetespib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
867,"EID867","HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines. Increased nuclear staining was also identified in xenograft and patient samples after trastuzumab treatment.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","N/A",364,2,NULL,"accepted",0,"evidence",582,"Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.","Mohd Nafi et al., 2014, Oncotarget",25153719,"http://www.ncbi.nlm.nih.gov/pubmed/25153719","true","PMC4171603","2014","8","15","Oncotarget","Oncotarget","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
868,"EID868","siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","N/A",364,2,NULL,"accepted",0,"evidence",582,"Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.","Mohd Nafi et al., 2014, Oncotarget",25153719,"http://www.ncbi.nlm.nih.gov/pubmed/25153719","true","PMC4171603","2014","8","15","Oncotarget","Oncotarget","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
869,"EID869","ERBB4 protein expression was identified in breast cancer cell lines with acquired lapatinib resistance. Genetic ablation of ERBB4 (not ERBB1-3) led to apoptosis in trastuzumab- and lapatinib resistant cells, probably through a decrease in the PI3K/Akt pathway.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","N/A",365,3,NULL,"accepted",0,"evidence",583,"Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.","Canfield et al., 2015, Cell Cycle",25590338,"http://www.ncbi.nlm.nih.gov/pubmed/25590338","true","PMC4614407","2015",NULL,NULL,"Cell Cycle","Cell cycle (Georgetown, Tex.)","fully curated","45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
870,"EID870","In this study, SLFN11 expression was associated with sensitivity to SN-38 (an active metabolite of topoisomerase inhibitor irinotecan).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",366,2,NULL,"accepted",0,"evidence",584,"Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.","Tian et al., 2014, Anticancer Drugs",25089570,"http://www.ncbi.nlm.nih.gov/pubmed/25089570",NULL,NULL,"2014","11",NULL,"Anticancer Drugs","Anti-cancer drugs","fully curated","166","SN-38",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
871,"EID871","High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisplatin-based chemotherapy. In-vitro data confirmed these results and overexpression or knockdown of AURKA decreased or increased in-vitro sensitivity to cisplatin.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","N/A",181,4,NULL,"accepted",0,"evidence",585,"Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis.","Xu et al., 2014, J Transl Med",25082261,"http://www.ncbi.nlm.nih.gov/pubmed/25082261","true","PMC4237886","2014",NULL,NULL,"J Transl Med","Journal of translational medicine","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
872,"EID872","In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was added to their platinum-based regimen (log-rank P = 0.04).",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Supports","Resistance or Non-Response","Germline Polymorphism",254,3,NULL,"accepted",0,"evidence",586,"A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.","Chung et al., 2014, Ann. Oncol.",25081901,"http://www.ncbi.nlm.nih.gov/pubmed/25081901","true","PMC4207729","2014","11",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
873,"EID873","Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and increased sensitivity to these drugs.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",367,4,"Substitutes","accepted",0,"evidence",587,"The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.","Watson et al., 2014, Cancer Res.",25056119,"http://www.ncbi.nlm.nih.gov/pubmed/25056119","true","PMC4167745","2014","9","1","Cancer Res.","Cancer research","fully curated","4","Vemurafenib",NULL,"22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
874,"EID874","Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",368,3,"Combination","accepted",0,"evidence",588,"Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.","Wu et al., 2014, Med. Oncol.",24961465,"http://www.ncbi.nlm.nih.gov/pubmed/24961465",NULL,NULL,"2014","8",NULL,"Med. Oncol.","Medical oncology (Northwood, London, England)","fully curated","167","Taxane",NULL,"103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
875,"EID875","In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",369,3,"Combination","accepted",0,"evidence",589,"TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.","Sclafani et al., 2014, J. Natl. Cancer Inst.",24957073,"http://www.ncbi.nlm.nih.gov/pubmed/24957073",NULL,NULL,"2014","7",NULL,"J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated","32","Capecitabine",NULL,"16","Cetuximab",NULL,"237","Oxaliplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL
876,"EID876","One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% of endometrial tumors (N=521).",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","D","Predictive","Supports","Sensitivity","N/A",370,2,NULL,"accepted",0,"evidence",590,"Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.","Koppensteiner et al., 2014, PLoS ONE",24927325,"http://www.ncbi.nlm.nih.gov/pubmed/24927325","true","PMC4057395","2014",NULL,NULL,"PLoS ONE","PloS one","fully curated","168","BMN-673",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
877,"EID877","One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11 gene and showed clinical response to PARP inhibitor olaparib.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","C","Predictive","Supports","Sensitivity","Somatic Mutation",370,2,NULL,"rejected",0,"evidence",409,"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.","Mateo et al., 2015, N. Engl. J. Med.",26510020,"http://www.ncbi.nlm.nih.gov/pubmed/26510020",NULL,NULL,"2015","10","29","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
878,"EID878","Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study).",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","D","Predictive","Supports","Sensitivity","N/A",179,4,NULL,"accepted",0,"evidence",591,"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.","Kubota et al., 2014, Cell Cycle",24841718,"http://www.ncbi.nlm.nih.gov/pubmed/24841718","true","PMC4111704","2014",NULL,NULL,"Cell Cycle","Cell cycle (Georgetown, Tex.)","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
879,"EID879","A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",33,4,NULL,"accepted",0,"evidence",592,"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","Sequist et al., 2013, J. Clin. Oncol.",23816960,"http://www.ncbi.nlm.nih.gov/pubmed/23816960",NULL,NULL,"2013","9","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
880,"EID880","A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). 308 patients had either exon 19 or L858 mutations.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",133,4,NULL,"accepted",0,"evidence",592,"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","Sequist et al., 2013, J. Clin. Oncol.",23816960,"http://www.ncbi.nlm.nih.gov/pubmed/23816960",NULL,NULL,"2013","9","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
881,"EID881","Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was assayed by Western blot. The 50% inhibitory concentration (IC50) of afatinib was significantly lower in cells harboring EGFR exon 19 deletion than in cells harboring EGFR L858R.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",133,2,NULL,"accepted",0,"evidence",593,"Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.","Banno et al., 2015, Anticancer Res.",25862853,"http://www.ncbi.nlm.nih.gov/pubmed/25862853",NULL,NULL,"2015","4",NULL,"Anticancer Res.","Anticancer research","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
882,"EID882","In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In total, 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",133,3,NULL,"accepted",0,"evidence",594,"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.","Yang et al., 2012, Lancet Oncol.",22452895,"http://www.ncbi.nlm.nih.gov/pubmed/22452895",NULL,NULL,"2012","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
883,"EID883","In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",33,3,NULL,"accepted",0,"evidence",594,"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.","Yang et al., 2012, Lancet Oncol.",22452895,"http://www.ncbi.nlm.nih.gov/pubmed/22452895",NULL,NULL,"2012","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
884,"EID884","A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",133,3,NULL,"accepted",0,"evidence",595,"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.","Rosell et al., 2012, Lancet Oncol.",22285168,"http://www.ncbi.nlm.nih.gov/pubmed/22285168",NULL,NULL,"2012","3",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
885,"EID885","A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",33,3,NULL,"accepted",0,"evidence",595,"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.","Rosell et al., 2012, Lancet Oncol.",22285168,"http://www.ncbi.nlm.nih.gov/pubmed/22285168",NULL,NULL,"2012","3",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
886,"EID886","Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.",93,"Uterine Corpus Endometrial Carcinoma","Uterine Corpus Endometrial Carcinoma",50939,"http://www.disease-ontology.org/?id=DOID:0050939","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,2,NULL,"accepted",0,"evidence",596,"Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.","Schwab et al., 2014, Br. J. Cancer",25268372,"http://www.ncbi.nlm.nih.gov/pubmed/25268372","true","PMC4453741","2014","10","28","Br. J. Cancer","British journal of cancer","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
887,"EID887","In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11). The primary end point was objective response rate. Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients. Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,2,"Substitutes","accepted",0,"evidence",597,"A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.","Rimawi et al., 2015, Clin. Breast Cancer",25537159,"http://www.ncbi.nlm.nih.gov/pubmed/25537159",NULL,NULL,"2015","4",NULL,"Clin. Breast Cancer","Clinical breast cancer","fully curated","84","Trastuzumab",NULL,"45","Lapatinib",NULL,"146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
888,"EID888","FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe.
TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",371,1,NULL,"accepted",0,"evidence",598,"Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.","NygÃ¥rd et al., 2014, Scand. J. Gastroenterol.",24256029,"http://www.ncbi.nlm.nih.gov/pubmed/24256029",NULL,NULL,"2014","1",NULL,"Scand. J. Gastroenterol.","Scandinavian journal of gastroenterology","fully curated","101","Irinotecan",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
889,"EID889","41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response after multivariate analysis (p=0.025; n=41 patients).",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Supports","Sensitivity","N/A",372,2,"Combination","accepted",0,"evidence",599,"p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.","Moreno-Galindo et al., 2014, Oral Oncol.",24239278,"http://www.ncbi.nlm.nih.gov/pubmed/24239278",NULL,NULL,"2014","2",NULL,"Oral Oncol.","Oral oncology","fully curated","326","Cisplatin",NULL,"395","5-fluorouracil",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
890,"EID890","Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was detected by FISH. Crizotinib led to a partial response.",153,"Lung Squamous Cell Carcinoma","Lung Squamous Cell Carcinoma",3907,"http://www.disease-ontology.org/?id=DOID:3907","C","Predictive","Supports","Sensitivity","Somatic Mutation",270,2,NULL,"accepted",0,"evidence",600,"Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.","Schwab et al., 2014, Lung Cancer",24192513,"http://www.ncbi.nlm.nih.gov/pubmed/24192513",NULL,NULL,"2014","1",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
891,"EID891","mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival (p= 0.0011, p = 0.0366 respectively). AGR2 protein expression as assessed by IHC was not significantly associated with treatment outcome.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Resistance or Non-Response","N/A",373,1,NULL,"accepted",0,"evidence",601,"AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients.","Hrstka et al., 2013, Dis. Markers",24167368,"http://www.ncbi.nlm.nih.gov/pubmed/24167368","true","PMC3776368","2013",NULL,NULL,"Dis. Markers","Disease markers","fully curated","53","Tamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
892,"EID892","94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.
No predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",311,3,"Substitutes","accepted",0,"evidence",602,"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.","Mackay et al., 2014, Cancer",24166148,"http://www.ncbi.nlm.nih.gov/pubmed/24166148",NULL,NULL,"2014","2","15","Cancer","Cancer","fully curated","170","Ridaforolimus",NULL,"83","Temsirolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
893,"EID893","94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.
No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",214,3,"Substitutes","accepted",0,"evidence",602,"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.","Mackay et al., 2014, Cancer",24166148,"http://www.ncbi.nlm.nih.gov/pubmed/24166148",NULL,NULL,"2014","2","15","Cancer","Cancer","fully curated","83","Temsirolimus",NULL,"170","Ridaforolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
894,"EID894","94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tumors, 10 of which were KRAS mutations. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",336,2,"Substitutes","accepted",0,"evidence",602,"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.","Mackay et al., 2014, Cancer",24166148,"http://www.ncbi.nlm.nih.gov/pubmed/24166148",NULL,NULL,"2014","2","15","Cancer","Cancer","fully curated","170","Ridaforolimus",NULL,"83","Temsirolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
895,"EID895","141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Resistance or Non-Response","N/A",306,1,"Combination","accepted",0,"evidence",603,"HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.","Sclafani et al., 2013, Ann. Oncol.",24146218,"http://www.ncbi.nlm.nih.gov/pubmed/24146218",NULL,NULL,"2013","12",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","16","Cetuximab",NULL,"237","Oxaliplatin",NULL,"32","Capecitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL
896,"EID896","In vitro studies showed efficacy of FGFR inhibitor NVP-BGJ398 in cell lines exhibiting high FGFR1 protein. Three cell lines (SNU-C1, HDC9, HCT116) were analyzed. FGFR1 amplification (24/454, assessed by FISH) and/or activated pFGFR1 protein (18/99, assessed by mRNA in situ hybridization) was identified in primary CRC tissue samples.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","N/A",268,2,NULL,"accepted",0,"evidence",604,"Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.","GÃ¶ke et al., 2013, Digestion",24135816,"http://www.ncbi.nlm.nih.gov/pubmed/24135816","true","PMC4186657","2013",NULL,NULL,"Digestion","Digestion","fully curated","151","BGJ398",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
897,"EID897","Tumor-specific promoter hypermethylation of NAPRT1 led to loss of NAPRT1 expression in most tumor types sensitive to treatment with Nampt inhibitor GNE-617 and nicotinic acid.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",374,3,NULL,"accepted",0,"evidence",605,"Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.","Shames et al., 2013, Clin. Cancer Res.",24097869,"http://www.ncbi.nlm.nih.gov/pubmed/24097869",NULL,NULL,"2013","12","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","172","GNE-617",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
898,"EID898","Overexpression of EGFR exon 18 (Affymetrix Human Exon 1.0 ST) in tumor or blood samples was associated with tumor shrinkage, independently of EGFR mutational status in NSCLC treated with bevacizumab and erlotinib. 76 patients were analyzed for this study.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",375,2,"Combination","accepted",0,"evidence",606,"EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.","Baty et al., 2013, PLoS ONE",24039832,"http://www.ncbi.nlm.nih.gov/pubmed/24039832","true","PMC3769372","2013",NULL,NULL,"PLoS ONE","PloS one","fully curated","33","Bevacizumab",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
899,"EID899","Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine.",38,"Mantle Cell Lymphoma","Mantle Cell Lymphoma",50746,"http://www.disease-ontology.org/?id=DOID:0050746","D","Predictive","Supports","Resistance or Non-Response","N/A",376,2,"Substitutes","accepted",0,"evidence",607,"The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.","SÃ¡nchez-TillÃ³ et al., 2014, Cell Death Differ.",24013721,"http://www.ncbi.nlm.nih.gov/pubmed/24013721","true","PMC3890947","2014","2",NULL,"Cell Death Differ.","Cell death and differentiation","fully curated","173","Cytarabine",NULL,"85","Gemcitabine",NULL,"68","Doxorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL
900,"EID900","Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine.
the combination of salinomycin (downregulating ZEB1) and doxorubicin was syngergistic.",243,"Mantle Cell Lymphoma","Mantle Cell Lymphoma",50476,"http://www.disease-ontology.org/?id=DOID:50476","D","Predictive","Supports","Sensitivity","Somatic Mutation",376,3,"Combination","accepted",0,"evidence",607,"The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.","SÃ¡nchez-TillÃ³ et al., 2014, Cell Death Differ.",24013721,"http://www.ncbi.nlm.nih.gov/pubmed/24013721","true","PMC3890947","2014","2",NULL,"Cell Death Differ.","Cell death and differentiation","fully curated","68","Doxorubicin",NULL,"174","Salinomycin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
901,"EID901","TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","N/A",377,2,NULL,"accepted",0,"evidence",608,"TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.","Bjerre et al., 2013, Tumour Biol.",23881388,"http://www.ncbi.nlm.nih.gov/pubmed/23881388",NULL,NULL,"2013","12",NULL,"Tumour Biol.","Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","fully curated","54","Fulvestrant",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
902,"EID902","In-vitro studies linked PRL-3 (PP4A3) expression to hyperactivation and dependence on EGFR signaling (through downregulation of PTP1B, an inhibitory phosphatase of EGFR). Retrospective analysis of 68 patients showed improved clinical response to the EGFR inhibitor cetuximab in tumors expressing PRL-3.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",378,3,NULL,"accepted",0,"evidence",609,"Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.","Al-Aidaroos et al., 2013, J. Clin. Invest.",23867504,"http://www.ncbi.nlm.nih.gov/pubmed/23867504","true","PMC4011027","2013","8",NULL,"J. Clin. Invest.","The Journal of clinical investigation","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
903,"EID903","TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",379,3,NULL,"accepted",0,"evidence",610,"Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.","Kasai et al., 2013, Anticancer Res.",23645741,"http://www.ncbi.nlm.nih.gov/pubmed/23645741",NULL,NULL,"2013","5",NULL,"Anticancer Res.","Anticancer research","fully curated","156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
904,"EID904","Expression of IGF1R in NSCLC cell lines (n=17) was associated with resistance to EGFR inhibitor gefitinib, however, knock-in or knock-out of IGF1R did not affect gefitinib sensitivity. IGF1R expression was also higher in patients with disease progression after gefitinib therapy in a clinical cohort (n=98).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","N/A",380,2,NULL,"accepted",0,"evidence",611,"Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.","Peled et al., 2013, Cell Oncol (Dordr)",23619944,"http://www.ncbi.nlm.nih.gov/pubmed/23619944","true","PMC4186686","2013","7",NULL,"Cell Oncol (Dordr)","Cellular oncology (Dordrecht)","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
905,"EID905","EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048). No difference was observed in a control group without bevacizumab treatment. qRT-PCR results were also shown to correlate with protein expression measured by IHC.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","N/A",381,2,NULL,"accepted",0,"evidence",612,"Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.","Guijarro-MuÃ±oz et al., 2013, Med. Oncol.",23579861,"http://www.ncbi.nlm.nih.gov/pubmed/23579861",NULL,NULL,"2013",NULL,NULL,"Med. Oncol.","Medical oncology (Northwood, London, England)","fully curated","33","Bevacizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
906,"EID906","Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040) in this meta-analysis (28 studies, 1497 cases).",104,"Esophageal Carcinoma","Esophageal Carcinoma",1107,"http://www.disease-ontology.org/?id=DOID:1107","B","Predictive","Supports","Sensitivity","N/A",369,3,NULL,"accepted",0,"evidence",613,"Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis.","Zhang et al., 2013, Ann. Surg. Oncol.",23515910,"http://www.ncbi.nlm.nih.gov/pubmed/23515910",NULL,NULL,"2013","7",NULL,"Ann. Surg. Oncol.","Annals of surgical oncology","fully curated","199","Chemotherapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
907,"EID907","49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes.
Patients with low TS (â‰¤150) expression had a longer median progression-free survival (PFS) than those with high TS (>150) expression (4.8 vs. 3.4 months; p=0.01).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",382,3,NULL,"accepted",0,"evidence",614,"Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.","Chen et al., 2011, Lung Cancer",21367480,"http://www.ncbi.nlm.nih.gov/pubmed/21367480",NULL,NULL,"2011","10",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
908,"EID908","Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","C","Predictive","Supports","Sensitivity","N/A",382,2,NULL,"accepted",0,"evidence",615,"A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service.","Russell et al., 2014, Front Pharmacol",24782778,"http://www.ncbi.nlm.nih.gov/pubmed/24782778","true","PMC3997001","2014",NULL,NULL,"Front Pharmacol","Frontiers in pharmacology","fully curated","156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
909,"EID909","In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin treated but not in docetaxel treated breast cancer patients.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","N/A",383,2,NULL,"accepted",0,"evidence",616,"Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.","Durbecq et al., 2004, Mol. Cancer Ther.",15486187,"http://www.ncbi.nlm.nih.gov/pubmed/15486187",NULL,NULL,"2004","10",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","68","Doxorubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
910,"EID910","Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with topotecan, cyclophosphamide and carboplatin followed by an autologous hematopoietic stem cell transplant.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","N/A",384,2,"Combination","accepted",0,"evidence",617,"Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.","Litzow et al., 2010, Bone Marrow Transplant.",19648970,"http://www.ncbi.nlm.nih.gov/pubmed/19648970","true","PMC2836387","2010","3",NULL,"Bone Marrow Transplant.","Bone marrow transplantation","fully curated","250","Cyclophosphamide",NULL,"93","Carboplatin",NULL,"175","Topotecan",NULL,NULL,NULL,NULL,NULL,NULL,NULL
911,"EID911","87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",190,3,NULL,"accepted",0,"evidence",618,"Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.","Personeni et al., 2008, Clin. Cancer Res.",18794099,"http://www.ncbi.nlm.nih.gov/pubmed/18794099",NULL,NULL,"2008","9","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
912,"EID912","498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a better overall survival according to multivariate analysis (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",384,3,NULL,"accepted",0,"evidence",619,"Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.","Kostopoulos et al., 2009, BMC Cancer",19775480,"http://www.ncbi.nlm.nih.gov/pubmed/19775480","true","PMC2759966","2009",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","101","Irinotecan",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
913,"EID913","Low levels of baseline p-AMPK (PRKAA2, measured at Thr172) were predictive of efficacy of ACLY inhibition by siRNA in cell lines of various cancer histologies.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","E","Predictive","Supports","Sensitivity","N/A",385,2,NULL,"accepted",0,"evidence",620,"Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact.","Migita et al., 2013, Am. J. Pathol.",23506848,"http://www.ncbi.nlm.nih.gov/pubmed/23506848",NULL,NULL,"2013","5",NULL,"Am. J. Pathol.","The American journal of pathology","fully curated","255","ACLY SiRNA",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
914,"EID914","Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition reduced response to 5-FU.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",386,4,NULL,"accepted",0,"evidence",621,"The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.","Thornton et al., 2013, Int. J. Cancer",23456958,"http://www.ncbi.nlm.nih.gov/pubmed/23456958",NULL,NULL,"2013","9","15","Int. J. Cancer","International journal of cancer","fully curated","395","5-fluorouracil",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
915,"EID915","A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed. PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",311,4,NULL,"accepted",0,"evidence",622,"PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.","Wu et al., 2013, J. Cancer Res. Clin. Oncol.",23435830,"http://www.ncbi.nlm.nih.gov/pubmed/23435830",NULL,NULL,"2013","5",NULL,"J. Cancer Res. Clin. Oncol.","Journal of cancer research and clinical oncology","fully curated","252","Anti-EGFR Monoclonal Antibody",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
916,"EID916","KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment.",169,"Pancreatic Carcinoma","Pancreatic Carcinoma",4905,"http://www.disease-ontology.org/?id=DOID:4905","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",75,3,NULL,"accepted",0,"evidence",623,"KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.","Boeck et al., 2013, J. Gastroenterol.",23435671,"http://www.ncbi.nlm.nih.gov/pubmed/23435671",NULL,NULL,"2013","4",NULL,"J. Gastroenterol.","Journal of gastroenterology","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
917,"EID917","KRAS exon 2 was mutated in 121 of 173 patients with advanced pancreatic cancer. Patients with KRAS wildtype had an improved OS (HR 1.68, p = 0.005).",169,"Pancreatic Carcinoma","Pancreatic Carcinoma",4905,"http://www.disease-ontology.org/?id=DOID:4905","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",75,3,NULL,"accepted",0,"evidence",623,"KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.","Boeck et al., 2013, J. Gastroenterol.",23435671,"http://www.ncbi.nlm.nih.gov/pubmed/23435671",NULL,NULL,"2013","4",NULL,"J. Gastroenterol.","Journal of gastroenterology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
918,"EID918","8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels were higher in cell lines and xenografts sensitive to everolimus.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","D","Predictive","Supports","Sensitivity","N/A",387,2,NULL,"accepted",0,"evidence",624,"Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.","Nishi et al., 2013, Cancer Lett.",23340172,"http://www.ncbi.nlm.nih.gov/pubmed/23340172",NULL,NULL,"2013","5","1","Cancer Lett.","Cancer letters","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
919,"EID919","Human GISTs with different KIT mutations were grafted in 136 nude muce. Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib. The combination showed superior antitumor efficacy that was sustained after treatment withdrawal.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Sensitivity","Somatic Mutation",388,2,"Combination","accepted",0,"evidence",625,"A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.","Floris et al., 2013, Clin. Cancer Res.",23231951,"http://www.ncbi.nlm.nih.gov/pubmed/23231951","true","PMC4405777","2013","2","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","141","Pictilisib",NULL,"5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
920,"EID920","High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Resistance or Non-Response","N/A",389,2,NULL,"accepted",0,"evidence",626,"Class III Î²-tubulin counteracts the ability of paclitaxel to inhibit cell migration.","Ganguly et al., 2011, Oncotarget",21576762,"http://www.ncbi.nlm.nih.gov/pubmed/21576762","true","PMC3248193","2011","5",NULL,"Oncotarget","Oncotarget","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
921,"EID921","High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","N/A",389,2,NULL,"accepted",0,"evidence",627,"High expression of class III Î²-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.","Wang et al., 2013, Clin. Breast Cancer",23218766,"http://www.ncbi.nlm.nih.gov/pubmed/23218766","true","PMC4039021","2013","4",NULL,"Clin. Breast Cancer","Clinical breast cancer","fully curated","167","Taxane",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
922,"EID922","mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671 Â± 0.844 versus 5.978 Â± 1.895, p=0.0142).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","N/A",347,3,NULL,"accepted",0,"evidence",628,"Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.","Shimizu et al., 2012, Anticancer Res.",23060591,"http://www.ncbi.nlm.nih.gov/pubmed/23060591",NULL,NULL,"2012","10",NULL,"Anticancer Res.","Anticancer research","fully curated","156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
923,"EID923","While EGFR mutation is a strong predictive factor for EGFR inhibition, some patients with EGFR wild-type also respond.  The authors investigated whether phosphorylated EGFR could be a potential predictive biomarker in patients with wild-type EGFR. Phosphorylation of Y1068 (assessed by IHC) was associated with improved progression free survival (PFS) in 205 patients with stage IIb and IV NSCLC treated with EGFR tyrosine kinase inhibitors (gefitinib or erlotinib) compared to phospho-Y1068 negative patients (median PFS 7.0 months vs. 1.2 months, Pâ€‰<â€‰0.001). In this group, 92 (44.9%) were EGFR mutant. In a subgroup of patients with wild-type EGFR, phospho-Y1068 expression positive patients had a significantly prolonged PFS (4.2â€‰months vs.1.2â€‰months Pâ€‰<â€‰0.001) compared with those without phospho-Y1068 expression.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",390,3,"Substitutes","accepted",0,"evidence",629,"Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.","Wang et al., 2012, J. Exp. Clin. Cancer Res.",22901364,"http://www.ncbi.nlm.nih.gov/pubmed/22901364","true","PMC3548765","2012",NULL,NULL,"J. Exp. Clin. Cancer Res.","Journal of experimental & clinical cancer research : CR","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
924,"EID924","IGF-1R nuclear immunostaining (IHC) was observed in 9 out of 16 samples of patients with different sarcomas (osteosarcoma, ewing sarcoma, liposarcoma, synovialsarcoma, desmoplastic tumor, rhabdomyosarcoma). Exclusive nuclear immunostaining was associated with better progression free survival and overall survival after therapy with IGF1R antibodies (R1507, IMC-A12, SCH 717454 and CP-751.871).",105,"Sarcoma","Sarcoma",1115,"http://www.disease-ontology.org/?id=DOID:1115","B","Predictive","Supports","Sensitivity","N/A",391,2,NULL,"accepted",0,"evidence",630,"Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.","Asmane et al., 2012, Eur. J. Cancer",22682017,"http://www.ncbi.nlm.nih.gov/pubmed/22682017",NULL,NULL,"2012","11",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","253","IGF1R Monoclonal Antibody",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
925,"EID925","Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two cell lines to bicalutamide.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Predictive","Supports","Resistance or Non-Response","N/A",392,3,NULL,"accepted",0,"evidence",631,"Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.","McCourt et al., 2012, Clin. Cancer Res.",22623731,"http://www.ncbi.nlm.nih.gov/pubmed/22623731","true","PMC3512078","2012","7","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","78","Bicalutamide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
926,"EID926","CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) were xenografted into mice, producing larger, more JNK inhibitor responsive tumors than CD133- xenografts.",196,"Hepatocellular Carcinoma","Hepatocellular Carcinoma",684,"http://www.disease-ontology.org/?id=DOID:684","B","Predictive","Supports","Resistance or Non-Response","N/A",393,2,NULL,"accepted",0,"evidence",632,"Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.","Hagiwara et al., 2012, Br. J. Cancer",22596232,"http://www.ncbi.nlm.nih.gov/pubmed/22596232","true","PMC3388555","2012","6","5","Br. J. Cancer","British journal of cancer","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
927,"EID927","High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were associated with worse 5-year disease free survival (71.1%) than low levels (88.5 %; P = 0.020). High TIMP-1 levels were also associated with worse 5-year overall survival (78.9 %) than low levels (96.7 %; P = 0.004).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Resistance or Non-Response","N/A",377,2,NULL,"accepted",0,"evidence",633,"High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.","Zhu et al., 2012, Med. Oncol.",22544540,"http://www.ncbi.nlm.nih.gov/pubmed/22544540",NULL,NULL,"2012","12",NULL,"Med. Oncol.","Medical oncology (Northwood, London, England)","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
928,"EID928","1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel). In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy. The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression). The authors observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","N/A",394,4,NULL,"accepted",0,"evidence",634,"FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.","Ladoire et al., 2012, Ann. Oncol.",22431701,"http://www.ncbi.nlm.nih.gov/pubmed/22431701",NULL,NULL,"2012","10",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","257","Epirubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
929,"EID929","In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Predictive","Supports","Resistance or Non-Response","N/A",347,2,NULL,"accepted",0,"evidence",635,"Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.","Shen et al., 2012, Int. J. Cancer",22422354,"http://www.ncbi.nlm.nih.gov/pubmed/22422354",NULL,NULL,"2012","9","15","Int. J. Cancer","International journal of cancer","fully curated","176","Raltitrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
930,"EID930","54 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser240/4) was associated with higher disease control rate and progression free survival (P=0.043, P=0.001 respectively; N=28).",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","D","Predictive","Supports","Sensitivity","N/A",395,2,NULL,"accepted",0,"evidence",636,"Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.","Yoon et al., 2012, Br. J. Cancer",22343617,"http://www.ncbi.nlm.nih.gov/pubmed/22343617","true","PMC3304416","2012","3","13","Br. J. Cancer","British journal of cancer","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
931,"EID931","Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin. Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance.  Overexpression of JAK1 (lentiviral mediated) led to sensitivity to enzastaurin.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","N/A",396,4,NULL,"accepted",0,"evidence",637,"Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.","Shimokawa et al., 2012, Br. J. Cancer",22333600,"http://www.ncbi.nlm.nih.gov/pubmed/22333600","true","PMC3305973","2012","2","28","Br. J. Cancer","British journal of cancer","fully curated","177","Enzastaurin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
932,"EID932","12 CRC cell lines were evaluated. 40% of these were intrinsically resistant to mTOR inhibition with  BEZ235, PP242 or WYE354. mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with resistance to mTOR inhibitors in one analyzed cell line (SW620).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","N/A",387,2,"Substitutes","accepted",0,"evidence",638,"mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.","Zhang et al., 2012, Cell Cycle",22262166,"http://www.ncbi.nlm.nih.gov/pubmed/22262166","true","PMC3315097","2012","2","1","Cell Cycle","Cell cycle (Georgetown, Tex.)","fully curated","256","WYE354",NULL,"179","PP242",NULL,"343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL
933,"EID933","Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies.",112,"Malignant Mesothelioma","Malignant Mesothelioma",1790,"http://www.disease-ontology.org/?id=DOID:1790","D","Predictive","Supports","Sensitivity","N/A",397,2,NULL,"accepted",0,"evidence",639,"BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.","Busacca et al., 2012, J. Pathol.",22190288,"http://www.ncbi.nlm.nih.gov/pubmed/22190288",NULL,NULL,"2012","6",NULL,"J. Pathol.","The Journal of pathology","fully curated","96","Vinorelbine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
934,"EID934","Expression of DUSP6 was associated with sensitivity to MEK inhibitor GSK1120212 (Sensitivity: 79%; specificity: 82%: P = 0.0027) in 218 solid cancer cell lines.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","N/A",398,3,NULL,"accepted",0,"evidence",640,"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.","Jing et al., 2012, Mol. Cancer Ther.",22169769,"http://www.ncbi.nlm.nih.gov/pubmed/22169769",NULL,NULL,"2012","3",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
935,"EID935","In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response to MEK inhibitor GSK1120212. 40 cell lines harbored a KRAS mutation. In RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic (9/10 cell lines) response rather than a cytotoxic response (1/10 cell lines).",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,4,NULL,"accepted",0,"evidence",640,"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.","Jing et al., 2012, Mol. Cancer Ther.",22169769,"http://www.ncbi.nlm.nih.gov/pubmed/22169769",NULL,NULL,"2012","3",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
936,"EID936","In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A mutation, one had G596R mutation and one had an unspecified mutation. Also of note, in RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic response rather than a cytotoxic response.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",399,4,NULL,"accepted",0,"evidence",640,"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.","Jing et al., 2012, Mol. Cancer Ther.",22169769,"http://www.ncbi.nlm.nih.gov/pubmed/22169769",NULL,NULL,"2012","3",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
937,"EID937","Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.",169,"Pancreatic Carcinoma","Pancreatic Carcinoma",4905,"http://www.disease-ontology.org/?id=DOID:4905","C","Predictive","Supports","Sensitivity","Somatic Mutation",79,2,NULL,"accepted",0,"evidence",641,"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.","Yap et al., 2011, J. Clin. Oncol.",22025163,"http://www.ncbi.nlm.nih.gov/pubmed/22025163",NULL,NULL,"2011","12","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","43","MK-2206",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
938,"EID938","Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.",169,"Pancreatic Carcinoma","Pancreatic Carcinoma",4905,"http://www.disease-ontology.org/?id=DOID:4905","C","Predictive","Supports","Sensitivity","Somatic Mutation",214,2,NULL,"accepted",0,"evidence",641,"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.","Yap et al., 2011, J. Clin. Oncol.",22025163,"http://www.ncbi.nlm.nih.gov/pubmed/22025163",NULL,NULL,"2011","12","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","43","MK-2206",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
939,"EID939","HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine.",141,"Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma",3498,"http://www.disease-ontology.org/?id=DOID:3498","D","Predictive","Supports","Sensitivity","N/A",400,2,NULL,"accepted",0,"evidence",642,"Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.","SchÃ¤fer et al., 2012, J. Cell. Mol. Med.",22004109,"http://www.ncbi.nlm.nih.gov/pubmed/22004109","true","PMC3822691","2012","8",NULL,"J. Cell. Mol. Med.","Journal of cellular and molecular medicine","fully curated","85","Gemcitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
940,"EID940","Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines.  siRNA knockdown of NQO1 (in two cell lines) increased amrubicinol cytotoxicity.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","D","Predictive","Supports","Resistance or Non-Response","N/A",401,2,NULL,"accepted",0,"evidence",643,"C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.","Takakuwa et al., 2011, J Thorac Oncol",21964527,"http://www.ncbi.nlm.nih.gov/pubmed/21964527",NULL,NULL,"2011","11",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","181","Amrubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
941,"EID941","The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines. 15 of these cell lines were genotyped for C609T (only 3 were T/T, and the rest were C/C or C/T). Cell lines with the T/T genotype had lower expression of NQ01 and greater response to amrubicinol.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","D","Predictive","Supports","Sensitivity","Germline Polymorphism",402,2,NULL,"accepted",0,"evidence",643,"C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.","Takakuwa et al., 2011, J Thorac Oncol",21964527,"http://www.ncbi.nlm.nih.gov/pubmed/21964527",NULL,NULL,"2011","11",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","181","Amrubicin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
942,"EID942","Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029).",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Somatic Mutation",403,3,"Combination","accepted",0,"evidence",644,"BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.","Carser et al., 2011, Gynecol. Oncol.",21920589,"http://www.ncbi.nlm.nih.gov/pubmed/21920589",NULL,NULL,"2011","12",NULL,"Gynecol. Oncol.","Gynecologic oncology","fully curated","167","Taxane",NULL,"103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
943,"EID943","TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,2,"Combination","accepted",0,"evidence",645,"Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.","Rosa et al., 2011, Clin. Cancer Res.",21890455,"http://www.ncbi.nlm.nih.gov/pubmed/21890455",NULL,NULL,"2011","10","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","182","IMO",NULL,"145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
944,"EID944","mRNA expression of ABCB1 in 17 NSCLC cell lines was associated with decreased response to paclitaxel (correlation of mRNA expression and paclitaxel IC50: r=0.5322, P=0.0279).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","N/A",404,2,NULL,"accepted",0,"evidence",646,"ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.","Meng et al., 2011, Respirology",21883677,"http://www.ncbi.nlm.nih.gov/pubmed/21883677",NULL,NULL,"2011","11",NULL,"Respirology","Respirology (Carlton, Vic.)","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
945,"EID945","Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS expression was lower in ALK-positive cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,3,NULL,"accepted",0,"evidence",647,"Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.","Lee et al., 2011, J Thorac Oncol",21642865,"http://www.ncbi.nlm.nih.gov/pubmed/21642865",NULL,NULL,"2011","9",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
946,"EID946","High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric cancer  (P=0.03/P=0.008, P(log-rank)=0.001, respectively). In one cisplatin resistant cell line, DAC treatment and cisplatin had a synergistic effect.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Predictive","Supports","Resistance or Non-Response","N/A",335,3,NULL,"accepted",0,"evidence",648,"DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.","Mutze et al., 2011, Eur. J. Cancer",21458988,"http://www.ncbi.nlm.nih.gov/pubmed/21458988",NULL,NULL,"2011","8",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
947,"EID947","Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitumor efficacy in-vitro and in xenografts. These results were based on three KRAS mutant cell lines (LS180, LoVo and HCT116) and two KRAS wild-type cell lines (SW48 and CaCo2).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,3,"Combination","accepted",0,"evidence",649,"Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.","Dunn et al., 2011, Oncogene",20956938,"http://www.ncbi.nlm.nih.gov/pubmed/20956938","true","PMC3025039","2011","2","3","Oncogene","Oncogene","fully curated","20","Dasatinib",NULL,"16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
948,"EID948","A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",190,4,NULL,"accepted",0,"evidence",650,"EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.","Dahabreh et al., 2011, Ann. Oncol.",20826716,"http://www.ncbi.nlm.nih.gov/pubmed/20826716",NULL,NULL,"2011","3",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
949,"EID949","CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resistant tumors among 25 patient samples.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Predictive","Supports","Resistance or Non-Response","N/A",405,2,NULL,"accepted",0,"evidence",651,"CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.","Xie et al., 2010, Anticancer Res.",20651371,"http://www.ncbi.nlm.nih.gov/pubmed/20651371",NULL,NULL,"2010","6",NULL,"Anticancer Res.","Anticancer research","fully curated","73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
950,"EID950","10 biliary tract carcinoma cell lines were sorted based on their gemcitabine sensitivity. MAGEH1 protein expression was negatively correlated with sensitivity.
In a clinical validation cohort, MAGEH protein expression was found in 4/4 \"non-effective\" cases and 2/5 effective cases based on RECIST criteria after gemcitabine treatment.",168,"Bile Duct Adenocarcinoma","Bile Duct Adenocarcinoma",4896,"http://www.disease-ontology.org/?id=DOID:4896","D","Predictive","Supports","Resistance or Non-Response","N/A",406,2,NULL,"accepted",0,"evidence",652,"Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.","Ojima et al., 2010, Cancer Sci.",20088962,"http://www.ncbi.nlm.nih.gov/pubmed/20088962",NULL,NULL,"2010","4",NULL,"Cancer Sci.","Cancer science","fully curated","85","Gemcitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
951,"EID951","44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide amplification was assessed by Affymetrix SNP arrays and expression was assessed by Affymetrix gene expression arrays. ABCC3 amplification (and expression) in ERBB2 (HER2) amplified breast cancer cell lines was associated with resistance to paclitaxel and  MMAE. Three independently derived EVSA-T cell lines overexpressing ABCC3 were at least 20-fold less sensitive to paclitaxel and MMAE based on EC50 values.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",407,3,"Substitutes","accepted",0,"evidence",653,"Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.","O'Brien et al., 2008, Cancer Res.",18593940,"http://www.ncbi.nlm.nih.gov/pubmed/18593940",NULL,NULL,"2008","7","1","Cancer Res.","Cancer research","fully curated","183","Monomethyl Auristatin E",NULL,"81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
952,"EID952","Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","N/A",408,3,NULL,"accepted",0,"evidence",654,"MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.","Oguri et al., 2008, Mol. Cancer Ther.",18445659,"http://www.ncbi.nlm.nih.gov/pubmed/18445659",NULL,NULL,"2008","5",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
953,"EID953","ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cell lines.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",409,2,NULL,"accepted",0,"evidence",655,"Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.","Lorenzi et al., 2006, Mol. Cancer Ther.",17088436,"http://www.ncbi.nlm.nih.gov/pubmed/17088436",NULL,NULL,"2006","11",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","258","L-asparaginase",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
954,"EID954","82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006). PFS but not OS was also longer in patients with high EGFR mRNA expression.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",193,3,NULL,"accepted",0,"evidence",656,"Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.","Dziadziuszko et al., 2006, Clin. Cancer Res.",16707605,"http://www.ncbi.nlm.nih.gov/pubmed/16707605",NULL,NULL,"2006","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
955,"EID955","Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",313,3,NULL,"accepted",0,"evidence",657,"PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.","Fujita et al., 2006, Br. J. Cancer",16404430,"http://www.ncbi.nlm.nih.gov/pubmed/16404430","true","PMC2361109","2006","1","30","Br. J. Cancer","British journal of cancer","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
956,"EID956","Patients with stage II/III colorectal cancer were analyzed for expression of CDX2 (by microarray and IHC). In the discovery (466 patients) and validation sets (314 patients), 5-year DFS was lower among patients with CDX2 negative tumors (discovery set:hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002; validation set: hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Better Outcome","Somatic Mutation",410,4,NULL,"accepted",0,"evidence",658,"CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.","Dalerba et al., 2016, N. Engl. J. Med.",26789870,"http://www.ncbi.nlm.nih.gov/pubmed/26789870","true","PMC4784450","2016","1","21","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
957,"EID957","Mutations in the Src homology 2 (SH2) domain (exon 21) of STAT3 were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia. Recurrent mutational hot spots included Y640F, D661V, D661Y, and N647I. Patients with these mutations presented more often with neutropenia and rheumatoid arthritis than did patients without.",351,"T-cell Large Granular Lymphocyte Leukemia","T-cell Large Granular Lymphocyte Leukemia",50751,"http://www.disease-ontology.org/?id=DOID:0050751","B","Diagnostic","Supports","Positive","Somatic Mutation",411,4,NULL,"accepted",0,"evidence",659,"Somatic STAT3 mutations in large granular lymphocytic leukemia.","Koskela et al., 2012, N. Engl. J. Med.",22591296,"http://www.ncbi.nlm.nih.gov/pubmed/22591296","true","PMC3693860","2012","5","17","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
958,"EID958","OCT4B1 (POU5F1 splice variant) expression reduced sensitivity to oxaliplatin (via P-gp and ABCG2 differential expression) in vitro.",119,"Colon Cancer","Colon Cancer",219,"http://www.disease-ontology.org/?id=DOID:219","D","Predictive","Supports","Resistance or Non-Response","N/A",412,2,NULL,"accepted",0,"evidence",660,"OCT4B1 promotes cell growth, migration and invasion suppressing sensitivity to Î¿xaliplatin in colon cancer.","Wen et al., 2015, Oncol. Rep.",26398480,"http://www.ncbi.nlm.nih.gov/pubmed/26398480",NULL,NULL,"2015","12",NULL,"Oncol. Rep.","Oncology reports","fully curated","237","Oxaliplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
959,"EID959","A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",413,3,NULL,"accepted",0,"evidence",661,"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.","De GrÃ¨ve et al., 2012, Lung Cancer",22325357,"http://www.ncbi.nlm.nih.gov/pubmed/22325357",NULL,NULL,"2012","4",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
960,"EID960","In preclinical studies of transgenic mice and xenografts, continuous expression of mutant ERBB2 (M774insAYVM or the equivalent A775insYVMA) was found to be essential for tumor maintenance. Furthermore, preclinical in vivo studies assessing erlotinib, trastuzumab, afatinib (aka BIBW2992), and/or sirolimus (aka rapamycin) revealed that the combination of afatinib and sirolimus was most effective in shrinking tumors harboring this insertion.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",414,3,"Combination","accepted",0,"evidence",662,"HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.","Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",19122144,"http://www.ncbi.nlm.nih.gov/pubmed/19122144","true","PMC2626727","2009","1","13","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","146","Afatinib",NULL,"352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
961,"EID961","A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated with trastuzumab and a median of three chemotherapy lines. 41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate. 4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response. Thus a total of 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",663,"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.","Lin et al., 2012, Breast Cancer Res. Treat.",22418700,"http://www.ncbi.nlm.nih.gov/pubmed/22418700","true","PMC3387495","2012","6",NULL,"Breast Cancer Res. Treat.","Breast cancer research and treatment","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
962,"EID962","Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors. Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells. In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization.",158,"Pancreas Adenocarcinoma","Pancreas Adenocarcinoma",4074,"http://www.disease-ontology.org/?id=DOID:4074","D","Predictive","Supports","Sensitivity","N/A",306,2,NULL,"accepted",0,"evidence",664,"Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.","Huguet et al., 2016, Target Oncol",26668065,"http://www.ncbi.nlm.nih.gov/pubmed/26668065",NULL,NULL,"2016","6",NULL,"Target Oncol","Targeted oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
963,"EID963","Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",34,3,NULL,"accepted",0,"evidence",665,"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.","Cross et al., 2014, Cancer Discov",24893891,"http://www.ncbi.nlm.nih.gov/pubmed/24893891","true","PMC4315625","2014","9",NULL,"Cancer Discov","Cancer discovery","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
964,"EID964","An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",415,3,NULL,"accepted",0,"evidence",666,"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.","Thress et al., 2015, Nat. Med.",25939061,"http://www.ncbi.nlm.nih.gov/pubmed/25939061","true","PMC4771182","2015","6",NULL,"Nat. Med.","Nature medicine","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
965,"EID965","A phase I/II trial (NCT01802632) involving 253 non-small cell lung cancer patients treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",34,4,NULL,"accepted",0,"evidence",667,"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.","JÃ¤nne et al., 2015, N. Engl. J. Med.",25923549,"http://www.ncbi.nlm.nih.gov/pubmed/25923549",NULL,NULL,"2015","4","30","N. Engl. J. Med.","The New England journal of medicine","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
966,"EID966","This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",34,3,NULL,"accepted",0,"evidence",668,"Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.","Sequist et al., 2016, JAMA Oncol",26720284,"http://www.ncbi.nlm.nih.gov/pubmed/26720284",NULL,NULL,"2016","4",NULL,"JAMA Oncol","JAMA oncology","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
967,"EID967","For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",34,2,"Substitutes","accepted",0,"evidence",669,"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.","Hirano et al., 2015, Oncotarget",26515464,"http://www.ncbi.nlm.nih.gov/pubmed/26515464","true","PMC4770737","2015","11","17","Oncotarget","Oncotarget","fully curated","91","Rociletinib",NULL,"187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
968,"EID968","Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",33,2,NULL,"accepted",0,"evidence",669,"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.","Hirano et al., 2015, Oncotarget",26515464,"http://www.ncbi.nlm.nih.gov/pubmed/26515464","true","PMC4770737","2015","11","17","Oncotarget","Oncotarget","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
969,"EID969","Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",133,2,NULL,"accepted",0,"evidence",669,"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.","Hirano et al., 2015, Oncotarget",26515464,"http://www.ncbi.nlm.nih.gov/pubmed/26515464","true","PMC4770737","2015","11","17","Oncotarget","Oncotarget","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
970,"EID970","Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF and FGFR1 were expressed in all tumor specimens, whereas expression of these proteins in cancer-associated fibroblasts was associated with lymph node metastasis (P < 0.05) and worse patient survival.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Poor Outcome","N/A",268,2,NULL,"accepted",0,"evidence",670,"Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma.","Hase et al., 2006, J. Oral Pathol. Med.",16454808,"http://www.ncbi.nlm.nih.gov/pubmed/16454808",NULL,NULL,"2006","3",NULL,"J. Oral Pathol. Med.","Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
971,"EID971","In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine,  and standard adjuvant temozolomide chemotherapy.  Median progression free survival (PFS) was 9.2 months, and median overall survival (OS) was 21.8 months.  A pivotal, randomized Phase III trial is currently underway.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Predictive","Supports","Sensitivity","Somatic Mutation",312,3,NULL,"accepted",0,"evidence",671,"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.","Schuster et al., 2015, Neuro-oncology",25586468,"http://www.ncbi.nlm.nih.gov/pubmed/25586468","true","PMC4483122","2015","6",NULL,"Neuro-oncology","Neuro-oncology","fully curated","204","Rindopepimut",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
972,"EID972","Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control.
Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 amplification (median sHER2 levels were 25.1 ng/mL in patients with HER2-positive tumors). Serum HER2 levels were Independent predictors of lapatinib progression free survival benefit (HR per 10-ng/mL increase in serum HER2: lapatinib-containing therapies, 1.009 v nonlapatinib-containing therapies, 1.044; P interaction < .001). Tissue HER2 levels were also predictive, but within this subgroup, serum HER2 still independently predicted lapatinib PFS benefit.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","N/A",416,4,NULL,"accepted",0,"evidence",672,"Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.","Lee et al., 2016, J. Clin. Oncol.",26811533,"http://www.ncbi.nlm.nih.gov/pubmed/26811533",NULL,NULL,"2016","3","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
973,"EID973","Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. In the control group (n = 936), higher serum HER2 (sHER2) was associated with worse prognosis in multivariable analyses (progression free survival hazard ratio per 10 ng/mL: PFS, 1.024; P < .001; and OS, 1.018; P < .001).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","N/A",416,3,NULL,"accepted",0,"evidence",672,"Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.","Lee et al., 2016, J. Clin. Oncol.",26811533,"http://www.ncbi.nlm.nih.gov/pubmed/26811533",NULL,NULL,"2016","3","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
974,"EID974","172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patients, GSE35452). Low expression was associated with advanced pretreatment tumor, nodal status, post-treatment tumor, vascular invasion and inferior regression grade. In multivariate analysis, low expression served as negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","N/A",417,3,NULL,"accepted",0,"evidence",673,"Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer.","Lin et al., 2015, Am J Transl Res",26807188,"http://www.ncbi.nlm.nih.gov/pubmed/26807188","true","PMC4697720","2015",NULL,NULL,"Am J Transl Res","American journal of translational research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
975,"EID975","74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC). CD8+ TIL density was an independent predictor of progression free survival (PFS) and overall survival (OS). Only when both TIL density and PD-L1 expression were both considered, was PD-L1 expression associated with survival. The subgroup, PD-L1+/CD8 low tumors had the shortest PFS (8.6 months, p = 0.02) and shortest, but not significantly different, OS (13.9 months, p = 0.11).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","N/A",276,2,NULL,"accepted",0,"evidence",674,"Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.","Tokito et al., 2016, Eur. J. Cancer",26771872,"http://www.ncbi.nlm.nih.gov/pubmed/26771872",NULL,NULL,"2016","3",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
976,"EID976","In this meta-analysis of 16 Trials, TERT mutations were more common in glioblastomas (69%), oligodendrogliomas (72%) in comparison to astrocytomas (24%) and oligoastrocytomas (38%).",98,"Brain Glioma","Brain Glioma",60108,"http://www.disease-ontology.org/?id=DOID:0060108","B","Diagnostic","Supports","Positive","Somatic Mutation",220,3,NULL,"accepted",0,"evidence",675,"TERT mutation in glioma: Frequency, prognosis and risk.","Yuan et al., 2016, J Clin Neurosci",26765760,"http://www.ncbi.nlm.nih.gov/pubmed/26765760",NULL,NULL,"2016","4",NULL,"J Clin Neurosci","Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
977,"EID977","In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",190,2,"Substitutes","accepted",0,"evidence",676,"Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.","Fiala et al., 2016, Anticancer Res.",26722081,"http://www.ncbi.nlm.nih.gov/pubmed/26722081",NULL,NULL,"2016","1",NULL,"Anticancer Res.","Anticancer research","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
978,"EID978","NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene fusion. These fusions were mutually exclusive with other oncogenic drivers and showed in-vitro sensitivity to TrkA Inhibitor ARRY470 (one cell line with fusion (KM12), one control cell line).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",419,2,NULL,"accepted",0,"evidence",677,"NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.","Park et al., 2016, Oncotarget",26716414,"http://www.ncbi.nlm.nih.gov/pubmed/26716414","true","PMC4885001","2016","2","16","Oncotarget","Oncotarget","fully curated","259","ARRY-470",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
979,"EID979","In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations.  A phase I clinical trial of the AG-120 IDH1 inhibitor in IDH1 mutant positive solid tumors, including glioma is currently underway.",241,"Anaplastic Oligodendroglioma","Anaplastic Oligodendroglioma",3181,"http://www.disease-ontology.org/?id=DOID:3181","D","Predictive","Supports","Sensitivity","Somatic Mutation",420,4,NULL,"accepted",0,"evidence",678,"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.","Rohle et al., 2013, Science",23558169,"http://www.ncbi.nlm.nih.gov/pubmed/23558169","true","PMC3985613","2013","5","3","Science","Science (New York, N.Y.)","fully curated","217","AG-5198",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
980,"EID980","Meta-analysis of 10 studies (9,411 patients, 13,708 controls) showed that TERT polymorphisms (rs2736100) were associated with an increased glioma risk (RR=1.28, 95% CI 1.23-1.33).",98,"Brain Glioma","Brain Glioma",60108,"http://www.disease-ontology.org/?id=DOID:0060108","B","Predisposing","Supports","Positive","Germline Polymorphism",421,2,NULL,"accepted",0,"evidence",675,"TERT mutation in glioma: Frequency, prognosis and risk.","Yuan et al., 2016, J Clin Neurosci",26765760,"http://www.ncbi.nlm.nih.gov/pubmed/26765760",NULL,NULL,"2016","4",NULL,"J Clin Neurosci","Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
981,"EID981","Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",133,4,NULL,"accepted",0,"evidence",679,"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.","Wu et al., 2014, Lancet Oncol.",24439929,"http://www.ncbi.nlm.nih.gov/pubmed/24439929",NULL,NULL,"2014","2",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
982,"EID982","Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",33,4,NULL,"accepted",0,"evidence",679,"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.","Wu et al., 2014, Lancet Oncol.",24439929,"http://www.ncbi.nlm.nih.gov/pubmed/24439929",NULL,NULL,"2014","2",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
983,"EID983","In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively).  This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",133,4,NULL,"accepted",0,"evidence",680,"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.","Yang et al., 2015, Lancet Oncol.",25589191,"http://www.ncbi.nlm.nih.gov/pubmed/25589191",NULL,NULL,"2015","2",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
984,"EID984","Tumor samples from 125 patients with bladder cancer were assessed by IHC for STAG2 expression. STAG2-negativity was associated with lower histological grade (pâ€‰=â€‰0.009). Complete loss of STAG2 expression was associated with a lower risk of recurrence (Pâ€‰=â€‰0.023) and diminished risk of death (Pâ€‰=â€‰0.034) in log-rank analysis and was a beneficial factor in uni- and multivariate analysis.",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","B","Prognostic","Supports","Better Outcome","N/A",422,2,NULL,"accepted",0,"evidence",681,"Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.","Qiao et al., 2016, Tumour Biol.",26838030,"http://www.ncbi.nlm.nih.gov/pubmed/26838030",NULL,NULL,"2016","2","2","Tumour Biol.","Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
985,"EID985","Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathway). In a discovery cohort, 30 patients underwent IHC for HLA-DRA. 11/14 (79%) patients with positive HLA-DR staining, had complete (n=3) or partial (n=8) response. 6/16 (38%) HLA-DR non-expressing melanomas responded to therapy (overall response rate 79 versus 38%, Fisherâ€™s exact test P=0.033). This finding was confirmed in a second independent data set of 23 melanoma patients with 6/8 (75%) of HLA-DR(+) tumours in comparison to 4/15 (27%) HLA-DR(âˆ’) responding (Fisherâ€™s exact test P=0.025). Preclinical models confirmed the result.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Sensitivity","N/A",423,3,"Substitutes","accepted",0,"evidence",682,"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.","Johnson et al., 2016, Nat Commun",26822383,"http://www.ncbi.nlm.nih.gov/pubmed/26822383","true","PMC4740184","2016",NULL,NULL,"Nat Commun","Nature communications","fully curated","137","Nivolumab",NULL,"138","Pembrolizumab",NULL,"261","Atezolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL
986,"EID986","A prospective study of ibrutinib in 63 symptomatic patients with WaldenstrÃ¶m's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with MYD88(L265P) and CXCR4(WT). The MYD88 L265P mutation was present in 56 patients (89%).",317,"WaldenstrÃ¶m's Macroglobulinemia","WaldenstrÃ¶m's Macroglobulinemia",NULL,"http://www.disease-ontology.org/","B","Predictive","Supports","Sensitivity","Somatic Mutation",424,4,NULL,"accepted",0,"evidence",683,"Ibrutinib in previously treated WaldenstrÃ¶m's macroglobulinemia.","Treon et al., 2015, N. Engl. J. Med.",25853747,"http://www.ncbi.nlm.nih.gov/pubmed/25853747",NULL,NULL,"2015","4","9","N. Engl. J. Med.","The New England journal of medicine","fully curated","227","Ibrutinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
987,"EID987","Retrospective analysis of data from 841 patients who underwent surgery and molecular testing for NSCLC.  Mutant KRAS was observed in 265 (31.5%) cases and 90 of these were G12V. Patients with KRAS G12V exhibited worse OS and TTR compared with the entire cohort. These results were confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.28â€“0.65), P<0.0001 for OS. Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.001â€“0.08), P<0.0001).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",425,3,NULL,"accepted",0,"evidence",684,"Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.","Renaud et al., 2015, Br. J. Cancer",26372703,"http://www.ncbi.nlm.nih.gov/pubmed/26372703","true","PMC4647870","2015","10","20","Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
988,"EID988","SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding could be reproduced in colorectal and lung cancer cell lines in a second, independent screen.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,4,"Combination","accepted",0,"evidence",685,"RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.","Lamba et al., 2014, Cell Rep",25199829,"http://www.ncbi.nlm.nih.gov/pubmed/25199829",NULL,NULL,"2014","9","11","Cell Rep","Cell reports","fully curated","122","Selumetinib (AZD6244)",NULL,"233","RAF265",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
989,"EID989","SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding was reproduced two NSCLC cell lines in a second, independent shRNA screen.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,2,"Combination","accepted",0,"evidence",685,"RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.","Lamba et al., 2014, Cell Rep",25199829,"http://www.ncbi.nlm.nih.gov/pubmed/25199829",NULL,NULL,"2014","9","11","Cell Rep","Cell reports","fully curated","122","Selumetinib (AZD6244)",NULL,"233","RAF265",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
990,"EID990","KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or placebo. KRAS mutations were identified in 103 patients using cfDNA. There was no difference betweeen overall survival of KRAS Mutation-positive and -negative patients. Of note, evaluation of KRAS mutations from archival tissue from 71/143 patients identified 8 patients with mutant KRAS (wildtype by cfDNA) and 3 patients with wildtype KRAS (mutant by cfDNA).",158,"Pancreas Adenocarcinoma","Pancreas Adenocarcinoma",4074,"http://www.disease-ontology.org/?id=DOID:4074","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",77,3,NULL,"accepted",0,"evidence",385,"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.","Infante et al., 2014, Eur. J. Cancer",24915778,"http://www.ncbi.nlm.nih.gov/pubmed/24915778",NULL,NULL,"2014","8",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
991,"EID991","An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,4,"Combination","accepted",0,"evidence",686,"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.","Sun et al., 2014, Cell Rep",24685132,"http://www.ncbi.nlm.nih.gov/pubmed/24685132",NULL,NULL,"2014","4","10","Cell Rep","Cell reports","fully curated","146","Afatinib",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
992,"EID992","An shDNA screen identified synergy between ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,2,"Combination","accepted",0,"evidence",686,"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.","Sun et al., 2014, Cell Rep",24685132,"http://www.ncbi.nlm.nih.gov/pubmed/24685132",NULL,NULL,"2014","4","10","Cell Rep","Cell reports","fully curated","19","Trametinib",NULL,"146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
993,"EID993","KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone.   42% of the tumors evaluated had at least one mutation in exon 2. Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab. The effectiveness of cetuximab was significantly associated with K-ras mutation status (P=0.01 for overall survival and P<0.001 for progression-free survival). In patients with wild-type K-ras tumors, treatment with cetuximab as compared with supportive care alone significantly improved overall survival. The related clinical trial ID is NCT00079066.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","A","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",75,5,NULL,"accepted",0,"evidence",687,"K-ras mutations and benefit from cetuximab in advanced colorectal cancer.","Karapetis et al., 2008, N. Engl. J. Med.",18946061,"http://www.ncbi.nlm.nih.gov/pubmed/18946061",NULL,NULL,"2008","10","23","N. Engl. J. Med.","The New England journal of medicine","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
994,"EID994","Phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655. Partial response was observed in 4 of 17 patients with BRAF V600 mutated melanoma. 2 patients with prior vemurafenib treatment progressed under treatment.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",17,2,NULL,"accepted",0,"evidence",688,"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.","Zimmer et al., 2014, Clin. Cancer Res.",24947927,"http://www.ncbi.nlm.nih.gov/pubmed/24947927",NULL,NULL,"2014","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","243","RO4987655",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
995,"EID995","Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial response or stable disease.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","N/A",426,2,NULL,"accepted",0,"evidence",688,"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.","Zimmer et al., 2014, Clin. Cancer Res.",24947927,"http://www.ncbi.nlm.nih.gov/pubmed/24947927",NULL,NULL,"2014","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","243","RO4987655",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
996,"EID996","Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 4 experienced SD or PR (1 Patient received study treatment for 323 days).",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",208,2,NULL,"accepted",0,"evidence",688,"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.","Zimmer et al., 2014, Clin. Cancer Res.",24947927,"http://www.ncbi.nlm.nih.gov/pubmed/24947927",NULL,NULL,"2014","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","243","RO4987655",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
997,"EID997","Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). 2 PR and 8 SD among 18 patients with KRAS Mutant NSCLC.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Does Not Support","N/A","Somatic Mutation",336,1,NULL,"accepted",0,"evidence",688,"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.","Zimmer et al., 2014, Clin. Cancer Res.",24947927,"http://www.ncbi.nlm.nih.gov/pubmed/24947927",NULL,NULL,"2014","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","243","RO4987655",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
998,"EID998","Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","N/A","Somatic Mutation",336,1,NULL,"accepted",0,"evidence",688,"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.","Zimmer et al., 2014, Clin. Cancer Res.",24947927,"http://www.ncbi.nlm.nih.gov/pubmed/24947927",NULL,NULL,"2014","8","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","243","RO4987655",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
999,"EID999","87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo. Median OS was 9Â·4 months (6Â·8-13Â·6) in selumetinib group and 5Â·2 months (95% CI 3Â·8-non-calculable) in placebo group (hazard ratio [HR] for death 0Â·80, 80% CI 0Â·56-1Â·14; one-sided p=0Â·21). Median PFS was 5Â·3 months (4Â·6-6Â·4) in selumetinib group and 2Â·1 months (95% CI 1Â·4-3Â·7) in placebo group (HR for progression 0Â·58, 80% CI 0Â·42-0Â·79; one-sided p=0Â·014). An objective response was observed in 16 (37%) patients in the selumetinib group and none in the placebo group(p<0Â·0001).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",336,4,"Combination","accepted",0,"evidence",689,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.","JÃ¤nne et al., 2013, Lancet Oncol.",23200175,"http://www.ncbi.nlm.nih.gov/pubmed/23200175",NULL,NULL,"2013","1",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","122","Selumetinib (AZD6244)",NULL,"73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1000,"EID1000","Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses administered in the study).",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",17,2,NULL,"accepted",0,"evidence",690,"Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.","Weekes et al., 2013, Clin. Cancer Res.",23434733,"http://www.ncbi.nlm.nih.gov/pubmed/23434733",NULL,NULL,"2013","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","309","BAY 86-9766",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1001,"EID1001","Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Does Not Support","Sensitivity","Somatic Mutation",336,2,NULL,"accepted",0,"evidence",690,"Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.","Weekes et al., 2013, Clin. Cancer Res.",23434733,"http://www.ncbi.nlm.nih.gov/pubmed/23434733",NULL,NULL,"2013","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","309","BAY 86-9766",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1002,"EID1002","In-vitro study in 5 neuroblastoma cell lines (2 with NRAS Q61K mutation). The combination of mTOR and MEK Inhibitors synergistically blocked cell growth in NRAS mutant but not wild type cell lines. Single agent MEK inhibition (AZD6244/selumetinib, MEK162 or PD0325901) and single agent mTOR inhibition (Everolimus or AZD8055) also blocked cell growth in NRAS mutant cell lines, whereas single agent PI3K inhibitors or MEK Inhibitors in combination with PIK3CA/AKT inhibitors did not show synergistic effects.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",427,3,"Combination","accepted",0,"evidence",691,"Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.","Kiessling et al., 2016, PLoS ONE",26821351,"http://www.ncbi.nlm.nih.gov/pubmed/26821351","true","PMC4731059","2016",NULL,NULL,"PLoS ONE","PloS one","fully curated","41","Everolimus",NULL,"355","Binimetinib (MEK162)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1003,"EID1003","Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either agent alone. Chemical library screen in two cell lines also identified mTOR, AKT Family Inhibitors (Temsirolimus, Everolimus) to act synergistically with ERK Inhibition.",158,"Pancreas Adenocarcinoma","Pancreas Adenocarcinoma",4074,"http://www.disease-ontology.org/?id=DOID:4074","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,4,"Combination","accepted",0,"evidence",692,"Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.","Hayes et al., 2016, Cancer Cell",26725216,"http://www.ncbi.nlm.nih.gov/pubmed/26725216","true","PMC4816652","2016","1","11","Cancer Cell","Cancer cell","fully curated","114","AZD8186",NULL,"245","SCH772984",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1004,"EID1004","Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other cell lines, activation of other RTKs (such as MET) were observed upon MEK Inhibition and combination of RTKi and METi also showed synergistic activity. A total of 16 cell lines were used in this study. 6 were KRAS wild type, and 10 harbored various KRAS mutations (G12C, G12D, G12V, G13D, and Q61L). Additional data was obtained from xenografts.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,3,"Combination","accepted",0,"evidence",693,"Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.","Ebi et al., 2011, J. Clin. Invest.",21985784,"http://www.ncbi.nlm.nih.gov/pubmed/21985784","true","PMC3204842","2011","11",NULL,"J. Clin. Invest.","The Journal of clinical investigation","fully curated","246","R1507",NULL,"122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1005,"EID1005","49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (BEZ235) and PI3K/mTOR (AZD6244 [selumetinib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition).",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",12,2,"Combination","accepted",0,"evidence",694,"Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.","Penna et al., 2016, Oncotarget",26678033,"http://www.ncbi.nlm.nih.gov/pubmed/26678033","true","PMC4826182","2016","1","26","Oncotarget","Oncotarget","fully curated","122","Selumetinib (AZD6244)",NULL,"343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1006,"EID1006","In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.  A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,"Combination","accepted",0,"evidence",695,"Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.","Xia et al., 2005, Oncogene",16091755,"http://www.ncbi.nlm.nih.gov/pubmed/16091755",NULL,NULL,"2005","9","15","Oncogene","Oncogene","fully curated","45","Lapatinib",NULL,"84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1007,"EID1007","In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.  In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.  From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  The authors conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,"Combination","accepted",0,"evidence",696,"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.","Guarneri et al., 2012, J. Clin. Oncol.",22493419,"http://www.ncbi.nlm.nih.gov/pubmed/22493419",NULL,NULL,"2012","6","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","84","Trastuzumab",NULL,"45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1008,"EID1008","This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.  8381 women were randomized to one of four treatment arms. Patients had HER2 positive non-metastatic operable BC. The primary endpoint was disease free survival.  First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.  The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.  This trial is ongoing but not recruiting patients (NCT00490139).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",306,4,"Combination","accepted",0,"evidence",697,"Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.","Zardavas et al., 2015, Breast",26255196,"http://www.ncbi.nlm.nih.gov/pubmed/26255196",NULL,NULL,"2015","11",NULL,"Breast","Breast (Edinburgh, Scotland)","fully curated","45","Lapatinib",NULL,"84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1009,"EID1009","This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.  In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab. Progression free survival (PFS) was the primary endpoint. For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).  The authors conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,"Combination","accepted",0,"evidence",698,"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.","Blackwell et al., 2010, J. Clin. Oncol.",20124187,"http://www.ncbi.nlm.nih.gov/pubmed/20124187",NULL,NULL,"2010","3","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","84","Trastuzumab",NULL,"45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1010,"EID1010","With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB receptors was tested in a single arm phase II trial on advanced stage HER2 positive metastatic breast cancer. From 41 treated patients, 10% had partial response, 37% had stable disease as best response and 46% achieved clinical benefit.  Median progression free survival (PFS) was 15.1 weeks and median overall survival (OS) was 61.0 weeks. The authors conclude that Afatinib monotherapy shows promise in treatment of metastatic HER2 positive breast cancer that has progressed under trastuzumab.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",663,"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.","Lin et al., 2012, Breast Cancer Res. Treat.",22418700,"http://www.ncbi.nlm.nih.gov/pubmed/22418700","true","PMC3387495","2012","6",NULL,"Breast Cancer Res. Treat.","Breast cancer research and treatment","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1011,"EID1011","This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.  121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose. Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.  Differences were not statistically significant, and afatanib patients experienced more adverse effects.  While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",699,"Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.","CortÃ©s et al., 2015, Lancet Oncol.",26596672,"http://www.ncbi.nlm.nih.gov/pubmed/26596672",NULL,NULL,"2015","12",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1012,"EID1012","LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance. Primary endpoint was intention-to-treat group PFS. 339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.  Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group. Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.  Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and the authors conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",700,"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.","Harbeck et al., 2016, Lancet Oncol.",26822398,"http://www.ncbi.nlm.nih.gov/pubmed/26822398",NULL,NULL,"2016","3",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1013,"EID1013","Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.  The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.  Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.  Objective response and disease control rates were 11% and 39%.  The authors conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,"Combination","accepted",0,"evidence",701,"Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.","Ring et al., 2015, Clin. Cancer Res.",25370464,"http://www.ncbi.nlm.nih.gov/pubmed/25370464",NULL,NULL,"2015","6","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","84","Trastuzumab",NULL,"146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1014,"EID1014","NOTCH1 mutations were found to be associated with worse overall survival (3.77-fold increase in the hazard of death, P < .001) in a series of 309 newly diagnosed CLL and confirmed in an additional set of 230 patients. NOTCH1 mutations were mostly represented (26/34, 76.5%) by a recurrent 2-bp frameshift deletion (c.7544_7545delCT), with the remaining being other frameshift deletions or insertions.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",207,4,NULL,"accepted",0,"evidence",702,"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.","Rossi et al., 2012, Blood",22077063,"http://www.ncbi.nlm.nih.gov/pubmed/22077063","true","PMC3257017","2012","1","12","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1015,"EID1015","In advanced stage follicular lymphoma patients receiving rituximab + chemotherapy (R-CHOP or R-CVP), EZH2 mutations were associated with better failure free survival in patients with high-risk FLIPI scores compared to patients that were EZH2 wildtype with high-risk FLIPI scores.",51,"Follicular Lymphoma","Follicular Lymphoma",50873,"http://www.disease-ontology.org/?id=DOID:0050873","B","Prognostic","Supports","Better Outcome","Somatic Mutation",163,4,NULL,"accepted",0,"evidence",703,"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.","Pastore et al., 2015, Lancet Oncol.",26256760,"http://www.ncbi.nlm.nih.gov/pubmed/26256760",NULL,NULL,"2015","9",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1016,"EID1016","One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks on Treatment).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predictive","Supports","Sensitivity","Somatic Mutation",428,2,NULL,"accepted",0,"evidence",409,"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.","Mateo et al., 2015, N. Engl. J. Med.",26510020,"http://www.ncbi.nlm.nih.gov/pubmed/26510020",NULL,NULL,"2015","10","29","N. Engl. J. Med.","The New England journal of medicine","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1017,"EID1017","Two human glioma cell lines (U87MG or LNZ308) overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both in vitro. Anti-tumor effects of nimotuzumab were greater in EGFRvIII in comparison to EGFRwt (as measured by antitumor effects, growth suppression, survival elongation and EGFR and Akt phosphorylation). Combination of nimotuzumab and temozolomide further increased efficacy.",98,"Brain Glioma","Brain Glioma",60108,"http://www.disease-ontology.org/?id=DOID:0060108","D","Predictive","Supports","Sensitivity","Somatic Mutation",312,1,NULL,"accepted",0,"evidence",704,"Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.","Nitta et al., 2016, Cancer Med",26778701,"http://www.ncbi.nlm.nih.gov/pubmed/26778701","true","PMC4799951","2016","3",NULL,"Cancer Med","Cancer medicine","fully curated","188","Nimotuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1018,"EID1018","In a study of 97 patients with AML  treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations. Patients with a TP53 mutation had a reduced three year probability of overall survival and event-free survival compared to patients with the wild-type TP53.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",705,"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.","Middeke et al., 2016, Br. J. Haematol.",26771088,"http://www.ncbi.nlm.nih.gov/pubmed/26771088",NULL,NULL,"2016","3",NULL,"Br. J. Haematol.","British journal of haematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1019,"EID1019","Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1.  Both of these fusions lead to constitutive kinase activity and were found to be oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity (ARRY-470, CEP-701 and, to a lesser extent, crizotinib) inhibited autophosphorylation of TRKA and cell growth.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","D","Predictive","Supports","Sensitivity","Somatic Mutation",419,3,"Substitutes","accepted",0,"evidence",706,"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.","Vaishnavi et al., 2013, Nat. Med.",24162815,"http://www.ncbi.nlm.nih.gov/pubmed/24162815","true","PMC3823836","2013","11",NULL,"Nat. Med.","Nature medicine","fully curated","260","Lestaurtinib (CEP-701)",NULL,"12","Crizotinib",NULL,"259","ARRY-470",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1020,"EID1020","Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as \"high expressor\" (either EREG or AREG mRNA level) or \"low expressor\" (neither EREG nor AREG in top tertile). 
For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; Pâ€‰<â€‰.001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; Pâ€‰=â€‰.73; interaction test results were significant [Pâ€‰=â€‰.01]). Results were less clear for response rate (interaction Pâ€‰=â€‰.17) and OS (interaction Pâ€‰=â€‰.11).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",315,4,NULL,"accepted",0,"evidence",707,"Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.","Seligmann et al., 2016, JAMA Oncol",26867820,"http://www.ncbi.nlm.nih.gov/pubmed/26867820",NULL,NULL,"2016","2","11","JAMA Oncol","JAMA oncology","fully curated","28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1021,"EID1021","Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as \"high expressor\" (either EREG or AREG mRNA level) or \"low expressor\" (neither EREG nor AREG in top tertile). For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; Pâ€‰<â€‰.001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; Pâ€‰=â€‰.73; interaction test results were significant [Pâ€‰=â€‰.01]). Results were less clear for response rate (interaction Pâ€‰=â€‰.17) and OS (interaction Pâ€‰=â€‰.11).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",318,4,NULL,"accepted",0,"evidence",707,"Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.","Seligmann et al., 2016, JAMA Oncol",26867820,"http://www.ncbi.nlm.nih.gov/pubmed/26867820",NULL,NULL,"2016","2","11","JAMA Oncol","JAMA oncology","fully curated","28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1022,"EID1022","ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",708,"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.","Bang et al., 2010, Lancet",20728210,"http://www.ncbi.nlm.nih.gov/pubmed/20728210",NULL,NULL,"2010","8","28","Lancet","Lancet (London, England)","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1023,"EID1023","TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.  Primary endpoint was Overall Survival (OS).  Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.  Patients were a mix of those having undergone gastrectomy and not.  OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.  In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.  The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",709,"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.","Satoh et al., 2014, J. Clin. Oncol.",24868024,"http://www.ncbi.nlm.nih.gov/pubmed/24868024",NULL,NULL,"2014","7","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1024,"EID1024","Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT).",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","C","Predictive","Supports","Sensitivity","N/A",429,2,NULL,"accepted",0,"evidence",710,"Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.","Kalender et al., 2009, Cancer Chemother. Pharmacol.",18607592,"http://www.ncbi.nlm.nih.gov/pubmed/18607592",NULL,NULL,"2009","2",NULL,"Cancer Chemother. Pharmacol.","Cancer chemotherapy and pharmacology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1025,"EID1025","Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment with imatinib led to an objective Response. Surgery was performed and the patient was free of disease two years later.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","C","Predictive","Supports","Sensitivity","N/A",429,2,NULL,"accepted",0,"evidence",711,"A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.","Salvatierra et al., 2006, Gynecol. Oncol.",16487996,"http://www.ncbi.nlm.nih.gov/pubmed/16487996",NULL,NULL,"2006","6",NULL,"Gynecol. Oncol.","Gynecologic oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1026,"EID1026","The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in patients with acute myeloid leukemia.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",431,4,NULL,"rejected",0,"evidence",712,"Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.","Estey, 2012, Am. J. Hematol.",22180162,"http://www.ncbi.nlm.nih.gov/pubmed/22180162",NULL,NULL,"2012","1",NULL,"Am. J. Hematol.","American journal of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1027,"EID1027","The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",431,4,NULL,"accepted",0,"evidence",712,"Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.","Estey, 2012, Am. J. Hematol.",22180162,"http://www.ncbi.nlm.nih.gov/pubmed/22180162",NULL,NULL,"2012","1",NULL,"Am. J. Hematol.","American journal of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1028,"EID1028","TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098). Of 20 patients studied, 5 had coding mutation in TP53. Four of the 5 patients with a TP53 mutation had metastases at diagnosis or detected soon thereafter, and 3 of 4 died of disease within 12 months of surgical resection.",154,"Adrenocortical Carcinoma","Adrenocortical Carcinoma",3948,"http://www.disease-ontology.org/?id=DOID:3948","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,2,NULL,"accepted",0,"evidence",723,"Mutation and methylation analysis of TP53 in adrenal carcinogenesis.","Sidhu et al., 2005, Eur J Surg Oncol",15922892,"http://www.ncbi.nlm.nih.gov/pubmed/15922892",NULL,NULL,"2005","6",NULL,"Eur J Surg Oncol","European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1029,"EID1029","The MLL-MLLT3 translocation, along with other MLL translocations, are so common in acute myeloid leukemia that the World Health Organization has developed a sub-type of \"AML with t(9;11)(p22;q23); MLLT3-MLL\" under the AML with recurrent genetic abnormalities diagnosis.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","A","Diagnostic","Supports","Positive","Somatic Mutation",432,4,NULL,"accepted",0,"evidence",19,"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","Vardiman et al., 2009, Blood",19357394,"http://www.ncbi.nlm.nih.gov/pubmed/19357394",NULL,NULL,"2009","7","30","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1030,"EID1030","In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement. On crizotinib, 24 of the patients achieved objective responses including 5 complete responses. Median progression free survival was 9.1 months and all patients had  been pretreated with 1 or more lines of chemotherapy.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",269,3,NULL,"accepted",0,"evidence",715,"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.","MaziÃ¨res et al., 2015, J. Clin. Oncol.",25667280,"http://www.ncbi.nlm.nih.gov/pubmed/25667280",NULL,NULL,"2015","3","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1031,"EID1031","The HIF1A rs2057482 SNP was genotyped in 410 pancreatic ductal adenocarcinoma cases and 490 healthy controls. The CC genotype was significantly correlated with PDAC risk (OR = 1.719, 95% CI: 1.293-2.286) and shorter overall survival (OS, P<0.0001), compared with the CT/TT alleles Group. After multivariate Analysis, CC-HIF1A and HIF-1Î± expression were still significantly associated with OS (P<0.0001). 
This SNP is expected to reduce MiR-199a induced repression of HIF-1Î± Expression.",158,"Pancreas Adenocarcinoma","Pancreas Adenocarcinoma",4074,"http://www.disease-ontology.org/?id=DOID:4074","B","Prognostic","Supports","Poor Outcome","Germline Polymorphism",433,2,NULL,"accepted",0,"evidence",716,"Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.","Wang et al., 2016, Oncotarget",26872370,"http://www.ncbi.nlm.nih.gov/pubmed/26872370","true","PMC4924673","2016","3","22","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1032,"EID1032","HIF1A overexpression was assessed by IHC in 731 colorectal cancers from two prospective cohort studies. 142 (19%) tumors showed HIF1A overexpression. Overexpression of HIF1A was associated with higher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univariate Cox regression (hazard ratio = 1.84; 95% confidence interval, 1.37 to 2.47; P < 0.0001) and multivariate analysis (adjusted hazard ratio = 1.72; 95% confidence interval, 1.26 to 2.36; P = 0.0007, adjusted for clinical and tumoral features: microsatellite instability, TP53 (p53), PTGS2 (cyclooxygenase-2), CpG island methylator phenotype, and KRAS, BRAF, PIK3CA, and LINE-1 methylation).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","N/A",434,3,NULL,"accepted",0,"evidence",717,"HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.","Baba et al., 2010, Am. J. Pathol.",20363910,"http://www.ncbi.nlm.nih.gov/pubmed/20363910","true","PMC2861094","2010","5",NULL,"Am. J. Pathol.","The American journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1033,"EID1033","Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies. EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not significantly associated with patient survival.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Does Not Support","Poor Outcome","N/A",435,3,NULL,"accepted",0,"evidence",717,"HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.","Baba et al., 2010, Am. J. Pathol.",20363910,"http://www.ncbi.nlm.nih.gov/pubmed/20363910","true","PMC2861094","2010","5",NULL,"Am. J. Pathol.","The American journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1034,"EID1034","Expression of HIF1A was analyzed by IHC in 49 soft-tissue sarcomas (29 malignant fibrous histiocytomas, 12 synovial sarcomas, 4 leiomyosarcomas and 4 malignant peripheral nerve sheath tumors). High (18.4%) or moderate (35.4%) expression of HIF-1alpha was significatnly associated with shorter overall survival rate in comparison with those with a weak or negative expression in univariate analysis (P = 0.029; log-rank test) and multivariate analysis (P = 0.018).",105,"Sarcoma","Sarcoma",1115,"http://www.disease-ontology.org/?id=DOID:1115","B","Prognostic","Supports","Poor Outcome","N/A",434,2,NULL,"accepted",0,"evidence",718,"Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas.","Shintani et al., 2006, Virchows Arch.",17103226,"http://www.ncbi.nlm.nih.gov/pubmed/17103226",NULL,NULL,"2006","12",NULL,"Virchows Arch.","Virchows Archiv : an international journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1035,"EID1035","Preclinical studies linking the efficacy of mTOR inhibitor CCI-779 to VHL loss in vitro and in mouse models of kidney cancer. VHL-deficient tumors were more sensitive to mTOR inhibition than VHL-proficient tumors. Growth arrest caused by CCI-779 correlated with a block in translation of HIF1A mRNA. Expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region rescued tumor growth.",161,"Renal Carcinoma","Renal Carcinoma",4451,"http://www.disease-ontology.org/?id=DOID:4451","D","Predictive","Supports","Sensitivity","Somatic Mutation",436,3,NULL,"accepted",0,"evidence",719,"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.","Thomas et al., 2006, Nat. Med.",16341243,"http://www.ncbi.nlm.nih.gov/pubmed/16341243",NULL,NULL,"2006","1",NULL,"Nat. Med.","Nature medicine","fully curated","83","Temsirolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1036,"EID1036","An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib. Mutations at 3 AL residues (D835 [n = 31], D839 [n = 3], and Y842 [n = 16]), with varying degrees of resistance to ponatinib were identified. FLT3 D835 mutations were shown to confer resistance to the tyrosine kinase inhibitor AC220 and ponatinib. 
This was especially found for D835Y and D835V mutations, whereas D835H mutations were found to confer moderate resistance to ponatinib but relatively minimal resistance to AC220.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",437,3,"Substitutes","accepted",0,"evidence",720,"Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.","Smith et al., 2013, Blood",23430109,"http://www.ncbi.nlm.nih.gov/pubmed/23430109","true","PMC3630831","2013","4","18","Blood","Blood","fully curated","55","Ponatinib",NULL,"266","Quizartinib (AC220)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1037,"EID1037","An in-vitro cell-based screening approach generated FLT3-ITD-expressing cell lines resistant to the FLT3 inhibitors SU5614, PKC412, and sorafenib. SU5614 resistance mutations were limited to exchanges in the second part of the kinase domain (TK2), with exchanges of D835 predominating (D835E were most common). In clones that emerged at 1,500 nmol/L SU5614 after ENU (mutagen) treatment, 127 of 179 clones (71%) displayed mutations, generating 9 different exchanges affecting 6 positions in the activation loop of FLT3.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",437,3,NULL,"accepted",0,"evidence",721,"FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.","von Bubnoff et al., 2009, Cancer Res.",19318574,"http://www.ncbi.nlm.nih.gov/pubmed/19318574",NULL,NULL,"2009","4","1","Cancer Res.","Cancer research","fully curated","35","SU5614",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1038,"EID1038","In an in-vitro study using an in vitro saturation mutagenesis assay, 4 residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. Mutations at three of these amino acid positions conferred high degrees of in vitro AC220 resistance (based on proliferation and cell-based biochemical assays). Among these residues, two within the activation loop were found (D835, Y842). 
Pre-treatment and relapse samples of 8 patients (treated with AC220) with FLT3-ITD+ acute myeloid leukemia were analyzed. The activation loop mutation D835Y was detected in three cases, D835V in two, and D835F was identified in a single patient. Cross-resistance to sorafenib was identified in-vitro.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",437,4,"Substitutes","accepted",0,"evidence",722,"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.","Smith et al., 2012, Nature",22504184,"http://www.ncbi.nlm.nih.gov/pubmed/22504184","true","PMC3390926","2012","5","10","Nature","Nature","fully curated","266","Quizartinib (AC220)",NULL,"6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1039,"EID1039","13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients responded, but sorafenib response was lost in most patients after 72 (range 54-287) days. Leukemia initiating cells bearing the D835 mutation expanded during sorafenib treatment and dominated during the subsequent clinical resistance. Results were recapitulated in-vivo.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",437,4,NULL,"accepted",0,"evidence",172,"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.","Man et al., 2012, Blood",22368270,"http://www.ncbi.nlm.nih.gov/pubmed/22368270",NULL,NULL,"2012","5","31","Blood","Blood","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1040,"EID1040","13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation of leukemia cells. Sorafenib response was lost in most patients after 72 (range 54-287) days.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",55,2,NULL,"accepted",0,"evidence",172,"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.","Man et al., 2012, Blood",22368270,"http://www.ncbi.nlm.nih.gov/pubmed/22368270",NULL,NULL,"2012","5","31","Blood","Blood","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1041,"EID1041","In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.  HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.  Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.  Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC. The authors conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",306,2,NULL,"accepted",0,"evidence",724,"Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.","Gatzemeier et al., 2004, Ann. Oncol.",14679114,"http://www.ncbi.nlm.nih.gov/pubmed/14679114",NULL,NULL,"2004","1",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1042,"EID1042","In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.  there was one partial response in the docetaxel group and none in the trastuzumab group.  The authors report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.  This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",725,"Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.","Lara et al., 2004, Clin Lung Cancer",14967075,"http://www.ncbi.nlm.nih.gov/pubmed/14967075",NULL,NULL,"2004","1",NULL,"Clin Lung Cancer","Clinical lung cancer","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1043,"EID1043","This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment.  All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions.  In patients (n=57) that had been treated with trastuzumab plus chemotherapy, an overall response rate of 75% and progression free survival of 5.1 months were observed.  No standard of care currently exists for HER2-mutant NSCLC.  While trastuzumab has not shown clear benefit yet in wild-type HER2 overexpressed NSCLC, the authors conclude that further prospective studies should be done with trastuzumab plus chemotherapy in advanced HER2 mutant NSCLC, and that trastuzumab plus chemotherapy should be considered in current treatment courses of this cancer type.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",413,4,NULL,"accepted",0,"evidence",726,"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.","MaziÃ¨res et al., 2016, Ann. Oncol.",26598547,"http://www.ncbi.nlm.nih.gov/pubmed/26598547",NULL,NULL,"2016","2",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1044,"EID1044","This report details 2 case studies in relapsed HER2 positive SCLC.  In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.  With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.  Case 2 involved a 68 year old never-smoker with relapsed SCLC.  Tumor showed HER2 positive SCLC cells with no amplification or mutation.  Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.  While the efficacy of trastuzumab against NSCLC with elevated levels of wild-type HER2 expression remains unclear, the authors conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC.",174,"Lung Small Cell Carcinoma","Lung Small Cell Carcinoma",5409,"http://www.disease-ontology.org/?id=DOID:5409","C","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,"Combination","accepted",0,"evidence",727,"Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.","Kinehara et al., 2015, Lung Cancer",25601188,"http://www.ncbi.nlm.nih.gov/pubmed/25601188",NULL,NULL,"2015","3",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","101","Irinotecan",NULL,"84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1045,"EID1045","A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion.  Afatinib monotherapy resulted in resolution of symptoms and 10 months before progressive disease.  The patient was subsequently given trastuzumab with no response.  The observed efficacy of afatinib against M774insAYVM, and studies reporting afatinib activity against other variants in the HER2 kinase domain, are cited by the authors as motivation for the arm of NCI-MATCH focusing on afatinib and activating HER2 mutations.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",414,4,NULL,"accepted",0,"evidence",728,"HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.","Li et al., 2015, Lung Cancer",26559459,"http://www.ncbi.nlm.nih.gov/pubmed/26559459","true","PMC4724317","2015","12",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1046,"EID1046","In mice, human HER2 with YVMA insertion was placed under a doxycycline-inducible, clara cell specific promoter. Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung tumors, where tumor maintenance was dependent on continued mutant HER2 induction by doxycycline.  It was found that treating these mice with afatinib and rapamycin had stronger effects than either treatment alone, including greater tumor regression and increased tumor necrosis.  The authors cite findings that HER2 activity in cancer may be highly dependent on its Akt/mTOR signaling arm as a possible explanation for this effect, and conclude that their results give rationale for testing of afatinib/rapamycin treatment in lung cancer.",152,"Lung Carcinoma","Lung Carcinoma",3905,"http://www.disease-ontology.org/?id=DOID:3905","D","Predictive","Supports","Sensitivity","Somatic Mutation",414,4,"Combination","accepted",0,"evidence",662,"HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.","Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",19122144,"http://www.ncbi.nlm.nih.gov/pubmed/19122144","true","PMC2626727","2009","1","13","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","146","Afatinib",NULL,"352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1047,"EID1047","Human HER2 with YVMA insertion was put under a clara cell specific, rtTA promoter system inducible via doxycycline.  Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung tumors, where tumor maintenance was dependent on continued YMVA HER2 induction by doxycycline.  Administration of afatinib had a stronger effect than erlotinib or trastuzumab, as measured by histology and tumor volume regression.  Authors state that in the case of afatinib vs. trastuzumab, intracellular HER2 signaling may be blocked by afatanib but remain unaltered by trastuzumab.",152,"Lung Carcinoma","Lung Carcinoma",3905,"http://www.disease-ontology.org/?id=DOID:3905","D","Predictive","Supports","Sensitivity","Somatic Mutation",414,4,NULL,"accepted",0,"evidence",662,"HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.","Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",19122144,"http://www.ncbi.nlm.nih.gov/pubmed/19122144","true","PMC2626727","2009","1","13","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1048,"EID1048","In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration between 3 and 14 months, while 13 patients with the more common HER2 p. A775_G776insYVMA showed no partial responses.  The authors conclude that in the set of activating HER2 mutations, benefits of an individual agent may be specific to certain mutations, and that \"HER2-positive lung cancers\" is not an adequate term to describe this group of distinguishable illnesses.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",41,3,NULL,"accepted",0,"evidence",729,"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.","Kris et al., 2015, Ann. Oncol.",25899785,"http://www.ncbi.nlm.nih.gov/pubmed/25899785",NULL,NULL,"2015","7",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","44","Dacomitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1049,"EID1049","In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, a cohort of 12 cases with the AYVM insertion did not show any partial responses to dacomitinib, in contrast to a 50% PR rate in P780_Y781insGSP patients in this same study.  The authors conclude that in the set of activating HER2 mutations, benefits of an individual agent may be specific to certain mutations, and that \"HER2-positive lung cancers\" is not an adequate term to describe this group of distinguishable illnesses.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Does Not Support","Sensitivity","Somatic Mutation",414,3,NULL,"accepted",0,"evidence",729,"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.","Kris et al., 2015, Ann. Oncol.",25899785,"http://www.ncbi.nlm.nih.gov/pubmed/25899785",NULL,NULL,"2015","7",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","44","Dacomitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1050,"EID1050","Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.  In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).  Trastuzumab did not show notable effects on cell growth in any tested cells.  HER2 positivity in NSCLC is fairly common at 2-20%.  A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",730,"Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.","Cretella et al., 2014, Mol. Cancer",24898067,"http://www.ncbi.nlm.nih.gov/pubmed/24898067","true","PMC4058446","2014",NULL,NULL,"Mol. Cancer","Molecular cancer","fully curated","293","Trastuzumab Emtansine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1051,"EID1051","Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched in good and poor prognosis subtypes, respectively. Of these genes, upregulation of proteasome subunit beta type 8 PSMB8 and PDZ binding kinase PBK was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival durations of the (-), (+), and (++) groups, classified according to nuclear PSMB8 expression, were 77.2, 70.6, and 62.2 months, respectively; P = 0.004). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate Analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively).",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Prognostic","Supports","Poor Outcome","N/A",438,2,NULL,"accepted",0,"evidence",731,"PSMB8 and PBK as potential gastric cancer subtype-specific biomarkers associated with prognosis.","Kwon et al., 2016, Oncotarget",26894977,"http://www.ncbi.nlm.nih.gov/pubmed/26894977",NULL,NULL,"2016","4","19","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1052,"EID1052","Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8 (PSMB8) and PDZ binding kinase (PBK) was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival duration, months according to nuclear PBK Expression: -, 72.3 Â± 1.2; +, 66.2 Â± 3.4; ++, 53.1 Â± 9.2; P = 0.002). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively).",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Prognostic","Supports","Poor Outcome","N/A",439,2,NULL,"accepted",0,"evidence",731,"PSMB8 and PBK as potential gastric cancer subtype-specific biomarkers associated with prognosis.","Kwon et al., 2016, Oncotarget",26894977,"http://www.ncbi.nlm.nih.gov/pubmed/26894977",NULL,NULL,"2016","4","19","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1053,"EID1053","144 cases (discovery set: N=62 discovery; independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing, or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest progression free survival was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results at the protein level.",144,"Meningioma","Meningioma",3565,"http://www.disease-ontology.org/?id=DOID:3565","B","Prognostic","Supports","Poor Outcome","N/A",440,2,NULL,"accepted",0,"evidence",732,"Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.","Schmidt et al., 2016, Oncotarget",26894859,"http://www.ncbi.nlm.nih.gov/pubmed/26894859","true","PMC4924735","2016","3","22","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1054,"EID1054","144 cases (discovery set: N=62 discovery; Independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest PFS was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results on protein level.",144,"Meningioma","Meningioma",3565,"http://www.disease-ontology.org/?id=DOID:3565","B","Prognostic","Supports","Poor Outcome","N/A",441,2,NULL,"accepted",0,"evidence",732,"Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.","Schmidt et al., 2016, Oncotarget",26894859,"http://www.ncbi.nlm.nih.gov/pubmed/26894859","true","PMC4924735","2016","3","22","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1055,"EID1055","Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoters (3-methylcholanthrene or control, butylated hydroxytoluene) was assessed in mice lacking Ereg (Ereg-/-) and wildtype controls (BALB/ByJ; Ereg+/+) at multiple time points and endpoints (bronchoalveolar lavage analysis, tumor analysis, mRNA expression, ELISA, wound assay). Initially a significantly reduced amount of inflammation (macrophages, PMNs) was observed in the Ereg-/- mice. At 20â€‰wk, tumor multiplicity was also significantly decreased in the Ereg-/- mice.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","E","Prognostic","Supports","Poor Outcome","N/A",318,2,NULL,"accepted",0,"evidence",733,"Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.","Bauer et al., 2016, Mol. Carcinog.",26894620,"http://www.ncbi.nlm.nih.gov/pubmed/26894620",NULL,NULL,"2016","2","19","Mol. Carcinog.","Molecular carcinogenesis","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1056,"EID1056","In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines.
In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines. Analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 Treatment. An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab. Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",442,3,NULL,"rejected",0,"evidence",746,"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.","SÃ¡nchez-MartÃ­n et al., 2016, Clin. Cancer Res.",26888827,"http://www.ncbi.nlm.nih.gov/pubmed/26888827",NULL,NULL,"2016","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","273","Sym004",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1057,"EID1057","An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Supports","Sensitivity","Somatic Mutation",443,4,NULL,"accepted",0,"evidence",746,"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.","SÃ¡nchez-MartÃ­n et al., 2016, Clin. Cancer Res.",26888827,"http://www.ncbi.nlm.nih.gov/pubmed/26888827",NULL,NULL,"2016","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","273","Sym004",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1058,"EID1058","An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. Sym004 is a 1:1 mixture
of two non-overlapping anti-EGFR monoclonal antibodies. In vitro analysis in the murine fibroblast cell line NIH3T3 with ectopic expression of EGFR mutations S492R, R451C, K467T, and G465R showed that Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines.
G465R mutant cell lines were resistant to treatment with panitumumab or cetuximab in-vitro.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",443,4,"Substitutes","accepted",0,"evidence",746,"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.","SÃ¡nchez-MartÃ­n et al., 2016, Clin. Cancer Res.",26888827,"http://www.ncbi.nlm.nih.gov/pubmed/26888827",NULL,NULL,"2016","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","28","Panitumumab",NULL,"16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1059,"EID1059","IHC was performed in 123 hepatocellular carcinoma tissues and their adjacent normal liver tissues for protein expression of HEF1 (NEDD9). Overexpression of HEF1 protein was observed in HCC tissue when compared with their adjacent non-malignant liver tissue. High expression of HEF1 correlated with higher advanced tumor, node, metastasis (TNM) stage and vascular invasion (P<0.05). In univariate and multivariate analysis, the expression of HEF1 was identified as an independent prognostic factor (Spearman's rank correlation, Kaplan-Meier plots and Cox regression model). In subgroup analysis, high expression of HEF1 correlated with a poorer prognosis in advanced (TNM III+IV) stages (P<0.05).",196,"Hepatocellular Carcinoma","Hepatocellular Carcinoma",684,"http://www.disease-ontology.org/?id=DOID:684","B","Prognostic","Supports","Poor Outcome","N/A",444,3,NULL,"accepted",0,"evidence",734,"High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.","Li et al., 2016, Mol Clin Oncol",26893853,"http://www.ncbi.nlm.nih.gov/pubmed/26893853","true","PMC4733949","2016","2",NULL,"Mol Clin Oncol","Molecular and clinical oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1060,"EID1060","Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advanced NSCLC patients using a sequenom mass spectrometry-based genotype assay. 16 SNPs were significantly associated with the clinical outcomes after chemotherapy with paclitaxel-cisplatin: ETS2 SNP: OR = 1.34, 95% CI = 1.00â€“1.81, P = 0.05; aHR = 0.80, 95% CI = 0.69â€“0.94, P = 0.006, under additive model. ETS2 rs461155A>G was significantly associated with decreased ETS2 mRNA expression in both tumor and paired normal lung tissues (Ptrend = 4 Ã— 10-7, and 3 Ã— 10-4, respectively).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Germline Polymorphism",445,2,"Combination","accepted",0,"evidence",735,"A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.","Hong et al., 2016, Oncotarget",26893365,"http://www.ncbi.nlm.nih.gov/pubmed/26893365","true","PMC4941289","2016","3","29","Oncotarget","Oncotarget","fully curated","326","Cisplatin",NULL,"81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1061,"EID1061","Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (CK18) as downregulated in DU145-TxR cells (validated at mRNA, NMP and total cellular protein levels). An in-vivo assay of xenograft transplantation showed higher tumorigenicity of DU145-TxR cells. Immunohistochemistry showed that CK18 expression in PCa tissues was statistically significant inversely correlated with tumor grade.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Prognostic","Supports","Poor Outcome","N/A",446,2,NULL,"accepted",0,"evidence",736,"Downregulation of cytokeratin 18 is associated with paclitaxelâ€‘resistance and tumor aggressiveness in prostate cancer.","Yin et al., 2016, Int. J. Oncol.",26892177,"http://www.ncbi.nlm.nih.gov/pubmed/26892177",NULL,NULL,"2016","4",NULL,"Int. J. Oncol.","International journal of oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1062,"EID1062","243 primary PCa, 37 metastatic PCa, and 
20  castration-resistant  PCa  (CRPC) specimens underwent IHC and microarray analysis. Immunohistochemistry (IHC) showed that FGF13 was detectable in the majority of human PCa samples, and FGF13 IHC scores were higher in high-grade prostatic intraepithelial neoplasia, in primary PCa, and in metastatic PCa than in benign prostatic tissue. There was a significant association between high cytoplasmic FGF13 staining and a risk of biochemical recurrence (BCR) after radical prostatectomy. Multivariate regression analysis indicated that high cytoplasmic FGF13 staining was associated with BCR. Results were recapitulated in cell lines and public databases.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Prognostic","Supports","Poor Outcome","N/A",447,3,NULL,"accepted",0,"evidence",737,"Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.","Yu et al., 2016, Int. J. Cancer",26891277,"http://www.ncbi.nlm.nih.gov/pubmed/26891277",NULL,NULL,"2016","7","1","Int. J. Cancer","International journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1063,"EID1063","A t(X;18) translocation resulting in the fusion SYT-SSX (SS18-SSX1 or SS18-SSX2) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. The prevalence of this fusion in synovial sarcoma approaches 100% when there is adequate tumor RNA for RT-PCR. Its specificity for synovial sarcoma, has been confirmed by molecular screening of other morphologically similar sarcomas.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","A","Diagnostic","Supports","Positive","Somatic Mutation",448,4,NULL,"accepted",0,"evidence",738,"Fusions of the SYT and SSX genes in synovial sarcoma.","Ladanyi, 2001, Oncogene",11607825,"http://www.ncbi.nlm.nih.gov/pubmed/11607825",NULL,NULL,"2001","9","10","Oncogene","Oncogene","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1064,"EID1064","A t(X;18) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. This translocation results primarily in two fusions. SYT-SSX1 (aka SS18-SSX1) and SYT-SSX2 (aka SS18-SSX2). The ratio of SYT-SSX1 to SYT-SSX2 cases is close to 2:1.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","A","Diagnostic","Supports","Positive","Somatic Mutation",449,4,NULL,"accepted",0,"evidence",738,"Fusions of the SYT and SSX genes in synovial sarcoma.","Ladanyi, 2001, Oncogene",11607825,"http://www.ncbi.nlm.nih.gov/pubmed/11607825",NULL,NULL,"2001","9","10","Oncogene","Oncogene","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1065,"EID1065","A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as SSX (especially SSX1, and SSX2). In this study, 45 synovial sarcomas were assayed for SYT-SSX by RT-PCR using tumor cDNA as template. 29 (64%) had a SYTâ€“SSX1 (SS18-SSX1) fusion transcript.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","B","Diagnostic","Supports","Positive","Somatic Mutation",448,3,NULL,"accepted",0,"evidence",739,"SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.","Kawai et al., 1998, N. Engl. J. Med.",9428816,"http://www.ncbi.nlm.nih.gov/pubmed/9428816",NULL,NULL,"1998","1","15","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1066,"EID1066","A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as SSX (especially SSX1, and SSX2). In this study, 45 synovial sarcomas were assayed for SYT-SSX by RT-PCR using tumor cDNA as template. 16 (36%) contained a SYTâ€“SSX2 (SS18-SSX2) fusion transcript.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","B","Diagnostic","Supports","Positive","Somatic Mutation",449,3,NULL,"accepted",0,"evidence",739,"SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.","Kawai et al., 1998, N. Engl. J. Med.",9428816,"http://www.ncbi.nlm.nih.gov/pubmed/9428816",NULL,NULL,"1998","1","15","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1067,"EID1067","In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0).",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","B","Prognostic","Supports","Better Outcome","Somatic Mutation",449,3,NULL,"accepted",0,"evidence",739,"SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.","Kawai et al., 1998, N. Engl. J. Med.",9428816,"http://www.ncbi.nlm.nih.gov/pubmed/9428816",NULL,NULL,"1998","1","15","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1068,"EID1068","In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0).",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",448,3,NULL,"accepted",0,"evidence",739,"SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.","Kawai et al., 1998, N. Engl. J. Med.",9428816,"http://www.ncbi.nlm.nih.gov/pubmed/9428816",NULL,NULL,"1998","1","15","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1069,"EID1069","In this review, the author summarize the role of this fusion in diagnosis of synovial sarcomas. Cytogenetic studies have repeatedly demonstrated the t(X;18)(p11;q11) translocation in approximately 90% of both monophasic and biphasic synovial sarcomas. The fusion has clear diagnostic value, though the authors caution that it is not perfectly specific to synovial sarcomas, and suggest that demonstration of t(X;18) in a spindle cell neoplasm should be integrated with the morphology, immunoprofile, and clinical setting of the tumour.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","B","Diagnostic","Supports","Positive","Somatic Mutation",448,4,NULL,"accepted",0,"evidence",740,"Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics?","Pfeifer et al., 2000, Histopathology",11122430,"http://www.ncbi.nlm.nih.gov/pubmed/11122430",NULL,NULL,"2000","12",NULL,"Histopathology","Histopathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1070,"EID1070","In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 85% of the synovial sarcomas were positive for this event. The study did not indicate the specific fusion detected but from related studies we know that the majority of these fusions are SYT-SSX1 (aka SS18-SSX1).",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","B","Diagnostic","Supports","Positive","Somatic Mutation",448,4,NULL,"accepted",0,"evidence",741,"Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study.","O'Sullivan et al., 2000, Mod. Pathol.",11144931,"http://www.ncbi.nlm.nih.gov/pubmed/11144931",NULL,NULL,"2000","12",NULL,"Mod. Pathol.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1071,"EID1071","In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 75% of the malignant peripheral nerve sheath tumors (MPNSTs) were positive for this event. The study did not indicate the specific fusion detected but from related studies we know that the majority of these fusions are SYT-SSX1 (aka SS18-SSX1).",326,"Malignant Peripheral Nerve Sheath Tumor","Malignant Peripheral Nerve Sheath Tumor",5940,"http://www.disease-ontology.org/?id=DOID:5940","B","Diagnostic","Supports","Positive","Somatic Mutation",448,3,NULL,"accepted",0,"evidence",741,"Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study.","O'Sullivan et al., 2000, Mod. Pathol.",11144931,"http://www.ncbi.nlm.nih.gov/pubmed/11144931",NULL,NULL,"2000","12",NULL,"Mod. Pathol.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1072,"EID1072","This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-SSX2 fusions were detected in 147 tumors (61%) and 91 tumors (37%), respectively. Histologically, 61 (25%) were classified as biphasic type and 180 (74%) as monophasic type based on the presence or absence of areas of glandular epithelial differentiation, respectively. Median and 5-year overall survivals for the SYT-SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7 years and 73%, respectively.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",448,4,NULL,"accepted",0,"evidence",742,"Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.","Ladanyi et al., 2002, Cancer Res.",11782370,"http://www.ncbi.nlm.nih.gov/pubmed/11782370",NULL,NULL,"2002","1","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1073,"EID1073","This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-SSX2 fusions were detected in 147 tumors (61%) and 91 tumors (37%), respectively. Histologically, 61 (25%) were classified as biphasic type and 180 (74%) as monophasic type based on the presence or absence of areas of glandular epithelial differentiation, respectively. Median and 5-year overall survivals for the SYT-SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7 years and 73%, respectively.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","B","Prognostic","Supports","Better Outcome","Somatic Mutation",449,3,NULL,"accepted",0,"evidence",742,"Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.","Ladanyi et al., 2002, Cancer Res.",11782370,"http://www.ncbi.nlm.nih.gov/pubmed/11782370",NULL,NULL,"2002","1","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1074,"EID1074","Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterized by SS18-SSX1 or SS18-SSX2, but other rare events such as this SS18-SSX4 may explain some or all of the synovial sarcomas that are negative for the most common fusions.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","C","Diagnostic","Supports","Positive","Somatic Mutation",450,2,NULL,"accepted",0,"evidence",743,"A novel fusion gene, SYT-SSX4, in synovial sarcoma.","Skytting et al., 1999, J. Natl. Cancer Inst.",10359553,"http://www.ncbi.nlm.nih.gov/pubmed/10359553",NULL,NULL,"1999","6","2","J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1075,"EID1075","A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 G2677T carriers had a longer progression-free survival (p = 0.037) along with a tendency toward a longer overall survival (p = 0.057).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Better Outcome","Germline Polymorphism",451,3,NULL,"accepted",0,"evidence",744,"ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.","Kim et al., 2012, Oncology",22906996,"http://www.ncbi.nlm.nih.gov/pubmed/22906996",NULL,NULL,"2012",NULL,NULL,"Oncology","Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1076,"EID1076","A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along with a tendency toward a longer overall survival (p = 0.093).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Better Outcome","Germline Polymorphism",263,3,NULL,"accepted",0,"evidence",744,"ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.","Kim et al., 2012, Oncology",22906996,"http://www.ncbi.nlm.nih.gov/pubmed/22906996",NULL,NULL,"2012",NULL,NULL,"Oncology","Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1077,"EID1077","CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.  Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.  The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.  Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.  Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.  These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,5,"Combination","accepted",0,"evidence",745,"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.","Swain et al., 2015, N. Engl. J. Med.",25693012,"http://www.ncbi.nlm.nih.gov/pubmed/25693012",NULL,NULL,"2015","2","19","N. Engl. J. Med.","The New England journal of medicine","fully curated","73","Docetaxel",NULL,"84","Trastuzumab",NULL,"247","Pertuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1078,"EID1078","Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed. The S492R mutation was identified in two persons. One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Supports","Sensitivity","Somatic Mutation",453,2,NULL,"accepted",0,"evidence",472,"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.","Montagut et al., 2012, Nat. Med.",22270724,"http://www.ncbi.nlm.nih.gov/pubmed/22270724",NULL,NULL,"2012","2",NULL,"Nat. Med.","Nature medicine","fully curated","28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1079,"EID1079","In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",453,4,"Substitutes","accepted",0,"evidence",746,"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.","SÃ¡nchez-MartÃ­n et al., 2016, Clin. Cancer Res.",26888827,"http://www.ncbi.nlm.nih.gov/pubmed/26888827",NULL,NULL,"2016","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","273","Sym004",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1080,"EID1080","In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",453,4,NULL,"accepted",0,"evidence",746,"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.","SÃ¡nchez-MartÃ­n et al., 2016, Clin. Cancer Res.",26888827,"http://www.ncbi.nlm.nih.gov/pubmed/26888827",NULL,NULL,"2016","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1081,"EID1081","In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetuximab and panitumumab treatment and inhibition of EGFR phosphorylation.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",454,2,"Substitutes","accepted",0,"evidence",746,"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.","SÃ¡nchez-MartÃ­n et al., 2016, Clin. Cancer Res.",26888827,"http://www.ncbi.nlm.nih.gov/pubmed/26888827",NULL,NULL,"2016","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","16","Cetuximab",NULL,"273","Sym004",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1082,"EID1082","In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",455,3,"Substitutes","accepted",0,"evidence",746,"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.","Sanchez-Marti­n et al., 2016, Clin. Cancer Res.",26888827,"http://www.ncbi.nlm.nih.gov/pubmed/26888827",NULL,NULL,"2016","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","273","Sym004",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1083,"EID1083","In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",455,3,NULL,"accepted",0,"evidence",746,"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.","Sanchez-Martin et al., 2016, Clin. Cancer Res.",26888827,"http://www.ncbi.nlm.nih.gov/pubmed/26888827",NULL,NULL,"2016","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1084,"EID1084","A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR2A H131R carriers did not have a significantly different response rate, progression-free survival, or overall survival.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Does Not Support","N/A","Germline Polymorphism",456,3,NULL,"accepted",0,"evidence",744,"ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.","Kim et al., 2012, Oncology",22906996,"http://www.ncbi.nlm.nih.gov/pubmed/22906996",NULL,NULL,"2012",NULL,NULL,"Oncology","Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1085,"EID1085","A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR3A V158F carriers did not have a significantly different response rate, progression-free survival, or overall survival.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Does Not Support","N/A","Germline Polymorphism",457,3,NULL,"accepted",0,"evidence",744,"ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.","Kim et al., 2012, Oncology",22906996,"http://www.ncbi.nlm.nih.gov/pubmed/22906996",NULL,NULL,"2012",NULL,NULL,"Oncology","Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1086,"EID1086","1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was a difference in disease-free survival for FCGR2B I232T, with I/I patients deriving benefit from trastuzumab (p<0.001) compared to the T carriers who did not (p=0.81). The interaction between FCGR2B genotype and treatment was statistically significant (p=0.03).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","Germline Polymorphism",458,4,NULL,"accepted",0,"evidence",747,"Association studies of FcÎ³ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.","Norton et al., 2014, Cancer Immunol Res",24989892,"http://www.ncbi.nlm.nih.gov/pubmed/24989892","true","PMC4215796","2014","10",NULL,"Cancer Immunol Res","Cancer immunology research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1087,"EID1087","1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survival between trastuzumab-treated patients who had the FCGR3A 158 V/V high-affinity genotype and patients without that genotype (V/F and F/F).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Does Not Support","N/A","Germline Polymorphism",457,4,NULL,"accepted",0,"evidence",747,"Association studies of FcÎ³ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.","Norton et al., 2014, Cancer Immunol Res",24989892,"http://www.ncbi.nlm.nih.gov/pubmed/24989892","true","PMC4215796","2014","10",NULL,"Cancer Immunol Res","Cancer immunology research","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1088,"EID1088","1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Does Not Support","N/A","Germline Polymorphism",456,4,NULL,"accepted",0,"evidence",747,"Association studies of FcÎ³ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.","Norton et al., 2014, Cancer Immunol Res",24989892,"http://www.ncbi.nlm.nih.gov/pubmed/24989892","true","PMC4215796","2014","10",NULL,"Cancer Immunol Res","Cancer immunology research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1089,"EID1089","72-year old male patient presents with SCC with a mutation profile consistent with UV exposure. Sequencing revealed a number of abnormalities including P753S mutation in EGFR. Patient began therapy with cetuximab and sirolimus and continued for 9 months. Disease burden was not measurable by Response Evaluation Criteria in Solid Tumors.",130,"Skin Squamous Cell Carcinoma","Skin Squamous Cell Carcinoma",3151,"http://www.disease-ontology.org/?id=DOID:3151","C","Predictive","Supports","Sensitivity","Somatic Mutation",460,3,"Combination","accepted",0,"evidence",748,"Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.","Ganesan et al., 2016, J. Clin. Oncol.",24934779,"http://www.ncbi.nlm.nih.gov/pubmed/24934779",NULL,NULL,"2016","2","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","16","Cetuximab",NULL,"352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1090,"EID1090","The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML.",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","A","Diagnostic","Supports","Positive","Somatic Mutation",108,5,NULL,"accepted",0,"evidence",749,"The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.","Diverio et al., Haematologica",7628753,"http://www.ncbi.nlm.nih.gov/pubmed/7628753",NULL,NULL,NULL,NULL,NULL,"Haematologica","Haematologica","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1091,"EID1091","ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","A","Predictive","Supports","Sensitivity","Somatic Mutation",108,5,"Combination","accepted",0,"evidence",750,"All trans retinoic acid in acute promyelocytic leukemia.","Degos et al., 2001, Oncogene",11704842,"http://www.ncbi.nlm.nih.gov/pubmed/11704842",NULL,NULL,"2001","10","29","Oncogene","Oncogene","fully curated","265","All-trans Retinoic Acid",NULL,"47","Arsenic Trioxide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1092,"EID1092","Mutations in the B2 domain of PML in the PML-RARa fusion have been shown to be associated with resistance to standard ATRA treatment in patients with acute promyelocytic leukemia.",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",461,4,NULL,"accepted",0,"evidence",751,"Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.","Tomita et al., 2013, Int. J. Hematol.",23670176,"http://www.ncbi.nlm.nih.gov/pubmed/23670176",NULL,NULL,"2013","6",NULL,"Int. J. Hematol.","International journal of hematology","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1093,"EID1093","The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia.",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",462,4,NULL,"accepted",0,"evidence",752,"Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.","Goto et al., 2011, Blood",21613260,"http://www.ncbi.nlm.nih.gov/pubmed/21613260",NULL,NULL,"2011","8","11","Blood","Blood","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1094,"EID1094","The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide.",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",463,3,NULL,"accepted",0,"evidence",752,"Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.","Goto et al., 2011, Blood",21613260,"http://www.ncbi.nlm.nih.gov/pubmed/21613260",NULL,NULL,"2011","8","11","Blood","Blood","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1095,"EID1095","64-year old female (non-smoker) was diagnosed with NSCLC. A c.3028 G->A mutation was identified in exon 14 resulting in exon 14 skipping. Further, amplification of the MET gene was observed. The patient was given crizotinib and CT scans showed a positive response after 8 weeks of treatment.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",464,3,NULL,"accepted",0,"evidence",754,"MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.","Awad et al., 2016, J. Clin. Oncol.",26729443,"http://www.ncbi.nlm.nih.gov/pubmed/26729443",NULL,NULL,"2016","3","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1096,"EID1096","In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.  Earlier deaths were seen with heavier HER2 expression.  Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.  The authors conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities.",185,"Uterine Corpus Serous Adenocarcinoma","Uterine Corpus Serous Adenocarcinoma",5750,"http://www.disease-ontology.org/?id=DOID:5750","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",755,"Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.","Santin et al., 2005, Am. J. Obstet. Gynecol.",15746676,"http://www.ncbi.nlm.nih.gov/pubmed/15746676",NULL,NULL,"2005","3",NULL,"Am. J. Obstet. Gynecol.","American journal of obstetrics and gynecology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1097,"EID1097","HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.  HER2 overexpression in USPC is more common in African American women.  This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.  Prior treatment involved surgery and chemotherapy.  Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.  The second patient had USPC, and was treated with surgery and radiation.  Trastuzumab monotheraby was then administered.  After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.  The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC.",185,"Uterine Corpus Serous Adenocarcinoma","Uterine Corpus Serous Adenocarcinoma",5750,"http://www.disease-ontology.org/?id=DOID:5750","C","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",756,"Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.","Santin et al., 2008, Int J Gynaecol Obstet",18555254,"http://www.ncbi.nlm.nih.gov/pubmed/18555254",NULL,NULL,"2008","8",NULL,"Int J Gynaecol Obstet","International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1098,"EID1098","This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.  Participants had stage III, IV or recurrent HER2 positive endometrial cancer.  During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.  In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.  The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria. No major objective tumor responses were observed in the study.  28% of the cancers were of the serous type that had shown trastuzumab response in case studies.  The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.  Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",306,2,NULL,"accepted",0,"evidence",757,"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.","Fleming et al., 2010, Gynecol. Oncol.",19840887,"http://www.ncbi.nlm.nih.gov/pubmed/19840887","true","PMC2804260","2010","1",NULL,"Gynecol. Oncol.","Gynecologic oncology","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1099,"EID1099","Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation.",97,"Brain Medulloblastoma","Brain Medulloblastoma",60105,"http://www.disease-ontology.org/?id=DOID:0060105","D","Predictive","Supports","Sensitivity","Somatic Mutation",299,3,NULL,"accepted",0,"evidence",758,"Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.","Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A.",22550175,"http://www.ncbi.nlm.nih.gov/pubmed/22550175","true","PMC3356655","2012","5","15","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","274","Saridegib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1100,"EID1100","Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. An acquired G2032R mutation in the ROS1 kinase domain was observed in the resistant tumor, and was found to confer resistance to ROS1 kinase inhibition through steric interference with drug binding.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",465,4,NULL,"accepted",0,"evidence",381,"Acquired resistance to crizotinib from a mutation in CD74-ROS1.","Awad et al., 2013, N. Engl. J. Med.",23724914,"http://www.ncbi.nlm.nih.gov/pubmed/23724914","true","PMC3878821","2013","6","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1101,"EID1101","Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival of CD74-ROS1 wild-type (WT) and resistant mutants harboring Ba/F3 and MGH047 cells. Furthermore, cabozantinib could overcome all the resistance by all newly identified secondary mutations.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",465,3,NULL,"accepted",0,"evidence",759,"Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.","Katayama et al., 2015, Clin. Cancer Res.",25351743,"http://www.ncbi.nlm.nih.gov/pubmed/25351743","true","PMC4286456","2015","1","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","144","Cabozantinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1102,"EID1102","Peripheral blood from NPM1 mutated AMLs was assessed for NPM1 mutation status at multiple time points using RT-qPCR with primers designed to amplify different mutant NPM1 transcripts. The test development cohort consisted of 194 cases and an independent validation cohort consisted of 91 cases. Persistence of NPM1-mutated transcripts in blood was present in 15% of the patients after the second chemotherapy cycle. This persistence was associated with a greater risk of relapse after 3 years of follow-up than was an absence of such transcripts (82% vs. 30%; hazard ratio, 4.80; 95% confidence interval [CI], 2.95 to 7.80; P<0.001) and a lower rate of survival (24% vs. 75%; hazard ratio for death, 4.38; 95% CI, 2.57 to 7.47; P<0.001). The presence of minimal residual disease was the only independent prognostic factor for death in multivariate analysis (hazard ratio, 4.84; 95% CI, 2.57 to 9.15; P<0.001). On sequential monitoring of minimal residual disease, relapse was reliably predicted by a rising level of NPM1-mutated transcripts.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",86,4,NULL,"accepted",0,"evidence",760,"Assessment of Minimal Residual Disease in Standard-Risk AML.","Ivey et al., 2016, N. Engl. J. Med.",26789727,"http://www.ncbi.nlm.nih.gov/pubmed/26789727",NULL,NULL,"2016","2","4","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1103,"EID1103","This preclinical study establishes that the p30 isoform of CEBPA expressed as a result of N-terminal truncating mutations preferentially interacts with WRD5, a component of the SET/MLL complex. Knockdown of WRD5 in 32D cells (mouse hematopoietic cell line) or transplanted primary mouse bone marrow expressing the p30 isoform restored myeloid differentiation in these cells. OICR-9429, a small molecule inhibitor of WRD5, and anti-WRD5 siRNAs selectively inhibited colony formation of mouse fetal liver cells homozygous for N-terminal CEBPA mutations but not wildtype colony formation. Finally, OICR-9429 reduced viability of primary human AML blasts harboring N-terminal domain CEBPA mutations in culture but not AML blasts with other mutations. Taken together, WRD5 inhibition is a potential therapeutic method for patients harboring N-terminal CEBPA mutations.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Sensitivity","Somatic Mutation",28,3,NULL,"accepted",0,"evidence",761,"Pharmacological targeting of the Wdr5-MLL interaction in C/EBPÎ± N-terminal leukemia.","Grebien et al., 2015, Nat. Chem. Biol.",26167872,"http://www.ncbi.nlm.nih.gov/pubmed/26167872","true","PMC4511833","2015","8",NULL,"Nat. Chem. Biol.","Nature chemical biology","fully curated","275","OICR-9429",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1104,"EID1104","A t(8;13)(p11;q12) patient with ZNF198-FGFR1-induced progressive myeloproliferative disorder was treated with PKC412. Radiographic studies performed 3 months after initiation of therapy revealed marked improvement of her cervical, mediastinal, and retroperitoneal lymphadenopathy, and marked regression of splenomegaly to normal size.",313,"Chronic Myeloproliferative Disease","Chronic Myeloproliferative Disease",2226,"http://www.disease-ontology.org/?id=DOID:2226","C","Predictive","Supports","Sensitivity","Somatic Mutation",466,4,NULL,"accepted",0,"evidence",762,"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.","Chen et al., 2004, Proc. Natl. Acad. Sci. U.S.A.",15448205,"http://www.ncbi.nlm.nih.gov/pubmed/15448205","true","PMC521956","2004","10","5","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","323","Midostaurin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1105,"EID1105","FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",267,3,NULL,"accepted",0,"evidence",763,"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.","Turner et al., 2010, Cancer Res.",20179196,"http://www.ncbi.nlm.nih.gov/pubmed/20179196","true","PMC2832818","2010","3","1","Cancer Res.","Cancer research","fully curated","277","4-hydroxytamoxifen",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1106,"EID1106","COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or A1065T-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib.",330,"Angiosarcoma","Angiosarcoma",1816,"http://www.disease-ontology.org/?id=DOID:0001816","D","Predictive","Supports","Sensitivity","Somatic Mutation",467,3,"Substitutes","accepted",0,"evidence",764,"KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.","Antonescu et al., 2009, Cancer Res.",19723655,"http://www.ncbi.nlm.nih.gov/pubmed/19723655","true","PMC2763376","2009","9","15","Cancer Res.","Cancer research","fully curated","6","Sorafenib",NULL,"157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1107,"EID1107","COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or D717V-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib.",330,"Angiosarcoma","Angiosarcoma",1816,"http://www.disease-ontology.org/?id=DOID:0001816","D","Predictive","Supports","Sensitivity","Somatic Mutation",468,3,"Substitutes","accepted",0,"evidence",764,"KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.","Antonescu et al., 2009, Cancer Res.",19723655,"http://www.ncbi.nlm.nih.gov/pubmed/19723655","true","PMC2763376","2009","9","15","Cancer Res.","Cancer research","fully curated","157","Sunitinib",NULL,"6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1108,"EID1108","The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months.",155,"Thyroid Carcinoma","Thyroid Carcinoma",3963,"http://www.disease-ontology.org/?id=DOID:3963","C","Predictive","Supports","Sensitivity","Somatic Mutation",469,5,NULL,"accepted",0,"evidence",372,"Response and acquired resistance to everolimus in anaplastic thyroid cancer.","Wagle et al., 2014, N. Engl. J. Med.",25295501,"http://www.ncbi.nlm.nih.gov/pubmed/25295501","true","PMC4564868","2014","10","9","N. Engl. J. Med.","The New England journal of medicine","partially curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1109,"EID1109","In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission (70% vs 87.5%), and lower 3-year Leukemia-Free Survival (44.4% vs. 84.4%).",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,3,NULL,"accepted",0,"evidence",765,"Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.","Hong et al., 2011, Korean J Hematol",21461300,"http://www.ncbi.nlm.nih.gov/pubmed/21461300","true","PMC3065622","2011","3",NULL,"Korean J Hematol","The Korean journal of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1110,"EID1110","The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months, after which time resistance developed. The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor.",155,"Thyroid Carcinoma","Thyroid Carcinoma",3963,"http://www.disease-ontology.org/?id=DOID:3963","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",470,5,NULL,"accepted",0,"evidence",372,"Response and acquired resistance to everolimus in anaplastic thyroid cancer.","Wagle et al., 2014, N. Engl. J. Med.",25295501,"http://www.ncbi.nlm.nih.gov/pubmed/25295501","true","PMC4564868","2014","10","9","N. Engl. J. Med.","The New England journal of medicine","partially curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1111,"EID1111","A healthy, 36-year-old woman presented with a palpable right breast mass upon biopsy determined to be high-grade, triple negative invasive ductal carcinoma. Her family history was notable for multiple relatives on her maternal side with breast cancer, including a distant male relative with breast cancer. Multigene panel testing with an 18-gene panel revealed a germline truncating pathogenic mutation in RAD51D (p.R186X; c. 556C>T).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Predisposing","Supports",NULL,"Germline Mutation",471,2,NULL,"accepted",0,"evidence",766,"Breast cancer in a RAD51D mutation carrier: case report and review of the literature.","Baker et al., 2015, Clin. Breast Cancer",25445424,"http://www.ncbi.nlm.nih.gov/pubmed/25445424",NULL,NULL,"2015","2",NULL,"Clin. Breast Cancer","Clinical breast cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1112,"EID1112","In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs. 82%), as well as higher CR achievement failure and early death.",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",55,4,"Combination","accepted",0,"evidence",767,"Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.","Lucena-Araujo et al., 2014, Ann. Hematol.",24981688,"http://www.ncbi.nlm.nih.gov/pubmed/24981688",NULL,NULL,"2014","12",NULL,"Ann. Hematol.","Annals of hematology","fully curated","278","Anthracyline",NULL,"265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1113,"EID1113","In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint.  HER2 positivity was assessed via FISH.  At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively.  Distant disease-free survival and time to distant recurrence were similar in both groups.  These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",768,"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","Chan et al., 2016, Lancet Oncol.",26874901,"http://www.ncbi.nlm.nih.gov/pubmed/26874901",NULL,NULL,"2016","3",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1114,"EID1114","IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck. High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or ALDH1A2 high and CRABP2 low) was significantly associated with OS and PFS in multivariate Cox analysis (OS, HR: 0.303, 95%CI 0.14â€“0.63, p-value 0.002 PFS, HR: 0.395, 95%CI 0.20â€“0.77, p-value 0.007).",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Better Outcome","N/A",472,3,NULL,"accepted",0,"evidence",769,"Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma.","Seidensaal et al., 2015, Mol. Cancer",26634247,"http://www.ncbi.nlm.nih.gov/pubmed/26634247","true","PMC4669670","2015",NULL,NULL,"Mol. Cancer","Molecular cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1115,"EID1115","FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide. This led to concentration dependent decrease in the survival fraction in both cell lines with higher efficacy in Cal27 (ED50 â‰ˆ 1 Î¼M) as compared to FaDu cells (ED â‰ˆ 44 Î¼M). Treatment with 3 Î¼M ATRA sensitized Cal27 cells to irradiation at a dose of 2 Gy, but had no or only a minor effect on ALDH1A2-postitive cells.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Sensitivity","N/A",473,2,NULL,"accepted",0,"evidence",769,"Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma.","Seidensaal et al., 2015, Mol. Cancer",26634247,"http://www.ncbi.nlm.nih.gov/pubmed/26634247","true","PMC4669670","2015",NULL,NULL,"Mol. Cancer","Molecular cancer","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1116,"EID1116","ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 nonâ€“HPV-driven; n = 26 HPV-driven). Low to moderate ALDH1A2 protein levels (combined as ALDH1A2low) were identified in keratinocytes of healthy mucosa as well as 73 (63.5%) primary tumors, and high ALDH1A2 protein levels in 42 (36.5%) primary tumors. Significantly higher ALDH1A2 protein levels were identified in HPV-driven than non-HPV-driven tumors. Moreover, PFS and OS strongly correlated with the ALDH1A2 protein expression level (OS, P < 0.001; PFS, P = 0.001; log-rank/Mantel-Cox test. Previous analyses in the same study identify hypermethylation of ALDH1A2 as the underlying mechanism of differential protein expression.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Prognostic","Supports","Better Outcome","N/A",472,3,NULL,"accepted",0,"evidence",770,"HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas.","Kostareli et al., 2013, J. Clin. Invest.",23635773,"http://www.ncbi.nlm.nih.gov/pubmed/23635773","true","PMC3668826","2013","6",NULL,"J. Clin. Invest.","The Journal of clinical investigation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1117,"EID1117","Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues. Immunohistochemistry revealed a significant difference in expression between tumor and adjacent normal samples. Furthermore, a statistically significant decrease in overall survival was discovered between positive and negative CIP2A expression.",141,"Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma",3498,"http://www.disease-ontology.org/?id=DOID:3498","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",474,3,NULL,"accepted",0,"evidence",774,"CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.","Xu et al., 2016, Oncotarget",26894380,"http://www.ncbi.nlm.nih.gov/pubmed/26894380","true","PMC4924755","2016","3","22","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1118,"EID1118","Researchers studied the effect of CIP2A expression in relation to  gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicating a sensitivity to gemcitabine.",141,"Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma",3498,"http://www.disease-ontology.org/?id=DOID:3498","D","Predictive","Supports","Sensitivity","Somatic Mutation",475,3,NULL,"accepted",0,"evidence",774,"CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.","Xu et al., 2016, Oncotarget",26894380,"http://www.ncbi.nlm.nih.gov/pubmed/26894380","true","PMC4924755","2016","3","22","Oncotarget","Oncotarget","fully curated","85","Gemcitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1119,"EID1119","Researchers examined the prognostic role of miR-218 expression in CRC tumor samples when receiving 5-FU based treatment. CRC samples from patients who received first-line 5-FU-based adjuvant chemotherapy were stratified into two groups (complete/partial response and stable/progressive disease) based on RECIST criteria. miR-218 expression levels were found to be significantly higher in the complete/partial response group.  Further Kaplan-Meier survival analysis revealed that in groups with higher miR-218 expression, overall survival was significantly greater.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Better Outcome","N/A",476,3,NULL,"accepted",0,"evidence",775,"MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.","Li et al., 2015, Carcinogenesis",26442524,"http://www.ncbi.nlm.nih.gov/pubmed/26442524",NULL,NULL,"2015","12",NULL,"Carcinogenesis","Carcinogenesis","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1121,"EID1121","A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance.",1594,"Lung Acinar Adenocarcinoma","Lung Acinar Adenocarcinoma",6482,"http://www.disease-ontology.org/?id=DOID:6482","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",5,2,NULL,"accepted",0,"evidence",776,"A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.","Tanaka et al., 2012, BMC Cancer",23181703,"http://www.ncbi.nlm.nih.gov/pubmed/23181703","true","PMC3515412","2012",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1122,"EID1122","HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.  Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.  In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.  At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.  A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.  1 year adjuvant trastuzumab is currently the standard of care.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","A","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",777,"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.","Piccart-Gebhart et al., 2005, N. Engl. J. Med.",16236737,"http://www.ncbi.nlm.nih.gov/pubmed/16236737",NULL,NULL,"2005","10","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1123,"EID1123","A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38). This mutation ultimately causes a downstream premature stop codon and truncated BRCA1.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Diagnostic","Supports","Positive","Germline Mutation",477,4,NULL,"accepted",0,"evidence",778,"A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.","Salgado et al., 2013, Oncol Lett",24137399,"http://www.ncbi.nlm.nih.gov/pubmed/24137399","true","PMC3788828","2013","9",NULL,"Oncol Lett","Oncology letters","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1124,"EID1124","A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38). This mutation ultimately causes a downstream premature stop codon and truncated BRCA1.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","C","Diagnostic","Supports","Positive","Germline Mutation",477,4,NULL,"accepted",0,"evidence",778,"A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.","Salgado et al., 2013, Oncol Lett",24137399,"http://www.ncbi.nlm.nih.gov/pubmed/24137399","true","PMC3788828","2013","9",NULL,"Oncol Lett","Oncology letters","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1125,"EID1125","A 51-year old female never smoker with stage IV lung adenocarcinoma carrying a HER2 insertion in exon 20 (p.A775_G776insYVMA) by sequencing archived material, HER2 overexpression by IHC (2+) and HER2 amplification by in situ hybridization was treated with T-DM1 (pemetrexed). Patient received two cycles off-label at 3.6mg/kg and was found to have morphologic response of lung and bone lesions by PET and CT. TDM-1 therapy was ongoing as of publication April 2015.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",414,3,NULL,"accepted",0,"evidence",779,"Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.","Weiler et al., 2015, J Thorac Oncol",25789838,"http://www.ncbi.nlm.nih.gov/pubmed/25789838",NULL,NULL,"2015","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","156","Pemetrexed",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1127,"EID1127","In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients.",665,"Hairy Cell Leukemia","Hairy Cell Leukemia",285,"http://www.disease-ontology.org/?id=DOID:285","B","Diagnostic","Supports","Positive","Somatic Mutation",12,4,NULL,"accepted",0,"evidence",780,"BRAF mutations in hairy-cell leukemia.","Tiacci et al., 2011, N. Engl. J. Med.",21663470,"http://www.ncbi.nlm.nih.gov/pubmed/21663470","true","PMC3689585","2011","6","16","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1128,"EID1128","Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Predictive","Supports","Sensitivity","Somatic Mutation",312,3,"Substitutes","accepted",0,"evidence",514,"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.","Mellinghoff et al., 2005, N. Engl. J. Med.",16282176,"http://www.ncbi.nlm.nih.gov/pubmed/16282176",NULL,NULL,"2005","11","10","N. Engl. J. Med.","The New England journal of medicine","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1129,"EID1129","Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Predictive","Supports","Sensitivity","N/A",313,3,"Substitutes","accepted",0,"evidence",514,"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.","Mellinghoff et al., 2005, N. Engl. J. Med.",16282176,"http://www.ncbi.nlm.nih.gov/pubmed/16282176",NULL,NULL,"2005","11","10","N. Engl. J. Med.","The New England journal of medicine","fully curated","15","Erlotinib",NULL,"14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1130,"EID1130","In patients with stage II colon cancer, positive CDX2 status was associated with longer overall survival.",119,"Colon Cancer","Colon Cancer",219,"http://www.disease-ontology.org/?id=DOID:219","B","Prognostic","Supports","Better Outcome","N/A",410,4,NULL,"rejected",0,"evidence",781,"Prognostic Subgroups among Patients with Stage II Colon Cancer.","Boland et al., 2016, N. Engl. J. Med.",26789877,"http://www.ncbi.nlm.nih.gov/pubmed/26789877","true","PMC4852473","2016","1","21","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1131,"EID1131","A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relapsed. EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab. However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*).",691,"Colon Mucinous Adenocarcinoma","Colon Mucinous Adenocarcinoma",3029,"http://www.disease-ontology.org/?id=DOID:3029","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",479,2,NULL,"accepted",0,"evidence",782,"A novel K-ras mutation in colorectal cancer. A case report and literature review.","Palmirotta et al., 2009, Anticancer Res.",19661358,"http://www.ncbi.nlm.nih.gov/pubmed/19661358",NULL,NULL,"2009","8",NULL,"Anticancer Res.","Anticancer research","fully curated","28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1132,"EID1132","This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.  Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163). The primary endpoint of the study was time to progression. Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).  The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,"Combination","accepted",0,"evidence",783,"Lapatinib plus capecitabine for HER2-positive advanced breast cancer.","Geyer et al., 2006, N. Engl. J. Med.",17192538,"http://www.ncbi.nlm.nih.gov/pubmed/17192538",NULL,NULL,"2006","12","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","45","Lapatinib",NULL,"32","Capecitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1133,"EID1133","In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.  Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.  Primary endpoint was time to progression.  78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.  The results are in contrast to the principle of change of treatment on disease progression, and authors suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",784,"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.","von Minckwitz et al., 2009, J. Clin. Oncol.",19289619,"http://www.ncbi.nlm.nih.gov/pubmed/19289619",NULL,NULL,"2009","4","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","84","Trastuzumab",NULL,"32","Capecitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1134,"EID1134","Previously only reported in haematopoietic and lymphoid malignancies, P904 is a likely activating event, whose function has not been well characterized. In the tertiary protein structure, the mutation is not within proximity of the better characterized R882 mutation, so downstream effects of activation by P904 are likely to differ from R882. DNMT3A P904 may confer sensitivity to a hypomethylating agent such as azacitadine. Any methyltransferase inhibitor or a hypomethylator is applicable. In addition to azacitadine and decitabine, there are other methyltransferase inhibitors in late stage clinical trials. Guadecitabine (analog of decitabine) and FdCyd should also be applicable.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","E","Predictive","Supports","Sensitivity","Somatic Mutation",480,3,"Combination","rejected",0,"evidence",785,"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.","Walter et al., 2011, Leukemia",21415852,"http://www.ncbi.nlm.nih.gov/pubmed/21415852","true","PMC3202965","2011","7",NULL,"Leukemia","Leukemia","fully curated","155","Decitabine",NULL,"282","5-fluoro-2-deoxycytidine","515328","280","Azacitidine",NULL,"281","Guadecitabine",NULL,NULL,NULL,NULL
1135,"EID1135","MEK inhibitor-resistant (selumetinib, PD0325901, GSK1129212) uveal melanoma cell lines were created from two GNAQ Q209L mutant cell lines. Overexpression of DDX43 mediated RAS-induced selumetinib resistance as demonstrated by depletion of DDX43 decreasing RAS proteins and ectopic expression of DDX43 induced RAS protein levels. These results were confirmed using biopsies from liver metastases in 14 patients with uveal melanoma harboring GNAQ or GNA11 mutations who were treated on a phase II study of selumetinib. 6 patients with partial response or stable disease for â‰¥16 weeks, were defined as â€œrespondersâ€ (R), 8 patients who had disease progression before 16 weeks were defined as â€œnonrespondersâ€ (NR). DDX43 Expression (qPCR) was higher in nonresponders (P = 0.045). Liver metastasis biopsy samples (3 R and 3 NR) were immunoblotted for DDX43, pERK and RAS proteins with consistent results.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",481,4,"Substitutes","accepted",0,"evidence",786,"Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.","Ambrosini et al., 2014, Mol. Cancer Ther.",24899684,"http://www.ncbi.nlm.nih.gov/pubmed/24899684",NULL,NULL,"2014","8",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","19","Trametinib",NULL,"29","PD0325901",NULL,"122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1136,"EID1136","Patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study of selumetinib and analyzed for mutations in KIT, NRAS, KRAS and FLT3. KIT mutation analysis (N=41) revealed the presence of a synonymous SNP rs3733542 (known population frequency of 20%) in exon 18 of the KIT gene in six of ten (60%) patients assessed as having a response or disease stabilization to selumetinib. In contrast, this SNP was detected in only seven of 31 (23%) patients without a response or disease stabilization (P = 0.027, Chi-squared test).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Germline Polymorphism",482,1,NULL,"accepted",0,"evidence",787,"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.","Jain et al., 2014, Clin. Cancer Res.",24178622,"http://www.ncbi.nlm.nih.gov/pubmed/24178622","true","PMC4310865","2014","1","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1137,"EID1137","Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study. In FLT3 wild-type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 uMR) that lasted a median of 58 days (range, 33â€“273 days). No patient with FLT3-ITD (n = 10) responded. One patient with unknown FLT3 status also had no response. Of note, this study did not meet its primary endpoint of 6 responses (CR, CRi, PR or MR) in the first 35 patients enrolled.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",55,2,NULL,"accepted",0,"evidence",787,"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.","Jain et al., 2014, Clin. Cancer Res.",24178622,"http://www.ncbi.nlm.nih.gov/pubmed/24178622","true","PMC4310865","2014","1","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1138,"EID1138","Preclinical study in melanoma cell lines. TBK1 depletion (siRNA) inhibited migration and invasion, whereas its constitutive overexpression led to an increase in invasion. In MEK-resistant NRAS mutant melanoma cell lines, TBK1 depletion or inhibition (AZ909) in combination with MEK inhibitors (selumetinib) promoted apoptosis in 3D culture.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","N/A",483,2,"Combination","accepted",0,"evidence",788,"Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.","Vu et al., 2014, Mol. Cancer Res.",24962318,"http://www.ncbi.nlm.nih.gov/pubmed/24962318","true","PMC4482471","2014","10",NULL,"Mol. Cancer Res.","Molecular cancer research : MCR","fully curated","122","Selumetinib (AZD6244)",NULL,"283","AZ909",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1139,"EID1139","Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P = 0.02). Median PFS in KRAS wild-type patients was significantly longer than in KRAS mut patients (HR = 0.85; 95 % confidence interval (CI) 0.74-0.98; P = 0.02). Median OS in wild-type KRAS patients compared was significantly better than in KRAS mut patients (HR = 0.65; 95 % CI 0.46-0.92; P = 0.01).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",336,4,"Combination","accepted",0,"evidence",789,"KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.","Petrelli et al., 2013, Med. Oncol.",23828442,"http://www.ncbi.nlm.nih.gov/pubmed/23828442",NULL,NULL,"2013",NULL,NULL,"Med. Oncol.","Medical oncology (Northwood, London, England)","fully curated","199","Chemotherapy",NULL,"33","Bevacizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1140,"EID1140","Preclinical study analyzing the differential response to MEK Inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Efficacy of MEK inhibitors (GDC-0623 and G-573) in KRAS-driven tumours is mediated by a hydrogen-bond interaction with S212 in MEK that is critical for blocking MEK feedback phosphorylation by wild-type RAF. This mechanism was distinct from GDC-0973 which is less potent in KRAS mutant tumors. Overall, this work indicates that MEK inhibitors with this mechanism of action will be most effective in patients with both BRAF and KRAS mutations.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,3,"Substitutes","accepted",0,"evidence",790,"Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.","Hatzivassiliou et al., 2013, Nature",23934108,"http://www.ncbi.nlm.nih.gov/pubmed/23934108",NULL,NULL,"2013","9","12","Nature","Nature","fully curated","285","G-573",NULL,"284","GDC-0623",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1141,"EID1141","Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573).",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",790,"Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.","Hatzivassiliou et al., 2013, Nature",23934108,"http://www.ncbi.nlm.nih.gov/pubmed/23934108",NULL,NULL,"2013","9","12","Nature","Nature","fully curated","342","Cobimetinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1142,"EID1142","83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",78,3,NULL,"accepted",0,"evidence",791,"Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.","JÃ¤nne et al., 2015, Br. J. Cancer",26125448,"http://www.ncbi.nlm.nih.gov/pubmed/26125448","true","PMC4506393","2015","7","14","Br. J. Cancer","British journal of cancer","fully curated","122","Selumetinib (AZD6244)",NULL,"73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1143,"EID1143","83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",425,1,"Combination","accepted",0,"evidence",791,"Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.","JÃ¤nne et al., 2015, Br. J. Cancer",26125448,"http://www.ncbi.nlm.nih.gov/pubmed/26125448","true","PMC4506393","2015","7","14","Br. J. Cancer","British journal of cancer","fully curated","122","Selumetinib (AZD6244)",NULL,"73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1144,"EID1144","A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Lkb1 (STK11) knockout mutant mice showed only mild response to combined treatment and very low response rates to docetaxel monotherapy compared to mice with Kras(G12D) alone or Kras(G12D) and Trp53 knockout. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",485,3,"Combination","accepted",0,"evidence",792,"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.","Chen et al., 2012, Nature",22425996,"http://www.ncbi.nlm.nih.gov/pubmed/22425996","true","PMC3385933","2012","3","29","Nature","Nature","fully curated","73","Docetaxel",NULL,"122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1145,"EID1145","A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",222,3,"Combination","accepted",0,"evidence",792,"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.","Chen et al., 2012, Nature",22425996,"http://www.ncbi.nlm.nih.gov/pubmed/22425996","true","PMC3385933","2012","3","29","Nature","Nature","fully curated","73","Docetaxel",NULL,"122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1146,"EID1146","A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",222,3,NULL,"accepted",0,"evidence",792,"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.","Chen et al., 2012, Nature",22425996,"http://www.ncbi.nlm.nih.gov/pubmed/22425996","true","PMC3385933","2012","3","29","Nature","Nature","fully curated","73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1147,"EID1147","Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA). Mutations (434; 36%) had no prognostic effect (OBS: HROS=0.99; [95%CI 0.77-1.28], p=0.95; HRDFS=0.99 [0.78-1.25], p=0.92) but were marginally predictive of benefit from ACT for OS (test for interaction: OS: p=0.06; DFS: p=0.11).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Does Not Support","Poor Outcome","Somatic Mutation",221,4,NULL,"accepted",0,"evidence",793,"Prognostic and Predictive Effect of TP53 Mutations inÂ Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials:Â A LACE-Bio Pooled Analysis.","Ma et al., 2016, J Thorac Oncol",26899019,"http://www.ncbi.nlm.nih.gov/pubmed/26899019",NULL,NULL,"2016","6",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1148,"EID1148","Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with TP53wt had significantly better PFS and OS with ACT vs. OBS (p=0.005, p=0.02, respectively) whereas patients with TP53 mutations did not show significant differences in PFS and OS between ACT and OBS (p=0.86, p=0.63).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",221,2,NULL,"accepted",0,"evidence",793,"Prognostic and Predictive Effect of TP53 Mutations inÂ Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials:Â A LACE-Bio Pooled Analysis.","Ma et al., 2016, J Thorac Oncol",26899019,"http://www.ncbi.nlm.nih.gov/pubmed/26899019",NULL,NULL,"2016","6",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","288","Adjuvant Chemotherapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1149,"EID1149","Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with wild-type TP53 had better outcomes with ACT than OBS (HROS=0.77 [0.62-0.95], p=0.02; HRDFS=0.75 [0.62-0.92], p=0.005).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",369,3,NULL,"accepted",0,"evidence",793,"Prognostic and Predictive Effect of TP53 Mutations inÂ Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials:Â A LACE-Bio Pooled Analysis.","Ma et al., 2016, J Thorac Oncol",26899019,"http://www.ncbi.nlm.nih.gov/pubmed/26899019",NULL,NULL,"2016","6",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","288","Adjuvant Chemotherapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1150,"EID1150","In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody. Two patients who developed adaptive resistance to anti-PD-1 treatment also showed TIM-3 upregulation in blocking antibody-bound T cells at treatment failure.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","N/A",486,3,NULL,"accepted",0,"evidence",794,"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.","Koyama et al., 2016, Nat Commun",26883990,"http://www.ncbi.nlm.nih.gov/pubmed/26883990","true","PMC4757784","2016",NULL,NULL,"Nat Commun","Nature communications","fully curated","289","PD-1 Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1151,"EID1151","In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","N/A",486,3,"Combination","accepted",0,"evidence",794,"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.","Koyama et al., 2016, Nat Commun",26883990,"http://www.ncbi.nlm.nih.gov/pubmed/26883990","true","PMC4757784","2016",NULL,NULL,"Nat Commun","Nature communications","fully curated","290","TIM-3 Inhibitor",NULL,"289","PD-1 Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1152,"EID1152","Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen using a total of 3,530 shRNAs to target 518 human kinases identified ERBB3 knockdown to confer sensitivity of selumetinib-resistant H358 cells (NSCLC cell line) to the MEK inhibitor selumetinib. The dual EGFR-ERBB2 inhibitors afatinib and dacomitinib each showed synergy with MEK Inhibition via selumetinib in 4 KRAS mutant cell lines. Western blot evaluation of 9 NSCLC and 12 CRC cell lines showed ERBB3 expression correlated with the synergy score for combination afatinib and trametinib treatment. I.e. the synergy score was low in cells having low basal levels of ERBB3 protein and high for cells having high basal ERBB3 expression. Using selumetinib in patient-derived CRC xenografts or trametinib in NSCLC xenografts, MEK inhibition by selumetinib or trametinib in combination with afatinib more effectively inhibited increases in tumor volume than either monotherapy.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","N/A",289,3,"Combination","accepted",0,"evidence",686,"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.","Sun et al., 2014, Cell Rep",24685132,"http://www.ncbi.nlm.nih.gov/pubmed/24685132",NULL,NULL,"2014","4","10","Cell Rep","Cell reports","fully curated","146","Afatinib",NULL,"122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1153,"EID1153","Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen identified ERBB3 blockade to confer sensitivity to MEK inhibitors. The dual EGFR-ERBB2 (both forming heterodimers with ERBB3) inhibitors afatinib and dacomitinib each showed strong synergy with MEK Inhibition (trametinib or selumetinib) in several KRAS mutant cell lines. MEK Inhibitors alone or the combination with gefitinib (EGFRi) or CP724714 (ERBB2i) showed strong synergy. Results were validated in-vivo. Basal ERBB3 expression was associated with higher synergy scores.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Resistance or Non-Response","N/A",289,4,"Substitutes","accepted",0,"evidence",686,"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.","Sun et al., 2014, Cell Rep",24685132,"http://www.ncbi.nlm.nih.gov/pubmed/24685132",NULL,NULL,"2014","4","10","Cell Rep","Cell reports","fully curated","14","Gefitinib",NULL,"122","Selumetinib (AZD6244)",NULL,"291","CP724714",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1154,"EID1154","This Phase I study was performed on NSCLC patients with EGFR activating mutations treated with 1st generation EGFR inhibitors or who had responded to 1st generation EGFR inhibitors.  Patients were also required to have progressed under this treatment.  Patients were then administered the 3rd generation EGFR inhibitor AZD9291 (osimertinib). Patients with T790M mutation (n=127) showed an objective response rate (ORR) of 61% and median progression free (PFS) survival of 9.6 months, while patients negative for T790M mutation (n=61) showed ORR of 21% and 2.8 months PFS. Along with these encouraging results, no dose limiting toxicity was seen at evaluated levels (20 to 240 mg once daily).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",34,3,NULL,"accepted",0,"evidence",667,"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.","JÃ¤nne et al., 2015, N. Engl. J. Med.",25923549,"http://www.ncbi.nlm.nih.gov/pubmed/25923549",NULL,NULL,"2015","4","30","N. Engl. J. Med.","The New England journal of medicine","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1155,"EID1155","Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 0Â·69 [95% CI 0Â·50â€“0Â·96], p=0.022) than in p16-positive disease (HR 0Â·95 [CI 0Â·51â€“1Â·75], p=0.67, interaction test p=0Â·32).",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","B","Predictive","Supports","Resistance or Non-Response","N/A",272,2,NULL,"accepted",0,"evidence",795,"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.","Machiels et al., 2015, Lancet Oncol.",25892145,"http://www.ncbi.nlm.nih.gov/pubmed/25892145",NULL,NULL,"2015","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1156,"EID1156","MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032). Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115). bMMP2 was associated with relapse (p=0.002) and death (p=0.049). During treatment, significant increase in MMP2 was observed in 100% of patients.",1550,"Inflammatory Breast Carcinoma","Inflammatory Breast Carcinoma",6263,"http://www.disease-ontology.org/?id=DOID:6263","B","Predictive","Supports","Sensitivity","N/A",487,3,NULL,"accepted",0,"evidence",796,"MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.","Tabouret et al., 2016, Oncotarget",26921265,"http://www.ncbi.nlm.nih.gov/pubmed/26921265","true","PMC4951307","2016","4","5","Oncotarget","Oncotarget","fully curated","33","Bevacizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1157,"EID1157","MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071). Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511). bMMP9 was associated with death (p=0.035). During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients.",1550,"Inflammatory Breast Carcinoma","Inflammatory Breast Carcinoma",6263,"http://www.disease-ontology.org/?id=DOID:6263","B","Predictive","Supports","Resistance or Non-Response","N/A",488,3,NULL,"accepted",0,"evidence",796,"MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.","Tabouret et al., 2016, Oncotarget",26921265,"http://www.ncbi.nlm.nih.gov/pubmed/26921265","true","PMC4951307","2016","4","5","Oncotarget","Oncotarget","fully curated","33","Bevacizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1158,"EID1158","Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas. Results were validated in a separate retrospective cohort (n = 50) and also tested in patients treated with cytotoxic agents without bevacizumab (n = 34). MMP2 level was correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005) in the discovery and validation cohorts but not in patients treated without bevacizumab.",98,"Brain Glioma","Brain Glioma",60108,"http://www.disease-ontology.org/?id=DOID:0060108","B","Predictive","Supports","Sensitivity","N/A",487,2,NULL,"accepted",0,"evidence",797,"Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.","Tabouret et al., 2014, Neuro-oncology",24327581,"http://www.ncbi.nlm.nih.gov/pubmed/24327581","true","PMC3922517","2014","3",NULL,"Neuro-oncology","Neuro-oncology","fully curated","33","Bevacizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1159,"EID1159","The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.  Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.  This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).  Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.  The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.  The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",798,"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.","Krop et al., 2014, Lancet Oncol.",24793816,"http://www.ncbi.nlm.nih.gov/pubmed/24793816",NULL,NULL,"2014","6",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","293","Trastuzumab Emtansine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1160,"EID1160","The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.  Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.   Primary endpoints included independently assessed progression free survival (PFS) and safety. PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.  Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.  These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",799,"Trastuzumab emtansine for HER2-positive advanced breast cancer.","Verma et al., 2012, N. Engl. J. Med.",23020162,"http://www.ncbi.nlm.nih.gov/pubmed/23020162",NULL,NULL,"2012","11","8","N. Engl. J. Med.","The New England journal of medicine","fully curated","293","Trastuzumab Emtansine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1161,"EID1161","ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA). ActA Levels were higher in patients than in controls and were significantly correlated with disease stage and metastasis. Patients were stratified as having high or low ActA levels using the median expression level. LADC patients with high serum or plasma ActA levels had significantly shorter OS than those with low circulating ActA concentrations (p < 0.0001 in both) and were identified as an independent prognostic factor (p=0.004 and p=0.002, respectively).",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Prognostic","Supports","Poor Outcome","N/A",546,2,NULL,"accepted",0,"evidence",800,"High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.","Hoda et al., 2016, Oncotarget",26950277,"http://www.ncbi.nlm.nih.gov/pubmed/26950277","true","PMC4924649","2016","3","22","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1162,"EID1162","HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear expression (N=121, 2+ moderate/3+ strong staining) than patients with low nuclear staining (N=89, 0 no/1+ weak staining)(P = 0.0169). Multivariate regression analysis identified expression of nuclear HSP110 as an independent prognostic factor for gastric cancer outcome (P = 0.0068). This was not found for cytoplasmic expression.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","B","Prognostic","Supports","Poor Outcome","N/A",490,2,NULL,"accepted",0,"evidence",801,"Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer.","Kimura et al., 2016, Oncotarget",26943774,"http://www.ncbi.nlm.nih.gov/pubmed/26943774","true","PMC4951298","2016","4","5","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1163,"EID1163","49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+ moderate/3+ strong staining) was significantly lower compared with the low expression group (0 no/1+ weak staining) (P = 0.0364). In gastric cancer cell lines (MKN7, MKN45), siRNA mediated HSP110 knockdown led to a higher sensitivity to 5-FU and cisplatin compared with the parent and control cells (p < 0.05).",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","D","Predictive","Supports","Sensitivity","N/A",490,1,"Substitutes","accepted",0,"evidence",801,"Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer.","Kimura et al., 2016, Oncotarget",26943774,"http://www.ncbi.nlm.nih.gov/pubmed/26943774","true","PMC4951298","2016","4","5","Oncotarget","Oncotarget","fully curated","395","5-fluorouracil",NULL,"326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1164,"EID1164","329 consecutive patients with stage IIâ€“III colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR. Patients underwent adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Patients with large HSP110 T(17) deletions (â‰¥5 bp; 18 of 77 patients, 23.4%) had longer times of relapse-free survival than patients with small or no deletions (â‰¤4 bp; 59 of 77 patients, 76.6%) in multivariate analysis (hazard ratio, 0.16; 95% confidence interval, 0.012â€“0.8; P = .03). A significant interaction between chemotherapy and T17 deletion was found (P =.009).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",491,2,"Combination","accepted",0,"evidence",802,"Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracilâ€“based chemotherapy.","Collura et al., 2014, Gastroenterology",24512910,"http://www.ncbi.nlm.nih.gov/pubmed/24512910",NULL,NULL,"2014","2",NULL,"Gastroenterology","Gastroenterology","fully curated","395","5-fluorouracil",NULL,"237","Oxaliplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1165,"EID1165","Biomarkers for response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08).",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Does Not Support","Sensitivity","N/A",492,1,NULL,"accepted",0,"evidence",803,"Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.","Pircher et al., 2016, Oncotarget",26956051,"http://www.ncbi.nlm.nih.gov/pubmed/26956051",NULL,NULL,"2016","4","12","Oncotarget","Oncotarget","fully curated","295","Antiangiogenic Therapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1166,"EID1166","Biomarkers for Response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08).",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Does Not Support","Sensitivity","N/A",493,1,NULL,"accepted",0,"evidence",803,"Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.","Pircher et al., 2016, Oncotarget",26956051,"http://www.ncbi.nlm.nih.gov/pubmed/26956051",NULL,NULL,"2016","4","12","Oncotarget","Oncotarget","fully curated","295","Antiangiogenic Therapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1167,"EID1167","Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining â‰¥1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",276,4,"Substitutes","accepted",0,"evidence",804,"PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.","Passiglia et al., 2016, Oncotarget",26918451,"http://www.ncbi.nlm.nih.gov/pubmed/26918451",NULL,NULL,"2016","4","12","Oncotarget","Oncotarget","fully curated","261","Atezolizumab",NULL,"137","Nivolumab",NULL,"138","Pembrolizumab",NULL,"296","Avelumab",NULL,NULL,NULL,NULL
1168,"EID1168","The expression of PIM1, p-STAT3, and c-MYC was tested (IHC) in 194 NSCLC archival tumor samples. High nuclear expression of PIM1 was detected in 43.3% of cases and was significantly correlated with advanced clinical stage (p<0.001) and poor pathologic differentiation (P = 0.004) and was an independent unfavorable prognostic factors for overall and disease-free survival (OS, P=0.009; DFS, P=0.034).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","N/A",494,2,NULL,"accepted",0,"evidence",805,"Association of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma.","Jiang et al., 2016, J Cancer",26918046,"http://www.ncbi.nlm.nih.gov/pubmed/26918046","true","PMC4747887","2016",NULL,NULL,"J Cancer","Journal of Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1169,"EID1169","66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compared with the TT genotype (p = 0.002).",453,"Head And Neck Cancer","Head And Neck Cancer",11934,"http://www.disease-ontology.org/?id=DOID:11934","B","Prognostic","Supports","Poor Outcome","Germline Polymorphism",495,2,NULL,"accepted",0,"evidence",806,"Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.","Vivenza et al., 2016, Int. J. Biol. Markers",26916894,"http://www.ncbi.nlm.nih.gov/pubmed/26916894",NULL,NULL,"2016",NULL,NULL,"Int. J. Biol. Markers","The International journal of biological markers","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1170,"EID1170","19 advanced sarcoma patients treated with pazopanib were retrospectively assessed for mutations associated with response using the Foundation one sarcoma/heme panel. Progression-free survival (PFS) of patients with TP53 mutations (all predicted to be loss of function) was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)].",105,"Sarcoma","Sarcoma",1115,"http://www.disease-ontology.org/?id=DOID:1115","B","Predictive","Supports","Sensitivity","Somatic Mutation",221,2,NULL,"accepted",0,"evidence",807,"TP53 mutational status is predictive of pazopanib response in advanced sarcomas.","Koehler et al., 2016, Ann. Oncol.",26646755,"http://www.ncbi.nlm.nih.gov/pubmed/26646755",NULL,NULL,"2016","3",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","56","Pazopanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1171,"EID1171","HCC827 cell lines harboring activated PI3K (HCC827 p110Î± E545K cells) were more resistant to gefitinib in vitro (IC50, 1 Î¼M) compared with those harboring GFP alone (IC50, 0.01 Î¼M). The presence of p110Î± E545K also protected HCC827 cells from gefitinib-mediated apoptosis.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",104,2,NULL,"accepted",0,"evidence",808,"Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.","Engelman et al., 2006, J. Clin. Invest.",16906227,"http://www.ncbi.nlm.nih.gov/pubmed/16906227","true","PMC1570180","2006","10",NULL,"J. Clin. Invest.","The Journal of clinical investigation","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1172,"EID1172","Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3â‰¥50%, TC2â‰¥5% and <50%, TC1â‰¥1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3â‰¥10%, IC2â‰¥5% and <10%, IC1â‰¥1% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 0Â·49 [0Â·22-1Â·07; p=0Â·068], TC2/3 or IC2/3 HR 0Â·54 [0Â·33-0Â·89; p=0Â·014], TC1/2/3 or IC1/2/3 HR 0Â·59 [0Â·40-0Â·85; p=0Â·005], TC0 and IC0 HR 1Â·04 [0Â·62-1Â·75; p=0Â·871]) but not progression free survival or overall response rate.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",276,4,NULL,"accepted",0,"evidence",809,"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.","Fehrenbacher et al., 2016, Lancet",26970723,"http://www.ncbi.nlm.nih.gov/pubmed/26970723",NULL,NULL,"2016","4","30","Lancet","Lancet (London, England)","fully curated","261","Atezolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1173,"EID1173","Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation. Results from a mass spectrometry-based assay to evaluate KRAS activity suggests that G12C mutant KRAS is in a â€œhyperexcitableâ€ rather than a â€œstatically activeâ€ state. ARS-853 targets the inactive state and inhibited proliferation in a subset  (3/11) of KRAS G12C mutant cell lines in 2-D growth assays and 11/11 cell lines in soft-agar colony formation and 3-D assays. This effect was specific for KRAS G12C as 12/12 cell lines with other KRAS mutations (including other G12 mutations V, D and A) were not inhibited in either soft-agar assay.  Relative resistance to ARS-853 developed after epidermal growth factor (50 ng/mL) administration and the combination of erlotinib or afatinib (EGFR-inhibitors) with ARS-853 greatly potentiated growth arrest, apoptosis and decrease of PI3K and MAPK-signaling over single-agent ARS-853 treatment, even in the presence of added EGF.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",78,3,"Combination","accepted",0,"evidence",810,"Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.","Patricelli et al., 2016, Cancer Discov",26739882,"http://www.ncbi.nlm.nih.gov/pubmed/26739882",NULL,NULL,"2016","3",NULL,"Cancer Discov","Cancer discovery","fully curated","297","ARS-853",NULL,"145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1174,"EID1174","Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.",119,"Colon Cancer","Colon Cancer",219,"http://www.disease-ontology.org/?id=DOID:219","D","Predictive","Supports","Sensitivity","Somatic Mutation",45,4,"Combination","accepted",0,"evidence",811,"HER2 activating mutations are targets for colorectal cancer treatment.","Kavuri et al., 2015, Cancer Discov",26243863,"http://www.ncbi.nlm.nih.gov/pubmed/26243863","true","PMC4527087","2015","8",NULL,"Cancer Discov","Cancer discovery","fully curated","45","Lapatinib",NULL,"84","Trastuzumab",NULL,"52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1175,"EID1175","Updated results from ASCEND-1 trial assessing safety and activity of ceritinib in ALK rearranged locally advanced or metastatic NSCLC. 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC (Median follow-up: 11.1 months). Overall response rate was 72% [95% CI 61-82] of 83 ALK inhibitor-naive patients and 56% [49-64] of 163 ALK inhibitor-pretreated patients. Median duration of response was 17Â·0 months (95% CI 11.3-non-estimable [NE]) in ALK inhibitor-naive patients and 8.3 months (6.8-9.7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18.4 months (95% CI 11.1-NE) in ALK inhibitor-naive patients and 6.9 months (5.6-8.7) in ALK inhibitor-pretreated patients. Brain metastases control was reported in 79% [95% CI 54-94] of 19 ALK inhibitor-naive patients and in 65% [54-76] of 75 ALK inhibitor-pretreated patients.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,4,NULL,"accepted",0,"evidence",812,"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.","Kim et al., 2016, Lancet Oncol.",26973324,"http://www.ncbi.nlm.nih.gov/pubmed/26973324",NULL,NULL,"2016","4",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1176,"EID1176","Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.",119,"Colon Cancer","Colon Cancer",219,"http://www.disease-ontology.org/?id=DOID:219","D","Predictive","Supports","Sensitivity","Somatic Mutation",39,4,"Combination","accepted",0,"evidence",811,"HER2 activating mutations are targets for colorectal cancer treatment.","Kavuri et al., 2015, Cancer Discov",26243863,"http://www.ncbi.nlm.nih.gov/pubmed/26243863","true","PMC4527087","2015","8",NULL,"Cancer Discov","Cancer discovery","fully curated","45","Lapatinib",NULL,"84","Trastuzumab",NULL,"52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1177,"EID1177","Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.",119,"Colon Cancer","Colon Cancer",219,"http://www.disease-ontology.org/?id=DOID:219","D","Predictive","Supports","Sensitivity","Somatic Mutation",44,4,"Combination","accepted",0,"evidence",811,"HER2 activating mutations are targets for colorectal cancer treatment.","Kavuri et al., 2015, Cancer Discov",26243863,"http://www.ncbi.nlm.nih.gov/pubmed/26243863","true","PMC4527087","2015","8",NULL,"Cancer Discov","Cancer discovery","fully curated","84","Trastuzumab",NULL,"45","Lapatinib",NULL,"52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1178,"EID1178","Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.",119,"Colon Cancer","Colon Cancer",219,"http://www.disease-ontology.org/?id=DOID:219","D","Predictive","Supports","Sensitivity","Somatic Mutation",496,4,"Combination","accepted",0,"evidence",811,"HER2 activating mutations are targets for colorectal cancer treatment.","Kavuri et al., 2015, Cancer Discov",26243863,"http://www.ncbi.nlm.nih.gov/pubmed/26243863","true","PMC4527087","2015","8",NULL,"Cancer Discov","Cancer discovery","fully curated","45","Lapatinib",NULL,"84","Trastuzumab",NULL,"52","Neratinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1179,"EID1179","Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.",119,"Colon Cancer","Colon Cancer",219,"http://www.disease-ontology.org/?id=DOID:219","D","Predictive","Supports","Sensitivity","Somatic Mutation",497,4,"Combination","accepted",0,"evidence",811,"HER2 activating mutations are targets for colorectal cancer treatment.","Kavuri et al., 2015, Cancer Discov",26243863,"http://www.ncbi.nlm.nih.gov/pubmed/26243863","true","PMC4527087","2015","8",NULL,"Cancer Discov","Cancer discovery","fully curated","45","Lapatinib",NULL,"52","Neratinib",NULL,"84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1180,"EID1180","12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.7â€“3.8) and 7.2 months (95% CI 5.7â€“9.7).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",81,3,NULL,"accepted",0,"evidence",813,"Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.","Schirripa et al., 2015, Ann. Oncol.",26371285,"http://www.ncbi.nlm.nih.gov/pubmed/26371285",NULL,NULL,"2015","12",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1181,"EID1181","Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",81,4,NULL,"accepted",0,"evidence",814,"Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.","Rowland et al., 2016, Eur. J. Cancer",26812186,"http://www.ncbi.nlm.nih.gov/pubmed/26812186",NULL,NULL,"2016","3",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1182,"EID1182","Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line. KRAS wild-type, but not KRAS mutant tumors were sensitive to proteasome inhibitor ixazomib",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",336,1,NULL,"accepted",0,"evidence",815,"KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.","Chattopadhyay et al., 2015, PLoS ONE",26709701,"http://www.ncbi.nlm.nih.gov/pubmed/26709701","true","PMC4692403","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated","298","Ixazomib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1183,"EID1183","CDK1 was identified in a preclinical siRNA screen to identify targets in KRAS mutant tumors. Cell viability was evaluated following knockdown of 834 genes in isogenic LIM1215 colorectal cancer cell lines harboring wildtype (parental), G12S, G12D or G12V KRAS. 6 targets identified by this screen were evaluated in a second set of isogenic colorectal cancer cell lines (SW48) harboring wildtype (parental), G12S, G12D, G12V or G13D KRAS where only CDK1 knockdown more profoundly reduced survival in mutant cells compared to wildtype. Results were validated in 5 KRAS mutant (BRAF WT) and 10 KRAS WT colorectal cancer cell lines. Chemical inhibition of CDK1 by AZD5438 in KRAS mutant vs WT pancreatic and colorectal cancer cell lines showed increased efficacy in mutant cell lines. Finally, AZD5438 reduced tumor growth induced by SW620 (KRAS p.G12V) colorectal tumour cells xenografted into immunodeficient mice.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",336,3,NULL,"accepted",0,"evidence",816,"CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.","Costa-Cabral et al., 2016, PLoS ONE",26881434,"http://www.ncbi.nlm.nih.gov/pubmed/26881434","true","PMC4755568","2016",NULL,NULL,"PLoS ONE","PloS one","fully curated","299","AZD5438",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1184,"EID1184","The study found mir-218 was significantly under-expressed when compared to matched adjacent normal tissue in 107 samples via qPCR. Further, low expression of mir-218 was revealed to be associated with lower overall survival (p < .001), and multivariate analysis revealed that low expression of mir-218 as an independent predictor of poor prognosis (p < .007).",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","D","Prognostic","Supports","Poor Outcome","Somatic Mutation",498,3,NULL,"accepted",0,"evidence",817,"Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis.","Li et al., 2015, Genet. Mol. Res.",26662432,"http://www.ncbi.nlm.nih.gov/pubmed/26662432",NULL,NULL,"2015",NULL,NULL,"Genet. Mol. Res.","Genetics and molecular research : GMR","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1185,"EID1185","A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to the therapy was demonstrated by comparing CAT scans obtained before treatment to those obtained during treatment (at 2 months of crizotinib therapy).",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",324,3,NULL,"accepted",0,"evidence",754,"MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.","Awad et al., 2016, J. Clin. Oncol.",26729443,"http://www.ncbi.nlm.nih.gov/pubmed/26729443",NULL,NULL,"2016","3","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1186,"EID1186","A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",324,3,NULL,"accepted",0,"evidence",818,"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.","Frampton et al., 2015, Cancer Discov",25971938,"http://www.ncbi.nlm.nih.gov/pubmed/25971938",NULL,NULL,"2015","8",NULL,"Cancer Discov","Cancer discovery","fully curated","300","Capmatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1187,"EID1187","In the Phase I study PROFILE 1001 (NCT00585195), a recommended crizotinib dose of 250 mg twice daily for 28 day cycles was established. Among 1,500 advanced NSCLC patients who were screened for ALK-rearrangement using a break-apart FISH assay, 82 patients were eligible for crizotinib treatment.  Overall response rate was 57%, with 46 partial responses and one complete response.  Since crizotinib inhibits MET, 33 patients with available tissue were screened for MET amplification and were found negative, further indicating that patient response was due to ALK inhibition.  31 patients were tested via RT-PCR for known EML4-ALK fusions, and 13 were shown to have EML4-ALK variant 1, four cases had variant 3, and one instance of variants 2, 3b and 5 were seen.  9 were unidentified, suggesting other fusion partners in these instances.  On the basis of this and a Phase II study, accelerated approval for crizotinib in ALK-positive advanced NSCLC was granted.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","A","Predictive","Supports","Sensitivity","Somatic Mutation",499,5,NULL,"accepted",0,"evidence",819,"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.","Kwak et al., 2010, N. Engl. J. Med.",20979469,"http://www.ncbi.nlm.nih.gov/pubmed/20979469","true","PMC3014291","2010","10","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1188,"EID1188","A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.  Analysis of clones from one transformed focus yielded a novel fusion. This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK. In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.  BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK. These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",5,5,NULL,"accepted",0,"evidence",820,"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.","Soda et al., 2007, Nature",17625570,"http://www.ncbi.nlm.nih.gov/pubmed/17625570",NULL,NULL,"2007","8","2","Nature","Nature","fully curated","301","WHI-P154",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1189,"EID1189","In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) was found. This patient had adenocarcinoma and a 9 pack year smoking history. Crizotinib treatment duration was over 16 weeks. The patient had multiple lines of prior treatment and showed a partial response to first-time crizotinib treatment. Overall, in the 82 ALK positive patients treated in the study, 46 had partial responses (including this patient) and 1 had a complete response for an overall response rate of 57%.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",500,2,NULL,"accepted",0,"evidence",819,"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.","Kwak et al., 2010, N. Engl. J. Med.",20979469,"http://www.ncbi.nlm.nih.gov/pubmed/20979469","true","PMC3014291","2010","10","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1190,"EID1190","Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion containing EML4 exon 2 and exon 20 of ALK. This was called variant 5. Two versions of this variant were seen: 5a consisted of EML4 exon 2 fused to ALK exon 20 while 5b contained a 117bp intronic ALK region between the two exons. Genomic PCR showed that EML4-ALK variant 5 tumor cells contained a single EML4-ALK fusion, suggesting 5a and 5b arise from alternate splicing.  5a and 5b showed in-vitro kinase activity and transformed 3T3 cells in cell culture. 5a and 5b transformed 3T3 cells formed tumors when injected in 8/8 nude mice, but 3T3 transformed with ALK alone did not.  These results suggest that EML4-ALK variant 5 is a driver mutation in lung adenocarcinoma targetable by ALK inhibitors like crizotinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","E","Predictive","Supports","Sensitivity","Somatic Mutation",501,4,NULL,"accepted",0,"evidence",821,"Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.","Takeuchi et al., 2008, Clin. Cancer Res.",18927303,"http://www.ncbi.nlm.nih.gov/pubmed/18927303",NULL,NULL,"2008","10","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1191,"EID1191","Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab.
NGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncertain significance were: a missense variant in ERBB2 and a missense variant in KDR at amino acid 961 converting the wild type residue, Arginine, to Tryptophan (frequency 28.25%). Because of the high frequency of the KDR (VEGFR2) mutation, the patient was considered a suitable candidate for a VEGFR inhibitor and received regorafenib monotherapy, which is approved for this situation, at 80mg daily which was later reduced to 40mg daily and had CEA normalization as well as partial metabolic and radiologic response. The patient remained almost asymptomatic and without disease progression after 39 weeks.",57,"Colorectal Adenocarcinoma","Colorectal Adenocarcinoma",50861,"http://www.disease-ontology.org/?id=DOID:0050861","C","Predictive","Supports","Sensitivity","Somatic Mutation",502,1,NULL,"accepted",0,"evidence",822,"KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.","Loaiza-Bonilla et al., 2016, Cureus",27004155,"http://www.ncbi.nlm.nih.gov/pubmed/27004155","true","PMC4780686","2016",NULL,NULL,"Cureus","CureÌ„us","fully curated","27","Regorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1192,"EID1192","In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of EML4 fused to the kinase domain of ALK. Genomic PCR resolved a single breakpoint, but 2 variants of the fusion were observed in cells. Variant 3a consisted of fusion at EML4 exon 6 and ALK exon 20, while variant 3b fused a 33 bp intronic EML4 region between EML4 exon 6 and ALK exon 20.  3a and 3b showed strong in-vitro kinase activity, transformed mouse 3T3 cells, and 3b-transformed 3T3 cells formed tumors in 8/8 nude mice.  The ALK inhibitor 2,4-pyrimidinediamine inhibited growth of the 3a/b containing NCI-H2228 NSCLC cell line.  The results indicate that 3a/b is a targetable driver-mutation as other EML4-ALK variants.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",503,4,NULL,"accepted",0,"evidence",823,"Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.","Choi et al., 2008, Cancer Res.",18593892,"http://www.ncbi.nlm.nih.gov/pubmed/18593892",NULL,NULL,"2008","7","1","Cancer Res.","Cancer research","fully curated","302","2,4-pyrimidinediamine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1193,"EID1193","In a set of 31 patients with NSCLC, RT-PCR was performed to test for known EML4-ALK variants.  Five patients tested positive for the 3a/3b EML4-ALK variant.  Of these, 4 had partial response (PR), and one had disease progression (DP), and this was the only DP in the group of 31.  In contrast, of the 13 testing positive for EML4-ALK variant 1, 12 showed PR, and 1 showed stable disease.  These results potentially mirror findings in the H2228 3a/3b containing NSCLC cell line where some literature indicates it does respond as strongly to ALK inhibition as other EML4-ALK NSCLC cell lines.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",503,4,NULL,"accepted",0,"evidence",819,"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.","Kwak et al., 2010, N. Engl. J. Med.",20979469,"http://www.ncbi.nlm.nih.gov/pubmed/20979469","true","PMC3014291","2010","10","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1194,"EID1194","In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20). TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",503,2,NULL,"accepted",0,"evidence",824,"Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.","McDermott et al., 2008, Cancer Res.",18451166,"http://www.ncbi.nlm.nih.gov/pubmed/18451166",NULL,NULL,"2008","5","1","Cancer Res.","Cancer research","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1195,"EID1195","Exon-array and RT-PCR was used to screen a panel of 83 NSCLC cell lines for EML4-ALK variants. The cell lines NCI-H3122 (containing EML4-ALK variant 1) and NCI-H2228 (containing the EML4 exon 6 and ALK exon 20 fusion-variant 3a/3b) were identified. TAE684 (0.1uM) appreciably inhibited growth as well as Akt and Erk1/2 phosphorylation in variant 1 containing H3122 cells. However, incomplete inhibition in 3a/3b containing H2228 cells was observed. H2228 growth inhibition by TAE684 was more similar to NSCLC cell lines harboring KRAS and EGFR mutations.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",503,2,NULL,"accepted",0,"evidence",825,"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.","Koivunen et al., 2008, Clin. Cancer Res.",18594010,"http://www.ncbi.nlm.nih.gov/pubmed/18594010","true","PMC3025451","2008","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1196,"EID1196","EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus.  While all constructs rendered Ba/F3 cells IL3-independant, marked differences in sensitivity to ALK inhibitors TAE684 and crizotinib were observed, where v2 was most sensitized to growth inhibition and v3a the least, with v1 and v3b intermediate.  While phospho-ALK western blots indicated that the ALK inhibitors acted similarly on both v2 and v3a EML4-ALK variants, blots of cyclohexamide-treated cells showed that v2 had a shorter half-life than 3a in the transduced cells, potentially explaining increased v2 sensitivity.  Assays with a panel of mutated EML4-ALK variants of varied length suggested that longer EML4-ALK variants are less stable in cells, although this tendency was not observed across other types of ALK fusion.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",500,2,NULL,"accepted",0,"evidence",826,"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.","Heuckmann et al., 2012, Clin. Cancer Res.",22912387,"http://www.ncbi.nlm.nih.gov/pubmed/22912387",NULL,NULL,"2012","9","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1197,"EID1197","Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive. The authors suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",503,2,NULL,"accepted",0,"evidence",826,"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.","Heuckmann et al., 2012, Clin. Cancer Res.",22912387,"http://www.ncbi.nlm.nih.gov/pubmed/22912387",NULL,NULL,"2012","9","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1198,"EID1198","This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (assessed by break-apart FISH) with locally advanced or metastatic disease. 347 patients with disease progression after one round of platinum-based chemotherapy were randomized to receive crizotinib (N=173) or chemotherapy (N=174) consisting of pemetrexed in pemetrexed-naive patients and docetaxel for patients previously treated with pemetrexed. The primary endpoint - progression free survival (PFS) - was found to be significantly better for patients treated with crizotinib (median 7.7 months) than with chemotherapy (median 3.0 months) (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001). Response rates were 65% for crizotinib treatment and 20% for chemotherapy (P<0.001). Improvements in quality of life were also reported.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","A","Predictive","Supports","Sensitivity","Somatic Mutation",499,5,NULL,"accepted",0,"evidence",827,"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.","Shaw et al., 2013, N. Engl. J. Med.",23724913,"http://www.ncbi.nlm.nih.gov/pubmed/23724913",NULL,NULL,"2013","6","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1199,"EID1199","This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease. The study consisted of 343 patients with advanced or metastatic NSCLC that tested positive for ALK rearrangement via break-apart FISH assay, and had no prior systemic treatment. Patients were assigned in a 1:1 ratio to crizotinib (N=172) or pemetrexed with cisplatin or carboplatin (N=171). Progression free survival was significantly longer with crizotinib treatment than chemotherapy (10.9 vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% CI, 0.35 to 0.60;P<0.001), and objective response rate was higher with crizotinib treatment than chemotherapy (75% vs. 45%, P<0.001). Improvement in quality of life was also reported.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","A","Predictive","Supports","Sensitivity","Somatic Mutation",499,5,NULL,"accepted",0,"evidence",828,"First-line crizotinib versus chemotherapy in ALK-positive lung cancer.","Solomon et al., 2014, N. Engl. J. Med.",25470694,"http://www.ncbi.nlm.nih.gov/pubmed/25470694",NULL,NULL,"2014","12","4","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1200,"EID1200","This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD), defined as continuation of crizotinib for 3 or more weeks after disease progression on crizotinib. 194 patients who had developed PD by data cutoff were studied, where 120 received crizotinib for a median duration of 19.4 weeks and 74 discontinued crizotinib after PD. No gross imbalances in clinicopathologic features of the two groups were evident.  Significantly longer overall survival was observed in the crizotinib continuing group from time of PD (16.4 vs. 3.9 months; hazard ratio 0.27, 95% CI: 0.17â€“0.42; P < 0.0001), and from the time of initial crizotinib (29.6 vs. 10.8 months; HR 0.30, 95% CI: 0.19â€“0.46; P < 0.0001).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,4,NULL,"accepted",0,"evidence",829,"Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.","Ou et al., 2014, Ann. Oncol.",24478318,"http://www.ncbi.nlm.nih.gov/pubmed/24478318",NULL,NULL,"2014","2",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1201,"EID1201","This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting treated brain metastasis (tBM). IC-DCR was significantly improved in the tBM group given crizotinib (N=39) over chemotherapy (pemetrexed + cisplatin or carboplatin; N=40) at 12 weeks (85% vs. 45%, P<0.001), and at 24 weeks (56% vs. 25%, P=0.006). Progression free survival was also significantly improved with crizotinib over chemotherapy in the tBM subgroup (9.0 vs. 4.0 months; HR 0.40; P<0.001), where in the intent to treat population it was 10.9 vs. 7.0 months (HR 0.45; P<0.001), indicating that the difficult to treat BM population obtained benefit from crizotinib at both the brain and systemic level.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,4,NULL,"accepted",0,"evidence",830,"Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.","Solomon et al., 2016, J. Clin. Oncol.",27022118,"http://www.ncbi.nlm.nih.gov/pubmed/27022118",NULL,NULL,"2016","8","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1202,"EID1202","In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the targeted endpoint of 20% ORR. However, of 3/12 patients found to be ALK-rearranged via break apart FISH assay, 2 showed a partial response and the third stable disease, which was durable for 7.2 months. The authors note that the break apart FISH assay used to determine ALK-rearrangement status does not determine the identity of the ALK fusion partner and the promising results shown here may be dependent on the nature of the ALK fusion partner.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",499,2,NULL,"accepted",0,"evidence",831,"Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.","Sequist et al., 2010, J. Clin. Oncol.",20940188,"http://www.ncbi.nlm.nih.gov/pubmed/20940188","true","PMC4676802","2010","11","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","303","IPI-504",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1203,"EID1203","In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein the authors had encountered.  IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.  Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",5,4,"Combination","accepted",0,"evidence",832,"The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.","Normant et al., 2011, Oncogene",21258415,"http://www.ncbi.nlm.nih.gov/pubmed/21258415",NULL,NULL,"2011","6","2","Oncogene","Oncogene","fully curated","12","Crizotinib",NULL,"303","IPI-504",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1204,"EID1204","EML4-ALK fusions occur in 2-7% of lung adenocarcinomas. Transduction of Ba/F3 cells with EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) caused the cells to grow independently of IL3 addition.  EML4-ALK may be a client protein of Hsp90. Addition of Hsp90 inhibitor 17-DMAG to the EML4-ALK variant 2 cells induced cell death which was rescued at lower 17-DMAG concentrations by IL3 addition. This result suggests that 17-DMAG specifically  targeted the EML4-ALK driver in these cells. Finally, 17-DMAG and crizotinib showed a synergistic effect in killing EML4-ALK variant 2 cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",500,2,"Combination","accepted",0,"evidence",826,"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.","Heuckmann et al., 2012, Clin. Cancer Res.",22912387,"http://www.ncbi.nlm.nih.gov/pubmed/22912387",NULL,NULL,"2012","9","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","304","17-DMAG",NULL,"12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1205,"EID1205","Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition.  While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation. This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",503,2,NULL,"accepted",0,"evidence",826,"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.","Heuckmann et al., 2012, Clin. Cancer Res.",22912387,"http://www.ncbi.nlm.nih.gov/pubmed/22912387",NULL,NULL,"2012","9","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","304","17-DMAG",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1206,"EID1206","Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth. Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90. The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.  Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",5,2,"Combination","accepted",0,"evidence",826,"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.","Heuckmann et al., 2012, Clin. Cancer Res.",22912387,"http://www.ncbi.nlm.nih.gov/pubmed/22912387",NULL,NULL,"2012","9","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","304","17-DMAG",NULL,"12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1207,"EID1207","In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.  13/31 tested patients had the EML4-ALK variant 1. Of these, 12/13 had a partial response, and 1 had stable disease. This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",5,4,NULL,"accepted",0,"evidence",819,"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.","Kwak et al., 2010, N. Engl. J. Med.",20979469,"http://www.ncbi.nlm.nih.gov/pubmed/20979469","true","PMC3014291","2010","10","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1208,"EID1208","102 mCRC patients treated with anti-EGFR therapy were analyzed for 34 hotspot mutations in KRAS, NRAS and BRAF with nanofluidic digital PCR and quantitative PCR. dPCR and qPCR results were correlated to PFS and OS. Analysis of only KRAS exon 2 hotspot mutations showed that patients with more than 1% mutant allele fraction (n = 19/83) had a hazard ratio of 3.43 for PFS (95% CI, 1.67â€“7.02; P=0.002) and 2.72 for OS (95% CI, 1.52â€“4.88; P=0.002) compared to wild-type patients or patients with less than 1% mutant allele fraction. Considering all RAS and BRAF mutations, the patients with more than 1% mutant allele fraction (n = 37/65) had a hazard ratio of 4.52 for PFS (95% CI, 2.25â€“9.07; P<0.001) and 2.5 for OS (95% CI, 1.57â€“4.02; P<0.001). ROC analysis showed that a cut-off of 1% for any mutated allele offered the best predictive value.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",75,3,NULL,"accepted",0,"evidence",833,"Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.","Azuara et al., 2016, Mol. Cancer Ther.",27037411,"http://www.ncbi.nlm.nih.gov/pubmed/27037411",NULL,NULL,"2016","5",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1209,"EID1209","The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports functional studies of this variant. Mouse models with this variant show an increase in spontaneous tumor formation. 16 out of 20 (80%) of S47 homozygous mice developed cancer between 12 and 18 months of age. Cancers predominantly included hepatocellular carcinoma, B-cell lymphoma, and histiocytic sarcoma, as well as other
tumor types. In S47/wild-type heterozygote mice an increased cancer incidence, with a predisposition for hepatocellular carcinoma, was also found. Mouse embryonic fibroblasts and human lymphoblastoid cell lines with S47 mutations were significantly less sensitive to cisplatinum treatment compared to TP53 wild-type cells (apoptosis and viability).",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","E","Predictive","Supports","Resistance or Non-Response","Germline Polymorphism",504,2,NULL,"accepted",0,"evidence",834,"An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model.","Jennis et al., 2016, Genes Dev.",27034505,"http://www.ncbi.nlm.nih.gov/pubmed/27034505","true","PMC4840298","2016","4","15","Genes Dev.","Genes & development","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1210,"EID1210","Preclinical study in uveal melanoma cell lines. Cell lines (n=4) with GNAQ mutation (92.1, Omm1.3, Mel270, Mel202) were more sensitive to BRD4 inhibition with JQ1 than GNAQ/GNA11 wild type (n=3) cell line. JQ1 also inhibited growth of a GNAQ mutant cell line (92.1) in a mouse xenograft model compared to vehicle (N=5 mice/group).",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","D","Predictive","Supports","Sensitivity","Somatic Mutation",505,2,NULL,"accepted",0,"evidence",835,"BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.","Ambrosini et al., 2015, Oncotarget",26397223,"http://www.ncbi.nlm.nih.gov/pubmed/26397223","true","PMC4741774","2015","10","20","Oncotarget","Oncotarget","fully curated","306","JQ1",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1211,"EID1211","Preclinical study in uveal melanoma cell lines. Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild type (n=3) cell line.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","D","Predictive","Supports","Sensitivity","Somatic Mutation",506,1,NULL,"accepted",0,"evidence",835,"BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.","Ambrosini et al., 2015, Oncotarget",26397223,"http://www.ncbi.nlm.nih.gov/pubmed/26397223","true","PMC4741774","2015","10","20","Oncotarget","Oncotarget","fully curated","306","JQ1",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1212,"EID1212","101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; Pâ€‰<â€‰0.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; Pâ€‰=â€‰0.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",558,3,NULL,"accepted",0,"evidence",836,"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.","Carvajal et al., 2014, JAMA",24938562,"http://www.ncbi.nlm.nih.gov/pubmed/24938562","true","PMC4249701","2014","6","18","JAMA","JAMA","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1213,"EID1213","101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; Pâ€‰<â€‰0.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; Pâ€‰=â€‰0.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",507,3,NULL,"accepted",0,"evidence",836,"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.","Carvajal et al., 2014, JAMA",24938562,"http://www.ncbi.nlm.nih.gov/pubmed/24938562","true","PMC4249701","2014","6","18","JAMA","JAMA","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1214,"EID1214","Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme. Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor prognostic markers. Germline homozygous c.2117delA, p. Lys706SerfsX19 mutation in PMS2, loss of PMS2 staining in the tumor and normal tissue confirmed a diagnosis of biallelic mismatch repair deficiency (bMMRD). Both tumors harbored driver mutations in POLE and were found to harbor 24,680 and 21,919 mutations per exome. Neoantigen load was assessed in 37 bMMRD patients and all malignant tumors had high numbers of predicted neoantigens (7-16x as high as in melanoma, lung or other immunoresponsive cancers). Treatment with nivolumab was begun and both patients had radiologic response. After 9 and 5 months of therapy, respectively, the patient and her brother resumed normal schooling and daily activities.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","C","Predictive","Supports","Sensitivity","Germline Mutation",508,4,NULL,"accepted",0,"evidence",837,"Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.","Bouffet et al., 2016, J. Clin. Oncol.",27001570,"http://www.ncbi.nlm.nih.gov/pubmed/27001570",NULL,NULL,"2016","7","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","137","Nivolumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1215,"EID1215","In 119 metastatic colorectal cancer patients treated with cetuximab-based first-line chemotherapy, KRAS G12D mutations (N=44) were associated with longer overall patient survival when compared to other KRAS G12 mutations (23.3 vs 14-18 months; G12V, A, C, S, R).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",79,3,NULL,"accepted",0,"evidence",838,"Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.","Modest et al., 2012, Oncology",22948721,"http://www.ncbi.nlm.nih.gov/pubmed/22948721",NULL,NULL,"2012",NULL,NULL,"Oncology","Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1216,"EID1216","In a study of 448 metastatic colorectal cancer patients treated with EGFR-TKIs and tested for EGFR and KRAS mutations, 69 tested positive for KRAS mutations. In 38 EGFR wildtype patients treated with erlotinib or gefitinib, those with KRAS G12C mutations (n=24) had shorter progression free survival rates compared to patients with non-G12C KRAS mutations (n=14; 4.3 vs 9 weeks; P = 0.009; HR=2.7). This was true when restricted to patients with an adenocarcinoma subtype only (n=18 vs 12; 4.1 vs 9 weeks; P = 0.007; HR=3.1). Overall survival was not different between groups.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",78,3,"Substitutes","accepted",0,"evidence",839,"The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.","Fiala et al., Cancer Genet",23313110,"http://www.ncbi.nlm.nih.gov/pubmed/23313110",NULL,NULL,NULL,NULL,NULL,"Cancer Genet","Cancer genetics","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1217,"EID1217","In a study of 48 NSCLC patients, those with G12C or G12V mutant KRAS were associated with decreased progression free survival (1.84 months) compared with other KRAS mutants or with wild-type KRAS (3.35 and 1.95 months).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",78,3,NULL,"accepted",0,"evidence",840,"Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.","Ihle et al., 2012, J. Natl. Cancer Inst.",22247021,"http://www.ncbi.nlm.nih.gov/pubmed/22247021","true","PMC3274509","2012","2","8","J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1218,"EID1218","In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",336,3,NULL,"accepted",0,"evidence",910,"A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.","Riely et al., 2011, J Thorac Oncol",21847063,"http://www.ncbi.nlm.nih.gov/pubmed/21847063",NULL,NULL,"2011","8",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","307","Farnesylthiosalicylic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1219,"EID1219","In a retrospective study of 136 pancreatic cancer patients, point mutations in KRAS exon 2 were associated with worse overall survival compared to that of wild-type KRAS (5.8 vs 8.0 months; P = 0.001; multivariate analysis). This difference was largely driven by the subgroup of patients with reduced response to gemcitabine-erlotinib combination therapy (7.5% vs 23.3%) with overall survival of 5.2 vs 9.7 months (N=40 vs 30) compared to those that received other therapies with an overall survival of 7.0 months for both KRAS mutated (N=31) and KRAS wildtype (N=35) patients.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",75,4,"Combination","accepted",0,"evidence",842,"Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.","Kim et al., 2011, Mol. Cancer Ther.",21862683,"http://www.ncbi.nlm.nih.gov/pubmed/21862683",NULL,NULL,"2011","10",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","85","Gemcitabine",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1220,"EID1220","In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 30 NSCLC patients harbored KRAS mutations. Of those 22 patients with mutant KRAS, 8 saw reductions in tumor size ranging from 6-52% including 2 partial responses.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",336,2,NULL,"accepted",0,"evidence",843,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.","Infante et al., 2012, Lancet Oncol.",22805291,"http://www.ncbi.nlm.nih.gov/pubmed/22805291",NULL,NULL,"2012","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1221,"EID1221","In a phase III clinical trial comparing different doses of imatinib in GIST patients, KIT exon 9 mutations were associated with significantly improved progression free survival (P=0.0013) and a 61% relative risk reduction in response to the higher dose regimen (N=31; 800mg/daily) when compared to the lower dose regimen (N=27; 400 mg/daily; HR 0.329; 95% CI 0.218â€“0.706). The same dose dependent responses were not observed with KIT exon 11 mutations (N=130 vs 118; P=0.25; HR 0.821; 95% CI 0.585â€“1.151) or with wild-type KIT (N=25 vs 27; P=0.07; HR 1.823; 95% CI 0.938â€“3.543).",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Predictive","Supports","Sensitivity","Somatic Mutation",509,4,NULL,"accepted",0,"evidence",844,"KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.","Debiec-Rychter et al., 2006, Eur. J. Cancer",16624552,"http://www.ncbi.nlm.nih.gov/pubmed/16624552",NULL,NULL,"2006","5",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1222,"EID1222","In a phase II clinical trial of 43 melanoma patients harboring KIT mutations or amplifications, imatinib treatment exhibited significant anti-tumor activity with a median progression free survival of 3.5 months, tumor regression in 41.9% of patients, and a 1-year overall survival rate of 51%. 9/10 partial responses were in patients with exon 11 or 13 KIT mutations.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",388,3,NULL,"accepted",0,"evidence",845,"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.","Guo et al., 2011, J. Clin. Oncol.",21690468,"http://www.ncbi.nlm.nih.gov/pubmed/21690468",NULL,NULL,"2011","7","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1223,"EID1223","Primary tumor genotyping of 89 patients with metastatic GIST given 2nd-line sunitinib treatment after prior imatinib therapy failure, revealed an improved response to sunitinib in patients with KIT exon 9 mutations or with wild-type KIT compared those with KIT exon 11 or PDGFRA mutations. 1-year progression free survival rates for exon 9 mutants and wild type were 68% and 57%, compared with 34% and 15% for exon 11 and PDGFRA mutants.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Predictive","Supports","Sensitivity","Somatic Mutation",509,3,NULL,"accepted",0,"evidence",846,"The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.","Rutkowski et al., 2012, BMC Cancer",22439647,"http://www.ncbi.nlm.nih.gov/pubmed/22439647","true","PMC3361487","2012",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1224,"EID1224","10 melanoma patients were evaluated after sunitinib treatment, among which 3 out of the 4 patients with KIT exon 11 mutations showed either complete or partial response.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",66,3,NULL,"accepted",0,"evidence",847,"Sunitinib therapy for melanoma patients with KIT mutations.","Minor et al., 2012, Clin. Cancer Res.",22261812,"http://www.ncbi.nlm.nih.gov/pubmed/22261812",NULL,NULL,"2012","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1225,"EID1225","Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four out of eight patients with NRAS mutations.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Sensitivity","Somatic Mutation",208,2,"Combination","accepted",0,"evidence",848,"PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.","Coupe et al., 2015, Eur. J. Cancer",25542057,"http://www.ncbi.nlm.nih.gov/pubmed/25542057",NULL,NULL,"2015","2",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","73","Docetaxel",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1226,"EID1226","Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9 Patients, Gln61Arg 15 Patients). Another 13 patients had stable disease (63% disease control rate).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Sensitivity","Somatic Mutation",94,2,NULL,"accepted",0,"evidence",849,"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.","Ascierto et al., 2013, Lancet Oncol.",23414587,"http://www.ncbi.nlm.nih.gov/pubmed/23414587",NULL,NULL,"2013","3",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","355","Binimetinib (MEK162)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1227,"EID1227","Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment). Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively).",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",208,2,NULL,"accepted",0,"evidence",850,"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.","Falchook et al., 2012, Lancet Oncol.",22805292,"http://www.ncbi.nlm.nih.gov/pubmed/22805292","true","PMC4109286","2012","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1228,"EID1228","Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","C","Predictive","Supports","Sensitivity","Somatic Mutation",506,2,NULL,"accepted",0,"evidence",850,"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.","Falchook et al., 2012, Lancet Oncol.",22805292,"http://www.ncbi.nlm.nih.gov/pubmed/22805292","true","PMC4109286","2012","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1229,"EID1229","Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","B","Predictive","Supports","Sensitivity","Somatic Mutation",505,2,NULL,"accepted",0,"evidence",850,"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.","Falchook et al., 2012, Lancet Oncol.",22805292,"http://www.ncbi.nlm.nih.gov/pubmed/22805292","true","PMC4109286","2012","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1230,"EID1230","Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations). The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model. Metformin-induced PI3K pathway suppression was identified as a potential mechanism.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",208,3,"Combination","accepted",0,"evidence",851,"Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.","Vujic et al., 2015, Oncotarget",25504439,"http://www.ncbi.nlm.nih.gov/pubmed/25504439","true","PMC4359268","2015","1","20","Oncotarget","Oncotarget","fully curated","19","Trametinib",NULL,"308","Metformin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1231,"EID1231","In a phase II trial on castration-resistant prostate cancer patients, FISH detection of PTEN deletion was associated with increased progression free survival (p=0.07) and with improved PSA response (p=0.02) in response to everolimus, an mTOR pathway inhibitor.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predictive","Supports","Sensitivity","Somatic Mutation",213,3,NULL,"accepted",0,"evidence",852,"Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).","Templeton et al., 2013, Eur. Urol.",23582881,"http://www.ncbi.nlm.nih.gov/pubmed/23582881",NULL,NULL,"2013","7",NULL,"Eur. Urol.","European urology","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1232,"EID1232","Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene mutations. No mutations found in PTEN were effective in predicting tumor response to everolimus treatment. The clinical trial associated with this study is NCT00870337.",123,"Endometrial Carcinoma","Endometrial Carcinoma",2871,"http://www.disease-ontology.org/?id=DOID:2871","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",510,3,NULL,"accepted",0,"evidence",853,"Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.","TrÃ©dan et al., 2013, Target Oncol",23238879,"http://www.ncbi.nlm.nih.gov/pubmed/23238879",NULL,NULL,"2013","12",NULL,"Target Oncol","Targeted oncology","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1233,"EID1233","Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stable disease, who later went on to complete 28 courses, was positive for GNAQ Q209L and PTEN R173S mutations. The PTEN mutation was identified only in the postdose biopsy and not in the predose biopsy.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","C","Predictive","Supports","Sensitivity","Somatic Mutation",507,2,NULL,"accepted",0,"evidence",690,"Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.","Weekes et al., 2013, Clin. Cancer Res.",23434733,"http://www.ncbi.nlm.nih.gov/pubmed/23434733",NULL,NULL,"2013","3","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","309","BAY 86-9766",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1234,"EID1234","Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanomas. HDAC inhibitors VPA, TSA, LBH-589, and SAHA (vorinostat) were tested in-vitro and led to decreased proliferation (all inhibitors) decreased viability and cytotoxicity (TSA, SAHA, LBH-589) in-vitro and in-vivo (VPA). RNAi mediated BAP1 knockdown increased sensitivity to HDAC inhibition (VPA).",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","D","Predictive","Supports","Sensitivity","Somatic Mutation",183,3,"Substitutes","accepted",0,"evidence",335,"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.","Landreville et al., 2012, Clin. Cancer Res.",22038994,"http://www.ncbi.nlm.nih.gov/pubmed/22038994","true","PMC3261307","2012","1","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","311","Trichostatin A (TSA)",NULL,"314","Vorinostat (SAHA)",NULL,"37","Valproic Acid",NULL,"312","LBH-589",NULL,NULL,NULL,NULL
1235,"EID1235","A siRNA screen identified BAP1 associated with HDAC1 and HDAC2 expression. HDAC2 or BAP1 depletion sensitized a mesothelioma cell line (MSTO-211H) to HDAC inhibitors MC1568, vorinostat or mocetinostat. The paper indicates however, that temporary BAP knockdown might not adequately reflect long-term BAP1 mutation.",112,"Malignant Mesothelioma","Malignant Mesothelioma",1790,"http://www.disease-ontology.org/?id=DOID:1790","E","Predictive","Supports","Sensitivity","Somatic Mutation",183,2,"Substitutes","accepted",0,"evidence",854,"Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.","Sacco et al., 2015, Oncotarget",25970771,"http://www.ncbi.nlm.nih.gov/pubmed/25970771","true","PMC4537048","2015","5","30","Oncotarget","Oncotarget","fully curated","315","Mocetinostat",NULL,"314","Vorinostat (SAHA)",NULL,"316","MC1568",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1236,"EID1236","Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor ponatinib (AP24534) than the FGFR2 wild type cell line (Ishikawa) and human embryonic kidney cell line (HEK293). Ponatinib also inhibited FGFR2 kinase activity and phosphorylation (MFE-296 and MFE-280) as well as cell migration and invasion (MFE-296 and AN3CA) of FGFR2 mutated cancer cell lines.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","D","Predictive","Supports","Sensitivity","Somatic Mutation",511,3,NULL,"accepted",0,"evidence",855,"Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.","Kim et al., 2016, Cancer Biol. Ther.",26574622,"http://www.ncbi.nlm.nih.gov/pubmed/26574622","true","PMC4847821","2016",NULL,NULL,"Cancer Biol. Ther.","Cancer biology & therapy","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1237,"EID1237","In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib.  Of 114 NSCLC patients treated with at least 400 mg/daily ceritinib, 1 had a complete response, 65 had a partial response, 25 had stable disease, 12 had progressive disease, and 11 withdrew from the study early. Ceritinib dosed at 400 mg or higher had similar results in patients who had or had not received prior crizotinib treatment. Overall response rate for patients with prior crizotinib treatment (83 out of 122) was 56% with median progression free survival of 6.9 months. For patients who had no prior crizotinib treatment, median progression free survival was 10.4 months.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",512,4,NULL,"accepted",0,"evidence",856,"Ceritinib in ALK-rearranged non-small-cell lung cancer.","Shaw et al., 2014, N. Engl. J. Med.",24670165,"http://www.ncbi.nlm.nih.gov/pubmed/24670165","true","PMC4079055","2014","3","27","N. Engl. J. Med.","The New England journal of medicine","partially curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1238,"EID1238","12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences. 1 patient was identified with 2 nonsynonymous coding mutations. R882 mutations accounted for 4/13 reported mutations, P904L for 2/13 mutations and the remaining had not been previously reported at the time of this report. Overall and event-free survival were worse for DNMT3A mutant patients although transplantation status was not considered (log-rank p=0.005 and p=0.009). Transformation to AML was increased for mutant 7/12 (58%) versus wildtype 39/138 (28%) patients (p=0.007). The authors note larger cohorts will be required to confirm these results.",34,"Myelodysplastic Syndrome","Myelodysplastic Syndrome",50908,"http://www.disease-ontology.org/?id=DOID:0050908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",189,3,NULL,"accepted",0,"evidence",785,"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.","Walter et al., 2011, Leukemia",21415852,"http://www.ncbi.nlm.nih.gov/pubmed/21415852","true","PMC3202965","2011","7",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1239,"EID1239","NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized.  In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib was assessed in cell lines and tumor xenograft models. Treatment of NPM-ALK positive ALCL cell lines Karpas299 and SU-DHL-1 potently inhibited growth, and this was seen to occur at concentrations which also inhibited NPM-ALK phosphorylation in these cells. Administration of 100mg/kg/d crizotinib resulted in complete regression of all tumors, indicating that NPM-ALK could be an effective target for crizotinib in ALCL.",348,"Anaplastic Large Cell Lymphoma","Anaplastic Large Cell Lymphoma",50744,"http://www.disease-ontology.org/?id=DOID:0050744","D","Predictive","Supports","Sensitivity","Somatic Mutation",513,5,NULL,"accepted",0,"evidence",857,"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.","Christensen et al., 2007, Mol. Cancer Ther.",18089725,"http://www.ncbi.nlm.nih.gov/pubmed/18089725",NULL,NULL,"2007","12",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1240,"EID1240","Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL). Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen, then salvage chemotherapy to prepare for autologous bone marrow transplant but ultimately relapsed. After initiation of crizotinib, PET, CT and bone marrow aspirates showed complete remission of previous lesions at 28 days. At time of publication the patient continued to show persistent response at 6 months. A 20 year old patient relapsed after one month of CHOP, and was treated with further chemotherapy and autologous bone marrow transplantation resulting in partial response of 1 month. Crizotinib was initialized, and after 12 days PET scan showed complete regression of all lesions. On day 60 bone marrow aspirates were ALK-negative (pretreatment evaluation showed 8% ALK-positive). The authors conclude these two cases indicate sensitivity to crizotinib of relapsed ALK-rearranged ALCL.",348,"Anaplastic Large Cell Lymphoma","Anaplastic Large Cell Lymphoma",50744,"http://www.disease-ontology.org/?id=DOID:0050744","C","Predictive","Supports","Sensitivity","Somatic Mutation",499,4,NULL,"accepted",0,"evidence",858,"Crizotinib in anaplastic large-cell lymphoma.","Gambacorti-Passerini et al., 2011, N. Engl. J. Med.",21345110,"http://www.ncbi.nlm.nih.gov/pubmed/21345110",NULL,NULL,"2011","2","24","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1241,"EID1241","In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib. Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease.  Crizotinib was well tolerated in these children.",348,"Anaplastic Large Cell Lymphoma","Anaplastic Large Cell Lymphoma",50744,"http://www.disease-ontology.org/?id=DOID:0050744","B","Predictive","Supports","Sensitivity","Somatic Mutation",513,4,NULL,"accepted",0,"evidence",859,"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.","MossÃ© et al., 2013, Lancet Oncol.",23598171,"http://www.ncbi.nlm.nih.gov/pubmed/23598171","true","PMC3730818","2013","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1242,"EID1242","Four adult ALK-rearranged anaplastic large cell lymphoma (ALCL) patients were resistant to chemotherapy after 3 or more lines of treatment.  The patients were administered 250 mg crizotinib twice daily. Normalization of symptoms was observed at a median time of 5 days, with an overall response rate of 100% (3 complete responses and one partial response)",348,"Anaplastic Large Cell Lymphoma","Anaplastic Large Cell Lymphoma",50744,"http://www.disease-ontology.org/?id=DOID:0050744","C","Predictive","Supports","Sensitivity","Somatic Mutation",499,3,NULL,"rejected",0,"evidence",860,"Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.","Foyil et al., Cancer J",23006951,"http://www.ncbi.nlm.nih.gov/pubmed/23006951",NULL,NULL,NULL,NULL,NULL,"Cancer J","Cancer journal (Sudbury, Mass.)","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1243,"EID1243","As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were given crizotinib. In six patients with measurable disease, responses included 3 with partial response and 3 with stable disease. One patient with evaluable disease had stable disease with treatment ongoing at the time of publication. Crizotinib was well tolerated in this group of pediatric patients.",12,"Inflammatory Myofibroblastic Tumor","Inflammatory Myofibroblastic Tumor",50905,"http://www.disease-ontology.org/?id=DOID:0050905","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,3,NULL,"accepted",0,"evidence",859,"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.","MossÃ© et al., 2013, Lancet Oncol.",23598171,"http://www.ncbi.nlm.nih.gov/pubmed/23598171","true","PMC3730818","2013","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1244,"EID1244","ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases. A 44 year old man was diagnosed with IMT.  He was treated with surgery and catheter placement for administration of cisplatin, doxyrubicin and mitomycin C.  Break-apart FISH showed ALK rearrangement, and immunohistochemical staining was characteristic of RANBP2 rearrangement. After further chemotherapy along with maintenance imatinib, crizotinib was started at 200mg twice daily, and a maximal partial response was achieved 5 months later, with regrowth occurring 2 months later. After further surgery, crizotinib was restarted at 250mg twice daily and almost 2 years later the patient was in complete radiographic remission. Another patient with non-ALK rearranged IMT was administered crizotinib in this study but did not respond.",12,"Inflammatory Myofibroblastic Tumor","Inflammatory Myofibroblastic Tumor",50905,"http://www.disease-ontology.org/?id=DOID:0050905","C","Predictive","Supports","Sensitivity","Somatic Mutation",514,4,NULL,"accepted",0,"evidence",861,"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.","Butrynski et al., 2010, N. Engl. J. Med.",20979472,"http://www.ncbi.nlm.nih.gov/pubmed/20979472","true","PMC3014292","2010","10","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1245,"EID1245","This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper extremity (RUE), scalp, and multiple lung lesions were apparent. A lung lesion sample with sufficient material for molecular profiling was not attainable but sufficient material was present from the RUE for hybrid capture genomic profiling  (FoundationOne kit was used). EML4-ALK variant 2 was found, and the patient was started on crizotinib. Rapid symptom improvement was seen. After 1 month, a CT scan showed significant size reduction in lung tumors, and after 5 months the patient was asymptomatic with an entirely negative examination.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","C","Predictive","Supports","Sensitivity","Somatic Mutation",500,3,NULL,"accepted",0,"evidence",862,"A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.","Chung et al., 2014, Case Rep Oncol",25408655,"http://www.ncbi.nlm.nih.gov/pubmed/25408655","true","PMC4209277","2014","9",NULL,"Case Rep Oncol","Case reports in oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1246,"EID1246","116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","E","Predictive","Supports","Sensitivity","Somatic Mutation",515,2,NULL,"accepted",0,"evidence",446,"Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.","Agelopoulos et al., 2015, Clin. Cancer Res.",26179511,"http://www.ncbi.nlm.nih.gov/pubmed/26179511",NULL,NULL,"2015","11","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1247,"EID1247","116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","D","Predictive","Supports","Sensitivity","N/A",267,3,NULL,"accepted",0,"evidence",446,"Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.","Agelopoulos et al., 2015, Clin. Cancer Res.",26179511,"http://www.ncbi.nlm.nih.gov/pubmed/26179511",NULL,NULL,"2015","11","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1248,"EID1248","Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement. CD72-ROS1 was identified in sequencing after progression on chemotherapy. Crizotinib at 250 mg orally twice daily led to resolution of metastatic disease. The patient remained disease-free for 13 months when a CT-scan showed a relapse with two nodules in the right lower lobe. Stereotactic radiation therapy, gamma knife radiosurgery, and ipilimumab did not lead to a relevant response (new pleural nodules, new intracranial metastases). The patient next received ceritinib on a â€œSignature Trial\" for tumors with aberrations in ALK or ROS1 that are treated with oral ceritinib (LDK378) at 750 mg daily (NCT02186821). Restaging scans after two cycles showed a partial response confirmed after four cycles (56% decrease) per RECIST1.1. MRI showed that his brain metastases decreased as well.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",269,1,NULL,"accepted",0,"evidence",865,"Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.","Subbiah et al., 2016, Proc. Natl. Acad. Sci. U.S.A.",26917690,"http://www.ncbi.nlm.nih.gov/pubmed/26917690","true","PMC4801313","2016","3","15","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1249,"EID1249","Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",465,3,"Substitutes","accepted",0,"evidence",866,"Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.","Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A.",26372962,"http://www.ncbi.nlm.nih.gov/pubmed/26372962","true","PMC4593101","2015","9","29","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","150","Foretinib",NULL,"144","Cabozantinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1250,"EID1250","Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",465,3,"Substitutes","accepted",0,"evidence",866,"Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.","Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A.",26372962,"http://www.ncbi.nlm.nih.gov/pubmed/26372962","true","PMC4593101","2015","9","29","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","318","Brigatinib",NULL,"159","Ceritinib",NULL,"12","Crizotinib",NULL,"319","AZD3463",NULL,NULL,NULL,NULL
1251,"EID1251","Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M mutations in ROS1.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",465,3,NULL,"accepted",0,"evidence",867,"PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.","Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.",25733882,"http://www.ncbi.nlm.nih.gov/pubmed/25733882","true","PMC4371934","2015","3","17","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","241","Lorlatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1252,"EID1252","Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cell viability and ROS1 phosphorylation. Crizotinib was also less effective at inhibiting kinase activity in ROS1 with L2026M mutation than wildtype. In contrast, PF-06463922 was effectively inhibited the fusion harboring this mutation in these assays.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",516,2,NULL,"accepted",0,"evidence",867,"PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.","Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.",25733882,"http://www.ncbi.nlm.nih.gov/pubmed/25733882","true","PMC4371934","2015","3","17","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1253,"EID1253","Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo, and in enzyme assays. After establishing that the CD74-ROS1 L2026M mutation confers crizotinib resistance in kinase activity and cell viability assays (in transduced BaF3 cells), response to PF-06463922 was tested.  Wild-type CD74-ROS1, CD74-ROS1 G2032R, and CD74-ROS1 L2026M all showed sensitivity to PF-06463922 in these assays.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",516,3,NULL,"accepted",0,"evidence",867,"PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.","Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.",25733882,"http://www.ncbi.nlm.nih.gov/pubmed/25733882","true","PMC4371934","2015","3","17","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","241","Lorlatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1254,"EID1254","ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line. The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one of the patients harboring the CD74â€“ROS1 fusion. Expression of CD74â€“ROS1 G2032R in Ba/F3 cells conferred resistance to crizotinib combared to CD74â€“ROS1 (IC50=353.62+/-20.15 vs. 2.76+/-0.82).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",465,3,NULL,"accepted",0,"evidence",868,"Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.","Song et al., 2015, Clin. Cancer Res.",25688157,"http://www.ncbi.nlm.nih.gov/pubmed/25688157",NULL,NULL,"2015","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1255,"EID1255","Ba/F3 cells expressing CD74â€“ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild-type CD74â€“ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (only ~6 fold higher IC50 than WT).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",465,2,NULL,"accepted",0,"evidence",868,"Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.","Song et al., 2015, Clin. Cancer Res.",25688157,"http://www.ncbi.nlm.nih.gov/pubmed/25688157",NULL,NULL,"2015","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","150","Foretinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1256,"EID1256","The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2â€“ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib treatment and CD74â€“ROS1 rearrangment. Crystal structure predicted ROS1 L2155S mutation to be highly destabilizating and cause protein structural modification. HCC78CR1, 2, and 3 cells and Ba/F3 cells transfected with CD74â€“ROS1 L2155S, showed resistance to crizotinib compared with parental HCC78 and Ba/F3 cells. In addition, these cell lines showed resistance to foretinib, a potent ROS1 inhibitor that is effective against ROS1 G2032R-mutant cells (16), and TAE684, a potent ALK inhibitor",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",517,3,"Substitutes","accepted",0,"evidence",868,"Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.","Song et al., 2015, Clin. Cancer Res.",25688157,"http://www.ncbi.nlm.nih.gov/pubmed/25688157",NULL,NULL,"2015","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,"150","Foretinib",NULL,"18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1257,"EID1257","Ba/F3 cells expressing CD74â€“ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74â€“ROS1; however, showed similar sensitivity to foretinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",516,2,NULL,"accepted",0,"evidence",868,"Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.","Song et al., 2015, Clin. Cancer Res.",25688157,"http://www.ncbi.nlm.nih.gov/pubmed/25688157",NULL,NULL,"2015","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1258,"EID1258","Ba/F3 cells expressing CD74â€“ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74â€“ROS1. This is in contrast to the increased resistance to crizotinib associated with this mutation in the same assay.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",516,2,NULL,"accepted",0,"evidence",868,"Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.","Song et al., 2015, Clin. Cancer Res.",25688157,"http://www.ncbi.nlm.nih.gov/pubmed/25688157",NULL,NULL,"2015","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","150","Foretinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1259,"EID1259","Ba/F3 cells expressing CD74â€“ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74â€“ROS1, and were sensitive to foretinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",518,2,NULL,"accepted",0,"evidence",868,"Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.","Song et al., 2015, Clin. Cancer Res.",25688157,"http://www.ncbi.nlm.nih.gov/pubmed/25688157",NULL,NULL,"2015","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1260,"EID1260","Ba/F3 cells expressing CD74â€“ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74â€“ROS1, and were sensitive to foretinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",518,2,NULL,"accepted",0,"evidence",868,"Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.","Song et al., 2015, Clin. Cancer Res.",25688157,"http://www.ncbi.nlm.nih.gov/pubmed/25688157",NULL,NULL,"2015","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","150","Foretinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1261,"EID1261","A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL). The patient had been heavily treated with chemotherapy before establishment of the cell line. The cell line maintained the tumor immunophenotype.  SNP analysis of patient bone marrow mononuclear cells and LM1 showed chromosomal changes associated with the cell line but 94.7% of SNPs were identically called.  ALK kinase inhibitor TAE684 induced cell death in LM1 cells at low nanomolar concentrations, while it did not significantly effect the ALK-rearrangement negative DLBCL cell line Karpas422.  LM1 cells formed tumors in 3/10 SCID and 9/10 NOD-SCID mice.  CD30 and CD138 immmunostaining were maintained between original tumor and LM1 xenografts. In mice, LM1 but not Karpas422 xenografts regressed with TAE684 administration, and complete remission for 13 weeks was observed before experiment was terminated.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","D","Predictive","Supports","Sensitivity","Somatic Mutation",520,4,NULL,"accepted",0,"evidence",871,"Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.","Cerchietti et al., 2011, PLoS ONE",21494621,"http://www.ncbi.nlm.nih.gov/pubmed/21494621","true","PMC3072987","2011",NULL,NULL,"PLoS ONE","PloS one","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1262,"EID1262","In a large study of patients with primary myelofibrosis evaluating mutations associated with anemia, 457 patients were evaluated for U2AF1 mutations. U2AF1 mutations were significantly associated with anemia in univariate and multivariate analysis (72 mutated vs 385 wildtype; P<0.0001). U2AF1 mutations were significantly associated with shorter overall survival in univariate analysis (P < 0.0001) but not in multivariate analysis with adjustment for age and anemia (P=0.24).",173,"Myelofibrosis","Myelofibrosis",4971,"http://www.disease-ontology.org/?id=DOID:4971","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",521,4,NULL,"accepted",0,"evidence",872,"Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.","Barraco et al., 2016, Blood Cancer J",27058230,"http://www.ncbi.nlm.nih.gov/pubmed/27058230","true","PMC4855254","2016",NULL,NULL,"Blood Cancer J","Blood cancer journal","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1263,"EID1263","CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL). In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive. Only one showed cytoplasmic, nuclear and nucleolar staining associated with NPM-ALK, while the others showed granular cytoplasmic ALK stain characteristic for CLTC-ALK.  Seven molecularly characterized cases were positive for CLTC-ALK.  6/7 patients were treated with CHOP chemotherapy with survival of 5, 10, 26 and 27 months, and two alive at end of study, and one CD20 positive patient was treated with CHOP chemotherapy supplemented with CD20-targeted rituximab, with survival of 8 months, resulting in median survival of 26 months for this group.  Although these numbers are not sufficient for statistical comparison, they compare unfavorably to 3.1 year overall survival and 45% 5 year survival of CHOP treated DLBCL patients, and even less favorably to R-CHOP standard of care for CD20 positive DLBCL, suggesting poor prognosis for CLTC-ALK DLBCL and need for updated treatment in this cohort.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","C","Prognostic","Supports","Poor Outcome","Somatic Mutation",520,3,NULL,"accepted",0,"evidence",873,"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.","Laurent et al., 2009, J. Clin. Oncol.",19636007,"http://www.ncbi.nlm.nih.gov/pubmed/19636007",NULL,NULL,"2009","9","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1264,"EID1264","A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL). ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to limited tissue. The patient underwent treatment with CHOP chemotherapy regimen and radiation but did not respond. The patient progressed following salvage chemotherapy and autologous stem cell transplant. Crizotinib was then administered at 250 mg twice daily, and LDH levels rapidly dropped along with disappearance of palpable lymphadenopathy, but progression ensued after 21 days and the patient died soon after. The authors attribute the short response to crizotinib to the possibility of this tumor having an ALK fusion variant less responsive to ALK inhibition and to a high Ki-67 index in the patient, and deem that despite the brief response, crizotinib shows promise in ALK rearranged DLBCL.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","C","Predictive","Supports","Sensitivity","Somatic Mutation",499,2,NULL,"accepted",0,"evidence",874,"Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.","Wass et al., 2014, Eur. J. Haematol.",24330038,"http://www.ncbi.nlm.nih.gov/pubmed/24330038",NULL,NULL,"2014","3",NULL,"Eur. J. Haematol.","European journal of haematology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1265,"EID1265","A 21 year old male presented with lymphadenopathy and a low density mass in pancreas. Histopathological analysis showed diffuse tumor cell infiltrate (CD20/EMA negative) with cytoplasmic ALK. RT-PCR indicated CLTC-ALK fusion. The patient was diagnosed with splenic ALK + diffuse large B cell lymphoma (DLBCL), Stage III, Group A with an IPI of 3. CHOP-21 chemotherapy regimen was administered with improvement in abdominal lymph nodes but worsening in retroperitoneal lymph nodes assessed via standardized uptake values. Subsequent ICE chemotherapy regiment relieved some symptoms prompting the patient to refuse further treatment despite other indications of disease progression. Therapy was reinstated after worsening of disease. GEMOX chemotherapy was administered with dexamethasone and 250mg crizotinib twice daily resulting in symptom relief, decreased lymphadenopathy and LDH decline. The disease then progressed and the patient died 2 months after crizotinib initiation. The authors conclude that partial response to crizotinib was observed and that in future trials ALK rearranged DLBCL patients might see increased benefit with earlier application of targeted therapy during the treatment course.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","C","Predictive","Supports","Sensitivity","Somatic Mutation",520,3,NULL,"accepted",0,"evidence",875,"Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature.","Li et al., 2015, Int J Clin Exp Med",26221234,"http://www.ncbi.nlm.nih.gov/pubmed/26221234","true","PMC4509179","2015",NULL,NULL,"Int J Clin Exp Med","International journal of clinical and experimental medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1266,"EID1266","Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman. Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A.  EML4-ALK variant 5 was discovered in tumor tissue using PCR with EML4 and ALK specific primers. The authors conclude that their findings confirm the potential for ALK targeting therapy in select cases of RCC.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","E","Predictive","Supports","Sensitivity","Somatic Mutation",501,3,NULL,"accepted",0,"evidence",876,"Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.","Sugawara et al., 2012, Cancer",22252991,"http://www.ncbi.nlm.nih.gov/pubmed/22252991",NULL,NULL,"2012","9","15","Cancer","Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1267,"EID1267","Cells harboring in-frame deletions in BRAF in the L485-P490 amino acid region were found to be sensitive to the RAF dimer inhibitor LY3009120, but not sensitive to the BRAF-selective inhibitors vemurafenib or dabrafenib. These deletions were observed in KRAS wildtype pancreatic, ovarian, NSCLC, and thyroid cancers. In three cell lines H2405 (NSCLC with L485-P490>Y), BxPC-3 (pancreatic with V487-P492>A), and OV-90 (ovarian with N486-P490del), BRAF deletionâ€“mediated MAPK activation was found to be sensitive to LY3009120 as evidenced by dose-dependent inhibition of phospho-MEK and ERK and cell growth inhibition with IC50 values of 0.04, 0.087, and 0.007 Î¼mol/L in these three cell lines. LY3009120, but not vemurafenib, also inhibited tumor growth of both H2405 and BxPC-3 cells xenografted into mice.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",522,3,NULL,"accepted",0,"evidence",877,"Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.","Chen et al., 2016, Cancer Discov",26732095,"http://www.ncbi.nlm.nih.gov/pubmed/26732095",NULL,NULL,"2016","3",NULL,"Cancer Discov","Cancer discovery","fully curated","320","LY3009120",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1268,"EID1268","Different ALK fusions were compared for crizotinib sensitivity using the Ba/F3 cell model. In Ba/F3 cells, AK fusions capable of acting as cancer drivers will cause IL3 independent growth, and ALK inhibition will reduce growth and cell viability. It was found that lower concentrations of crizotinib in the range of 0.3 micromolar, would inhibit Ba/F3 cells expressing EML4-ALK variant 2 and KIF5b-ALK, while concentrations around 1 micromolar would inhibit EML4-ALK variant 3a, with NPM-ALK cells being significantly inhibited around 0.7 micromolar crizotinib. 24 hour incubations with and without cyclohexamide (which inhibits protein synthesis) were performed in Ba/F3 cells ectopically expressing ALK fusions. The results indicated that NPM-ALK and EML4-ALK variant 3a protein levels were more stable in cells than other variants since there was more residual protein remaining in cells containing these variants after the cyclohexamide incubations, implying lower rate of protein turnover. These results may suggest subtle differences in NPM-ALK theraputic response compared to some other variants, although these fusions tend to arise in different cancer types.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",513,2,NULL,"rejected",0,"evidence",826,"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.","Heuckmann et al., 2012, Clin. Cancer Res.",22912387,"http://www.ncbi.nlm.nih.gov/pubmed/22912387",NULL,NULL,"2012","9","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1269,"EID1269","This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years. In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and two of these were germline mutations.  Of these 2 germline patients, 1 showed stable disease (SD) and 1 complete response (CR). In contrast, in the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The authors conclude this finding is promising and merits further study.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","C","Predictive","Supports","Sensitivity","Germline Mutation",9,2,NULL,"accepted",0,"evidence",859,"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.","MossÃ© et al., 2013, Lancet Oncol.",23598171,"http://www.ncbi.nlm.nih.gov/pubmed/23598171","true","PMC3730818","2013","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1270,"EID1270","A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study.  11 patients in this cohort had characterized ALK mutations, 4 of which were R1275Q mutation. Two of these R1275Q mutations were germline and two were somatic. Of these 2 somatic R1275Q patients, 1 showed progressive disease (PD) and 1 showed stable disease (SD). In contrast, of the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The stable disease patient had an R1275L mutation in ALK. In general, patients with germline or somatic R1275Q mutations or R1275L mutations had 1 complete response, 3 SD and one PD, while patients with other ALK mutations had 6 PD.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","C","Predictive","Supports","Sensitivity","Somatic Mutation",9,2,NULL,"accepted",0,"evidence",859,"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.","MossÃ© et al., 2013, Lancet Oncol.",23598171,"http://www.ncbi.nlm.nih.gov/pubmed/23598171","true","PMC3730818","2013","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1271,"EID1271","In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK. Of these 11 patients, 4 had the F1174L mutation. Among these 4 patients, stable disease (SD) was observed in one, and progressive disease (PD) was observed in 3 others after administration of crizotinib. In contrast, in the remaining 7 patients with mutations different than F1174L, 4 had PD, 2 had SD and one had complete response as best response after initiation of crizotinib.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",8,3,NULL,"accepted",0,"evidence",859,"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.","MossÃ© et al., 2013, Lancet Oncol.",23598171,"http://www.ncbi.nlm.nih.gov/pubmed/23598171","true","PMC3730818","2013","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1272,"EID1272","In this initial report of a single-arm Phase I and II study (JapicCTI-101264) of alectinib (CH5424802), 46 patients with advanced or metastatic ALK-rearranged non small cell lung cancer (NSCLC) were assessed for objective response during phase II. ALK positivity was assessed via IHC and verified with FISH or RT-PCR. Patients had received one or more rounds of previous chemotherapy, but no prior targeted therapy towards ALK. From the 46 patients, 41 showed partial response, and 2 showed complete response. CNS metastases in three patients which had not received prior brain irradiation showed response to alectinib. Alectinib was generally well tolerated, and the authors conclude that alectinib compared favorably to crizotinib and could be an effective and safe option in ALK-rearranged NSCLC.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,3,NULL,"accepted",0,"evidence",878,"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.","Seto et al., 2013, Lancet Oncol.",23639470,"http://www.ncbi.nlm.nih.gov/pubmed/23639470",NULL,NULL,"2013","6",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1273,"EID1273","In this case study of a critically ill 29 year old male nonsmoker with advanced metastatic ALK-positive NSCLC, alectinib (CH5424802), was administered as first line treatment. Where most clinical trials only admit patients with Eastern Cooperative Oncology Performance status (PS) of 0 or 1, this patient had PS 4 due to respiratory failure, multiple bone metastases and complications from disseminated intravascular coagulation (DIC). Administration of alectinib at 300 mg twice daily was followed by marked improvement seen in tests associated with DIC, pulmonary metastasis and change in PS from 4 to 0. Further improvements after a couple of months suggested a rapid complete response. Alectinib was well tolerated in this first line treatment of a critically ill ALK-positive NSCLC patient.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",499,3,NULL,"accepted",0,"evidence",879,"Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.","Yoshida et al., 2016, Anticancer Drugs",26938871,"http://www.ncbi.nlm.nih.gov/pubmed/26938871",NULL,NULL,"2016","7",NULL,"Anticancer Drugs","Anti-cancer drugs","fully curated","17","CH5424802",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1274,"EID1274","Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). Patients with increased PD-L1 protein had significantly shorter median DFS (36 months [membranous staining] and 49 months [cytoplasmic staining] vs. 186 months [negative], p < 0.001 and p < 0.01, respectively).",156,"Papillary Thyroid Carcinoma","Papillary Thyroid Carcinoma",3969,"http://www.disease-ontology.org/?id=DOID:3969","B","Prognostic","Supports","Poor Outcome","N/A",276,3,NULL,"accepted",0,"evidence",880,"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.","Chowdhury et al., 2016, Oncotarget",27086918,"http://www.ncbi.nlm.nih.gov/pubmed/27086918",NULL,NULL,"2016","4","12","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1275,"EID1275","465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous positivity, PD-L1 positivity in immune cells by at least 10% PD-L1 positive immune cells. Patients with PD-L1 positive tumor cells had a significant better overall (p=0.028) and tumor specific survival (p=0.018). The same applied for patients with PD-L1 positive immune cells (p<0.001 each).",1322,"Stomach Carcinoma","Stomach Carcinoma",5517,"http://www.disease-ontology.org/?id=DOID:5517","B","Prognostic","Supports","Better Outcome","N/A",276,3,NULL,"accepted",0,"evidence",881,"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.","BÃ¶ger et al., 2016, Oncotarget",27009855,"http://www.ncbi.nlm.nih.gov/pubmed/27009855",NULL,NULL,"2016","4","26","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1276,"EID1276","A screen for fusion genes in Ph- AYA-ALL (Philadelphia chromosome negative acute lymphoblastic leukemia in adolescents and young adults) was performed using RNA-seq from multiple cohorts of ALL patients. DUX4, ZNF384 and MEF2D fusions were the most frequent found.  DUX4 fusions were found only in AYA cases (age 15-39) and this was significant, p=0.016. DUX4 fusions clustered into groups distinct from the other fusions, and these fusions as a whole clustered with Ph- ALL cases. The authors performed extensive in vitro and in vivo experiments to demonstrate that DUX4 fusions are likely early initiating/events and that DUX4 fusion and not DUX4 wild type are tumorigenic. The authors conclude that DUX4 fusions may be a target driver resulting in AYA-ALL, and that AYA-ALL may be a distinct clinical entity.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","D","Diagnostic","Supports","Positive","Somatic Mutation",524,4,NULL,"accepted",0,"evidence",882,"Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.","Yasuda et al., 2016, Nat. Genet.",27019113,"http://www.ncbi.nlm.nih.gov/pubmed/27019113",NULL,NULL,"2016","5",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1277,"EID1277","Ph- ALL (Philadelphia chromosome negative acute lymphoblastic leukemia) gene expression profiles cluster into two main groups, Ph like and non-Ph like ALL.  Non-Ph like ALL have favorable outcomes when compared with Ph like ALL.  DUX4 fusions were discovered in a subset of Ph- ALL tumors through RNA-seq, and their mutation profile was found to cluster with non-Ph like ALL. It was found that patients with DUX4 fusions (N=9) had improved disease free survival over Ph like ALL patients (N=6) in the study. Eight years after complete remission, DUX4 fusion positive patients had over 0.8 disease free survival probability.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","C","Prognostic","Supports","Better Outcome","Somatic Mutation",524,3,NULL,"accepted",0,"evidence",882,"Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.","Yasuda et al., 2016, Nat. Genet.",27019113,"http://www.ncbi.nlm.nih.gov/pubmed/27019113",NULL,NULL,"2016","5",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1278,"EID1278","438 patients with non-metastatic clear-cell renal carcinoma were were retrospectively analysed for B4GALT1 expression via IHC. High B4GALT1 expression was associated with poor overall survival (P<0.001 and P<0.001 in training and validation cohort) and identified as an independent adverse prognostic factor for survival (P=0.007 and P=0.002).",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Prognostic","Supports","Poor Outcome","N/A",525,3,NULL,"accepted",0,"evidence",883,"Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.","Xie et al., 2016, Oncotarget",27092876,"http://www.ncbi.nlm.nih.gov/pubmed/27092876",NULL,NULL,"2016","4","15","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1279,"EID1279","In this Phase I trial (NCT01588028) in 47 patients, alectinib was assessed for its effectiveness in treating locally advanced or metastatic ALK-positive NSCLC that had progressed or been resistant to crizotinib treatment. ALK rearrangement was assessed via approved break apart FISH kit, and patients with asymptomatic CNS metastases were also included. Patients were divided into different cohorts receiving different doses of alectinib. In the 600 mg cohort (N=13), there were 4 confirmed partial responses, 3 unconfirmed partial responses and 3 instances of stable disease. Also, five of nine patients throughout the cohorts with measurable baseline CNS lesions showed partial response to alectinib. Cerebrospinal fluid levels of alectinib increased linearly with blood alectinib levels, indicating it effectively crossed the blood-brain barrier.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,4,NULL,"accepted",0,"evidence",884,"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.","Gadgeel et al., 2014, Lancet Oncol.",25153538,"http://www.ncbi.nlm.nih.gov/pubmed/25153538",NULL,NULL,"2014","9",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1280,"EID1280","DNA sequencing was performed in five Ph+ CML samples with sensitivity or resistance to imatinib. A structural variation in BIM2 (BCL2L11) with an identical 2,903-bp genomic deletion was identified in all three resistant samples. 2,597 healthy individuals were screened and the deletion polymorphism was identified in 12.3% of East Asian Population but 0% in African or European Population. In-vitro, imatinib-induced apoptosis was reduced in cells harboring the BIM deletion polymorphism.
Two East Asian CML cohorts (n=203) treated with imatinib were analzed for the polymorphism. Overall odds ratio for resistant disease among subjects with the deletion polymorphism compared to those without it was 2.94 (P = 0.02, 95% CI 1.17â€“7.43). Patients with the polymorphism, compared to those without, were more likely to be resistant without BCR-ABL mutations than resistant with BCR-ABL mutation or sensitive (odds ratio = 1.90, 95% CI 1.08â€“4.35).",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Predictive","Supports","Resistance or Non-Response","Germline Polymorphism",526,4,NULL,"accepted",0,"evidence",885,"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.","Ng et al., 2012, Nat. Med.",22426421,"http://www.ncbi.nlm.nih.gov/pubmed/22426421",NULL,NULL,"2012","4",NULL,"Nat. Med.","Nature medicine","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1281,"EID1281","The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensitive cell line led to TKI-resistance. In 141 NSCLC patients with EGFR mutations, the presence of the polymorphism (N=26) was predictive of a significantly shorter PFS under treatment with EGFR-TKI (6.6 months vs. 11.9 months, p = 0.0027). Patients received either gefitinib only (N=136) or erlotinib only (N=5).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Germline Polymorphism",526,4,NULL,"accepted",0,"evidence",885,"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.","Ng et al., 2012, Nat. Med.",22426421,"http://www.ncbi.nlm.nih.gov/pubmed/22426421",NULL,NULL,"2012","4",NULL,"Nat. Med.","Nature medicine","fully curated","145","EGFR Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1282,"EID1282","In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib. Of 69 patients with measurable disease, 35 achieved objective response, with median duration of response 13.5 months. Of 16 patients with measurable CNS disease, four achieved CNS complete response and 8 showed CNS partial response. median duration of CNS response was 11.1 months. 2 deaths were observed, and 1 was judged related to study treatment. In early 2016, alectinib was approved by the FDA partly based on this study for treatment of crizotinib-progressed ALK positive NSCLC",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","A","Predictive","Supports","Sensitivity","Somatic Mutation",499,5,NULL,"accepted",0,"evidence",886,"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.","Shaw et al., 2016, Lancet Oncol.",26708155,"http://www.ncbi.nlm.nih.gov/pubmed/26708155","true","PMC4752892","2016","2",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1283,"EID1283","The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again after 4 months of alectinib. The MGH056-1 cell line was derived from this patient, and this cell line was resistant to alectinib. Sequencing of MGH056-1 cells revealed the I1171T mutation in ALK. In cell culture studies Ba/F3 cells with EML4-ALK I1171T required more that 10x the concentration of alectinib to significantly reduce viability that was required for EML4-ALK wild-type expressing cells. Computer simulation studies indicated that the I1171T mutation interfered with alectinib binding at the ALK active site.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",527,4,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1284,"EID1284","The MGH056-1 cell line was derived from an NSCLC patient with ALK-rearrangement who had progressed on crizotinib and then on alectinib. the cell line was also resistant to crizotinib and alectinib, and sequencing of ALK from the cell line revealed the I1171T mutation. Further testing of this mutation in BaF3 cells revealed that cells expressing EML4-ALk with I1171T mutation required 10x higher concentration to induce cell death than BaF3 cells with wild-type EML4-ALK. In contrast, ceritinib caused loss of viability in EML4-ALK wild-type and I1171T BaF3 cells at comparable concentrations. Ceritinib was also effective at killing MGH056-1 cells that were resistant to alectinib, and reduced Akt and ERK phosphorylation in these cells. Finally, administration of ceritinib to the crizotinib and alectinib resistant patient let to tumor regression and partial response lasting 7 months.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",527,4,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1285,"EID1285","The I1171T ALK kinase domain mutaion was found in the MGH056-1 cell line which was derived from an ALK rearranged NSCLC patient who had progressed on crizotinib and then on alectinib given at lower dose (300mg twice daily).  Ectopic expression of EML4-ALK I1171T in Ba/F3 cells made these cells moderately resistant to crizotinib and resistant to alectinib. In contrast, the frequently used tool compound TAE684 was equally effective against EML4-ALK wild-type and I1171T, causing cell death at 1000x lower concentration then in unaltered Ba/F3 cells supplemented with IL3.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",527,3,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1286,"EID1286","The EML4 ALK variant 1 containing NSCLC cell line H3122 is highly sensitive to alectinib, and an alectinib resistant derivative cell line H3122 CHR-A1 was generated by incubation of H3122 in increasing levels of alectinib culminating in 1 micro-molar, over a course of 7 months. The ALK kinase domain mutation V1180L was found in these cells, and Ba/F3 cells expressing EML4 ALK  V1180L were highly resistant to alectinib. Simulations indicated that the V1180L mutation interfered with alectinib binding. The V1180L mutation was found to be more resistant to alectinib than the I1171T mutation found in an ALK-positive NSCLC patient who developed alectinib resistance on lower dose alectinib  (300mg twice daily).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",528,3,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1287,"EID1287","The MGH056-1 cell line was derived from a patient with ALK rearranged NSCLC who had progressed on crizotinib and then on lower dose alectinib (300 mg twice daily). The I1171T ALK kinase domain mutation was found in this cell line (established after alectinib resistance). MGH056-1 cells were resistant to crizotinib (IC50 236nmol/L; aproximately 50x higher than for ceritinib). About 50 fold higher concentration of crizotinib was required to inhibit Ba/F3 cells expressing EML4 ALK I1171T than was required for EML4 ALK wild-type.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",527,3,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1288,"EID1288","The alectinib resistant cell line H3122 CHR-A1 was generated by culturing of the EML4-ALK (variant 1) containing cell line H3122 with increasing levels of alectinib. Molecular characterization of H3122 CHR-A1 revealed a V1180L ALK kinase domain mutation. The H3122 CHR-A1 cell line required approximately 10 fold increase in crizotinib concentration to induce similar levels of cell death to H3122. Ectopic expression of EML4-ALK V1180L rendered Ba/F3 cells moderately less susceptible to crizotinib than ectopic EML4-ALK.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",528,2,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1289,"EID1289","Passaging of the alectinib sensitive EML4-ALK containing H3122 NSCLC cell line with increasing levels of alectinib resulted in an alectinib resistant derivative of this cell line named H3122 CHR-A1. A V1180L missense mutation was found in the kinase domain of ALK in H3122 CHR-A1 cells. Both H3122 and H3122 CHR-A1 cells were highly and equally sensitive to ceritinib induced death. In Ba/F3 cells, ectopic expression of EML4-ALK V1180L rendered cells significantly more sensitive to ceritinib than Ba/F3 containing EML4-ALK I1171T mutant (alectinib and crizotinib resistant) or EML4-ALK wt.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",528,3,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1290,"EID1290","The V1180L mutation in the kinase domain of rearranged ALK was found in an alectinib resistant cell line named H3122 CHR-A1, which was derived from the alectinib sensitive EML4-ALK variant 1 containing NSCLC cell line H3122 by passaging into higher concentrations of alectinib. This cell line is a model for gain of alectinib resistance, and also shows resistance to crizotinib. On the other hand, the often used tool ALK inhibitor TAE684 was highly effective in killing H3122 CHR-A1, where H3122 cells were only slightly more sensitized to TAE684-induced cell death. Ectopic expression of EML4-ALK V1180L in Ba/F3 cells caused IL3 independent growth as well as marked sensitization to TAE684, to a level greater than that seen in EML4-ALK I1171T (alectinib resistance mutation) or EML4-ALK wt, and over 1000x greater sensitivity than unaltered Ba/F3 + IL3.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",528,3,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1291,"EID1291","ALK mutation V1180L was found in an H3122 derivative cell line that had become alectinib resistant after being passaged in increasing levels of alectinib. EML4-ALK V1180L and EML4-ALK wild-type were ectopically expressed in Ba/F3 cells, and brigatinib showed strong activity against both variants. The IC50 for brigatinib against EML4-ALK wild-type was 0.95, which is about 3x higher than the IC50 that was observed for alectinib, but about 6x lower than that for crizotinib. In contrast, the IC50 for brigatinib against the alectinib resistance variant EML4-ALK V1180L was 0.49, indicating increased sensitivity to brigatinib over non mutant EML4-ALK.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",528,2,NULL,"accepted",0,"evidence",887,"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.","Katayama et al., 2014, Clin. Cancer Res.",25228534,"http://www.ncbi.nlm.nih.gov/pubmed/25228534","true","PMC4233168","2014","11","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","318","Brigatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1292,"EID1292","Absent expression of ATM, as assessed by IHC in 133 pancreatic ductal adenocarcinomas, was found to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM was associated with increased survival (17.7 months, P = 0.001). Furthermore loss of expression of nuclear phosphorylated Ser1981-ATM (IHC) was indicative of the worst prognosis (median survival, 10.8 vs 14.3 months [low expression] vs 31.1 months [high expression], P < 0.001).",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","B","Prognostic","Supports","Poor Outcome","N/A",179,2,NULL,"accepted",0,"evidence",888,"Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.","Kamphues et al., 2015, Pancreas",25423555,"http://www.ncbi.nlm.nih.gov/pubmed/25423555",NULL,NULL,"2015","3",NULL,"Pancreas","Pancreas","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1293,"EID1293","Nuclear Sirt1 expression was identified by IHC in 36 (27.9%) of 129 pancreatic ductal adenocarcinoma cases. SIRT1 expression was associated with poor survival in univariate (pâ€‰=â€‰0.002) and multivariate (HR 1.65, pâ€‰=â€‰0.045) analyses. Overexpression of Sirt1 in pancreas cancer cell lines MiaPaCa-2 and PANC-1 led to increased cell viability.",145,"Pancreatic Ductal Carcinoma","Pancreatic Ductal Carcinoma",3587,"http://www.disease-ontology.org/?id=DOID:3587","B","Prognostic","Supports","Poor Outcome","N/A",529,3,NULL,"accepted",0,"evidence",889,"High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.","Stenzinger et al., 2013, BMC Cancer",24088390,"http://www.ncbi.nlm.nih.gov/pubmed/24088390","true","PMC3850795","2013",NULL,NULL,"BMC Cancer","BMC cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1294,"EID1294","In-vitro study with MiaPaCa-2 and PANC-1 pancreatic cancer cell lines. Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a decrease in viability. Gefitinib treatment with concentrations of 50 Î¼M showed similar effects as observed for the application of 25 mM nicotinamide. Combinatory treatment with gefitinib and nicotinamide showed a synergistic effect on cell viability. In cell lines overexpressing Sirt1, higher concentrations of nicotinamide were required to abrogate increased cell viability mediated by Sirt1 overexpression compared to controls.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","D","Predictive","Supports","Resistance or Non-Response","N/A",529,1,NULL,"accepted",0,"evidence",889,"High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.","Stenzinger et al., 2013, BMC Cancer",24088390,"http://www.ncbi.nlm.nih.gov/pubmed/24088390","true","PMC3850795","2013",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","324","Nicotinamide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1295,"EID1295","In a phase 2 clinical study of 95 AML/high-risk MDS patients treated with either 50 or 100 mg midostaurin, 35 harbored FLT3 mutations (26 had FLT3 ITD, 9 had FLT3 D835Y mutations). A higher percentage of patients saw blast reductions in the FLT3 mutant group than in the FLT3 wild type group (71 vs 42%). Only one permanent response occurred in a FLT3 mutant patient receiving the 100 mg dose. No differences were observed in toxicity or response rate between the two doses of midostaurin.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",56,3,NULL,"accepted",0,"evidence",890,"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.","Fischer et al., 2010, J. Clin. Oncol.",20733134,"http://www.ncbi.nlm.nih.gov/pubmed/20733134","true","PMC4135183","2010","10","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","323","Midostaurin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1296,"EID1296","Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","B","Predictive","Supports","Sensitivity","Somatic Mutation",311,4,NULL,"accepted",0,"evidence",891,"Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.","AndrÃ© et al., 2016, J. Clin. Oncol.",27091708,"http://www.ncbi.nlm.nih.gov/pubmed/27091708",NULL,NULL,"2016","6","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1297,"EID1297","Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97).
The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","B","Predictive","Supports","Sensitivity","Somatic Mutation",214,4,NULL,"accepted",0,"evidence",891,"Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.","AndrÃ© et al., 2016, J. Clin. Oncol.",27091708,"http://www.ncbi.nlm.nih.gov/pubmed/27091708",NULL,NULL,"2016","6","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1298,"EID1298","In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28).",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",530,4,NULL,"accepted",0,"evidence",892,"Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.","Ogura et al., 2013, J. Gastroenterol.",22983505,"http://www.ncbi.nlm.nih.gov/pubmed/22983505",NULL,NULL,"2013","5",NULL,"J. Gastroenterol.","Journal of gastroenterology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1299,"EID1299","In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (as well as G12D) was associated with poorer prognosis (95% confidence interval of HR between 1.11 and 2.28).",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",530,4,NULL,"rejected",0,"evidence",892,"Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.","Ogura et al., 2013, J. Gastroenterol.",22983505,"http://www.ncbi.nlm.nih.gov/pubmed/22983505",NULL,NULL,"2013","5",NULL,"J. Gastroenterol.","Journal of gastroenterology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1300,"EID1300","In 219 patients with metastatic pancreatic ductal adenocarcinoma, a multivariate analysis identified KRAS G12D mutations as an independent predictor of poorer prognosis both in patients that have received chemotherapy (N=49/162), and the entire series (N=73/219). HR of 1.84 (P=0.02) and 1.44 (P=0.01), respectively.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",79,4,NULL,"accepted",0,"evidence",893,"KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.","Bournet et al., 2016, Clin Transl Gastroenterol",27010960,"http://www.ncbi.nlm.nih.gov/pubmed/27010960","true","PMC4822095","2016",NULL,NULL,"Clin Transl Gastroenterol","Clinical and translational gastroenterology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1301,"EID1301","A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Break apart FISH assay, which does not distinguish ROS1-fusion partner, was used on the tissue microarray to determine ROS1 fusion status. 2 cases of ROS1 fusions were found. 1 case was verified by RT-PCR to be a SLC34A2-ROS1 fusion, but this case was also positive for BRAF V600E.  The second case of ROS1 fusion was of undetermined fusion partner, where known ROS1 fusion parters SLC34A2, CD74 and SDC4 were tested. This case did not have KRAS or BRAF mutations, indicating that ROS1 fusion may act in a small subset of colorectal cancer as a driver targetable by crizotinib or other inhibitors.",57,"Colorectal Adenocarcinoma","Colorectal Adenocarcinoma",50861,"http://www.disease-ontology.org/?id=DOID:0050861","E","Predictive","Supports","Sensitivity","Somatic Mutation",269,2,NULL,"accepted",0,"evidence",894,"ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.","Aisner et al., 2014, Mol. Cancer Res.",24296758,"http://www.ncbi.nlm.nih.gov/pubmed/24296758","true","PMC4140177","2014","1",NULL,"Mol. Cancer Res.","Molecular cancer research : MCR","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1302,"EID1302","Large meta-analysis of 5,191 breast cancer patients and 3,834 controls did not find a conclusive link between codon 72 allele and breast cancer susceptibility. Odds ratios were 0.98 (95% CI, 0.91â€“1.05) for heterozygotes and 0.97 (95% CI, 0.86â€“1.11) in homozygotes (per-allele OR, 0.98; 95% CI, 0.91â€“1.04). Median age of onset was also not different between genotypes (GG: 49 years, GC: 50, CC: 50).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predisposing","Does Not Support","Positive","Germline Polymorphism",531,4,NULL,"accepted",0,"evidence",895,"Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.","Schmidt et al., 2007, Cancer Res.",17909070,"http://www.ncbi.nlm.nih.gov/pubmed/17909070",NULL,NULL,"2007","10","1","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1303,"EID1303","Pooled data from 13 studies of patients with lung cancer found little effect of codon 72 allele on the overall survival of patients with lung cancer. Proline homozygous patients were correlated with slightly poorer outcome, odds ratio 1.18 with a 95% confidence interval of 0.99-1.41. Heterozygotes had an OR of 1.02 (95% CI 0.86-1.20). Authors conclude that the effect of these alleles on prognosis in lung cancer is inconclusive at best.",152,"Lung Carcinoma","Lung Carcinoma",3905,"http://www.disease-ontology.org/?id=DOID:3905","B","Prognostic","Does Not Support","Poor Outcome","Germline Polymorphism",531,3,NULL,"accepted",0,"evidence",896,"TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis.","Matakidou et al., 2003, Mutagenesis",12840112,"http://www.ncbi.nlm.nih.gov/pubmed/12840112",NULL,NULL,"2003","7",NULL,"Mutagenesis","Mutagenesis","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1304,"EID1304","In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds ratios above one (3.5 and 2.2, respectively) after adjusting for age and HPV infection. However, both confidence intervals had minimums below one (0.9 and 0.6, respectively). So the overall conclusion remains mixed on the significance of this polymorphism in the prognosis for cervical cancer.",159,"Cervical Cancer","Cervical Cancer",4362,"http://www.disease-ontology.org/?id=DOID:4362","B","Prognostic","Does Not Support","Poor Outcome","Germline Polymorphism",531,2,NULL,"accepted",0,"evidence",897,"TP53 polymorphism, HPV infection, and risk of cervical cancer.","Klug et al., 2001, Cancer Epidemiol. Biomarkers Prev.",11535556,"http://www.ncbi.nlm.nih.gov/pubmed/11535556",NULL,NULL,"2001","9",NULL,"Cancer Epidemiol. Biomarkers Prev.","Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1305,"EID1305","In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mitomycin C, and the patient was shown to be asymptomatic after 3 years of follow-up.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","C","Predictive","Supports","Sensitivity","Somatic Mutation",532,4,NULL,"accepted",0,"evidence",898,"Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.","Villarroel et al., 2011, Mol. Cancer Ther.",21135251,"http://www.ncbi.nlm.nih.gov/pubmed/21135251","true","PMC3307340","2011","1",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","325","Mitomycin C",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1306,"EID1306","In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was assessed by IHC in 56 of 249 (22%).  Relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01-1.83; P = 0.04).",141,"Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma",3498,"http://www.disease-ontology.org/?id=DOID:3498","B","Prognostic","Supports","Better Outcome","N/A",533,3,NULL,"accepted",0,"evidence",899,"The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.","Tascilar et al., 2001, Clin. Cancer Res.",11751510,"http://www.ncbi.nlm.nih.gov/pubmed/11751510",NULL,NULL,"2001","12",NULL,"Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1307,"EID1307","In the pancreatic cell lines PL11 (FANCC homozygous deletion) and Hs766T (FANCG-mutated), sensitivity to DNA cross-linking agents was observed. PL11 cells (empty vector transduced) were more sensitive to mitomycin C (MMC), cisplatin, chlorambucil, and melphalan than PL11 cells transduced with a vector wildtype FANCC. Similarly, mouse xenografts of PL11 cells (empty vector) were more sensitive to MMC or gemcitabine than PL11 cells expressing a wildtype FANCC.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","D","Predictive","Supports","Sensitivity","Unknown",534,3,"Substitutes","accepted",0,"evidence",900,"In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.","van der Heijden et al., 2005, Clin. Cancer Res.",16243825,"http://www.ncbi.nlm.nih.gov/pubmed/16243825",NULL,NULL,"2005","10","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","325","Mitomycin C",NULL,"85","Gemcitabine",NULL,"328","Melphalan",NULL,"326","Cisplatin",NULL,"327","Chlorambucil",NULL
1308,"EID1308","In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and MiaPaCa2). Mitomycin C specifically led to regression in 8/11 xenografts of the CAPAN1 cell line compared to 2/9 in the CFPAC (BRCA2 wildtype) cell line.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","D","Predictive","Supports","Sensitivity","Germline Mutation",132,2,NULL,"accepted",0,"evidence",900,"In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.","van der Heijden et al., 2005, Clin. Cancer Res.",16243825,"http://www.ncbi.nlm.nih.gov/pubmed/16243825",NULL,NULL,"2005","10","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","325","Mitomycin C",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1309,"EID1309","15/127 patients with metastatic gastrointestinal stromal tumors were tested for PDGFRA mutations. 1 patient had a deletion of I843. CHO cells expressing this variant showed similar sensitivity to imatinib as cells expressing wildtype PDGFRA. 2/3 patients with a mutation determined to be sensitive in vitro (del I843 included) achieved partial response on imatinib treatment.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","D","Predictive","Supports","Sensitivity","Somatic Mutation",101,3,NULL,"accepted",0,"evidence",412,"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.","Heinrich et al., 2003, J. Clin. Oncol.",14645423,"http://www.ncbi.nlm.nih.gov/pubmed/14645423",NULL,NULL,"2003","12","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1310,"EID1310","A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate). Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH. Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","C","Predictive","Supports","Sensitivity","Somatic Mutation",535,3,NULL,"accepted",0,"evidence",901,"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.","Weston et al., 2013, J. Clin. Oncol.",23835704,"http://www.ncbi.nlm.nih.gov/pubmed/23835704",NULL,NULL,"2013","9","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1311,"EID1311","In 171 patients with tumors of the exocrine pancreas, a KRAS G12D mutation (N=60) was associated with shorter overall survival than being wild-type for KRAS (N=21; Hazard Ratio: 95% CI between 1.14 and 2.67). Additionally, KRAS mutations combined with CDKN2A alterations (N=26) showed an even worse OS than those wild-type for both (N=17; HR: 95%CI 1.33-7.10).",557,"Tumor Of Exocrine Pancreas","Tumor Of Exocrine Pancreas",1795,"http://www.disease-ontology.org/?id=DOID:1795","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",79,3,NULL,"accepted",0,"evidence",902,"Somatic mutations in exocrine pancreatic tumors: association with patient survival.","Rachakonda et al., 2013, PLoS ONE",23565280,"http://www.ncbi.nlm.nih.gov/pubmed/23565280","true","PMC3614935","2013",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1312,"EID1312","68 Caucasian men with metastatic castration resistant prostate cancer underwent treatment with abiraterone acetate. 832 single nucleotide polymorphisms (SNPs, Illumina OmniExpress) of 61 candidate genes reported to be involved in the androgen metabolic pathway were investigated for association with time to treatment failure (TTF). Occurence of >= 1 out of 6 SNPs in SULT1E1 were associated with decreased TTF on AA therapy (FDR q < 0.05) compared to patients without rare alleles.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predictive","Supports","Resistance or Non-Response","Germline Polymorphism",536,2,NULL,"rejected",0,"evidence",903,"Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer.","Agarwal et al., 2016, J. Urol.",27150425,"http://www.ncbi.nlm.nih.gov/pubmed/27150425",NULL,NULL,"2016","5","3","J. Urol.","The Journal of urology","fully curated","329","Arbiraterone Acetate",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1313,"EID1313","Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study. This finding was independent from other genomic and clinical factors explored by the authors.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","N/A",537,2,NULL,"accepted",0,"evidence",904,"Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.","Zhao et al., 2012, J Oncol",22619677,"http://www.ncbi.nlm.nih.gov/pubmed/22619677","true","PMC3350860","2012",NULL,NULL,"J Oncol","Journal of oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1314,"EID1314","In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",272,2,NULL,"accepted",0,"evidence",904,"Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.","Zhao et al., 2012, J Oncol",22619677,"http://www.ncbi.nlm.nih.gov/pubmed/22619677","true","PMC3350860","2012",NULL,NULL,"J Oncol","Journal of oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1315,"EID1315","The methylation status of MLH1 was analyzed in a study of 53 paraffin-embedded gastric cancer samples. No association was found between methylation status and clinical factors. The study showed that MLH1 methylation was associated with resistance to treatment with oxaliplatin.",1322,"Stomach Carcinoma","Stomach Carcinoma",5517,"http://www.disease-ontology.org/?id=DOID:5517","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",538,2,NULL,"accepted",0,"evidence",905,"Predictive value of CHFR and MLH1 methylation in human gastric cancer.","Li et al., 2015, Gastric Cancer",24748501,"http://www.ncbi.nlm.nih.gov/pubmed/24748501","true","PMC4894312","2015","4",NULL,"Gastric Cancer","Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","fully curated","237","Oxaliplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1316,"EID1316","Study explored the expression of the PTPN11 protein (SHP2) and found that expression was increased in a cohort of 112 laryngeal cancer samples. Expression was also associated with poor survival (p=.02) and in vitro models showed SHP2 expression promoted tumor growth.",623,"Laryngeal Carcinoma","Laryngeal Carcinoma",2600,"http://www.disease-ontology.org/?id=DOID:2600","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",539,2,NULL,"accepted",0,"evidence",906,"SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.","Gu et al., 2014, Int. J. Oncol.",24297342,"http://www.ncbi.nlm.nih.gov/pubmed/24297342",NULL,NULL,"2014","2",NULL,"Int. J. Oncol.","International journal of oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1317,"EID1317","In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia. 95% confidence interval of hazard ratio of between .17 and .77.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Predictive","Supports","Adverse Response","Germline Polymorphism",540,3,NULL,"accepted",0,"evidence",914,"Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.","van Erp et al., 2009, J. Clin. Oncol.",19667267,"http://www.ncbi.nlm.nih.gov/pubmed/19667267",NULL,NULL,"2009","9","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1318,"EID1318","Study explored the known PALB2 variant c.1592delT (p.L531C) in the context of breast cancer. The study found that among an augmented cohort of breast cancer patients with the variant, there was a hazard ratio of 6.1 (p=.01).  Further there is weak evidence to conclude that breast cancer risk for this variant decreases with age (p=.06).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Diagnostic","Supports","Positive","Germline Polymorphism",541,3,NULL,"accepted",0,"evidence",909,"Penetrance analysis of the PALB2 c.1592delT founder mutation.","Erkko et al., 2008, Clin. Cancer Res.",18628482,"http://www.ncbi.nlm.nih.gov/pubmed/18628482",NULL,NULL,"2008","7","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1319,"EID1319","Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L).",666,"Endometrial Adenocarcinoma","Endometrial Adenocarcinoma",2870,"http://www.disease-ontology.org/?id=DOID:2870","D","Predictive","Supports","Sensitivity","Somatic Mutation",542,2,NULL,"accepted",0,"evidence",911,"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.","Grabiner et al., 2014, Cancer Discov",24631838,"http://www.ncbi.nlm.nih.gov/pubmed/24631838","true","PMC4012430","2014","5",NULL,"Cancer Discov","Cancer discovery","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1320,"EID1320","Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L).",227,"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Leukemia",5603,"http://www.disease-ontology.org/?id=DOID:5603","D","Predictive","Supports","Sensitivity","Somatic Mutation",543,2,NULL,"accepted",0,"evidence",911,"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.","Grabiner et al., 2014, Cancer Discov",24631838,"http://www.ncbi.nlm.nih.gov/pubmed/24631838","true","PMC4012430","2014","5",NULL,"Cancer Discov","Cancer discovery","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1321,"EID1321","Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L).",48,"Renal Clear Cell Carcinoma","Renal Clear Cell Carcinoma",4467,"http://www.disease-ontology.org/?id=DOID:4467","D","Predictive","Supports","Sensitivity","Somatic Mutation",544,2,NULL,"accepted",0,"evidence",911,"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.","Grabiner et al., 2014, Cancer Discov",24631838,"http://www.ncbi.nlm.nih.gov/pubmed/24631838","true","PMC4012430","2014","5",NULL,"Cancer Discov","Cancer discovery","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1322,"EID1322","The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2.).",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","D","Predictive","Supports","Sensitivity","Somatic Mutation",545,3,NULL,"accepted",0,"evidence",952,"Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.","Byron et al., 2008, Cancer Res.",18757403,"http://www.ncbi.nlm.nih.gov/pubmed/18757403",NULL,NULL,"2008","9","1","Cancer Res.","Cancer research","fully curated","36","PD173074",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1323,"EID1323","Development of second generation ALK inhibitors has been underway in order to address resistance to first line treatments such as crizotinib in ALK-rearranged NSCLC.  Brigatinib is a potent dual inhibitor against ALK and EGFR.  In an update from the Phase I/II trial NCT01449461 of brigatinib in ALK+ NSCLC, patients were given 90 mg/day, 180 mg/day, or 90 followed by 180 mg/day. In crizotinib-naive patients, overall response rate (ORR) was 7/7 patients with progression free survival (PFS) of 56 weeks. In patients who failed on crizotinib treatment ORR was 69% (45/65 patients) with PFS of 47 weeks, and activity against CNS metastases was seen with ORR 37% in 38 patients with PFS 97 weeks indicating substantial brigatinib activity in crizotinib-progressed patients, as well as promise in CNS metastases.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,4,NULL,"rejected",0,"evidence",912,"Second- and third-generation ALK inhibitors for non-small cell lung cancer.","Wu et al., 2016, J Hematol Oncol",26951079,"http://www.ncbi.nlm.nih.gov/pubmed/26951079","true","PMC4782349","2016",NULL,NULL,"J Hematol Oncol","Journal of hematology & oncology","fully curated","318","Brigatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1324,"EID1324","In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depletion because, in two separate cell lines, also transfected with p16, that retained high pRB expression, chemotherapy resistance was still observed.",158,"Pancreas Adenocarcinoma","Pancreas Adenocarcinoma",4074,"http://www.disease-ontology.org/?id=DOID:4074","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",547,2,"Substitutes","accepted",0,"evidence",913,"Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis.","Plath et al., 2002, J. Natl. Cancer Inst.",11792751,"http://www.ncbi.nlm.nih.gov/pubmed/11792751",NULL,NULL,"2002","1","16","J. Natl. Cancer Inst.","Journal of the National Cancer Institute","fully curated","325","Mitomycin C",NULL,"68","Doxorubicin",NULL,"85","Gemcitabine",NULL,"395","5-fluorouracil",NULL,NULL,NULL,NULL
1325,"EID1325","Exome and RNA sequencing was performed in tumor and matched normal tissue of 19 patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. The variant PPP1R15A (rs557806) showed the most significant association (P = 0.000401) with FOLFIRI-bevacizumab-driven tumor inhibition rate in exome sequencing data and the highest correlation (r = 0.74) with the drug responses in RNA sequencing data. Patients who were homozygous for the reference alleles (GG) of PPP1R15A rs557806 exhibited greater disease control rates and a tendency toward greater overall response rate than those with homozygous or heterozygous substitution alleles (GC and CC; P = 0.027 and 0.073) when treated with bevacizumab-containing regimens. PPP1R15A rs557806 nonsignificantly correlated with DCR in multivariate analysis (P = 0.054). In HCT116 xenograft tumors, tumor growth IR with FRB was 25 % in mock cells, 24 % in clones with reference alleles (G alleles) of PPP1R15A rs557806, and 17 % in clones with substitution alleles (C alleles) of PPP1R15A rs557806 (P = 0.004, day 13). FDG-PET imaging on day 7 showed FDG uptake (mean SUV max) of 0.219 and 0.500 in HCT116 xenografts expressing the reference allele (G) and substitution allele (C) of PPP1R15A rs557806, respectively (P = 0.032).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Germline Polymorphism",548,1,"Combination","accepted",0,"evidence",915,"Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.","Roh et al., 2016, J. Cancer Res. Clin. Oncol.",27177629,"http://www.ncbi.nlm.nih.gov/pubmed/27177629",NULL,NULL,"2016","8",NULL,"J. Cancer Res. Clin. Oncol.","Journal of cancer research and clinical oncology","fully curated","332","FOLFIRI Regimen",NULL,"33","Bevacizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1326,"EID1326","31 patients with KRAS exon 2 mutation (codons 12 and 13) were treated with selumetinib and irinotecan. All patients had ECOG status 0 or 1 and confirmed progression after first line therapy with oxaliplatin-based chemotherapy and bevacizumab. Patients with more than one line of therapy, MEK or B-RAF inhibitor treatment or prior irinotecan treatment were excluded. The study was terminated before full accrual due to non-protocol considerations.
Three patients had a PR, 16 patients had SD >= 4 weeks. Median PFS for all patients was 105 days, median OS was 267 days.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",75,1,"Combination","accepted",0,"evidence",916,"Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.","Hochster et al., 2015, Cancer Chemother. Pharmacol.",25322874,"http://www.ncbi.nlm.nih.gov/pubmed/25322874",NULL,NULL,"2015","1",NULL,"Cancer Chemother. Pharmacol.","Cancer chemotherapy and pharmacology","fully curated","122","Selumetinib (AZD6244)",NULL,"101","Irinotecan",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1327,"EID1327","The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neuroblastoma cell lines containing wild-type ALK. Marked inhibition of soft agar colony formation of SH-SY5Y cells was also observed with drug treatment. AZD3463 inhibited Akt signaling in these cells within two hours of treatment, and activated apoptosis and autophagy pathways. Treatment of SH-SY5Y cells implanted into left kidneys of nude mice resulted in almost complete tumor regression.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",8,3,NULL,"accepted",0,"evidence",917,"Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.","Wang et al., 2016, Sci Rep",26786851,"http://www.ncbi.nlm.nih.gov/pubmed/26786851","true","PMC4726162","2016",NULL,NULL,"Sci Rep","Scientific reports","fully curated","319","AZD3463",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1328,"EID1328","In a cohort of 1596 neuroblastoma patients.   Five year event free survival was 74 months in non-MYCN amplified cases and 39 months in amplified cases. Differences were significant with p < 0.0001. Five year overall survival was 83 months and non-MYCN amplified cases and 46  months in amplified cases, with p < 0.0001, indicating poorer prognosis for MYCN-amplified cases.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","A","Prognostic","Supports","Poor Outcome","Somatic Mutation",298,4,NULL,"accepted",0,"evidence",918,"ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.","Bresler et al., 2014, Cancer Cell",25517749,"http://www.ncbi.nlm.nih.gov/pubmed/25517749","true","PMC4269829","2014","11","10","Cancer Cell","Cancer cell","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1329,"EID1329","Efficacy of the second generation ALK inhibitor PF-06463922 was tested on ALK mutation F1174L containing neuroblastoma-derived cells.  COG-N-453x and SH-SY5Y xenografts showed some inhibition when treated with crizotinib, but showed complete growth inhibition with PF-06463922 treatment.  This corresponded to 0% event free survival (EFS) in these mice by 6 weeks with crizotinib treatment, but 100% EFS with PF-06463922 treatment. Comparison of crizotinib and PF-06463922 growth inhibition in F1174L cells SH-SY5Y, NBSD 415-IMDM and KELLY showed increased sensitivity to PF-06463922, as compared to crizotinib. Inhibition effects were not seen on neuroblastoma cells with wild type ALK (NB-EBc1, SK-N-BE(2)C). Decreased phosphorylation on ALK tyrosine 1278 was seen with PF-06463922 over crizotinib at 10 and 100 nM concentrations in SH-SY5Y cells. PF-06463922 was well tolerated in the in-vivo models.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",8,4,NULL,"accepted",0,"evidence",919,"The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.","Infarinato et al., 2016, Cancer Discov",26554404,"http://www.ncbi.nlm.nih.gov/pubmed/26554404","true","PMC4707106","2016","1",NULL,"Cancer Discov","Cancer discovery","fully curated","241","Lorlatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1330,"EID1330","Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of event-free survival (EFS) with crizotinib treatment over vehicle, but EFS with crizotinib went down to 0% by six weeks.  In contrast, PF-06463922 treatment induced complete tumor regression and EFS rate of 100% at six weeks.  PF-06463922 inhibited viability in Felix cells at 37x efficacy over crizotinib, with IC50 values of 21.8 +/- 0.4 and 814.0 +/- 119 respectively.  PF-06463922 was well tolerated in the animal models.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",549,3,NULL,"accepted",0,"evidence",919,"The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.","Infarinato et al., 2016, Cancer Discov",26554404,"http://www.ncbi.nlm.nih.gov/pubmed/26554404","true","PMC4707106","2016","1",NULL,"Cancer Discov","Cancer discovery","fully curated","241","Lorlatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1331,"EID1331","In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and 19 fold greater effect on cell viability over crizotinib treatment respectively. ALK wild-type neuroblastoma cell lines did not show differential sensitivity to the treatments within the sensitivity range of R1275Q cells, and had IC50 values above 3800 nM to the inhibitors. NB-1653 cells induced tumors in CB17 SCID mice and crizotinib treatment inhibited tumor growth over vehicle treatment, but PF-06463922 induced complete tumor regression.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",9,4,NULL,"accepted",0,"evidence",919,"The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.","Infarinato et al., 2016, Cancer Discov",26554404,"http://www.ncbi.nlm.nih.gov/pubmed/26554404","true","PMC4707106","2016","1",NULL,"Cancer Discov","Cancer discovery","fully curated","241","Lorlatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1332,"EID1332","EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",5,2,NULL,"accepted",0,"evidence",919,"The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.","Infarinato et al., 2016, Cancer Discov",26554404,"http://www.ncbi.nlm.nih.gov/pubmed/26554404","true","PMC4707106","2016","1",NULL,"Cancer Discov","Cancer discovery","fully curated","241","Lorlatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1333,"EID1333","A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib.",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",549,3,NULL,"accepted",0,"evidence",859,"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.","MossÃ© et al., 2013, Lancet Oncol.",23598171,"http://www.ncbi.nlm.nih.gov/pubmed/23598171","true","PMC3730818","2013","5",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1334,"EID1334","26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potential rearrangements.  One sample showed potential rearrangement and RT-PCR demonstrated an EML4-ALK fusion where EML4 exon 21 was fused to ALK exon 13. This EML4-ALK variant is different from those commonly found in NSCLC. Genomic PCR verified the existence of the fusion breakpoint in intronic space, indicating that some colorectal adenocarcinoma may have targetable ALK-fusion driver mutations.",57,"Colorectal Adenocarcinoma","Colorectal Adenocarcinoma",50861,"http://www.disease-ontology.org/?id=DOID:0050861","E","Predictive","Supports","Sensitivity","Somatic Mutation",499,1,NULL,"accepted",0,"evidence",920,"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.","Lin et al., 2009, Mol. Cancer Res.",19737969,"http://www.ncbi.nlm.nih.gov/pubmed/19737969",NULL,NULL,"2009","9",NULL,"Mol. Cancer Res.","Molecular cancer research : MCR","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1335,"EID1335","84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential exon expression between the 3' and 5' ends of each gene. Two potential fusions were found and assessed using RNA ligase mediated rapid amplifiation of cDNA ends and RT-PCR. The fusions were EML4-ALK variants 1 and 2. Genomic PCR identified fusion breakpoints, and these differed from breakpoints for these EML4-ALK variants reported in NSCLC.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","E","Predictive","Supports","Sensitivity","Somatic Mutation",499,1,NULL,"accepted",0,"evidence",920,"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.","Lin et al., 2009, Mol. Cancer Res.",19737969,"http://www.ncbi.nlm.nih.gov/pubmed/19737969",NULL,NULL,"2009","9",NULL,"Mol. Cancer Res.","Molecular cancer research : MCR","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1336,"EID1336","The MYCN amplification positive relapsed neuroblastoma-derived cell line CLB-BAR contains the driver ALK DEL 11-14 mutation, which removes extracellular domain exons 4 through 11. Brigatinib treatment of CLB-BAR cells reduced MYCN protein levels and ALK phosphorylation (Y1604) similar to crizotnib. Brigatinib reduced CLB-BAR cellular proliferation more effectively than crizotinib (IC50 75.2 vs 186.4nM). CLB-BAR xenografts in BalbC/NUDE mice responded to brigatinib with reduced tumor volume and weight (N=8/group) as well as reduced ALK phosphorylation and MYCN levels compared to untreated controls. Release of brigatinib administration at day 15 resulted in tumor growth (N=2).",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","D","Predictive","Supports","Sensitivity","Somatic Mutation",550,3,NULL,"accepted",0,"evidence",921,"Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.","Siaw et al., 2016, Oncotarget",27049722,"http://www.ncbi.nlm.nih.gov/pubmed/27049722",NULL,NULL,"2016","3","31","Oncotarget","Oncotarget","fully curated","318","Brigatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1337,"EID1337","A Ba/F3 cell line expressing EML4-ALK variant 1 was created, and then exposed to the DNA modifying agent ENU. Cells were subsequently cultured in 96 well plates at increasing concentrations of crizotinib (250, 500, 720, 1000, 1440 and 2000 nM). Cell growth occurred in all wells at 250 nM, and was absent at 2000 nM. From 500 through 1440 nM there were progressively fewer resistant clones present. 422 mutations representing 16 different sites were identified. EML4-ALK F1245C was found at 500 nM crizotinib, and was among the 10 most frequently observed mutations. Ba/F3 cells with unaltered EML4-ALK had crizotinib IC50 values for viability of 132 +/- 45 nM. EML4-ALK F1245C clones from the selection assay had IC50 viability value of 425 +/- 100 nM, while Ba/F3 cells expressing reintroduced EML4-ALK F1245C had IC50 value of 269 +/- 194 nM.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",551,2,NULL,"accepted",0,"evidence",922,"Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.","Zhang et al., 2011, Chem Biol Drug Des",22034911,"http://www.ncbi.nlm.nih.gov/pubmed/22034911","true","PMC3265718","2011","12",NULL,"Chem Biol Drug Des","Chemical biology & drug design","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1338,"EID1338","A 52 year old male never smoker was diagnosed with stage IV NSCLC adenocarcinoma and was treated with chemotherapy with eventual disease progression. He tested positive for ALK rearrangement via break apart FISH assay, and started crizotinib with near complete response for 27 months. Progression then occurred and biopsy of a pleural nodule was performed with hybrid-capture NGS. EML4-ALK variant 3 with F1245C mutation was found with allele frequency of 2% and tumor purity 13%. Due to slow progression and low tumor burden crizotinib was maintained for additional 8 months, and then he was transitioned onto ceritinib at 750 mg daily. After 3 months ceritinib, complete radiographic response was seen and the patient was without evidence of disease at 6 months. Dose was reduced to 600 mg ceritinib daily due to gastrointestinal side effects.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",551,3,NULL,"accepted",0,"evidence",923,"A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.","Kodityal et al., 2016, Lung Cancer",26775591,"http://www.ncbi.nlm.nih.gov/pubmed/26775591",NULL,NULL,"2016","2",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1339,"EID1339","A 52 year old with a non-smoking history was diagnosed with stage IV NSCLC-adenocarcinoma and treated with chemotherapy.  Upon disease progression, the initial diagnostic biopsy tested positive for ALK-rearrangement using break apart FISH, but the ALK fusion was not sequenced for mutations. Break-apart signal was positive in 66% of tumor cells. Crizotinib was initiated and a sustained near complete response for 27 months was observed, after which an FDG-avid cervical lymph node appeared along with pleural effusions and pleural nodules. A pleural nodule was biopsied and profiled using hybrid-capture next generation sequencing, and revealed EML4-ALK variant 3 with F1245C mutation at mutant allele frequency of 2% and tumor purity of 13%. Crizotinib was maintained for 8 additional months due to low tumor burden and slow progression.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",551,2,NULL,"accepted",0,"evidence",923,"A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.","Kodityal et al., 2016, Lung Cancer",26775591,"http://www.ncbi.nlm.nih.gov/pubmed/26775591",NULL,NULL,"2016","2",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1340,"EID1340","Ceritinib was 28x more potent (GI50 3.8nM) than crizotinib (GI50 107nM) at inhibiting growth of  H2228, an NSCLC cell line which harbors the EML4-ALK variant 3a/3b. SCID mice xenografted with H2228 were treated for 14 days with crizotinib (100 mg/kg) or ceritinib (25 or 50 mg/kg). All treatments caused tumor regression, but tumors recurred within 11 days after crizotinib treatment withdrawal. 4/8 mice treated with 25 mg/kg ceritinib showed regrowth after 1 month treatment withdrawal. The remaining 4/8 mice treated at 25 mg/kg ceritinib, and all mice treated at 50 mg/kg ceritinib maintained complete remission for four months. While 100 mg/kg crizotinib in mice approximates levels 3-5 times the maximal tolerated dose in humans, the authors state 25 to 50 mg/kg ceritinib in mice is predicted to approximate tolerable doses in humans.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",503,3,NULL,"accepted",0,"evidence",924,"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","Friboulet et al., 2014, Cancer Discov",24675041,"http://www.ncbi.nlm.nih.gov/pubmed/24675041","true","PMC4068971","2014","6",NULL,"Cancer Discov","Cancer discovery","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1341,"EID1341","The crizotinib-resistant MGH045 cell line with EML4-ALK L1196M was treated with crizotinib or ceritinib. In nude mice with MGH045 xenografts, tumor response to crizotinib did not differ appreciably from vehicle, while ceritinib controlled tumor growth. Ceritinib inhibited Ba/F3 cells expressing EML4-ALK L1196M slightly stronger than ALK wild-type, but approximately double the potency as crizotinib, indicating ceritinib sensitivity in Ba/F3 EML4-ALK L1196M cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",7,4,NULL,"accepted",0,"evidence",924,"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","Friboulet et al., 2014, Cancer Discov",24675041,"http://www.ncbi.nlm.nih.gov/pubmed/24675041","true","PMC4068971","2014","6",NULL,"Cancer Discov","Cancer discovery","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1342,"EID1342","The NSCLC cell line MGH021-4, harboring SQSTM1-ALK G1269A, was 6 times more sensitive to ceritinib (80nM GI50) than crizotinib (500 nM) in proliferation assays and caused notable reductions in phospho-ALK and phospho-AKT (detected by Western blot) at concentrations 10 fold lower than crizotinib. GI50 values were similar in Ba/F3 cells expressing either EML4-ALK wild-type or EML4-ALK G1269A (1.6nM and 2.2nM, respectively). In contrast, crizotinib treatment of Ba/F3 with EML4-ALK G1269A had survival GI50 of 130nM.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",552,3,NULL,"accepted",0,"evidence",924,"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","Friboulet et al., 2014, Cancer Discov",24675041,"http://www.ncbi.nlm.nih.gov/pubmed/24675041","true","PMC4068971","2014","6",NULL,"Cancer Discov","Cancer discovery","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1343,"EID1343","Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensitive EML4-ALK wild-type variant obtained in parallel experiments, as well as the GI50 value of 16 nM obtained for crizotinib treatment of EML4-ALK wild-type.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",172,2,NULL,"accepted",0,"evidence",924,"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","Friboulet et al., 2014, Cancer Discov",24675041,"http://www.ncbi.nlm.nih.gov/pubmed/24675041","true","PMC4068971","2014","6",NULL,"Cancer Discov","Cancer discovery","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1344,"EID1344","Ba/F3 cells expressing EML4-ALK variant 3 with ALK I1171T mutation were treated with ceritinib, and survival IC50 of 2.6 nM was observed, which compares favorably with highly ceritinib sensitive EML4-ALK wild-type variant 1 survival IC50 of 1.7 nM reported from parallel experiments. Tumors from mice with EML4-ALK variant 3 H2228 NSCLC cell xenografts which had progressed after approximately 40 days of crizotinib treatment were sequenced for ALK mutations. I1171T was found as one of 6 ALK resistance mutations from 80 sequenced tumors. Treatment of these mouse xenograft models with ceritinib reduced tumor volume to zero, while in contrast tumor size increased with crizotinib treatment.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",527,4,NULL,"accepted",0,"evidence",924,"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","Friboulet et al., 2014, Cancer Discov",24675041,"http://www.ncbi.nlm.nih.gov/pubmed/24675041","true","PMC4068971","2014","6",NULL,"Cancer Discov","Cancer discovery","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1345,"EID1345","Ba/F3 cells expressing EML4-ALK variant 1 with ALK G1202R mutation were assessed for ceritinib sensitivity. Crizotinib was shown to confer significantly more potency than ceritinib (43-fold decrease in IC50). EML4-ALK variant 3 NSCLC cell line H2228 was used in SCID mouse xenografts which were exposed to increasing crizotinib up to 100 mg/kg. Within 40 days tumors progressed, and progressed tumors were assayed for ALK mutation. Of 80 tumors, 6 had ALK mutation and 3 of these were G1202R. Treatment of crizotinib progressed tumors with ceritinib resulted in tumor growth which did not differ appreciably from crizotinib or vehicle treatment of these tumors.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",171,4,NULL,"accepted",0,"evidence",924,"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","Friboulet et al., 2014, Cancer Discov",24675041,"http://www.ncbi.nlm.nih.gov/pubmed/24675041","true","PMC4068971","2014","6",NULL,"Cancer Discov","Cancer discovery","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1346,"EID1346","EML4-ALK variant 3 containing NSCLC cell line H2228 xenografts in SCID beige mice were treated with increasing doses of crizotinib up to 100 mg/kg per day by oral gavage. At approximately 40 days tumors progressed. 80 progressed tumors were tested for ALK mutations, and 6 mutant ALK variants were found. Two of the mutations were at ALK C1156Y. In Ba/F3 cells, EML4-ALK variant 3 with C1156Y was introduced and tested for crizotinib sensitivity. Survival IC50 value of 177 nM was reported, which is 9.3 times the IC50 reported for crizotinib in EML4-ALK wild-type Ba/F3 cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",6,4,NULL,"accepted",0,"evidence",924,"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","Friboulet et al., 2014, Cancer Discov",24675041,"http://www.ncbi.nlm.nih.gov/pubmed/24675041","true","PMC4068971","2014","6",NULL,"Cancer Discov","Cancer discovery","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1347,"EID1347","Ba/F3 cells expressing EML4-ALK with 1151 Tins treated with alectinib had an IC50 of 165.7 nM, 16x higher than those expressing EML4-ALK wildtype variant 1. EML4-ALK variant 1 expressing H3122 NSCLC cell line was cultured in increasing levels of crizotinib to produce crizotinib resistant cell lines CR1, CR2 and CR3. H3122 CR2 was found to contain an 1151 insT ALK mutation and increased EML4-ALK levels. The H3122 CR2 cell line survival IC50 value for alectinib treatment was approximately 20x higher than that for H3122 cells.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",173,3,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1348,"EID1348","Treatment of Ba/F3 cells expressing EML4-ALK 1151 insT with TAE684 produced an IC50 value (28.3 nM) 20x higher cells expressing EML4-ALK wildtype variant 1. The crizotinib resistant clones were produced from parental H3122 cells (CR1, CR2, CR3). H3122 CR2 was found to contain the 1151 Tins variant as well as elevated EML4-ALK expression. H3122 CR2 cells treated with TAE684 produced IC50 values 20-30 times that of the parental H3122 cells. These results suggest possible variant resistance to the TAE684-derived compound ceritinib.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",173,3,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","18","TAE684",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1349,"EID1349","Ba/F3 cells transduced with EML4-ALK 1151 insT were treated with 17-AAG producing an IC50 value of 44.5 nM, which was 0.4 times that reported for EML4-ALK wildtype in Ba/F3, indicating possible increased dependence of EML4-ALK 1151 insT on HSP90. 17-AAG also reduced survival of the parental IL3-dependent Ba/F3 cells (183.7 nM), indicating increased nonspecific effects of 17_AAG treatment. Crizotinib resistant clones were produced from the parental EML4-ALK variant 1 containing cell line H3122 (CR1, CR2, CR3). H3122 CR2 was found to contain the EML4-ALK InsT variant. H3122 CR2 and H3122 cells were similarly sensitized to 17-AAG death with an IC50 value of approximately 5 nM, while control cells without EML4-ALK had IC50 values approximately 10x higher.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",173,2,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","10","17-AAG",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1350,"EID1350","Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reported for alectinib on Ba/F3 with EML4-ALK wild-type. Similar experiments using NPM-ALK instead of EML4-ALK yielded survival IC50 of 549 nM of NPM-ALK G1202R to alectinib, which was 27.9 times higher than IC50 for NPM-ALK wild-type. Western blots of Ba/F3 with NPM-ALK wild-type showed ablation of pALK levels above 100 nM alectinib, while pALK levels were essentially unchanged up to 1000 nM in NPM-ALK G1202R Ba/F3 cells.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",171,3,NULL,"accepted",0,"evidence",925,"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.","Fontana et al., 2015, Cancer Med",25727400,"http://www.ncbi.nlm.nih.gov/pubmed/25727400","true","PMC4529334","2015","7",NULL,"Cancer Med","Cancer medicine","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1351,"EID1351","This study compared drug responses in Ba/F3 cells expressing either EML4-ALK or NPM-ALK fusions, with or without G1202R ALK mutation. Cells expressing the EML4-ALK variant 3 with G1202R ALK mutation were more resistant to brigatinib treatment (IC50 325 nM) than cells expressing wildtype EML4-ALK variant 3 (IC50 6 nM). These same experiments performed with the NPM-ALK fusion resulted in IC50 of 149 nM for G1202R and 11nM for wild type, consistent with resistance. In Western blots, ablation of pALK with brigatinib treatment above 100 nM was seen in Ba/F3 cells expressing NPM-ALK wildtype, but remained apparent at 1000 nM brigatinib in NPM-ALK G1202R cells, despite dose-dependent reduction.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",171,3,NULL,"accepted",0,"evidence",925,"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.","Fontana et al., 2015, Cancer Med",25727400,"http://www.ncbi.nlm.nih.gov/pubmed/25727400","true","PMC4529334","2015","7",NULL,"Cancer Med","Cancer medicine","fully curated","318","Brigatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1352,"EID1352","The G1202R ALK mutation was found in a crizotinib-resistant ALK-rearranged NSCLC, and the mutant ALK fusion was further characterized in Ba/F3 cells. EML4-ALK variant 1 with G1202R mutation was expressed in Ba/F3 and subject to 17-AAG. IC50 for cell number in response to 17-AAG was 33.4 nM, in contrast to IC50 for EML4-ALK wild-type, which was 98.9 nM, suggesting sensitization of this variant to HSP90 inhibition.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",171,2,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","10","17-AAG",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1353,"EID1353","EML4-ALK with ALK G1269A has been seen in crizotinib resistant NSCLC, and this mutation was tested for Brigatinib sensitivity via ectopic expression in Ba/F3 cells, where half maximal inhibitory concentration of 9 nM was seen, which was 1.5 times the IC50 of EML4-ALK wild-type to brigatinib. NPM-ALK G1269A was also tested for brigatinib sensitivity, and IC50 values of 11 nM were reported for both NPM-ALK G1269A and NPM-ALK wild-type. In western blotting, brigatinib at and above 100 nM ablated pALK signal (Y 1604), indicating sensitivity of this variant to brigatinib together with the other results.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",552,2,NULL,"accepted",0,"evidence",925,"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.","Fontana et al., 2015, Cancer Med",25727400,"http://www.ncbi.nlm.nih.gov/pubmed/25727400","true","PMC4529334","2015","7",NULL,"Cancer Med","Cancer medicine","fully curated","318","Brigatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1354,"EID1354","EML4-ALK with ALK G1269A mutation was tested for sensitivity to alectinib using Ba/F3 cells. In Ba/F3 cells with ectopic EML4-ALK variant 1 G1269A, IC50 of 84 nM was reported with alectinib, which was a 6 fold increase over IC50 for EML4-ALK wild-type. The authors considered a fold difference of 4 to 10 between the alectinib-sensitized wild-type and mutant variant to indicate a resistant mutant variant. In the background of the NPM-ALK fusion, IC50 for G1269A mutation was 104 nM, which was 5.3 fold that reported for NPM-ALK wild-type. Western blots of alectinib treated NPM-ALK G1269A were performed and reduced pALK Y1604 was seen at 300 nM alectinib, and no pALK at 1000 nM. In contrast pALK signal was ablated at and above 100 nM in NPM-ALK wild-type.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",552,3,NULL,"accepted",0,"evidence",925,"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.","Fontana et al., 2015, Cancer Med",25727400,"http://www.ncbi.nlm.nih.gov/pubmed/25727400","true","PMC4529334","2015","7",NULL,"Cancer Med","Cancer medicine","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1355,"EID1355","EML4-ALK with G1269A mutation was tested for sensitivity to ceritinib via transduction into Ba/F3 cells and generation of survival curves varying ceritinib concentration. IC50 of 33 nM was seen, which was 1.5 times the IC50 for EML4-ALK wild-type, indicating sensitivity of the G1269A mutation to ceritinib in the context of EML4-ALK. The mutation was also tested for ceritinib sensitivity in the context of NPM-ALK, where IC50 values were reported of 19 nM and 20 nM for mutant and wild-type versions, respectively, also indicating sensitivity. In western blots,  Y1604 pALK levels for wild-type NPM-ALK were ablated at 100 nM, while at 100 nM residual pALK levels were seen in G1269A blotting, with ablation of signal at and above 300 nM, which differed somewhat from the equivalent IC50 values reported for mutant and wild-type in the NPM-ALK background, but still agrees with sensitivity to ceritinib for this mutation.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",552,2,NULL,"accepted",0,"evidence",925,"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.","Fontana et al., 2015, Cancer Med",25727400,"http://www.ncbi.nlm.nih.gov/pubmed/25727400","true","PMC4529334","2015","7",NULL,"Cancer Med","Cancer medicine","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1356,"EID1356","In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3. 50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was approximately 4x greater than IC50 of 11 nM obtained for EML4-ALK. The IC50 for parental Ba/F3 supplemented with IL3 was 2299 nM, resulting in a fold difference of 209.2 for EML4-ALK and 55.1 for NPM-ALK, indicating some reduced sensitivity for NPM-ALK in direct comparison to EML4-ALK, but substantial sensitization to crizotinib for NPM-ALK in Ba/F3 cells.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",513,2,NULL,"accepted",0,"evidence",925,"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.","Fontana et al., 2015, Cancer Med",25727400,"http://www.ncbi.nlm.nih.gov/pubmed/25727400","true","PMC4529334","2015","7",NULL,"Cancer Med","Cancer medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1357,"EID1357","A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28, which correspond to the tyrosine kinase domain of ALK, were sequenced, and ALK G1202A was found. CKIT focal amplification by FISH was also observed. Tumor sample before crizotinib treatment was not available in this case.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",171,3,NULL,"accepted",0,"evidence",262,"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","Katayama et al., 2012, Sci Transl Med",22277784,"http://www.ncbi.nlm.nih.gov/pubmed/22277784","true","PMC3385512","2012","2","8","Sci Transl Med","Science translational medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1358,"EID1358","Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GDC-0941 (p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines).
IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the sanger cell line screening but these results could not be reproduced in the cancer cell line encyclopedia screening.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",311,2,"Substitutes","accepted",0,"evidence",926,"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.","Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg",25855885,"http://www.ncbi.nlm.nih.gov/pubmed/25855885","true","PMC4474763","2015","6",NULL,"JAMA Otolaryngol Head Neck Surg","JAMA otolaryngology-- head & neck surgery","fully curated","10","17-AAG",NULL,"141","Pictilisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1359,"EID1359","Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to the class I PI3K inhibitor GDC-0941(p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the Sanger cell line screening but these results could not be reproduced in the Broad cancer cell line encyclopedia screening.",453,"Head And Neck Cancer","Head And Neck Cancer",11934,"http://www.disease-ontology.org/?id=DOID:11934","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",510,2,"Substitutes","accepted",0,"evidence",926,"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.","Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg",25855885,"http://www.ncbi.nlm.nih.gov/pubmed/25855885","true","PMC4474763","2015","6",NULL,"JAMA Otolaryngol Head Neck Surg","JAMA otolaryngology-- head & neck surgery","fully curated","141","Pictilisib",NULL,"10","17-AAG",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1360,"EID1360","Preclinical analysis of the predicitive value of PIK3CA mutations for mTOR/PI3K Inhibition with BEZ-235. Two cell lines with PIK3CA Mutation (H1047R) were more sensitive to BEZ-235 than two cell lines with wild-type PIK3CA (in-vitro, results from one cell line also confirmed in-vivo). Two patient-derived xenografts with PIK3CA mutations (E110K, E542K) showed sensitivity to BEZ-235.",453,"Head And Neck Cancer","Head And Neck Cancer",11934,"http://www.disease-ontology.org/?id=DOID:11934","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,3,NULL,"accepted",0,"evidence",927,"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.","Lui et al., 2013, Cancer Discov",23619167,"http://www.ncbi.nlm.nih.gov/pubmed/23619167","true","PMC3710532","2013","7",NULL,"Cancer Discov","Cancer discovery","fully curated","343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1361,"EID1361","Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM).",453,"Head And Neck Cancer","Head And Neck Cancer",11934,"http://www.disease-ontology.org/?id=DOID:11934","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,1,NULL,"accepted",0,"evidence",926,"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.","Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg",25855885,"http://www.ncbi.nlm.nih.gov/pubmed/25855885","true","PMC4474763","2015","6",NULL,"JAMA Otolaryngol Head Neck Surg","JAMA otolaryngology-- head & neck surgery","fully curated","343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1362,"EID1362","Two head and neck cancer cell lines with PIK3CA H1047R mutation were more sensitive to PI3K/mTOR inhibition with BEZ-235 (NVP-BEZ235, Dactolisib) than two wild type cell lines in vitro. One cell line with H1047R mutation was also found to be sensitive to BEZ-235 in vivo. PIK3CA (H1047R) mutation positive cell lines used were \"CAL-33\" and \"Detroit 562\". Wild type cell lines used here were \"SCC-9\" and \"PE/CA-PJ34(clone C12)\".",453,"Head And Neck Cancer","Head And Neck Cancer",11934,"http://www.disease-ontology.org/?id=DOID:11934","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,2,NULL,"accepted",0,"evidence",927,"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.","Lui et al., 2013, Cancer Discov",23619167,"http://www.ncbi.nlm.nih.gov/pubmed/23619167","true","PMC3710532","2013","7",NULL,"Cancer Discov","Cancer discovery","fully curated","343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1363,"EID1363","Xenografts from one head and neck cancer cell line (CAL-33) with a PIK3CA H1047R mutation were more sensitive to the combined inhibition of PI3K/mTOR and EGFR with BEZ-235 and cetuximab (N=9) than cetuximab (N=9, P=0.0039) or BEZ-235 alone (N=9, P=0.0002) in-vivo.",453,"Head And Neck Cancer","Head And Neck Cancer",11934,"http://www.disease-ontology.org/?id=DOID:11934","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,2,"Combination","accepted",0,"evidence",927,"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.","Lui et al., 2013, Cancer Discov",23619167,"http://www.ncbi.nlm.nih.gov/pubmed/23619167","true","PMC3710532","2013","7",NULL,"Cancer Discov","Cancer discovery","fully curated","343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,"16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1364,"EID1364","6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type cell lines and there was a trend towards increased resistance. SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation. Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib.",453,"Head And Neck Cancer","Head And Neck Cancer",11934,"http://www.disease-ontology.org/?id=DOID:11934","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",311,2,"Substitutes","accepted",0,"evidence",926,"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.","Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg",25855885,"http://www.ncbi.nlm.nih.gov/pubmed/25855885","true","PMC4474763","2015","6",NULL,"JAMA Otolaryngol Head Neck Surg","JAMA otolaryngology-- head & neck surgery","fully curated","141","Pictilisib",NULL,"10","17-AAG",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1365,"EID1365","In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed.",15,"Thyroid Medullary Carcinoma","Thyroid Medullary Carcinoma",3973,"http://www.disease-ontology.org/?id=DOID:3973","B","Predictive","Supports","Sensitivity","Somatic Mutation",113,3,NULL,"accepted",0,"evidence",928,"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.","Lam et al., 2010, J. Clin. Oncol.",20368568,"http://www.ncbi.nlm.nih.gov/pubmed/20368568","true","PMC2881718","2010","5","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1366,"EID1366","In a phase 2 clinical trial, NCT01209598, 30 patients with CDK4-amplified and RB-expressing well differentiated and dedifferentiated liposarcomas (WDLS/DDLS) were treated with a selective CDK 4/6 inhibitor, PD0332991. Treatment with PD0332991 was associated with favorable progression free survival rates (66% PFS rate, primary end point being greater than 40%) suggesting that CDK4 amplification is predictive of sensitivity to CDK4 inhibitor therapy.",137,"Liposarcoma","Liposarcoma",3382,"http://www.disease-ontology.org/?id=DOID:3382","B","Predictive","Supports","Sensitivity","Somatic Mutation",553,3,NULL,"accepted",0,"evidence",360,"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.","Dickson et al., 2013, J. Clin. Oncol.",23569312,"http://www.ncbi.nlm.nih.gov/pubmed/23569312","true","PMC3661937","2013","6","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","149","PD0332991",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1367,"EID1367","A 51 year old female never-smoker was diagnosed with stage IV NSCLC with liver metastases. ALK rearrangement was verified via FISH. She was treated with crizotinib at 250 mg twice daily but discontinued due to adverse response. She then started alectinib at 600 mg twice daily with partial response, but new liver metastases then formed at 5 months. Liver tumor biopsy was performed and was estimated to be 15% tumor tissue. Next-generation sequencing discovered an ALK I1171N mutation. The tumor was not sequenced prior to alectinib resistance.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",527,2,NULL,"accepted",0,"evidence",929,"I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.","Ou et al., 2015, Lung Cancer",25736571,"http://www.ncbi.nlm.nih.gov/pubmed/25736571",NULL,NULL,"2015","5",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1368,"EID1368","A 51 year old female never smoker was diagnosed with stage IV NSCLC with liver metastases, and had adverse response to crizotinib treatment, after which she responded to alectinib until disease progressed after 5 months with new liver metastases. Liver tumor biopsy was taken and estimated to be 15% tumor. Hybrid capture next generation sequencing was performed and an I1171N mutation was found in rearranged ALK, and estimated to be in 33% of the tumor cells. Ceritinib was given at 750 mg once daily but dose reduction to 600 mg once daily was required due to persistent nausea. CT showed regression of liver lesions and primary lung lesion and ongoing response was seen at 3 months.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",527,3,NULL,"accepted",0,"evidence",929,"I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.","Ou et al., 2015, Lung Cancer",25736571,"http://www.ncbi.nlm.nih.gov/pubmed/25736571",NULL,NULL,"2015","5",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","159","Ceritinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1369,"EID1369","In normal karyotype patients with AML (15-65 years old), complete remission rates and overall, event-free and relapse-free survival were not different for patients harboring NPM1 exon 12 mutations (N=50) than those wildtype for NPM1 (N=56).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","Better Outcome","Somatic Mutation",86,3,NULL,"accepted",0,"evidence",930,"Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.","Boissel et al., 2005, Blood",16046528,"http://www.ncbi.nlm.nih.gov/pubmed/16046528",NULL,NULL,"2005","11","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1370,"EID1370","In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","A","Predictive","Supports","Sensitivity","Germline Mutation",185,4,NULL,"accepted",0,"evidence",359,"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.","Fong et al., 2009, N. Engl. J. Med.",19553641,"http://www.ncbi.nlm.nih.gov/pubmed/19553641",NULL,NULL,"2009","7","9","N. Engl. J. Med.","The New England journal of medicine","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1371,"EID1371","In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","A","Predictive","Supports","Sensitivity","Germline Mutation",186,4,NULL,"accepted",0,"evidence",359,"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.","Fong et al., 2009, N. Engl. J. Med.",19553641,"http://www.ncbi.nlm.nih.gov/pubmed/19553641",NULL,NULL,"2009","7","9","N. Engl. J. Med.","The New England journal of medicine","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1372,"EID1372","Preclinical study in 9 melanoma cell lines. Three cell lines did not have CDKN2A (p16) mutations and showed expression of the protein on western blot analysis. Two of the other six cell lines had stop codons leading to a truncated protein, and three had missense mutations with evidence of protein expression on western blot (two cell lines with a P114L mutation and one with an E88K mutation). Mean IC50s of flavopiridol were significantly lower in cell lines with a mutated or non-expressed p16 (p16-) (mean 50% inhibitory concentration [IC(50)] = 12.5 nM), than in cell lines with intact p16 (p16+) (mean IC(50) = 25 nM).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",554,2,NULL,"accepted",0,"evidence",931,"The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.","Robinson et al., 2003, Melanoma Res.",12777976,"http://www.ncbi.nlm.nih.gov/pubmed/12777976",NULL,NULL,"2003","6",NULL,"Melanoma Res.","Melanoma research","fully curated","335","Flavopiridol",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1373,"EID1373","Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","D","Predictive","Supports","Sensitivity","Somatic Mutation",554,3,NULL,"accepted",0,"evidence",212,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.","Logan et al., 2013, Anticancer Res.",23898052,"http://www.ncbi.nlm.nih.gov/pubmed/23898052",NULL,NULL,"2013","8",NULL,"Anticancer Res.","Anticancer research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1374,"EID1374","Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","D","Predictive","Supports","Sensitivity","Somatic Mutation",555,3,NULL,"accepted",0,"evidence",212,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.","Logan et al., 2013, Anticancer Res.",23898052,"http://www.ncbi.nlm.nih.gov/pubmed/23898052",NULL,NULL,"2013","8",NULL,"Anticancer Res.","Anticancer research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1375,"EID1375","In a cohort of 143 patients with primary invasive melanoma hemizygous or homozygous loss of CDKN2A was observed (FISH) in 56% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Loss of functional p16INK4A (CDKN2A) due to gene deletion (49% of cells), methylation (4% of cells), or mutation (19% of cells) was the most prevalent alteration occurring in 71% of cell lines, and significantly correlated with PD0332991 sensitivity (Fisher's exact test P < 0.02).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",554,3,NULL,"accepted",0,"evidence",932,"Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.","Young et al., 2014, Pigment Cell Melanoma Res",24495407,"http://www.ncbi.nlm.nih.gov/pubmed/24495407",NULL,NULL,"2014","7",NULL,"Pigment Cell Melanoma Res","Pigment cell & melanoma research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1376,"EID1376","In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Four cell lines had an R24C activating mutation in CDK4, three of these were sensitive to PD0332991 (palbociclib).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",556,1,NULL,"accepted",0,"evidence",932,"Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.","Young et al., 2014, Pigment Cell Melanoma Res",24495407,"http://www.ncbi.nlm.nih.gov/pubmed/24495407",NULL,NULL,"2014","7",NULL,"Pigment Cell Melanoma Res","Pigment cell & melanoma research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1377,"EID1377","Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines. Rb-proficient cell lines with low p16 expression were significantly more sensitive to PD-0332991 (as defined by IC50 < mean) in mRNA expression (Agilent), protein level (Western Blot) and copy number (Array CGH) analyses.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Sensitivity","Somatic Mutation",554,3,NULL,"accepted",0,"evidence",933,"Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.","Konecny et al., 2011, Clin. Cancer Res.",21278246,"http://www.ncbi.nlm.nih.gov/pubmed/21278246","true","PMC4598646","2011","3","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1378,"EID1378","In older patients (>59 years) with cytogenetically normal acute myeloid leukemia classified as ELN favorable, multivariate analysis identified ASXL1 mutations (12/99 patients) were associated with lower complete remission rates (P = 0.03), disease-free survival (P < 0.001), overall survival (P < 0.001), and event-free survival (P < 0.001). This confirmed results from univariate analysis of patients not stratified by ELN category, but cytogenetically normal and older (38/220 patients).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",177,3,NULL,"accepted",0,"evidence",935,"ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.","Metzeler et al., 2011, Blood",22031865,"http://www.ncbi.nlm.nih.gov/pubmed/22031865","true","PMC3245212","2011","12","22","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1379,"EID1379","In patients with de novo AML who received intensive chemotherapy, ASXL1 mutations (N=51) were associated with shorter overall (P<0.001) and event free survival (P=0.012) compared to ASXL1 wild-type (N=430). Multivariate analysis identified ASXL1 mutations as an independent factor for adverse overall survival (P=0.032, relative risk: 1.70).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",557,4,NULL,"accepted",0,"evidence",936,"ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.","Schnittger et al., 2013, Leukemia",23018865,"http://www.ncbi.nlm.nih.gov/pubmed/23018865",NULL,NULL,"2013","1",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1380,"EID1380","The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice. GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA. Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941. Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells. Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",937,"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.","Utermark et al., 2012, Genes Dev.",22802530,"http://www.ncbi.nlm.nih.gov/pubmed/22802530","true","PMC3404385","2012","7","15","Genes Dev.","Genes & development","fully curated","141","Pictilisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1381,"EID1381","Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors). A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,2,NULL,"accepted",0,"evidence",937,"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.","Utermark et al., 2012, Genes Dev.",22802530,"http://www.ncbi.nlm.nih.gov/pubmed/22802530","true","PMC3404385","2012","7","15","Genes Dev.","Genes & development","fully curated","337","A66",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1382,"EID1382","Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels. In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform. Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",937,"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.","Utermark et al., 2012, Genes Dev.",22802530,"http://www.ncbi.nlm.nih.gov/pubmed/22802530","true","PMC3404385","2012","7","15","Genes Dev.","Genes & development","fully curated","338","Tgx 221",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1383,"EID1383","A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in trastuzumab resistant populations was PTEN. Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",214,2,NULL,"accepted",0,"evidence",938,"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.","Berns et al., 2007, Cancer Cell",17936563,"http://www.ncbi.nlm.nih.gov/pubmed/17936563",NULL,NULL,"2007","10",NULL,"Cancer Cell","Cancer cell","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1384,"EID1384","The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007).",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",311,2,NULL,"accepted",0,"evidence",938,"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.","Berns et al., 2007, Cancer Cell",17936563,"http://www.ncbi.nlm.nih.gov/pubmed/17936563",NULL,NULL,"2007","10",NULL,"Cancer Cell","Cancer cell","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1385,"EID1385","A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008).",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",214,3,NULL,"accepted",0,"evidence",939,"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.","Esteva et al., 2010, Am. J. Pathol.",20813970,"http://www.ncbi.nlm.nih.gov/pubmed/20813970","true","PMC2947262","2010","10",NULL,"Am. J. Pathol.","The American journal of pathology","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1386,"EID1386","While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863).",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","B","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",214,3,NULL,"accepted",0,"evidence",939,"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.","Esteva et al., 2010, Am. J. Pathol.",20813970,"http://www.ncbi.nlm.nih.gov/pubmed/20813970","true","PMC2947262","2010","10",NULL,"Am. J. Pathol.","The American journal of pathology","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1387,"EID1387","Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survival yrs: CALR 15.9, JAK2 5.9)",173,"Myelofibrosis","Myelofibrosis",4971,"http://www.disease-ontology.org/?id=DOID:4971","A","Prognostic","Supports","Better Outcome","Somatic Mutation",559,4,NULL,"accepted",0,"evidence",940,"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","Tefferi et al., 2014, Blood",25037629,"http://www.ncbi.nlm.nih.gov/pubmed/25037629","true","PMC4199952","2014","10","16","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1388,"EID1388","Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)",2127,"Chronic Neutrophilic Leukemia","Chronic Neutrophilic Leukemia",NULL,"http://www.disease-ontology.org/","B","Diagnostic","Supports","Positive","Somatic Mutation",560,3,NULL,"accepted",0,"evidence",941,"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.","Maxson et al., 2013, N. Engl. J. Med.",23656643,"http://www.ncbi.nlm.nih.gov/pubmed/23656643","true","PMC3730275","2013","5","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1389,"EID1389","Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)",2128,"Atypical Chronic Myeloid Leukemia","Atypical Chronic Myeloid Leukemia",60597,"http://www.disease-ontology.org/?id=DOID:0060597","B","Diagnostic","Supports","Positive","Somatic Mutation",560,3,NULL,"accepted",0,"evidence",941,"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.","Maxson et al., 2013, N. Engl. J. Med.",23656643,"http://www.ncbi.nlm.nih.gov/pubmed/23656643","true","PMC3730275","2013","5","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1390,"EID1390","Study describes a phase 1 clinical trial of ponatinib in treatment of 81 refractory Philadelphia chromosome-positive leukemias. 43 of these patients were considered to have chronic-phase CML. All 12 chronic-phase CML patients with a T315I mutation showed a complete hematologic response. Furthermore, 91% of these patients were estimated to  remain in response at 1 year (95% CI, Kaplan-Meier analysis).",4,"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia",8552,"http://www.disease-ontology.org/?id=DOID:8552","B","Predictive","Supports","Sensitivity","Somatic Mutation",2,4,NULL,"accepted",0,"evidence",942,"Ponatinib in refractory Philadelphia chromosome-positive leukemias.","Cortes et al., 2012, N. Engl. J. Med.",23190221,"http://www.ncbi.nlm.nih.gov/pubmed/23190221","true","PMC3777383","2012","11","29","N. Engl. J. Med.","The New England journal of medicine","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1391,"EID1391","155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",34,3,"Substitutes","accepted",0,"evidence",943,"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.","Yu et al., 2013, Clin. Cancer Res.",23470965,"http://www.ncbi.nlm.nih.gov/pubmed/23470965","true","PMC3630270","2013","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1392,"EID1392","155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). MET amplification was seen in 4 of 75 patients tested (no baseline samples available). One patient had small cell transformation and MET amplification, two patients had EGFR T790M mutation and MET amplification.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Resistance or Non-Response","N/A",270,2,"Substitutes","accepted",0,"evidence",943,"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.","Yu et al., 2013, Clin. Cancer Res.",23470965,"http://www.ncbi.nlm.nih.gov/pubmed/23470965","true","PMC3630270","2013","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1393,"EID1393","155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis). One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Resistance or Non-Response","N/A",306,1,"Substitutes","accepted",0,"evidence",943,"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.","Yu et al., 2013, Clin. Cancer Res.",23470965,"http://www.ncbi.nlm.nih.gov/pubmed/23470965","true","PMC3630270","2013","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1394,"EID1394","A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation. Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",562,3,NULL,"accepted",0,"evidence",944,"Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.","Hellmann et al., 2014, J Thorac Oncol",25521405,"http://www.ncbi.nlm.nih.gov/pubmed/25521405","true","PMC4655969","2014","10",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1395,"EID1395","Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",562,2,NULL,"accepted",0,"evidence",945,"Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).","Masago et al., 2010, Jpn. J. Clin. Oncol.",20522446,"http://www.ncbi.nlm.nih.gov/pubmed/20522446",NULL,NULL,"2010","11",NULL,"Jpn. J. Clin. Oncol.","Japanese journal of clinical oncology","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1396,"EID1396","Case report of a patient with stage IV lung adenocarcinoma and a 15â€“base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression. Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations. In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",415,1,NULL,"accepted",0,"evidence",946,"Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.","Yu et al., 2015, JAMA Oncol",26181354,"http://www.ncbi.nlm.nih.gov/pubmed/26181354","true","PMC4665629","2015","10",NULL,"JAMA Oncol","JAMA oncology","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1397,"EID1397","Case report of a patient with stage IV lung adenocarcinoma and a 15â€“base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",34,1,NULL,"accepted",0,"evidence",946,"Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.","Yu et al., 2015, JAMA Oncol",26181354,"http://www.ncbi.nlm.nih.gov/pubmed/26181354","true","PMC4665629","2015","10",NULL,"JAMA Oncol","JAMA oncology","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1398,"EID1398","The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",12,5,NULL,"accepted",0,"evidence",947,"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.","McArthur et al., 2014, Lancet Oncol.",24508103,"http://www.ncbi.nlm.nih.gov/pubmed/24508103","true","PMC4382632","2014","3",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1399,"EID1399","In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation. In this subgroup of treatment-naive patients, significant differences were seen in overall survival (14.5 months with vemurafenib vs. 7.6 months with dacarbazine), as well as median progression free survival (5.9 months with vemurafenib vs. 1.7 months with dacarbazine).",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",563,4,NULL,"accepted",0,"evidence",947,"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.","McArthur et al., 2014, Lancet Oncol.",24508103,"http://www.ncbi.nlm.nih.gov/pubmed/24508103","true","PMC4382632","2014","3",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1400,"EID1400","A 53 year old male presented with a scalp lesion which was incompletely excised. Metastases were seen in lymph node biopsy and subsequently in CT. BRAF inhibitor vemurafenib was then administered at 960 mg twice daily and later at 720 mg twice daily and reduction in metastases was observed. After 2 years complete radiological response was seen, while treatment was discontinued due to cardiomyopathy. 12 months after stopping vemurafenib patient did not show evidence of metastatic melanoma.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",563,3,NULL,"accepted",0,"evidence",948,"Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation.","Sahadudheen et al., 2016, Case Rep Oncol Med",26989536,"http://www.ncbi.nlm.nih.gov/pubmed/26989536","true","PMC4775779","2016",NULL,NULL,"Case Rep Oncol Med","Case reports in oncological medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1401,"EID1401","In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha specific inhibitor BYL719 (Alepelisib) than 3 of 4 lines with wild type PI3K (SNU-1066 IC50 1.13 Î¼M; SNU-1041, 20.65 Î¼M; FaDu, 19.67 Î¼M; SCC25, 49.30 Î¼M). In the H1047R mutant cell lines and the wildtype cell line tested, phospho-Akt and phospho-S6 levels were diminished with increasing BYL719 levels.",453,"Head And Neck Cancer","Head And Neck Cancer",11934,"http://www.disease-ontology.org/?id=DOID:11934","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,1,NULL,"accepted",0,"evidence",949,"In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.","Keam et al., 2015, Anticancer Res.",25550549,"http://www.ncbi.nlm.nih.gov/pubmed/25550549",NULL,NULL,"2015","1",NULL,"Anticancer Res.","Anticancer research","fully curated","339","BYL719 (Alpelisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1402,"EID1402","A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib). In the PIK3CA wild type subroup of cell lines, 22% were assessed as responsive, while in the subgroup of cell lines with PIK3CA mutations, 64% were labeled as responders. 7 patient derived xenografts with PIK3CA mutations (H1047R, E545K, M1043I, C420R, Q546K) were transplanted into mice and treated with BYL719. 6/7 mice responded with strong tumor growth inhibition or regression, while one (H1047R) responded with weak growth inhibition.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,4,NULL,"accepted",0,"evidence",950,"Characterization of the novel and specific PI3KÎ± inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.","Fritsch et al., 2014, Mol. Cancer Ther.",24608574,"http://www.ncbi.nlm.nih.gov/pubmed/24608574",NULL,NULL,"2014","5",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","339","BYL719 (Alpelisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1403,"EID1403","474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 response. A gastric cancer patient derived xenograft (PDX) was transplanted into two athymic mice and one was treated with BYL719. The untreated PDX grew by over 100 percent while the BYL719 tumor was reduced by 86 percent.",1322,"Stomach Carcinoma","Stomach Carcinoma",5517,"http://www.disease-ontology.org/?id=DOID:5517","D","Predictive","Supports","Sensitivity","Somatic Mutation",212,3,NULL,"accepted",0,"evidence",950,"Characterization of the novel and specific PI3KÎ± inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.","Fritsch et al., 2014, Mol. Cancer Ther.",24608574,"http://www.ncbi.nlm.nih.gov/pubmed/24608574",NULL,NULL,"2014","5",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","339","BYL719 (Alpelisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1404,"EID1404","A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targeted inhibitors. It was found that in the patient subgroup with BRAF mutation (V600E in the majority of cases), there were no benefits to overall survival, progression free survival, or overall response rate with addition of cetuximab or panitumumab to treatment. This conclusion held in the first line treatment as well as general treatment setting.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",399,3,"Substitutes","accepted",0,"evidence",951,"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.","Pietrantonio et al., 2015, Eur. J. Cancer",25673558,"http://www.ncbi.nlm.nih.gov/pubmed/25673558",NULL,NULL,"2015","3",NULL,"Eur. J. Cancer","European journal of cancer (Oxford, England : 1990)","fully curated","16","Cetuximab",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1405,"EID1405","In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",12,4,NULL,"accepted",0,"evidence",953,"Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.","Kopetz et al., 2015, J. Clin. Oncol.",26460303,"http://www.ncbi.nlm.nih.gov/pubmed/26460303","true","PMC4669589","2015","12","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1406,"EID1406","In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",345,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.","Falchook et al., 2012, Lancet",22608338,"http://www.ncbi.nlm.nih.gov/pubmed/22608338","true","PMC4109288","2012","5","19","Lancet","Lancet (London, England)","fully curated","22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1407,"EID1407","In the NCT00880321 trial using mutant BRAF inhibitor dabrafenib in solid tumors, 10 cases of melanoma brain metastases were assessed for dabrafenib response. In nine patients a decrease in size of metastases was seen, and in four cases a complete resolution of brain lesions was observed. This subset of patients had median progression free survival of 4.2 months.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",17,4,NULL,"accepted",0,"evidence",345,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.","Falchook et al., 2012, Lancet",22608338,"http://www.ncbi.nlm.nih.gov/pubmed/22608338","true","PMC4109288","2012","5","19","Lancet","Lancet (London, England)","fully curated","22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1408,"EID1408","5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.  Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker. WiDr and VACO432 cells were injected into immunodeficient mice. Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",12,3,"Combination","accepted",0,"evidence",344,"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.","Prahallad et al., 2012, Nature",22281684,"http://www.ncbi.nlm.nih.gov/pubmed/22281684",NULL,NULL,"2012","3","1","Nature","Nature","fully curated","16","Cetuximab",NULL,"4","Vemurafenib",NULL,"14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1409,"EID1409","Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","A","Predictive","Supports","Sensitivity","Somatic Mutation",12,5,NULL,"accepted",0,"evidence",954,"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","Chapman et al., 2011, N. Engl. J. Med.",21639808,"http://www.ncbi.nlm.nih.gov/pubmed/21639808","true","PMC3549296","2011","6","30","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1410,"EID1410","Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation. 
Confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Sensitivity","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",354,"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.","Sosman et al., 2012, N. Engl. J. Med.",22356324,"http://www.ncbi.nlm.nih.gov/pubmed/22356324","true","PMC3724515","2012","2","23","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1411,"EID1411","Open-label, randomized phase 3 trial with 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafenib and trametinib or vemurafenib orally as first-line therapy. At preplanned interim analysis the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","A","Predictive","Supports","Sensitivity","Somatic Mutation",12,5,"Combination","accepted",0,"evidence",353,"Improved overall survival in melanoma with combined dabrafenib and trametinib.","Robert et al., 2015, N. Engl. J. Med.",25399551,"http://www.ncbi.nlm.nih.gov/pubmed/25399551",NULL,NULL,"2015","1","1","N. Engl. J. Med.","The New England journal of medicine","fully curated","22","Dabrafenib",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1412,"EID1412","Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes. 63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DPC4) via immunolabeling. Among the patterns of failure \"metastatic and locally destructive\", It was discovered that DPC4 loss was significantly associated with metastatic disease (p=.007).",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",564,3,NULL,"accepted",0,"evidence",956,"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.","Iacobuzio-Donahue et al., 2009, J. Clin. Oncol.",19273710,"http://www.ncbi.nlm.nih.gov/pubmed/19273710","true","PMC2668706","2009","4","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1413,"EID1413","Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patients had confirmed partial responses, and 2 showed stable disease over 6 months. The authors conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",12,3,"Combination","accepted",0,"evidence",957,"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.","Yaeger et al., 2015, Clin. Cancer Res.",25589621,"http://www.ncbi.nlm.nih.gov/pubmed/25589621",NULL,NULL,"2015","3","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","28","Panitumumab",NULL,"4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1414,"EID1414","A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease.",156,"Papillary Thyroid Carcinoma","Papillary Thyroid Carcinoma",3969,"http://www.disease-ontology.org/?id=DOID:3969","C","Predictive","Supports","Sensitivity","Somatic Mutation",12,4,NULL,"accepted",0,"evidence",958,"Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.","Ali et al., 2014, Case Rep Oncol",24987354,"http://www.ncbi.nlm.nih.gov/pubmed/24987354","true","PMC4067722","2014","5",NULL,"Case Rep Oncol","Case reports in oncology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1415,"EID1415","In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed  partial response or better, with one complete response lasting 36 months and ongoing after data cutoff. 56% of patients achieved stable disease. The median progression free survival (PFS) was 3.5 months, longer than the median PFS (2.5 months) reported for metastatic CRC treated with standard chemotherapy. The authors conclude that MAPK targeting in CRC is a valid approach that can produce meaningful responses but additional work is required to more effectively inhibit the pathway.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",17,2,"Combination","accepted",0,"evidence",959,"Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.","Corcoran et al., 2015, J. Clin. Oncol.",26392102,"http://www.ncbi.nlm.nih.gov/pubmed/26392102","true","PMC4669588","2015","12","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","22","Dabrafenib",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1416,"EID1416","Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Resistance or Non-Response","N/A",287,3,NULL,"accepted",0,"evidence",476,"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.","Hutchinson et al., 2013, Clin. Cancer Res.",24345920,"http://www.ncbi.nlm.nih.gov/pubmed/24345920","true","PMC3880773","2013","12","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1417,"EID1417","Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",565,2,NULL,"accepted",0,"evidence",960,"SF3B1 mutations constitute a novel therapeutic target in breast cancer.","Maguire et al., 2015, J. Pathol.",25424858,"http://www.ncbi.nlm.nih.gov/pubmed/25424858","true","PMC4643177","2015","3",NULL,"J. Pathol.","The Journal of pathology","fully curated","341","Spliceostatin A",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1418,"EID1418","Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",114,2,NULL,"accepted",0,"evidence",960,"SF3B1 mutations constitute a novel therapeutic target in breast cancer.","Maguire et al., 2015, J. Pathol.",25424858,"http://www.ncbi.nlm.nih.gov/pubmed/25424858","true","PMC4643177","2015","3",NULL,"J. Pathol.","The Journal of pathology","fully curated","341","Spliceostatin A",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1419,"EID1419","In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated with improved survival. For the crizotinib-treated, ALK-positive patient group, 1 year survival was 74% and 2 year overall survival was 54%, compared with 72% and 36% for the control group (ALK-positive crizotinib naive patients).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,3,NULL,"accepted",0,"evidence",961,"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.","Shaw et al., 2011, Lancet Oncol.",21933749,"http://www.ncbi.nlm.nih.gov/pubmed/21933749","true","PMC3328296","2011","10",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1420,"EID1420","Study examined rare SNPs on MAP2K7 among a discovery and two validation cohorts. It was discovered that the E116K genotype was associated with a reduced median survival time of 4 and 7 months for E/K or K/K genotypes (P=2.61E-7) and an increased cancer death risk for heterozygous (HR=1.49) and homozygous (HR=1.94) genotypes for a pooled cohort. Further nude mice harboring this variant showed increased xenograft growth and metastasis.",23,"Lung Cancer","Lung Cancer",1324,"http://www.disease-ontology.org/?id=DOID:1324","B","Prognostic","Supports","Poor Outcome","Germline Polymorphism",566,5,NULL,"accepted",0,"evidence",962,"The MKK7 p.Glu116Lys Rare Variant Serves as a Predictor for Lung Cancer Risk and Prognosis in Chinese.","Qiu et al., 2016, PLoS Genet.",27028764,"http://www.ncbi.nlm.nih.gov/pubmed/27028764","true","PMC4814107","2016","3",NULL,"PLoS Genet.","PLoS genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1421,"EID1421","In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",12,4,"Combination","accepted",0,"evidence",963,"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.","Larkin et al., 2014, N. Engl. J. Med.",25265494,"http://www.ncbi.nlm.nih.gov/pubmed/25265494",NULL,NULL,"2014","11","13","N. Engl. J. Med.","The New England journal of medicine","fully curated","342","Cobimetinib",NULL,"4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1422,"EID1422","In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",563,4,"Combination","accepted",0,"evidence",963,"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.","Larkin et al., 2014, N. Engl. J. Med.",25265494,"http://www.ncbi.nlm.nih.gov/pubmed/25265494",NULL,NULL,"2014","11","13","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,"342","Cobimetinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1423,"EID1423","In 5 patients with KIT M541L mutation-positive chronic eosinophilic leukemia (4 somatic and 1 germline mutation), treatment with low dose imatinib resulted in complete and lasting remission with a median follow up of 74 months and 1 patient relapse at 50 months.",251,"Chronic Leukemia","Chronic Leukemia",1036,"http://www.disease-ontology.org/?id=DOID:1036","C","Predictive","Supports","Sensitivity","Somatic Mutation",201,2,NULL,"accepted",0,"evidence",964,"Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.","Iurlo et al., 2014, Oncotarget",25015329,"http://www.ncbi.nlm.nih.gov/pubmed/25015329","true","PMC4148089","2014","7","15","Oncotarget","Oncotarget","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1424,"EID1424","In a study of 78 patients with gastrointestinal stromal tumors treated with sunitinib, patients with Kit exon 9 mutations or wildtype (lacking KIT or PDGFRA mutations) showed increased progression free survival and overall survival compared to patients with Kit exon 11 mutations.",2,"Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor",9253,"http://www.disease-ontology.org/?id=DOID:9253","B","Predictive","Supports","Sensitivity","Somatic Mutation",509,3,NULL,"accepted",0,"evidence",965,"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.","Heinrich et al., 2008, J. Clin. Oncol.",18955458,"http://www.ncbi.nlm.nih.gov/pubmed/18955458","true","PMC2651076","2008","11","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1425,"EID1425","The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia.",2129,"Chronic Myelomonocytic Leukemia","Chronic Myelomonocytic Leukemia",NULL,"http://www.disease-ontology.org/","A","Diagnostic","Supports","Negative","Somatic Mutation",567,5,NULL,"accepted",0,"evidence",966,"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","Arber et al., 2016, Blood",27069254,"http://www.ncbi.nlm.nih.gov/pubmed/27069254",NULL,NULL,"2016","5","19","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1426,"EID1426","The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia.",2129,"Chronic Myelomonocytic Leukemia","Chronic Myelomonocytic Leukemia",NULL,"http://www.disease-ontology.org/","A","Diagnostic","Supports","Negative","Somatic Mutation",568,5,NULL,"accepted",0,"evidence",966,"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","Arber et al., 2016, Blood",27069254,"http://www.ncbi.nlm.nih.gov/pubmed/27069254",NULL,NULL,"2016","5","19","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1427,"EID1427","The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia.",2129,"Chronic Myelomonocytic Leukemia","Chronic Myelomonocytic Leukemia",NULL,"http://www.disease-ontology.org/","A","Diagnostic","Supports","Negative","Somatic Mutation",569,5,NULL,"accepted",0,"evidence",966,"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","Arber et al., 2016, Blood",27069254,"http://www.ncbi.nlm.nih.gov/pubmed/27069254",NULL,NULL,"2016","5","19","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1428,"EID1428","In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone. Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells. In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors. Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Sensitivity","Somatic Mutation",12,3,"Combination","accepted",0,"evidence",967,"Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.","Coffee et al., 2013, Clin. Cancer Res.",23549875,"http://www.ncbi.nlm.nih.gov/pubmed/23549875","true","PMC3815598","2013","5","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,"344","GDC-0879",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1429,"EID1429","In six NRAS mutant melanoma cell lines, concomitant use of MEK inhibitor and PI3K/mTOR inhibitor resulted in greater decrease in cell viability than either alone, with the synergistic effect being marked in 4/6 cell lines. MEK inhibitor JTP-74057 and PI3K/mTOR inhibitor GSK2126458 together induced synergistic increase in apoptotic Annexin V+/PI+ cells in these cell lines. Tumor xenografts in nude mice were established with 5 of the 6 cell lines. Effects of single agent treatment with JTP-74057 or GSK2126458 ranged from minor inhibition to tumor stasis, while dual inhibitor treatment showed synergistic effects in each case, with marked tumor reductions in 2/5 cases and the authors report one compete response in a MaMel301 cell line xenograft mouse.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",208,4,NULL,"accepted",0,"evidence",968,"Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.","Posch et al., 2013, Proc. Natl. Acad. Sci. U.S.A.",23431193,"http://www.ncbi.nlm.nih.gov/pubmed/23431193","true","PMC3593920","2013","3","5","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","346","Omipalisib (GSK2126458)",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1430,"EID1430","BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively). Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients. BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2).",53,"Gastrointestinal Neuroendocrine Tumor","Gastrointestinal Neuroendocrine Tumor",50626,"http://www.disease-ontology.org/?id=DOID:0050626","C","Predictive","Supports","Sensitivity","Somatic Mutation",12,3,"Combination","accepted",0,"evidence",969,"BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.","Klempner et al., 2016, Cancer Discov",27048246,"http://www.ncbi.nlm.nih.gov/pubmed/27048246",NULL,NULL,"2016","6",NULL,"Cancer Discov","Cancer discovery","fully curated","22","Dabrafenib",NULL,"4","Vemurafenib",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1432,"EID1432","In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT).",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,3,NULL,"accepted",0,"evidence",970,"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.","Hurvitz et al., 2013, J. Clin. Oncol.",23382472,"http://www.ncbi.nlm.nih.gov/pubmed/23382472",NULL,NULL,"2013","3","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","293","Trastuzumab Emtansine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1433,"EID1433","The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","A","Diagnostic","Supports","Positive","Somatic Mutation",567,5,NULL,"accepted",0,"evidence",966,"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","Arber et al., 2016, Blood",27069254,"http://www.ncbi.nlm.nih.gov/pubmed/27069254",NULL,NULL,"2016","5","19","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1434,"EID1434","The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","A","Diagnostic","Supports","Positive","Somatic Mutation",568,5,NULL,"accepted",0,"evidence",966,"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","Arber et al., 2016, Blood",27069254,"http://www.ncbi.nlm.nih.gov/pubmed/27069254",NULL,NULL,"2016","5","19","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1435,"EID1435","The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","A","Diagnostic","Supports","Positive","Somatic Mutation",569,5,NULL,"accepted",0,"evidence",966,"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","Arber et al., 2016, Blood",27069254,"http://www.ncbi.nlm.nih.gov/pubmed/27069254",NULL,NULL,"2016","5","19","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1436,"EID1436","The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","A","Diagnostic","Supports","Positive","Somatic Mutation",571,5,NULL,"accepted",0,"evidence",966,"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","Arber et al., 2016, Blood",27069254,"http://www.ncbi.nlm.nih.gov/pubmed/27069254",NULL,NULL,"2016","5","19","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1437,"EID1437","In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,"Combination","accepted",0,"evidence",971,"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.","Baselga et al., 2012, N. Engl. J. Med.",22149875,"http://www.ncbi.nlm.nih.gov/pubmed/22149875",NULL,NULL,"2012","1","12","N. Engl. J. Med.","The New England journal of medicine","fully curated","84","Trastuzumab",NULL,"73","Docetaxel",NULL,"247","Pertuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1438,"EID1438","A phase 1 clinical trial identified a patient with chemotherapy-refractory urothelial carcinoma who had complete radiographic response lasting 14 months after combined everolimus and pazopanib treatment. This patient was exome sequenced and two mutations co-occurring in MTOR were identified. Expression of these mutations in HEK293T cells demonstrated these were activating mutations. The authors propose that these two activating mutations are the reason for the dramatic response to mTOR inhibition and considered them as \"biologically plausible\" to confer sensitivity to everolimus.",2132,"Urothelial Carcinoma","Urothelial Carcinoma",2671,"http://www.disease-ontology.org/?id=DOID:2671","C","Predictive","Supports","Sensitivity","Somatic Mutation",572,2,"Combination","accepted",0,"evidence",463,"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.","Wagle et al., 2014, Cancer Discov",24625776,"http://www.ncbi.nlm.nih.gov/pubmed/24625776","true","PMC4122326","2014","5",NULL,"Cancer Discov","Cancer discovery","fully curated","41","Everolimus",NULL,"56","Pazopanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1439,"EID1439","In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,"Combination","accepted",0,"evidence",972,"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.","Baselga et al., 2012, Lancet",22257673,"http://www.ncbi.nlm.nih.gov/pubmed/22257673",NULL,NULL,"2012","2","18","Lancet","Lancet (London, England)","fully curated","84","Trastuzumab",NULL,"45","Lapatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1440,"EID1440","Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alteration. RICTOR amplification was confirmed via FISH and IHC. On two separate treatments with dual mTOR1/2 inhibitors patient exhibited stable disease for more than 18 months.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",573,2,"Substitutes","accepted",0,"evidence",973,"RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.","Cheng et al., 2015, Cancer Discov",26370156,"http://www.ncbi.nlm.nih.gov/pubmed/26370156","true","PMC4670806","2015","12",NULL,"Cancer Discov","Cancer discovery","fully curated","347","Cc-223",NULL,"348","MLN0128",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1441,"EID1441","A cohort of seven male patients with myeloproliferative hypereosinophilic syndrome and elevated serum tryptase levels were enrolled in a study of imatinib mesylate therapy. All seven patients demonstrated improvement in clinical symptoms and resolution of laboratory abnormalities and bone marrow pathology in response to treatment. Complete molecular remission of FIP1L1-PDGFRA was observed in 5 of 6 patients tested post-therapy.",2133,"Hypereosinophilic Syndrome, Myeloproliferative Subtype","Hypereosinophilic Syndrome, Myeloproliferative Subtype",NULL,"http://www.disease-ontology.org/","B","Predictive","Supports","Sensitivity","Somatic Mutation",574,4,NULL,"accepted",0,"evidence",974,"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.","Klion et al., 2004, Blood",14504092,"http://www.ncbi.nlm.nih.gov/pubmed/14504092",NULL,NULL,"2004","1","15","Blood","Blood","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1442,"EID1442","Study describes the expansion of a phase 1 study of crizotinib in a 50 patient cohort with advanced NSCLC and exhibiting ROS1 rearrangements. Among the 50 patients 72% exhibited a response (3 complete, 33 partial) according to RECIST defined criteria. The median duration of response and median progression free survival were 14.5 and 19.2 months respectively (95% CI).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",269,4,NULL,"rejected",0,"evidence",447,"Crizotinib in ROS1-rearranged non-small-cell lung cancer.","Shaw et al., 2014, N. Engl. J. Med.",25264305,"http://www.ncbi.nlm.nih.gov/pubmed/25264305","true","PMC4264527","2014","11","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1443,"EID1443","Study describes a 31-year old male, never-smoker patient with advanced NSCLC with a ROS1 rearrangement. The patient was treated with crizotinib with marked response at 1 week and resolution of the tumor confirmed at 8 and 12 weeks via CT-scans. It was also demonstrated that crizotinib inhibits ROS1 phosphorylation in HEK 293 cells transfected with a CD14-ROS1 fusion gene, and crizotinib inhibited growth in the HCC78 cell line containing a ROS1 rearrangement to a similar degree as ALK-fusion positive cell lines.",1163,"Bronchiolo-alveolar Adenocarcinoma","Bronchiolo-alveolar Adenocarcinoma",4926,"http://www.disease-ontology.org/?id=DOID:4926","C","Predictive","Supports","Sensitivity","Somatic Mutation",269,3,NULL,"accepted",0,"evidence",975,"ROS1 rearrangements define a unique molecular class of lung cancers.","Bergethon et al., 2012, J. Clin. Oncol.",22215748,"http://www.ncbi.nlm.nih.gov/pubmed/22215748","true","PMC3295572","2012","3","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1444,"EID1444","Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-ROS1 fusion. CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment.",12,"Inflammatory Myofibroblastic Tumor","Inflammatory Myofibroblastic Tumor",50905,"http://www.disease-ontology.org/?id=DOID:0050905","C","Predictive","Supports","Sensitivity","Somatic Mutation",576,3,NULL,"accepted",0,"evidence",976,"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.","Lovly et al., 2014, Cancer Discov",24875859,"http://www.ncbi.nlm.nih.gov/pubmed/24875859","true","PMC4125481","2014","8",NULL,"Cancer Discov","Cancer discovery","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1445,"EID1445","Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion.",2133,"Hypereosinophilic Syndrome, Myeloproliferative Subtype","Hypereosinophilic Syndrome, Myeloproliferative Subtype",NULL,"http://www.disease-ontology.org/","A","Predictive","Supports","Sensitivity","Somatic Mutation",574,3,NULL,"accepted",0,"evidence",376,"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","Cools et al., 2003, N. Engl. J. Med.",12660384,"http://www.ncbi.nlm.nih.gov/pubmed/12660384",NULL,NULL,"2003","3","27","N. Engl. J. Med.","The New England journal of medicine","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1446,"EID1446","A patient treated with imatinib for a FIP1L1-PDGFRA mutation relapsed during treatment. A T674I mutation in the PDGFRA split kinase domain was hypothesized to confer resistance, due to the strong evidence of this fusion in driving myeloproliferative hypereosinophilic syndrome and the contextual similarity to T315I mutations in BCR-ABL.",2133,"Hypereosinophilic Syndrome, Myeloproliferative Subtype","Hypereosinophilic Syndrome, Myeloproliferative Subtype",NULL,"http://www.disease-ontology.org/","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",577,2,NULL,"accepted",0,"evidence",376,"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","Cools et al., 2003, N. Engl. J. Med.",12660384,"http://www.ncbi.nlm.nih.gov/pubmed/12660384",NULL,NULL,"2003","3","27","N. Engl. J. Med.","The New England journal of medicine","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1447,"EID1447","Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha catalytic domain mutation. Administration of pan-p110 isoform and mTOR inhibitor BEZ235 to H1047R mice with established tumors resulted in reduced tumor phospho-Akt and phosoho-S6 levels, and significant regression of tumor volume.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,3,NULL,"accepted",0,"evidence",193,"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.","Engelman et al., 2008, Nat. Med.",19029981,"http://www.ncbi.nlm.nih.gov/pubmed/19029981","true","PMC2683415","2008","12",NULL,"Nat. Med.","Nature medicine","fully curated","343","BEZ235 (NVP-BEZ235, Dactolisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1448,"EID1448","In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone. In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment. Apoptotic markers were apparent with combination treatment. In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form. Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,"Combination","accepted",0,"evidence",977,"Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.","Chakrabarty et al., 2013, Cancer Res.",23204226,"http://www.ncbi.nlm.nih.gov/pubmed/23204226","true","PMC3563941","2013","2","1","Cancer Res.","Cancer research","fully curated","349","XL147 (Pilaralisib)",NULL,"84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1449,"EID1449","13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray performed. 5 of 13 patients responded to treatment, and pretreatment biopsies from non-responders showed significantly higher survivin (BIRC5) mRNA (p=0.026) levels than responders. In HER2 positive, trastuzumab-sensitive BT474 cells, overexpression of survivin blunted sensitivity to trastuzumab. In HER2 positive trastuzumab-resistant breast cancer cell lines, knockdown of survivin with RNAi or with YM155 induced growth inhibition and apoptosis.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",578,4,NULL,"accepted",0,"evidence",977,"Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.","Chakrabarty et al., 2013, Cancer Res.",23204226,"http://www.ncbi.nlm.nih.gov/pubmed/23204226","true","PMC3563941","2013","2","1","Cancer Res.","Cancer research","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1450,"EID1450","A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated patients without.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,3,NULL,"accepted",0,"evidence",978,"p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.","el Rouby et al., 1993, Blood",8241511,"http://www.ncbi.nlm.nih.gov/pubmed/8241511",NULL,NULL,"1993","12","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1451,"EID1451","In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis. The median survival from the time of first observation of a TP53 mutation was much more pronounced (P = <0.001). These findings were statistically independent of 17p deletions.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,4,NULL,"accepted",0,"evidence",979,"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.","Zenz et al., 2008, Blood",18689542,"http://www.ncbi.nlm.nih.gov/pubmed/18689542",NULL,NULL,"2008","10","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1452,"EID1452","The authors analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations. Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.001) and overall survival (HR = 7.2; P < 0.001).",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,5,NULL,"accepted",0,"evidence",980,"TP53 mutation and survival in chronic lymphocytic leukemia.","Zenz et al., 2010, J. Clin. Oncol.",20697090,"http://www.ncbi.nlm.nih.gov/pubmed/20697090",NULL,NULL,"2010","10","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1453,"EID1453","PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",104,2,NULL,"accepted",0,"evidence",981,"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.","Serra et al., 2008, Cancer Res.",18829560,"http://www.ncbi.nlm.nih.gov/pubmed/18829560",NULL,NULL,"2008","10","1","Cancer Res.","Cancer research","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1454,"EID1454","Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","E","Predictive","Supports","Sensitivity","Somatic Mutation",579,3,"Substitutes","accepted",0,"evidence",982,"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.","Heidorn et al., 2010, Cell",20141835,"http://www.ncbi.nlm.nih.gov/pubmed/20141835","true","PMC2872605","2010","1","22","Cell","Cell","fully curated","6","Sorafenib",NULL,"110","MEK Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1455,"EID1455","Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells. BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance. Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Sensitivity","Somatic Mutation",214,3,"Combination","accepted",0,"evidence",983,"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.","Nagata et al., 2004, Cancer Cell",15324695,"http://www.ncbi.nlm.nih.gov/pubmed/15324695",NULL,NULL,"2004","8",NULL,"Cancer Cell","Cancer cell","fully curated","84","Trastuzumab",NULL,"115","LY294002",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1456,"EID1456","Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors could instead block ERK pathway hyperactivation in RAS mutated cancers.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","E","Predictive","Supports","Sensitivity","Somatic Mutation",580,3,"Substitutes","accepted",0,"evidence",982,"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.","Heidorn et al., 2010, Cell",20141835,"http://www.ncbi.nlm.nih.gov/pubmed/20141835","true","PMC2872605","2010","1","22","Cell","Cell","fully curated","19","Trametinib",NULL,"6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1457,"EID1457","Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","E","Predictive","Supports","Sensitivity","Somatic Mutation",581,3,"Substitutes","accepted",0,"evidence",982,"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.","Heidorn et al., 2010, Cell",20141835,"http://www.ncbi.nlm.nih.gov/pubmed/20141835","true","PMC2872605","2010","1","22","Cell","Cell","fully curated","110","MEK Inhibitor",NULL,"6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1458,"EID1458","Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantâ€“expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",288,2,"Substitutes","accepted",0,"evidence",338,"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.","Dahlman et al., 2012, Cancer Discov",22798288,"http://www.ncbi.nlm.nih.gov/pubmed/22798288","true","PMC3449158","2012","9",NULL,"Cancer Discov","Cancer discovery","fully curated","4","Vemurafenib",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1459,"EID1459","Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantâ€“expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",582,2,"Substitutes","accepted",0,"evidence",338,"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.","Dahlman et al., 2012, Cancer Discov",22798288,"http://www.ncbi.nlm.nih.gov/pubmed/22798288","true","PMC3449158","2012","9",NULL,"Cancer Discov","Cancer discovery","fully curated","19","Trametinib",NULL,"4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1460,"EID1460","Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diameters of target metastatic lesions in the liver and spleen was noted after 2 cycles of therapy and remained progression free at more than 24 weeks. 
Follow-up sequencing analysis of DNA from the patient's tumor revealed a somatic BRAF L597S mutation.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Sensitivity","Somatic Mutation",582,3,NULL,"accepted",0,"evidence",338,"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.","Dahlman et al., 2012, Cancer Discov",22798288,"http://www.ncbi.nlm.nih.gov/pubmed/22798288","true","PMC3449158","2012","9",NULL,"Cancer Discov","Cancer discovery","fully curated","350","TAK-733",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1461,"EID1461","Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantâ€“expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",583,2,"Substitutes","accepted",0,"evidence",338,"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.","Dahlman et al., 2012, Cancer Discov",22798288,"http://www.ncbi.nlm.nih.gov/pubmed/22798288","true","PMC3449158","2012","9",NULL,"Cancer Discov","Cancer discovery","fully curated","4","Vemurafenib",NULL,"19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1462,"EID1462","Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantâ€“expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",584,3,"Substitutes","accepted",0,"evidence",338,"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.","Dahlman et al., 2012, Cancer Discov",22798288,"http://www.ncbi.nlm.nih.gov/pubmed/22798288","true","PMC3449158","2012","9",NULL,"Cancer Discov","Cancer discovery","fully curated","19","Trametinib",NULL,"4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1463,"EID1463","Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response with 60% tumour reduction and received study treatment for more than 2 years.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Sensitivity","Somatic Mutation",585,3,NULL,"accepted",0,"evidence",850,"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.","Falchook et al., 2012, Lancet Oncol.",22805292,"http://www.ncbi.nlm.nih.gov/pubmed/22805292","true","PMC4109286","2012","8",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1464,"EID1464","The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction in phospho-Akt pro-survival signal was apparent, along with increased levels of pro-apoptotic marker cleaved PARP. A general tendency for taselisib sensitivity to PI3K activation (mutation/amplification) was also seen in a panel of 26 HNSCC cell lines",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Sensitivity","Somatic Mutation",212,1,NULL,"accepted",0,"evidence",984,"Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.","Zumsteg et al., 2016, Clin. Cancer Res.",26589432,"http://www.ncbi.nlm.nih.gov/pubmed/26589432","true","PMC4870591","2016","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","351","Taselisib (GDC-0032)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1465,"EID1465","The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib concentration induced reduction of phospho-Akt levels in Call-33 cells, while upregulating the cleaved PARP apoptotic marker. Among a panel of 26 HNSCC cell lines, activating PI3K mutations were associated with taselisib sensitivity in comparison to wild-type PI3K or PTEN mutant cell lines.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,2,NULL,"accepted",0,"evidence",984,"Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.","Zumsteg et al., 2016, Clin. Cancer Res.",26589432,"http://www.ncbi.nlm.nih.gov/pubmed/26589432","true","PMC4870591","2016","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","351","Taselisib (GDC-0032)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1466,"EID1466","Phase 2 trial in metastatic mucosal, acral or chronically sun-damaged melanoma. Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT amplifications, and five (21%) with both. Median follow-up was 10.6 months. Best overall response rate was statistically significantly different by mutation status: 7 of 13 or 54% KIT mutated v 0% KIT amplified only.",83,"Mucosal Melanoma","Mucosal Melanoma",50929,"http://www.disease-ontology.org/?id=DOID:0050929","B","Predictive","Supports","Resistance or Non-Response","N/A",586,3,NULL,"accepted",0,"evidence",85,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.","Hodi et al., 2013, J. Clin. Oncol.",23775962,"http://www.ncbi.nlm.nih.gov/pubmed/23775962","true","PMC4878082","2013","9","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1467,"EID1467","In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably higher antiproliferative IC50 than taselisib sensitized cell lines. Western blots of UD-SCC-3 cells with increasing taselisib concentration showed reduction of phospho-Akt only at micro-molar doses, in contrast to nano-molar range for sensitized cells. Slight induction of the apoptotic marker cleaved PARP was only apparent at 4 micro-molar dose. Similar results were reported with the PTEN mutant HNSCC cell line UPCI-SCC-90, and 4 of the 6 most taselisib resistant cell lines had PTEN mutation.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",510,3,NULL,"accepted",0,"evidence",984,"Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.","Zumsteg et al., 2016, Clin. Cancer Res.",26589432,"http://www.ncbi.nlm.nih.gov/pubmed/26589432","true","PMC4870591","2016","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","351","Taselisib (GDC-0032)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1468,"EID1468","Preclinical study of mouse melanoma in-vitro and in-vivo. In-vitro treament of Braf-mutant melanomas were 10-fold more sensitive to vermurafenib (PLX4032) treatment than Braf/Nf1-mutant melanomas. In vivo treatment of mice with Braf/Nf1-mutant allografts showed less sensitivity to vemurafenib (PLX4032) than the MEK inhibitor, PD0325901.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",587,2,NULL,"accepted",0,"evidence",985,"Elucidating distinct roles for NF1 in melanomagenesis.","Maertens et al., 2013, Cancer Discov",23171796,"http://www.ncbi.nlm.nih.gov/pubmed/23171796","true","PMC3595355","2013","3",NULL,"Cancer Discov","Cancer discovery","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1469,"EID1469","Preclinical study of mouse melanoma both in-vitro and in-vivo. Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901. mTOR inhibition with rapamycin had a more pronounced effect than GDC-0941 on mouse melanoma, but synergized with PD0325901(but not vemurafenib) to promote tumor regression.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",587,3,"Combination","accepted",0,"evidence",985,"Elucidating distinct roles for NF1 in melanomagenesis.","Maertens et al., 2013, Cancer Discov",23171796,"http://www.ncbi.nlm.nih.gov/pubmed/23171796","true","PMC3595355","2013","3",NULL,"Cancer Discov","Cancer discovery","fully curated","352","Rapamycin (Sirolimus)",NULL,"29","PD0325901",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1470,"EID1470","NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. Knockdown of NF1 led to PLX4720 resistance in-vitro. MEK inhibition with AZD6244 (selumetinib) had some efficacy but was also less active than in NF1 proficient cells.  4 patients with mutant alleles of NF1 were identified among patients relapsed after vemurafenib. Of these, one was a nonsense mutation (p.R2450*) present in both pretreatment and postrelapse biopsies. The patient had a progression-free survival (PFS) of about 10 weeks. The other NF1 mutations were silent events (patient 15, c.135T>C, patient 45 c.4023G>A, and patient 50 c3018C>T) located within candidate splicing motifs. Patients 15 and 50 exhibited response rates of relatively short duration (10 and 12 weeks, respectively) and the mutations were observed in both the pretreatment and postrelapse biopsies. Patient 45 experienced a PFS of 5 months, and the NF1 mutation was only present in the postrelapse biopsy indicative of acquired resistance.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",587,4,NULL,"accepted",0,"evidence",986,"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.","Whittaker et al., 2013, Cancer Discov",23288408,"http://www.ncbi.nlm.nih.gov/pubmed/23288408","true","PMC3606893","2013","3",NULL,"Cancer Discov","Cancer discovery","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1471,"EID1471","NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. BRAF V600E/NF1 mutant cell lines were sensitive to ERK inhibition with VTX-11e, modest resistance was observed against RAF inhibitor AZ628. Combined PLX4720 and AZD6244 (selumetinib) achieved greater efficacy than either agent alone but NF1 knockdown was still associated with residual resistance to combined RAF/MEK inhibition in vitro.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",587,2,"Substitutes","accepted",0,"evidence",986,"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.","Whittaker et al., 2013, Cancer Discov",23288408,"http://www.ncbi.nlm.nih.gov/pubmed/23288408","true","PMC3606893","2013","3",NULL,"Cancer Discov","Cancer discovery","fully curated","354","AZ628",NULL,"353","VTX-11e",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1472,"EID1472","Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Sensitivity","Somatic Mutation",208,2,NULL,"accepted",0,"evidence",849,"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.","Ascierto et al., 2013, Lancet Oncol.",23414587,"http://www.ncbi.nlm.nih.gov/pubmed/23414587",NULL,NULL,"2013","3",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","355","Binimetinib (MEK162)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1473,"EID1473","Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of selumetinib (AZD6244) but developed symptomatic brain metastases before confirmatory scans could be performed.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Sensitivity","Somatic Mutation",94,2,NULL,"accepted",0,"evidence",987,"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.","Adjei et al., 2008, J. Clin. Oncol.",18390968,"http://www.ncbi.nlm.nih.gov/pubmed/18390968","true","PMC2718422","2008","5","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1474,"EID1474","Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",427,2,NULL,"accepted",0,"evidence",988,"Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.","Atefi et al., 2011, PLoS ONE",22194965,"http://www.ncbi.nlm.nih.gov/pubmed/22194965","true","PMC3237573","2011",NULL,NULL,"PLoS ONE","PloS one","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1475,"EID1475","Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",427,2,NULL,"accepted",0,"evidence",988,"Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.","Atefi et al., 2011, PLoS ONE",22194965,"http://www.ncbi.nlm.nih.gov/pubmed/22194965","true","PMC3237573","2011",NULL,NULL,"PLoS ONE","PloS one","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1476,"EID1476","Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",208,1,NULL,"accepted",0,"evidence",989,"Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.","Fedorenko et al., 2014, Melanoma Res.",24950457,"http://www.ncbi.nlm.nih.gov/pubmed/24950457","true","PMC4384823","2014","10",NULL,"Melanoma Res.","Melanoma research","fully curated","384","Amuvatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1477,"EID1477","Study explored the response to the SMO inhibitor sonidegib (LDE225) in a cohort of 9 patients with advanced basal cell carcinoma  that exhibited treatment resistance with vismodegib (GDC0449). Sequencing revealed that 5 of these patients harbored SMO mutations known to confer resistance to the Smoothened inhibitors (D473G, D473H, Q477E, S533N, W535L) an additional patient harbored a SMO mutation of unknown consequence (R168H). Of these patients, 4 with a SMO mutation displayed progressive disease and 1 stable disease for 58 weeks according to RECIST v1.1 criteria.",314,"Basal Cell Carcinoma","Basal Cell Carcinoma",2513,"http://www.disease-ontology.org/?id=DOID:2513","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",300,2,"Sequential","accepted",0,"evidence",990,"An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.","Danial et al., 2016, Clin. Cancer Res.",26546616,"http://www.ncbi.nlm.nih.gov/pubmed/26546616","true","PMC4794361","2016","3","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","357","LDE225",NULL,"190","Vismodegib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1478,"EID1478","In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%), shorter progression free survival (5 year PFS 5% vs 17%), and overall survival (20% vs 59%) compared to patients without TP53 mutations.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,3,NULL,"accepted",0,"evidence",991,"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.","Gonzalez et al., 2011, J. Clin. Oncol.",21483000,"http://www.ncbi.nlm.nih.gov/pubmed/21483000",NULL,NULL,"2011","6","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1479,"EID1479","In the randomized UK LRF CCL4 phase 3 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, univariate analysis of patients with NOTCH1 mutations (within amino acids 2405-2525, a 399bp region of the PEST domain) demonstrated poorer overall survival (54.8 vs 74.6 months, P=0.02) and progression free survival (22 vs 26.4 months, P=0.02) compared to patients with wild-type NOTCH1. Progression-free survival was not significant (P = 0.21), however, overall survival remained significant (P = 0.03) under multivariate analysis.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Unknown",206,2,NULL,"accepted",0,"evidence",992,"The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.","Oscier et al., 2013, Blood",23086750,"http://www.ncbi.nlm.nih.gov/pubmed/23086750",NULL,NULL,"2013","1","17","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1480,"EID1480","In the randomized phase 3 UK LRF CCL4 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, SF3B1 mutations (73/437 patients) were associated with poorer overall survival (median 54.3 vs 79 months, P <0.001), independent of treatment. Additionally, controlling for cases with TP53 deletions/mutations, SF3B1 mutations were associated with reduced progression free survival for patients in the fludarabine plus cyclophosphamide treatment arm when compared to wildtype SF3B1 (29.4 vs 46 months, P=0.002).",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",215,4,NULL,"accepted",0,"evidence",992,"The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.","Oscier et al., 2013, Blood",23086750,"http://www.ncbi.nlm.nih.gov/pubmed/23086750",NULL,NULL,"2013","1","17","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1481,"EID1481","Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statistically significant, but the authors suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Predictive","Supports","Sensitivity","Somatic Mutation",222,2,NULL,"accepted",0,"evidence",993,"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.","Lozanski et al., 2004, Blood",14726385,"http://www.ncbi.nlm.nih.gov/pubmed/14726385",NULL,NULL,"2004","5","1","Blood","Blood","fully curated","358","Alemtuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1482,"EID1482","Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations. All 31 patients exhibited a hematologic response at the time of followup (European LeukemiaNet criteria). In regards to molecular response, before treatment the CALR mutant allele displayed a median frequency of 41% across the cohort, during treatment a significant decrease was observed in comparison to controls treated with hydroxyurea and aspirin.",612,"Thrombocytosis","Thrombocytosis",2228,"http://www.disease-ontology.org/?id=DOID:2228","B","Predictive","Supports","Sensitivity","Somatic Mutation",559,4,NULL,"accepted",0,"evidence",994,"Clinical and molecular response to interferon-Î± therapy in essential thrombocythemia patients with CALR mutations.","Verger et al., 2015, Blood",26486786,"http://www.ncbi.nlm.nih.gov/pubmed/26486786",NULL,NULL,"2015","12","10","Blood","Blood","fully curated","8","Pegylated IFN-alphaâ€“2a",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1483,"EID1483","Case study describes a female (age 58) never-smoker presenting with stage IV NSCLC with an ALK rearrangement (confirmed by fish). Patient was treated with crizotinib (partial response) and alectinib (complete response). Liver metastasis was noted after 12 months with sequencing revealing a HIP1-ALK fusion with a I1171N variant.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",588,2,NULL,"accepted",0,"evidence",995,"Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.","Ou et al., 2014, J Thorac Oncol",25393796,"http://www.ncbi.nlm.nih.gov/pubmed/25393796",NULL,NULL,"2014","12",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,"321","Alectinib (CH5424802)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1484,"EID1484","Case study describes a caucasian male (age 38) never smoker presenting with stage IV non-small cell lung cancer with an ALK rearrangement. Patient was given crizotinib and exhibited a partial response after 5 months with brain metastasis occurring at 21 months. Patient then received alectinib and exhibited partial response however liver metastasis presented after 12 months on alectinib. Sequencing of this liver metastasis revealed an EML4-ALK fusion with an I1171S variant at a variant frequency of 36% (tumor purity estimated as 70%).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",589,2,"Sequential","accepted",0,"evidence",995,"Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.","Ou et al., 2014, J Thorac Oncol",25393796,"http://www.ncbi.nlm.nih.gov/pubmed/25393796",NULL,NULL,"2014","12",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","321","Alectinib (CH5424802)",NULL,"12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1485,"EID1485","In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021). This finding was independent of IGHV mutation status.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,5,NULL,"accepted",0,"evidence",997,"Recurrent mutations refine prognosis in chronic lymphocytic leukemia.","Baliakas et al., 2015, Leukemia",24943832,"http://www.ncbi.nlm.nih.gov/pubmed/24943832",NULL,NULL,"2015","2",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1486,"EID1486","In a multivariate analysis of 774 CLL patients, NOTCH1 mutations were not significantly correlated with shorter time to first treatment (HR=1.305; 95% CI=0.923-1.847).",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Does Not Support","N/A","Somatic Mutation",206,5,NULL,"accepted",0,"evidence",997,"Recurrent mutations refine prognosis in chronic lymphocytic leukemia.","Baliakas et al., 2015, Leukemia",24943832,"http://www.ncbi.nlm.nih.gov/pubmed/24943832",NULL,NULL,"2015","2",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1487,"EID1487","In a multivariate analysis of 774 CLL patients, SF3B1 mutations were significantly correlated with shorter time to first treatment (HR=1.644; 95% CI=1.134-2.383). This finding was independent of IGHV mutation status.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",215,5,NULL,"accepted",0,"evidence",997,"Recurrent mutations refine prognosis in chronic lymphocytic leukemia.","Baliakas et al., 2015, Leukemia",24943832,"http://www.ncbi.nlm.nih.gov/pubmed/24943832",NULL,NULL,"2015","2",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1488,"EID1488","BIRC3 mutations were identified in 23 of 919 screened  CLLs. They are strongly linked to non-mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for poor outcome.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",590,2,NULL,"accepted",0,"evidence",997,"Recurrent mutations refine prognosis in chronic lymphocytic leukemia.","Baliakas et al., 2015, Leukemia",24943832,"http://www.ncbi.nlm.nih.gov/pubmed/24943832",NULL,NULL,"2015","2",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1489,"EID1489","MYD88 mutations were identified in 24 of 1080 screened  CLLs. They were exclusively seen in instances of mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for better outcome in CLL.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Better Outcome","Somatic Mutation",424,2,NULL,"accepted",0,"evidence",997,"Recurrent mutations refine prognosis in chronic lymphocytic leukemia.","Baliakas et al., 2015, Leukemia",24943832,"http://www.ncbi.nlm.nih.gov/pubmed/24943832",NULL,NULL,"2015","2",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1490,"EID1490","A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensitive. Four HNSCC cell lines with activating PIK3CA alterations showed synergistic cell death response to the combination of drug with radiation treatment. This synergism was not apparent in 4 tested HNSCC cell lines with wild-type PIK3CA or PTEN mutation. Nude mouse xenografts were established with Cal-33 PIK3CA H1047R cells. Radiation and taselisib treatments alone showed some growth inhibition in comparison to control, but only the combined treatment led durable tumor regressions.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,3,"Combination","accepted",0,"evidence",984,"Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.","Zumsteg et al., 2016, Clin. Cancer Res.",26589432,"http://www.ncbi.nlm.nih.gov/pubmed/26589432","true","PMC4870591","2016","4","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","360","Radiation",NULL,"351","Taselisib (GDC-0032)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1491,"EID1491","IC50 for the pan-Akt inhibitor ipatasertib (GDC-0068) was determined over a panel of 100 cancer cell lines. Loss or mutation of PTEN (e.g. PTEN deletion, T319fsX1/Y155C, etc.) was significantly associated with ipatasertib sensitivity (p=0.000071). Non-transformed human mammary epithelial MCF10A cells were compared to an isogenic line with PTEN knockout. With low or high EGF culture conditions, a 4x or 3.5x decrease in IC50 for ipatasertib was seen in PTEN knockout cells, respectively.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",510,3,NULL,"accepted",0,"evidence",998,"Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.","Lin et al., 2013, Clin. Cancer Res.",23287563,"http://www.ncbi.nlm.nih.gov/pubmed/23287563",NULL,NULL,"2013","4","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","361","Ipatasertib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1492,"EID1492","A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",214,2,NULL,"accepted",0,"evidence",999,"Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.","Lee et al., 2005, Gynecol. Oncol.",15790433,"http://www.ncbi.nlm.nih.gov/pubmed/15790433",NULL,NULL,"2005","4",NULL,"Gynecol. Oncol.","Gynecologic oncology","fully curated","326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1493,"EID1493","Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing. Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay.",1322,"Stomach Carcinoma","Stomach Carcinoma",5517,"http://www.disease-ontology.org/?id=DOID:5517","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",214,2,NULL,"accepted",0,"evidence",1000,"Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.","Oki et al., 2005, Int. J. Cancer",15900596,"http://www.ncbi.nlm.nih.gov/pubmed/15900596",NULL,NULL,"2005","11","10","Int. J. Cancer","International journal of cancer","fully curated","199","Chemotherapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1494,"EID1494","Preclinical study in melanoma cell lines. EZH2 expression was higher in EZH2 mutant (N=3) and wild-type melanoma cell lines (N=12) than untransformed cells (human epithelial melanocytes and human dermal fibroblasts). EZH2 mutant cell lines were the most sensitive to GSK126 compared to wild-type and untransformed.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",165,2,NULL,"accepted",0,"evidence",1001,"Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.","Tiffen et al., 2015, Oncotarget",26304929,"http://www.ncbi.nlm.nih.gov/pubmed/26304929","true","PMC4694971","2015","9","29","Oncotarget","Oncotarget","fully curated","362","GSK126",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1495,"EID1495","Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel, Â± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Sensitivity","Somatic Mutation",18,2,"Combination","accepted",0,"evidence",1002,"Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.","Wilson et al., 2016, Clin. Cancer Res.",26307133,"http://www.ncbi.nlm.nih.gov/pubmed/26307133","true","PMC4821426","2016","1","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","93","Carboplatin",NULL,"6","Sorafenib",NULL,"81","Paclitaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1496,"EID1496","Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, Â± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors that were positive for RAF1 gene copy gains (HR = 0.372; P = 0.025).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Sensitivity","Somatic Mutation",591,2,"Combination","accepted",0,"evidence",1002,"Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.","Wilson et al., 2016, Clin. Cancer Res.",26307133,"http://www.ncbi.nlm.nih.gov/pubmed/26307133","true","PMC4821426","2016","1","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","6","Sorafenib",NULL,"81","Paclitaxel",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1497,"EID1497","Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, Â± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved overall survival compared with CP in patients with tumors positive for KRAS gene copy gains (HR = 0.25; P = 0.035).",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Sensitivity","N/A",592,2,"Combination","accepted",0,"evidence",1002,"Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.","Wilson et al., 2016, Clin. Cancer Res.",26307133,"http://www.ncbi.nlm.nih.gov/pubmed/26307133","true","PMC4821426","2016","1","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","93","Carboplatin",NULL,"73","Docetaxel",NULL,"6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1498,"EID1498","Twelve patients with BCR-ABL-negative chronic myeloproliferative disease and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had prompt responses, 10 had complete resolution of cytogenetic abnormalities and decrease or disappearance of fusion transcripts as measured by reverse transcriptase-polymerase chain reaction (RT-PCR). Updates were sought from 8 further patients previously described in the literature; prompt responses were described in 7 and persist in 6.",313,"Chronic Myeloproliferative Disease","Chronic Myeloproliferative Disease",2226,"http://www.disease-ontology.org/?id=DOID:2226","A","Predictive","Supports","Sensitivity","Somatic Mutation",568,4,NULL,"accepted",0,"evidence",1003,"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.","David et al., 2007, Blood",16960151,"http://www.ncbi.nlm.nih.gov/pubmed/16960151",NULL,NULL,"2007","1","1","Blood","Blood","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1499,"EID1499","ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.",147,"Gastric Adenocarcinoma","Gastric Adenocarcinoma",3717,"http://www.disease-ontology.org/?id=DOID:3717","A","Predictive","Supports","Sensitivity","N/A",306,4,NULL,"accepted",0,"evidence",708,"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.","Bang et al., 2010, Lancet",20728210,"http://www.ncbi.nlm.nih.gov/pubmed/20728210",NULL,NULL,"2010","8","28","Lancet","Lancet (London, England)","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1500,"EID1500","A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel. When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control.",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","D","Predictive","Supports","Sensitivity","Somatic Mutation",214,1,"Combination","accepted",0,"evidence",1004,"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.","Li et al., 2013, J Transl Med",24088382,"http://www.ncbi.nlm.nih.gov/pubmed/24088382","true","PMC3850695","2013",NULL,NULL,"J Transl Med","Journal of translational medicine","fully curated","73","Docetaxel",NULL,"112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1501,"EID1501","In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mouse model was established with PIK3CA H1047R mutant cells, and treatment with AZD5363 induced significant tumor growth inhibition in comparison to vehicle control.",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,3,NULL,"accepted",0,"evidence",1004,"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.","Li et al., 2013, J Transl Med",24088382,"http://www.ncbi.nlm.nih.gov/pubmed/24088382","true","PMC3850695","2013",NULL,NULL,"J Transl Med","Journal of translational medicine","fully curated","112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1502,"EID1502","In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059). In the subpopulation free of RAS mutation (N=19) the correlation was increased.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",214,3,NULL,"accepted",0,"evidence",1005,"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.","Davies et al., 2012, Mol. Cancer Ther.",22294718,"http://www.ncbi.nlm.nih.gov/pubmed/22294718",NULL,NULL,"2012","4",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1503,"EID1503","Sensitivity to pan-Akt inhibitor AZD5363 was assessed in a panel of 182 cell lines (160 with PTEN evaluated) derived from solid and hematological tumors. PTEN loss of function due to loss or mutation (N=32) was found to be significantly correlated with AZD5363 sensitivity (p=0.0099), and correlation improved in the subpopulation free of RAS mutation. Mouse xenografts with 786-0 (PTEN-null renal cancer) cells were established. 75 mg/kg twice daily AZD5363 caused tumor growth inhibition while 150 mg/kg twice daily induced moderate tumor regression.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,3,NULL,"accepted",0,"evidence",1005,"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.","Davies et al., 2012, Mol. Cancer Ther.",22294718,"http://www.ncbi.nlm.nih.gov/pubmed/22294718",NULL,NULL,"2012","4",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1504,"EID1504","HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZD5363 caused significant tumor inhibition (200 mg/kg twice daily > 200 mg/kg once daily > 100 mg/kg once daily). In HCC-1954 xenografts two doses of AZD5363 induced significant tumor inhibition (150 mg/kg twice daily > 75 mg/kg twice daily) while 30 mg/kg twice weekly trastuzumab was inactive.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,2,NULL,"accepted",0,"evidence",1005,"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.","Davies et al., 2012, Mol. Cancer Ther.",22294718,"http://www.ncbi.nlm.nih.gov/pubmed/22294718",NULL,NULL,"2012","4",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1505,"EID1505","Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation. KPL4 has suboptimal responses to trastuzumab and lapatinib. Xengraft treatment with trastuzumab and AZD5363 monotherapy induced moderate growth inhibition which was significant for AZD5363, but co-treatment with trastuzumab and AZD5363 induced significant tumor regression and enhanced growth delay upon removal of treatment.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,3,"Combination","accepted",0,"evidence",1005,"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.","Davies et al., 2012, Mol. Cancer Ther.",22294718,"http://www.ncbi.nlm.nih.gov/pubmed/22294718",NULL,NULL,"2012","4",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","84","Trastuzumab",NULL,"112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1506,"EID1506","The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts. Treatment of mice with monotherapy of AZD5363 or lapatinib alone induced growth inhibition (37%, not significant; 65%, P = 0.004), but treatment with AZD5363 and lapatinib together induced significant tumor regression (109%, P < 0.0001) as well as delayed tumor regrowth after removal of therapy.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,3,"Combination","accepted",0,"evidence",1005,"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.","Davies et al., 2012, Mol. Cancer Ther.",22294718,"http://www.ncbi.nlm.nih.gov/pubmed/22294718",NULL,NULL,"2012","4",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","45","Lapatinib",NULL,"112","AZD5363",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1507,"EID1507","In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001).",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","A","Prognostic","Supports","Poor Outcome","Somatic Mutation",222,5,NULL,"accepted",0,"evidence",1006,"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.","Nadeu et al., 2016, Blood",26837699,"http://www.ncbi.nlm.nih.gov/pubmed/26837699","true","PMC4912011","2016","4","28","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1508,"EID1508","An ASXL1 mutation, especially in conjunction with DNMT3A and EZH2 mutations, results in a fourfold increase in resistance to treatment with ruxolitinib and a reduced time to treatment discontinuation (TTD) for patients with myelofibrosis.",173,"Myelofibrosis","Myelofibrosis",4971,"http://www.disease-ontology.org/?id=DOID:4971","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",177,3,NULL,"accepted",0,"evidence",1007,"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.","Patel et al., 2015, Blood",26124496,"http://www.ncbi.nlm.nih.gov/pubmed/26124496","true","PMC4528066","2015","8","6","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1509,"EID1509","In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162. In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Sensitivity","Somatic Mutation",208,3,NULL,"accepted",0,"evidence",1008,"MEK targeting in N-RAS mutated metastatic melanoma.","Thumar et al., 2014, Mol. Cancer",24588908,"http://www.ncbi.nlm.nih.gov/pubmed/24588908","true","PMC3945937","2014",NULL,NULL,"Mol. Cancer","Molecular cancer","fully curated","355","Binimetinib (MEK162)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1510,"EID1510","In a study of 1,540 patients with Acute Myeloid Leukemia, 418(27%) had mutations in NPM1, mostly W288fs, and there was a preferential co-mutation with NRAS(G12/13), however there was no co-mutation association between NPM1 and NRAS(Q61).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","A","Diagnostic","Supports","Positive","Somatic Mutation",87,5,NULL,"rejected",0,"evidence",1009,"Genomic Classification and Prognosis in Acute Myeloid Leukemia.","Papaemmanuil et al., 2016, N. Engl. J. Med.",27276561,"http://www.ncbi.nlm.nih.gov/pubmed/27276561","true","PMC4979995","2016","6","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1511,"EID1511","In a study of 1,540 patients with Acute Myeloid Leukemia, 18 patients had a mutation in IDH2(R172).  IDH2(R172) mutations rarely showed co-mutation with NPM1 (odds ratio= 0.06; P=4x10-5), whereas IDH2(R140) mutations showed strong co-mutation with NPM1 (odds ratio= 3.6; P=5x10-10).  In an absence of gene fusion products, patients with IDH2(R172) mutations showed higher survival rates when compared to mutations in NPM1, chromatin-spliceosome mutations and TP53â€“aneuploidy.  Patients with IDH2(R172) mutations showed worse prognosis when compared to CEBPA(biallelic) mutations.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",199,4,NULL,"accepted",0,"evidence",1009,"Genomic Classification and Prognosis in Acute Myeloid Leukemia.","Papaemmanuil et al., 2016, N. Engl. J. Med.",27276561,"http://www.ncbi.nlm.nih.gov/pubmed/27276561","true","PMC4979995","2016","6","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1512,"EID1512","In a study of 1,540 patients with Acute Myeloid Leukemia, 66 patients (4%) had a CEBPA (biallelic) mutation.  In the absence of gene fusion products, patients with biallelic CEBPA mutations showed the highest rate of survival (~78%) when compared to IDH2 (R172) mutations, NPM1(W288fs) mutations, chromatin-spliceosome mutations and TP53â€“aneuploidy.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Better Outcome","Somatic Mutation",594,5,NULL,"accepted",0,"evidence",1009,"Genomic Classification and Prognosis in Acute Myeloid Leukemia.","Papaemmanuil et al., 2016, N. Engl. J. Med.",27276561,"http://www.ncbi.nlm.nih.gov/pubmed/27276561","true","PMC4979995","2016","6","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1513,"EID1513","Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",177,5,NULL,"accepted",0,"evidence",1009,"Genomic Classification and Prognosis in Acute Myeloid Leukemia.","Papaemmanuil et al., 2016, N. Engl. J. Med.",27276561,"http://www.ncbi.nlm.nih.gov/pubmed/27276561","true","PMC4979995","2016","6","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1514,"EID1514","Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",595,5,NULL,"accepted",0,"evidence",1009,"Genomic Classification and Prognosis in Acute Myeloid Leukemia.","Papaemmanuil et al., 2016, N. Engl. J. Med.",27276561,"http://www.ncbi.nlm.nih.gov/pubmed/27276561","true","PMC4979995","2016","6","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1515,"EID1515","In the absence of a FLT3 (ITD) mutation, a co-mutation of NPM1 and DNMT3A had a 50% 10-year survival rate, whereas triple-mutation of NPM1, DNMT3A, and FLT3 (ITD) had a 20% 10-year survival rate.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",55,5,NULL,"accepted",0,"evidence",1009,"Genomic Classification and Prognosis in Acute Myeloid Leukemia.","Papaemmanuil et al., 2016, N. Engl. J. Med.",27276561,"http://www.ncbi.nlm.nih.gov/pubmed/27276561","true","PMC4979995","2016","6","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1516,"EID1516","Patients with a triple mutation of NPM1, DNMT3A, and NRAS (G12/13) (three-way interaction p=0.04) showed a relatively benign prognosis with an 8-year survival rate of 75% and a 10-year survival rate of 55%.  Conversely, patients with a concomitant NPM1/DNMT3A co-mutation, in the absence of an NRASG (12/13) mutation, showed a clinically unfavorable 10-year survival rate of 30%.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",596,4,NULL,"accepted",0,"evidence",1009,"Genomic Classification and Prognosis in Acute Myeloid Leukemia.","Papaemmanuil et al., 2016, N. Engl. J. Med.",27276561,"http://www.ncbi.nlm.nih.gov/pubmed/27276561","true","PMC4979995","2016","6","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1517,"EID1517","Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Supports","Sensitivity","Somatic Mutation",276,2,NULL,"accepted",0,"evidence",1010,"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","Topalian et al., 2012, N. Engl. J. Med.",22658127,"http://www.ncbi.nlm.nih.gov/pubmed/22658127","true","PMC3544539","2012","6","28","N. Engl. J. Med.","The New England journal of medicine","fully curated","137","Nivolumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1518,"EID1518","A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment.  Tumor sequencing showed increased MAPK activity due to RET over-expression and PTEN deletion, therefore sunitinib (RET inhibitor) was initiated.  After 28 days post-administration, the lung metastases decreased in size by 22% (28mm to 21mm) and no new metastatic lesions had appeared.  After 4 months, the patient grew resistant to treatment.",706,"Papillary Adenocarcinoma","Papillary Adenocarcinoma",3112,"http://www.disease-ontology.org/?id=DOID:3112","C","Predictive","Supports","Sensitivity","Somatic Mutation",597,3,NULL,"accepted",0,"evidence",1011,"Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.","Jones et al., 2010, Genome Biol.",20696054,"http://www.ncbi.nlm.nih.gov/pubmed/20696054","true","PMC2945784","2010",NULL,NULL,"Genome Biol.","Genome biology","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1519,"EID1519","A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication).",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","C","Predictive","Supports","Sensitivity","Somatic Mutation",108,3,NULL,"accepted",0,"evidence",1012,"Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.","Welch et al., 2011, JAMA",21505136,"http://www.ncbi.nlm.nih.gov/pubmed/21505136","true","PMC3156695","2011","4","20","JAMA","JAMA","fully curated","265","All-trans Retinoic Acid",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1520,"EID1520","A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation. The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life. However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later.",2060,"Sezary's Disease","Sezary's Disease",8541,"http://www.disease-ontology.org/?id=DOID:8541","C","Predictive","Supports","Sensitivity","Somatic Mutation",599,2,NULL,"accepted",0,"evidence",1013,"Personalized treatment of SÃ©zary syndrome by targeting a novel CTLA4:CD28 fusion.","Sekulic et al., 2015, Mol Genet Genomic Med",25802883,"http://www.ncbi.nlm.nih.gov/pubmed/25802883","true","PMC4367085","2015","3",NULL,"Mol Genet Genomic Med","Molecular genetics & genomic medicine","fully curated","365","Ipilimumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1521,"EID1521","In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations.   Within the AR mutation cohort, 78 patients had AR amplification mutations, 16 patients had AR missense mutations, and 13 patients had mutations in ZBTB16, NCOR1, FOXA1, and SPOP, which are all AR regulators or downstream effectors.  All AR mutations were exclusive to mCRPC neoplasms and were not found in primary prostate cancer.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",600,4,"Substitutes","accepted",0,"evidence",1014,"Integrative clinical genomics of advanced prostate cancer.","Robinson et al., 2015, Cell",26000489,"http://www.ncbi.nlm.nih.gov/pubmed/26000489","true","PMC4484602","2015","5","21","Cell","Cell","fully curated","78","Bicalutamide",NULL,"367","Cyproterone Acetate",NULL,"368","Nilutamide",NULL,"366","Flutamide",NULL,NULL,NULL,NULL
1522,"EID1522","Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100).  Mice treated with single therapy of either MDV3100, BYL719, or AZD8186 resulted in mild tumor growth inhibition of 90%, 36%, and 40% respectively (n=5 mice/group).  However, triple therapy of MDV300, BYL719, and AZD8186 resulted in tumor regression of 113% (n=5 mice).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Predictive","Supports","Sensitivity","Somatic Mutation",510,3,"Combination","accepted",0,"evidence",1015,"Feedback suppression of PI3KÎ± signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3KÎ².","Schwartz et al., 2015, Cancer Cell",25544636,"http://www.ncbi.nlm.nih.gov/pubmed/25544636","true","PMC4293347","2015","1","12","Cancer Cell","Cancer cell","fully curated","114","AZD8186",NULL,"163","Enzalutamide",NULL,"339","BYL719 (Alpelisib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1523,"EID1523","In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Prognostic","Supports","Poor Outcome","Germline Mutation",131,3,NULL,"accepted",0,"evidence",1016,"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.","Castro et al., 2013, J. Clin. Oncol.",23569316,"http://www.ncbi.nlm.nih.gov/pubmed/23569316","true","PMC3641696","2013","5","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1524,"EID1524","In a study of 2,019 patients with prostate cancer, 18 had germ-line BRCA1 mutations, 61 had germ-line BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Prognostic","Supports","Poor Outcome","Germline Mutation",132,3,NULL,"accepted",0,"evidence",1016,"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.","Castro et al., 2013, J. Clin. Oncol.",23569316,"http://www.ncbi.nlm.nih.gov/pubmed/23569316","true","PMC3641696","2013","5","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1525,"EID1525","In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome sequenced, 6 cell lines had NOTCH1 loss-of-function mutations (N-terminal frameshift/nonsense) and 5/6 cell lines that had NOTCH1 mutations were susceptible to LGK974 (PORCN inhibitor).",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","D","Predictive","Supports","Sensitivity","Somatic Mutation",601,2,NULL,"accepted",0,"evidence",1017,"Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.","Liu et al., 2013, Proc. Natl. Acad. Sci. U.S.A.",24277854,"http://www.ncbi.nlm.nih.gov/pubmed/24277854","true","PMC3864356","2013","12","10","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","370","LGK974",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1526,"EID1526","In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression). CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy). Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7/SO.5. Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives. Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity.",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","B","Predictive","Supports","Resistance or Non-Response","N/A",602,4,NULL,"accepted",0,"evidence",1018,"High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer.","Alves et al., 2016, Clin. Cancer Res.",27252418,"http://www.ncbi.nlm.nih.gov/pubmed/27252418",NULL,NULL,"2016","6","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","54","Fulvestrant",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1527,"EID1527","Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line. Derivative cell lines showed some sensitivity to CDK4/6 inhibitor palbociclib, and increased growth inhibition when treated with fulvestrant and palbociclib together.",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","D","Predictive","Supports","Sensitivity","Somatic Mutation",602,2,"Combination","accepted",0,"evidence",1018,"High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer.","Alves et al., 2016, Clin. Cancer Res.",27252418,"http://www.ncbi.nlm.nih.gov/pubmed/27252418",NULL,NULL,"2016","6","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","48","Palbociclib (PD0332991)",NULL,"54","Fulvestrant",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1528,"EID1528","A 25-year-old Caucasian male presented with a second relapse of B-ALL. RNA sequencing revealed FLT3 overexpression (also confirmed by IHC). The patient was treated with 22 days of sunitinib, permitting the patient to undergo a bone marrow transplant. A bone marrow biopsy showed complete clearance by variant allele frequency and the patient remains in remission 4-years post matched-unrelated donor allograft.",2135,"Adult B-Lymphoblastic Leukemia","Adult B-Lymphoblastic Leukemia",NULL,"http://www.disease-ontology.org/","C","Predictive","Supports","Sensitivity","Somatic Mutation",603,3,NULL,"accepted",0,"evidence",1019,"Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.","Griffith et al., 2016, Exp. Hematol.",27181063,"http://www.ncbi.nlm.nih.gov/pubmed/27181063","true","PMC4914477","2016","7",NULL,"Exp. Hematol.","Experimental hematology","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1529,"EID1529","In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.",47,"Ovarian Carcinoma","Ovarian Carcinoma",4001,"http://www.disease-ontology.org/?id=DOID:4001","B","Predictive","Supports","Sensitivity","Germline Mutation",185,3,NULL,"accepted",0,"evidence",1020,"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.","Pennington et al., 2014, Clin. Cancer Res.",24240112,"http://www.ncbi.nlm.nih.gov/pubmed/24240112","true","PMC3944197","2014","2","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1530,"EID1530","In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.",47,"Ovarian Carcinoma","Ovarian Carcinoma",4001,"http://www.disease-ontology.org/?id=DOID:4001","B","Predictive","Supports","Sensitivity","Germline Mutation",186,3,NULL,"accepted",0,"evidence",1020,"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.","Pennington et al., 2014, Clin. Cancer Res.",24240112,"http://www.ncbi.nlm.nih.gov/pubmed/24240112","true","PMC3944197","2014","2","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1531,"EID1531","In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy.",47,"Ovarian Carcinoma","Ovarian Carcinoma",4001,"http://www.disease-ontology.org/?id=DOID:4001","B","Predictive","Supports","Sensitivity","Somatic Mutation",185,3,NULL,"accepted",0,"evidence",1020,"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.","Pennington et al., 2014, Clin. Cancer Res.",24240112,"http://www.ncbi.nlm.nih.gov/pubmed/24240112","true","PMC3944197","2014","2","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1532,"EID1532","In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy.",47,"Ovarian Carcinoma","Ovarian Carcinoma",4001,"http://www.disease-ontology.org/?id=DOID:4001","B","Predictive","Supports","Sensitivity","Somatic Mutation",186,3,NULL,"accepted",0,"evidence",1020,"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.","Pennington et al., 2014, Clin. Cancer Res.",24240112,"http://www.ncbi.nlm.nih.gov/pubmed/24240112","true","PMC3944197","2014","2","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1533,"EID1533","A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",604,2,NULL,"accepted",0,"evidence",1021,"Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.","Turajlic et al., 2014, Ann. Oncol.",24504448,"http://www.ncbi.nlm.nih.gov/pubmed/24504448","true","PMC3999800","2014","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1534,"EID1534","A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma. Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift mutation at V317) was identified as unanimously present in all five tumors and a pre-treatment biopsy. The other copy of PTEN was lost with a chromosome-wide loss of chr 10. Subsequently, a patient-derived tumor cell line (designated 22 092) was suspended in a solution of PD18352/MK2206 combination therapy and cell growth inhibition confirmed tumor sensitivity to MEK/AKT inhibitors compared to the BRAF V600E-containing A375P cell line. ERK inhibitor resistance was demonstrated as a result of a GNAQ Q209P mutation also identified in the patient. This cell line showed overexpression of AKT and no expression of PTEN.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Sensitivity","Somatic Mutation",605,3,"Combination","accepted",0,"evidence",1021,"Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.","Turajlic et al., 2014, Ann. Oncol.",24504448,"http://www.ncbi.nlm.nih.gov/pubmed/24504448","true","PMC3999800","2014","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","374","PD184352",NULL,"43","MK-2206",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1535,"EID1535","In 3 ER positive and 2 ER negative breast cancer cell lines with intact Rb, significant growth inhibition, as measured by BrdU incorporation, was seen with incubation in CDK4/6 inhibitor palbociclib (PD-0332991). In contrast, two ER negative cell lines lacking detectable Rb were fully resistant to palbociclib. Knockdown of Rb in 3 of the tested Rb positive cell lines led to moderate palbociclib resistance in short term incubation experiments. 
In longer term (15 day) palbociclib incubations of ER negative MDA-MB-231 cells and ER positive MCF-7 cells, significant resistance to palbociclib was seen in Rb knockdown conditions while wild-type Rb cells maintained sensitivity.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",606,3,NULL,"accepted",0,"evidence",1022,"Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.","Dean et al., 2010, Oncogene",20473330,"http://www.ncbi.nlm.nih.gov/pubmed/20473330",NULL,NULL,"2010","7","15","Oncogene","Oncogene","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1536,"EID1536","A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing for the t(11:14) rearrangement  causing Cyclin D overexpression in MCL. 1 patient demonstrated complete response, and 2 showed partial response for an 18% overall response rate. 7 patients showed stable disease. Patient population was heavily pretreated.",243,"Mantle Cell Lymphoma","Mantle Cell Lymphoma",50476,"http://www.disease-ontology.org/?id=DOID:50476","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",20,2,NULL,"accepted",0,"evidence",1023,"Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.","Leonard et al., 2012, Blood",22383795,"http://www.ncbi.nlm.nih.gov/pubmed/22383795",NULL,NULL,"2012","5","17","Blood","Blood","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1537,"EID1537","Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation. 20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild-type A375P cells. Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",604,3,NULL,"accepted",0,"evidence",1021,"Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.","Turajlic et al., 2014, Ann. Oncol.",24504448,"http://www.ncbi.nlm.nih.gov/pubmed/24504448","true","PMC3999800","2014","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","30","PLX4720",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1538,"EID1538","In a study of 406 previously untreated CLL cases, a multivariate analysis indicated clonal NOTCH1 mutations (N=55) were significantly associated with reduced overall survival (HR: 1.5; 95%CI: 1.13-1.99; P = 0.0049). Subclonal mutations (VAF <12%) were not associated with reduced OS (N=29, P=0.94, univariate analysis).",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","A","Prognostic","Supports","Poor Outcome","Somatic Mutation",206,5,NULL,"accepted",0,"evidence",1006,"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.","Nadeu et al., 2016, Blood",26837699,"http://www.ncbi.nlm.nih.gov/pubmed/26837699","true","PMC4912011","2016","4","28","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1539,"EID1539","In a study of 406 previously untreated CLL cases, a multivariate analysis indicated that aberrations (N=44; mixed pathogenic germline and somatic) in exons 2-63 of ATM were significantly associated with shorter time to first treatment (HR: 1.36; 95% CI: 1.05-1.76; P = 0.021). These mutations were not significantly associated with overall survival.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","A","Prognostic","Supports","Poor Outcome","N/A",178,5,NULL,"accepted",0,"evidence",1006,"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.","Nadeu et al., 2016, Blood",26837699,"http://www.ncbi.nlm.nih.gov/pubmed/26837699","true","PMC4912011","2016","4","28","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1540,"EID1540","In a study of 406 previously untreated CLL cases, a multivariate analysis indicated SF3B1 mutations (N=51) were significantly associated with reduced time to first treatment (HR: 1.73; 95%CI: 1.05-2.86; P = 0.031). While clonal mutations (VAF >= 12%) were associated with reduced time to first treatment by univariate analysis (N=28, P<0.0001), subclonal mutations were not (N=21, P=0.22).",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","A","Prognostic","Supports","Poor Outcome","Somatic Mutation",215,5,NULL,"accepted",0,"evidence",1006,"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.","Nadeu et al., 2016, Blood",26837699,"http://www.ncbi.nlm.nih.gov/pubmed/26837699","true","PMC4912011","2016","4","28","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1541,"EID1541","A phase 2 clinical trial evaluated 165 patients with oestrogen receptor positive and HER2-negative breast cancer such that 84 patients received combination therapy of palbociclib plus letrozole and 81 patients received letrozole alone. The combination therapy arm had higher median duration of progression-free survival when compared to the letrozole only group (20.2 months vs. 10.2 months; p<0.0004). A subcategory of patients taking combination therapy, who lacked mutations in p16 or CCND1 (n=34), had an even higher median free survival of 26.1 months.  Noticeable side effects in the combination therapy group included neutropenia (54%) leucopenia (19%), fatigue (4%) back pain (2%), diarrhea (2%) and pulmonary embolism (4%).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","Somatic Mutation",607,4,"Combination","accepted",0,"evidence",1024,"The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.","Finn et al., 2015, Lancet Oncol.",25524798,"http://www.ncbi.nlm.nih.gov/pubmed/25524798",NULL,NULL,"2015","1",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","48","Palbociclib (PD0332991)",NULL,"375","Letrozole",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1542,"EID1542","In patients with acute myeloid leukemia, the presence of IDH2 R140Q (nâ€‰=â€‰7), IDH2 R172K (nâ€‰=â€‰3) or IDH1 R132 (N=4) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients overall (N=102; P=0.177). IDH1/2 mutations were significantly more common in cytogenetically normal AML (P=0.004). IDH1/2 mutations did also not confer an overall survival benefit in patients with an intermediate risk karyotype (N=68, P=0.484).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Does Not Support","N/A","Somatic Mutation",62,2,NULL,"accepted",0,"evidence",204,"IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.","Lin et al., 2012, Ann. Hematol.",21997850,"http://www.ncbi.nlm.nih.gov/pubmed/21997850",NULL,NULL,"2012","4",NULL,"Ann. Hematol.","Annals of hematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1543,"EID1543","MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",470,4,NULL,"accepted",0,"evidence",1025,"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.","Rodrik-Outmezguine et al., 2016, Nature",27279227,"http://www.ncbi.nlm.nih.gov/pubmed/27279227","true","PMC4902179","2016","6","9","Nature","Nature","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1544,"EID1544","MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",609,4,NULL,"accepted",0,"evidence",1025,"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.","Rodrik-Outmezguine et al., 2016, Nature",27279227,"http://www.ncbi.nlm.nih.gov/pubmed/27279227","true","PMC4902179","2016","6","9","Nature","Nature","fully curated","124","AZD8055",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1545,"EID1545","MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. These cells remained sensitive to rapamycin and RapaLink-1 in vitro and in mouse xenografts. Expression of the mutation in MDA-MB-468 cells led to AZD8055 resistance and these cells were also rapamycin and RapaLink-1 sensitive.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",609,3,"Substitutes","accepted",0,"evidence",1025,"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.","Rodrik-Outmezguine et al., 2016, Nature",27279227,"http://www.ncbi.nlm.nih.gov/pubmed/27279227","true","PMC4902179","2016","6","9","Nature","Nature","fully curated","352","Rapamycin (Sirolimus)",NULL,"376","RapaLink-1",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1546,"EID1546","MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in another cell line led to resistance. A novel mTOR inhibitor RapaLink-1 was designed and showed efficacy in A2034V mTOR mutant cell lines in-vivo and in-vitro. AZD8055 also retained efficacy in these clones in xenograft.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",609,4,NULL,"rejected",0,"evidence",1025,"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.","Rodrik-Outmezguine et al., 2016, Nature",27279227,"http://www.ncbi.nlm.nih.gov/pubmed/27279227","true","PMC4902179","2016","6","9","Nature","Nature","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1547,"EID1547","MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",610,4,NULL,"accepted",0,"evidence",1025,"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.","Rodrik-Outmezguine et al., 2016, Nature",27279227,"http://www.ncbi.nlm.nih.gov/pubmed/27279227","true","PMC4902179","2016","6","9","Nature","Nature","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1548,"EID1548","MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance to rapamycin but maintained sensistivity to AZD8055. A novel mTOR inhibitor RapaLink-1 was designed and showed efficacy in A2034V mTOR mutant cell lines in-vivo and in-vitro. AZD8055 also retained efficacy in these clones in xenograft.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",610,4,"Substitutes","accepted",0,"evidence",1025,"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.","Rodrik-Outmezguine et al., 2016, Nature",27279227,"http://www.ncbi.nlm.nih.gov/pubmed/27279227","true","PMC4902179","2016","6","9","Nature","Nature","fully curated","376","RapaLink-1",NULL,"124","AZD8055",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1549,"EID1549","Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses. One of the partial responses harbored a PIK3CA E542K mutation.",37,"Head And Neck Squamous Cell Carcinoma","Head And Neck Squamous Cell Carcinoma",5520,"http://www.disease-ontology.org/?id=DOID:5520","C","Predictive","Supports","Sensitivity","Somatic Mutation",103,2,NULL,"accepted",0,"evidence",1026,"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.","Dolly et al., 2016, Clin. Cancer Res.",26787751,"http://www.ncbi.nlm.nih.gov/pubmed/26787751","true","PMC4876928","2016","6","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","377","Apitolisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1550,"EID1550","Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one head and neck squamous cell carcinoma patient and a patient with ovarian cancer) had unconfirmed partial responses. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","C","Predictive","Supports","Sensitivity","Somatic Mutation",104,1,NULL,"accepted",0,"evidence",1026,"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.","Dolly et al., 2016, Clin. Cancer Res.",26787751,"http://www.ncbi.nlm.nih.gov/pubmed/26787751","true","PMC4876928","2016","6","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","377","Apitolisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1551,"EID1551","In a study of 908 patients with colorectal cancer, 7 patients had BRAF (D594G) mutations and 45 patients had BRAF (V600E) mutations. Overall clinicopathological implications of BRAF V600E and D594G mutant tumors were similar but BRAF D594G mutations were more likely to be left-sided tumors (85.7% vs. 31.1%; p<0.0098) and they were more likely to present as metastatic tumors (71.4% vs. 28.9%; p<0.04) than BRAF V600E mutant tumors. The overall log-rank was p < 0.001 when all three groups were calculated simultaneously; p < 0.0001 comparing BRAF wild-type and BRAF V600E survival, p = 0.015 comparing BRAF wild-type and BRAF D594G survival, and p = 0.98 comparing BRAF V600E and BRAF D594G.  There was no statistically significant difference in OS between BRAF D594G and BRAF wt but BRAF V600E mutant patients had significantly worse survival when only stage IV patients (BRAF D594G N=5) were analyzed.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",611,1,NULL,"accepted",0,"evidence",1027,"Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.","Amaki-Takao et al., 2016, Oncology",27404270,"http://www.ncbi.nlm.nih.gov/pubmed/27404270",NULL,NULL,"2016","7","13","Oncology","Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1552,"EID1552","In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type.  BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%; p<0.0001), they were more likely to be poorly differentiated (17.7%, 1.9%; p<0.0001), they were more likely to be mucinous carcinoma type (20.0%, 4.2%; p=0.0003), they were more likely to have lymphatic invasion (77.6%, 49.9%; p=0.0003), and they had a shorter survival time (31.1 mo, 41.6 mo; p=0.001).  The 3-year survival rate was significantly poorer in the V600E group when compared to the wild type group (63.8%, 87.9%; p<0.0001).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",1027,"Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.","Amaki-Takao et al., 2016, Oncology",27404270,"http://www.ncbi.nlm.nih.gov/pubmed/27404270",NULL,NULL,"2016","7","13","Oncology","Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1553,"EID1553","In a study of 908 patients with colorectal cancer (CRC), 7 patients had BRAF D595G mutations and 589 patients were BRAF wild type. The survival rate of CRC patients at 3 years was significantly poorer in the BRAF D595G mutations when compared to the wild type group (50%, 87.9%; p<0.00152).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",611,2,NULL,"accepted",0,"evidence",1027,"Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.","Amaki-Takao et al., 2016, Oncology",27404270,"http://www.ncbi.nlm.nih.gov/pubmed/27404270",NULL,NULL,"2016","7","13","Oncology","Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1554,"EID1554","Two patients with stage IV BRAF (D594G) mutations received anti-EGFR antibody therapy (cetuximab and panitumumab). The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months. No response was observed after cetuximab was given as a third line therapy. The second patient received panitumumab with FOLFOX and showed no signs of progression for 8 months with reduction of the size of metastases.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",611,1,"Substitutes","accepted",0,"evidence",1027,"Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.","Amaki-Takao et al., 2016, Oncology",27404270,"http://www.ncbi.nlm.nih.gov/pubmed/27404270",NULL,NULL,"2016","7","13","Oncology","Oncology","fully curated","16","Cetuximab",NULL,"28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1555,"EID1555","Six children with relapsed or refractory FLT3-ITD-positive AML received initial therapy with sorafenib (alone or in combination with clofarabine and cytarabine).  Four of the patients initially achieved morphological complete remission (bone marrow blasts <5%), however, 3 patients developed resistance within 14-37 weeks and and 1 required a bone marrow transplant.  Two patients did not have any clinical response to sorafenib upon initial treatment.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","C","Predictive","Supports","Sensitivity","Somatic Mutation",55,1,NULL,"accepted",0,"evidence",1028,"Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.","Baker et al., 2013, Clin. Cancer Res.",23969938,"http://www.ncbi.nlm.nih.gov/pubmed/23969938","true","PMC3878304","2013","10","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1556,"EID1556","Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients. Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",612,3,NULL,"accepted",0,"evidence",1028,"Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.","Baker et al., 2013, Clin. Cancer Res.",23969938,"http://www.ncbi.nlm.nih.gov/pubmed/23969938","true","PMC3878304","2013","10","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1557,"EID1557","Mouse Ba/F3 cells with FLT3 mutations were evaluated for sorafenib resistance.  Cells with single FLT3 (D835H/Y) mutants were resistant to sorafenib (IC50 81 nm/210 nM) whereas cells with FLT3 (ITD) mutants were not resistant to sorafenib (IC50 1.1 nM).  Cells with double mutants (ITD-D835H/Y or ITD F691L) were highly resistant to sorafenib (IC50 460-3300 nM).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",613,1,NULL,"accepted",0,"evidence",1028,"Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.","Baker et al., 2013, Clin. Cancer Res.",23969938,"http://www.ncbi.nlm.nih.gov/pubmed/23969938","true","PMC3878304","2013","10","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","6","Sorafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1558,"EID1558","In patients with acute myeloid leukemia, those with RUNX1 mutations (n=245) had significantly worse outcomes when compared to those with RUNX1 wild-type alleles (n=2,194).  The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001).",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",155,3,NULL,"accepted",0,"evidence",1029,"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.","Gaidzik et al., 2016, Leukemia",27137476,"http://www.ncbi.nlm.nih.gov/pubmed/27137476",NULL,NULL,"2016","6","10","Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1559,"EID1559","Short term explant cultures from 20 glioblastoma multiforme (GBM) tumor xenograft lines were evaluated for CDKN2A (p16 aka INK4A) expression by western blot and RT-PCR as well as deletion by aCGH and Sanger sequencing. Two lines with intact CDKN2A showed resistance to the CDK4/6 inhibitor palbociclib (PD0332991). The two resistant lines had additional mutations (RB1 mutation or CDK4 amplification).  In contrast, three CDKN2A mutant (homozygous deletion) lines showed significant growth inhibition in comparison to vehicle/DMSO controls.  Screening of another 20 lines identified one with CDKN2A deletion and wildtype CDK4 which was tested in vitro and in vivo, and found to be sensitive to palbociclib.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","D","Predictive","Supports","Sensitivity","Somatic Mutation",554,2,NULL,"submitted",0,"evidence",1030,"p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.","Cen et al., 2012, Neuro-oncology",22711607,"http://www.ncbi.nlm.nih.gov/pubmed/22711607","true","PMC3379801","2012","7",NULL,"Neuro-oncology","Neuro-oncology","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1560,"EID1560","28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cyclin D1 (CCND1) expression which did not correlate significantly with palbociclib sensitivity (p=0.348).",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",18,2,NULL,"accepted",0,"evidence",212,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.","Logan et al., 2013, Anticancer Res.",23898052,"http://www.ncbi.nlm.nih.gov/pubmed/23898052",NULL,NULL,"2013","8",NULL,"Anticancer Res.","Anticancer research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1561,"EID1561","In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,2,"Combination","accepted",0,"evidence",1031,"PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.","Finn et al., 2009, Breast Cancer Res.",19874578,"http://www.ncbi.nlm.nih.gov/pubmed/19874578","true","PMC2790859","2009",NULL,NULL,"Breast Cancer Res.","Breast cancer research : BCR","fully curated","84","Trastuzumab",NULL,"48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1562,"EID1562","A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991),  where IC50 below 150nM was sensitive, and above 1000nM resistant. Cyclin D1 had higher expression levels in sensitive cell lines.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",18,2,NULL,"accepted",0,"evidence",1031,"PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.","Finn et al., 2009, Breast Cancer Res.",19874578,"http://www.ncbi.nlm.nih.gov/pubmed/19874578","true","PMC2790859","2009",NULL,NULL,"Breast Cancer Res.","Breast cancer research : BCR","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1563,"EID1563","In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991). Palbociclib caused Rb dephosphorylation in MCL cell lines and patient derived tumor cells. MCL cell lines overexpressing cyclin D1 showed growth inhibition with Palbociclib. The VAL DLBCL cell line was used as control to verify cyclin D1 overexpression but was not used as a control in Palbociclib inhibitor experiments. Instead, the investigators report that other publications report cell lines without cyclin D1 overexpression had higher IC50 values for palbociclib, suggesting overexpresssed cyclin D1 targetability in MCL.",243,"Mantle Cell Lymphoma","Mantle Cell Lymphoma",50476,"http://www.disease-ontology.org/?id=DOID:50476","D","Predictive","Supports","Sensitivity","Somatic Mutation",20,1,NULL,"accepted",0,"evidence",1032,"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.","Marzec et al., 2006, Blood",16690963,"http://www.ncbi.nlm.nih.gov/pubmed/16690963","true","PMC1895502","2006","9","1","Blood","Blood","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1564,"EID1564","43 B-CLL patients with LoH or reduced protein levels (<50% normal expression, radioimmunoassay, western blot) of ATM were found to have significantly shorter overall survival (35.6 vs. 97.3 months; P=0.003) when compared to 108 patients with normal expression levels.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","N/A",179,3,NULL,"accepted",0,"evidence",1033,"Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.","Starostik et al., 1998, Cancer Res.",9788599,"http://www.ncbi.nlm.nih.gov/pubmed/9788599",NULL,NULL,"1998","10","15","Cancer Res.","Cancer research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1565,"EID1565","A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizotinib treatment was started. A 40% reduction in size of contrast enhancing lesion was seen. After 6 months, progressive disease was seen and crizotinib withdrawn. The authors state this is a first report of response to prospective MET targeted therapy in GBM.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","C","Predictive","Supports","Sensitivity","Somatic Mutation",270,3,NULL,"accepted",0,"evidence",1034,"Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.","Chi et al., 2012, J. Clin. Oncol.",22162573,"http://www.ncbi.nlm.nih.gov/pubmed/22162573",NULL,NULL,"2012","1","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1566,"EID1566","2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had IC50 100 fold lower than the non MET amplified cell lines. Both crizotinib treatment and siRNA against MET increased apoptotic markers in MET amplified cells but not controls, indicating that crizotinib targeting of amplified MET was inducing the apoptotic effects. Tumors caused by MET amplified EBC-1 cells injected into mice were significantly inhibited with crizotinib treatment, while tumors from non-MET amplified cells showed no substantial effect.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",270,4,NULL,"accepted",0,"evidence",1035,"MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.","Tanizaki et al., 2011, J Thorac Oncol",21716144,"http://www.ncbi.nlm.nih.gov/pubmed/21716144",NULL,NULL,"2011","10",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1567,"EID1567","Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1).
A JAK1 Q503* mutation was observed at the time of relapse in patient 1. This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor. CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",614,4,NULL,"accepted",0,"evidence",1036,"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.","Zaretsky et al., 2016, N. Engl. J. Med.",27433843,"http://www.ncbi.nlm.nih.gov/pubmed/27433843",NULL,NULL,"2016","7","13","N. Engl. J. Med.","The New England journal of medicine","fully curated","138","Pembrolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1568,"EID1568","Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A JAK2 F547 splice site mutation was observed at the time of relapse in patient 2. RNA sequencing revealed an in-frame stop codon after exon 12. The JAK2 mutation was the only homozygous mutation (allele frequency >85%) of 76 new nonsynonymous mutations in patient 2. Cell line modelling of baseline and relapse JAK2 mutational status revealed a loss of response to interferon gamma and  loss of JAK2 protein. This loss of response was also modeled in another cell line.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",615,4,NULL,"accepted",0,"evidence",1036,"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.","Zaretsky et al., 2016, N. Engl. J. Med.",27433843,"http://www.ncbi.nlm.nih.gov/pubmed/27433843",NULL,NULL,"2016","7","13","N. Engl. J. Med.","The New England journal of medicine","fully curated","138","Pembrolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1569,"EID1569","Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A B2M frame-shift deletion in exon 1 was identified as the only new homozygous mutation among 24 new relapse-specific mutations. Immunohistochemistry revealed loss of MHC1 outer-membrane localization.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",616,3,NULL,"accepted",0,"evidence",1036,"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.","Zaretsky et al., 2016, N. Engl. J. Med.",27433843,"http://www.ncbi.nlm.nih.gov/pubmed/27433843",NULL,NULL,"2016","7","13","N. Engl. J. Med.","The New England journal of medicine","fully curated","138","Pembrolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1570,"EID1570","Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF). Trametinib was introduced and anemia and ECOG status improved. Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks. Trametinib was stopped and pembrolizumab introduced at this time. Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Sensitivity","Somatic Mutation",617,2,NULL,"accepted",0,"evidence",1037,"Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.","Menzies et al., 2015, Pigment Cell Melanoma Res",26072686,"http://www.ncbi.nlm.nih.gov/pubmed/26072686","true","PMC4539279","2015","9",NULL,"Pigment Cell Melanoma Res","Pigment cell & melanoma research","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1571,"EID1571","A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression. Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive). No new metastases were identified. The patient was switched to pembrolizumab and major disease progression was noted.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","C","Predictive","Supports","Sensitivity","Somatic Mutation",618,1,NULL,"accepted",0,"evidence",1037,"Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.","Menzies et al., 2015, Pigment Cell Melanoma Res",26072686,"http://www.ncbi.nlm.nih.gov/pubmed/26072686","true","PMC4539279","2015","9",NULL,"Pigment Cell Melanoma Res","Pigment cell & melanoma research","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1572,"EID1572","Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285). Patients receiving cetuximab had increased overall survival (HR=0.77, 95%CI 0.64-0.92; p=0.005), increased progression-free survival (HR=0.68, 95%CI 0.57-0.80; p<0.001), and improved quality of life at 4 months measured by survey on physical deterioration (-5.9 vs -12.5; p=0.03) and global health status (-3.6 vs. -15.2; p<0.001).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",354,4,NULL,"accepted",0,"evidence",1038,"Cetuximab for the treatment of colorectal cancer.","Jonker et al., 2007, N. Engl. J. Med.",18003960,"http://www.ncbi.nlm.nih.gov/pubmed/18003960",NULL,NULL,"2007","11","15","N. Engl. J. Med.","The New England journal of medicine","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1573,"EID1573","Mail-in surveys conducted every two years since 1980 evaluated 82,911 woman and 47,363 men for regular aspirin use.  In this cohort, aspirin use was associated with a lower relative risk of colorectal cancer (RR=0.73; 95% CI 0.69-0.87; p<0.001).  Immunohistochemical analysis was employed on a subset of 636 cases to evaluate COX2 overexpression.  Of these tumors, 67% had moderate or strong COX2 expression and 33% had weak or absent COX-2 expression.  In tumors with COX-2 overexpression, regular aspirin use conferred significant risk reduction of colorectal cancer (RR=0.64; 95%CI 0.52-0.78) however, in tumors with reduced COX2 expression, aspirin use had no influence on colorectal cancer incidence (RR=0.96, 95%CI 0.73-1.26).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","Somatic Mutation",619,3,NULL,"accepted",0,"evidence",1039,"Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.","Chan et al., 2007, N. Engl. J. Med.",17522398,"http://www.ncbi.nlm.nih.gov/pubmed/17522398",NULL,NULL,"2007","5","24","N. Engl. J. Med.","The New England journal of medicine","fully curated","379","Aspirin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1574,"EID1574","Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRAF V600G and one with BRAF V600 unknown status), 19 were evaluable and the response rate to vemurafenib was 42%, tumor regression was observed in 14/19 patients, progression-free survival was 7.3 months, and 12-month overall survival was 66%.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",17,3,NULL,"accepted",0,"evidence",1040,"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.","Hyman et al., 2015, N. Engl. J. Med.",26287849,"http://www.ncbi.nlm.nih.gov/pubmed/26287849","true","PMC4971773","2015","8","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1575,"EID1575","Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 14 patients with Langerhansâ€™-cell histiocytosis, 43% of patients had a response to vemurafenib (1 complete and 5 partial responses), disease regression was observed in 12/14 patients, all patients detailed improvement in disease-related symptoms, 0 patients had progressive disease during treatment, 12-month progression free survival was 91%, and overall survival rate was 100%.
Among all 18 patients with Erdheim-Chester disease or Langerhans histiocytosis, 94% had BRAF V600E mutations and the remaining 6 percent (1 patient) had an unknown V600 mutation.",2136,"Langerhans-Cell Histiocytosis","Langerhans-Cell Histiocytosis",2571,"http://www.disease-ontology.org/?id=DOID:2571","B","Predictive","Supports","Sensitivity","Somatic Mutation",17,3,NULL,"accepted",0,"evidence",1040,"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.","Hyman et al., 2015, N. Engl. J. Med.",26287849,"http://www.ncbi.nlm.nih.gov/pubmed/26287849","true","PMC4971773","2015","8","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1576,"EID1576","Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 10 patients with colorectal cancer (80% BRAF V600E, 20% V600 unknown status), no responses were observed and overall survival was 9.3 months with a median progression-free survival of 4.5 months.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",17,3,NULL,"accepted",0,"evidence",1040,"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.","Hyman et al., 2015, N. Engl. J. Med.",26287849,"http://www.ncbi.nlm.nih.gov/pubmed/26287849","true","PMC4971773","2015","8","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1577,"EID1577","A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer.  The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174).  In the crizotinib arm, the response rate was significantly higher (65% vs 20%; P<0.001), the progression-free survival was increased (7.7 months vs. 3.0 months; HR=0.49, 95%CI:14 months-26 months; p<0.001), however, there was no significant improvement in overall survival (HR=1.02; 95%CI:0.68-1.54; P=0.54).  Of the patients on crizotinib treatment, global quality of life was improved relative to baseline when compared to chemotherapy patients (+5 mean change, -5 mean change; P<0.001).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",499,3,NULL,"accepted",0,"evidence",1041,"Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.","2015, N. Engl. J. Med.",26466010,"http://www.ncbi.nlm.nih.gov/pubmed/26466010",NULL,NULL,"2015","10","15","N. Engl. J. Med.","The New England journal of medicine","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1578,"EID1578","Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression.  The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61).",311,"Merkel Cell Carcinoma","Merkel Cell Carcinoma",3965,"http://www.disease-ontology.org/?id=DOID:3965","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",276,2,NULL,"accepted",0,"evidence",1042,"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.","Nghiem et al., 2016, N. Engl. J. Med.",27093365,"http://www.ncbi.nlm.nih.gov/pubmed/27093365","true","PMC4927341","2016","6","30","N. Engl. J. Med.","The New England journal of medicine","fully curated","138","Pembrolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1579,"EID1579","Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%.",665,"Hairy Cell Leukemia","Hairy Cell Leukemia",285,"http://www.disease-ontology.org/?id=DOID:285","B","Predictive","Supports","Sensitivity","Somatic Mutation",12,2,NULL,"accepted",0,"evidence",1043,"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.","Tiacci et al., 2015, N. Engl. J. Med.",26352686,"http://www.ncbi.nlm.nih.gov/pubmed/26352686","true","PMC4811324","2015","10","29","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1580,"EID1580","One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the patientâ€™s genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission. BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%).",665,"Hairy Cell Leukemia","Hairy Cell Leukemia",285,"http://www.disease-ontology.org/?id=DOID:285","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",79,2,NULL,"accepted",0,"evidence",1043,"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.","Tiacci et al., 2015, N. Engl. J. Med.",26352686,"http://www.ncbi.nlm.nih.gov/pubmed/26352686","true","PMC4811324","2015","10","29","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1581,"EID1581","Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were analyzed. 39% of resistant melanomas were not accounted for by any validated mutational mechanism. c-MET was overexpressed in 21 of 48 (44%) resistant samples. Methylome analysis revealed three CpG clusters (C1â€“3) with differential methylation to be negatively correlated with differential c-MET mRNA expression. In nearly all (90%) pairwise comparisons of tumors and cell lines, differential c-MET mRNA expression could be accounted for by at least one differential CpG cluster methylation (Î”Î² â‰¥ 10% and FDR adjusted p â‰¤ 0.05). In contrast, only 48% displayed a concordant differential expression pattern of at least one c-MET transcription factor. In an independent study, c-MET was overexpressed in 8 of 35 (23%) MAPKi-resistant tumors from 7 of 26 (27%) patients. In two human BRAF V600E mutant cell lines, BRAFi treatment led to progressive methylation-expression changes akin to observations across MAPKi-sensitive versus resistant tumors.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Supports","Resistance or Non-Response","N/A",621,4,NULL,"accepted",0,"evidence",1044,"Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.","Hugo et al., 2015, Cell",26359985,"http://www.ncbi.nlm.nih.gov/pubmed/26359985","true","PMC4821508","2015","9","10","Cell","Cell","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1582,"EID1582","Preclinical study in uveal melanoma cell lines. c-MET was identified as a transcriptional target of miR-144. miR-144 was downregulated in 4 uveal melanoma cell lines and 5 human uveal melanoma tumor tissues compared to normal controls. siRNA mediated c-MET downregulation reduced profileration and invasion of uveal melanoma cell lines. Overexpression of c-Met promoted cell proliferation and invasion in uveal melanoma.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","E","Predictive","Supports","Sensitivity","N/A",621,2,NULL,"rejected",0,"evidence",1045,"MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression.","Sun et al., 2015, PLoS ONE",25961751,"http://www.ncbi.nlm.nih.gov/pubmed/25961751","true","PMC4427317","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1583,"EID1583","c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiRNA mediated MET-knockdown reduced cell migration but not cell growth. Crizotinib treatment led to a decrease in cell growth and migration. At 25 nmol/L of crizotinib, only the migration of G-protein mutant cells lines and not G-protein wild type cell lines was decreased. Crizotinib did not lead to a reduction in tumor volume of two cell lines in vivo but reduced the formation of macrometastases (luciferase activity, p=0.03).",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","D","Predictive","Supports","Sensitivity","N/A",621,1,NULL,"accepted",0,"evidence",1046,"Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.","Surriga et al., 2013, Mol. Cancer Ther.",24140933,"http://www.ncbi.nlm.nih.gov/pubmed/24140933",NULL,NULL,"2013","12",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1584,"EID1584","FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC). Pretreatment MET expression was frequent at the â‰¥1 + cutoff (BRIM3, 31%; BRIM2, 49%), but relatively infrequent at the â‰¥2 + cutoff (BRIM3, 9%; BRIM2, 19%). Retrospective subset analyses showed that, irrespective of the cutoff used or the treatment arm, MET expression did not show prognostic significance, in terms of objective response rate, progression-free survival, or overall survival.",206,"Skin Melanoma","Skin Melanoma",8923,"http://www.disease-ontology.org/?id=DOID:8923","B","Predictive","Does Not Support","Resistance or Non-Response","N/A",621,3,NULL,"accepted",0,"evidence",1047,"Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.","Jubb et al., 2013, Histopathology",23802768,"http://www.ncbi.nlm.nih.gov/pubmed/23802768",NULL,NULL,"2013","9",NULL,"Histopathology","Histopathology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1585,"EID1585","In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses. Mutated DNMT3A associated with shorter RFS (HR 1.38; P=.034) irrespective of patient age.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",189,4,NULL,"accepted",0,"evidence",1048,"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.","Metzeler et al., 2016, Blood",27288520,"http://www.ncbi.nlm.nih.gov/pubmed/27288520",NULL,NULL,"2016","8","4","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1586,"EID1586","DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",189,4,NULL,"accepted",0,"evidence",1009,"Genomic Classification and Prognosis in Acute Myeloid Leukemia.","Papaemmanuil et al., 2016, N. Engl. J. Med.",27276561,"http://www.ncbi.nlm.nih.gov/pubmed/27276561","true","PMC4979995","2016","6","9","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1587,"EID1587","Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","B","Predictive","Supports","Sensitivity","Somatic Mutation",189,3,NULL,"accepted",0,"evidence",1049,"DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.","Metzeler et al., 2012, Leukemia",22124213,"http://www.ncbi.nlm.nih.gov/pubmed/22124213","true","PMC3696987","2012","5",NULL,"Leukemia","Leukemia","fully curated","155","Decitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1588,"EID1588","Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy at the time of progression showed a MET amplification and overexpression (IHC, ISH) but no secondary mutations in candidate resistance genes (EGFR, KRAS, NRAS, MAP2K1). MET amplification was also present in a subset of tumor cells in the pretreatment sample. MET amplification was also identified in 3/17 (18%) chemonaive BRAF V600E colorectal cancer tumor tissues.
Overexpression of MET in a BRAF mutant CRC cell line (WiDr) confered resistance to combined vemurafenib and panitumumab. The addition of crizotinib to this combination restored sensitivity in vitro.
The patient was started on combined vemurafenib and crizotinib in January 2016 and had a metabolic, clinical and tumor marker response that was ongoing at the time of publication (06/16) without significant toxicity.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Supports","Sensitivity","N/A",270,4,"Combination","accepted",0,"evidence",1050,"MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.","Pietrantonio et al., 2016, Cancer Discov",27325282,"http://www.ncbi.nlm.nih.gov/pubmed/27325282",NULL,NULL,"2016","6","20","Cancer Discov","Cancer discovery","fully curated","12","Crizotinib",NULL,"4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1589,"EID1589","Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","C","Predictive","Supports","Sensitivity","Somatic Mutation",12,2,"Combination","accepted",0,"evidence",1050,"MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.","Pietrantonio et al., 2016, Cancer Discov",27325282,"http://www.ncbi.nlm.nih.gov/pubmed/27325282",NULL,NULL,"2016","6","20","Cancer Discov","Cancer discovery","fully curated","28","Panitumumab",NULL,"4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1590,"EID1590","In previously untreated patients with chronic lymphocytic leukemia, POT1 mutations (N=13) were associated with shorter overall survival than wildtype POT1 (N=148) in univariate and multivariate analysis (HR, 4.0; 95% CI, 1.6-10.1; P = .003) independent of IGHV mutation status, Binet stage, and serum beta-2-microglobulin.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",623,3,NULL,"accepted",0,"evidence",1051,"Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.","Herling et al., 2016, Blood",27226433,"http://www.ncbi.nlm.nih.gov/pubmed/27226433",NULL,NULL,"2016","7","21","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1591,"EID1591","Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors.
51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months.
In cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months.",156,"Papillary Thyroid Carcinoma","Papillary Thyroid Carcinoma",3969,"http://www.disease-ontology.org/?id=DOID:3969","B","Predictive","Supports","Sensitivity","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",1052,"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.","Brose et al., 2016, Lancet Oncol.",27460442,"http://www.ncbi.nlm.nih.gov/pubmed/27460442",NULL,NULL,"2016","7","22","Lancet Oncol.","The Lancet. Oncology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1592,"EID1592","Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","A","Predictive","Supports","Sensitivity","Somatic Mutation",34,5,NULL,"accepted",0,"evidence",1053,"Osimertinib: First Global Approval.","Greig, 2016, Drugs",26729184,"http://www.ncbi.nlm.nih.gov/pubmed/26729184",NULL,NULL,"2016","2",NULL,"Drugs","Drugs","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1593,"EID1593","A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer. The studies included ER positive and negative cases, and the MIB-1 antibody was used in the large majority of studies. 25 studies that employed multivariate analysis were used, and a hazard ratio of 2.05 for overall survival was obtained when Ki67 cutoff value was set at greater or equal to 25%.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Supports","Poor Outcome","N/A",624,4,NULL,"accepted",0,"evidence",1055,"Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.","Petrelli et al., 2015, Breast Cancer Res. Treat.",26341751,"http://www.ncbi.nlm.nih.gov/pubmed/26341751",NULL,NULL,"2015","10",NULL,"Breast Cancer Res. Treat.","Breast cancer research and treatment","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1594,"EID1594","293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation. IHC staining was used to generate a Ki67 score, and cases were divided into 2 groups with Ki67 score greater or less than 10%. Primary endpoint was death due to prostate cancer. A hazard ratio for high Ki67 values of 3.42 was seen in univariate analysis, and  Ki67 score also added significant predictive value in multivariate analysis, with a hazard ratio of 2.78.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Prognostic","Supports","Poor Outcome","N/A",624,3,NULL,"accepted",0,"evidence",1056,"Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.","Fisher et al., 2013, Br. J. Cancer",23329234,"http://www.ncbi.nlm.nih.gov/pubmed/23329234","true","PMC3566811","2013","2","5","Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1595,"EID1595","A panel of 21 glioblastoma cell lines harboring various mutations was treated with palbociclib. 16 of the cell lines with intact Rb showed decreased proliferation (bromodeoxyuridine incorporation, BrdU flow cytometry) and growth arrest characteristic of senescence, while the 5 cell lines that did not show a palbociclib response had homozygous deletion of Rb. Rb positive and palbociclib responsive GBM cell line U87MG was treated with shRNA against Rb. shRb treated cells showed restoration of cell proliferation (BrdU incorporation) under palbociclib treatment, indicating resistance.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",606,3,NULL,"accepted",0,"evidence",1057,"Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.","Michaud et al., 2010, Cancer Res.",20354191,"http://www.ncbi.nlm.nih.gov/pubmed/20354191","true","PMC2855904","2010","4","15","Cancer Res.","Cancer research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1596,"EID1596","40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRAS mutations were independently associated with PFS (p=0.012) after multivariate analysis.",143,"Pseudomyxoma Peritonei","Pseudomyxoma Peritonei",3559,"http://www.disease-ontology.org/?id=DOID:3559","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",336,3,NULL,"accepted",0,"evidence",1058,"Towards the molecular dissection of peritoneal pseudomyxoma.","Pietrantonio et al., 2016, Ann. Oncol.",27502722,"http://www.ncbi.nlm.nih.gov/pubmed/27502722",NULL,NULL,"2016","8","8","Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1597,"EID1597","Western blot analyses were performed for HR23b (RAD23B) expression sarcoma cell lines after treatment with vorinostat, belinostat, mocetinostat and entinostat. All HDACi were able to regulate proliferation and apoptosis in vitro. Sensitivity to vorinostat correlated significantly with HR23b protein expression. IHC in 523 patient samples revealed high HR23b expression in 12.5% of sarcomas (among them malignant peripheral nerve sheath tumours, pleomorphic liposarcomas, leiomyosarcomas, dedifferentiated liposarcomas, synovial sarcomas and angiosarcomas) and 23.2% of GIST.",105,"Sarcoma","Sarcoma",1115,"http://www.disease-ontology.org/?id=DOID:1115","D","Predictive","Supports","Sensitivity","N/A",625,2,NULL,"accepted",0,"evidence",1059,"HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.","Angelika Ihle et al., 2016, J Pathol Clin Res",27499916,"http://www.ncbi.nlm.nih.gov/pubmed/27499916","true","PMC4907056","2016","4",NULL,"J Pathol Clin Res","The journal of pathology. Clinical research","fully curated","314","Vorinostat (SAHA)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1598,"EID1598","Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with BRAF V600E mutation, N=3 with V600 unknown status). One response was observed; however, approximately half the patients had tumor regression that did not meet the standard criteria for a partial response. Median progression-free survival and overall survival for patients receiving combination therapy were 3.7 months (95% CI, 1.8 to 5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively. Patients were heavily pretreated, with a median of two lines of previous therapy (range, one to six).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",17,2,"Combination","accepted",0,"evidence",1040,"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.","Hyman et al., 2015, N. Engl. J. Med.",26287849,"http://www.ncbi.nlm.nih.gov/pubmed/26287849","true","PMC4971773","2015","8","20","N. Engl. J. Med.","The New England journal of medicine","fully curated","16","Cetuximab",NULL,"4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1599,"EID1599","A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proliferation. Large variation in palbociclib sensitivity was observed and cell lines (N=40) were classified as above (resistant) or below (sensitive) the mean log of all IC50 values. 6/18 (33%) of the resistant lines and in only 1/22 (5%) of the sensitive lines (P = 0.017) had CCND1 copy number gain. Increased CCND1 expression was not correlated with sensitivity to palbociclib (p=0.671).",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",18,3,NULL,"accepted",0,"evidence",933,"Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.","Konecny et al., 2011, Clin. Cancer Res.",21278246,"http://www.ncbi.nlm.nih.gov/pubmed/21278246","true","PMC4598646","2011","3","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1600,"EID1600","Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the cells to PI3K inhibition. The CDK4/6 inhibitor ribociclib (LEE011) acted synergistically with PI3K inhibitor to reduce viability in all three resistant cell lines. In a panel of 12 PIK3CA mutant and 10 wild type cell lines, synergistic effects between P110alpha inhibitor BYL719 and ribociclib were significantly stronger (weighted synergy score calculation, ANOVA, p=0.012) in PIK3CA mutant cells, indicating variant specific sensitization. Mouse xenografts of 4 different PIK3CA mutant breast cancer cells resistant to PI3K inhibitor showed stronger regression under dual PI3K inhibitor and ribociclib treatment than with either treatment alone.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,4,"Combination","accepted",0,"evidence",178,"CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.","Vora et al., 2014, Cancer Cell",25002028,"http://www.ncbi.nlm.nih.gov/pubmed/25002028","true","PMC4155598","2014","7","14","Cancer Cell","Cancer cell","fully curated","382","PI3K Inhibitor",NULL,"381","Ribociclib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1601,"EID1601","Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedanib-docetaxel trial. Docetaxel was discontinued after 22 cycles because of edema and fatigue. A total of 48 treatment cycles (26 cycles of nintedanib alone) was administered over 33 months before documentation of disease progression in March 2013. Genomic testing revealed a CCDC6-RET fusion but no other actionable mutations (confirmed by FISH).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",626,2,NULL,"accepted",0,"evidence",1061,"Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.","Takeda et al., 2016, Ann. Oncol.",26787234,"http://www.ncbi.nlm.nih.gov/pubmed/26787234",NULL,NULL,"2016","4",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","383","Nintedanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1602,"EID1602","A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib). The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor. In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",627,4,NULL,"accepted",0,"evidence",1062,"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.","Wagle et al., 2011, J. Clin. Oncol.",21383288,"http://www.ncbi.nlm.nih.gov/pubmed/21383288","true","PMC3157968","2011","8","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1603,"EID1603","Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement. Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%). Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months.",2132,"Urothelial Carcinoma","Urothelial Carcinoma",2671,"http://www.disease-ontology.org/?id=DOID:2671","C","Predictive","Supports","Sensitivity","Somatic Mutation",628,2,NULL,"accepted",0,"evidence",1063,"Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.","Palma et al., 2015, Eur. Urol.",25766722,"http://www.ncbi.nlm.nih.gov/pubmed/25766722",NULL,NULL,"2015","7",NULL,"Eur. Urol.","European urology","fully curated","56","Pazopanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1604,"EID1604","Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study.
Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model.
81 patients were enrolled in the trial and treated with dovitinib. Unconfirmed response or stable disease >6 months was observed in 25% of FGFR1-amplified/HR-positive vs. 3% FGFR1-nonamplified/HR-positive breast cancer patientes. When FGF3 and FGFR2 amplifications were also assessed, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","N/A",267,2,NULL,"accepted",0,"evidence",1064,"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.","AndrÃ© et al., 2013, Clin. Cancer Res.",23658459,"http://www.ncbi.nlm.nih.gov/pubmed/23658459",NULL,NULL,"2013","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","228","Dovitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1605,"EID1605","Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. 2 patients were reported to harbor FGFR2 amplifications and both had a reduction in tumor size of 18.5 and 28.2%, respectively. When FGFR1, FGF3 and FGFR2 amplifications were combined, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","N/A",629,2,NULL,"accepted",0,"evidence",1064,"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.","AndrÃ© et al., 2013, Clin. Cancer Res.",23658459,"http://www.ncbi.nlm.nih.gov/pubmed/23658459",NULL,NULL,"2013","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","228","Dovitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1606,"EID1606","81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively. 3 of these 4 patients also had FGFR1 amplifications (â‰¥6 copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH negative).",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Sensitivity","N/A",630,2,NULL,"accepted",0,"evidence",1064,"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.","AndrÃ© et al., 2013, Clin. Cancer Res.",23658459,"http://www.ncbi.nlm.nih.gov/pubmed/23658459",NULL,NULL,"2013","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","228","Dovitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1607,"EID1607","Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure. Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 inhibitor palbociclib resulted in synergistic reductions in cell viability which were not seen with treatment of either compound alone, and resulted in similar suppression to viability as seen in the respective PI3K inhibitor sensitive parental cell lines.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,3,"Combination","accepted",0,"evidence",178,"CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.","Vora et al., 2014, Cancer Cell",25002028,"http://www.ncbi.nlm.nih.gov/pubmed/25002028","true","PMC4155598","2014","7","14","Cancer Cell","Cancer cell","fully curated","382","PI3K Inhibitor",NULL,"48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1608,"EID1608","Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment.",2137,"Chuvash Polycythemia","Chuvash Polycythemia",60474,"http://www.disease-ontology.org/?id=DOID:0060474","C","Predictive","Supports","Sensitivity","Germline Mutation",631,4,NULL,"accepted",0,"evidence",1065,"Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.","Zhou et al., 2016, N. Engl. J. Med.",27518686,"http://www.ncbi.nlm.nih.gov/pubmed/27518686",NULL,NULL,"2016","8","4","N. Engl. J. Med.","The New England journal of medicine","fully curated","386","Ruxolitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1609,"EID1609","The p110alpha-specific PI3K inhibitor BYL719 was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced phospho-Rb (p-Rb) western blot levels in response to BYL719 treatment, while resistant cell lines (IC50>800nM) showed significantly less reduction in p-Rb after BYL719. Paired biopsies before and after treatment were taken from a set of eight patients classified as either responder or non-responder to BYL719. Responder samples showed significantly reduced p-Rb staining after treatment in comparison to non-responder biopsies. In biopsies taken from a group of three responders who progressed, p-Rb levels were increased after progression.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Resistance or Non-Response","N/A",632,3,NULL,"accepted",0,"evidence",178,"CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.","Vora et al., 2014, Cancer Cell",25002028,"http://www.ncbi.nlm.nih.gov/pubmed/25002028","true","PMC4155598","2014","7","14","Cancer Cell","Cancer cell","fully curated","387","Alpelisib (NVP-BYL719)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1610,"EID1610","A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measured and SF50 less than one micro molar was considered sensitive. PIK3CA mutant cell lines were significantly more sensitive to both everolimus and PP242 than PIK3CA wild type cell lines. Apoptotic indicators and cell cycle analysis indicated that the mTOR inhibitors induced G1 arrest instead of apoptosis in the cell lines.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,3,"Substitutes","accepted",0,"evidence",1066,"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.","Weigelt et al., 2011, Oncogene",21358673,"http://www.ncbi.nlm.nih.gov/pubmed/21358673",NULL,NULL,"2011","7","21","Oncogene","Oncogene","fully curated","41","Everolimus",NULL,"179","PP242",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1611,"EID1611","In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",214,3,"Substitutes","accepted",0,"evidence",1066,"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.","Weigelt et al., 2011, Oncogene",21358673,"http://www.ncbi.nlm.nih.gov/pubmed/21358673",NULL,NULL,"2011","7","21","Oncogene","Oncogene","fully curated","179","PP242",NULL,"41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1612,"EID1612","Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However, a PTEN and PIK3CA wild type cell line 'HS578T' was found to harbor a mutation in the PI3K regulatory protein PIK3R1. Like PIK3CA mutant cell lines, the PIK3R1 mutant HS578T line was also determined to be sensitive to PP242. Approximately 70% of PIK3CA wild type lines were not sensitive to PP242. This suggests that mutations in the PI3K holoenzyme may be targetable by mTORC1/2 inhibition.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",633,2,NULL,"accepted",0,"evidence",1066,"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.","Weigelt et al., 2011, Oncogene",21358673,"http://www.ncbi.nlm.nih.gov/pubmed/21358673",NULL,NULL,"2011","7","21","Oncogene","Oncogene","fully curated","179","PP242",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1613,"EID1613","In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).  8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242). This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",306,2,NULL,"accepted",0,"evidence",1066,"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.","Weigelt et al., 2011, Oncogene",21358673,"http://www.ncbi.nlm.nih.gov/pubmed/21358673",NULL,NULL,"2011","7","21","Oncogene","Oncogene","fully curated","179","PP242",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1614,"EID1614","A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity. .",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","D","Predictive","Supports","Sensitivity","Somatic Mutation",214,3,NULL,"accepted",0,"evidence",1067,"PI3K pathway dependencies in endometrioid endometrial cancer cell lines.","Weigelt et al., 2013, Clin. Cancer Res.",23674493,"http://www.ncbi.nlm.nih.gov/pubmed/23674493","true","PMC3700760","2013","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","83","Temsirolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1615,"EID1615","A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative). In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative).",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",276,3,"Combination","accepted",0,"evidence",1068,"Nivolumab plus ipilimumab in advanced melanoma.","Wolchok et al., 2013, N. Engl. J. Med.",23724867,"http://www.ncbi.nlm.nih.gov/pubmed/23724867",NULL,NULL,"2013","7","11","N. Engl. J. Med.","The New England journal of medicine","fully curated","365","Ipilimumab",NULL,"137","Nivolumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1616,"EID1616","A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed. EEC cell lines with PIK3CA mutations were significantly more sensitive to GDC-0941 (Fisherâ€™s exact test, two-tailed, P=0.038). Some of the PIK3CA mutant cells contained PTEN and KRAS mutations, but in these cells, these mutations did not effect sensitivity.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","D","Predictive","Supports","Sensitivity","Somatic Mutation",311,3,NULL,"accepted",0,"evidence",1067,"PI3K pathway dependencies in endometrioid endometrial cancer cell lines.","Weigelt et al., 2013, Clin. Cancer Res.",23674493,"http://www.ncbi.nlm.nih.gov/pubmed/23674493","true","PMC3700760","2013","7","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","141","Pictilisib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1617,"EID1617","Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein staining was observed in the tumor indicating mTOR pathway activation. Everolimus treatement led to partial response (but no change in phospho-S6 ribosomal protein staining) for 9 months.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","C","Predictive","Supports","Sensitivity","Germline Mutation",634,2,NULL,"accepted",0,"evidence",1069,"mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.","KlÃ¼mpen et al., 2011, J. Clin. Oncol.",21189378,"http://www.ncbi.nlm.nih.gov/pubmed/21189378","true","PMC4856022","2011","2","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1618,"EID1618","Preclinical study in a mouse model of Peutz-Jeghers syndrome. Heterozygous Lkb1 (STK11) knockout mice were generated and treated with rapamycin after the onset of polyposis at 9 months of age. Rapamycin treatment significantly suppressed polyposis (p=0.017) and pS6 staining (IHC, p=0.011).",2138,"Peutz-Jeghers Syndrome","Peutz-Jeghers Syndrome",3852,"http://www.disease-ontology.org/?id=DOID:3852","D","Predictive","Supports","Sensitivity","Germline Mutation",485,1,NULL,"accepted",0,"evidence",1070,"Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling.","Wei et al., 2008, Clin. Cancer Res.",18281551,"http://www.ncbi.nlm.nih.gov/pubmed/18281551",NULL,NULL,"2008","2","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1619,"EID1619","Treatment of mice with a heterozygous loss of Lkb1 (STK11) with rapamycin led to reduction in polyp size (p < 0.0001) and number of polyps (p=0.00022). pS6 staining was also reduced after rapamycin treatment. Rapamycin treatment abolished FDG-PET signal on imaging.",2138,"Peutz-Jeghers Syndrome","Peutz-Jeghers Syndrome",3852,"http://www.disease-ontology.org/?id=DOID:3852","D","Predictive","Supports","Sensitivity","Germline Mutation",485,1,NULL,"accepted",0,"evidence",1071,"mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.","Shackelford et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",19541609,"http://www.ncbi.nlm.nih.gov/pubmed/19541609","true","PMC2708689","2009","7","7","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1620,"EID1620","Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus or rapamycin) than two wild type cell lines. Knockdown of LKB1 in one additional cell line did not lead to an increase in sensitivity to mTOR inhibitors.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Does Not Support","Sensitivity","Somatic Mutation",485,3,"Substitutes","accepted",0,"evidence",1072,"LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.","Xiao et al., 2015, Acta Pharmacol. Sin.",26027660,"http://www.ncbi.nlm.nih.gov/pubmed/26027660","true","PMC4561965","2015","9",NULL,"Acta Pharmacol. Sin.","Acta pharmacologica Sinica","fully curated","352","Rapamycin (Sirolimus)",NULL,"41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1621,"EID1621","Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","N/A",635,1,"Combination","accepted",0,"evidence",1074,"Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.","Subbiah et al., 2015, Lung Cancer",25982012,"http://www.ncbi.nlm.nih.gov/pubmed/25982012","true","PMC4998046","2015","7",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","41","Everolimus",NULL,"388","Vandetanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1622,"EID1622","Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","N/A",273,2,"Combination","accepted",0,"evidence",1074,"Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.","Subbiah et al., 2015, Lung Cancer",25982012,"http://www.ncbi.nlm.nih.gov/pubmed/25982012","true","PMC4998046","2015","7",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","388","Vandetanib",NULL,"41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1623,"EID1623","Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","C","Predictive","Supports","Sensitivity","Somatic Mutation",107,2,"Combination","accepted",0,"evidence",1075,"Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.","Sun et al., 2016, Onco Targets Ther",27445490,"http://www.ncbi.nlm.nih.gov/pubmed/27445490","true","PMC4936809","2016",NULL,NULL,"Onco Targets Ther","OncoTargets and therapy","fully curated","54","Fulvestrant",NULL,"41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1624,"EID1624","Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","C","Predictive","Supports","Resistance or Non-Response",NULL,313,1,"Combination","accepted",0,"evidence",1075,"Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.","Sun et al., 2016, Onco Targets Ther",27445490,"http://www.ncbi.nlm.nih.gov/pubmed/27445490","true","PMC4936809","2016",NULL,NULL,"Onco Targets Ther","OncoTargets and therapy","fully curated","41","Everolimus",NULL,"54","Fulvestrant",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1625,"EID1625","Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway.
Among the alterations, One cell line harbored a PIK3CA H1047R mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector. Perifosine treatment also increased apoptosis of a thyroid tumor xenograft with PIK3CA H1047R mutation.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","D","Predictive","Supports","Sensitivity","Somatic Mutation",107,3,"Substitutes","accepted",0,"evidence",1076,"Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.","Liu et al., 2009, Cancer Res.",19706758,"http://www.ncbi.nlm.nih.gov/pubmed/19706758","true","PMC2756336","2009","9","15","Cancer Res.","Cancer research","fully curated","389","Perifosine",NULL,"83","Temsirolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1626,"EID1626","Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA E542K mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","D","Predictive","Supports","Sensitivity","Somatic Mutation",103,3,"Substitutes","accepted",0,"evidence",1076,"Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.","Liu et al., 2009, Cancer Res.",19706758,"http://www.ncbi.nlm.nih.gov/pubmed/19706758","true","PMC2756336","2009","9","15","Cancer Res.","Cancer research","fully curated","389","Perifosine",NULL,"83","Temsirolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1627,"EID1627","Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, one cell line harbored a PTEN allele deletion and R130* mutation. This cell line harbored the lowest IC50 values to both perifosine and temsirolimus and also showed increased apoptosis with perifosine in a xenograft model.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","D","Predictive","Supports","Sensitivity","N/A",636,2,"Substitutes","accepted",0,"evidence",1076,"Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.","Liu et al., 2009, Cancer Res.",19706758,"http://www.ncbi.nlm.nih.gov/pubmed/19706758","true","PMC2756336","2009","9","15","Cancer Res.","Cancer research","fully curated","83","Temsirolimus",NULL,"389","Perifosine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1628,"EID1628","mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-dependency consistent with mTOR protein levels. It could be hypothesized that FBXW7 loss leads to an increase in mTOR protein levels independent of circadian regulation and higher sensitivity to mTOR inhibitors.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","E","Predictive","Supports","Sensitivity","N/A",637,2,NULL,"accepted",0,"evidence",1077,"Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma.","Okazaki et al., 2014, Cancer Res.",24253377,"http://www.ncbi.nlm.nih.gov/pubmed/24253377",NULL,NULL,"2014","1","15","Cancer Res.","Cancer research","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1629,"EID1629","Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were derived through chronic exposure to 1 Î¼mol/L palbociclib during 3 to 4 months. Copy number profiling from exome sequencing of MCF-7 and MCF-7pR, confirmed relative amplification of CCNE1. Silencing of CCNE1 or CDK2 alone in MCF-7pR cells had no effect on cell-cycle arrest, but resulted in substantially increased cell-cycle arrest and reduction in cell growth in combination with palbociclib.",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","D","Predictive","Supports","Resistance or Non-Response","N/A",187,3,NULL,"accepted",0,"evidence",1078,"Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.","Herrera-Abreu et al., 2016, Cancer Res.",27020857,"http://www.ncbi.nlm.nih.gov/pubmed/27020857",NULL,NULL,"2016","4","15","Cancer Res.","Cancer research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1630,"EID1630","Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Palbociclib-resistant xenografts from one cell line (PDX244) were developed in-vivo. In resistant xenografts, western blot analysis showed a decrease of pRb protein levels in 4 of 7 CDK4/6-acquired resistant tumors and a sustained expression of the E2F target cyclin E2, in contrast to CDK4/6 inhibitor-sensitive PDX244. Genomic characterization of PDX244LR1 showed the acquisition of an RB1 frameshift mutation (RB1 p.M695fs*26).",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",638,2,NULL,"accepted",0,"evidence",1078,"Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.","Herrera-Abreu et al., 2016, Cancer Res.",27020857,"http://www.ncbi.nlm.nih.gov/pubmed/27020857",NULL,NULL,"2016","4","15","Cancer Res.","Cancer research","fully curated","48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1631,"EID1631","418 patients with advanced cancer were screened for FBXW7 mutations using a multiplex gene panel. 17 FBXW7 mutations were detected (isolated mutation in 2 patients).
Ten patients were treated with an mTOR inhibitor with 7 patients having stable disease as best responses and a median time to treatment failure of 2.8 months, two patients had prolonged stable disease of >16 weeks.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Supports","Sensitivity","Somatic Mutation",281,2,NULL,"accepted",0,"evidence",1079,"FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.","Jardim et al., 2014, PLoS ONE",24586741,"http://www.ncbi.nlm.nih.gov/pubmed/24586741","true","PMC3929689","2014",NULL,NULL,"PLoS ONE","PloS one","fully curated","67","MTOR Inhibitors",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1632,"EID1632","FBXW7 was shown to target mTOR for ubiquitination and degradation.  A reciprocal relationship between FBXW7 or PTEN loss was identified in breast cancer tumors and cell lines (mutual exclusivity of these two events).  In total only 4 out of 450 tumor and cell line samples had concomitant loss of both genes (p=4.9x10^-7). Cell lines (n=5) with FBXW7 mutations or deletions were significantly sensitive to rapamycin and downregulation of FBXW7 (shRNA) increased the sensitivity to rapamycin. In summary, this evidence suggests that FBXW7 may be a biomarker for cancers sensitivity to inhibitors of the mTOR pathway.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","D","Predictive","Supports","Sensitivity","Somatic Mutation",637,4,NULL,"accepted",0,"evidence",1080,"FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.","Mao et al., 2008, Science",18787170,"http://www.ncbi.nlm.nih.gov/pubmed/18787170","true","PMC2849753","2008","9","12","Science","Science (New York, N.Y.)","fully curated","352","Rapamycin (Sirolimus)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1633,"EID1633","A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4.",57,"Colorectal Adenocarcinoma","Colorectal Adenocarcinoma",50861,"http://www.disease-ontology.org/?id=DOID:0050861","C","Predictive","Supports","Sensitivity","Somatic Mutation",639,2,NULL,"accepted",0,"evidence",1081,"Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.","Jones et al., 2016, Ann. Oncol.",27022066,"http://www.ncbi.nlm.nih.gov/pubmed/27022066","true","PMC4843189","2016","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","390","Irbesartan",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1634,"EID1634","A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with Irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4.",120,"Colon Adenocarcinoma","Colon Adenocarcinoma",234,"http://www.disease-ontology.org/?id=DOID:234","C","Predictive","Supports","Sensitivity","Somatic Mutation",640,2,NULL,"accepted",0,"evidence",1081,"Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.","Jones et al., 2016, Ann. Oncol.",27022066,"http://www.ncbi.nlm.nih.gov/pubmed/27022066","true","PMC4843189","2016","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","390","Irbesartan",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1635,"EID1635","124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.33â€“5.75, P = 0.006, Pc = 0.030) and decreased disease-free survival (DFS) (HR = 2.45, 95% CI: 1.30â€“4.61, P = 0.005) compared to patients without this mutation.",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",641,3,NULL,"accepted",0,"evidence",1082,"Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection.","Li et al., 2016, PLoS ONE",27414035,"http://www.ncbi.nlm.nih.gov/pubmed/27414035","true","PMC4944974","2016",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1636,"EID1636","124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival (HR = 0.27, 95% CI: 0.13â€“0.56, P = 4.7Ã—10âˆ’4, Pc = 0.003) and increased disease free survival (HR = 0.22, 95% CI: 0.11â€“0.43, P < .0001) when compared to patients without this mutation.",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Prognostic","Supports","Better Outcome","Somatic Mutation",642,2,NULL,"accepted",0,"evidence",1082,"Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection.","Li et al., 2016, PLoS ONE",27414035,"http://www.ncbi.nlm.nih.gov/pubmed/27414035","true","PMC4944974","2016",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1637,"EID1637","Samples from 393 patients with NSCLC were evaluated for 3 SNPs in CBLB (rs1042852, rs2305035, and rs7649466).  Genotypes rs7649466 and rs1042852 were not associated with a change in clinical outcome compared to wildtype however, rs2305035 A genotype  (A/A or A/G) had better local recurrence-free survival, metastasis-free survival and overall survival when compared to GG genotype (n=186).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Prognostic","Supports","Better Outcome","Germline Polymorphism",643,2,NULL,"accepted",0,"evidence",1083,"Single Nucleotide Polymorphisms in CBLB, aÂ Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer.","Li et al., 2016, Clin Lung Cancer",26732495,"http://www.ncbi.nlm.nih.gov/pubmed/26732495",NULL,NULL,"2016","7",NULL,"Clin Lung Cancer","Clinical lung cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1638,"EID1638","Biopsies from 520 DLBCL patients treated with R-CHOP were evaluated for PRDM1 mutations or protein (BLIMP-1) expression. Patients with a homozygous deletion of PRDM1 (7%, N=19) had a significantly shorter overall survival and poorer progression free survival compared to heterozygous or wildtype PRDM1.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",644,2,NULL,"accepted",0,"evidence",1084,"Loss of PRDM1/BLIMP-1 function contributes to poor prognosis for activated B-cell-like diffuse large B-cell lymphoma.","Xia et al., 2016, Leukemia",27568520,"http://www.ncbi.nlm.nih.gov/pubmed/27568520",NULL,NULL,"2016","8","29","Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1639,"EID1639","Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).",98,"Brain Glioma","Brain Glioma",60108,"http://www.disease-ontology.org/?id=DOID:0060108","B","Prognostic","Supports","Better Outcome","Somatic Mutation",645,3,NULL,"accepted",0,"evidence",1085,"Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.","2015, N. Engl. J. Med.",26061751,"http://www.ncbi.nlm.nih.gov/pubmed/26061751","true","PMC4530011","2015","6","25","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1640,"EID1640","Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).",98,"Brain Glioma","Brain Glioma",60108,"http://www.disease-ontology.org/?id=DOID:0060108","B","Prognostic","Supports","Better Outcome","Somatic Mutation",570,3,NULL,"accepted",0,"evidence",1085,"Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.","2015, N. Engl. J. Med.",26061751,"http://www.ncbi.nlm.nih.gov/pubmed/26061751","true","PMC4530011","2015","6","25","N. Engl. J. Med.","The New England journal of medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1641,"EID1641","In a study of 30 patients with WaldenstrÃ¶mâ€™s macroglobulinemia, 87% had MYD88(L265P) mutations.  Waldenstrom macroglobulinemia cells expressing MYD88(L265P) were treated with an MYD88 homodimerization inhibitor or an IRAK 1/4 kinase inhibitor.  The cells showed a decrease in staining of NF-kappa-B p65 phosphorylation.",317,"WaldenstrÃ¶m's Macroglobulinemia","WaldenstrÃ¶m's Macroglobulinemia",NULL,"http://www.disease-ontology.org/","D","Predictive","Supports","Sensitivity","Somatic Mutation",424,1,"Substitutes","accepted",0,"evidence",1086,"MYD88 L265P somatic mutation in WaldenstrÃ¶m's macroglobulinemia.","Treon et al., 2012, N. Engl. J. Med.",22931316,"http://www.ncbi.nlm.nih.gov/pubmed/22931316",NULL,NULL,"2012","8","30","N. Engl. J. Med.","The New England journal of medicine","fully curated","392","IMGENEX",NULL,"393","IRAK-1/4 Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1642,"EID1642","Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR.",196,"Hepatocellular Carcinoma","Hepatocellular Carcinoma",684,"http://www.disease-ontology.org/?id=DOID:684","B","Predictive","Supports","Sensitivity","Somatic Mutation",336,2,"Combination","accepted",0,"evidence",1088,"A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.","Lim et al., 2014, Clin. Cancer Res.",25294897,"http://www.ncbi.nlm.nih.gov/pubmed/25294897",NULL,NULL,"2014","12","1","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","6","Sorafenib",NULL,"394","Refametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1643,"EID1643","A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed that the fusion was detectable in conventional components. An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples.",2139,"Hepatocellular Mixed Fibrolamellar Carcinoma","Hepatocellular Mixed Fibrolamellar Carcinoma",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Positive","Somatic Mutation",31,4,NULL,"accepted",0,"evidence",1089,"A genomic case study of mixed fibrolamellar hepatocellular carcinoma.","Griffith et al., 2016, Ann. Oncol.",27029710,"http://www.ncbi.nlm.nih.gov/pubmed/27029710","true","PMC4880064","2016","6",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1644,"EID1644","A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment. The hazard ratio for disease-free survival was 2.89 times greater for patients with SMAD4 deletion as compared to those  with normal SMAD4 diploidy (P = .045).  For overall survival, the hazard ratio was 3.23 times greater for SMAD4 deletion (P = .056).",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","N/A",646,3,NULL,"accepted",0,"evidence",1090,"SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.","Boulay et al., 2002, Br. J. Cancer",12237773,"http://www.ncbi.nlm.nih.gov/pubmed/12237773","true","PMC2364238","2002","9","9","Br. J. Cancer","British journal of cancer","fully curated","395","5-fluorouracil",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1645,"EID1645","A retrospective study of 178 glioblastoma patients found that LRP1B deletion (complete transcript, N=4 or focal transcript deletion of >150kb, N=13) was associated with a lower progress free survival (6.4 months vs. 10.1 months; P = 0.004) and overall free survival (13.4 months vs. 17.8 months; P = 0.001). Multivariate analysis adjusting for age and type of surgery also supported LRP1B deletion being associated with a higher hazard ratio.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","B","Prognostic","Supports","Poor Outcome","N/A",647,4,NULL,"accepted",0,"evidence",1091,"LRP1B deletion is associated with poor outcome for glioblastoma patients.","Tabouret et al., 2015, J. Neurol. Sci.",26428308,"http://www.ncbi.nlm.nih.gov/pubmed/26428308",NULL,NULL,"2015","11","15","J. Neurol. Sci.","Journal of the neurological sciences","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1646,"EID1646","In 308 thyroid fine-needle aspiration biopsies, 0 of the 179 benign tumors displayed either the C228T or the C250T TERT promoter mutation; however, 9 of the 129 differentiated thyroid cancers had either of these mutations. The biomarker displayed 100% diagnostic specificity and 7% sensitivity.",16,"Thyroid Cancer","Thyroid Cancer",1781,"http://www.disease-ontology.org/?id=DOID:1781","B","Diagnostic","Supports","Positive","Somatic Mutation",248,3,NULL,"accepted",0,"evidence",1092,"Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.","Liu et al., 2014, Endocr. Relat. Cancer",25121551,"http://www.ncbi.nlm.nih.gov/pubmed/25121551","true","PMC4175020","2014","10",NULL,"Endocr. Relat. Cancer","Endocrine-related cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1647,"EID1647","A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine was associated with a greater time to treatment failure (55.6 months vs. 31.8 months; P = .0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = .038).",35,"Astrocytoma","Astrocytoma",3069,"http://www.disease-ontology.org/?id=DOID:3069","B","Predictive","Supports",NULL,"N/A",648,3,"Substitutes","accepted",0,"evidence",1093,"ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.","Wiestler et al., 2013, Acta Neuropathol.",23904111,"http://www.ncbi.nlm.nih.gov/pubmed/23904111",NULL,NULL,"2013","9",NULL,"Acta Neuropathol.","Acta neuropathologica","fully curated","398","Vincristine",NULL,"396","Procarbazine",NULL,"11","Temozolomide",NULL,"397","Lomustine",NULL,NULL,NULL,NULL
1648,"EID1648","In a glioblastoma mouse model induced by NRAS and p53 knockdown, ATRX loss was associated with a decreased median survival (69 days vs. 84 days; P = .0032). Also, the tumors grew to a larger size at earlier time points. ATRX loss was also associated with greater microsatellite instability.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","D","Prognostic","Supports","Poor Outcome","N/A",648,4,NULL,"accepted",0,"evidence",1094,"ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.","Koschmann et al., 2016, Sci Transl Med",26936505,"http://www.ncbi.nlm.nih.gov/pubmed/26936505",NULL,NULL,"2016","3","2","Sci Transl Med","Science translational medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1649,"EID1649","In patients with primary myelofibrosis CALR mutations were associated with improved median survival. For 277 patients, CALR mutated, ASXL1 wildtype patients (median survival, 10.4 years, N=46); CALR wildtype, ASXL1 mutant patients (2.3 years; HR, 5.9; 95% CI, 3.5â€“10.0, N=62); and either CALR/ASXL1wildtype or CALR/ASXL1 mutant patients (5.8 years; HR, 2.5; 95% CI, 1.5â€“4.0, N=169). These results were independent of DIPSS-plus risk but added prognostic information to this risk categorization. These results were also validated in an independent cohort of 293 patients.",173,"Myelofibrosis","Myelofibrosis",4971,"http://www.disease-ontology.org/?id=DOID:4971","B","Prognostic","Supports","Better Outcome","Somatic Mutation",559,4,NULL,"accepted",0,"evidence",1113,"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.","Tefferi et al., 2014, Leukemia",24496303,"http://www.ncbi.nlm.nih.gov/pubmed/24496303",NULL,NULL,"2014","7",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1650,"EID1650","A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (Pâ€‰=â€‰0.001; HR 0.14) and platinum therapy resistance (P < 0.001). Expression of AURKA was measured using immunohistochemical techniques on tumor samples.",87,"Ovarian Serous Carcinoma","Ovarian Serous Carcinoma",50933,"http://www.disease-ontology.org/?id=DOID:0050933","B","Predictive","Supports","Resistance or Non-Response","N/A",181,3,NULL,"accepted",0,"evidence",1114,"Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.","Mignogna et al., 2016, J Ovarian Res",27209210,"http://www.ncbi.nlm.nih.gov/pubmed/27209210","true","PMC4875597","2016",NULL,NULL,"J Ovarian Res","Journal of ovarian research","fully curated","103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1651,"EID1651","Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",324,2,NULL,"accepted",0,"evidence",1115,"Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.","Shea et al., 2016, J Thorac Oncol",26845194,"http://www.ncbi.nlm.nih.gov/pubmed/26845194","true","PMC4920699","2016","7",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1652,"EID1652","Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",649,2,NULL,"accepted",0,"evidence",1116,"Acquired Resistance to Crizotinib in NSCLC with METÂ Exon 14 Skipping.","Heist et al., 2016, J Thorac Oncol",27343442,"http://www.ncbi.nlm.nih.gov/pubmed/27343442",NULL,NULL,"2016","8",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1653,"EID1653","A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated with increased clinical response to chemoradiation therapy consisting of cisplatin, 5-fluorouracil, and 40 gy radiation (P = 0.0003).",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Predictive","Supports","Sensitivity","N/A",158,3,"Combination","accepted",0,"evidence",1117,"Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma.","Tamotsu et al., 2015, BMC Cancer",25924824,"http://www.ncbi.nlm.nih.gov/pubmed/25924824","true","PMC4423148","2015",NULL,NULL,"BMC Cancer","BMC cancer","fully curated","326","Cisplatin",NULL,"395","5-fluorouracil",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1654,"EID1654","21 SNPs were analyzed using qRT-PCR genotyping assays in 500 Neuroblastoma tumor samples, and the CASP8 D302H missense variant was found to be associated with worse overall survival (P = 0.0006; Q = 0.049) and worse event-free survival (P = 0.0002; Q = 0.042) in those samples that had MYCN amplification (N = 94).",13,"Neuroblastoma","Neuroblastoma",769,"http://www.disease-ontology.org/?id=DOID:769","B","Prognostic","Supports","Poor Outcome","Germline Polymorphism",650,3,NULL,"accepted",0,"evidence",1118,"CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.","Rihani et al., 2014, PLoS ONE",25502557,"http://www.ncbi.nlm.nih.gov/pubmed/25502557","true","PMC4263607","2014",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1655,"EID1655","Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of death (HR = 2.09 ; P = 0.028), and increased risk of distant metastasis (OR = 3.96 ; P = 0.029).",149,"Esophagus Squamous Cell Carcinoma","Esophagus Squamous Cell Carcinoma",3748,"http://www.disease-ontology.org/?id=DOID:3748","B","Prognostic","Supports","Poor Outcome","N/A",651,4,NULL,"accepted",0,"evidence",1119,"The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.","Hsieh et al., 2016, Oncotarget",27172793,"http://www.ncbi.nlm.nih.gov/pubmed/27172793",NULL,NULL,"2016","5","9","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1656,"EID1656","Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with docetaxel. Docetaxel efficiently induced apoptosis in the cells cultured without any GAS6, but it was not able to do so in the cells that were in media with GAS6 present or that were co-cultured with osteoblasts expressing GAS6. PCa cells in the presence of GAS6 were found to be in G1 phase for a greater duration which may help explain the increased resistance to docetaxel.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","D","Predictive","Supports","Resistance or Non-Response","N/A",652,3,NULL,"accepted",0,"evidence",1120,"Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptotic Pathway During Chemotherapy in Bone Marrow.","Lee et al., 2016, J. Cell. Biochem.",27153245,"http://www.ncbi.nlm.nih.gov/pubmed/27153245",NULL,NULL,"2016","5","5","J. Cell. Biochem.","Journal of cellular biochemistry","fully curated","73","Docetaxel",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1657,"EID1657","128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with a significantly higher level of GAS6 in serum ( P = .05 ). Furthermore, within the OSCC patients, increased GAS6 serum concentration was associated with higher stage tumors ( P < .01) , poorly differentiated tumors ( P < .01 ), and increased lymph node metastasis ( OR = 2.79 ; CI = 1.72-4.48 ).",58,"Oral Squamous Cell Carcinoma","Oral Squamous Cell Carcinoma",50866,"http://www.disease-ontology.org/?id=DOID:0050866","B","Prognostic","Supports","Poor Outcome","N/A",652,4,NULL,"accepted",0,"evidence",1121,"Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma.","Jiang et al., 2015, PLoS ONE",26207647,"http://www.ncbi.nlm.nih.gov/pubmed/26207647","true","PMC4514879","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1658,"EID1658","Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.045) , pathological tumor stage (P = 0.041),  and an unfavorable prognosis (P = 0.040).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Prognostic","Supports","Poor Outcome","N/A",653,3,NULL,"accepted",0,"evidence",1122,"Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.","Qi et al., 2015, Tumour Biol.",25544710,"http://www.ncbi.nlm.nih.gov/pubmed/25544710",NULL,NULL,"2015","5",NULL,"Tumour Biol.","Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1659,"EID1659","A375 melanoma cells containing an inducible shRNA for STAG2 were grown as xenograft tumors in nude mice. The mice in which STAG2 was silenced had tumors that were more sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","N/A",422,4,NULL,"accepted",0,"evidence",1123,"Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.","Shen et al., 2016, Nat. Med.",27500726,"http://www.ncbi.nlm.nih.gov/pubmed/27500726","true","PMC5014622","2016","9",NULL,"Nat. Med.","Nature medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1660,"EID1660","A375 melanoma cells containing an inducible shRNA for STAG3 were grown as xenograft tumors in nude mice. The mice in which STAG3 was silenced had tumors that were more sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","N/A",654,4,NULL,"accepted",0,"evidence",1123,"Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.","Shen et al., 2016, Nat. Med.",27500726,"http://www.ncbi.nlm.nih.gov/pubmed/27500726","true","PMC5014622","2016","9",NULL,"Nat. Med.","Nature medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1661,"EID1661","Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT Panel) was performed on the patients tumor and germline and identified a 15-bp in-frame deletion of MAP2K1 (8.3% of tumor reads but 0% in germline). In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild-type MEK1 as well as increased colony formation and tumor growth in-vivo. Selumetinib treatment of MEK1-transfected cells confirmed retained sensitivity to MEK inhibition and inhibition of colony formation.",87,"Ovarian Serous Carcinoma","Ovarian Serous Carcinoma",50933,"http://www.disease-ontology.org/?id=DOID:0050933","C","Predictive","Supports","Sensitivity","Somatic Mutation",655,4,NULL,"accepted",0,"evidence",1124,"Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.","Grisham et al., 2015, J. Clin. Oncol.",26324360,"http://www.ncbi.nlm.nih.gov/pubmed/26324360","true","PMC4669594","2015","12","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","122","Selumetinib (AZD6244)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1662,"EID1662","One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months.",87,"Ovarian Serous Carcinoma","Ovarian Serous Carcinoma",50933,"http://www.disease-ontology.org/?id=DOID:0050933","C","Predictive","Supports","Sensitivity","Somatic Mutation",656,2,NULL,"accepted",0,"evidence",1124,"Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.","Grisham et al., 2015, J. Clin. Oncol.",26324360,"http://www.ncbi.nlm.nih.gov/pubmed/26324360","true","PMC4669594","2015","12","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","110","MEK Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1663,"EID1663","Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. Clinical data were available for two patients. Among them one 46-year old woman with spitzoid melanoma that  harbored  a
ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib. Subcutaneous  tumor  nodules  exhibited  clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45. Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with
clean surgical margins.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","C","Predictive","Supports","Sensitivity","Somatic Mutation",657,3,NULL,"accepted",0,"evidence",1126,"The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.","Ross et al., 2016, Int. J. Cancer",26314551,"http://www.ncbi.nlm.nih.gov/pubmed/26314551",NULL,NULL,"2016","2","15","Int. J. Cancer","International journal of cancer","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1664,"EID1664","A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension). Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well.",105,"Sarcoma","Sarcoma",1115,"http://www.disease-ontology.org/?id=DOID:1115","C","Predictive","Supports","Sensitivity","Somatic Mutation",618,2,"Combination","submitted",0,"evidence",1198,"Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.","Subbiah et al., 2014, J Hematol Oncol",24422672,"http://www.ncbi.nlm.nih.gov/pubmed/24422672","true","PMC3896681","2014","1","14","J Hematol Oncol","Journal of hematology & oncology","fully curated","83","Temsirolimus",NULL,"6","Sorafenib",NULL,"33","Bevacizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1665,"EID1665","90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were  treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR(median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for TTF (HR = 0.1030; P = .0004).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",33,3,NULL,"accepted",0,"evidence",1127,"Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.","Yang et al., 2008, J. Clin. Oncol.",18509184,"http://www.ncbi.nlm.nih.gov/pubmed/18509184",NULL,NULL,"2008","6","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1666,"EID1666","90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-type EGFR (median 8.9 versus 2.1). In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",133,3,NULL,"accepted",0,"evidence",1127,"Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.","Yang et al., 2008, J. Clin. Oncol.",18509184,"http://www.ncbi.nlm.nih.gov/pubmed/18509184",NULL,NULL,"2008","6","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1667,"EID1667","48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients,  had the T790M EGFR mutation present, indicating its importance in the development of resistance.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",34,3,"Substitutes","accepted",0,"evidence",1128,"Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.","Belchis et al., 2016, Oncotarget",27304188,"http://www.ncbi.nlm.nih.gov/pubmed/27304188",NULL,NULL,"2016","6","9","Oncotarget","Oncotarget","fully curated","146","Afatinib",NULL,"14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1668,"EID1668","Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK. Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",658,4,NULL,"accepted",0,"evidence",1129,"Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.","Wagenaar et al., 2014, Pigment Cell Melanoma Res",24112705,"http://www.ncbi.nlm.nih.gov/pubmed/24112705","true","PMC4260813","2014","1",NULL,"Pigment Cell Melanoma Res","Pigment cell & melanoma research","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1669,"EID1669","In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",658,3,NULL,"accepted",0,"evidence",1130,"Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.","Hoogstraat et al., 2015, Pigment Cell Melanoma Res",25515853,"http://www.ncbi.nlm.nih.gov/pubmed/25515853",NULL,NULL,"2015","5",NULL,"Pigment Cell Melanoma Res","Pigment cell & melanoma research","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1670,"EID1670","48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",104,2,"Substitutes","accepted",0,"evidence",1128,"Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.","Belchis et al., 2016, Oncotarget",27304188,"http://www.ncbi.nlm.nih.gov/pubmed/27304188",NULL,NULL,"2016","6","9","Oncotarget","Oncotarget","fully curated","15","Erlotinib",NULL,"14","Gefitinib",NULL,"146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1671,"EID1671","Ten patients with Neurofibromatosis 2 were enrolled for treatment with Everolimus.  At 12 months, no patients had reduction in tumor volume >20%, however, five patients had stable disease with a reduction in annual growth rate from 67% growth/year to 0.5% growth/year.  Growth of tumors ensued after discontinuation of Everolimus.",2140,"Acoustic Neuroma","Acoustic Neuroma",12689,"http://www.disease-ontology.org/?id=DOID:12689","B","Predictive","Supports","N/A","Germline Mutation",659,3,NULL,"accepted",0,"evidence",1131,"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.","Goutagny et al., 2015, J. Neurooncol.",25567352,"http://www.ncbi.nlm.nih.gov/pubmed/25567352",NULL,NULL,"2015","4",NULL,"J. Neurooncol.","Journal of neuro-oncology","fully curated","41","Everolimus",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1672,"EID1672","VHL mutations were evaluated in 78 tumors samples of patients with metastatic RCC treated with pazopanib as part of a clinical trial. Overall, 87% had one VHL mutation, 12% showed promoter hypermethylation, and 6 patients had both. 8 patients exhibited neither mutation nor methylation of VHL. There was no correlation between VHL status and overall response rate or progression free survival under pazopanib therapy.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",160,2,NULL,"accepted",0,"evidence",1132,"The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.","Choueiri et al., 2013, Clin. Cancer Res.",23881929,"http://www.ncbi.nlm.nih.gov/pubmed/23881929","true","PMC4522695","2013","9","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","56","Pazopanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1673,"EID1673","HIF-2A (EPAS1) staining was conducted on 66 tumors.  Of the 66 patients, 25 were classified as responders and 41 were classified as non-responders.  There was no significant difference between responders and non-responders with regards to overall response rate to pazopanib (44% vs 33%; P=0.36).",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Predictive","Does Not Support","N/A","Somatic Mutation",435,3,NULL,"accepted",0,"evidence",1132,"The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.","Choueiri et al., 2013, Clin. Cancer Res.",23881929,"http://www.ncbi.nlm.nih.gov/pubmed/23881929","true","PMC4522695","2013","9","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","56","Pazopanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1674,"EID1674","Immunohistochemical staining was performed on 65 patients for HIF1A such that 23 were considered responders and 42 were considered non-responders.  There was no difference between the two groups with regards to overall response rate to pazopanib.  There was no difference between the two groups with regards to progression free survival.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Predictive","Does Not Support","N/A","N/A",660,2,NULL,"accepted",0,"evidence",1132,"The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.","Choueiri et al., 2013, Clin. Cancer Res.",23881929,"http://www.ncbi.nlm.nih.gov/pubmed/23881929","true","PMC4522695","2013","9","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","56","Pazopanib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1675,"EID1675","664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Prognostic","Supports","Better Outcome","Germline Mutation",185,3,NULL,"accepted",0,"evidence",1133,"BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.","Harter et al., 2016, Gynecol. Oncol.",26740259,"http://www.ncbi.nlm.nih.gov/pubmed/26740259",NULL,NULL,"2016","3",NULL,"Gynecol. Oncol.","Gynecologic oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1676,"EID1676","664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Prognostic","Supports","Better Outcome","Germline Mutation",186,3,NULL,"accepted",0,"evidence",1133,"BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.","Harter et al., 2016, Gynecol. Oncol.",26740259,"http://www.ncbi.nlm.nih.gov/pubmed/26740259",NULL,NULL,"2016","3",NULL,"Gynecol. Oncol.","Gynecologic oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1677,"EID1677","46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Germline Mutation",185,3,"Combination","accepted",0,"evidence",1134,"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.","Liu et al., 2014, Lancet Oncol.",25218906,"http://www.ncbi.nlm.nih.gov/pubmed/25218906","true","PMC4294183","2014","10",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","42","Olaparib",NULL,"400","Cediranib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1678,"EID1678","46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Germline Mutation",186,3,"Combination","accepted",0,"evidence",1134,"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.","Liu et al., 2014, Lancet Oncol.",25218906,"http://www.ncbi.nlm.nih.gov/pubmed/25218906","true","PMC4294183","2014","10",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","400","Cediranib",NULL,"42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1679,"EID1679","49-year old woman diagnosed with breast cancer was assessed for BRCA2 mutations.  Algorithms including Align-GVGD predicted pathogenicity, however PolyPhen predicted that this variant was benign. The authorâ€™s assessment of the factors predicts a pathogenicity probability of 0.73 and an Odds Ratio of 2.7.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Diagnostic","Supports","Positive","Germline Mutation",661,1,NULL,"accepted",0,"evidence",1135,"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.","Plon et al., 2008, Hum. Mutat.",18951446,"http://www.ncbi.nlm.nih.gov/pubmed/18951446","true","PMC3075918","2008","11",NULL,"Hum. Mutat.","Human mutation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1680,"EID1680","46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations and MLH1 expression (immunohistochemistry). Overall survival rate of MLH1 negative cases were significantly better than MLH1 positive cases (p=0.020).",1322,"Stomach Carcinoma","Stomach Carcinoma",5517,"http://www.disease-ontology.org/?id=DOID:5517","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",662,3,NULL,"accepted",0,"evidence",1136,"Comprehensive mutation profiling of mucinous gastric carcinoma.","Rokutan et al., 2016, J. Pathol.",27313181,"http://www.ncbi.nlm.nih.gov/pubmed/27313181",NULL,NULL,"2016","6","17","J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1681,"EID1681","46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations.  Overall survival rate of BCOR positive cases were significantly better than BCOR negative cases cases (p=0.038).",21,"Stomach Cancer","Stomach Cancer",10534,"http://www.disease-ontology.org/?id=DOID:10534","B","Prognostic","Supports","Better Outcome","Somatic Mutation",663,3,NULL,"accepted",0,"evidence",1136,"Comprehensive mutation profiling of mucinous gastric carcinoma.","Rokutan et al., 2016, J. Pathol.",27313181,"http://www.ncbi.nlm.nih.gov/pubmed/27313181",NULL,NULL,"2016","6","17","J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1682,"EID1682","285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001).",1322,"Stomach Carcinoma","Stomach Carcinoma",5517,"http://www.disease-ontology.org/?id=DOID:5517","E","Prognostic","Supports","Poor Outcome","Somatic Mutation",664,2,NULL,"accepted",0,"evidence",1136,"Comprehensive mutation profiling of mucinous gastric carcinoma.","Rokutan et al., 2016, J. Pathol.",27313181,"http://www.ncbi.nlm.nih.gov/pubmed/27313181",NULL,NULL,"2016","6","17","J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1683,"EID1683","285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001).",1322,"Stomach Carcinoma","Stomach Carcinoma",5517,"http://www.disease-ontology.org/?id=DOID:5517","E","Prognostic","Supports","Poor Outcome","Somatic Mutation",665,2,NULL,"accepted",0,"evidence",1136,"Comprehensive mutation profiling of mucinous gastric carcinoma.","Rokutan et al., 2016, J. Pathol.",27313181,"http://www.ncbi.nlm.nih.gov/pubmed/27313181",NULL,NULL,"2016","6","17","J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1684,"EID1684","In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.",370,"Triple-receptor Negative Breast Cancer","Triple-receptor Negative Breast Cancer",60081,"http://www.disease-ontology.org/?id=DOID:0060081","B","Predictive","Supports","Sensitivity","Germline Mutation",185,3,"Substitutes","accepted",0,"evidence",1137,"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.","Isakoff et al., 2015, J. Clin. Oncol.",25847936,"http://www.ncbi.nlm.nih.gov/pubmed/25847936","true","PMC4451173","2015","6","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","326","Cisplatin",NULL,"93","Carboplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1685,"EID1685","In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.",370,"Triple-receptor Negative Breast Cancer","Triple-receptor Negative Breast Cancer",60081,"http://www.disease-ontology.org/?id=DOID:0060081","B","Predictive","Supports","Sensitivity","Germline Mutation",186,3,"Substitutes","accepted",0,"evidence",1137,"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.","Isakoff et al., 2015, J. Clin. Oncol.",25847936,"http://www.ncbi.nlm.nih.gov/pubmed/25847936","true","PMC4451173","2015","6","10","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","93","Carboplatin",NULL,"326","Cisplatin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1686,"EID1686","A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.
Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","N/A",306,4,NULL,"accepted",0,"evidence",1138,"A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.","Bertotti et al., 2011, Cancer Discov",22586653,"http://www.ncbi.nlm.nih.gov/pubmed/22586653",NULL,NULL,"2011","11",NULL,"Cancer Discov","Cancer discovery","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1687,"EID1687","A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","N/A",306,4,NULL,"accepted",0,"evidence",1138,"A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.","Bertotti et al., 2011, Cancer Discov",22586653,"http://www.ncbi.nlm.nih.gov/pubmed/22586653",NULL,NULL,"2011","11",NULL,"Cancer Discov","Cancer discovery","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1688,"EID1688","HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab.
HER2 copy number status was significantly correlated with respoinse rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability)",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Resistance or Non-Response","N/A",306,2,"Substitutes","accepted",0,"evidence",1139,"HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.","Martin et al., 2013, Br. J. Cancer",23348520,"http://www.ncbi.nlm.nih.gov/pubmed/23348520","true","PMC3593567","2013","2","19","Br. J. Cancer","British journal of cancer","fully curated","28","Panitumumab",NULL,"16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1689,"EID1689","Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib.
After a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease.
A total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",306,4,"Combination","accepted",0,"evidence",1140,"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.","Sartore-Bianchi et al., 2016, Lancet Oncol.",27108243,"http://www.ncbi.nlm.nih.gov/pubmed/27108243",NULL,NULL,"2016","6",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","45","Lapatinib",NULL,"84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1690,"EID1690","In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC4-ROS1 rearrangement was identified using comprehensive genomic profiling. The patient attained a decrease in RESIST target lesions by 26.8% (stable disease); however, the patient relapsed 4 months later. This patient also harbored a TP53 mutation, MCL1 amplification and CDKN2A deletion.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",269,3,NULL,"accepted",0,"evidence",1141,"Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.","Le et al., 2015, Clin Lung Cancer",25922291,"http://www.ncbi.nlm.nih.gov/pubmed/25922291","true","PMC4418215","2015","9",NULL,"Clin Lung Cancer","Clinical lung cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1691,"EID1691","In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.  The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",499,3,NULL,"accepted",0,"evidence",1141,"Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.","Le et al., 2015, Clin Lung Cancer",25922291,"http://www.ncbi.nlm.nih.gov/pubmed/25922291","true","PMC4418215","2015","9",NULL,"Clin Lung Cancer","Clinical lung cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1692,"EID1692","In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP.  The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",270,3,NULL,"accepted",0,"evidence",1141,"Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.","Le et al., 2015, Clin Lung Cancer",25922291,"http://www.ncbi.nlm.nih.gov/pubmed/25922291","true","PMC4418215","2015","9",NULL,"Clin Lung Cancer","Clinical lung cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1693,"EID1693","A 71-year old male with metastatic extramammary Pagetâ€™s disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease.",779,"Scrotum Paget's Disease","Scrotum Paget's Disease",3444,"http://www.disease-ontology.org/?id=DOID:3444","C","Predictive","Supports","Sensitivity","Somatic Mutation",306,2,NULL,"accepted",0,"evidence",1142,"Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.","Barth et al., 2015, Case Rep Oncol Med",25692060,"http://www.ncbi.nlm.nih.gov/pubmed/25692060","true","PMC4322830","2015",NULL,NULL,"Case Rep Oncol Med","Case reports in oncological medicine","fully curated","84","Trastuzumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1694,"EID1694","In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemotherapy (n=38) and non-responders to platinum chemotherapy (n=33) were evaluated for 178 cancer-associated genes. Of the complete responders, 24% had an ERBB2 missense mutations and no non-responders had ERBB2 mutations (p=0.003).",18,"Bladder Carcinoma","Bladder Carcinoma",4007,"http://www.disease-ontology.org/?id=DOID:4007","C","Predictive","Supports","Sensitivity","Somatic Mutation",666,3,NULL,"accepted",0,"evidence",1143,"ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.","Groenendijk et al., 2016, Eur. Urol.",25636205,"http://www.ncbi.nlm.nih.gov/pubmed/25636205",NULL,NULL,"2016","3",NULL,"Eur. Urol.","European urology","fully curated","103","PLATINUM",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1695,"EID1695","Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations.  One tumor showed 592-end deletion of MEN1 and the other showed a 521 frameshift mutation.  These mutations are similar to the ones seen in MEN1 syndrome inducing endocrine gland tumors.",2006,"Thyroid Hurthle Cell Carcinoma","Thyroid Hurthle Cell Carcinoma",8161,"http://www.disease-ontology.org/?id=DOID:8161","C","Diagnostic","Supports","Positive","Somatic Mutation",667,2,NULL,"accepted",0,"evidence",1144,"MEN1 mutations in HÃ¼rthle cell (oncocytic) thyroid carcinoma.","Kasaian et al., 2015, J. Clin. Endocrinol. Metab.",25625803,"http://www.ncbi.nlm.nih.gov/pubmed/25625803","true","PMC4399284","2015","4",NULL,"J. Clin. Endocrinol. Metab.","The Journal of clinical endocrinology and metabolism","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1696,"EID1696","Evaluation of 39 aggressive cutaneous squamous cell carcinomas revealed that tumors with a KMT2C mutation were 5x more likely to invade the bone (53% versus 10%; p=0.008).  Patients with KMT2C mutations also had significantly shorter recurrent free survival (21.6 versus 167.5; p=0.003) and an increased hazards ratio for death (HR=5.16; 95%CI:1.55 to 17.18).  This worse prognosis did not appear to be correlated with bone invasion (p=0.98).",130,"Skin Squamous Cell Carcinoma","Skin Squamous Cell Carcinoma",3151,"http://www.disease-ontology.org/?id=DOID:3151","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",668,3,NULL,"accepted",0,"evidence",1145,"Mutational landscape of aggressive cutaneous squamous cell carcinoma.","Pickering et al., 2014, Clin. Cancer Res.",25303977,"http://www.ncbi.nlm.nih.gov/pubmed/25303977","true","PMC4367811","2014","12","15","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1697,"EID1697","In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis.  Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27% of patients who expressed STAG2 on IHC (P=0.002).",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","B","Prognostic","Supports","Poor Outcome","N/A",669,4,NULL,"accepted",0,"evidence",1146,"The genomic landscape of pediatric Ewing sarcoma.","Crompton et al., 2014, Cancer Discov",25186949,"http://www.ncbi.nlm.nih.gov/pubmed/25186949",NULL,NULL,"2014","11",NULL,"Cancer Discov","Cancer discovery","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1698,"EID1698","A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died.",41,"Multiple Myeloma","Multiple Myeloma",9538,"http://www.disease-ontology.org/?id=DOID:9538","C","Predictive","Supports","Sensitivity","Somatic Mutation",12,3,NULL,"accepted",0,"evidence",1147,"Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.","Sharman et al., 2014, Clin Lymphoma Myeloma Leuk",24997557,"http://www.ncbi.nlm.nih.gov/pubmed/24997557",NULL,NULL,"2014","10",NULL,"Clin Lymphoma Myeloma Leuk","Clinical lymphoma, myeloma & leukemia","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1699,"EID1699","A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.",41,"Multiple Myeloma","Multiple Myeloma",9538,"http://www.disease-ontology.org/?id=DOID:9538","C","Predictive","Supports","Sensitivity","Somatic Mutation",12,2,NULL,"accepted",0,"evidence",1147,"Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.","Sharman et al., 2014, Clin Lymphoma Myeloma Leuk",24997557,"http://www.ncbi.nlm.nih.gov/pubmed/24997557",NULL,NULL,"2014","10",NULL,"Clin Lymphoma Myeloma Leuk","Clinical lymphoma, myeloma & leukemia","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1700,"EID1700","In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048).",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",336,4,NULL,"accepted",0,"evidence",1148,"Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.","Johnson et al., 2013, Cancer",22810899,"http://www.ncbi.nlm.nih.gov/pubmed/22810899","true","PMC3966555","2013","1","15","Cancer","Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1701,"EID1701","In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001).",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Prognostic","Supports","Better Outcome","Somatic Mutation",442,4,NULL,"accepted",0,"evidence",1148,"Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.","Johnson et al., 2013, Cancer",22810899,"http://www.ncbi.nlm.nih.gov/pubmed/22810899","true","PMC3966555","2013","1","15","Cancer","Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1702,"EID1702","A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",336,3,NULL,"accepted",0,"evidence",1138,"A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.","Bertotti et al., 2011, Cancer Discov",22586653,"http://www.ncbi.nlm.nih.gov/pubmed/22586653",NULL,NULL,"2011","11",NULL,"Cancer Discov","Cancer discovery","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1703,"EID1703","A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",208,2,NULL,"accepted",0,"evidence",1138,"A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.","Bertotti et al., 2011, Cancer Discov",22586653,"http://www.ncbi.nlm.nih.gov/pubmed/22586653",NULL,NULL,"2011","11",NULL,"Cancer Discov","Cancer discovery","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1704,"EID1704","A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",399,2,NULL,"accepted",0,"evidence",1138,"A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.","Bertotti et al., 2011, Cancer Discov",22586653,"http://www.ncbi.nlm.nih.gov/pubmed/22586653",NULL,NULL,"2011","11",NULL,"Cancer Discov","Cancer discovery","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1705,"EID1705","A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",311,1,NULL,"accepted",0,"evidence",1138,"A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.","Bertotti et al., 2011, Cancer Discov",22586653,"http://www.ncbi.nlm.nih.gov/pubmed/22586653",NULL,NULL,"2011","11",NULL,"Cancer Discov","Cancer discovery","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1706,"EID1706","Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strongly inhibited by the BET inhibitors. Microarray analysis showed a downregulation of MYC-dependent genes after treatment. qRT-PCR showed that MYCL1 but not c-MYC and MYCN was expressed in U266 cells and I-BET151 induced downregulation of MYCL1. In contrast, c-MYC but not MYCL was expressed in the other cell lines and I-BET151 induced downregulation of c-MYC.",41,"Multiple Myeloma","Multiple Myeloma",9538,"http://www.disease-ontology.org/?id=DOID:9538","D","Predictive","Supports","Sensitivity","N/A",670,1,"Substitutes","accepted",0,"evidence",1149,"Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.","Suzuki et al., 2016, Anticancer Drugs",27276402,"http://www.ncbi.nlm.nih.gov/pubmed/27276402","true","PMC4969056","2016","9",NULL,"Anticancer Drugs","Anti-cancer drugs","fully curated","306","JQ1",NULL,"402","I-BET151",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1707,"EID1707","Three metastatic glioblastoma cell lines were compared with their parental cell lines with regard to differential gene expression. HGF signalling was among the top pathways identified. Exogenous HFG led to an increase in MET activity (except in one cell line with high endogenous HGF levels) which was abrogated by MET inhibitor SGX523. Three HGF autocrine cell lines were grown in mice and showed significantly increased sensitivity to SGX523 than three non-HGF autocrine cell lines (P<0.05).",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","D","Predictive","Supports","Sensitivity","N/A",671,2,NULL,"accepted",0,"evidence",1150,"Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.","Xie et al., 2012, Proc. Natl. Acad. Sci. U.S.A.",22203985,"http://www.ncbi.nlm.nih.gov/pubmed/22203985","true","PMC3258605","2012","1","10","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","403","SGX523",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1708,"EID1708","463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or BSC alone (n = 232). Panitumumab significantly prolonged PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66, [P < .0001]). Objective response rates favored panitumumab over BSC; after a 12-month minimum follow-up, response rates were 10% for panitumumab and 0% for BSC (P < .0001). No difference was observed in OS (HR, 1.00; 95% CI, 0.82 to 1.22), but 76% of BSC patients entered the cross-over study.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",354,2,NULL,"accepted",0,"evidence",1151,"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.","Van Cutsem et al., 2007, J. Clin. Oncol.",17470858,"http://www.ncbi.nlm.nih.gov/pubmed/17470858",NULL,NULL,"2007","5","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","28","Panitumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1709,"EID1709","57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer was 6.4 months.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predictive","Supports","Sensitivity","N/A",354,1,NULL,"accepted",0,"evidence",1152,"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.","Saltz et al., 2004, J. Clin. Oncol.",14993230,"http://www.ncbi.nlm.nih.gov/pubmed/14993230",NULL,NULL,"2004","4","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","16","Cetuximab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1710,"EID1710","FACS-assisted shRNA genetic screen identified SOX10 as a determinant of vemurafenib resistance. Suppression of SOX10 in melanoma cells confers resistance to BRAF and MEK inhibitors through activation of TGF-Î² signalling and upregulation of EGFR and PDGFRB. EGFR expression or exposure to TGF-Î² becomes beneficial for proliferation of melanoma cells in the presence of BRAF or MEK inhibitors. Melanoma cells with low SOX10 and consequently high EGFR expression are enriched in the presence of vemurafenib. This study finds evidence for SOX10 loss (N=2) and/or activation of TGF-Î² signalling (N=2) in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","D","Predictive","Supports","Resistance or Non-Response","N/A",672,4,NULL,"accepted",0,"evidence",1153,"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.","Sun et al., 2014, Nature",24670642,"http://www.ncbi.nlm.nih.gov/pubmed/24670642",NULL,NULL,"2014","4","3","Nature","Nature","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1711,"EID1711","AML MOLM14 cells were cocultured with FLT3 inhibitor AC220 (10 nM) and selected proteins expressed in the bone marrow microenvironment. FL and FGF2 were the only proteins that increased viability >2 standard deviations. FGFR inhibitor PD173074 (and FGFR1 siRNA) was able to attenuate the protective effect of FGF2.  Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance mutations. 10 FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression (IHC) in marrow stromal cells, which peaked prior to overt clinical relapse and detection of resistance mutations",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","D","Predictive","Supports","Resistance or Non-Response","N/A",673,4,NULL,"accepted",0,"evidence",1154,"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia.","Traer et al., 2016, Cancer Res.",27671675,"http://www.ncbi.nlm.nih.gov/pubmed/27671675",NULL,NULL,"2016","9","26","Cancer Res.","Cancer research","fully curated","266","Quizartinib (AC220)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1712,"EID1712","EIF1AX was identified as a uveal melanoma (UM) driver gene by whole-exome sequencing. Approximately 14%â€“20% of UM carry a mutation in EIF1AX, with most mutations found in exons 1 and 2. EIF1AX mutations are associated with a good prognosis, and are inversely associated with metastasis. This assertion is based on observed survival for 19 EIF1AX mutant UM cases compared to 69 EIF1AX wildtype cases.",188,"Uveal Melanoma","Uveal Melanoma",6039,"http://www.disease-ontology.org/?id=DOID:6039","C","Prognostic","Supports","Better Outcome","Somatic Mutation",674,4,NULL,"accepted",0,"evidence",1155,NULL,"Martin et al., 2013, Nat. Genet.",23793026,"http://www.ncbi.nlm.nih.gov/pubmed/23793026",NULL,NULL,NULL,NULL,NULL,NULL,NULL,"fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1713,"EID1713","Case report of two patients with MET amplification (MET:CEP7 ratio â‰¥5) and no concomitant MET exon 14 deletion. A response to crizotinib was observed in both cases suggesting that MET amplification may predict response to this drug even in the absence of MET exon 14 mutations.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","N/A",270,2,NULL,"accepted",0,"evidence",1157,"Responses to crizotinib can occur in high level MET-amplified non-small cell lung cancer independent of MET exon 14 alterations: A brief report.","Caparica et al., 2016, J Thorac Oncol",27664533,"http://www.ncbi.nlm.nih.gov/pubmed/27664533",NULL,NULL,"2016","9","21","J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1714,"EID1714","Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","C","Predictive","Supports","Sensitivity","N/A",270,3,NULL,"accepted",0,"evidence",1158,"Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.","Palma et al., 2014, Case Rep Oncol",25232318,"http://www.ncbi.nlm.nih.gov/pubmed/25232318","true","PMC4164090","2014","5",NULL,"Case Rep Oncol","Case reports in oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1715,"EID1715","Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","C","Predictive","Does Not Support","Resistance or Non-Response","Somatic Mutation",425,2,NULL,"accepted",0,"evidence",1158,"Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.","Palma et al., 2014, Case Rep Oncol",25232318,"http://www.ncbi.nlm.nih.gov/pubmed/25232318","true","PMC4164090","2014","5",NULL,"Case Rep Oncol","Case reports in oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1716,"EID1716","The authors explored the viability of PAX8 expression as a biomarker for differentiating mullerian from non-mullerian tumors. 74 tumors (37 Mullerian/37 non-Mullerian) were examined for PAX8 expression via IHC. Of these 29/37 Mullerian and 1/37 non-Mullerian tumors exhibited PAX8 expression. The sensitivity and specificity of using this as a biomarker to differentiate between the two tumor types was 78.4% and 97.3% respectively.",454,"Female Reproductive Organ Cancer","Female Reproductive Organ Cancer",120,"http://www.disease-ontology.org/?id=DOID:120","A","Diagnostic","Supports","Positive","Somatic Mutation",683,4,NULL,"accepted",0,"evidence",1159,"Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors.","Heidarpour et al., 2014, Adv Biomed Res",24800185,"http://www.ncbi.nlm.nih.gov/pubmed/24800185","true","PMC4007335","2014",NULL,NULL,"Adv Biomed Res","Advanced biomedical research","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1717,"EID1717","In 177 patients with activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), PRDM1 mutations (N=46) were associated with worse overall (P=0.016) and progression-free (P=0.023) survival compared to wildtype patients. This may have been driven by patients with exon1-2 mutations (N=15; P=0.021 for OS; P=0.024 for PFS) versus those with exon 3-7 mutations (N=31; P=0.16 for OS; P=0.24 for PFS) when compared to wildtype patients. Multivariate analysis did not identify PRDM1 mutations as an independent prognostic factor.",45,"Diffuse Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma",50745,"http://www.disease-ontology.org/?id=DOID:0050745","B","Prognostic","Supports","Poor Outcome",NULL,644,2,NULL,"accepted",0,"evidence",1084,"Loss of PRDM1/BLIMP-1 function contributes to poor prognosis for activated B-cell-like diffuse large B-cell lymphoma.","Xia et al., 2016, Leukemia",27568520,"http://www.ncbi.nlm.nih.gov/pubmed/27568520",NULL,NULL,"2016","8","29","Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1724,"EID1724","An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF. The patient was treated with erlotinib 150 mg orally/daily. After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed.",29,"Cholangiocarcinoma","Cholangiocarcinoma",4947,"http://www.disease-ontology.org/?id=DOID:4947","C","Predictive","Supports","Sensitivity","Somatic Mutation",691,2,NULL,"accepted",0,"evidence",186,"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.","Borad et al., 2014, PLoS Genet.",24550739,"http://www.ncbi.nlm.nih.gov/pubmed/24550739","true","PMC3923676","2014","2",NULL,"PLoS Genet.","PLoS genetics","partially curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1725,"EID1725","In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin.",2150,"Systemic Mastocytosis","Systemic Mastocytosis",349,"http://www.disease-ontology.org/?id=DOID:349","B","Predictive","Supports","Sensitivity","Somatic Mutation",65,4,NULL,"accepted",0,"evidence",1170,"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.","Gotlib et al., 2016, N. Engl. J. Med.",27355533,"http://www.ncbi.nlm.nih.gov/pubmed/27355533",NULL,NULL,"2016","6","30","N. Engl. J. Med.","The New England journal of medicine","fully curated","323","Midostaurin",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1726,"EID1726","The D816V+ advanced systemic mastocytosis patients with additional mutations in SRSF2 (N=30), ASLX1 (N=20), or RUNX1 (N=16) exhibited lower overall survival over 14 years as compared to D816V+ patients with wildtype SRSF2 (N=40), ASXL1(N=50), or RUNX1 (N=54).",2150,"Systemic Mastocytosis","Systemic Mastocytosis",349,"http://www.disease-ontology.org/?id=DOID:349","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",65,4,NULL,"accepted",0,"evidence",1171,"Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.","Jawhar et al., 2016, Leukemia",26464169,"http://www.ncbi.nlm.nih.gov/pubmed/26464169",NULL,NULL,"2016","1",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1727,"EID1727","ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. This mutation displayed elevated levels of Ser118 phosphorylation compared to wild-type ERÎ± and appeared to possess estrogen-independent activity.",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",692,2,NULL,"accepted",0,"evidence",171,"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.","Toy et al., 2013, Nat. Genet.",24185512,"http://www.ncbi.nlm.nih.gov/pubmed/24185512","true","PMC3903423","2013","12",NULL,"Nat. Genet.","Nature genetics","fully curated","407","Aromatase Inhibitor",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1728,"EID1728","In the LUX-LUNG 7 trial, (NCT01466660) stage IIIB or IV NSCLC patients with EGFR exon 19 deletion, (n=186) Leu858Arg mutation, (n=132) or both (n=1) were divided into equal groups and treated with first line reversible EGFR inhibitor gefitinib or irreversible pan-ErbB family inhibitor afatinib in order to obtain a direct comparison of these two approved first line treatments. Significant difference was seen in objective response with 70%  of cases with afatinib vs. 56% of cases with gefitinib. Median progression free survival was 11.0 months (10.6-12.9) with afatinib and 10.9 months (9.1-11.5) with gefitinib, HR 0.73 [0.57-0.95] p=0.017.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",442,4,NULL,"accepted",0,"evidence",1172,"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.","Park et al., 2016, Lancet Oncol.",27083334,"http://www.ncbi.nlm.nih.gov/pubmed/27083334",NULL,NULL,"2016","5",NULL,"Lancet Oncol.","The Lancet. Oncology","partially curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1729,"EID1729","SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib in comparison to five sensitive cell lines. Western blots showed clear elevation of protein levels in 3/5 resistant cell lines. Ectopic SGK1 expression in sensitive MDA-MB-361 cells resulted in alpelisib resistance and preservation of phopho-S6K and phospho-4EBP with alpelisib treatment. Knockdown of SGK1 in resistant HCC1954 cells increased alpelisib sensitivity and reduced p-S6K and p-4EBP levels with alpelisib treatment. Promoter methylation at SGK1 was increased in sensitive cells compared to alpelisib resistant cell lines.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",693,5,NULL,"accepted",0,"evidence",1174,"PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3KÎ± Inhibition.","Castel et al., 2016, Cancer Cell",27451907,"http://www.ncbi.nlm.nih.gov/pubmed/27451907","true","PMC4982440","2016","8","8","Cancer Cell","Cancer cell","partially curated","387","Alpelisib (NVP-BYL719)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1730,"EID1730","A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4/15 having disease progression as best response.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",693,3,NULL,"accepted",0,"evidence",1174,"PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3KÎ± Inhibition.","Castel et al., 2016, Cancer Cell",27451907,"http://www.ncbi.nlm.nih.gov/pubmed/27451907","true","PMC4982440","2016","8","8","Cancer Cell","Cancer cell","partially curated","387","Alpelisib (NVP-BYL719)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1731,"EID1731","The alpelisib (PI3Kalpha inhibitor) resistant breast cancer cell line HCC1954 was treated with alpelsisb alone or in combination with the SGK1 kinase inhibitor SGK1-Inh. Addition of SGK1 reduced viability over alpelisib alone, and phospho-S6K as well as phospho-4EBP1 levels decreased with combination treatment. HCC1954 xenografts showed increased tumor volume with treatment of alpelisib or SGK1-Inh alone, but only combination treatment resulted in lack of volume increase and decreased phospho-S6K levels in tumors by IHC.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","D","Predictive","Supports","Sensitivity","Somatic Mutation",693,4,NULL,"accepted",0,"evidence",1174,"PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3KÎ± Inhibition.","Castel et al., 2016, Cancer Cell",27451907,"http://www.ncbi.nlm.nih.gov/pubmed/27451907","true","PMC4982440","2016","8","8","Cancer Cell","Cancer cell","partially curated","339","BYL719 (Alpelisib)",NULL,"408","SGK1-Inh",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1732,"EID1732","Exon-2 KRAS mutation status was analyzed in 219 patients with pancreatic ductal carcinoma, excluding those who had previously undergone chemotherapy, first-line pancreatic resection, or neoadjuvant treatment with chemotherapy or radiotherapy. 72 patients had wild-type KRAS, 147 had a codon-12 KRAS mutation (G12D, G12V, or G12R) and 73 had a G12D KRAS mutation, specifically. There was no significant difference in overall survival between wild-type patients and patients with any type of exon-12 mutation. However, patients with the G12D mutation exhibited significantly lower overall survival compared to wild-type patients in univariate and multivariate analyses. This difference in overall survival between wild-type and G12D patients persisted in the subset of patients who underwent chemotherapy at any point after enrollment.",145,"Pancreatic Ductal Carcinoma","Pancreatic Ductal Carcinoma",3587,"http://www.disease-ontology.org/?id=DOID:3587","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",79,3,NULL,"accepted",0,"evidence",893,"KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.","Bournet et al., 2016, Clin Transl Gastroenterol",27010960,"http://www.ncbi.nlm.nih.gov/pubmed/27010960","true","PMC4822095","2016",NULL,NULL,"Clin Transl Gastroenterol","Clinical and translational gastroenterology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1733,"EID1733","This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","N/A",276,3,NULL,"accepted",0,"evidence",1176,"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.","Reck et al., 2016, N. Engl. J. Med.",27718847,"http://www.ncbi.nlm.nih.gov/pubmed/27718847",NULL,NULL,"2016","10","8","N. Engl. J. Med.","The New England journal of medicine","fully curated","138","Pembrolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1734,"EID1734","Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the survival of mice with CCNE1 overexpressing xenografts.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","D","Predictive","Supports","Sensitivity","N/A",24,2,NULL,"accepted",0,"evidence",1177,"Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.","Yang et al., 2015, Oncotarget",26204491,"http://www.ncbi.nlm.nih.gov/pubmed/26204491","true","PMC4673230","2015","8","28","Oncotarget","Oncotarget","fully curated","412","BMS-387032 (SNS-032)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1735,"EID1735","A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors",184,"Ovarian Serous Cystadenocarcinoma","Ovarian Serous Cystadenocarcinoma",5746,"http://www.disease-ontology.org/?id=DOID:5746","D","Predictive","Supports","Sensitivity","Somatic Mutation",187,4,"Combination","accepted",0,"evidence",1178,"Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.","Au-Yeung et al., 2016, Clin. Cancer Res.",27663592,"http://www.ncbi.nlm.nih.gov/pubmed/27663592",NULL,NULL,"2016","9","23","Clin. Cancer Res.","Clinical cancer research : an official journal of the American Association for Cancer Research","fully curated","410","Dinaciclib",NULL,"43","MK-2206",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1736,"EID1736","This small clinical (n=56) study suggests that patients with minor mutations of EGFR, like G719S, are likely to have a moderate response to Tyrosine kinase inhibitors like Gefitinib and Erlotinib. In this study 44 of 56 patients were treated with either gefitinib or erlotinib. 35 patients had a G719X mutation but the majority of these were G719S (20 with G719S, 9 with G719A, 3 with G719C).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Sensitivity","Somatic Mutation",134,3,"Substitutes","accepted",0,"evidence",1180,"Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).","Otsuka et al., 2015, Anticancer Res.",26124334,"http://www.ncbi.nlm.nih.gov/pubmed/26124334",NULL,NULL,"2015","7",NULL,"Anticancer Res.","Anticancer research","fully curated","14","Gefitinib",NULL,"15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1737,"EID1737","In a series of 33 patients with Peutz-Jeghers Syndrome, 17 mutations in STK11/LKB1 were observed in exons 1-8 (none in exon 9). 11 of these mutations were predicted to be truncating. These mutations occurred in 10/13 patients with familial PJS and 7/20 patients with sporadic PJS.",2138,"Peutz-Jeghers Syndrome","Peutz-Jeghers Syndrome",3852,"http://www.disease-ontology.org/?id=DOID:3852","B","Predisposing","Supports","Positive","Germline Mutation",485,3,NULL,"accepted",0,"evidence",1181,"Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome.","Lim et al., 2003, Br. J. Cancer",12865922,"http://www.ncbi.nlm.nih.gov/pubmed/12865922","true","PMC2394252","2003","7","21","Br. J. Cancer","British journal of cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1738,"EID1738","non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",694,NULL,"Combination","accepted",1,"evidence",1184,"Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.","Noeparast et al., 2016, Oncotarget",27577079,"http://www.ncbi.nlm.nih.gov/pubmed/27577079",NULL,NULL,"2016","8","26","Oncotarget","Oncotarget","fully curated","19","Trametinib",NULL,"22","Dabrafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1739,"EID1739","Treatment with tazemetostat , a small-molecule inhibitor of EZH2, results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX-positive, SMARCB1-deficient synovial sarcomas.",1310,"Synovial Sarcoma","Synovial Sarcoma",5485,"http://www.disease-ontology.org/?id=DOID:5485","D","Predictive","Supports","Sensitivity","N/A",695,2,NULL,"accepted",0,"evidence",1185,"Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.","Kawano et al., 2016, PLoS ONE",27391784,"http://www.ncbi.nlm.nih.gov/pubmed/27391784","true","PMC4938529","2016",NULL,NULL,"PLoS ONE","PloS one","fully curated","411","EPZ-6438",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1740,"EID1740","EPZ-6438 (Tazemetostat) induces apoptosis and differentiation specifically in SMARCB1-deleted malignant rhabdoid tumors (MRT) cells. This study compared in vitro EPZ-6438 treatment of four SMARCB1-deleted MRT cell lines to three control (wild-type) cell lines. These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and suggest treatment of these genetically defined cancers with EZH2 inhibitors.",834,"Rhabdoid Cancer","Rhabdoid Cancer",3672,"http://www.disease-ontology.org/?id=DOID:3672","D","Predictive","Supports","Sensitivity","Somatic Mutation",696,3,NULL,"accepted",0,"evidence",1186,"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.","Knutson et al., 2013, Proc. Natl. Acad. Sci. U.S.A.",23620515,"http://www.ncbi.nlm.nih.gov/pubmed/23620515","true","PMC3651445","2013","5","7","Proc. Natl. Acad. Sci. U.S.A.","Proceedings of the National Academy of Sciences of the United States of America","fully curated","411","EPZ-6438",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1741,"EID1741","A meta-analysis of 26 published studies including 8097 prostate cancer patients showed that, compared to patients with normal PTEN, patients with PTEN deletion exhibited a greater aggressive Gleason score (OR: 1.284, 95% CI = 1.145â€“1.439), pathological stage (OR: 1.628, 95% CI = 1.270â€“2.087), and risk for recurrence of prostate cancer (HR: 1.738, 95% CI = 1.264â€“2.390).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",213,4,NULL,"accepted",0,"evidence",1190,"The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis.","Gao et al., 2016, Biomed. Pharmacother.",27470558,"http://www.ncbi.nlm.nih.gov/pubmed/27470558",NULL,NULL,"2016","10",NULL,"Biomed. Pharmacother.","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1742,"EID1742","NF2 loss promotes oncogenic RAS-signaling via YAP-dependent transactivation of RAS and sensitizes to MEK inhibition. The authors demonstrate this in (A) isogenic lines derived from C643 cells (HRASG13R, NF2-WT) modified to stably express shNF2, (B) in set of 7 RAS-mutant thyroid cancer cell lines that differ in their NF2 expression levels, and (C) in a Hras-G12V/Nf2-null mouse model.",155,"Thyroid Carcinoma","Thyroid Carcinoma",3963,"http://www.disease-ontology.org/?id=DOID:3963","D","Predictive","Supports","Sensitivity","Somatic Mutation",697,4,NULL,"accepted",0,"evidence",1191,"NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.","Garcia-Rendueles et al., 2015, Cancer Discov",26359368,"http://www.ncbi.nlm.nih.gov/pubmed/26359368","true","PMC4642441","2015","11",NULL,"Cancer Discov","Cancer discovery","fully curated","413","AZD6244(Selumetinib)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1743,"EID1743","BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts",326,"Malignant Peripheral Nerve Sheath Tumor","Malignant Peripheral Nerve Sheath Tumor",5940,"http://www.disease-ontology.org/?id=DOID:5940","D","Predictive","Supports","Sensitivity","Somatic Mutation",698,3,NULL,"accepted",0,"evidence",1192,"BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.","Patel et al., 2014, Cell Rep",24373973,"http://www.ncbi.nlm.nih.gov/pubmed/24373973","true","PMC3904298","2014","1","16","Cell Rep","Cell reports","fully curated","414","JQ1 Compound",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1744,"EID1744","A genome wide association study (GWAS) meta-analysis of 13,265 cancer cases (colorectal cancer and endometrial cancer) and 40,245 controls found this variant to be associated with colorectal cancer (ORâ€‰=â€‰1.10, Pâ€‰=â€‰7.23â€‰Ã—â€‰10âˆ’9). The authors speculated that since this polymorphism, a missense variant in the gene SH2B3, is also associated with haematological and autoimmune disorders, it might influence cancer risk through its role in the immune response.",11,"Colorectal Cancer","Colorectal Cancer",9256,"http://www.disease-ontology.org/?id=DOID:9256","B","Predisposing","Supports","Positive","Germline Polymorphism",699,2,NULL,"accepted",0,"evidence",1193,"Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.","Cheng et al., 2015, Sci Rep",26621817,"http://www.ncbi.nlm.nih.gov/pubmed/26621817","true","PMC4664893","2015","12","1","Sci Rep","Scientific reports","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1745,"EID1745","KIF23 variant 1 was found to be expressed in the cDNA of tumor tissues from a large cohort of HCC patients of chinese descent via PCR. This expression was absent in the normal tissues of these patients for this isoform. The overall survival of this expression was evaluated using the kaplan-meier method with a log rank test. It was found that expression of KIF23 V1 was correlated with longer overall survival over a period of 5 years (p=.0052). This pattern was seen to a lesser degree over a period of 3 years (p=.1604). This observation was independent of gender, age, tumor size, or TNM stage.",196,"Hepatocellular Carcinoma","Hepatocellular Carcinoma",684,"http://www.disease-ontology.org/?id=DOID:684","B","Prognostic","Supports","Better Outcome","Somatic Mutation",700,3,NULL,"accepted",1,"evidence",1203,"Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.","Sun et al., 2015, BMC Cancer",26674738,"http://www.ncbi.nlm.nih.gov/pubmed/26674738","true","PMC4682286","2015","12","16","BMC Cancer","BMC cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1746,"EID1746","In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.",2132,"Urothelial Carcinoma","Urothelial Carcinoma",2671,"http://www.disease-ontology.org/?id=DOID:2671","B","Predictive","Supports","Sensitivity","Somatic Mutation",701,3,NULL,"accepted",0,"evidence",1208,"Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.","Choudhury et al., 2016, J. Clin. Oncol.",27044931,"http://www.ncbi.nlm.nih.gov/pubmed/27044931",NULL,NULL,"2016","6","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1747,"EID1747","In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.",2132,"Urothelial Carcinoma","Urothelial Carcinoma",2671,"http://www.disease-ontology.org/?id=DOID:2671","B","Predictive","Supports","Sensitivity","Somatic Mutation",702,3,NULL,"accepted",0,"evidence",1208,"Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.","Choudhury et al., 2016, J. Clin. Oncol.",27044931,"http://www.ncbi.nlm.nih.gov/pubmed/27044931",NULL,NULL,"2016","6","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1748,"EID1748","In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.",2132,"Urothelial Carcinoma","Urothelial Carcinoma",2671,"http://www.disease-ontology.org/?id=DOID:2671","B","Predictive","Supports","Sensitivity","Somatic Mutation",703,3,NULL,"accepted",0,"evidence",1208,"Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.","Choudhury et al., 2016, J. Clin. Oncol.",27044931,"http://www.ncbi.nlm.nih.gov/pubmed/27044931",NULL,NULL,"2016","6","20","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1749,"EID1749","Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. Patients without the V600E mutation had evidence of tumor regression.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",12,4,NULL,"accepted",0,"evidence",352,"Inhibition of mutated, activated BRAF in metastatic melanoma.","Flaherty et al., 2010, N. Engl. J. Med.",20818844,"http://www.ncbi.nlm.nih.gov/pubmed/20818844","true","PMC3724529","2010","8","26","N. Engl. J. Med.","The New England journal of medicine","fully curated","4","Vemurafenib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1750,"EID1750","Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study. 322 eligible patients (281 with the V600E mutation, 40 with the V600K mutation, and 1 with both mutations) in a 2:1 ratio to receive oral trametinib (2 mg once daily) or intravenous chemotherapy consisting of either dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter), at the discretion of the investigator, every 3 weeks. 
   The primary end point was progression-free survival; secondary end points included overall survival, overall response rate, duration of response, and safety. Treatment continued until disease progression, death, or withdrawal from the study
    In the intention-to-treat population, the median duration of progression-free survival was 4.8 months in the trametinib group as compared with 1.5 months in the chemotherapy group (hazard ratio for progression, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001).  The 6-month overall survival rate in the intention-to-treat population was 81% in the trametinib group and 67% in the chemotherapy group.",7,"Melanoma","Melanoma",1909,"http://www.disease-ontology.org/?id=DOID:1909","B","Predictive","Supports","Sensitivity","Somatic Mutation",17,3,NULL,"accepted",0,"evidence",1210,"Improved survival with MEK inhibition in BRAF-mutated melanoma.","Flaherty et al., 2012, N. Engl. J. Med.",22663011,"http://www.ncbi.nlm.nih.gov/pubmed/22663011",NULL,NULL,"2012","7","12","N. Engl. J. Med.","The New England journal of medicine","fully curated","19","Trametinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1751,"EID1751","GADD45A (1506T>C)  association with ovarian cancer was investigated with 258 ovarian cancer patients and 332 age matched healthy women as controls using sequence analysis. A statistically significant difference in the GADD454A (1506T>C) variant between the controls groups was found in correlation with an increased risk of ovarian cancer.  Presence of the GADD454A (1506T>C) variant was also found to have higher GADD34A mRNA expression, longer ovarian cancer relapse free survival and overall survival.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predisposing","Supports","Positive","Somatic Mutation",705,3,NULL,"accepted",2,"evidence",1211,"The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.","Yuan et al., 2015, PLoS ONE",26422378,"http://www.ncbi.nlm.nih.gov/pubmed/26422378","true","PMC4589388","2015",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1752,"EID1752","A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI).",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","B","Diagnostic","Supports","Positive","Somatic Mutation",706,4,NULL,"accepted",0,"evidence",1212,"Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12).","Turc-Carel et al., 1988, Cancer Genet. Cytogenet.",3163261,"http://www.ncbi.nlm.nih.gov/pubmed/3163261",NULL,NULL,"1988","6",NULL,"Cancer Genet. Cytogenet.","Cancer genetics and cytogenetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1753,"EID1753","The authors propose RT-PCR as a diagnostic test for Ewing sarcoma using FFPE materials.  Starting with 40 cases, intact RNA could be isolated from 6, and of these the EWS-FLI event was detected in 2 by nested PCR. Alternative diagnostic assays for this event are also considered.",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","B","Diagnostic","Supports","Positive","Somatic Mutation",706,2,NULL,"accepted",0,"evidence",1215,"Detection of t(11;22)(q24;q12) translocation of Ewing's sarcoma in paraffin embedded tissue by nested reverse transcription-polymerase chain reaction.","Park et al., 1998, J. Korean Med. Sci.",9741544,"http://www.ncbi.nlm.nih.gov/pubmed/9741544","true","PMC3054425","1998","8",NULL,"J. Korean Med. Sci.","Journal of Korean medical science","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1754,"EID1754","An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).  Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both.",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","B","Diagnostic","Supports","Positive","Somatic Mutation",706,3,NULL,"accepted",0,"evidence",1216,"Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors.","Bridge et al., 2006, Mod. Pathol.",16258512,"http://www.ncbi.nlm.nih.gov/pubmed/16258512",NULL,NULL,"2006","1",NULL,"Mod. Pathol.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1755,"EID1755","Non-invasive detection of multiple TMPRSS2:ERG fusion mutations in urine samples of  patients with prostate cancer. Rapid 60 minute screening  using DNA ligase and isothermal amplification to detect multiple fusion RNA events to 2 amol detection sensitivity from 30ng of RNA.  Screening method is an improvement over traditional ligase/pcr methods.  Possibility exists to modify probes for use in multiple gene detection of fusions found in other cancers.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Diagnostic","Supports","Positive","N/A",707,4,NULL,"rejected",0,"evidence",1217,"High-speed biosensing strategy for non-invasive profiling of multiple cancer fusion genes in urine.","Koo et al., 2016, Biosens Bioelectron",27865106,"http://www.ncbi.nlm.nih.gov/pubmed/27865106",NULL,NULL,"2016","11","12","Biosens Bioelectron","Biosensors & bioelectronics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1756,"EID1756","Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T  (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai.  Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T  which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","B","Prognostic","Supports","Better Outcome","Germline Mutation",258,4,NULL,"accepted",0,"evidence",1218,"MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.","Wu et al., 2016, Sci Rep",27819322,"http://www.ncbi.nlm.nih.gov/pubmed/27819322","true","PMC5098242","2016","11","7","Sci Rep","Scientific reports","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1757,"EID1757","Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T/T).",579,"Rectum Cancer","Rectum Cancer",1993,"http://www.disease-ontology.org/?id=DOID:1993","B","Predictive","Supports","Sensitivity",NULL,258,4,NULL,"accepted",0,"evidence",1221,"A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer.","Nikas et al., 2015, Am J Cancer Res",26693073,"http://www.ncbi.nlm.nih.gov/pubmed/26693073","true","PMC4656744","2015",NULL,NULL,"Am J Cancer Res","American journal of cancer research","fully curated","415","Fluorouracil, 5-FU, Carac, Efudex, Fluoroplex, Adrucil",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1758,"EID1758","De novo Alu element insertions were identified within the BRCA2 coding sequences in 3 out of 50 Portuguese families.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predisposing","Supports","Positive","Germline Mutation",708,4,NULL,"accepted",1,"evidence",1222,"De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes.","Teugels et al., 2005, Hum. Mutat.",16088935,"http://www.ncbi.nlm.nih.gov/pubmed/16088935",NULL,NULL,"2005","9",NULL,"Hum. Mutat.","Human mutation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1759,"EID1759","In Portuguese families",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Predisposing","Supports","N/A","Germline Mutation",709,NULL,NULL,"submitted",0,"evidence",1222,"De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes.","Teugels et al., 2005, Hum. Mutat.",16088935,"http://www.ncbi.nlm.nih.gov/pubmed/16088935",NULL,NULL,"2005","9",NULL,"Hum. Mutat.","Human mutation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1760,"EID1760","G84E (rs138213197) substitution in HBOX13 is associated with an increased risk for prostate cancer.  31% (49 out of 9012, n=2,595) carried the mutation, G84E was highly prevalent in patients with prostate cancer than those without. Evidence also supported a possible link between G84E with bladder cancer and leukemia. Patient family history indicated a history of prostate cancer with a first degree relative when compared to non carriers.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predisposing","Supports","Positive","Somatic Mutation",772,4,NULL,"accepted",1,"evidence",1224,"The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.","Beebe-Dimmer et al., 2015, Cancer Epidemiol. Biomarkers Prev.",26108461,"http://www.ncbi.nlm.nih.gov/pubmed/26108461","true","PMC4560608","2015","9",NULL,"Cancer Epidemiol. Biomarkers Prev.","Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1761,"EID1761","123 patients with Cowden or Cowden-like syndrome (from the IRB8458-PTEN series) and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KILLIN. 45 out of 123 patients (37%; 95% CI, 29%-45%) showed hypermethylation of the bidirectional promoter of PTEN and KILLIN. Individuals with KILLIN-promoter methylation had a 3-fold increased prevalence of breast cancer (35/42 vs 24/64; p<0.0001) over individuals with germline PTEN mutations.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predisposing","Supports","Positive","N/A",711,3,NULL,"submitted",0,"evidence",1225,"Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.","Bennett et al., 2010, JAMA",21177507,"http://www.ncbi.nlm.nih.gov/pubmed/21177507","true","PMC3655326","2010","12","22","JAMA","JAMA","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1762,"EID1762","123 patients with Cowden or Cowden-like syndrome (from the IRB8458-PTEN series) and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KILLIN. 45 out of 123 patients (37%; 95% CI, 29%-45%) showed hypermethylation of the bidirectional promoter of PTEN and KILLIN. Individuals with KILLIN-promoter methylation had a greater than 2-fold increase of kidney cancer (4/45 vs 6/155; p=0.004) over individuals with germline PTEN mutations.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","B","Predisposing","Supports","Positive","N/A",711,3,NULL,"submitted",0,"evidence",1225,"Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.","Bennett et al., 2010, JAMA",21177507,"http://www.ncbi.nlm.nih.gov/pubmed/21177507","true","PMC3655326","2010","12","22","JAMA","JAMA","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1763,"EID1763","D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","E","Predictive",NULL,"Resistance or Non-Response","Unknown",712,NULL,NULL,"submitted",1,"evidence",1227,"Epidermal growth factor receptor mutations in lung cancer.","Sharma et al., 2007, Nat. Rev. Cancer",17318210,"http://www.ncbi.nlm.nih.gov/pubmed/17318210",NULL,NULL,"2007","3",NULL,"Nat. Rev. Cancer","Nature reviews. Cancer","submitted","15","Erlotinib",NULL,"14","Gefitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1764,"EID1764","In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate. 95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal. Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients. Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients.",368,"Her2-receptor Positive Breast Cancer","Her2-receptor Positive Breast Cancer",60079,"http://www.disease-ontology.org/?id=DOID:0060079","B","Predictive","Supports","Sensitivity","Somatic Mutation",306,4,NULL,"accepted",0,"evidence",1229,"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.","Burris et al., 2011, J. Clin. Oncol.",21172893,"http://www.ncbi.nlm.nih.gov/pubmed/21172893",NULL,NULL,"2011","2","1","J. Clin. Oncol.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","partially curated","293","Trastuzumab Emtansine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1765,"EID1765","A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole.",369,"Her2-receptor Negative Breast Cancer","Her2-receptor Negative Breast Cancer",60080,"http://www.disease-ontology.org/?id=DOID:0060080","C","Predictive","Supports","Sensitivity","Somatic Mutation",554,3,"Combination","accepted",0,"evidence",1231,"Does CDKN2A loss predict palbociclib benefit?","Gao et al., 2015, Curr Oncol",26715889,"http://www.ncbi.nlm.nih.gov/pubmed/26715889","true","PMC4687677","2015","12",NULL,"Curr Oncol","Current oncology (Toronto, Ont.)","fully curated","375","Letrozole",NULL,"48","Palbociclib (PD0332991)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1766,"EID1766","case report",41,"Multiple Myeloma","Multiple Myeloma",9538,"http://www.disease-ontology.org/?id=DOID:9538","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",713,3,NULL,"submitted",0,"evidence",1232,"Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.","Egan et al., 2013, Br. J. Haematol.",23480694,"http://www.ncbi.nlm.nih.gov/pubmed/23480694","true","PMC3655110","2013","6",NULL,"Br. J. Haematol.","British journal of haematology","fully curated","417","Pomalidomide",NULL,"416","Lenalidomide",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1767,"EID1767","In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L.",28,"Estrogen-receptor Positive Breast Cancer","Estrogen-receptor Positive Breast Cancer",60075,"http://www.disease-ontology.org/?id=DOID:0060075","D","Predictive","Supports","Sensitivity","Somatic Mutation",267,3,NULL,"accepted",0,"evidence",1233,"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.","Gozgit et al., 2012, Mol. Cancer Ther.",22238366,"http://www.ncbi.nlm.nih.gov/pubmed/22238366",NULL,NULL,"2012","3",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1768,"EID1768",NULL,216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predisposing","Does Not Support","N/A","Somatic Mutation",714,3,NULL,"submitted",0,"evidence",1234,"Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex.","Qin et al., 2010, Hum. Genet.",20165957,"http://www.ncbi.nlm.nih.gov/pubmed/20165957","true","PMC2854849","2010","3",NULL,"Hum. Genet.","Human genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1769,"EID1769","Retrospective analysis of the Danish tumor bank. 43 patients with Peutz-Jeghers Syndrome were identified (clinical criteria + STK11 mutations). STK11 mutations included included eight nonsense mutations, five frameshift mutations, two splice site mutations, two large genomic rearrangements, and one missense mutation. The E33fs mutation (96delC) was among the identified ones.",2138,"Peutz-Jeghers Syndrome","Peutz-Jeghers Syndrome",3852,"http://www.disease-ontology.org/?id=DOID:3852","B","Predisposing","Supports","Positive","Germline Mutation",715,4,NULL,"submitted",1,"evidence",1235,"Disease pattern in Danish patients with Peutz-Jeghers syndrome.","Jelsig et al., 2016, Int J Colorectal Dis",26979979,"http://www.ncbi.nlm.nih.gov/pubmed/26979979",NULL,NULL,"2016","5",NULL,"Int J Colorectal Dis","International journal of colorectal disease","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1770,"EID1770","In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richterâ€™s transformation). 11/13 patients were deep sequenced for BTK and PLCG2. 9 patients were identified with BTK mutations (C481S in 8 patients). In 5 patients, C481S was the sole abnormality.",52,"Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",1040,"http://www.disease-ontology.org/?id=DOID:1040","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",168,4,NULL,"accepted",0,"evidence",1237,"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.","Maddocks et al., 2015, JAMA Oncol",26182309,"http://www.ncbi.nlm.nih.gov/pubmed/26182309","true","PMC4520535","2015","4",NULL,"JAMA Oncol","JAMA oncology","fully curated","227","Ibrutinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1771,"EID1771","In the sunitinib-sensitive adenosquamous NSCLC cell line, PDGFRA expression was associated with focal PFGRA gene amplification, which was similarly detected in a small fraction of squamous cell NSCLC primary tumor specimens. Moreover, in this NSCLC cell line, focal amplification of the gene encoding the PDGFR ligand PDGFC was also detected.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","D","Predictive","Supports","Sensitivity","Somatic Mutation",716,3,NULL,"submitted",0,"evidence",1238,"Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.","McDermott et al., 2009, Cancer Res.",19366796,"http://www.ncbi.nlm.nih.gov/pubmed/19366796","true","PMC2676215","2009","5","1","Cancer Res.","Cancer research","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1772,"EID1772","In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Germline Mutation",185,3,NULL,"accepted",0,"evidence",1239,"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.","Gelmon et al., 2011, Lancet Oncol.",21862407,"http://www.ncbi.nlm.nih.gov/pubmed/21862407",NULL,NULL,"2011","9",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1773,"EID1773","In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Germline Mutation",186,3,NULL,"accepted",0,"evidence",1239,"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.","Gelmon et al., 2011, Lancet Oncol.",21862407,"http://www.ncbi.nlm.nih.gov/pubmed/21862407",NULL,NULL,"2011","9",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1774,"EID1774","A patient with monoblastic myeloid sarcoma harbouring a PCR confirmed FIP1L1-PDGFRA rearrangement was treated with imatinib monotherapy. The patient demonstrated a durable response (10 wks) while on therapy which was reversed when the patient discontinued treatment. Imatinib therapy was subsequently restarted, with peripheral blood and BM analyses returning to normal after 4 weeks.",2081,"Myeloid Sarcoma","Myeloid Sarcoma",8683,"http://www.disease-ontology.org/?id=DOID:8683","C","Predictive","Supports","Sensitivity","Somatic Mutation",574,3,NULL,"accepted",0,"evidence",1240,"Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.","Srinivas et al., 2014, Br. J. Haematol.",24456122,"http://www.ncbi.nlm.nih.gov/pubmed/24456122",NULL,NULL,"2014","6",NULL,"Br. J. Haematol.","British journal of haematology","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1775,"EID1775","In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Resistance or Non-Response","Germline Mutation",185,3,NULL,"accepted",0,"evidence",1239,"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.","Gelmon et al., 2011, Lancet Oncol.",21862407,"http://www.ncbi.nlm.nih.gov/pubmed/21862407",NULL,NULL,"2011","9",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1776,"EID1776","In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Predictive","Supports","Resistance or Non-Response","Germline Mutation",186,3,NULL,"accepted",0,"evidence",1239,"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.","Gelmon et al., 2011, Lancet Oncol.",21862407,"http://www.ncbi.nlm.nih.gov/pubmed/21862407",NULL,NULL,"2011","9",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","42","Olaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1777,"EID1777","In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound.",2152,"Chronic Eosinophilic Leukemia","chronic eosinophilic leukemia",NULL,"http://www.disease-ontology.org/","D","Predictive","Supports","Sensitivity",NULL,574,3,NULL,"accepted",0,"evidence",1241,"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.","Sadovnik et al., 2014, Exp. Hematol.",24407160,"http://www.ncbi.nlm.nih.gov/pubmed/24407160","true","PMC4338611","2014","4",NULL,"Exp. Hematol.","Experimental hematology","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1778,"EID1778","Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3.",1297,"Myxoid Liposarcoma","Myxoid Liposarcoma",5363,"http://www.disease-ontology.org/?id=DOID:5363","C","Diagnostic","Supports","Positive","Somatic Mutation",717,3,NULL,"accepted",0,"evidence",1243,"Fusion of the EWS and CHOP genes in myxoid liposarcoma.","Panagopoulos et al., 1996, Oncogene",8637704,"http://www.ncbi.nlm.nih.gov/pubmed/8637704",NULL,NULL,"1996","2","1","Oncogene","Oncogene","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1779,"EID1779","In Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V. Strong inhibitory effects on both mutants were seen only with ponatinib.",2152,"Chronic Eosinophilic Leukemia","chronic eosinophilic leukemia",NULL,"http://www.disease-ontology.org/","D","Predictive","Supports","Sensitivity",NULL,577,3,NULL,"accepted",1,"evidence",1241,"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.","Sadovnik et al., 2014, Exp. Hematol.",24407160,"http://www.ncbi.nlm.nih.gov/pubmed/24407160","true","PMC4338611","2014","4",NULL,"Exp. Hematol.","Experimental hematology","fully curated","55","Ponatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1780,"EID1780",NULL,26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",718,4,NULL,"submitted",0,"evidence",1244,"Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.","Klughammer et al., 2016, J Thorac Oncol",26773740,"http://www.ncbi.nlm.nih.gov/pubmed/26773740",NULL,NULL,"2016","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1781,"EID1781","Treatment of the patient-derived 797 NMC cell line for 48 hours with JQ1 (500 nM)  provoked terminal differentiation which was accompanied by growth arrest and sustained inhibition of proliferation.  Non-BRD4-dependent cell lines including a squamous carcinoma cell line (TE10) failed to exhibit differentiation effects when treated with JQ1.",381,"NUT Midline Carcinoma","NUT Midline Carcinoma",60463,"http://www.disease-ontology.org/?id=DOID:0060463","D","Predictive","Supports","Sensitivity","Somatic Mutation",719,3,NULL,"accepted",0,"evidence",1246,"Selective inhibition of BET bromodomains.","Filippakopoulos et al., 2010, Nature",20871596,"http://www.ncbi.nlm.nih.gov/pubmed/20871596","true","PMC3010259","2010","12","23","Nature","Nature","fully curated","306","JQ1",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1782,"EID1782","Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor survival outcomes.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",720,3,NULL,"accepted",0,"evidence",1244,"Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.","Klughammer et al., 2016, J Thorac Oncol",26773740,"http://www.ncbi.nlm.nih.gov/pubmed/26773740",NULL,NULL,"2016","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1783,"EID1783","Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT.",12,"Inflammatory Myofibroblastic Tumor","Inflammatory Myofibroblastic Tumor",50905,"http://www.disease-ontology.org/?id=DOID:0050905","C","Diagnostic","Supports","Positive","Somatic Mutation",499,4,NULL,"accepted",0,"evidence",1245,"Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.","Griffin et al., 1999, Cancer Res.",10383129,"http://www.ncbi.nlm.nih.gov/pubmed/10383129",NULL,NULL,"1999","6","15","Cancer Res.","Cancer research","partially curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1784,"EID1784","Meta-analysis of 25 studies involving 13,629 women with tamoxifen treated breast cancer. The meta-analysis investigated the association between CYP2D6 genotypes and response to tamoxifen treatment (loss/reduced function vs. unchanged/increased function). The authors examine a prevailing hypothesis that individuals carrying a reduced function CYP2D6 allele have poorer outcomes due to less metabolism of tamoxifen to active metabolites. The study concludes that there is insufficient evidence to support use of CYP2D6 genotyping as a guide for tamoxifen use in breast cancer.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","B","Prognostic","Does Not Support","Poor Outcome","Germline Polymorphism",721,4,NULL,"accepted",0,"evidence",1248,"CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.","Lum et al., 2013, PLoS ONE",24098545,"http://www.ncbi.nlm.nih.gov/pubmed/24098545","true","PMC3788742","2013",NULL,NULL,"PLoS ONE","PloS one","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1785,"EID1785","The FUS-DDIT3 fusion is pathognomonic of myxoid liposarcomas.  It encompasses parts  of the FUS gene on l6pll at its 5â€™ end and the DDIT3 gene at 12q13 at its 3â€™ ends",1297,"Myxoid Liposarcoma","Myxoid Liposarcoma",5363,"http://www.disease-ontology.org/?id=DOID:5363","A","Diagnostic","Supports","Positive","Somatic Mutation",722,5,NULL,"accepted",0,"evidence",1249,"Cytogenetic findings in liposarcoma correlate with histopathologic subtypes.","Sreekantaiah et al., 1992, Cancer",1568170,"http://www.ncbi.nlm.nih.gov/pubmed/1568170",NULL,NULL,"1992","5","15","Cancer","Cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1786,"EID1786",NULL,26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",723,3,NULL,"submitted",0,"evidence",1244,"Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.","Klughammer et al., 2016, J Thorac Oncol",26773740,"http://www.ncbi.nlm.nih.gov/pubmed/26773740",NULL,NULL,"2016","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1787,"EID1787",NULL,26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","B","Predictive","Supports","Sensitivity","Somatic Mutation",724,3,NULL,"submitted",0,"evidence",1244,"Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.","Klughammer et al., 2016, J Thorac Oncol",26773740,"http://www.ncbi.nlm.nih.gov/pubmed/26773740",NULL,NULL,"2016","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1788,"EID1788","This variant identified in a case of endometrial cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2153,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",725,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1789,"EID1789","In retrospective analysis of clinical trials and case studies, most patients with EGFR exon 20 insertion mutations did not benefit from first-generation EGFR kinase inhibitors.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",726,3,NULL,"submitted",0,"evidence",1244,"Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.","Klughammer et al., 2016, J Thorac Oncol",26773740,"http://www.ncbi.nlm.nih.gov/pubmed/26773740",NULL,NULL,"2016","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1790,"EID1790","This variant identified in two patients was confirmed to be a somatic mutation in two patients (one endometrial cancer, one ovarian cancer) with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was confirmed in the case of ovarian cancer.",2154,"Lynch Syndrome (DOID:3883)","Lynch Syndrome (DOID:3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",727,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1791,"EID1791","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer",2155,"Lynch Syndrome (DOID:3883)","Lynch syndrome (DOID:3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",728,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1792,"EID1792","The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","A","Predictive","Supports","Adverse Response","Germline Polymorphism",729,5,NULL,"accepted",0,"evidence",1252,"Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.","Goey et al., 2016, J Clin Pharmacol",26313268,"http://www.ncbi.nlm.nih.gov/pubmed/26313268",NULL,NULL,"2016","4",NULL,"J Clin Pharmacol","Journal of clinical pharmacology","fully curated","419","Belinostat",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1793,"EID1793","This variant identified in a case of endometrial cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2153,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",730,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1794,"EID1794","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2157,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",731,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1795,"EID1795","In a phase 1 trial belinostat (400-800mg/m2/24h) was administered to 25 patients in combination with cisplatin and etoposide. Endpoints were associations between genotype of UGT1A1 and pharmacokinetics, toxicities and proteine lysine acetylation.
Belinostat AUC and t1/2 as well as thrombocytopenia was significantly increased in UGT1A1*60 carriers.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Supports","Adverse Response","Germline Polymorphism",732,4,NULL,"submitted",0,"evidence",1252,"Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.","Goey et al., 2016, J Clin Pharmacol",26313268,"http://www.ncbi.nlm.nih.gov/pubmed/26313268",NULL,NULL,"2016","4",NULL,"J Clin Pharmacol","Journal of clinical pharmacology","fully curated","419","Belinostat",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1796,"EID1796","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2158,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",733,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1797,"EID1797","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2159,"Lynch Syndrome (DOID:3883)","Lynch syndrome (DOID:3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",734,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1798,"EID1798","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was demonstrated.",2153,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",735,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1799,"EID1799","Although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Sensitivity","Somatic Mutation",736,3,NULL,"submitted",0,"evidence",1244,"Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.","Klughammer et al., 2016, J Thorac Oncol",26773740,"http://www.ncbi.nlm.nih.gov/pubmed/26773740",NULL,NULL,"2016","4",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","15","Erlotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1800,"EID1800","The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","A","Predictive","Supports","Adverse Response","Germline Polymorphism",737,5,"Substitutes","accepted",0,"evidence",1253,"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.","Caudle et al., 2013, Clin. Pharmacol. Ther.",23988873,"http://www.ncbi.nlm.nih.gov/pubmed/23988873","true","PMC3831181","2013","12",NULL,"Clin. Pharmacol. Ther.","Clinical pharmacology and therapeutics","fully curated","32","Capecitabine",NULL,"420","5-FU",NULL,"421","Tegafur",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1801,"EID1801","The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","A","Predictive","Supports","Adverse Response","Germline Polymorphism",738,5,"Substitutes","accepted",0,"evidence",1253,"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.","Caudle et al., 2013, Clin. Pharmacol. Ther.",23988873,"http://www.ncbi.nlm.nih.gov/pubmed/23988873","true","PMC3831181","2013","12",NULL,"Clin. Pharmacol. Ther.","Clinical pharmacology and therapeutics","fully curated","32","Capecitabine",NULL,"420","5-FU",NULL,"421","Tegafur",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1802,"EID1802","FOS was found fused  with 3 different genes in 3 cases of bone epithelioid hemangioma. The fusion partners were not recurrent, respectively MBNL1, VIM and a lincRNA.  The truncation of the FOS gene would result in the loss of the transactivation domain (TAD) in all three cases.",2161,"Bone Epithelioid Hemangioma","bone epithelioid hemangioma",6610,"http://www.disease-ontology.org/?id=DOID:6610","C","Diagnostic","Supports","Positive","Somatic Mutation",739,3,NULL,"submitted",0,"evidence",1254,"Fusion events lead to truncation of FOS in epithelioid hemangioma of bone.","van IJzendoorn et al., 2015, Genes Chromosomes Cancer",26173738,"http://www.ncbi.nlm.nih.gov/pubmed/26173738",NULL,NULL,"2015","9",NULL,"Genes Chromosomes Cancer","Genes, chromosomes & cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1803,"EID1803","The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","A","Predictive","Supports","Adverse Response","Germline Polymorphism",740,5,"Substitutes","accepted",0,"evidence",1253,"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.","Caudle et al., 2013, Clin. Pharmacol. Ther.",23988873,"http://www.ncbi.nlm.nih.gov/pubmed/23988873","true","PMC3831181","2013","12",NULL,"Clin. Pharmacol. Ther.","Clinical pharmacology and therapeutics","fully curated","421","Tegafur",NULL,"420","5-FU",NULL,"32","Capecitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL
1804,"EID1804","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was confirmed.",2162,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",741,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1805,"EID1805","Performed a systematic molecular analysis of 17 epithelioid hemangioendothelioma (EHE) and compared to 13 epithelioid hemangiomas, five epithelioid angiosarcomas, and four epithelioid sarcoma-like EHE. A FISH positional cloning strategy, and RT-PCR analysis identified WWTR1-CAMTA1 in all EHE cases and none of the other benign or malignant epithelioid vascular tumors examined.",2163,"Epithelioid Hemangioendothelioma","epithelioid hemangioendothelioma",NULL,"http://www.disease-ontology.org/","B","Diagnostic","Supports","Positive","Somatic Mutation",742,4,NULL,"accepted",0,"evidence",1255,"A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites.","Errani et al., 2011, Genes Chromosomes Cancer",21584898,"http://www.ncbi.nlm.nih.gov/pubmed/21584898","true","PMC3264678","2011","8",NULL,"Genes Chromosomes Cancer","Genes, chromosomes & cancer","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1806,"EID1806","This variant identified in three cases of colorectal cancer was confirmed to be a somatic mutation thereby indicating a lack of hereditary predisposition for cancer despite suspected Lynch Syndrome (sLS). LOH of the WT allele was demonstrated in 1/3 patients.",2153,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",743,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1807,"EID1807","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the wildtype allele was demonstrated.",2165,"Lynch Syndrome (DOID:3883)","Lynch syndrome (DOID:3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",744,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1808,"EID1808","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was demonstrated.",2166,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",745,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1809,"EID1809","In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 mutations.",26,"Lung Adenocarcinoma","Lung Adenocarcinoma",3910,"http://www.disease-ontology.org/?id=DOID:3910","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",726,3,NULL,"submitted",0,"evidence",1257,"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.","Yang et al., 2015, Lancet Oncol.",26051236,"http://www.ncbi.nlm.nih.gov/pubmed/26051236",NULL,NULL,"2015","7",NULL,"Lancet Oncol.","The Lancet. Oncology","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1810,"EID1810","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was demonstrated.",2167,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",746,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1811,"EID1811","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2168,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",747,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1812,"EID1812","This variant identified in a case of villous adenoma was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2169,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",748,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1813,"EID1813","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was demonstrated.",2170,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",749,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1814,"EID1814","This variant identified in two cases of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2153,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",750,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1815,"EID1815","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2172,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",751,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1816,"EID1816","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2173,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",752,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1817,"EID1817","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2174,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",753,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1818,"EID1818","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2175,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",754,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1819,"EID1819","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2176,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",755,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1820,"EID1820","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.  LOH of the WT allele was demonstrated.",2177,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",756,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1821,"EID1821","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was demonstrated.",2178,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",757,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1822,"EID1822","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was demonstrated.",2179,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",758,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1823,"EID1823","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2180,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",759,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1824,"EID1824","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was demonstrated.",2181,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",760,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1825,"EID1825","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2182,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",761,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1826,"EID1826","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. LOH of the WT allele was demonstrated.",2154,"Lynch Syndrome (DOID:3883)","Lynch Syndrome (DOID:3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",762,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1827,"EID1827","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. This patient had two pathogenic mutations in MSH2 (E28fs, K172*).",2154,"Lynch Syndrome (DOID:3883)","Lynch Syndrome (DOID:3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",763,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1828,"EID1828","In a 54 year old male patient with sporadic renal cell carcinoma, a c.163_164delGA causing a p.Glu55Gly Stop at 130 frameshift mutation was observed. Loss of heterozygosity analysis was non-informative.",160,"Renal Cell Carcinoma","Renal Cell Carcinoma",4450,"http://www.disease-ontology.org/?id=DOID:4450","C","Diagnostic","Supports","Positive","Somatic Mutation",764,3,NULL,"accepted",0,"evidence",1258,"Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.","Gallou et al., 1999, Hum. Mutat.",10408776,"http://www.ncbi.nlm.nih.gov/pubmed/10408776",NULL,NULL,"1999",NULL,NULL,"Hum. Mutat.","Human mutation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1829,"EID1829","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2186,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",765,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1830,"EID1830","This is a frameshift mutation that results in a stop at codon 66.  
Family 3682 in this publication, variant segregates with disease. 
VHL Type 1 disease is reported: CNS tumors, retinal angioma, renal cell carcinoma but no pheochromocytoma",2187,"Von Hippel-Lindau","Von Hippel-Lindau",NULL,"http://www.disease-ontology.org/","C","Predisposing","Supports","Uncertain Significance","Germline Mutation",766,3,NULL,"accepted",0,"evidence",1259,"Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.","Zbar et al., 1996, Hum. Mutat.",8956040,"http://www.ncbi.nlm.nih.gov/pubmed/8956040",NULL,NULL,"1996",NULL,NULL,"Hum. Mutat.","Human mutation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1831,"EID1831","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2188,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",767,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1832,"EID1832","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2189,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",768,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1833,"EID1833","This variant identified in a case of endometrial cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2190,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",769,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1834,"EID1834","This variant identified in a case of colorectal cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer. This patient had two pathogenic mutations in MSH2 (E28fs, K172*).",2191,"Lynch Syndrome (DOID:3883)","Lynch Syndrome (DOID:3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative",NULL,770,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1835,"EID1835","c.164insG causes a framehift and truncation allele. One family is described with this allele segregating with disease; 10 affected individuals: 2  patients with renal cell carcinoma, 3 with pheochromocytoma, 7 with retinal angioma, 3 with central nervous system hemangioma. ACMG evidence codes supported by this paper are possibly PVS1 and PP1.",2187,"Von Hippel-Lindau","Von Hippel-Lindau",NULL,"http://www.disease-ontology.org/","B","Predisposing","Supports","Uncertain Significance","Germline Mutation",771,4,NULL,"accepted",0,"evidence",1264,"Genotype-phenotype correlations in von Hippel-Lindau disease.","Ong et al., 2007, Hum. Mutat.",17024664,"http://www.ncbi.nlm.nih.gov/pubmed/17024664",NULL,NULL,"2007","2",NULL,"Hum. Mutat.","Human mutation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1836,"EID1836","Meta-analysis of prostate cancer with sixteen case-control studies including 50,048 cases and 123,211 controls.  In a random effect model the pooled OR (3.38 (95% CI: 2.45â€“4.66)) of the studies supported the link between HOXB13 G84E variant and a susceptibility to prostate cancer.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predisposing","Supports","Positive","Germline Mutation",772,4,NULL,"accepted",0,"evidence",1265,"Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.","Zhang et al., 2016, Oncotarget",27626483,"http://www.ncbi.nlm.nih.gov/pubmed/27626483",NULL,NULL,"2016","9","10","Oncotarget","Oncotarget","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1837,"EID1837","This variant identified in a case of endometrial cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2192,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",773,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1838,"EID1838","A patient harbouring a novel TNKS2â€“PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.",2152,"Chronic Eosinophilic Leukemia","chronic eosinophilic leukemia",NULL,"http://www.disease-ontology.org/","C","Predictive","Supports","Sensitivity","Somatic Mutation",774,3,NULL,"accepted",0,"evidence",1266,"Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.","Chalmers et al., 2015, Blood Cancer J",25658984,"http://www.ncbi.nlm.nih.gov/pubmed/25658984","true","PMC4349257","2015","2","6","Blood Cancer J","Blood cancer journal","fully curated","5","Imatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1839,"EID1839","This variant identified in a case of endometrial cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2193,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",775,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1840,"EID1840","This variant identified in a case of endometrial cancer was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (sLS) thereby indicating lack of hereditary predisposition for cancer.",2194,"Lynch Syndrome (DOID: 3883)","Lynch Syndrome (DOID: 3883)",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",776,3,NULL,"submitted",0,"evidence",1251,"Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.","Geurts-Giele et al., 2014, J. Pathol.",25111426,"http://www.ncbi.nlm.nih.gov/pubmed/25111426",NULL,NULL,"2014","12",NULL,"J. Pathol.","The Journal of pathology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1841,"EID1841","499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 rs4149056 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Supports","Adverse Response","Germline Polymorphism",777,3,NULL,"accepted",0,"evidence",1268,"Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.","Radtke et al., 2013, Blood",23652803,"http://www.ncbi.nlm.nih.gov/pubmed/23652803",NULL,NULL,"2013","6","27","Blood","Blood","fully curated","422","MTX",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1842,"EID1842","499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 RS2306283 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Supports","Adverse Response","Germline Polymorphism",778,3,NULL,"accepted",0,"evidence",1268,"Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.","Radtke et al., 2013, Blood",23652803,"http://www.ncbi.nlm.nih.gov/pubmed/23652803",NULL,NULL,"2013","6","27","Blood","Blood","fully curated","422","MTX",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1843,"EID1843","499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The TYMS rs34743033 tandem repeat polymorphism was the only significant predictor of stomatitis in a multiple regression model considering sex, age, MRD class, WBC, MTX AUC0-48h, and genotypes as independent variables (B = âˆ’0.48; 95% CI, âˆ’0.84, âˆ’0.12; R2 = 0.018; P = .009)",216,"Cancer","Cancer",162,"http://www.disease-ontology.org/?id=DOID:162","B","Predictive","Supports","Adverse Response","Germline Polymorphism",779,3,NULL,"accepted",0,"evidence",1268,"Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.","Radtke et al., 2013, Blood",23652803,"http://www.ncbi.nlm.nih.gov/pubmed/23652803",NULL,NULL,"2013","6","27","Blood","Blood","fully curated","422","MTX",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1844,"EID1844","Pericytoma with t(7;12) is a soft tissue tumor characterized by fusion of the ACTB and GLI genes through the translocation t(7;12)(p22;q13). In this study the genomic breakpoints of 5 cases were characterized.",2195,"Pericytoma","pericytoma",NULL,"http://www.disease-ontology.org/","B","Diagnostic","Supports","Positive","Somatic Mutation",780,3,NULL,"accepted",0,"evidence",1269,"Molecular genetic characterization of the genomic ACTB-GLI fusion in pericytoma with t(7;12).","DahlÃ©n et al., 2004, Biochem. Biophys. Res. Commun.",15555571,"http://www.ncbi.nlm.nih.gov/pubmed/15555571",NULL,NULL,"2004","12","24","Biochem. Biophys. Res. Commun.","Biochemical and biophysical research communications","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1845,"EID1845","Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC",2196,"NSCLC","NSCLC",NULL,"http://www.disease-ontology.org/","C","Diagnostic","Supports","Negative","Somatic Mutation",781,NULL,NULL,"submitted",0,"evidence",1267,"Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.","Umelo et al., 2016, Oncotarget",26689995,"http://www.ncbi.nlm.nih.gov/pubmed/26689995","true","PMC4823091","2016","1","19","Oncotarget","Oncotarget","submitted",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1846,"EID1846","Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%).",29,"Cholangiocarcinoma","Cholangiocarcinoma",4947,"http://www.disease-ontology.org/?id=DOID:4947","B","Diagnostic","Supports","Positive","Somatic Mutation",782,4,NULL,"accepted",0,"evidence",1270,"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.","Arai et al., 2014, Hepatology",24122810,"http://www.ncbi.nlm.nih.gov/pubmed/24122810",NULL,NULL,"2014","4",NULL,"Hepatology","Hepatology (Baltimore, Md.)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1847,"EID1847","Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%).",29,"Cholangiocarcinoma","Cholangiocarcinoma",4947,"http://www.disease-ontology.org/?id=DOID:4947","B","Diagnostic","Supports","Positive",NULL,783,4,NULL,"submitted",0,"evidence",1270,"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.","Arai et al., 2014, Hepatology",24122810,"http://www.ncbi.nlm.nih.gov/pubmed/24122810",NULL,NULL,"2014","4",NULL,"Hepatology","Hepatology (Baltimore, Md.)","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1848,"EID1848","This study analyses 45 new acute promyelocytic leukemia patients (22 male and 23 female). CDKN2B was found to be a negative prognostic biomarker for disease free survival (DFS). The 5-year DFS was 9.6% in methylated and 62.5% in unmethylated samples. While methylation also associated with young age, a multivariate analysis found CDKN2B methylation to be the only independent marker with significance (P=0.008) for DFS.",379,"Acute Promyelocytic Leukemia","Acute Promyelocytic Leukemia",60318,"http://www.disease-ontology.org/?id=DOID:0060318","B","Prognostic","Supports","Poor Outcome","Somatic Mutation",784,4,NULL,"submitted",0,"evidence",1271,"CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia.","Chim et al., 2006, Leukemia",16307009,"http://www.ncbi.nlm.nih.gov/pubmed/16307009",NULL,NULL,"2006","1",NULL,"Leukemia","Leukemia","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1849,"EID1849","Meta-analysis linking CHEK2 1100delC to a higher risk in prostate cancer ((OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) ).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predisposing","Supports","Positive","Germline Mutation",785,3,NULL,"rejected",0,"evidence",1272,"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.","Wang et al., 2015, Int J Clin Exp Med",26629066,"http://www.ncbi.nlm.nih.gov/pubmed/26629066","true","PMC4658955","2015",NULL,NULL,"Int J Clin Exp Med","International journal of clinical and experimental medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1850,"EID1850","Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predisposing","Supports","Positive","Germline Mutation",785,3,NULL,"submitted",0,"evidence",1272,"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.","Wang et al., 2015, Int J Clin Exp Med",26629066,"http://www.ncbi.nlm.nih.gov/pubmed/26629066","true","PMC4658955","2015",NULL,NULL,"Int J Clin Exp Med","International journal of clinical and experimental medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1851,"EID1851","Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.",29,"Cholangiocarcinoma","Cholangiocarcinoma",4947,"http://www.disease-ontology.org/?id=DOID:4947","D","Predictive","Supports","Sensitivity","Somatic Mutation",782,3,NULL,"accepted",0,"evidence",1270,"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.","Arai et al., 2014, Hepatology",24122810,"http://www.ncbi.nlm.nih.gov/pubmed/24122810",NULL,NULL,"2014","4",NULL,"Hepatology","Hepatology (Baltimore, Md.)","fully curated","36","PD173074",NULL,"151","BGJ398",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1852,"EID1852","Meta-analysis linking CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00).",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predisposing","Supports","Positive","Germline Mutation",787,3,NULL,"submitted",0,"evidence",1272,"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.","Wang et al., 2015, Int J Clin Exp Med",26629066,"http://www.ncbi.nlm.nih.gov/pubmed/26629066","true","PMC4658955","2015",NULL,NULL,"Int J Clin Exp Med","International journal of clinical and experimental medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1853,"EID1853","Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.",29,"Cholangiocarcinoma","Cholangiocarcinoma",4947,"http://www.disease-ontology.org/?id=DOID:4947","D","Predictive","Supports","Sensitivity","Somatic Mutation",783,3,NULL,"submitted",0,"evidence",1270,"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.","Arai et al., 2014, Hepatology",24122810,"http://www.ncbi.nlm.nih.gov/pubmed/24122810",NULL,NULL,"2014","4",NULL,"Hepatology","Hepatology (Baltimore, Md.)","fully curated","151","BGJ398",NULL,"36","PD173074",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1854,"EID1854","Meta-analysis of eight studies of CHECK2 and prostate cancer showing that the  IVS2+1G>A mutation is irrelevant as a predictor of prostate cancer.",46,"Prostate Cancer","Prostate Cancer",10283,"http://www.disease-ontology.org/?id=DOID:10283","B","Predisposing","Does Not Support","Positive","Germline Mutation",788,3,NULL,"submitted",0,"evidence",1272,"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.","Wang et al., 2015, Int J Clin Exp Med",26629066,"http://www.ncbi.nlm.nih.gov/pubmed/26629066","true","PMC4658955","2015",NULL,NULL,"Int J Clin Exp Med","International journal of clinical and experimental medicine","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1855,"EID1855","c.165insG
Frameshift
This is another family, with a different genetic background (Chinese) with the same mutation and VHL disease. Affected individuals retinal angioma and central nervous",2197,"Von Hippel-Lindau","Von Hippel-Lindau",NULL,"http://www.disease-ontology.org/","B","Diagnostic","Supports","Positive","Germline Mutation",771,5,NULL,"rejected",0,"evidence",1264,"Genotype-phenotype correlations in von Hippel-Lindau disease.","Ong et al., 2007, Hum. Mutat.",17024664,"http://www.ncbi.nlm.nih.gov/pubmed/17024664",NULL,NULL,"2007","2",NULL,"Hum. Mutat.","Human mutation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1856,"EID1856","Case report of complete response to IGF1-R antibody, with or without mTOR inhibitor tensirolimus in Ewing Sarcoma patients with germline PTPRD mutations.",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","C","Predictive","Supports","Sensitivity","Germline Mutation",792,4,NULL,"submitted",0,"evidence",1276,"Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.","Jiang et al., 2013, Oncotarget",23800680,"http://www.ncbi.nlm.nih.gov/pubmed/23800680","true","PMC3757245","2013","6",NULL,"Oncotarget","Oncotarget","fully curated","423","Cixutumumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1857,"EID1857","c.165insA results in a Ala56Gly frameshift-Stop at 131
This is family 146 in the publication.
VHL: Phenotype is not described in detail.",2198,"Von Hippel-Lindau","von Hippel-Lindau",NULL,"http://www.disease-ontology.org/","B","Diagnostic","Supports","Positive","Germline Mutation",793,3,NULL,"submitted",0,"evidence",1277,"Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours.","Crossey et al., 1994, Hum. Genet.",8270255,"http://www.ncbi.nlm.nih.gov/pubmed/8270255",NULL,NULL,"1994","1",NULL,"Hum. Genet.","Human genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1858,"EID1858","c.165G>A results in synonymous change Glu55Glu, however this causes a demonstrated splice defect and loss-of-function.
This is family V5 in the paper.
VHL Type 1 (no phechromocytoma)",2187,"Von Hippel-Lindau","Von Hippel-Lindau",NULL,"http://www.disease-ontology.org/","B","Diagnostic","Supports","Positive","Germline Mutation",794,4,NULL,"accepted",1,"evidence",1278,"Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.","Olschwang et al., 1998, Hum. Mutat.",9829912,"http://www.ncbi.nlm.nih.gov/pubmed/9829912",NULL,NULL,"1998",NULL,NULL,"Hum. Mutat.","Human mutation","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1859,"EID1859","The mRNA expression level of RRM1 was analyzed by RT-PCR in 8 human pancreatic cancer cell lines. Expression levels of RRM1 progressively increased during the development of gemcitabine resistance.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","D","Predictive","Supports","Resistance or Non-Response","N/A",795,2,NULL,"accepted",1,"evidence",1279,"Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.","Nakano et al., 2007, Br. J. Cancer",17224927,"http://www.ncbi.nlm.nih.gov/pubmed/17224927","true","PMC2360025","2007","2","12","Br. J. Cancer","British journal of cancer","fully curated","85","Gemcitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1860,"EID1860","The mRNA expression level of RRM2 was analyzed by RT-PCR in 8 human pancreatic cancer cell lines. Expression levels of RRM2 progressively increased during the development of gemcitabine resistance.",556,"Pancreatic Cancer","Pancreatic Cancer",1793,"http://www.disease-ontology.org/?id=DOID:1793","D","Predictive","Supports","Resistance or Non-Response","N/A",796,2,NULL,"submitted",0,"evidence",1279,"Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.","Nakano et al., 2007, Br. J. Cancer",17224927,"http://www.ncbi.nlm.nih.gov/pubmed/17224927","true","PMC2360025","2007","2","12","Br. J. Cancer","British journal of cancer","fully curated","424","17224927",NULL,"85","Gemcitabine",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1861,"EID1861","Case report of a patient with glioblastoma multiforme and POLE germline mutation. The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasis. An objective radiographic response was noted in the intracranial lesion. A high neoantigen load was identified.",19,"Glioblastoma Multiforme","Glioblastoma Multiforme",3068,"http://www.disease-ontology.org/?id=DOID:3068","C","Predictive","Supports","Sensitivity","Germline Mutation",797,3,NULL,"accepted",0,"evidence",1280,"Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.","Johanns et al., 2016, Cancer Discov",27683556,"http://www.ncbi.nlm.nih.gov/pubmed/27683556","true","PMC5140283","2016","11",NULL,"Cancer Discov","Cancer discovery","partially curated","138","Pembrolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1862,"EID1862","Case report of a patient with endometrial cancer and exceptional response to pembrolizumab. POLE mutations: V411L, R114* were identified in the primary tumor as well as a resected lymph node metastasis. The tumor harbored a high mutational load as assessed by panel sequencing. TCGA analysis revealed an association between POLE mutations and high mutational load.",108,"Endometrial Cancer","Endometrial Cancer",1380,"http://www.disease-ontology.org/?id=DOID:1380","C","Predictive","Supports","Sensitivity","Somatic Mutation",797,3,NULL,"submitted",0,"evidence",1281,"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.","Mehnert et al., 2016, J. Clin. Invest.",27159395,"http://www.ncbi.nlm.nih.gov/pubmed/27159395","true","PMC4887167","2016","6","1","J. Clin. Invest.","The Journal of clinical investigation","fully curated","138","Pembrolizumab",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1863,"EID1863","Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",34,4,NULL,"accepted",0,"evidence",1282,"Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.","Sun et al., 2013, Lung Cancer",24035188,"http://www.ncbi.nlm.nih.gov/pubmed/24035188",NULL,NULL,"2013","11",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1864,"EID1864","Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined MET (savolitinib) and EGFR (osimertinib) inhibition wand responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",798,4,NULL,"submitted",0,"evidence",1283,"Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.","Bahcall et al., 2016, Cancer Discov",27694386,"http://www.ncbi.nlm.nih.gov/pubmed/27694386","true","PMC5140694","2016","12",NULL,"Cancer Discov","Cancer discovery","fully curated","144","Cabozantinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1865,"EID1865","Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined MET (savolitinib) and EGFR (osimertinib) inhibition wand responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",798,4,NULL,"submitted",0,"evidence",1283,"Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.","Bahcall et al., 2016, Cancer Discov",27694386,"http://www.ncbi.nlm.nih.gov/pubmed/27694386","true","PMC5140694","2016","12",NULL,"Cancer Discov","Cancer discovery","fully curated","425","Savolitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1866,"EID1866","Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds ratio 5.58 compared to WT, p=.038). Kaplan-Meier survival analysis revealed patients with RB1 mutations exhibited better overall survival (p = .04, Odds Ratio CI = 1.1-28.2).",343,"Small Cell Carcinoma","Small Cell Carcinoma",50685,"http://www.disease-ontology.org/?id=DOID:0050685","B","Predictive","Supports","Sensitivity","Somatic Mutation",799,2,NULL,"submitted",0,"evidence",1285,"Clinical correlation of extensive-stage small-cell lung cancer genomics.","Dowlati et al., 2016, Ann. Oncol.",26802149,"http://www.ncbi.nlm.nih.gov/pubmed/26802149","true","PMC4803453","2016","4",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology","fully curated","199","Chemotherapy",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1867,"EID1867","Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","A","Predictive","Supports","Sensitivity","Somatic Mutation",34,5,NULL,"accepted",0,"evidence",1286,"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.","Mok et al., 2016, N. Engl. J. Med.",27959700,"http://www.ncbi.nlm.nih.gov/pubmed/27959700",NULL,NULL,"2016","12","6","N. Engl. J. Med.","The New England journal of medicine","fully curated","187","Osimertinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1868,"EID1868","1378 cases of NSCLC were screened. One patient (frequency 0.1%) with NTRK1 gene rearrangement treated with entrectinib in a phase 1 study. The patient had resolution of prior dyspnea and pain within 3 weeks. CT scans showed a partial response and complete resolution of brain metastases. The patient has continued treatment for over 6 months with ongoing PR.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",800,3,NULL,"submitted",0,"evidence",1288,"Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.","Farago et al., 2015, J Thorac Oncol",26565381,"http://www.ncbi.nlm.nih.gov/pubmed/26565381","true","PMC4643748","2015","12",NULL,"J Thorac Oncol","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","fully curated","426","Entrectinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1869,"EID1869","Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Predictive","Supports","Sensitivity","Somatic Mutation",801,3,NULL,"accepted",2,"evidence",1289,"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).","Drilon et al., 2016, Ann. Oncol.",26884591,"http://www.ncbi.nlm.nih.gov/pubmed/26884591","true","PMC4843186","2016","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology","fully curated","426","Entrectinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1870,"EID1870","Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after18 weeks.
The patient was subsequently treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Predictive","Does Not Support","Sensitivity","Somatic Mutation",801,2,NULL,"accepted",1,"evidence",1289,"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).","Drilon et al., 2016, Ann. Oncol.",26884591,"http://www.ncbi.nlm.nih.gov/pubmed/26884591","true","PMC4843186","2016","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology","fully curated","12","Crizotinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1871,"EID1871","A pedigree of 48 individuals with multiple instances of bleeding and platelet disorders and 8 cases of leukemia showed an A>G substitution in RUNX1 exon 3 which segregated with Familial Platelet Disorder and Acute Myeloid Leukemia. The mutation was not present in 188 unrelated control chromosomes. Functional assay suggested the mutant RUNX1 transcription factor had impaired DNA binding.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","C","Predisposing","Supports","Positive","Germline Mutation",802,4,NULL,"submitted",0,"evidence",1290,"In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.","Michaud et al., 2002, Blood",11830488,"http://www.ncbi.nlm.nih.gov/pubmed/11830488",NULL,NULL,"2002","2","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1872,"EID1872","A pedigree (Pedigree number 3) with 24 members with multiple instances of bleeding disorder and three cases of familial leukemia showed a C>A substitution in exon 7B of the transcription factor RUNX1.  This mutation resulted in a nonsense mutation, and the mutation segregated with familial platelet disorder and acute myeloid leukemia in the pedigree.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","C","Predisposing","Supports","Positive","Germline Mutation",803,3,NULL,"submitted",0,"evidence",1290,"In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.","Michaud et al., 2002, Blood",11830488,"http://www.ncbi.nlm.nih.gov/pubmed/11830488",NULL,NULL,"2002","2","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1873,"EID1873","A pedigree (Pedigree number 2) with familial platelet disorder and acute myeloid leukemia (FPD/AML) was studied and a one-base deletion was found in RUNX1 splice donor site. This resulted in use of a cryptic donor splice site and a novel transcript with frameshift, 41 novel amino acids and termination at codon 177. This mutation segregated with FDP/AML and was not found in 184 unrelated control chromosomes.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","C","Predisposing","Supports","Positive","Germline Mutation",804,4,NULL,"submitted",0,"evidence",1290,"In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.","Michaud et al., 2002, Blood",11830488,"http://www.ncbi.nlm.nih.gov/pubmed/11830488",NULL,NULL,"2002","2","15","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1874,"EID1874","Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.  A NTRK3 exon 16 G623R (c.1867G>A) mutation was identified in the progressive tumor. Cell line and structural models revealed that this mutation conferred relative resistance to entrectinib.",22,"Breast Cancer","Breast Cancer",1612,"http://www.disease-ontology.org/?id=DOID:1612","C","Predictive","Supports","Resistance or Non-Response","Somatic Mutation",805,4,NULL,"accepted",0,"evidence",1289,"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).","Drilon et al., 2016, Ann. Oncol.",26884591,"http://www.ncbi.nlm.nih.gov/pubmed/26884591","true","PMC4843186","2016","5",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology","fully curated","426","Entrectinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1875,"EID1875","In a pedigree with familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) spanning three generations, five members of generation II were sequenced at exons 3, 4 and 5 of the RUNX1 (or CBFA2) gene and the D198Y mutation (in the DNA binding RUNT domain) was found in 3/5 of the individuals with FPD/AML but not in 2/5 without FPD/AML. The mutation was not found in 108 control subjects.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","C","Predisposing","Supports","Positive","Germline Mutation",806,3,NULL,"submitted",0,"evidence",1292,"A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies.","Buijs et al., 2001, Blood",11675361,"http://www.ncbi.nlm.nih.gov/pubmed/11675361",NULL,NULL,"2001","11","1","Blood","Blood","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1876,"EID1876","A pedigree of 3 generations and 8 individuals with familial platelet disease with propensity to acute myeloid leukemia (FPD/AML) was assessed for mutation in RUNX1 exons 3, 4, 5 and 6. Mutation was found in DNA binding RUNT domain at amino acid 107 from alanine to proline. This mutation was found in 5/8 individuals with FPD/AML but not in 3/8 unaffected individuals as well as 10 unrelated control samples.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","C","Predisposing","Supports","Positive","Germline Mutation",807,5,NULL,"submitted",0,"evidence",1294,"A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia.","Walker et al., 2002, Br. J. Haematol.",12060124,"http://www.ncbi.nlm.nih.gov/pubmed/12060124",NULL,NULL,"2002","6",NULL,"Br. J. Haematol.","British journal of haematology","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1877,"EID1877","Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells.  The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months.",2132,"Urothelial Carcinoma","Urothelial Carcinoma",2671,"http://www.disease-ontology.org/?id=DOID:2671","C","Predictive","Supports","Sensitivity","Somatic Mutation",808,3,"Combination","submitted",0,"evidence",1304,"Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.","Castro et al., 2015, J Immunother Cancer",26674132,"http://www.ncbi.nlm.nih.gov/pubmed/26674132","true","PMC4678532","2015",NULL,NULL,"J Immunother Cancer","Journal for immunotherapy of cancer","fully curated","428","MEDI0680",NULL,"427","MEDI4736",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1878,"EID1878","Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells. The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months.",2132,"Urothelial Carcinoma","Urothelial Carcinoma",2671,"http://www.disease-ontology.org/?id=DOID:2671","C","Predictive","Supports","Sensitivity",NULL,809,3,"Combination","submitted",0,"evidence",1304,"Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.","Castro et al., 2015, J Immunother Cancer",26674132,"http://www.ncbi.nlm.nih.gov/pubmed/26674132","true","PMC4678532","2015",NULL,NULL,"J Immunother Cancer","Journal for immunotherapy of cancer","fully curated","428","MEDI0680",NULL,"427","MEDI4736",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1879,"EID1879","A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth.",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","D","Predictive","Supports","Sensitivity","Somatic Mutation",554,2,"Substitutes","accepted",0,"evidence",1305,"Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.","Murakami et al., 2016, Oncotarget",27286459,"http://www.ncbi.nlm.nih.gov/pubmed/27286459",NULL,NULL,"2016","7","26","Oncotarget","Oncotarget","fully curated","430","Linsitinib",NULL,"429","Palbociclib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1880,"EID1880","A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin.",135,"Bone Ewing's Sarcoma","Bone Ewing's Sarcoma",3368,"http://www.disease-ontology.org/?id=DOID:3368","D","Predictive","Supports","Sensitivity","N/A",555,2,"Substitutes","submitted",0,"evidence",1305,"Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.","Murakami et al., 2016, Oncotarget",27286459,"http://www.ncbi.nlm.nih.gov/pubmed/27286459",NULL,NULL,"2016","7","26","Oncotarget","Oncotarget","fully curated","430","Linsitinib",NULL,"429","Palbociclib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1881,"EID1881","An imatinib-resistant cell line, DFSP105, was established from a dermatofibrosarcoma protuberans which had progressed to a high-grade fibrosarcomatous DFSP. The disease-associated PDGFB-COL1A1 fusion was consistent with the most common form, a supernumerary ring chromosome. Genetically characterization of the cell line with a SNP array identified a homozygous CDKN2A/B deletion. Treatment of this cell line with CDK4/6 inhibitor palbociclib led to growth inhibition and reduced RB1 phosphorylation in vitro and in-vivo.",142,"Dermatofibrosarcoma Protuberans","Dermatofibrosarcoma Protuberans",3507,"http://www.disease-ontology.org/?id=DOID:3507","D","Predictive","Supports","Sensitivity","N/A",554,2,NULL,"accepted",1,"evidence",1306,"CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.","Eilers et al., 2015, Mol. Cancer Ther.",25852058,"http://www.ncbi.nlm.nih.gov/pubmed/25852058","true","PMC4458458","2015","6",NULL,"Mol. Cancer Ther.","Molecular cancer therapeutics","fully curated","429","Palbociclib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1882,"EID1882","A 2 year old male presented with easy bruising and bleeding. At 6 years old he was diagnosed with AML. The patients mother showed mile thrombocytopenia. Sequencing of RUNX1 exons 3-6 revealed an 8 bp deletion which was hypothesized to result in a null allele. The mutation was found in the mother and son. The patient's maternal grandparents were haematologicaly  normal.",3,"Acute Myeloid Leukemia","Acute Myeloid Leukemia",9119,"http://www.disease-ontology.org/?id=DOID:9119","C","Predisposing","Supports","Positive","Germline Mutation",810,2,NULL,"submitted",0,"evidence",1310,"Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions.","BÃ©ri-Dexheimer et al., 2008, Eur. J. Hum. Genet.",18478040,"http://www.ncbi.nlm.nih.gov/pubmed/18478040",NULL,NULL,"2008","8",NULL,"Eur. J. Hum. Genet.","European journal of human genetics : EJHG","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1883,"EID1883","Hematologic deficiencies and cancers were found to segregate in a dominant negative fashion with 5 genes discovered by exome sequencing of 5 members of a 10 member pedigree over three generations. Only transcription factor ETV6 mutation Arg399Cys (c.1195C>T) was then found in individuals not affected by hematological disease or hematological cancers. In vitro characterization of the ETV6 mutation showed reduction of nuclear localization in comparison to wild type and mutant ETV6 impaired hematopoietic stem cell proliferation.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","C","Predisposing","Supports","Positive","Germline Mutation",811,4,NULL,"submitted",0,"evidence",1315,"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.","Zhang et al., 2015, Nat. Genet.",25581430,"http://www.ncbi.nlm.nih.gov/pubmed/25581430","true","PMC4540357","2015","2",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1884,"EID1884","13 members of a larger pedigree with some affected by thrombocytopenia and propensity to hematological cander were characterized with targeted sequencing of transcriptional repressor ETV6 and 84 other genes. ETV6 mutation Arg369Gln, or c.1106G>A segregated in a pattern consistent with a dominant transmission of thrombocytopenia. Thrombocytopenia associated RUNX1, CEBPA, GATA2 were not mutated. One positive family member developed CMML, and another colon cancer. The mutation abrogated ETV6 DNA binding in gel-shift assay, and impaired hematopoietic stem cell proliferation was seen in ETV6 R369Q mutant cells.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","C","Predisposing","Supports","Positive",NULL,812,4,NULL,"submitted",0,"evidence",1315,"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.","Zhang et al., 2015, Nat. Genet.",25581430,"http://www.ncbi.nlm.nih.gov/pubmed/25581430","true","PMC4540357","2015","2",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1885,"EID1885","3 members of a small four member pedigree with thrombocytopenia and tendency for hematologic cancer were characterized with an 85 gene panel. Thrombocytopenia associated RUNX1, CEBPA and GATA2 were not mutated. ETV6 mutation Pro214Leu (c.641C>T) segregated consistent with a dominant thrombocytopenia transmission pattern. The mutation was not found in Exome Variant Server or the 1000 genomes project. ETV6 P214L strongly reduced ETV6 nuclear localization and also reduced hematopoietic stem cell proliferation in mutant cells.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","C","Predisposing","Supports","Positive","Germline Mutation",813,3,NULL,"submitted",0,"evidence",1315,"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.","Zhang et al., 2015, Nat. Genet.",25581430,"http://www.ncbi.nlm.nih.gov/pubmed/25581430","true","PMC4540357","2015","2",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1886,"EID1886","Two family pedigrees (one family with three generations and a small 4 member family spanning two generations) are presented. Exome sequencing was performed with 8 individuals from the first family, and sanger sequencing of ETV6 was performed on the second family. In the first family exome sequencing revealed ETV6 mutation c.641C>T or P214L, which segregated completely with thrombocytopenia. Two affected members of this family developed ALL. In the second family, this mutation was found via sanger sequencing. The mutation segregated with hematological deficiencies, where one affected member also had ALL. The variant was not found in 1000 genomes or dbSNP databases. In vitro experiments indicated reduced nuclear localization of ETV6 P214L compared to wild type ETV6 in cells.",43,"Acute Lymphocytic Leukemia","Acute Lymphocytic Leukemia",9952,"http://www.disease-ontology.org/?id=DOID:9952","C","Predisposing","Supports","Positive","Germline Mutation",813,4,NULL,"submitted",0,"evidence",1316,"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.","Noetzli et al., 2015, Nat. Genet.",25807284,"http://www.ncbi.nlm.nih.gov/pubmed/25807284","true","PMC4631613","2015","5",NULL,"Nat. Genet.","Nature genetics","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1887,"EID1887","Eight members of larger pedigree spanning four generations with inherited hematological cancers were sequenced with whole exome sequencing or sanger sequencing of DDX41 exons 5 and 6. A mutation c.490C>T or R164W was found in 5/5 members with Non Hodkin's lymphoma, Hodgkin lymphoma, or multiple myeloma but not in 3/3 unaffected individuals. The site of mutation is reported to potentially be important for DDX41 helicase activity.",217,"Hematologic Cancer","Hematologic Cancer",2531,"http://www.disease-ontology.org/?id=DOID:2531","C","Predisposing","Supports","Positive","Germline Mutation",814,3,NULL,"accepted",0,"evidence",1323,"Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.","Lewinsohn et al., 2016, Blood",26712909,"http://www.ncbi.nlm.nih.gov/pubmed/26712909","true","PMC4968341","2016","2","25","Blood","Blood","partially curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1888,"EID1888","A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",815,3,NULL,"submitted",0,"evidence",661,"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.","De GrÃ¨ve et al., 2012, Lung Cancer",22325357,"http://www.ncbi.nlm.nih.gov/pubmed/22325357",NULL,NULL,"2012","4",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1889,"EID1889","A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",816,3,NULL,"submitted",0,"evidence",661,"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.","De GrÃ¨ve et al., 2012, Lung Cancer",22325357,"http://www.ncbi.nlm.nih.gov/pubmed/22325357",NULL,NULL,"2012","4",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1890,"EID1890","A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",817,3,NULL,"submitted",0,"evidence",661,"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.","De GrÃ¨ve et al., 2012, Lung Cancer",22325357,"http://www.ncbi.nlm.nih.gov/pubmed/22325357",NULL,NULL,"2012","4",NULL,"Lung Cancer","Lung cancer (Amsterdam, Netherlands)","fully curated","146","Afatinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1891,"EID1891","Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Does Not Support","Sensitivity","N/A",306,3,NULL,"accepted",0,"evidence",729,"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.","Kris et al., 2015, Ann. Oncol.",25899785,"http://www.ncbi.nlm.nih.gov/pubmed/25899785",NULL,NULL,"2015","7",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","44","Dacomitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1892,"EID1892","Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Two patients were identified with identical p.G778_P780dup mutations (p. P780_Y781insGSP, c. 2339_2340ins GGCTCCCCA). Both had a confirmed partial response lasting 11 and 14 months.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",817,3,NULL,"submitted",0,"evidence",729,"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.","Kris et al., 2015, Ann. Oncol.",25899785,"http://www.ncbi.nlm.nih.gov/pubmed/25899785",NULL,NULL,"2015","7",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","44","Dacomitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1893,"EID1893","Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Thirteen tumors harbored identical 12 base pair exon 20 insertions [A775_G776insYVMA, alternative nomenclature p.Y772_A775dup(c.2313_2324dup)]. No partial responses were found in this subgroup even though some were on study treatment for >2years.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","B","Predictive","Does Not Support","Sensitivity","Somatic Mutation",815,1,NULL,"submitted",0,"evidence",729,"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.","Kris et al., 2015, Ann. Oncol.",25899785,"http://www.ncbi.nlm.nih.gov/pubmed/25899785",NULL,NULL,"2015","7",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","44","Dacomitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1894,"EID1894","Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. One patient was found to harbor an Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response.",8,"Non-small Cell Lung Carcinoma","Non-small Cell Lung Carcinoma",3908,"http://www.disease-ontology.org/?id=DOID:3908","C","Predictive","Supports","Sensitivity","Somatic Mutation",818,3,NULL,"submitted",0,"evidence",729,"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.","Kris et al., 2015, Ann. Oncol.",25899785,"http://www.ncbi.nlm.nih.gov/pubmed/25899785",NULL,NULL,"2015","7",NULL,"Ann. Oncol.","Annals of oncology : official journal of the European Society for Medical Oncology / ESMO","fully curated","44","Dacomitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1895,"EID1895","The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored truncating mutations in 10 of 39 angiosarcomas (26%) which correlated with MYC amplifications. In HUVEC cell line model, silencing of PTPRB  induced features of angiogenesis which were abolished in the presence of sunitinib or vatalinib, inhibitors of VEGFR.",330,"Angiosarcoma","Angiosarcoma",1816,"http://www.disease-ontology.org/?id=DOID:0001816","D","Predictive","Supports","Sensitivity","Somatic Mutation",819,3,NULL,"accepted",0,"evidence",1324,"Recurrent PTPRB and PLCG1 mutations in angiosarcoma.","Behjati et al., 2014, Nat. Genet.",24633157,"http://www.ncbi.nlm.nih.gov/pubmed/24633157","true","PMC4032873","2014","4",NULL,"Nat. Genet.","Nature genetics","fully curated","157","Sunitinib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1896,"EID1896","Study of a large kindred with von Hippel-Lindau disease (VHLD) and pheochromocytoma (spread over four generations). 25 proven cases of VHLD and 17 cases with pheochromocytoma were identified. Mutation analysis was performed in 14 family members (7 affected, 7 unaffected).  11 cases had the same mutation resulting in a predicted amino acid substitution of A149S.  The cases with mutation that appeared unaffected were all very young (before the likely age of onset). The three cases without the mutation that appeared unaffected were aged 18, 54, and 69.  ACMG evidence codes: 'PP1' based on segregation results, 'PM5' because the authors describe a prior report of a similar mutation at the same site (A149T), 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease, and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology.",2187,"Von Hippel-Lindau","Von Hippel-Lindau",NULL,"http://www.disease-ontology.org/","C","Predisposing","Supports","Uncertain Significance","Germline Mutation",820,4,NULL,"accepted",0,"evidence",1327,"Pheochromocytoma in von Hippel-Lindau disease: clinical presentation and mutation analysis in a large, multigenerational kindred.","Atuk et al., 1998, J. Clin. Endocrinol. Metab.",9435426,"http://www.ncbi.nlm.nih.gov/pubmed/9435426",NULL,NULL,"1998","1",NULL,"J. Clin. Endocrinol. Metab.","The Journal of clinical endocrinology and metabolism","fully curated",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
1897,"EID1897","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor Rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant patients, 10 had somatic BRCA1 mutation. Confirmed objective response was seen in 79% of the BRCA1 mutant subgroup, and 74% confirmed objective response was seen in the somatic BRCA mutant subgroup. In a BRCA wild-type subgroup, with low levels of Loss of Heterozygosity, confirmed objective response was observed in 10% of the patients.",20,"Ovarian Cancer","Ovarian Cancer",2394,"http://www.disease-ontology.org/?id=DOID:2394","B","Predictive","Supports","Sensitivity","Somatic Mutation",185,4,NULL,"submitted",0,"evidence",1328,"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.","Swisher et al., 2017, Lancet Oncol.",27908594,"http://www.ncbi.nlm.nih.gov/pubmed/27908594",NULL,NULL,"2017","1",NULL,"Lancet Oncol.","The Lancet. Oncology","submitted","431","Rucaparib",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
